

NEWS 1 Web Page for STN Seminar Schedule - N. America  
 NEWS 2 JAN 02 STN pricing information for 2008 now available  
 NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
 prophetic substances  
 NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
 custom IPC display formats  
 NEWS 5 JAN 28 MARPAT searching enhanced  
 NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
 of publication  
 NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
 NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
 NEWS 9 FEB 08 STN Express, Version 8.3, now available  
 NEWS 10 FEB 20 PCI now available as a replacement to DPIC  
 NEWS 11 FEB 25 IFIREF reloaded with enhancements  
 NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
 NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
 U.S. National Patent Classification  
 NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
 IPC display formats  
 NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
 spectra  
 NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S.  
 applications updated  
 NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
 NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
 NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
 NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
 predefined hit display formats  
 NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
 NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family  
 searching  
 NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
 sequence search option  
 NEWS 25 JUN 06 EFFULL enhanced with 260,000 English abstracts  
 NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents  
 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24  
FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> e us2007-599748/apps
E1      1      US2007-599745/AP
E2      1      US2007-599747/AP
E3      0 -->  US2007-599748/AP
E4      0      US2007-599748/PRN
E5      1      US2007-599750/AP
E6      1      US2007-599753/AP
E7      1      US2007-599779/AP
E8      1      US2007-599793/AP
E9      1      US2007-599811/AP
E10     1      US2007-599813/AP
E11     1      US2007-599816/AP
E12     1      US2007-599856/AP
```

```
=> e us2006-599748/apps
E1      1      US2006-599741/AP
E2      1      US2006-599744/AP
E3      1 -->  US2006-599748/AP
E4      0      US2006-599748/PRN
E5      1      US2006-599749/AP
E6      1      US2006-599749/PRN
E7      1      US2006-599753/AP
E8      1      US2006-599754/AP
E9      2      US2006-599758/AP
E10     3      US2006-599760/AP
E11     2      US2006-599763/AP
E12     1      US2006-599766/AP
```

```
=> s e3
L1      1      US2006-599748/AP
```

```
=> sel rn l1
E1 THROUGH E162 ASSIGNED
```

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
```

FULL ESTIMATED COST

ENTRY	SESSION
3.17	3.38

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2  
DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s e1-e162

```
1 10453-86-8/BI
  (10453-86-8/RN)
1 1072-84-0/BI
  (1072-84-0/RN)
1 115926-52-8/BI
  (115926-52-8/RN)
1 122-04-3/BI
  (122-04-3/RN)
1 129-46-4/BI
  (129-46-4/RN)
1 129318-43-0/BI
  (129318-43-0/RN)
1 130-15-4/BI
  (130-15-4/RN)
1 145-73-3/BI
  (145-73-3/RN)
1 146903-18-6/BI
  (146903-18-6/RN)
1 150560-58-0/BI
  (150560-58-0/RN)
1 15084-51-2/BI
  (15084-51-2/RN)
1 16037-91-5/BI
  (16037-91-5/RN)
1 162086-14-8/BI
  (162086-14-8/RN)
1 1710-98-1/BI
  (1710-98-1/RN)
1 17325-26-7/BI
  (17325-26-7/RN)
1 17630-76-1/BI
  (17630-76-1/RN)
```

1 1821-12-1/BI  
(1821-12-1/RN)  
1 18496-54-3/BI  
(18496-54-3/RN)  
1 18711-13-2/BI  
(18711-13-2/RN)  
1 2058-74-4/BI  
(2058-74-4/RN)  
1 20780-76-1/BI  
(20780-76-1/RN)  
1 220965-34-4/BI  
(220965-34-4/RN)  
1 2243-83-6/BI  
(2243-83-6/RN)  
1 237756-11-5/BI  
(237756-11-5/RN)  
1 2632-13-5/BI  
(2632-13-5/RN)  
1 2650-44-4/BI  
(2650-44-4/RN)  
1 27318-90-7/BI  
(27318-90-7/RN)  
1 296771-71-6/BI  
(296771-71-6/RN)  
1 296773-88-1/BI  
(296773-88-1/RN)  
1 301166-54-1/BI  
(301166-54-1/RN)  
1 303092-45-7/BI  
(303092-45-7/RN)  
1 303149-87-3/BI  
(303149-87-3/RN)  
1 303998-01-8/BI  
(303998-01-8/RN)  
1 304883-18-9/BI  
(304883-18-9/RN)  
1 311321-81-0/BI  
(311321-81-0/RN)  
1 312519-17-8/BI  
(312519-17-8/RN)  
1 315671-49-9/BI  
(315671-49-9/RN)  
1 339205-70-8/BI  
(339205-70-8/RN)  
1 339205-73-1/BI  
(339205-73-1/RN)  
1 345630-40-2/BI  
(345630-40-2/RN)  
1 345630-42-4/BI  
(345630-42-4/RN)  
1 36043-49-9/BI  
(36043-49-9/RN)  
1 376383-76-5/BI  
(376383-76-5/RN)  
1 39755-95-8/BI  
(39755-95-8/RN)  
1 401646-54-6/BI  
(401646-54-6/RN)  
1 42494-71-3/BI  
(42494-71-3/RN)  
1 42494-73-5/BI



(42494-73-5/RN)  
1 43100-25-0/BI  
(43100-25-0/RN)  
1 43100-38-5/BI  
(43100-38-5/RN)  
1 443-69-6/BI  
(443-69-6/RN)  
1 458553-48-5/BI  
(458553-48-5/RN)  
1 477847-81-7/BI  
(477847-81-7/RN)  
1 478063-72-8/BI  
(478063-72-8/RN)  
1 478077-73-5/BI  
(478077-73-5/RN)  
1 478077-74-6/BI  
(478077-74-6/RN)  
1 478077-78-0/BI  
(478077-78-0/RN)  
1 478077-79-1/BI  
(478077-79-1/RN)  
1 478257-55-5/BI  
(478257-55-5/RN)  
1 478257-73-7/BI  
(478257-73-7/RN)  
1 478257-76-0/BI  
(478257-76-0/RN)  
1 484-17-3/BI  
(484-17-3/RN)  
1 511518-73-3/BI  
(511518-73-3/RN)  
1 512796-41-7/BI  
(512796-41-7/RN)  
1 512796-49-5/BI  
(512796-49-5/RN)  
1 512796-50-8/BI  
(512796-50-8/RN)  
1 512796-65-5/BI  
(512796-65-5/RN)  
1 512796-67-7/BI  
(512796-67-7/RN)  
1 512796-72-4/BI  
(512796-72-4/RN)  
1 512796-76-8/BI  
(512796-76-8/RN)  
1 512796-99-5/BI  
(512796-99-5/RN)  
1 51630-58-1/BI  
(51630-58-1/RN)  
1 52315-07-8/BI  
(52315-07-8/RN)  
1 524-42-5/BI  
(524-42-5/RN)  
1 52918-63-5/BI  
(52918-63-5/RN)  
1 5315-25-3/BI  
(5315-25-3/RN)  
1 547730-75-6/BI  
(547730-75-6/RN)  
1 5725-96-2/BI  
(5725-96-2/RN)

1 585557-83-1/BI  
(585557-83-1/RN)  
1 5908-27-0/BI  
(5908-27-0/RN)  
1 604-95-5/BI  
(604-95-5/RN)  
1 611-09-6/BI  
(611-09-6/RN)  
1 650620-84-1/BI  
(650620-84-1/RN)  
1 68782-46-7/BI  
(68782-46-7/RN)  
1 694-83-7/BI  
(694-83-7/RN)  
1 69736-76-1/BI  
(69736-76-1/RN)  
1 701-99-5/BI  
(701-99-5/RN)  
1 722494-26-0/BI  
(722494-26-0/RN)  
1 731831-41-7/BI  
(731831-41-7/RN)  
1 7440-62-2/BI  
(7440-62-2/RN)  
1 75899-68-2/BI  
(75899-68-2/RN)  
1 774184-51-9/BI  
(774184-51-9/RN)  
1 79183-26-9/BI  
(79183-26-9/RN)  
1 819-83-0/BI  
(819-83-0/RN)  
1 827034-63-9/BI  
(827034-63-9/RN)  
1 84-11-7/BI  
(84-11-7/RN)  
1 847363-06-8/BI  
(847363-06-8/RN)  
1 860207-88-1/BI  
(860207-88-1/RN)  
1 867339-05-7/BI  
(867339-05-7/RN)  
1 867375-71-1/BI  
(867375-71-1/RN)  
1 867375-74-4/BI  
(867375-74-4/RN)  
1 867375-77-7/BI  
(867375-77-7/RN)  
1 867375-78-8/BI  
(867375-78-8/RN)  
1 867375-79-9/BI  
(867375-79-9/RN)  
1 867375-82-4/BI  
(867375-82-4/RN)  
1 867375-88-0/BI  
(867375-88-0/RN)  
1 867375-89-1/BI  
(867375-89-1/RN)  
1 867375-90-4/BI  
(867375-90-4/RN)  
1 867375-91-5/BI

(867375-91-5/RN)  
1 867375-92-6/BI  
(867375-92-6/RN)  
1 867375-93-7/BI  
(867375-93-7/RN)  
1 867375-94-8/BI  
(867375-94-8/RN)  
1 867375-96-0/BI  
(867375-96-0/RN)  
1 867375-97-1/BI  
(867375-97-1/RN)  
1 867375-99-3/BI  
(867375-99-3/RN)  
1 867376-00-9/BI  
(867376-00-9/RN)  
1 867376-01-0/BI  
(867376-01-0/RN)  
1 867376-02-1/BI  
(867376-02-1/RN)  
1 867376-03-2/BI  
(867376-03-2/RN)  
1 867376-04-3/BI  
(867376-04-3/RN)  
1 867376-05-4/BI  
(867376-05-4/RN)  
1 867376-06-5/BI  
(867376-06-5/RN)  
1 867376-07-6/BI  
(867376-07-6/RN)  
1 867376-08-7/BI  
(867376-08-7/RN)  
1 867376-10-1/BI  
(867376-10-1/RN)  
1 867376-11-2/BI  
(867376-11-2/RN)  
1 867376-12-3/BI  
(867376-12-3/RN)  
1 867376-13-4/BI  
(867376-13-4/RN)  
1 867376-14-5/BI  
(867376-14-5/RN)  
1 867376-15-6/BI  
(867376-15-6/RN)  
1 867376-16-7/BI  
(867376-16-7/RN)  
1 867376-17-8/BI  
(867376-17-8/RN)  
1 867376-18-9/BI  
(867376-18-9/RN)  
1 867376-19-0/BI  
(867376-19-0/RN)  
1 867376-20-3/BI  
(867376-20-3/RN)  
1 867376-27-0/BI  
(867376-27-0/RN)  
1 867376-28-1/BI  
(867376-28-1/RN)  
1 867376-29-2/BI  
(867376-29-2/RN)  
1 867376-33-8/BI  
(867376-33-8/RN)

1 867376-34-9/BI  
 (867376-34-9/RN)  
 1 867376-35-0/BI  
 (867376-35-0/RN)  
 1 867376-36-1/BI  
 (867376-36-1/RN)  
 1 867376-37-2/BI  
 (867376-37-2/RN)  
 1 867376-38-3/BI  
 (867376-38-3/RN)  
 1 867376-39-4/BI  
 (867376-39-4/RN)  
 1 867376-46-3/BI  
 (867376-46-3/RN)  
 1 867376-63-4/BI  
 (867376-63-4/RN)  
 1 867376-74-7/BI  
 (867376-74-7/RN)  
 1 867376-75-8/BI  
 (867376-75-8/RN)  
 1 867376-76-9/BI  
 (867376-76-9/RN)  
 1 867376-77-0/BI  
 (867376-77-0/RN)  
 1 867376-80-5/BI  
 (867376-80-5/RN)  
 1 867376-81-6/BI  
 (867376-81-6/RN)  
 1 867376-83-8/BI  
 (867376-83-8/RN)  
 1 867376-85-0/BI  
 (867376-85-0/RN)  
 1 867376-86-1/BI  
 (867376-86-1/RN)  
 1 867380-85-6/BI  
 (867380-85-6/RN)  
 1 87-48-9/BI  
 (87-48-9/RN)  
 1 91-56-5/BI  
 (91-56-5/RN)  
 1 939-97-9/BI  
 (939-97-9/RN)  
 1 98-59-9/BI  
 (98-59-9/RN)  
 1 98-74-8/BI  
 (98-74-8/RN)  
 1 99304-37-7/BI  
 (99304-37-7/RN)

L2


162 (10453-86-8/BI OR 1072-84-0/BI OR 115926-52-8/BI OR 122-04-3/BI  
 OR 129-46-4/BI OR 129318-43-0/BI OR 130-15-4/BI OR 145-73-3/BI  
 OR 146903-18-6/BI OR 150560-58-0/BI OR 15084-51-2/BI OR 16037-91  
 -5/BI OR 162086-14-8/BI OR 1710-98-1/BI OR 17325-26-7/BI OR 1763  
 0-76-1/BI OR 1821-12-1/BI OR 18496-54-3/BI OR 18711-13-2/BI OR  
 2058-74-4/BI OR 20780-76-1/BI OR 220965-34-4/BI OR 2243-83-6/BI  
 OR 237756-11-5/BI OR 2632-13-5/BI OR 2650-44-4/BI OR 27318-90-7/  
 BI OR 296771-71-6/BI OR 296773-88-1/BI OR 301166-54-1/BI OR 3030  
 92-45-7/BI OR 303149-87-3/BI OR 303998-01-8/BI OR 304883-18-9/BI  
 OR 311321-81-0/BI OR 312519-17-8/BI OR 315671-49-9/BI OR 339205  
 -70-8/BI OR 339205-73-1/BI OR 345630-40-2/BI OR 345630-42-4/BI  
 OR 36043-49-9/BI OR 376383-76-5/BI OR 39755-95-8/BI OR 401646-54  
 -6/BI OR 42494-71-3/BI OR 42494-73-5/BI OR 43100-25-0/BI OR 4310

0-38-5/BI OR 443-69-6/BI OR 458553-48-5/BI OR 477847-81-7/BI OR  
478063-72-8/BI OR 478077-73-5/BI OR 478077-74-6/BI OR 478077-78-  
0/BI OR 478077-79-1/BI OR 478257

=> s l2 and dione  
1031736 DIONE  
2 DIONES  
1031736 DIONE  
(DIONE OR DIONES)  
L3 22 L2 AND DIONE

=> d scan l3


L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
IN 1H-Indole-2,3-dione, 5-methoxy-  
MF C9 H7 N O3  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):22

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
IN 1H-Indole-2,3-dione, 5-bromo-  
MF C8 H4 Br N O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
IN 1H-Indole-2,3-dione, 4,7-dichloro-  
MF C8 H3 Cl2 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
 IN 1H-Indole-2,3-dione, 1-[(4-chlorophenyl)methyl]-5-methyl-  
 MF C16 H12 Cl N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
 IN 9,10-Phenanthrenedione, 2-nitro-  
 MF C14 H7 N O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on SIN  
 IN 1H-Indole-2,3-dione, 5-bromo-1-ethyl-  
 MF C10 H8 Br N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1H-Indole-2,3-dione  
 MF C8 H5 N O2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1H-Indole-2,3-dione, 5-iodo-  
 MF C8 H4 I N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1H-Indole-2,3-dione, 1-[(4-fluorophenyl)sulfonyl]-  
 MF C14 H8 F N O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Indole-2,3-dione, 5-nitro-  
MF C8 H4 N2 O4  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Indole-2,3-dione, 1-[(4-methylphenyl)methyl]-  
MF C16 H13 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1,4-Naphthalenedione  
MF C10 H6 O2  
CI COM






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1,10-Phenanthroline-5,6-dione  
MF C12 H6 N2 O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 9,10-Phenanthrenedione, 2-[(phenylmethyl)amino]-  
MF C21 H15 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Indole-2,3-dione, 1-methyl-  
MF C9 H7 N O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Indole-2,3-dione, 5-(1-methylethyl)-  
MF C11 H11 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Indole-2,3-dione, 5-fluoro-  
MF C8 H4 F N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 9,10-Phenanthrenedione, 2-amino-  
MF C14 H9 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 9,10-Phenanthrenedione  
MF C14 H8 O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1H-Indole-2,3-dione, 5-chloro-  
 MF C8 H4 Cl N O2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1H-Indole-2,3-dione, 1-[(2,4-dichlorophenyl)methyl]-5-nitro-  
 MF C15 H8 Cl2 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Naphthalenedione  
 MF C10 H6 O2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162

L3 22 S L2 AND DIONE

=> s l2 and phenanthroline  
5 PHENANTHROLINEDIONE

L4 0 L2 AND PHENANTHROLINEDIONE

=> s l2 and phenanthroline  
53251 PHENANTHROLINE

L5 2 L2 AND PHENANTHROLINE


=> d scan l5

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,10-Phenanthroline-5,6-dione

MF C12 H6 N2 O2

CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Vanadate(1-), oxodiperoxy(1,10-phenanthroline-κN1,κN10)-,  
 potassium, (PB-7-23-111'1'3)- (9CI)  
 MF C12 H8 N2 O5 V . K  
 CI CCS



● K<sup>+</sup>

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

```
=> s "substituted phenanthroline"
      902 "SUBSTITUTED"
      53251 "PHENANTHROLINE"
L6      0 "SUBSTITUTED PHENANTHROLINE"
          ("SUBSTITUTED" (W) "PHENANTHROLINE")

=> d his
      (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

      FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
          E US2007-599748/APPS
          E US2006-599748/APPS
L1      1 S E3
          SEL RN L1

      FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2      162 S E1-E162
L3      22 S L2 AND DIONE
L4      0 S L2 AND PHENANTHROLINE DIONE
L5      2 S L2 AND PHENANTHROLINE
L6      0 S "SUBSTITUTED PHENANTHROLINE"
```

=> file caplus medline embase biosis scisearch  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
31.27	34.65

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:54:34 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:54:34 ON 11 JUN 2008

FILE 'EMBASE' ENTERED AT 09:54:34 ON 11 JUN 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:54:34 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

=> s l2  
L7 224329 L2

=> s l3  
L8 13877 L3

=> s l5  
L9 406 L5

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008  
E US2007-599748/APPS  
E US2006-599748/APPS  
L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008  
L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON  
11 JUN 2008

L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5

=> s l7 or l8 or l9  
L10 224329 L7 OR L8 OR L9

=> s l10 and antiangiogenic  
L11 3300 10 AND ANTIANGIOGENIC

=> s l11 and ischemia  
L12 56 L11 AND ISCHEMIA

=> s l11 and ("heart disease")  
L13 28 L11 AND ("HEART DISEASE")

=> s l13 and l12  
 L14 2 L13 AND L12  
 => d l14 1-2 hitstr ibib all

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:143140 CAPLUS  
 DOCUMENT NUMBER: 140:181449  
 TITLE: Preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents  
 INVENTOR(S): Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee Hee; Kim, Nak Jeong; Hwang, Sun Kyung; Lee, Byung-ho; Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un  
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea  
 SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014898	A1	20040219	WO 2003-KR1534	20030730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2004014023	A	20040214	KR 2002-47189	20020809
CA 2493966	A1	20040219	CA 2003-2493966	20030730
AU 2003247213	A1	20040225	AU 2003-247213	20030730
AU 2003247213	B2	20070405		
EP 1546136	A1	20050629	EP 2003-784665	20030730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675202	A	20050928	CN 2003-819195	20030730
JP 2006509725	T	20060323	JP 2004-527422	20030730
US 20050267188	A1	20051201	US 2005-523015	20050202
US 7279497	B2	20071009		

PRIORITY APPLN. INFO.: KR 2002-47189 A 20020809  
 WO 2003-KR1534 W 20030730

OTHER SOURCE(S): CASREACT 140:181449; MARPAT 140:181449

AN 2004:143140 CAPLUS

DN 140:181449

ED Entered STN: 22 Feb 2004

TI Preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents

IN Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee Hee; Kim, Nak Jeong; Hwang, Sun Kyung; Lee, Byung-ho; Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un

PA Korea Research Institute of Chemical Technology, S. Korea

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English  
 IC ICM C07D405-12  
 CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 27, 63

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014898	A1	20040219	WO 2003-KR1534	20030730
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	KR 2004014023	A	20040214	KR 2002-47189	20020809
	CA 2493966	A1	20040219	CA 2003-2493966	20030730
	AU 2003247213	A1	20040225	AU 2003-247213	20030730
	AU 2003247213	B2	20070405		
	EP 1546136	A1	20050629	EP 2003-784665	20030730
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1675202	A	20050928	CN 2003-819195	20030730
	JP 2006509725	T	20060323	JP 2004-527422	20030730
	US 20050267188	A1	20051201	US 2005-523015	20050202
	US 7279497	B2	20071009		
PRAI	KR 2002-47189	A	20020809		
	WO 2003-KR1534	W	20030730		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004014898	ICM	C07D405-12
	IPCI	C07D0405-12 [ICM,7]; C07D0405-00 [ICM,7,C*]
	IPCR	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	ECLA	C07D405/12+311C+233
KR 2004014023	IPCI	C07D0405-12 [ICM,7]; C07D0405-00 [ICM,7,C*]
	ECLA	C07D405/12+311C+233
CA 2493966	IPCI	C07D0405-12 [ICM,7]; C07D0405-00 [ICM,7,C*]
	IPCR	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	ECLA	C07D405/12+311C+233
AU 2003247213	IPCI	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	IPCR	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	ECLA	C07D405/12+311C+233
EP 1546136	IPCI	C07D0405-12 [ICM,7]; C07D0405-00 [ICM,7,C*]
	IPCR	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	ECLA	C07D405/12+311C+233
CN 1675202	IPCI	C07D0405-12 [ICM,7]; C07D0405-00 [ICM,7,C*]
	IPCR	C07D0405-00 [I,C*]; C07D0405-12 [I,A]
	ECLA	C07D405/12+311C+233
JP 2006509725	IPCI	C07D0405-12 [I,A]; C07D0405-00 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4164 [I,C*]; A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0025-02 [I,A]; A61P0025-28 [I,A]; A61P0025-00 [I,C*]; A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0027-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,A]; A61P0039-06 [I,A]; A61P0039-00 [I,C*]; C07B0061-00 [N,A]
	IPCR	C07D0405-00 [I,C]; C07D0405-12 [I,A]; A61K0031-4164



[I,C]; A61K0031-4178 [I,A]; A61P0009-00 [I,C];  
A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10  
[I,A]; A61P0025-00 [I,C]; A61P0025-02 [I,A];  
A61P0025-28 [I,A]; A61P0027-00 [I,C]; A61P0027-02  
[I,A]; A61P0027-06 [I,A]; A61P0029-00 [I,C];  
A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00  
[I,A]; A61P0039-00 [I,C]; A61P0039-06 [I,A];  
C07B0061-00 [N,C]; C07B0061-00 [N,A]  
FTERM 4C063/AA01; 4C063/BB09; 4C063/CC79; 4C063/DD25;  
4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;  
4C086/AA04; 4C086/BC82; 4C086/GA02; 4C086/GA07;  
4C086/GA16; 4C086/MA01; 4C086/MA04; 4C086/NA14;  
4C086/ZA02; 4C086/ZA15; 4C086/ZA20; 4C086/ZA33;  
4C086/ZA36; 4C086/ZA45; 4C086/ZB15; 4H039/CA60;  
4H039/CA71; 4H039/CB40; 4H039/CF30  
US 20050267188 IPCI A61K0031-4164 [I,A]; C07D0233-54 [I,A]; C07D0233-00  
[I,C\*]  
IPCR C07D0405-00 [I,C\*]; C07D0405-12 [I,A]  
NCL 514/397.000; 548/311.400; 514/385.000; 514/396.000;  
548/300.100; 548/311.100  
ECLA C07D405/12+311C+233  
OS CASREACT 140:181449; MARPAT 140:181449  
GI



AB Imidazolylmethylaminobenzopyrans I [R1 = H, CN, NO2, NH2; R2 =  
dialkoxymethyl, alkylenedioxymethyl; R3, R4 = H, Cl, Br, F, alkyl, CF3,  
OCF3, NO2, (un)substituted OH, CO2H] were prepared for use in the treatment  
of cancer, rheumatoid arthritis, and diabetic retinopathies through  
anti-angiogenic properties, and in the protection of heart and neuronal  
cells against ischemia-reperfusion injury or preserving organs.  
Thus, (2S,3R,4R)-3,4-dihydro-2-dimethoxymethyl-3,4-epoxy-2-methyl-6-nitro-  
2H-1-benzopyran was treated with N-(4-chlorophenyl)-N-(1H-imidazol-2-  
ylmethyl)amine to give (2S,3R,4R)-I [R1 = NO2, R2 = CH(OMe)2, R3 = 4-Cl,  
R4 = H] which showed strong inhibition of HUVEC tube formation at  
10  $\mu$ M.  
ST imidazolylmethylaminobenzopyran prepn antiangiogenic  
IT Heart, disease  
(angina pectoris; preparation of imidazolylmethylaminobenzopyrans as  
antiangiogenic agents)  
IT Nerve, disease  
(diabetic neuropathy; preparation of imidazolylmethylaminobenzopyrans as  
antiangiogenic agents)  
IT Eye, disease  
(diabetic retinopathy; preparation of imidazolylmethylaminobenzopyrans as  
antiangiogenic agents)  
IT Heart, disease

(failure; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Asphyxia  
(infant; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Heart, disease  
(infarction; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Angiogenesis  
Antiarrhythmics  
Antitumor agents  
Atherosclerosis  
Glaucoma (disease)  
Human  
Neoplasm  
Rheumatoid arthritis  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Mental and behavioral disorders  
(senile psychosis; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Head and Neck, disease  
(trauma; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 571141-37-2P 571141-39-4P 660404-73-9P 660404-74-0P 660404-75-1P  
660404-76-2P 660404-77-3P 660404-78-4P 660404-80-8P 660404-81-9P  
660404-82-0P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 571141-36-1P 571141-38-3P 571141-47-4P 571141-49-6P 660404-90-0P  
660404-91-1P 660404-92-2P 660404-93-3P 660404-94-4P 660404-95-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 106-47-8, 4-Chloroaniline, reactions 10111-08-7, 2-  
Imidazolecarboxaldehyde 380912-55-0 380912-56-1 380912-57-2  
380912-58-3 660405-19-6 663598-14-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 166096-16-8P 166096-17-9P 660405-04-9P 660405-05-0P 660405-06-1P  
660405-07-2P 660405-08-3P 660405-09-4P 660405-10-7P 660405-11-8P  
660405-12-9P 660405-13-0P 660405-14-1P 660405-15-2P 660405-16-3P  
660405-17-4P 660405-18-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 660404-79-5P 660404-83-1P 660404-84-2P 660404-89-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 660404-85-3P 660404-86-4P 660404-87-5P 660404-88-6P 660404-96-6P  
660404-97-7P 660404-98-8P 660404-99-9P 660405-00-5P 660405-01-6P

660405-02-7P 660405-03-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Bristol-Myers Squibb Co; EP 648758 A1 1995 CAPLUS
- (2) Bristol-Myers Squibb Co; US 5629429 A 1997 CAPLUS
- (3) Bristol-Myers Squibb Co; US 5837702 A 1998 CAPLUS
- (4) Ding, C; Journal of Medicinal Chemistry 1999, V42(18), P3711 CAPLUS
- (5) Grover, G; The Journal of Pharmacology and Experimental Therapeutics 2001, V297(3), P1184 CAPLUS
- (6) Merck And Co Inc; US 20020082292 A1 2002
- (7) Rovnyak, G; Journal of Medicinal Chemistry 1997, V40(1), P24 CAPLUS

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:492385 CAPLUS

DOCUMENT NUMBER: 136:288753

TITLE: Effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44

AUTHOR(S): Wang, Yongmei; Wu, Zonggui; Li, Li; Zhang, Lingzhen; Zhong, Renqian

CORPORATE SOURCE: Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, Peop. Rep. China

SOURCE: Dier Junyi Daxue Xuebao (2001), 22(2), 144-147  
CODEN: DJXUE5; ISSN: 0258-879X

PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal  
LANGUAGE: Chinese

AN 2001:492385 CAPLUS

DN 136:288753

ED Entered STN: 09 Jul 2001

TI Effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44

AU Wang, Yongmei; Wu, Zonggui; Li, Li; Zhang, Lingzhen; Zhong, Renqian

CS Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, Peop. Rep. China

SO Dier Junyi Daxue Xuebao (2001), 22(2), 144-147

CODEN: DJXUE5; ISSN: 0258-879X

PB Dier Junyi Daxue Xuebao Bianjibu

DT Journal

LA Chinese

CC 1-8 (Pharmacology)

AB The effects of hyaluronidase (HAase) and hyaluronan (HA) on proliferation of vascular endothelial cells and its mechanism were studied. The cultured aortic endothelial cells (BAEC) were treated with HAase or HA, cell proliferation rate was detected by MTT assay, and expression of CD44 and DNA content of the cells were measured by flow cytometry. The cell proliferation was increased by (50.10 ± 1.23)%, S phase cell rate was increased, and expression of CD44 was induced by HAase (50 µg mL<sup>-1</sup>). The cell proliferation and expression of CD44 were inhibited by HA (100 µg mL<sup>-1</sup>). The results showed that HAase may degrade antiangiogenic HA of extracellular matrix, which may stimulate proliferation of endothelial cells and enhance the curative effect of growth factors to myocardial ischemia.

ST hyaluronidase hyaluronan angiogenesis vascular endothelium CD44 myocardial ischemia

IT Ischemia

(cardiac; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Cardiovascular agents  
Cytoprotective agents  
(cardioprotective agents; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Angiogenesis  
Cell cycle  
Cell proliferation  
Extracellular matrix  
(effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT CD44 (antigen)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Blood vessel  
(endothelium; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Heart, disease  
(ischemia; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Endothelium  
(vascular; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT 9004-61-9, Hyaluronan  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT 37326-33-3, Hyaluronidase  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

=>

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINE DIONE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5  
L10 224329 S L7 OR L8 OR L9  
L11 3300 S 10 AND ANTIANGIOGENIC


L12 56 S L11 AND ISCHEMIA  
 L13 28 S L11 AND ("HEART DISEASE")  
 L14 2 S L13 AND L12

=> s (l3 or l5) and antiangiogenic  
 L15 7 (L3 OR L5) AND ANTIANGIOGENIC

=>

=> d l15 1-7 hitstr ibib all

L15 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 91-56-5, Isatin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (isatin and its analog acted on large number of biol. targets and had  
 variety of actual and potential pharmacol. action)  
 RN 91-56-5 CAPLUS  
 CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2008:344354 CAPLUS  
 TITLE: Biological targets for isatin and its analogues:  
 implications for therapy  
 AUTHOR(S): Medvedev, Alexei; Buneeva, Olga; Glover, Vivette  
 CORPORATE SOURCE: Institute of Biomedical Chemistry, Russian Academy of  
 Medical Sciences, Moscow, Russia  
 SOURCE: Biologics: Targets & Therapy (2007), 1(2), 151-162  
 CODEN: BTICT; ISSN: 1177-5475  
 PUBLISHER: Dove Medical Press (NZ) Ltd.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AN 2008:344354 CAPLUS  
 ED Entered STN: 20 Mar 2008  
 TI Biological targets for isatin and its analogues: implications for therapy  
 AU Medvedev, Alexei; Buneeva, Olga; Glover, Vivette  
 CS Institute of Biomedical Chemistry, Russian Academy of Medical Sciences,  
 Moscow, Russia  
 SO Biologics: Targets & Therapy (2007), 1(2), 151-162  
 CODEN: BTICT; ISSN: 1177-5475  
 PB Dove Medical Press (NZ) Ltd.  
 DT Journal; General Review  
 LA English  
 CC 1-0 (Pharmacology)  
 AB A review. Isatin and its metabolites are constituents of many natural  
 substances. They are also components of many synthetic compds. exhibiting  
 a wide range of effects, including antiviral activity, antitumor and  
 antiangiogenic activity, antibacterial, antitubercular,  
 antifungal, antiapoptotic, anticonvulsant and anxiolytic activities. Isatin  
 itself is an endogenous oxidized indole with a wide spectrum of behavioral  
 and metabolic effects. It has a distinct and discontinuous distribution  
 in the brain, peripheral tissues and body fluids and isatin binding sites  
 are widely distributed also. Its output is increased during stress. Its  
 most potent known in vitro actions are as an antagonist of atrial

natriuretic peptide (ANP) function and NO signaling. As we understand more about its function and sites of action we may be able to develop new pharmacol. agents to mimic or counteract its activity. We consider here the most promising biol. targets for various isatin analogs and/or metabolites, which are employed for the development of various groups of therapeutics. It is also possible that the level of endogenous isatin may influence the in vivo pharmacol. activity of compds. possessing the isatin moiety.

ST review isatin analog drug target sensitivity

IT Drug targets

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

IT 91-56-5, Isatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

L15 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN


IT 87-48-9, 5-Bromo-2,3-indoledione 91-56-5,  
2,3-Indoledione 17630-76-1, 5-Chloro-2,3-indoledione

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)


RN 87-48-9 CAPLUS

CN 1H-Indole-2,3-dione, 5-bromo- (CA INDEX NAME)




RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



RN 17630-76-1 CAPLUS

CN 1H-Indole-2,3-dione, 5-chloro- (CA INDEX NAME)



ACCESSION NUMBER:

2006:374270 CAPLUS

DOCUMENT NUMBER:

145:62745

TITLE:

Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and

antiangiogenic agents

AUTHOR(S): Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

SOURCE: European Journal of Medicinal Chemistry (2006), 41(3), 296-305  
CODEN: EJMCAS; ISSN: 0223-5234

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:62745

AN 2006:374270 CAPLUS

DN 145:62745

ED Entered STN: 25 Apr 2006

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents

AU Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

SO European Journal of Medicinal Chemistry (2006), 41(3), 296-305  
CODEN: EJMCAS; ISSN: 0223-5234

PB Elsevier B.V.


DT Journal

LA English

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1

OS CASREACT 145:62745

GI



I

AB Several analogs of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or haloisatin with some amino acids or histamine under neutral conditions. All the imino derivs. produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and GSK3 $\alpha/\beta$ . Most of the histidine derivs. showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivs. were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3 $\alpha/\beta$ . So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of

oxindoline I [R = Br] to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3 $\beta$ , the ligand poses itself in another orientation, and four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compds. were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compds. was cytotoxic at 10<sup>-4</sup> molar concentration. Moreover, I [R = H, Br] were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only I [R = Br] showed moderate inhibitory properties to HUVECs proliferation and cord formation while I [R = H] did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases.

ST oxindole prepn kinase neoplasm angiogenesis inhibitor  
 IT Angiogenesis  
 Angiogenesis inhibitors  
 Antitumor agents  
 Human  
 Neoplasm

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 9031-44-1, Kinase (phosphorylating)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 153535-71-8P 167489-36-3P 891192-12-4P 891192-13-5P 891192-14-6P

891192-15-7P 891192-16-8P 891192-17-9P 891192-18-0P 891192-19-1P

891192-20-4P 891192-21-5P 891192-22-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 51-45-6, Histamine, reactions 71-00-1, L-Histidine, reactions 72-18-4,

L-Valine, reactions 72-19-5, L-Threonine, reactions 87-48-9,

5-Bromo-2,3-indoleione 91-56-5, 2,3-Indoleione 6341-92-0,

6-Chloroisatin 6344-05-4, 4-Chloroisatin 7477-63-6, 7-Chloroisatin

17630-76-1, 5-Chloro-2,3-indoleione

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aly, M; Tetrahedron 1994, V50, P895 CAPLUS

(2) Andreani, A; J Med Chem 2002, V45, P2666 CAPLUS

(3) Belotti, D; Clin, Cancer Res 1996, V2, P1843 CAPLUS

(4) Borgne, A; J Biol Chem 1996, V271, P27847 CAPLUS

(5) Bramson, H; J Med Chem 2001, V44, P4339 CAPLUS

(6) Clark, R; J Soc Dyers Colour 1997, V113, P316 CAPLUS

(7) Cohen, P; Eur J Biochem 2001, V268, P5001 CAPLUS

(8) Cohen, P; Nat Rev Drug Discov 2002, V1, P309 CAPLUS

(9) Cornell, R; Expert Opin, Ther Patents 2003, V13, P738

(10) De Strooper, B; Nature 2003, V423, P392 CAPLUS

(11) Delano, W; The PYMOL Molecular Graphics Syssem, <http://www.pymol.org> 2002

(12) Folkman, J; J Natl Cancer Inst 1990, V82, P4 MEDLINE

(13) Fong, T; Cancer Res 1999, V59, P99 CAPLUS

(14) Ganellin, C; J Med Chem 1973, V16, P610 CAPLUS

(15) Ganellin, R; J Med Chem 1996, V39, P3806

(16) GraBman, S; Bioorg Med Chem 2003, V11, P2163

(17) Greever, M; Semin Oncol 1992, V19, P622



- (18) Ham, N; J Med Chem 1973, V16, P470 CAPLUS
- (19) Haspel, H; Microvasc Res 2002, V63, P304 CAPLUS
- (20) Hassaan, A; Egypt J Pharm Sci 1992, V33, P679 CAPLUS
- (21) Hassaan, A; Egypt J Pharm Sci 1993, V34, P253 CAPLUS
- (22) Hassaan, A; Egypt J Pharm Sci 1994, V35, P165 CAPLUS
- (23) Hassaan, A; Egypt J Pharm Sci 1995, V36, P309 CAPLUS
- (24) Huang, C; Pacific Symposium on Biocomputing 1996, V1, P724
- (25) Jianguo, M; J Pharmacol Exp Ther 2003, V305, P833
- (26) Knockaert, M; Trends Pharmacol Sci 2002, V23, P417 CAPLUS
- (27) Lane, M; Cancer Res 2001, V15, P6170
- (28) Leclerc, S; J Biol Chem 2001, V276, P251 CAPLUS
- (29) Malumbres, M; Nat Rev Cancer 2001, V1, P222 CAPLUS
- (30) Marzola, P; Clin Cancer Res 2004, V15, P739
- (31) Meijer, L; Trends Pharmacol Sci 2004, V25, P471 CAPLUS
- (32) Milne, G; J Am Chem Soc 1970, V92, P5170 CAPLUS
- (33) Mohamadi, F; J Comput Chem 1990, V11, P440 CAPLUS
- (34) Monks, A; J Natl Cancer Inst 1991, V83, P757 CAPLUS
- (35) Noble, W; Neuron 2003, V38, P555 CAPLUS
- (36) Polychronopoulos, P; J Med Chem 2004, V47, P935 CAPLUS
- (37) Primot, A; Protein Expr Purif 2000, V20, P394 CAPLUS
- (38) Rehn, S; Eur J Org Chem 2004, P413 CAPLUS
- (39) Roth, G; DE 10117204 A1 2002 CAPLUS
- (40) Roublevskaia, I; Anticancer Res 2000, V20, P3163 CAPLUS
- (41) Sridhar, R; Pharm Res 2000, V17, P1345 CAPLUS
- (42) Sun, L; J Med Chem 1998, V41, P2588 CAPLUS
- (43) Sun, L; J Med Chem 1999, V42, P5120 CAPLUS
- (44) Tarabolletti, G; Clin Cancer Res 2002, V8, P1182

L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN


IT 130-15-4, 1,4-Naphthalenedione

RL: PAC (Pharmacological activity); BIOL (Biological study)

(methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

RN 130-15-4 CAPLUS

CN 1,4-Naphthalenedione (CA INDEX NAME)



ACCESSION NUMBER: 2005:322408 CAPLUS

DOCUMENT NUMBER: 142:367706

TITLE: 2-Methylthio-1,4-naphthoquinone and derivatives thereof, method for production thereof, pharmaceutical compositions, and therapeutic use

INVENTOR(S): Muller, Werner E. G.; Thakur, Narsinh L.; Thakur, Arachana N.; Schroder, Heinz C.; Lang, Gerhard; Tsuruta, Hideyuki; Bringmann, Gerhard

PATENT ASSIGNEE(S): Johannes-Gutenberg-Universitat Mainz, Germany; Julius-Maximilians-Universitat Wurzburg

SOURCE: Ger. Offen., 19 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10343798	A1	20050414	DE 2003-10343798	20030922
WO 2005042442	A2	20050512	WO 2004-EP10465	20040917
WO 2005042442	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: DE 2003-10343798 A 20030922  
OTHER SOURCE(S): MARPAT 142:367706  
AN 2005:322408 CAPLUS  
DN 142:367706  
ED Entered STN: 15 Apr 2005  
TI 2-Methylthio-1,4-naphthoquinone and derivatives thereof, method for production thereof, pharmaceutical compositions, and therapeutic use  
IN Muller, Werner E. G.; Thakur, Narsinh L.; Thakur, Arachana N.; Schroder, Heinz C.; Lang, Gerhard; Tsuruta, Hideyuki; Bringmann, Gerhard  
PA Johannes-Gutenberg-Universitat Mainz, Germany; Julius-Maximilians-Universitat Wurzburg  
SO Ger. Offen., 19 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
IC ICM C07C323-22  
ICS C07C319-14  
CC 1-12 (Pharmacology)  
Section cross-reference(s): 10, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10343798	A1	20050414	DE 2003-10343798	20030922
WO 2005042442	A2	20050512	WO 2004-EP10465	20040917
WO 2005042442	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI DE 2003-10343798 A 20030922

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 10343798	ICM	C07C323-22
	ICS	C07C319-14

WO 2005042442 IPCI C07C0323-22 [ICM,7]; C07C0323-00 [ICM,7,C\*];  
 C07C0319-14 [ICS,7]; C07C0319-00 [ICS,7,C\*]  
 IPCR C07C0323-00 [I,C\*]; C07C0323-22 [I,A]; C12P0011-00  
 [I,C\*]; C12P0011-00 [I,A]  
 ECLA C07C323/22; C12P011/00  
 IPCI C07C [ICM,7]  
 IPCR C07C0323-00 [I,C\*]; C07C0323-22 [I,A]; C12P0011-00  
 [I,C\*]; C12P0011-00 [I,A]  
 ECLA C07C323/22; C12P011/00  
 OS MARPAT 142:367706  
 AB 2-Methylthio-1,4-naphthoquinone (MTN) and derivs. thereof are disclosed,  
 as are methods for the production and/or isolation thereof. MTN and MTN  
 derivs. have antitumor and antiangiogenic properties in cell  
 culture models. These compds. also have neointimal proliferation-  
 inhibiting properties. The compds. can also be used to treat infections  
 by Gram-neg. bacteria.  
 ST methylthionaphthoquinone compd prodn antitumor antibacterial; angiogenesis  
 inhibitor methylthionaphthoquinone compd; neointimal proliferation  
 inhibitor methylthionaphthoquinone compd  
 IT Animal cell line  
 (PC12; methylthionaphthoquinone compds., production method, pharmaceutical  
 compns., and therapeutic use)  
 IT HeLa cell  
 (S3; methylthionaphthoquinone compds., production method, pharmaceutical  
 compns., and therapeutic use)  
 IT Proteobacteria  
 (alpha group, MBIC3368; methylthionaphthoquinone compds., production  
 method, pharmaceutical compns., and therapeutic use)  
 IT Infection  
 (bacterial; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Drug delivery systems  
 (capsules; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Uterus, neoplasm  
 (cervix, carcinoma; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Carcinoma  
 (cervix; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Drug delivery systems  
 (drops; methylthionaphthoquinone compds., production method, pharmaceutical  
 compns., and therapeutic use)  
 IT Gram-negative bacteria  
 (infection; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Drug delivery systems  
 (infusions; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Drug delivery systems  
 (injections; methylthionaphthoquinone compds., production method,  
 pharmaceutical compns., and therapeutic use)  
 IT Angiogenesis  
 Angiogenesis inhibitors  
 Antibacterial agents  
 Antitumor agents  
 Bacillus subtilis  
 Chemotherapy  
 Combination chemotherapy  
 Drug delivery systems  
 Dysidea avara

Escherichia coli  
 Fermentation  
 Human  
 Lymphoma  
 Neoplasm  
 Pheochromocytoma  
 (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Natural products, pharmaceutical  
 RL: DEV (Device component use); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)  
 (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Blood vessel  
 Cytotoxic agents  
 (neointimal proliferation inhibitors; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Cell proliferation  
 (neointimal; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (oral; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (parenterals; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (rectal; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (sols.; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Medical goods  
 (stents; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (suppositories; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (suspensions; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT Drug delivery systems  
 (tablets; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT 26037-60-5P 55699-85-9P  
 RL: DEV (Device component use); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)  
 (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT 849658-75-9 849658-76-0  
 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

IT 130-15-4, 1,4-Naphthalenedione  
 RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (methylthionaphthoquinone compds., production method, pharmaceutical

comps., and therapeutic use)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Anon; EP 0863442 A2 CAPLUS
- (2) Coll, G; J Org Chem 1998, V53, P5345
- (3) Kametani, T; J Chem Soc Perkin Trans 1 1977, P386 CAPLUS
- (4) Prakash, G; J Med Chem 1978, V21(4), P369 CAPLUS

L15 ANSWER 4 OF 7 MEDLINE on STN  
ACCESSION NUMBER: 2006264196 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 16494969  
TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.  
AUTHOR: Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E; Klein Christian; Lozach Olivier; Meijer Laurent  
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Egypt.. ahabadi@yahoo.com  
SOURCE: European journal of medicinal chemistry, (2006 Mar) Vol. 41, No. 3, pp. 296-305. Electronic Publication: 2006-02-21.  
Journal code: 0420510. ISSN: 0223-5234.  
PUB. COUNTRY: France  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200609  
ENTRY DATE: Entered STN: 13 May 2006  
Last Updated on STN: 30 Sep 2006  
Entered Medline: 29 Sep 2006

AN 2006264196 MEDLINE  
DN PubMed ID: 16494969  
TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.  
AU Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E; Klein Christian; Lozach Olivier; Meijer Laurent  
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Egypt.. ahabadi@yahoo.com  
SO European journal of medicinal chemistry, (2006 Mar) Vol. 41, No. 3, pp. 296-305. Electronic Publication: 2006-02-21.  
Journal code: 0420510. ISSN: 0223-5234.  
CY France  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Priority Journals  
EM 200609  
ED Entered STN: 13 May 2006  
Last Updated on STN: 30 Sep 2006  
Entered Medline: 29 Sep 2006  
AB Several analogues of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or the appropriate haloisatin with some amino acids or histamine under neutral conditions. All the imino derivatives produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and GSK3alpha/beta. Most of the histidine derivatives showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3alpha/beta. So, the management of the carboxyl function may be a tool to impart selectivity in such family of

kinases. Docking of 2-[[5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-imidazol-2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration. Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases.

CT \*Angiogenesis Inhibitors: CS, chemical synthesis  
 Angiogenesis Inhibitors: CH, chemistry  
 Angiogenesis Inhibitors: PD, pharmacology  
 \*Antineoplastic Agents: CS, chemical synthesis  
 Antineoplastic Agents: CH, chemistry  
 Antineoplastic Agents: PD, pharmacology  
 Cell Line  
 Cell Proliferation: DE, drug effects  
 Drug Screening Assays, Antitumor  
 Endothelial Cells: DE, drug effects  
 Histidine: AA, analogs & derivatives  
 Histidine: CS, chemical synthesis  
 Histidine: PD, pharmacology  
 Humans  
 Indoles: CS, chemical synthesis  
 \*Indoles: CH, chemistry  
 \*Indoles: PD, pharmacology  
 Inhibitory Concentration 50  
 Isatin: AA, analogs & derivatives  
 Isatin: CH, chemistry  
 Models, Molecular  
 Molecular Structure  
 Protein Kinase Inhibitors: CS, chemical synthesis  
 \*Protein Kinase Inhibitors: CH, chemistry  
 \*Protein Kinase Inhibitors: PD, pharmacology  
 Umbilical Veins: CY, cytology  
 RN 61-71-2 (3-hydroxy-2-oxoindole); 71-00-1 (Histidine); 91-56-5 (Isatin)  
 CN 0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (Indoles); 0 (Protein Kinase Inhibitors)

L15 ANSWER 5 OF 7 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2006190028 EMBASE  
 TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.  
 AUTHOR: Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.  
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini street, Cairo, 11562, Egypt. ahabadi@yahoo.com  
 AUTHOR: Klein, Christian  
 CORPORATE SOURCE: Pharmaceutical and Medicinal Chemistry, Saarland

AUTHOR: University, P.O. Box 151150, D-66041 Saarbrücken, Germany.  
 Lozach, Olivier; Meijer, Laurent  
 CORPORATE SOURCE: CNRS, Station Biologique, BP 74, 29682 Roscoff cedex,  
 France.  
 SOURCE: European Journal of Medicinal Chemistry, (Mar 2006) Vol.  
 41, No. 3, pp. 296-305.  
 Refs: 45  
 ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5  
 PUBLISHER IDENT.: S 0223-5234(06)00020-1  
 COUNTRY: France  
 DOCUMENT TYPE: Journal; Article  
 FILE SEGMENT: 030 Clinical and Experimental Pharmacology  
 037 Drug Literature Index  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 6 Jun 2006  
 Last Updated on STN: 6 Jun 2006  
 AN 2006190028 EMBASE  
 TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as  
 kinase inhibitors, anticancer and antiangiogenic agents.  
 AU Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.; Abdel-Rahman, Doaa  
 E.  
 CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo  
 University, Kasr El-Aini street, Cairo, 11562, Egypt. ahabadi@yahoo.com  
 AU Klein, Christian  
 CS Pharmaceutical and Medicinal Chemistry, Saarland University, P.O. Box  
 151150, D-66041 Saarbrücken, Germany.  
 AU Lozach, Olivier; Meijer, Laurent  
 CS CNRS, Station Biologique, BP 74, 29682 Roscoff cedex, France.  
 SO European Journal of Medicinal Chemistry, (Mar 2006) Vol. 41, No. 3, pp.  
 296-305.  
 Refs: 45  
 ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5  
 PUI S 0223-5234(06)00020-1  
 CY France  
 DT Journal; Article  
 FS 030 Clinical and Experimental Pharmacology  
 037 Drug Literature Index  
 LA English  
 SL English  
 ED Entered STN: 6 Jun 2006  
 Last Updated on STN: 6 Jun 2006  
 AB Several analogues of the 3-substituted-2-oxoindole chemotype were  
 synthesized by condensing isatin or the appropriate haloisatin with some  
 amino acids or histamine under neutral conditions. All the imino  
 derivatives produced were tested for kinase inhibitory properties against  
 three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and  
 GSK3 $\alpha/\beta$ . Most of the histidine derivatives showed inhibitory  
 properties to the three kinases in the low micromolar range. The  
 histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25  
 and totally inactive against GSK3 $\alpha/\beta$ . So, the management of  
 the carboxyl function may be a tool to impart selectivity in such family  
 of kinases. Docking of 2-[[5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-  
 imidazol-2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound  
 can interact with the enzyme through four hydrogen bonds; for GSK3 $\beta$ ,  
 the ligand poses itself in another orientation, also four hydrogen bonds  
 can be formed between the ligand and the receptor, otherwise hydrophobic  
 interactions seem to predominate. Also, all the final compounds were  
 tested for their in vitro antitumor properties against MCF7 (breast),  
 NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the  
 synthesized compounds was cytotoxic at 10<sup>-4</sup> molar concentration.

Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. .COPYRGT. 2006 Elsevier SAS. All rights reserved.

CT Medical Descriptors:

antiangiogenic activity  
antineoplastic activity  
article  
breast cell  
bromination  
cancer cell culture  
cell migration  
cell proliferation  
central nervous system  
concentration (parameters)  
controlled study  
cytotoxicity  
drug synthesis  
endothelium cell  
enzyme inhibition  
human  
human cell  
hydrogen bond  
hydrophobicity  
lung alveolus cell  
polymerization  
protein family  
protein protein interaction  
umbilical vein

CT Drug Descriptors:

2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development  
2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: DV, drug development  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: PD, pharmacology  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: DV, drug development  
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: PD, pharmacology  
2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development  
2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology  
2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development  
2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology  
2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development  
2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology



acid : PD, pharmacology  
 3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: DV,  
 drug development  
 3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: PD,  
 pharmacology  
 3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: DV, drug  
 development  
 3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: PD, pharmacology  
 3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: DV, drug  
 development  
 3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: PD, pharmacology  
 3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: DV, drug development  
 3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: PD, pharmacology  
 3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: DV, drug  
 development  
 3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: PD, pharmacology  
 3 methyl 2 (2 oxoindolin 3 ylideneamino)butanoic acid: DV, drug  
 development  
 3 methyl 2 (2 oxoindolin 3 ylideneamino)butanoic acid: PD, pharmacology  
 amino acid  
 \*angiogenesis inhibitor: DV, drug development  
 \*angiogenesis inhibitor: PD, pharmacology  
 \*antineoplastic agent: DV, drug development  
 \*antineoplastic agent: PD, pharmacology  
 carboxyl group  
 cyclin B  
 cyclin dependent kinase 1  
 cyclin dependent kinase 5  
 histamine  
 histamine derivative  
 histidine derivative  
 \*indole derivative: DV, drug development  
 \*indole derivative: PD, pharmacology  
 isatin  
 \*phosphotransferase inhibitor: DV, drug development  
 \*phosphotransferase inhibitor: PD, pharmacology  
 propionic acid derivative: DV, drug development  
 propionic acid derivative: PD, pharmacology  
 protein p25  
 protein serine threonine kinase  
 unclassified drug  
 unindexed drug  
 RN (amino acid) 65072-01-7; (histamine) 51-45-6, 56-92-8, 93443-21-1;  
 (isatin) 91-56-5

L15 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2006:437778 BIOSIS  
 DOCUMENT NUMBER: PREV200600440686  
 TITLE: Synthesis of 3-substituted-2-oxoindolin analogues and their  
 evaluation as kinase inhibitors, anticancer and  
 antiangiogenic agents.  
 AUTHOR(S): Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.;  
 Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier;  
 Meijer, Laurent  
 CORPORATE SOURCE: Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini  
 St, Cairo 11562, Egypt  
 ahabadi@yahoo.com  
 SOURCE: European Journal of Medicinal Chemistry, (MAR 2006) Vol.  
 41, No. 3, pp. 296-305.  
 CODEN: EJMCA5. ISSN: 0223-5234.  
 DOCUMENT TYPE: Article

LANGUAGE: English  
ENTRY DATE: Entered STN: 6 Sep 2006  
Last Updated on STN: 6 Sep 2006

AN 2006:437778 BIOSIS

DN PREV200600440686

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.

AU Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CS Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini St, Cairo 11562, Egypt

ahabadi@yahoo.com

SO European Journal of Medicinal Chemistry, (MAR 2006) Vol. 41, No. 3, pp. 296-305.

CODEN: EJMCAS. ISSN: 0223-5234.

DT Article

LA English

ED Entered STN: 6 Sep 2006

Last Updated on STN: 6 Sep 2006

AB Several analogues of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or the appropriate haloisatin with some amino acids or histamine under neutral conditions. All the imino derivatives produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDKI/cyclin B, CDK5/p25 and GSK alpha/beta. Most of the histidine derivatives showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivatives were less potent against CDKI/cyclin B and CDK5/p25 and totally inactive against GSU alpha/beta. So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of 2-[(5-bromo-2-oxoindolin-3-ylidene)amino)-3-[(H-imidazol-2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3 beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration. Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. (c) 2006 Elsevier SAS. All rights reserved.

CC Cytology - Human 02508

Biochemistry studies - Proteins, peptides and amino acids 10064

Enzymes - General and comparative studies: coenzymes 10802

Pathology - Therapy 12512

Respiratory system - Physiology and biochemistry 16004

Respiratory system - Pathology 16006

Reproductive system - Physiology and biochemistry 16504

Reproductive system - Pathology 16506

Nervous system - Physiology and biochemistry 20504

Nervous system - Pathology 20506

Pharmacology - General 22002

Neoplasms - Pathology, clinical aspects and systemic effects 24004

Neoplasms - Therapeutic agents and therapy 24008

IT Major Concepts

Pharmaceuticals (Pharmacology); Enzymology (Biochemistry and Molecular

Biophysics); Tumor Biology  
 IT Parts, Structures, & Systems of Organisms  
 breast: reproductive system; lung: respiratory system; glia: nervous system  
 IT Diseases  
 glioblastoma: nervous system disease, neoplastic disease  
 Glioblastoma (MeSH)  
 IT Diseases  
 breast cancer: neoplastic disease, reproductive system disease/female  
 Breast Neoplasms (MeSH)  
 IT Diseases  
 lung cancer: respiratory system disease, neoplastic disease  
 Lung Neoplasms (MeSH)  
 IT Chemicals & Biochemicals  
 histidine; isatin; histamine; threonine kinase; serine kinase;  
 3-substituted-2-oxoindole: synthesis; haloisatin; 2-([5-bromo-2-oxoindolin-3-ylidene]amino)-3-(1H-imidazol-2-yl)propionic acid;  
 CDK1/cyclin B: antineoplastic-drug; CDK5/p25: antineoplastic-drug;  
 GSK-3 alpha/beta [glycogen synthase kinase-3 alpha/beta]:  
 antineoplastic-drug  
 ORGN Classifier  
 Hominidae 86215  
 Super Taxa  
 Primates; Mammalia; Vertebrata; Chordata; Animalia  
 Organism Name  
 MCF-7 cell line (cell\_line): human breast cancer cells  
 NCI-H460 cell line (cell\_line): human lung cancer cells  
 SF268 cell line (cell\_line): human glioblastoma cells  
 HUVECs cell line (cell\_line): human umbilical vein endothelial cells  
 Taxa Notes  
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates  
 RN 4998-57-6 (histidine)  
 91-56-5 (isatin)  
 51-45-6 (histamine)  
 9026-43-1 (serine kinase)

L15 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2005:450611 BIOSIS  
 DOCUMENT NUMBER: PREV200510241116  
 TITLE: Comparison of the antiinflammatory effects of Drosera rotundifolia and Drosera madagascariensis in the HET-CAM assay.  
 AUTHOR(S): Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela; Krenn, Liselotte [Reprint Author]  
 CORPORATE SOURCE: Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090 Vienna, Austria  
 liselotte.krenn@univie.ac.at  
 SOURCE: PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp. 323-326.  
 ISSN: 0951-418X.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 3 Nov 2005  
 Last Updated on STN: 3 Nov 2005  
 AN 2005:450611 BIOSIS  
 DN PREV200510241116  
 TI Comparison of the antiinflammatory effects of Drosera rotundifolia and Drosera madagascariensis in the HET-CAM assay.  
 AU Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela; Krenn, Liselotte [Reprint Author]  
 CS Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090 Vienna, Austria

liselotte.krenn@univie.ac.at  
 SO PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp. 323-326.  
 ISSN: 0951-418X.  
 DT Article  
 LA English  
 ED Entered STN: 3 Nov 2005  
 Last Updated on STN: 3 Nov 2005  
 AB The antinflammatory effects of ethanol and aqueous extracts from *Drosera rotundifolia* and from *Drosera madagascariensis* were compared in vivo in the HET-CAM assay. Both extracts from *D. rotundifolia* and the ethanol extract from *D. madagascariensis* showed remarkable efficacy at doses of 500 µg/pellet. The inhibition of the inflammation by the extracts was stronger than that by 50 µg hydrocortisone/pellet. In contrast, there was only a very weak effect observed at a dose of 500 µg/pellet of the water extract from *D. madagascariensis*. The chemical analyses of the extracts showed that the effect cannot be attributed to naphthoquinones, but might be due to flavonoids. Ellagic acid obviously plays an important role in the antiangiogenic effect of the *Drosera* extracts.  
 Copyright (c) 2005 John Wiley & Sons, Ltd.  
 CC Biochemistry studies - General 10060  
 Pathology - Therapy 12512  
 Pharmacology - Connective tissue, bone and collagen-acting drugs 22012  
 Pharmacology - Immunological processes and allergy 22018  
 Pharmacognosy and pharmaceutical botany 54000  
 IT Major Concepts  
 Methods and Techniques; Pharmacognosy (Pharmacology)  
 IT Chemicals & Biochemicals  
 flavonoids; ellagic acid; naphthoquinone; ethanol extract;  
 antiinflammatory-drug, immunologic-drug, dosage, crude drug, efficacy,  
 inhibition; aqueous extract: antiinflammatory-drug, immunologic-drug,  
 dosage, crude drug, efficacy, inhibition  
 IT Methods & Equipment  
 hen's egg test-chorioallantoic membrane assay: laboratory techniques  
 IT Miscellaneous Descriptors  
 antiinflammatory effect  
 ORGN Classifier  
 Droseraceae 25990  
 Super Taxa  
 Dicotyledones; Angiospermae; Spermatophyta; Plantae  
 Organism Name  
*Drosera madagascariensis* (species): medicinal plant  
*Drosera rotundifolia* (species): medicinal plant  
 Taxa Notes  
 Angiosperms, Dicots, Plants, Spermatophytes, Vascular Plants  
 RN 476-66-4 (ellagic acid)  
 130-15-4 (naphthoquinone)

=> s 1,1"-Phenanthroline-5,6-dione  
 MISMATCHED QUOTE '1,1"-PHENANTHR'  
 Quotation marks (or apostrophes) must be used in pairs,  
 one before and one after the expression you are setting  
 off or masking.

=> s "1,10-Phenanthroline-5,6-dione"  
 L16 587 "1,10-PHENANTHROLINE-5,6-DIONE"

=> s l16 and phenanthrene  
 L17 4 L16 AND PHENANTHRENE

=> d l17 1-4 hitstr ibib all

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:943703 CAPLUS

DOCUMENT NUMBER: 147:117706

TITLE: Product class 6: phenanthrene-9,10-diones, stilbenequinones, diphenoquinones, and related ring assemblies

AUTHOR(S): Echavarren, A. M.; Porcel, S.

CORPORATE SOURCE: Institute of Chemical Research of Catalonia (ICIQ), Tarragona, 43007, Spain

SOURCE: Science of Synthesis (2006), 28, 507-560

CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AN 2006:943703 CAPLUS

DN 147:117706

ED Entered STN: 14 Sep 2006

TI Product class 6: phenanthrene-9,10-diones, stilbenequinones, diphenoquinones, and related ring assemblies

AU Echavarren, A. M.; Porcel, S.

CS Institute of Chemical Research of Catalonia (ICIQ), Tarragona, 43007, Spain

SO Science of Synthesis (2006), 28, 507-560

CODEN: SSCYJ9

PB Georg Thieme Verlag

DT Journal; General Review

LA English

CC 21-0 (General Organic Chemistry)

AB A review of methods to prepare phenanthrene-9,10-diones, stilbenequinones, diphenoquinones, and related ring assemblies.

ST review phenanthrenedione analog prepn; stilbenequinone analog prepn review; diphenoquinone analog prepn review

IT Quinones

RL: SPN (Synthetic preparation); PREP (Preparation)

(review preparation of phenanthrenedione, stilbenequinones, diphenoquinones, and related ring analogs)

IT 141-78-6, Acetic acid ethyl ester, uses 536-80-1

RL: CAT (Catalyst use); USES (Uses)

(review preparation of phenanthrenedione, stilbenequinones, diphenoquinones, and related ring analogs)

IT 56-53-1 66-71-7, 1,10-Phenanthroline 67-64-1, 2-Propanone, reactions

78-94-4, 3-Buten-2-one, reactions 85-01-8, Phenanthrene,

reactions 85-02-9, Benzo[f]quinoline 85-97-2 87-65-0 91-10-1

92-88-6, [1,1'-Biphenyl]-4,4'-diol 93-58-3 93-89-0 94-08-6 99-75-2

100-42-5, reactions 110-18-9 128-38-1 128-39-2 129-00-0, Pyrene,

reactions 134-81-6 230-27-3, Benzo[h]quinoline 484-11-7 527-60-6

554-34-7 576-26-1 584-03-2, 1,2-Butanediol 603-35-0, reactions

604-95-5 617-04-9 951-06-4 1068-47-9 1188-33-6 1519-46-6

1576-69-8 1629-58-9, 1-Penten-3-one 1879-09-0 2078-54-8 2219-82-1

2416-98-0 2417-04-1 2432-11-3, [1,1':3',1''-Terphenyl]-2'-ol

2950-01-8 3011-45-8 3697-13-0, 1,7-Phenanthroline-6-ol 4344-45-0

4844-17-1 5398-75-4 5417-63-0 5807-64-7 7693-47-2 13388-73-3

14328-91-7 14970-83-3 15058-36-3 17755-10-1 20185-55-1

21509-95-5 24300-91-2 24415-26-7, 1-Nonen-3-one 24620-40-4

24909-10-2 27018-91-3, 4H-Cyclopenta[def]phenanthrene

-8,9-dione 28622-70-0 28713-50-0 29176-55-4 38256-25-6

40152-05-4 40352-56-5 53622-33-6 54258-41-2, 1,10-Phenanthroline-5-

amine 58245-82-2 65564-60-5 70005-88-8 73049-18-0 74825-06-2

74825-07-3 74825-08-4 74825-09-5 74825-11-9 74825-12-0

74825-13-1 78891-39-1 78939-36-3 80232-65-1 80721-43-3

84405-44-7 85575-93-5 92346-53-7 92599-23-0 95912-03-1  
 98126-29-5 99248-71-2 100125-12-0 102420-54-2 124974-15-8  
 127753-94-0 138145-24-1 138145-26-3 138145-28-5 139975-70-5  
 152660-60-1 153399-67-8 155587-64-7 155587-72-7 155587-84-1  
 156235-29-9 156235-35-7 156235-36-8 176956-19-7 176956-23-3  
 176956-24-4 176956-29-9 188677-27-2 188677-28-3 188677-29-4  
 188677-30-7 190127-31-2 206200-31-9 206200-32-0 216657-09-9  
 268538-85-8 336184-07-7 682750-08-9 682750-11-4 682750-15-8  
 682750-26-1 697299-12-0 791637-63-3 791637-64-4 791637-65-5  
 837421-16-6 855360-67-7 872809-85-3 943126-95-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 84-11-7P, 9,10-Phenanthrenedione 128-37-0P, preparation 809-73-4P  
 2607-52-5P 5664-37-9P 6217-22-7P, 4,5-Pyrenedione 6546-78-7P  
 60373-53-7P 60373-54-8P 72909-34-3P 74447-88-4P 78939-38-5P  
 78939-39-6P 78939-40-9P 92346-54-8P 92346-55-9P 95912-14-4P  
 98126-30-8P 99248-72-3P 99248-73-4P 121793-75-7P 139975-66-9P  
 142422-23-9P 142422-24-0P 161470-06-0P 190127-32-3P 524746-74-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 84-12-8P, 4,7-Phenanthroline-5,6-dione 96-09-3P 110-01-0P 215-58-7P,  
 Benzo[h]triphenylene 482-05-3P, [1,1'-Biphenyl]-2,2'-dicarboxylic acid  
 493-74-3P 494-72-4P 604-84-2P, 9,10-Phenanthrenediol 1072-43-1P  
 1498-99-3P 1516-94-5P 1613-51-0P 1620-98-0P 2178-51-0P  
 2179-51-3P 2455-14-3P 3457-53-2P 3550-01-4P 4906-22-3P  
 6787-57-1P 13421-38-0P 13693-18-0P 14328-90-6P 14387-17-8P  
 17816-26-1P 17816-27-2P 17825-35-3P 20246-79-1P 20851-85-8P  
 21736-38-9P 24378-09-4P 27318-90-7P, 1,10-

Phenanthroline-5,6-dione

27728-29-6P 35495-11-5P 36909-24-7P 39250-93-6P 54389-66-1P  
 54389-67-2P 58856-98-7P 59869-79-3P 60373-56-0P 60566-01-0P  
 65938-98-9P, Benzo[h]quinoline-5,6-dione 65938-99-0P,  
 Benzo[f]quinoline-5,6-dione 66788-08-7P, Benzo[e]pyrene-4,5-dione  
 67080-37-9P 69097-25-2P 73030-04-3P 73049-19-1P 74809-56-6P  
 74809-57-7P 74809-58-8P 74809-59-9P 74809-60-2P 74809-61-3P  
 74825-14-2P 80721-44-4P 82701-91-5P, 1,7-Phenanthroline-5,6-dione  
 84405-38-9P 92599-27-4P 99248-74-5P 99419-91-7P 99420-18-5P  
 99520-63-5P, Indeno[1,2,3-cd]pyrene-1,2-dione 102331-54-4P  
 102331-58-8P 108744-18-9P 113736-80-4P 117745-54-7P 121793-76-8P  
 137936-95-9P 139220-15-8P 139975-73-8P 139975-74-9P 139975-75-0P  
 141622-77-7P 142422-22-8P 143255-68-9P, 4H-

Benzo[b]cyclopenta[jkl]triphenylene 147120-00-1P 153399-73-6P

153399-74-7P 153399-75-8P 155306-04-0P 155587-66-9P 155587-67-0P  
 155587-81-8P 156235-18-6P 156235-19-7P 157488-04-5P 176956-25-5P  
 180999-63-7P 180999-65-9P 180999-67-1P 180999-68-2P 188677-34-1P  
 188677-35-2P 188677-36-3P 188677-37-4P 190127-36-7P 215674-97-8P  
 216656-90-5P 336184-12-4P 337312-91-9P 337312-93-3P 337312-94-4P  
 337312-95-5P 337312-96-6P 337312-97-7P 337312-98-8P 379711-32-7P  
 602331-25-9P 682749-93-5P 682749-96-8P 682749-99-1P 704860-92-4P  
 791637-66-6P 791637-67-7P 791637-69-9P 791637-70-2P 837421-17-7P  
 943126-96-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

RE.CNT 229 THERE ARE 229 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

(1) Abul-Hajj, Y; J Am Chem Soc 1995, V117, P5600 CAPLUS  
 (2) Altwickier, E; Chem Rev 1967, V67, P475 CAPLUS

- (3) Amouyal, E; J Chem Soc, Dalton Trans 1990, P1841 CAPLUS
- (4) Andres, J; J Am Chem Soc 1995, V117, P8807 CAPLUS
- (5) Anthony, C; Biochim Biophys Acta 2003, V1647, P18 CAPLUS
- (6) Azuma, J; JP 2003270821 2003 CAPLUS
- (7) Bacon, R; Chem Commun 1967, P977 CAPLUS
- (8) Badesha, S; US 5166016 1992 CAPLUS
- (9) Balog, V; J Org Chem 1971, V36, P1339
- (10) Balogh-Hergovich, E; Synthesis 1982, P731 CAPLUS
- (11) Basavalaiah, D; Tetrahedron Lett 2001, V42, P1147 CAPLUS
- (12) Bauer, R; Tetrahedron 1963, V19, P1201 CAPLUS
- (13) Becker, H; J Org Chem 1965, V30, P982 CAPLUS
- (14) Becker, H; J Org Chem 1982, V47, P1095 CAPLUS
- (15) Becker, H; Tetrahedron Lett 1976, P4883 CAPLUS
- (16) Bedell, S; J Am Chem Soc 1985, V107, P7909 CAPLUS
- (17) Benjamin, B; J Org Chem 1978, V43, P2986 CAPLUS
- (18) Bing, Y; Tetrahedron Lett 2004, V45, P6361 CAPLUS
- (19) Bodine, R; J Org Chem 1978, V43, P4025 CAPLUS
- (20) Bolton, J; Chem Res Toxicol 2000, V13, P135 CAPLUS
- (21) Bonhote, P; Synlett 1997, P897 CAPLUS
- (22) Bora, U; Tetrahedron 2001, V57, P2445 CAPLUS
- (23) Braven, J; J Heterocycl Chem 1995, V32, P1051 CAPLUS
- (24) Brink, G; J Org Chem 2001, V66, P2429
- (25) Brooks, H; Biochemistry 1993, V32, P2725 CAPLUS
- (26) Bruce, J; J Chem Soc, Perkin Trans 1 1974, P295 CAPLUS
- (27) Buchi, G; J Am Chem Soc 1985, V107, P5555 CAPLUS
- (28) Byrne, L; J Chem Soc, Perkin Trans 1 1982, P2855 CAPLUS
- (29) Chae, K; Steroids 1998, V63, P149 CAPLUS
- (30) Cho, A; Aerosol Sci Technol 2004, V38(Suppl 1), P68
- (31) Cisek, J; Tetrahedron Lett 2004, V45, P2801
- (32) Cook, C; J Am Chem Soc 1955, V77, P1783 CAPLUS
- (33) Cook, C; J Org Chem 1953, V18, P261 CAPLUS
- (34) Corey, E; J Am Chem Soc 1981, V103, P5599 CAPLUS
- (35) Cosgrove, S; J Chem Soc 1951, P388 CAPLUS
- (36) Cozzi, F; Org Biomol Chem 2003, V1, P157 CAPLUS
- (37) Crivello, J; J Org Chem 1981, V46, P3056 CAPLUS
- (38) DaRooge, M; J Org Chem 1967, V32, P1 CAPLUS
- (39) Davidson, V; Biochem J 1995, V308, P487 CAPLUS
- (40) Davidson, V; Biochemistry 1992, V31, P3385 CAPLUS
- (41) Dekker, R; Eur J Biochem 1982, V125, P69 CAPLUS
- (42) Denes, V; J Prakt Chem 1976, V318, P459 CAPLUS
- (43) Dickeson, G; Aust J Chem 1970, V23, P1023
- (44) Douglas, N; Synlett 1996, P793 CAPLUS
- (45) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (46) Dudley, K; J Org Chem 1967, V32, P3210 CAPLUS
- (47) Duine, J; J Biosci Bioeng 1999, V88, P231 CAPLUS
- (48) Eckert, T; J Am Chem Soc 1983, V105, P4431 CAPLUS
- (49) Edlmann, M; Helv Chim Acta 2002, V85, P2195 CAPLUS
- (50) Edge, M; Polym Degrad Stab 1996, V53, P141 CAPLUS
- (51) Firouzabadi, H; Synthesis 1986, P285 CAPLUS
- (52) Firouzabadi, H; Synthesis 1986, P946 CAPLUS
- (53) Firouzabadi, H; Tetrahedron 1986, V42, P719 CAPLUS
- (54) Flowers-Geary, L; Chem-Biol Interact 1996, V99, P55 CAPLUS
- (55) Foster, E; Chem Commun (Cambridge) 2004, P2052 CAPLUS
- (56) Fouchard, D; J Org Chem 2004, V69, P2626 CAPLUS
- (57) Fujiyama, H; J Catal 1999, V188, P417 CAPLUS
- (58) Fukuzumi, S; J Am Chem Soc 2000, V122, P8435 CAPLUS
- (59) Gainor, J; J Org Chem 1981, V46, P4317 CAPLUS
- (60) Gainor, J; J Org Chem 1982, V47, P2833 CAPLUS
- (61) Garas, A; J Heterocycl Chem 2000, V37, P151 CAPLUS
- (62) Ge, Y; J Org Chem 2000, V65, P8831 CAPLUS
- (63) Goh, S; J Am Chem Soc 1973, V95, P242 CAPLUS

(64) Guo, H; Res Chem Intermed 1992, V17, P137 CAPLUS  
 (65) Gupta, R; Tetrahedron Lett 2000, V41, P7763 CAPLUS  
 (66) Hatchard, W; J Am Chem Soc 1958, V80, P3640  
 (67) Hav, A; US 3210384 1965 CAPLUS  
 (68) Hebri, H; Synlett 1991, P901 CAPLUS  
 (69) Hendrickson, J; J Org Chem 1982, V47, P1148 CAPLUS  
 (70) Hendrickson, J; J Org Chem 1985, V50, P1688 CAPLUS  
 (71) Hense, A; J Chem Soc, Perkin Trans 1 1997, P2023 CAPLUS  
 (72) Hewgill, F; J Chem Soc, Perkin Trans 1 1983, P131 CAPLUS  
 (73) Hewitt, D; J Chem Soc C 1971, P2967 CAPLUS  
 (74) Higashimura, H; JP 2002030026 2002 CAPLUS  
 (75) Higuchi, T; J Am Chem Soc 1995, V117, P8879 CAPLUS  
 (76) Hiort, C; J Am Chem Soc 1993, V115, P3448 CAPLUS  
 (77) Hirano, M; Bull Chem Soc Jpn 1991, V64, P1434 CAPLUS  
 (78) Hirao, T; Tetrahedron Lett 1990, V31, P6039 CAPLUS  
 (79) Horhold, H; Z Chem 1987, V27, P438  
 (80) Hu, J; J Org Chem 2005, V70, P707 CAPLUS  
 (81) Husain, M; Biochemistry 1987, V26, P4139 CAPLUS  
 (82) Hyun, Y; Biochemistry 1995, V34, P816 CAPLUS  
 (83) Imor, S; Synth Commun 1996, V26, P2197 CAPLUS  
 (84) Ishida, T; J Am Chem Soc 1989, V111, P6822 CAPLUS  
 (85) Ishida, T; J Am Chem Soc 1995, V117, P3278 CAPLUS  
 (86) Itoh, S; J Am Chem Soc 1993, V115, P9960 CAPLUS  
 (87) Itoh, S; J Am Chem Soc 1997, V119, P439 CAPLUS  
 (88) Itoh, S; J Chem Soc, Perkin Trans 2 1992, P1245 CAPLUS  
 (89) Itoh, S; J Org Chem 1992, V57, P2788 CAPLUS  
 (90) Itoh, S; J Org Chem 1992, V57, P4452 CAPLUS  
 (91) Itoh, S; J Org Chem 1996, V61, P8967 CAPLUS  
 (92) Iwai, K; Chem Lett 2003, V32, P58 CAPLUS  
 (93) Jacob, J; Inorg Chim Acta 1998, V270, P55 CAPLUS  
 (94) Jagannandan, I; J Pharm Sci 1979, V68, P916 CAPLUS  
 (95) Jerussi, R; J Org Chem 1970, V35, P2105 CAPLUS  
 (96) Jayaraman, R; J Am Chem Soc 1984, V106, P2462 CAPLUS  
 (97) Jungclauss, G; Environ Sci Technol 1978, V12, P88 CAPLUS  
 (98) Kaplan, G; WO 2004018401 2004 CAPLUS  
 (99) Karnes, H; J Am Chem Soc 1968, V90, P458 CAPLUS  
 (100) Kasahara, T; Nature (London) 2003, V422, P832 CAPLUS  
 (101) Kawase, M; Tetrahedron 1989, V45, P1653 CAPLUS  
 (102) Kay, C; J Am Chem Soc 2005, V127, P7974 CAPLUS  
 (103) Kelly, J; J Org Chem 1986, V51, P4473 CAPLUS  
 (104) Kessler, H; Tetrahedron Lett 1966, P5257 CAPLUS  
 (105) Kikuchi, N; JP 9281728 1997 CAPLUS  
 (106) Kikuchi, N; JP 9281729 1997 CAPLUS  
 (107) Kikugawa, Y; Tetrahedron Lett 1988, V29, P4297 CAPLUS  
 (108) Kitahara, Y; Tetrahedron 1997, V53, P6001 CAPLUS  
 (109) Kitajima, N; J Am Chem Soc 1990, V112, P8833 CAPLUS  
 (110) Kloc, K; J Prakt Chem 1977, V319, P959 CAPLUS  
 (111) Komissarov, V; Izv Akad Nauk SSSR, Ser Khim 1991, V5, P1121  
 (112) Konig, K; Chem Ber 1960, V93, P554 CAPLUS  
 (113) Kovarova, J; Can J Chem 1995, V73, P1862 CAPLUS  
 (114) Kuhn, R; Chem Ber 1950, V83, P412  
 (115) Kumagai, Y; Free Radical Biol Med 1997, V22, P479 CAPLUS  
 (116) Kuwabata, S; J Am Chem Soc 1994, V116, P5437 CAPLUS  
 (117) Lantos, I; Tetrahedron Lett 1978, P2761 CAPLUS  
 (118) Lehr, R; J Org Chem 1978, V43, P3462 CAPLUS  
 (119) Leventhal, B; Food Sci 1976, V41, P467 CAPLUS  
 (120) Levin, J; J Org Chem 1984, V49, P4325 CAPLUS  
 (121) Levin, R; US 6080518 2000 CAPLUS  
 (122) Li, N; Environ Health Perspect 2003, V111, P455 CAPLUS  
 (123) Lin, L; US 2004096761 2004 CAPLUS  
 (124) Linsker, F; J Am Chem Soc 1946, V68, P403 CAPLUS



(125) Lissel, M; Tetrahedron Lett 1992, V33, P1795 CAPLUS  
 (126) Loy, B; J Org Chem 1966, V31, P2386 CAPLUS  
 (127) Magnusson, O; J Am Chem Soc 2004, V126, P5342 CAPLUS  
 (128) Magnusson, R; Acta Chem Scand 1966, V20, P2211 CAPLUS  
 (129) Mahjoub, A; Tetrahedron Lett 2003, V44, P4555 CAPLUS  
 (130) Mahoney, L; J Am Chem Soc 1967, V89, P5619 CAPLUS  
 (131) Margiotta, N; Inorg Chim Acta 2004, V357, P149 CAPLUS  
 (132) Martin, P; Helv Chim Acta 1994, V77, P100 CAPLUS  
 (133) Martin, P; Helv Chim Acta 1994, V77, P111 CAPLUS  
 (134) Matsuse, T; JP 6027693 1994 CAPLUS  
 (135) McLachlan, J; Steroids 1979, V33, P543 CAPLUS  
 (136) Meier, H; Eur J Org Chem 2001, P779 CAPLUS  
 (137) Menger, F; J Org Chem 1985, V50, P3927 CAPLUS  
 (138) Mervic, M; J Org Chem 1980, V45, P4720 CAPLUS  
 (139) Mincey, T; Biochemistry 1981, V20, P7502 CAPLUS  
 (140) Mirifico, M; J Electroanal Chem 2004, V566, P7 CAPLUS  
 (141) Miyamoto, E; JP 2002148834 2002 CAPLUS  
 (142) Mohr, B; J Org Chem 1994, V59, P635 CAPLUS  
 (143) Moore, R; J Chem Soc 1954, P243 CAPLUS  
 (144) Moriarty, R; Tetrahedron Lett 1975, P2557 CAPLUS  
 (145) Mure, M; Acc Chem Res 2004, V37, P131 CAPLUS  
 (146) Musgrave, O; J Chem Soc D 1970, P1461 CAPLUS  
 (147) Nakamori, H; EP 0591010 1994 CAPLUS  
 (148) Neureiter, N; J Org Chem 1963, V28, P3486 CAPLUS  
 (149) Nishino, H; J Chem Soc, Perkin Trans 2 1999, P1919 CAPLUS  
 (150) Noar, J; J Am Chem Soc 1985, V107, P7198 CAPLUS  
 (151) Nyquist, E; J Heterocycl Chem 1967, P539 CAPLUS  
 (152) Obare, S; Inorg Chem 2001, V40, P6080 CAPLUS  
 (153) Ohkura, K; JP 2000204083 2000 CAPLUS  
 (154) Okubo, H; J Org Chem 2001, V66, P557 CAPLUS  
 (155) Omura, K; J Am Oil Chem Soc 1992, V69, P461 CAPLUS  
 (156) Omura, K; J Am Oil Chem Soc 1995, V72, P1565 CAPLUS  
 (157) Omura, K; J Org Chem 1984, V49, P3046 CAPLUS  
 (158) Omura, K; J Org Chem 1991, V56, P921 CAPLUS  
 (159) Omura, K; J Org Chem 1992, V57, P306 CAPLUS  
 (160) Oyaizu, K; Chem Lett 2000, P1318 CAPLUS  
 (161) O'Brien, P; Chem-Biol Interact 1991, V80, P1 CAPLUS  
 (162) Pandey, G; IN 180089 1989 CAPLUS  
 (163) Pandey, G; Tetrahedron Lett 1990, V31, P3771 CAPLUS  
 (164) Paruch, K; J Org Chem 2000, V65, P7602 CAPLUS  
 (165) Pascal, R; J Am Chem Soc 1987, V109, P4660 CAPLUS  
 (166) Paw, W; Inorg Chem 1997, V36, P2287 CAPLUS  
 (167) Pelter, A; Tetrahedron Lett 1988, V29, P677 CAPLUS  
 (168) Plietker, B; Org Biomol Chem 2004, V2, P1116 CAPLUS  
 (169) Pospisil, J; Polym Degrad Stab 2002, V78, P251 CAPLUS  
 (170) Putala, M; Tetrahedron: Asymmetry 2001, V12, P3333  
 (171) Qian, W; J Am Chem Soc 2000, V122, P8333 CAPLUS  
 (172) Rabinovitz, M; J Org Chem 1987, V52, P3472  
 (173) Ranganathan, S; Tetrahedron 1984, V40, P3145 CAPLUS  
 (174) Ranganathan, S; Tetrahedron Lett 1985, V26, P4955 CAPLUS  
 (175) Rayne, S; Photochem Photobiol Sci 2005, P876 CAPLUS  
 (176) Rebelo, S; Chem Commun (Cambridge) 2004, P608 CAPLUS  
 (177) Rice, J; J Org Chem 1986, V51, P2428 CAPLUS  
 (178) Rockcliffe, D; J Chem Soc, Chem Commun 1992, P1758 CAPLUS  
 (179) Rodriguez, C; Chem-Biol Interact 2005, V155, P97 CAPLUS  
 (180) Rodriguez, E; J Am Chem Soc 1989, V111, P7947 CAPLUS  
 (181) Rubin, M; J Org Chem 1980, V45, P1847 CAPLUS  
 (182) Sain, B; Tetrahedron Lett 1994, V35, P5083 CAPLUS  
 (183) Sakamoto, T; J Org Chem 1994, V59, P6859 CAPLUS  
 (184) Salisbury, S; Nature (London) 1979, V280, P843 CAPLUS  
 (185) Schmidt, P; Helv Chim Acta 1957, V40, P350 CAPLUS

- (186) Schroeter, S; J Org Chem 1969, V34, P4012 CAPLUS
- (187) Schuetzle, D; Int J Environ Anal Chem 1981, V9, P93 MEDLINE
- (188) Schulte-Frohlinde, D; Justus Liebigs Ann Chem 1964, V671, P92 CAPLUS
- (189) Seigle, C; Steroids 1984, V43, P529 CAPLUS
- (190) Shimada, H; Chem Res Toxicol 2004, V17, P1145 CAPLUS
- (191) Simandi, L; J Mol Catal A: Chem 1997, V117, P299 CAPLUS
- (192) Sleath, P; J Am Chem Soc 1985, V107, P3328 CAPLUS
- (193) Smith, G; J Org Chem 1947, V12, P781 CAPLUS
- (194) Speck, M; J Chem Soc, Perkin Trans 2 2002, P455 CAPLUS
- (195) Srinivasan, R; Synth Commun 1997, V27, P2057 CAPLUS
- (196) Starnes, W; J Org Chem 1969, V34, P3404 CAPLUS
- (197) Taimr, L; Tetrahedron Lett 1971, P2809 CAPLUS
- (198) Taimr, L; Tetrahedron Lett 1972, P4279 CAPLUS
- (199) Takizawa, Y; J Org Chem 1985, V50, P4383 CAPLUS
- (200) Takuwa, A; J Org Chem 1997, V62, P2658 CAPLUS
- (201) Thomas, R; Carcinogenesis 2004, V25, P787 CAPLUS
- (202) Thomas, R; Int J Mol Med 2001, V7, P389 CAPLUS
- (203) Thomas, R; Oncol Rep 2001, V8, P1035 CAPLUS
- (204) Togashi, D; Synth Commun 1998, V28, P1051 CAPLUS
- (205) Tommasi, L; Inorg Chem 1995, V34, P1514 CAPLUS
- (206) Toshikazu, T; J Org Chem 1983, V48, P4764
- (207) Vakhitova, M; Izv Akad Nauk SSSR, Ser Khim 1987, V8, P1808
- (208) Villemin, D; Synlett 1994, P435
- (209) Vladimir, A; J Am Chem Soc 2001, V123, P5292
- (210) Wan, P; J Chem Soc, Chem Commun 1993, P409
- (211) Wang, X; Tetrahedron Lett 1991, V32, P4883 CAPLUS
- (212) Wang, Z; Angew Chem 2004, V116, P2006
- (213) Wang, Z; Angew Chem Int Ed 2004, V43, P1972 CAPLUS
- (214) Wang, Z; J Am Chem Soc 2004, V126, P7794 CAPLUS
- (215) Warncke, K; J Am Chem Soc 1993, V115, P6464 CAPLUS
- (216) Wenz, G; Makromol Chem, Rapid Commun 1985, V6, P577 CAPLUS
- (217) Wyllie, S; Arch Biochem Biophys 1997, V346, P180 CAPLUS
- (218) Xia, T; Environ Health Perspect 2004, V112, P1347 CAPLUS
- (219) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS
- (220) Yamamoto, T; Macromolecules 2003, V36, P6722 CAPLUS
- (221) Yamazaki, S; Tetrahedron Lett 2001, V42, P3355 CAPLUS
- (222) Yang, C; Synlett 1992, P799 CAPLUS
- (223) Yohe, G; J Am Chem Soc 1953, V75, P2688 CAPLUS
- (224) Young, E; J Org Chem 1998, V63, P9995 CAPLUS
- (225) Zabik, M; J Org Chem 1967, V32, P300 CAPLUS
- (226) Zbiral, E; Monatsh Chem 1964, V95, P512 CAPLUS
- (227) Zhang, J; J Org Chem 1998, V63, P8125 CAPLUS
- (228) Zhang, J; Tetrahedron 1999, V55, P625 CAPLUS
- (229) Zhang, Z; Synthesis 1996, P377 CAPLUS

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:695873 CAPLUS

DOCUMENT NUMBER: 143:183097

TITLE: Contact charging type electrophotographic  
photoconductor showing excellent faulty image  
suppression, process cartridge, and  
electrophotographic apparatus

INVENTOR(S): Nagasaka, Hideaki; Sekido, Kunihiro; Sekiya, Michiyo;  
Miki, Nobumichi; Morikawa, Yosuke

PATENT ASSIGNEE(S): Canon Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005208618	A	20050804	JP 2004-373350	20041224
US 20060292469	A1	20061228	US 2005-159307	20050623
PRIORITY APPLN. INFO.:			JP 2003-434017	A 20031226
OTHER SOURCE(S): MARPAT 143:183097				
AN 2005:695873 CAPLUS				
DN 143:183097				
ED Entered STN: 05 Aug 2005				
TI Contact charging type electrophotographic photoconductor showing excellent faulty image suppression, process cartridge, and electrophotographic apparatus				
IN Nagasaka, Hideaki; Sekido, Kunihiro; Sekiya, Michiyo; Miki, Nobumichi; Morikawa, Yosuke				
PA Canon Inc., Japan				
SO Jpn. Kokai Tokkyo Koho, 44 pp.				
CODEN: JKXXAF				
DT Patent				
LA Japanese				
IC ICM G03G0005-06				
CC 74-3 (Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes)				

# FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005208618	A	20050804	JP 2004-373350	20041224
JP 20060292469	A1	20061228	US 2005-159307	20050623
PRAI JP 2003-434017	A	20031226		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2005208618	ICM	G03G0005-06
	IPCI	G03G0005-06 [ICM,7]
	IPCR	G03G0005-06 [I,A]; G03G0005-06 [I,C*]
	FTERM	2H068/AA14; 2H068/AA19; 2H068/AA34; 2H068/AA35; 2H068/BA39; 2H068/BA63; 2H068/BA64; 2H068/FA27
US 20060292469	IPCI	G03G0005-047 [I,A]; G03G0005-043 [I,C*]
	IPCR	G03G0005-043 [I,C]; G03G0005-047 [I,A]
	NCL	430/059.400; 399/159.000; 430/059.100
	ECLA	G03G0005/06H6; G03G0005/05C2D; G03G0005/05C4B; G03G0005/06B3; G03G0005/06B5; G03G0005/06B5B; G03G0005/06D4B3; G03G0005/10C; G03G0005/14B

OS MARPAT 143:183097

AB The title electrophotog. photoconductor contains an electron transport material dispersed in a binder resin of a charge generation layer. The electron transport material shows a reduction potential between -0.8 and 0 V. The electron transport material may be selected from a specified naphthalenetetracarboxylic diimide compound, a specified phenanthrene compound, a specified phenanthroline compound, and a specified acenaphthoquinone compound. A charge generation material is Ga phthalocyanine, preferably hydroxygallium phthalocyanine.

ST electrophotog photoconductor electron transport material process cartridge app

IT Polyvinyl butyrals

RL: DEV (Device component use); USES (Uses)

(binder resin in charge generation layer of contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT Electrophotographic apparatus

Electrophotographic photoconductors (photoreceptors)

(contact charging type electrophotog. photoconductor showing excellent faulty image suppression, process cartridge, and electrophotog. apparatus)

IT 84-65-1, 9,10-Anthracenedione 809-73-4 20725-71-7 27318-90-7,  
1,10-Phenanthroline-5,6-  
dione 27471-02-9 56403-67-9 56403-73-7 56961-98-9  
171258-57-4 860806-49-1 860806-50-4  
RL: DEV (Device component use); USES (Uses)  
(electron transport material in charge generation layer of contact  
charging type electrophotog. photoconductor showing excellent faulty  
image suppression)

IT 63371-84-6P, Hydroxygallium phthalocyanine  
RL: DEV (Device component use); PEP (Physical, engineering or chemical  
process); PYP (Physical process); SPN (Synthetic preparation); PREP  
(Preparation); PROC (Process); USES (Uses)  
(preparation of hydroxygallium phthalocyanine charge generation material for  
contact charging type electrophotog. photoconductor showing excellent  
faulty image suppression)

IT 91-15-6, 1,2-Benzenedicarbonitrile 13450-90-3, Gallium trichloride  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of hydroxygallium phthalocyanine charge generation material for  
contact charging type electrophotog. photoconductor showing excellent  
faulty image suppression)

IT 19717-79-4P, Chlorogallium phthalocyanine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of hydroxygallium phthalocyanine charge generation material for  
contact charging type electrophotog. photoconductor showing excellent  
faulty image suppression)

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:41818 CAPLUS  
DOCUMENT NUMBER: 140:119650  
TITLE: Charge transport compositions and electronic devices  
made with such compositions  
INVENTOR(S): Lecloux, Daniel David; Guidry, Mark A.; Herron,  
Norman; Radu, Nora S.; Smith, Eric Maurice; Wang, Ying  
PATENT ASSIGNEE(S): E.I. Du Pont De Nemours and Company, USA  
SOURCE: PCT Int. Appl., 54 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006355	A2	20040115	WO 2003-US21618	20030709
WO 2004006355	A3	20040318		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040066135	A1	20040408	US 2003-612482	20030702
US 7265378	B2	20070904		
US 20040068115	A1	20040408	US 2003-612493	20030702

US 6962995	B2	20051108		
US 20040092687	A1	20040513	US 2003-612237	20030702
US 7074534	B2	20060711		
US 20040097725	A1	20040520	US 2003-612244	20030702
CA 2492692	A1	20040115	CA 2003-2492692	20030709
AU 2003247965	A1	20040123	AU 2003-247965	20030709
EP 1520305	A2	20050406	EP 2003-763463	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1666357	A	20050907	CN 2003-816185	20030709
CN 1666577	A	20050907	CN 2003-816188	20030709
CN 1668703	A	20050914	CN 2003-816415	20030709
CN 1668616	A	20050914	CN 2003-816462	20030709
JP 2005533343	T	20051104	JP 2004-520125	20030709
CN 1726603	A	20060125	CN 2003-816467	20030709
US 20040077860	A1	20040422	US 2003-612704	20031208
US 20050236980	A1	20051027	US 2005-155068	20050617
US 7119204	B2	20061010		
US 20070194698	A1	20070823	US 2007-676401	20070219
US 20070267968	A1	20071122	US 2007-835085	20070807

PRIORITY APPLN. INFO.:

US 2002-394767P	P	20020710
US 2003-458277P	P	20030328
US 2003-612244	B3	20030702
US 2003-612482	A3	20030702
US 2003-612493	A3	20030702
WO 2003-US21618	W	20030709

OTHER SOURCE(S): MARPAT 140:119650

AN 2004:41818 CAPLUS  
 DN 140:119650  
 ED Entered STN: 18 Jan 2004  
 TI Charge transport compositions and electronic devices made with such compositions  
 IN Lecloux, Daniel David; Guidry, Mark A.; Herron, Norman; Radu, Nora S.; Smith, Eric Maurice; Wang, Ying  
 PA E.I. Du Pont De Nemours and Company, USA  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM H01L051-50  
 ICS H01L051-30; C07D471-14; C07D241-46; C07D241-44; C07D241-42; C07D401-14; C07F007-08; C07F015-00; C07D519-00; C07D409-14  
 CC 73-11 (Optical, Electron, and Mass Spectroscopy and Other Related Properties)  
 Section cross-reference(s): 28, 72, 76

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006355	A2	20040115	WO 2003-US21618	20030709
	WO 2004006355	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20040066135	A1	20040408	US 2003-612482	20030702

US 7265378	B2	20070904		
US 20040068115	A1	20040408	US 2003-612493	20030702
US 6962995	B2	20051108		
US 20040092687	A1	20040513	US 2003-612237	20030702
US 7074534	B2	20060711		
US 20040097725	A1	20040520	US 2003-612244	20030702
CA 2492692	A1	20040115	CA 2003-2492692	20030709
AU 2003247965	A1	20040123	AU 2003-247965	20030709
EP 1520305	A2	20050406	EP 2003-763463	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1666357	A	20050907	CN 2003-816185	20030709
CN 1666577	A	20050907	CN 2003-816188	20030709
CN 1668703	A	20050914	CN 2003-816415	20030709
CN 1668616	A	20050914	CN 2003-816462	20030709
JP 2005533343	T	20051104	JP 2004-520125	20030709
CN 1726603	A	20060125	CN 2003-816467	20030709
US 20040077860	A1	20040422	US 2003-612704	20031208
US 20050236980	A1	20051027	US 2005-155068	20050617
US 7119204	B2	20061010		
US 20070194698	A1	20070823	US 2007-676401	20070219
US 20070267968	A1	20071122	US 2007-835085	20070807
PRAI US 2002-394767P	P	20020710		
US 2003-458277P	P	20030328		
US 2003-612244	B3	20030702		
US 2003-612482	A3	20030702		
US 2003-612493	A3	20030702		
WO 2003-US21618	W	20030709		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006355	ICM	H01L051-50
	ICS	H01L051-30; C07D471-14; C07D241-46; C07D241-44; C07D241-42; C07D401-14; C07F007-08; C07F015-00; C07D519-00; C07D409-14
	IPCI	H01L0051-50 [ICM,7]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0241-46 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-42 [ICS,7]; C07D0241-00 [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*]; C07F0015-00 [ICS,7]; C07D0519-00 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];

C09B0011-10 [I,A]; C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0033-00 [I,C\*]; H01L0033-00 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A]

ECLA C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; H01L051/00M6H14; H01L051/00M16; T01L; T01L; T01L; T01L; T01L; T01L; M07D; M07D

US 20040066135 IPCI H01L0051-00 [I,A]  
 IPCR H01L0051-00 [N,C\*]; H01L0051-00 [N,A]; H01L0051-05 [N,C\*]; H01L0051-30 [N,A]; H01L0051-50 [I,C\*]; H01L0051-50 [I,A]

NCL 313/503.000; 428/690.000; 257/040.000; 136/263.000; 257/431.000; 257/E51.049; 313/504.000; 313/506.000; 428/917.000

ECLA H01L051/50E3; H01L051/50G; T01L; T01L

US 20040068115 IPCI C07D0471-04 [ICM,7]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7]

IPCR C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C08G0061-00 [I,C\*]; C08G0061-12 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50 [N,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A]

NCL 546/088.000; 546/081.000

ECLA C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/30D6; H01L051/30H4; H01L051/30H6; H01L051/30H8; H01L051/30S; C09K011/06; C07D471/04+221A+221A; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14

US 20040092687 IPCI G03G0005-04 [I,A]; C07D0241-38 [I,A]; C07D0241-00 [I,C\*]; C08F0032-08 [I,A]; C08F0032-00 [I,C\*]; C08F0132-08 [I,A]; C08F0132-00 [I,C\*]

IPCR C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C08G0061-00 [I,C\*]; C08G0061-12 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50 [N,A]

NCL 526/259.000; 430/076.000; 428/917.000; 430/096.000; 544/349.000; 544/353.000; 548/428.000

ECLA C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/30D2; H01L051/30D6; H01L051/30H4; H01L051/30H6; H01L051/30H8; H01L051/30S; H01L051/00M2B; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16

US 20040097725 IPCI C09B0011-04 [ICM,7]; C09B0011-00 [ICM,7,C\*]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C\*]

IPCR C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C08G0061-00 [I,C\*]; C08G0061-12 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50 [N,A]

	NCL	540/472.000; 552/101.000
	ECLA	T01L; T01L; T01L
CA 2492692	IPCI	H01L0051-00 [ICM,7]; C07D0519-00 [ICS,7]; C07F0015-00 [ICS,7]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; C07D0241-42 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-46 [ICS,7]; C07D0241-00 [ICS,7,C*]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
AU 2003247965	IPCI	C07F0015-00 [ICM,7]; C07D0519-00 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0241-46 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-42 [ICS,7]; C07D0241-00 [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];



EP 1520305

IPCI  
IPCR

C07D0519-00 [I,A]; C07F0007-00 [I,C\*]; C07F0007-21 [I,A]; C07F0015-00 [I,C\*]; C07F0015-00 [I,A]; C08G0061-00 [I,C\*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C\*]; C08K0005-18 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; C08L0083-00 [I,C\*]; C08L0083-08 [I,A]; C09B0011-00 [I,C\*]; C09B0011-10 [I,A]; C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0033-00 [I,C\*]; H01L0033-00 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A]; H01L0051-00 [ICM,7]; H01L0051-50 [I,C\*]; H01L0051-50 [I,A]; C07C0211-00 [I,C\*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C\*]; C07C0215-74 [I,A]; C07C0217-00 [I,C\*]; C07C0217-80 [I,A]; C07C0255-00 [I,C\*]; C07C0255-58 [I,A]; C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C07D0241-00 [I,C\*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C\*]; C07D0401-14 [I,A]; C07D0409-00 [I,C\*]; C07D0409-14 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]; C07F0007-00 [I,C\*]; C07F0007-21 [I,A]; C07F0015-00 [I,C\*]; C07F0015-00 [I,A]; C08G0061-00 [I,C\*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C\*]; C08K0005-18 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; C08L0083-00 [I,C\*]; C08L0083-08 [I,A]; C09B0011-00 [I,C\*]; C09B0011-10 [I,A]; C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0033-00 [I,C\*]; H01L0033-00 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A]

ECLA

C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14

CN 1666357

IPCI  
IPCR


H01L0051-30 [ICM,7]; H01L0051-05 [ICM,7,C\*]; C08G0061-00 [ICS,7]; C08G0061-12 [ICS,7]; H01L0051-50 [I,C\*]; H01L0051-50 [I,A]; C07C0211-00 [I,C\*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C\*]; C07C0215-74 [I,A]; C07C0217-00 [I,C\*]; C07C0217-80 [I,A]; C07C0255-00 [I,C\*]; C07C0255-58 [I,A]; C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C07D0241-00 [I,C\*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C\*]; C07D0401-14 [I,A]; C07D0409-00 [I,C\*]; C07D0409-14 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]; C07F0007-00 [I,C\*]; C07F0007-21 [I,A]; C07F0015-00 [I,C\*]; C07F0015-00 [I,A]; C08G0061-00 [I,C\*]; C08G0061-00 [I,A]; C08G0061-12

		[I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1666577	IPCI	H05B0033-14 [ICM,7]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; H01L0027-00 [ICS,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1668703	IPCI	C09B0011-00 [ICM,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00

		[I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1668616	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; C07F0015-00 [ICS,7]; H01L0051-00 [ICS,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
JP 2005533343	IPCI	H05B0033-22 [ICM,7]; H05B0033-14 [ICS,7]; C07D0241-40 [ICS,7]; C07D0241-00 [ICS,7,C*]; C07F0007-21 [ICS,7]; C07F0007-00 [ICS,7,C*]; C07F0015-00 [ICS,7]

	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	FTERM	3K007/AB03; 3K007/DB03; 4H049/VN01; 4H049/VP02; 4H049/VQ67; 4H049/VQ78; 4H049/VR23; 4H049/VR41; 4H049/VU29; 4H049/VW02; 4H050/AA03; 4H050/AB91; 4H050/WB11; 4H050/WB14; 4H050/WB21
CN 1726603	IPCI	H01L0051-00 [I,A]; H01L0051-30 [I,A]; H01L0051-05 [I,C*]; C07D0471-14 [I,A]; C07D0471-00 [I,C*]; C07D0241-46 [I,A]; C07D0241-44 [I,A]; C07D0241-42 [I,A]; C07D0241-00 [I,C*]; C07D0401-14 [I,A]; C07D0401-00 [I,C*]; C07F0007-08 [I,A]; C07F0007-00 [I,C*]; C07F0015-00 [I,A]
US 20040077860	IPCR	H01L0051-00 [I,A]; H01L0051-00 [I,C]
	IPCI	A61K0031-498 [I,C*,7]; C07D0043-02 [I,C*,7]; C07D0241-36 [I,C*,7]; C07D0241-00 [I,C*,7,C*]
	IPCR	C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0471-00 [I,C*]; C07D0471-16 [I,A]; C07D0475-00 [I,C*]; C07D0475-00 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-08 [I,A]; C08G0061-00 [I,C*]; C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50 [N,A]
	NCL	544/353.000; 257/E51.051
	ECLA	C07D409/04; C07D209/86; C07D213/38; C07D241/38B; C07D241/42; C07D401/04; C07D403/04; C07D471/16+241B+221B+221B+2; C07D475/00; C07D519/00+471/00+471/00; C07F007/08D4H4F; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16
US 20050236980	IPCI	C07D0471-02 [I,A]; C07D0471-00 [I,A]
	IPCR	C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C08G0061-00 [I,C*]; C08G0061-12

[I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A];  
C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0051-00  
[I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*];  
H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50  
[N,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A]  
NCL 313/504.000; 546/002.000; 546/088.000; 546/081.000  
ECLA C09K011/06; C07D209/86; C07D213/38;  
C07D471/04+221A+221A; C08G061/12D; C08G061/12D1B;  
C08L065/00; H01L051/00M2F; H01L051/00M6D;  
H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14  
US 20070194698 IPCI H01J0001-62 [I,A]; H01J0001-00 [I,C\*]; H01J0063-04  
[I,A]; H01J0063-00 [I,C\*]; H01L0051-00 [I,A]  
IPCR H01J0001-00 [I,C]; H01J0001-62 [I,A]; C07D0209-00  
[I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*];  
C07D0213-38 [I,A]; C08G0061-00 [I,C\*]; C08G0061-12  
[I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A];  
H01J0063-00 [I,C]; H01J0063-04 [I,A]; H01L0051-00  
[I,C]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*];  
H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50  
[N,A]  
NCL 313/504.000; 257/040.000  
ECLA C07D213/38; C07D209/86; C08G061/12D; C08G061/12D1B;  
C08L065/00; H01L051/00M6; H01L051/00M6F;  
H01L051/00M6H14; H01L051/00M16; T01L; T01L; T01L  
US 20070267968 IPCI H01J0063-02 [I,A]; H01J0063-00 [I,C\*]  
IPCR H01J0063-00 [I,C]; H01J0063-02 [I,A]; H01L0051-00  
[N,C\*]; H01L0051-00 [N,A]; H01L0051-05 [N,C\*];  
H01L0051-30 [N,A]; H01L0051-50 [I,C\*]; H01L0051-50  
[I,A]  
NCL 313/503.000  
ECLA H01L051/50E3; H01L051/50G; T01L; T01L  
OS MARPAT 140:119650  
GI



- AB Compns. are described which comprise quinoxaline derivs. described by the general formula I (R1 and R2 are the same or different at each occurrence and are selected from H, F, Cl, Br, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylenearyl, alkenylaryl, alkynylaryl, alkyleneheteroaryl, alkenylheteroaryl, alkynylheteroaryl, CnHaFb, OCnHaFb, C6HcFd, and OC6HcFd; both R2 together may constitute an arylene or heteroarylene group; a, b, c, and d = 0 or an integer such that a+b = 2n + 1, and c + d = 5; n = an integer; and z = 0-4). Electronic devices (e.g., light-emitting diodes, light-emitting electrochem. cells, or photodetectors) comprising  $\geq 1$  photoactive layer and a second layer are also described in which  $\geq 1$  layer comprises the quinoxaline derivs.
- ST quinoxaline deriv compn electronic device; electroluminescent device quinoxaline deriv; photodetector quinoxaline deriv; light emitting electrochem cell quinoxaline deriv
- IT Electrochemical cells  
(light-emitting; quinoxaline derivative-containing compns. and electronic

devices made using them)

IT Electroluminescent devices  
Optical detectors  
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 647375-47-1P  
RL: DEV (Device component use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 4559-60-8P 17401-62-6P 19802-70-1P 32387-86-3P 36305-56-3P  
36305-63-2P 112657-94-0P 205367-28-8P 364067-15-2P 370851-72-2P  
410526-67-9P 647375-50-6P 647375-53-9P 647375-59-5P 647375-61-9P  
647375-62-0P 647375-63-1P 647375-64-2P 647375-65-3P 647375-66-4P  
647375-67-5P 647375-68-6P 647375-69-7P  
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)  
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 84-11-7, Phenanthrene quinone 95-54-5, 1,2-Phenylenediamine, reactions 128-37-0, 2,6-Di-tert-butyl-p-cresol, reactions 134-81-6, Benzil 492-73-9, 2,2'-Pyridil 496-72-0, 3,4-Diaminotoluene 766-98-3, 4-Fluorophenylacetylene 1226-42-2, 4,4'-Dimethoxybenzil 1746-23-2 1765-93-1, 4-Fluorophenylboronic acid 2050-89-7, [1,1'-Biphenyl]-3,3'-diamine 2627-95-4, 1,3-Divinyltetramethyldisiloxane 2687-25-4, 2,3-Diaminotoluene 3141-27-3 3171-45-7, 4,5-Dimethyl-1,2-phenylenediamine 3363-97-1 4612-26-4 10025-83-9, Iridium trichloride 27318-90-7, 1,10-Phenanthroline-5,6-dione 35578-47-3, 4,4'-Dibromobenzil 36692-49-6, Methyl 3,4-diaminobenzoate 52334-81-3, 2-Chloro-5-trifluoromethylpyridine 647375-45-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 370878-58-3P 647375-70-0P 647375-71-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(quinoxaline derivative-containing compns. and electronic devices made using them)

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:628032 CAPLUS

DOCUMENT NUMBER: 138:4578

TITLE: Dramatically enhanced fluorescence of heteroaromatic chromophores upon insertion as spacers into oligo(triacetylene)s

AUTHOR(S): Edlmann, Michael J.; Raimundo, Jean-Manuel; Utesch, Nils F.; Diederich, Francois

CORPORATE SOURCE: Lab. Organische Chemie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz.

SOURCE: Helvetica Chimica Acta (2002), 85(7), 2195-2213

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:4578


AN 2002:628032 CAPLUS

DN 138:4578

ED Entered STN: 21 Aug 2002

TI Dramatically enhanced fluorescence of heteroaromatic chromophores upon insertion as spacers into oligo(triacetylene)s

AU Edlmann, Michael J.; Raimundo, Jean-Manuel; Utesch, Nils F.; Diederich, Francois  
 CS Lab. Organische Chemie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz.  
 SO Helvetica Chimica Acta (2002), 85(7), 2195-2213  
 CODEN: HCACAV; ISSN: 0018-019X  
 PB Verlag Helvetica Chimica Acta  
 DT Journal  
 LA English  
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 22, 72, 73, 78  
 OS CASREACT 138:4578  
 GI



AB In continuation of a previous study on the modulation of  $\pi$ -electron conjugation of oligo(triacetylene)s by insertion of central hetero-spacer fragments between two (E)-hex-3-ene-1,5-diyne ((E)-1,2-diethynylethene, DEE) moieties, trimeric hybrid oligomers (I; A = spacer, R = SiEt<sub>3</sub>, SiMe<sub>3</sub>) were prepared. Spacers used were both electron-deficient (quinoxaline-based heterocycles, pyridazine) and electron-rich (2,2'-bithiophene, 9,9-dioctyl-9H-fluorene) chromophores. With a dipyrrophenazine spacer, transition metal complexes were synthesized as potential precursors for nanoscale scaffolding based on both covalent acetylenic coupling and supramol. assembly. The UV/visible spectra revealed that the majority of spacers provided heterotrimers featuring extended  $\pi$ -electron delocalization. The new hybrid chromophores show a dramatically enhanced fluorescence compared with the DEE dimer and homo-trimer. This increase in emission intensity appears as a general feature of these systems: even if the spacer mol. is nonfluorescent, the corresponding hetero-trimer may show a strong emission. The redox properties of the new hybrid chromophores were determined by cyclic voltammetry (CV) and rotating disk voltammetry (RDV). In each case, the first 1-electron reduction step in the hetero-trimers appeared anodically shifted compared with DEE dimer and homo-trimer. With larger spacer chromophore extending into two dimensions, the anodic shift (by 240-490 mV) seems to originate from inductive effects of the two strongly electron-accepting DEE substituents rather than from extended  $\pi$ -electron conjugation along the oligomeric backbone, as had previously been observed for DEE substituted porphyrins.

ST hexenediynyl benzopyrazine benzothiadiazole phenazine bithiophene pyridazine fluorene prepn fluorescence; benzopyrazine hexenediynyl prepn fluorescence electrochem; benzothiadiazole hexenediynyl prepn fluorescence electrochem; phenazine hexenediynyl prepn fluorescence electrochem; bithiophene hexenediynyl prepn fluorescence electrochem; fluorene hexenediynyl prepn fluorescence electrochem; transition metal dipyrrophenazine prepn fluorescence electrochem

IT Fluorescence  
 Oxidation, electrochemical  
 Redox potential

Reduction, electrochemical  
 (preparation, electrochem. properties and dramatically enhanced fluorescence of compds. consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT Transition metal complexes  
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)  
 (preparation, electrochem. properties and dramatically enhanced fluorescence of compds. consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 198277-07-5 198277-13-3  
 RL: PRP (Properties)  
 (fluorescence and redox potentials)

IT 273-13-2, 2,1,3-Benzothiadiazole  
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)  
 (fluorescence, electrochem. properties and reactant for preparation of compds. having enhanced fluorescence consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 15155-41-6P 27318-90-7P, 1,10-Phenanthroline  
 -5,6-dione 69272-50-0P,  
 3,6-Dibromobenzene-1,2-diamine 94544-77-1P 148231-12-3P 200503-12-4P  
 285129-85-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate product in preparation of compds. having enhanced fluorescence consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 19535-47-8P, Dipyrro[3,2-a:2',3'-c]phenazine  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and redox potentials)

IT 477293-98-4P 477293-99-5P 477294-00-1P 477294-01-2P 477294-02-3P  
 477294-04-5P 477294-06-7P 477294-08-9P 477294-09-0P 477294-10-3P  
 477294-11-4P  
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)  
 (preparation, electrochem. properties and dramatically enhanced fluorescence of compds. consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 108-31-6, 2,5-Furandione, miscellaneous 111-83-1 123-33-1 141-30-0  
 492-97-7, 2,2'-Bithiophene 16433-88-8  
 RL: MSC (Miscellaneous)  
 (preparation, electrochem. properties and dramatically enhanced fluorescence of compds. consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 66-71-7, 1,10-Phenanthroline 84-11-7, Phenanthrene-9,10-dione  
 95-54-5, Benzene-1,2-diamine, reactions 107-22-2, Glyoxal 134-81-6,  
 Benzil 3339-80-8, 5,5'-Diiodo-2,2'-bithiophene 20698-04-8,  
 3,6-Diiodopyridazine 177500-78-6 198964-46-4, 2,7-Dibromo-9,9-dioctylfluorene 309721-72-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant for preparation of compds. having enhanced fluorescence consisting of heteroarom. chromophores inserted as spacers into oligo(triacetylene)s)

IT 91-19-0, Benzopyrazine 1684-14-6  
 RL: PRP (Properties)  
 (redox potentials)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD



RE

- (1) Albota, M; Science 1998, V281, P1653 CAPLUS
- (2) Amouyal, E; J Chem Soc, Dalton Trans 1990, V19, P1841
- (3) Bard, A; 'Electrochemical Methods: Fundamentals and Applications' 1980, P488
- (4) Bircckner, E; J Phys Chem A 2001, V105, P10307 CAPLUS
- (5) Chung, S; J Phys Chem B 1999, V103, P10741 CAPLUS
- (6) Diaz, R; Tetrahedron Lett 2001, V42, P6463 CAPLUS
- (7) Dickeson, J; Aust J Chem 1970, V23, P1023 CAPLUS
- (8) Dieck, H; J Organomet Chem 1975, V93, P259 CAPLUS
- (9) Dorr, F; Ber Bunsen-Ges Phys Chem 1963, V67, P193
- (10) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (11) Edelmann, M; Chimia 2001, V55, P132 CAPLUS
- (12) Edelmann, M; Helv Chim Acta 2001, V84, P473 CAPLUS
- (13) Guilbault, G; 'Practical Fluorescence' 1990, P1
- (14) Halkyard, C; Macromolecules 1998, V31, P8655 CAPLUS
- (15) Hay, A; J Org Chem 1962, V27, P3320 CAPLUS
- (16) Huheey, J; 'Anorganische Chemie Prinzipien von Struktur und Reaktivitat' 1988
- (17) Kraft, A; Angew Chem 1998, V110, P416
- (18) Kraft, A; Angew Chem, Int Ed 1998, V37, P402
- (19) Lopez, R; Tetrahedron Lett 1996, V37, P5437
- (20) Martin, R; Chem - Eur J 1997, V3, P1505 CAPLUS
- (21) Martin, R; Chem - Eur J 2000, V6, P3622 CAPLUS
- (22) Martin, R; Helv Chim Acta 1999, V82, P1470 CAPLUS
- (23) Meerholz, K; Electrochim Acta 1996, V41, P1839 CAPLUS
- (24) Miller, L; J Org Chem 1995, V60, P6813 CAPLUS
- (25) Miteva, T; Macromolecules 2000, V33, P652 CAPLUS
- (26) Mizzoni, R; J Am Chem Soc 1951, V73, P1873 CAPLUS
- (27) Moody, C; Tetrahedron 1992, V48, P3589 CAPLUS
- (28) Osipov, V; Teor Eksp Khim 1978, V14, P703 CAPLUS
- (29) Osipov, V; Theor Exp Chem 1978, V14, P549
- (30) Pilgram, K; J Heterocycl Chem 1970, V7, P629 CAPLUS
- (31) Rtishchev, N; Russ J Gen Chem 1999, V69, P1658 CAPLUS
- (32) Rtishchev, N; Zh Obshch Khim 1999, V69, P1731
- (33) Setayesh, S; J Am Chem Soc 2001, V123, P946 CAPLUS
- (34) Setayesh, S; Macromolecules 2000, V33, P2016 CAPLUS
- (35) Shin, M; J Heterocycl Chem 1999, V36, P1135 CAPLUS
- (36) Siensen, P; Angew Chem 2000, V112, P2740
- (37) Siensen, P; Angew Chem, Int Ed 2000, V39, P2632 CAPLUS
- (38) Skoog, D; 'Molekulfluoreszenz-, Phosphoreszenz- und Chemilumineszenzspektroskopie' 1996
- (39) Sonogashira, K; 'Metalcatalyzed Cross-coupling Reactions' 1998, P203 CAPLUS
- (40) Takahashi, S; Synthesis 1980, P627 CAPLUS
- (41) Tsubata, Y; J Org Chem 1992, V57, P6749 CAPLUS
- (42) Tykwinski, R; Helv Chim Acta 1996, V79, P2249 CAPLUS
- (43) Wytko, J; Helv Chim Acta 1998, V81, P1964 CAPLUS
- (44) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	164.00	198.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2  
DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> STR 27318-90-7

:END

L18 STRUCTURE CREATED

=> S L18 FAM SAM

SAMPLE SEARCH INITIATED 10:17:57 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 6 TO 266  
PROJECTED ANSWERS: 1 TO 80

L19 1 SEA FAM SAM L18

=>

=> D SCAN

L19 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1,10-Phenanthroline-5,6-dione, radical ion(2+) (9CI)  
MF C12 H6 N2 O2  
CI RIS



ALL ANSWERS HAVE BEEN SCANNED

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

L15 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S  
Enter SET SMARTSELECT ON before using SELECT to create an L-number of  
terms extracted from an L-number that contains answers or terms from  
more than one file. SET SMARTSELECT ON must be entered before you  
execute the SELECT command.

=> SET SMA ON

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

NO ANSWERS SELECTED.

THE ANSWER SET WAS CREATED IN FILES 'CAPLUS, MEDLINE, EMBASE, BIOSIS'.  
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILES.  
To use the SELECT command, you must be in the same file environment  
in which the answer set was created.

=>

=> FIL

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.98	204.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

=> SEL RAN.CAPLUS(1) L15 2

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APP5

E US2006-599748/APP5

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5  
L10 224329 S L7 OR L8 OR L9  
L11 3300 S 10 AND ANTIANGIOGENIC  
L12 56 S L11 AND ISCHEMIA  
L13 28 S L11 AND ("HEART DISEASE")  
L14 2 S L13 AND L12  
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC  
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"  
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7  
L19 1 S L18 FAM SAM  
SET SMA OFF  
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

=> s "1,4-naphthalenedione?"

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file medline caplus embase biosis scisearch

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	205.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'MEDLINE' ENTERED AT 10:26:36 ON 11 JUN 2008

FILE 'CAPLUS' ENTERED AT 10:26:36 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:26:36 ON 11 JUN 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:26:36 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

```
=> s ("1,4-naphthalenedione?")
L20      1303 ("1,4-NAPHTHALENEDIONE?")

=> s l20 and (treat or treatment or treating)
L21      129 L20 AND (TREAT OR TREATMENT OR TREATING)

=> s l21 and ("heart attack")
L22      0 L21 AND ("HEART ATTACK")

=> s l21 and ("myocardial infarction")
L23      2 FILES SEARCHED...
        0 L21 AND ("MYOCARDIAL INFARCTION")

=> s l21 and ischemia
L24      4 L21 AND ISCHEMIA

=> d scan l24

L24      4 ANSWERS  CAPLUS  COPYRIGHT 2008 ACS on STN
CC       1-8 (Pharmacology)
TI       Effect of venotropic drugs on the respiratory activity of isolated
         mitochondria and in endothelial cells
ST       venotropic mitochondrion respiration vascular endothelium hypoxia; venous
         insufficiency mitochondrion respiration ischemia venotropic;
         oxidative phosphorylation venotropic ATP mitochondria
IT       Transport proteins
         RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
         (Biological study); PROC (Process)
         (ADP/ATP carrier; effect of venotropic drugs on respiratory activity of
         isolated mitochondria and in endothelial cells)
IT       Anti-ischemic agents
         Hypoxia, animal
         Oxidative phosphorylation, biological
         (effect of venotropic drugs on respiratory activity of isolated
         mitochondria and in endothelial cells)
IT       Blood vessel
         (endothelium; effect of venotropic drugs on respiratory activity of
         isolated mitochondria and in endothelial cells)
IT       Sweet clover (Melilotus officinalis)
         (exts.; effect of venotropic drugs on respiratory activity of isolated
         mitochondria and in endothelial cells)
IT       Vein
         (insufficiency; effect of venotropic drugs on respiratory activity of
         isolated mitochondria and in endothelial cells)
IT       Respiration, animal
         (mitochondrial; effect of venotropic drugs on respiratory activity of
         isolated mitochondria and in endothelial cells)
```

IT Procyanidins  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (procyanidolic oligomers; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Mitochondria  
 (respiration; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Cardiovascular agents  
 (venotropics; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 130-15-4, 1,4-Naphthalenedione 153-18-4D, Ginkor Fort 520-27-4, Diosmin 6805-41-0, Aescine 31329-57-4, Naftidrofuryl 205886-26-6, Cyclo 3 Fort  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 56-65-5, 5'-ATP, biological studies  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
 IC ICM C07D  
 CC 1-12 (Pharmacology)

TI Quinone compound cysteine protease inhibitors, and therapeutic use  
 ST quinone compd cysteine protease inhibitor therapeutic; infectious disease treatment quinone compd cysteine protease inhibitor; caspase inhibitor quinone compd therapeutic

IT Nervous system, disease  
 (Huntington's chorea; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biliary tract, disease  
 Inflammation  
 (cholangitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Inflammation  
 Intestine, disease  
 (colitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cysteine protease-like, inhibitors; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Nervous system, disease  
 (degeneration; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biological transport  
 (drug; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Disease, animal  
 (endocenteritis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Allergy  
 (hypersensitivity; quinone compound cysteine protease inhibitors, and

therapeutic use)

IT Virus  
(immunodeficiency; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Heart, disease  
(infarction; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Nerve, disease  
Reperfusion  
Spinal cord, disease  
(injury; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Drug delivery systems  
(nasal; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Injury  
(neural; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Transplant and Transplantation  
(organ damage; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Inflammation  
Pancreas, disease  
(pancreatitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Alopecia  
Alzheimer's disease  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiarthritics  
Antidiabetic agents  
Antiparkinsonian agents  
Antiviral agents  
Apoptosis  
Arthritis  
Autoimmune disease  
Blood-brain barrier  
Cardiovascular agents  
Cardiovascular system, disease  
Diabetes mellitus  
Drug delivery systems  
Encephalitis  
Hepatitis  
Hepatitis virus  
Immune disease  
Immunodeficiency  
Inflammation  
Influenza virus  
Ischemia  
Multiple sclerosis  
Nervous system, disease  
Nervous system agents  
Parkinson's disease  
Picornaviridae  
QSAR (quantitative structure-activity relationship)  
Rhinovirus  
Spinal muscular atrophy  
(quinone compound cysteine protease inhibitors, and therapeutic use)

IT Injury  
(reperfusion; quinone compound cysteine protease inhibitors, and

therapeutic use)

IT Injury  
(spinal cord; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Brain, disease  
(stroke; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Reducing agents  
(sulfur reducing agents; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Multiple sclerosis  
(therapeutic agents; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Infection  
(viral; quinone compound cysteine protease inhibitors, and therapeutic use)

IT 9001-73-4, Papain 9002-07-7, Trypsin 9004-07-3,  $\alpha$ -Chymotrypsin 37353-41-6, Cysteine protease 97162-88-4, 3C Protease 169592-56-7, Caspase 3 186322-81-6, Caspase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(quinone compound cysteine protease inhibitors, and therapeutic use)

IT 58-27-5 70-18-8, Glutathione, biological studies 70-18-8D, Glutathione, adducts with naphthoquinone derivs. 81-54-9 81-64-1 83-61-4 84-79-7 116-85-8 117-80-6 130-15-4, 1,4-Naphthalenedione 130-15-4D, 1,4-Naphthalenedione, derivs. adducts 389-08-2, Nalidixic acid 389-08-2D, Nalidixic acid, derivs. 475-38-7 480-40-0 481-39-0 481-42-5 517-88-4D, derivs. 517-88-4D, Alkannin, naphthoquinone derivs. 517-89-5, Shikonin 517-89-5D, derivs. 517-89-5D, Shikonin, naphthoquinone derivs. 520-36-5 569-77-7 583-63-1D, 3,5-Cyclohexadiene-1,2-dione, derivs. 930-68-7D, 2-Cyclohexen-1-one, derivs. 1015-62-9D, derivs. 2379-57-9D, derivs. 3483-12-3, DTT 3483-12-3D, DTT, derivs. 3952-78-1 4613-08-5 6041-00-5D, derivs. 6336-72-7 13243-65-7 23444-65-7, Alkannin 33440-64-1 40881-75-2 50614-69-2D, derivs. 59887-87-5 69008-03-3 69016-66-6 70730-92-6 71860-31-6D, derivs. 74839-40-0 75753-48-9 75753-51-4 75753-52-5 78651-40-8D, derivs. 81818-54-4D, derivs. 82789-18-2D, derivs. 85192-90-1 86703-96-0D, derivs. 88818-34-2D, derivs. 92629-07-7 93831-47-1 97136-23-7D, derivs. 100440-78-6 101068-35-3 108772-19-6 117746-18-6D, derivs. 133011-82-2D, derivs. 184529-66-6 187753-94-2D, derivs. 192126-76-4, Mycothiol 192126-76-4D, Mycothiol, adducts with naphthoquinone derivs. 202350-24-1D, derivs. 208254-19-7D, derivs. 215778-63-5D, derivs. 298208-05-6D, derivs. 304883-59-8 313253-12-2D, derivs. 313471-02-2 313493-32-2D, derivs. 313531-31-6 313549-28-9D, derivs. 313955-32-7D, derivs. 313955-40-7D, derivs. 313957-75-4D, derivs. 313957-76-5D, derivs. 313958-25-7D, derivs. 317337-15-8 324527-07-3D, derivs. 399038-37-0D, derivs. 403496-99-1D, derivs. 464157-05-9D, derivs. 464157-06-0D, derivs. 464157-07-1D, derivs. 464157-08-2D, derivs. 464157-09-3D, derivs. 464157-10-6D, derivs. 464157-11-7D, derivs. 464157-13-9D, derivs. 464157-14-0D, derivs. 464157-15-1D, derivs. 464157-16-2D, derivs. 464157-17-3D, derivs. 464157-18-4D, derivs. 464157-19-5D, derivs. 464157-20-8D, derivs. 464157-21-9D, derivs. 464157-22-0D, derivs. 464157-23-1D, derivs. 464157-24-2D, derivs. 464157-25-3D, derivs. 464157-26-4D, derivs. 464157-27-5D, derivs. 464157-28-6D, derivs. 464157-29-7D, derivs. 464157-30-0D, derivs. 464157-31-1D, derivs. 464157-32-2D, derivs. 464157-33-3D, derivs. 464157-34-4D, derivs. 464157-35-5D, derivs. 464157-36-6D, derivs. 464157-37-7 464157-38-8 464157-39-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(quinone compound cysteine protease inhibitors, and therapeutic use)

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
CC 1-10 (Pharmacology)  
Section cross-reference(s): 27, 62, 63  
TI Pharmaceutical composition for the treatment or prevention of  
diseases involving obesity, diabetes, metabolic syndrome,  
neurodegenerative diseases and mitochondria dysfunction diseases  
ST naphthoquinone deriv obesity diabetes metabolic syndrome neurodegenerative  
mitochondria disease; Danshen drug formulation cosmetic naphthoquinone  
deriv beta lapachone prep  
IT Natural products, pharmaceutical  
(Salviae miltiorrhizae radix; pharmaceutical composition for  
treatment obesity, diabetes, metabolic syndrome,  
neurodegenerative diseases and mitochondria dysfunction diseases)  
IT Brain, disease  
(cerebrovascular; pharmaceutical composition for treatment  
obesity, diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Disease, animal  
(degenerative; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Eye, disease  
(diabetic retinopathy, diabetic; pharmaceutical composition for  
treatment obesity, diabetes, metabolic syndrome,  
neurodegenerative diseases and mitochondria dysfunction diseases)  
IT Hyperlipidemia  
Hypertension  
(diabetic; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Mitochondria  
(disease; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Kidney, disease  
(failure, diabetic; pharmaceutical composition for treatment  
obesity, diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Heart, disease  
(infarction; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Cosmetics  
(lotions; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Metabolic disorders  
(metabolic syndrome X; pharmaceutical composition for treatment  
obesity, diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Disease, animal  
(mitochondrial; pharmaceutical composition for treatment obesity,  
diabetes, metabolic syndrome, neurodegenerative diseases and  
mitochondria dysfunction diseases)  
IT Antidiabetic agents  
Antiobesity agents  
Arteriosclerosis  
Cardiovascular system, disease  
Claisen rearrangement

Cyclization  
 Diabetes mellitus  
 Diels-Alder reaction  
 Drug delivery systems  
 Inflammation  
 Ischemia  
 Liver, disease  
 Obesity  
 Salvia miltiorrhiza

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

- IT Drug delivery systems  
 (prodrugs; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)
- IT 4707-32-8P,  $\beta$ -Lapachone  
 RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)
- IT 33404-57-8P, Dunnione 52436-88-1P 83156-01-8P,  $\alpha$ -Dunnione 90149-94-3P 90149-95-4P 90149-97-6P 359762-51-9P 906459-31-2P 906459-32-3P 906459-34-5P 906459-35-6P  
 RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)
- IT 130-15-4DP, 1,4-Naphthalenedione, derivs.  
 15297-93-5P 17112-93-5P 32013-77-7P 52422-61-4P 82420-29-9P 83156-21-2P 90149-96-5P 90149-98-7P 90149-99-8P 104277-62-5P 118949-98-7P 118949-99-8P 195156-60-6P 476213-05-5P 855275-10-4P 906459-29-8P 906459-30-1P 906459-33-4P 906459-36-7P 906459-37-8P  
 RL: COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)
- IT 42164-69-2P  
 RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)
- IT 78-79-5, 2-Methyl-1,3-butadiene, reactions 83-72-7, 2-Hydroxy-1,4-naphthoquinone 84-58-2 106-51-4, p-Benzoquinone, reactions 115-19-5, 2-Methyl-3-butyn-2-ol 123-91-1, 1,4-Dioxane, reactions 673-84-7, 2,6-Dimethyl-2,4,6-octatriene 869-72-7, 1-Bromo-3-methyl-2-pentene 870-63-3, 1-Bromo-3-methyl-2-butene 932-86-5, 2-Bromo-ethylidenecyclohexane 1000-86-8, 2,4-Dimethyl-1,3-pentadiene 3017-69-4, 1-Bromo-2-methylpropene 4392-24-9, 3-Phenylallyl bromide 6138-90-5, Geranyl bromide 6674-22-2, 1,8-Diazabicyclo[5.4.0]undec-7-ene 8013-00-1, Terpinene 13961-36-9 17173-25-0 21378-06-3, 1-Bromo-3-ethyl-2-pentene 30525-89-4, Paraformaldehyde 58472-21-2, 2-Hydroxy-6-methyl-1,4-naphthoquinone 74237-21-1, 6-Chloro-2-hydroxy-1,4-

naphthoquinone 90149-85-2 114521-72-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 40432-22-2P, 4,5-Benzofurandione 906459-39-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 125911-68-4  
 RL: PRP (Properties)  
 (unclaimed sequence; pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
 IC ICM C07D223-16  
 ICS C07D401-04; C07D403-12; A61K031-55  
 CC 27-21 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 TI 2,5-Dioxo-2,5-dihydro-1H-benz[b]azepines as NMDA receptor antagonists  
 ST benzazepine prepn NMDA receptor antagonist  
 IT Nervous system agents  
 (benzazepine derivs.)  
 IT Neurotransmitter antagonists  
 (glycinergic, benzazepine derivs.)  
 IT Brain, disease  
 (ischemia, treatment of, benzazepine derivs. for)  
 IT Neurotransmitter antagonists  
 (methyl-D-aspartate, benzazepine derivs.)  
 IT Brain, disease  
 (stroke, treatment of, benzazepine derivs. for)  
 IT 3984-34-7, 3-(4-Chlorobenzoyl)propionic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Wolff-Kishner reduction of, in preparation of benzazepine NMDA receptor antagonists)

IT 74-88-4, Methyl iodide, reactions 100-39-0, Benzyl bromide 2417-72-3, Methyl 4-(bromomethyl)benzoate  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (alkylation of benzazepinedione derivative by, in preparation of benzazepine NMDA receptor antagonists)

IT 51-45-6, 2-(4-Imidazolyl)ethylamine, reactions 62-53-3, Benzenamine, reactions 64-04-0, Phenethylamine 74-89-5, Methylamine, reactions 92-54-6, 1-Phenylpiperazine 100-46-9, Benzylamine, reactions 107-11-9, Allylamine 108-00-9, 2-(N,N-Dimethylamino)ethylamine 109-89-7, Diethylamine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-42-2, Diethanolamine, reactions 111-49-9, Perhydroazepine 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 141-43-5, reactions 488-43-7, D-Glucamine 2516-47-4, Cyclopropylmethylamine 2627-86-3, (S)- $\alpha$ -Methylbenzylamine 2759-28-6, 1-Benzylpiperazine 3202-33-3, 4-Phenoxy-piperidine 3886-69-9, (R)- $\alpha$ -Methylbenzylamine 16066-84-5, tert-Butoxycarbonylmethylamine 55536-65-7, 3,4-Dibenzoyloxyphenethylamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (aminolysis of methoxybenzazepinedione derivative by, in preparation of benzazepine NMDA receptor antagonists)

IT 52280-65-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(ammonolysis and aminolysis of, in preparation of benzazepine NMDA receptor antagonists)

IT 696-59-3, 2,5-Dimethoxytetrahydrofuran  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(cyclocondensation of, with aminobenzazepine derivative, in preparation of benzazepine NMDA receptor antagonists)

IT 55406-29-6P 154314-66-6P 154314-67-7P 154314-68-8P 154314-69-9P  
154314-70-2P 154314-71-3P 154314-72-4P 154314-73-5P 154314-74-6P  
154314-75-7P 154314-76-8P 154314-77-9P 154314-78-0P 154314-79-1P  
154314-80-4P 154314-81-5P 154314-82-6P 154314-83-7P 154314-84-8P  
154314-85-9P 154314-86-0P 154314-87-1P 154314-88-2P 154314-89-3P  
154314-90-6P 154314-91-7P 154314-92-8P 154314-93-9P 154314-94-0P  
154314-95-1P 154314-96-2P 154314-97-3P 154314-98-4P 154314-99-5P  
154315-00-1P 154315-01-2P 154315-02-3P 154315-03-4P 154315-04-5P  
154315-05-6P 154315-06-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as NMDA receptor antagonist)

IT 4619-18-5P, 4-(4-Chlorophenyl)butyric acid 26673-32-5P,  
7-Chloro-1-tetralone 90685-39-5P, 1,4-Naphthalenedione, 7-chloro-2-hydroxy- 90700-78-0P, 1,4-Naphthalenedione, 7-chloro-2-methoxy- 144066-30-8P  
154315-07-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for benzazepine NMDA receptor antagonists)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008  
E US2007-599748/APPS  
E US2006-599748/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINEDIONE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS', MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5  
L10 224329 S L7 OR L8 OR L9  
L11 3300 S 10 AND ANTIANGIOGENIC  
L12 56 S L11 AND ISCHEMIA  
L13 28 S L11 AND ("HEART DISEASE")  
L14 2 S L13 AND L12  
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC  
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"  
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7  
L19 1 S L18 FAM SAM  
SET SMA OFF  
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008

L20 1303 S ("1,4-NAPHTHALEDIONE?")  
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)  
L22 0 S L21 AND ("HEART ATTACK")  
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")  
L24 4 S L21 AND ISCHEMIA

=> s l16 and ("myocardial infarction")

2 FILES SEARCHED...

L25 1 L16 AND ("MYOCARDIAL INFARCTION")

=> d scan l25

L25 1 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 78

TI Therapeutic delivery of carbon monoxide employing Mn complexes having CO ligands, and additional halogen, monodentate and/or bidentate ligands

ST carbon monoxide manganese complex halogen monodentate bidentate ligand antiinflammatory; manganese complex carbon monoxide ligand neurotransmission vasodilation inflammation hypertension

IT Hyperoxia

(-induced injury; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Respiratory distress syndrome

(adult; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Ligands

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bidentate; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Radiation

(damage; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Ligands

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(halogen, monodentate; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Shock (circulatory collapse)

(hemorrhagic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections

(i.m. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections

- (i.p. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Pharmaceutical injections
  - (i.v. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Sexual disorders
  - (impotence; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Halogens
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (ligands; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Injury
  - (postischemic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Pharmaceutical injections
  - (s.c. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Shock (circulatory collapse)
  - (septic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Neurotransmission
  - (stimulation; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Angina pectoris
  - Anti-inflammatory agents
  - Apoptosis
  - Arteriosclerosis
  - Cytotoxicity
  - Dissolution
  - Hypertension
  - Inflammation
  - Inhalation drug delivery systems
  - Myocardial infarction
  - Nasal drug delivery systems
  - Neoplasm
  - Oral drug delivery systems
  - Pharmaceutical solutions
  - Pharmaceutical suppositories
  - Sepsis
  - Solubility
  - Transdermal drug delivery systems
  - Transplant rejection
  - Vasodilators
    - (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
- IT Carbonyl complexes
  - RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
  - (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate

- ligands)
- IT 14100-30-2P, Chloropentacarbonylmanganese 14516-54-2P,  
Bromopentacarbonylmanganese 14879-42-6P, Pentacarbonylironmanganese  
38173-71-6P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)
- IT 10170-70-4P 14321-60-9P 20480-91-5P 20624-20-8P 52841-89-1P  
59893-04-8P 108267-31-8P 115958-82-2P 178935-53-0P 438552-30-8P  
1001014-97-6P 1001014-98-7P 1001014-99-8P 1001015-00-4P  
1001015-02-6P 1001015-04-8P 1001015-06-0P 1001015-08-2P  
1001015-09-3P 1001015-11-7P 1001015-13-9P 1001015-14-0P  
1001015-16-2P 1001015-17-3P 1001015-18-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)
- IT 630-08-0D, Carbon monoxide, manganese complexes, ligand of 7439-96-5D,  
Manganese, complexes  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)
- IT 56-23-5, Carbon tetrachloride, reactions 64-19-7, Acetic acid, reactions  
65-85-0, Benzoic acid, reactions 67-48-1, Choline chloride 75-09-2,  
Methylene chloride, reactions 75-15-0, Carbon disulfide, reactions  
75-31-0, Isopropylamine, reactions 75-59-2, Tetramethylammonium  
hydroxide 107-22-2, Glyoxal 111-42-2, Diethanolamine, reactions  
115-86-6, Triphenyl phosphate 119-91-5, 2,2'-Biquinolyl 121-45-9,  
Trimethyl phosphite 127-08-2, Potassium acetate 140-89-6 141-82-2,  
Malonic acid, reactions 148-18-5, Sodium diethyldithiocarbamate  
366-18-7, 2,2'-Bipyridine 507-09-5, Thioacetic acid, reactions  
1310-73-2, Sodium hydroxide (NaOH), reactions 2923-28-6, Silver  
triflate 7553-56-2, Iodine, reactions 7647-15-6, Sodium bromide  
(NaBr), reactions 7726-95-6, Bromine, reactions 10170-69-1,  
Decacarbonylironmanganese 11110-52-4, Sodium amalgam 13442-87-0  
14104-20-2, Silver fluoroborate (AgBF4) 15761-38-3 17773-10-3, Choline  
iodide 21050-13-5 27318-90-7, 1,10-  
Phenanthroline-5,6-dione  
33100-27-5, 15-Crown-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)
- IT 2801-04-9P, Sodium bis(2-hydroxyethyl)dithiocarbamate 10581-12-1P,  
Tetramethylammonium acetate 24764-90-7P 25255-90-7P,  
Tetramethylammonium benzoate 33299-53-5P, Tetramethylammonium malonate  
62698-51-5P, Tetramethylammonium thioacetate 63321-11-9P 81436-35-3P  
89689-95-2P 1001015-19-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)
- IT 630-08-0, Carbon monoxide, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic delivery of carbon monoxide employing manganese complexes  
having CO ligands, and addnl. halogen, monodentate and/or bidentate  
ligands)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON  
11 JUN 2008

L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5  
L10 224329 S L7 OR L8 OR L9  
L11 3300 S 10 AND ANTIANGIOGENIC  
L12 56 S L11 AND ISCHEMIA  
L13 28 S L11 AND ("HEART DISEASE")  
L14 2 S L13 AND L12  
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC  
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"  
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7  
L19 1 S L18 FAM SAM  
SET SMA OFF  
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON  
11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE")  
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)  
L22 0 S L21 AND ("HEART ATTACK")  
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")  
L24 4 S L21 AND ISCHEMIA  
L25 1 S L16 AND ("MYOCARDIAL INFARCTION")

=> s l16 and ("angiogenesis inhibitor?")  
L26 0 L16 AND ("ANGIOGENESIS INHIBITOR?")

=> s l2 and ("angiogenesis inhibitor?")  
L27 552 L2 AND ("ANGIOGENESIS INHIBITOR?")



```
=> s l3 and ("angiogenesis inhibitor?")
L28      24 L3 AND ("ANGIOGENESIS INHIBITOR?")

=> s l5 and ("angiogenesis inhibitor?")
L29      2 L5 AND ("ANGIOGENESIS INHIBITOR?")


=> s (l27 or l28 or l29) and HEART
L30      53 (L27 OR L28 OR L29) AND HEART

=> s L30 AND ISCHEMIA
L31      24 L30 AND ISCHEMIA

=> s L31 and (treat or treating or treatment)
L32      19 L31 AND (TREAT OR TREATING OR TREATMENT)

=> d l32 1-19 hitstr ibib all

L32 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
IT 5315-25-3, 2-Bromo-6-methylpyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
    (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in
    treatment of diseases)
RN 5315-25-3 CAPLUS
CN Pyridine, 2-bromo-6-methyl- (CA INDEX NAME)
```



```
IT 115926-52-8, PI3 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (α and γ isoforms; preparation of thiazolidinedione derivs. as
    PI3 kinase inhibitors useful in treatment of diseases)
RN 115926-52-8 CAPLUS
CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)
```

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

```
ACCESSION NUMBER: 2008:127697 CAPLUS
DOCUMENT NUMBER: 148:191939
TITLE: Preparation of thiazolidinedione derivatives as PI3
        kinase inhibitors
INVENTOR(S): Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven
              David; Schaller, Lee; Tang, Jun
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 72pp.
          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008014219	A2	20080131	WO 2007-US74155	20070724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-820147P P 20060724  
 US 2006-820973P P 20060801

OTHER SOURCE(S): MARPAT 148:191939

AN 2008:127697 CAPLUS

DN 148:191939

ED Entered STN: 01 Feb 2008

TI Preparation of thiazolidinedione derivatives as PI3 kinase inhibitors

IN Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven David; Schaller, Lee;  
 Tang, Jun

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 72pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008014219	A2	20080131	WO 2007-US74155	20070724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US	2006-820147P	P	20060724		
	US 2006-820973P	P	20060801		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2008014219	IPC1	A61K0031-519 [I,A]
	IPCR	A61K0031-519 [I,C]; A61K0031-519 [I,A]

OS MARPAT 148:191939

GI



II

- AB Invented is a method of inhibiting the activity/function of PB kinases using thiazolidinedione derivs. I [R1 = H, alkyl, aryl, etc.; R2, R3 = H, halo, acyl, etc.; n = 0-3; m = 0-2; A, B, D, E and G together form a ring containing from 1 to 2 double bonds and from 1 to 4 N atoms; X, Y, Z = CH, CR3 and N; provided that one and only one of A and B = N]. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivs. I. Twenty-six compds. I were prepared E.g., a multi-step synthesis of II, starting from 2-amino-5-bromopyridine and Et 2-chloro-3-oxopropanoate potassium salt, was described. Exemplified compds. I showed IC50 values from 1 nM to 10  $\mu$ M against PI3K $\alpha$ . Pharmaceutical composition comprising compound I is claimed.
- ST thiazolidinedione imidazopyridine prepn phosphatidylinositol PI3 kinase inhibitor antiinflammatory cardiovascular; autoimmune disorder treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; neurodegenerative kidney disease treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; allergy inhibitor treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; pancreatitis multiorgan failure treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; antiasthmatic antitumor immunosuppressant thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; platelet aggregation inhibitor thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase
- IT Nervous system, disease  
(Huntington's chorea; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Sarcoma  
(Kaposi's; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Microtubule  
(anti-microtubule agents, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Cytotoxic agents  
(antimetabolites, codrugs; preparation of thiazolidinedione derivs. as PI3

kinase inhibitors useful in treatment of diseases)

IT Muscle, disease  
(atrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection  
(bacterial, acute; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection  
(bacterial, chronic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
(chronic obstructive pulmonary disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Alkylating agents, biological  
Antibiotics  
Antitumor agents  
Immunotherapy  
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Hormones, animal, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease  
(degeneration; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Skeletal muscle  
(disease, atrophy; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Angiogenesis  
(disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Sperm motility  
(disorder; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cardiomyocyte  
(dysfunction; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung  
(epithelium, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(fibrosis, progressive; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Muscle, disease  
(hypertrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Brain, disease  
(infection; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Respiratory system, disease  
(inflammation; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
(injury, endothelial; preparation of thiazolidinedione derivs. as PI3 kinase

inhibitors useful in treatment of diseases)

IT Lung, disease  
(injury, epithelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
Reperfusion  
(injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Neoplasm  
(leukocyte recruitment in; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Endothelium  
(lung, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Neoplasm  
(metastasis, invasion; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Hypertrophy  
(muscular, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Angiogenesis inhibitors  
(non-receptor tyrosine kinase, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Pancreas, disease  
(pancreatitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Signal transduction  
(pathway inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Coordination compounds  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(platinum, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Lung, disease  
(pneumonitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Allergy  
Allergy inhibitors  
Alzheimer's disease  
Anaphylaxis  
Anti-Alzheimer's agents  
Anti-infective agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Anticoagulants  
Antifibrotic agents  
Antihypertensives  
Antirheumatic agents  
Antiviral agents  
Asthma  
Atherosclerosis  
Autoimmune disease  
Cardiac hypertrophy  
Cardiovascular agents  
Cardiovascular system, disease  
Central nervous system agents

Combination chemotherapy  
 Encephalitis  
 Fibrosis  
 Glomerulosclerosis  
   Heart, disease  
 Human  
 Hypertension  
 Immunosuppressants  
 Inflammation  
 Inflammatory bowel disease  
   Ischemia  
 Kidney, disease  
 Leukemia  
 Mammary gland, neoplasm  
 Melanoma  
 Meningitis  
 Multiple organ failure  
 Multiple sclerosis  
 Neoplasm  
 Nervous system agents  
 Neuroprotective agents  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Pharmaceutical carriers  
 Platelet activation  
 Platelet aggregation  
 Platelet aggregation inhibitors  
 Prodrugs  
 Prostate gland, neoplasm  
 Psoriasis  
 Respiratory system agents  
 Rheumatoid arthritis  
 Sepsis  
 Stroke  
 Thrombosis  
 Transplant rejection  
 Vasoconstriction  
 Vasodilators  
   (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in  
   treatment of diseases)  
 IT Apoptosis  
   (proapoptotic agents, codrugs; preparation of thiazolidinedione derivs. as  
   PI3 kinase inhibitors useful in treatment of diseases)  
 IT Injury  
   (pulmonary, endothelial; preparation of thiazolidinedione derivs. as PI3  
   kinase inhibitors useful in treatment of diseases)  
 IT Injury  
   (pulmonary, epithelial; preparation of thiazolidinedione derivs. as PI3  
   kinase inhibitors useful in treatment of diseases)  
 IT Epithelium  
   (pulmonary, injury; preparation of thiazolidinedione derivs. as PI3 kinase  
   inhibitors useful in treatment of diseases)  
 IT Injury  
   (pulmonary; preparation of thiazolidinedione derivs. as PI3 kinase  
   inhibitors useful in treatment of diseases)  
 IT Leukocyte  
   (recruitment in cancer tissue; preparation of thiazolidinedione derivs. as  
   PI3 kinase inhibitors useful in treatment of diseases)  
 IT Fibrosis  
   (renal, progressive; preparation of thiazolidinedione derivs. as PI3 kinase  
   inhibitors useful in treatment of diseases)

IT Injury  
(reperfusion; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation  
(respiratory tract; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cell cycle  
(signaling inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus  
(systemic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Central nervous system, disease  
(trauma; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection  
(viral, acute; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection  
(viral, chronic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 7440-06-4D, Platinum, complexes  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 142805-56-9, Topoisomerase II 143180-75-0  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 866261-76-9  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 1004549-86-3P 1004549-93-2P 1004549-94-3P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 1004549-83-0P 1004549-84-1P 1004549-85-2P 1004549-87-4P  
1004549-88-5P 1004549-89-6P 1004549-90-9P 1004549-91-0P  
1004549-92-1P 1004549-95-4P 1004549-96-5P 1004549-97-6P  
1004549-98-7P 1004549-99-8P 1004550-00-8P 1004550-01-9P  
1004550-02-0P 1004550-03-1P 1004550-04-2P 1004550-05-3P  
1004550-06-4P 1004550-07-5P 1004550-08-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 109-04-6, 2-Bromopyridine 431-35-6, 3-Bromo-1,1,1-trifluoro-2-propanone  
626-55-1, 3-Bromopyridine 816-40-0, 1-Bromo-2-butanone 1072-97-5,  
2-Amino-5-bromopyridine 1532-97-4, 4-Bromoisoquinoline 1692-15-5,  
Pyridine-4-boronic acid 1694-29-7, 3-Chloroacetylacetone 2295-31-0,  
2,4-Thiazolidinedione 5315-25-3, 2-Bromo-6-methylpyridine  
5469-26-1, 1-Bromo-3,3-dimethyl-2-butanone 7752-82-1,  
2-Amino-5-bromopyrimidine 20503-40-6 29681-44-5, Methyl  
5-bromocitrate 35216-39-8, 3-(Methylsulfonyl)aniline 40235-68-5,  
3-Chloro-2-oxopropyl acetate 116355-16-9, Imidazo[1,2-a]pyridine-6-carboxaldehyde 132213-07-1, Imidazo[1,2-a]pyridine-6-methanol

387350-88-1 1004550-24-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 6188-23-4P 30493-41-5P 138888-98-9P 154877-65-3P 167884-21-1P  
372198-69-1P 474706-74-6P 474708-98-0P 865156-68-9P 936638-00-5P  
1004550-09-7P 1004550-10-0P 1004550-11-1P 1004550-12-2P  
1004550-13-3P 1004550-14-4P 1004550-15-5P 1004550-16-6P  
1004550-17-7P 1004550-18-8P 1004550-19-9P 1004550-20-2P  
1004550-21-3P 1004550-22-4P 1004550-23-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

( $\alpha$  and  $\gamma$  isoforms; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

L32 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 129318-43-0, Fosamax


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

RN 129318-43-0 CAPLUS

CN Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1) (CA INDEX NAME)



● Na

ACCESSION NUMBER: 2008:123834 CAPLUS

DOCUMENT NUMBER: 148:183423

TITLE: Preparation of indole compounds having CRTH2 antagonist activity for treating allergic diseases, asthma, and inflammatory conditions

INVENTOR(S): Armer, Richard Edward; Wynne, Graham Michael

PATENT ASSIGNEE(S): Oxagen Limited, UK

SOURCE: PCT Int. Appl., 68pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008012511	A1	20080131	WO 2007-GB2761	20070720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				



GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-14608 A 20060722  
 GB 2006-24176 A 20061204

OTHER SOURCE(S): MARPAT 148:183423

AN 2008:123834 CAPLUS

DN 148:183423

ED Entered STN: 31 Jan 2008

TI Preparation of indole compounds having CRTH2 antagonist activity for  
 treating allergic diseases, asthma, and inflammatory conditions

IN Armer, Richard Edward; Wynne, Graham Michael

PA Oxagen Limited, UK

SO PCT Int. Appl., 68pp.

CODEN: PIXXD2

DT Patent

LA English

CC 1-7 (Pharmacology)

Section cross-reference(s): 27

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008012511	A1	20080131	WO 2007-GB2761	20070720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2006-14608	A	20060722		
	GB 2006-24176	A	20061204		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2008012511	IPCI	C07D0209-10 [I,A]; C07D0209-00 [I,C*]; A61K0031-405 [I,A]; A61K0031-403 [I,C*]
	IPCR	C07D0209-00 [I,C]; C07D0209-10 [I,A]; A61K0031-403 [I,C]; A61K0031-405 [I,A]

OS MARPAT 148:183423

GI



- AB Compds. of general formula I (wherein R is Ph optionally substituted with one or more halo substituents) and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are antagonists at the CRTH2 receptor and are useful in the treatment of conditions mediated by PGD2 or other agonists binding to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases. A process for preparing I was addnl. claimed. Example compound II was prepared by
- measuring reacting 2-(phenylsulfonyl)benzaldehyde with 2-(5-fluoro-2-methyl-1H-indol-1-yl)acetic acid and saponification of the resulting ester. In an assay inhibition of 13,14-dihydro-15-keto-prostaglandin D2 induced blood eosinophilia in rats, II had an ED50 of 0.0025  $\mu\text{g/mL}$ .
- ST indole compd prepn CRTH2 antagonist immune inflammatory disease treatment
- IT Bradykinin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (B1, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Bradykinin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (B2, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Inflammatory bowel disease  
 (Crohn's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Hand  
 (Dupuytren's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLAP (arachidonate lipoxygenase-activating protein), inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Fever and Hyperthermia  
 (Familial Hibernian fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Ulcer  
 (Hunner's ulcer; preparation of indole compds. having CRTH2 antagonist

activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihistamines  
(H4, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tumor necrosis factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(IGs as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(IgE, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(Kikuchi disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Monoamine oxidase inhibitors  
(MAOB inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(Muckle-Wells syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists  
(M1, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists  
(M2, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Glutamate antagonists  
(NMDA antagonists, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT P2x purinoreceptor antagonists  
(P2X7, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Peroxisome proliferators  
(PPAR-γ agonists as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(Sweet's syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(Weber-Christian syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy  
 Eye, disease  
 Inflammation  
 (allergic conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant rejection  
 (allotransplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Edema  
 (angioneurotic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
 Spinal column, disease  
 (ankylosing spondylitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gout  
 (anti-gout drugs, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anti-idiotypic, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antiarteriosclerotics  
 (antiatherosclerotics; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antitumor agents  
 (antibiotic, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cytotoxic agents  
 (antimetabolites, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mitosis  
 (antimitotic agents, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibiotics  
 (antitumor, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Artery, disease  
 (aorta, aortitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia  
 (areata; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
 (arthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy  
(as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis  
(atopic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Autoimmune disease  
Inflammation  
Thyroid gland, disease  
(autoimmune thyroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pain  
(back; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Leukotrienes  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(biosynthesis inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease  
Inflammation  
(blepharitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Drug delivery systems  
(bronchial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease  
(bronchiectasis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease  
Inflammation  
(bronchitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fibrosis  
(cardiac; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
(cellulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gallbladder, disease  
Inflammation  
(cholecystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease  
(choroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease  
(chronic obstructive pulmonary disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases,

asthma, inflammatory conditions, and other diseases)

IT Anti-infective agents  
 Antiandrogens  
 Antiestrogens  
 Aromatase inhibitors  
 Cytotoxic agents  
 Fungicides  
 H1-antihistamines  
 H2-antihistamines  
 $\beta$ 1-Adrenoceptor agonists  
 $\beta$ 2-Adrenoceptor agonists  
 $\beta$ 3-Adrenoceptor agonists  
 (codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Anthracyclines  
 Antisense oligonucleotides  
 Progestogens  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Angiogenesis inhibitors  
 Angiotensin AT2 receptor antagonists  
 Angiotensin-converting enzyme inhibitors  
 Anti-Alzheimer's agents  
 Antidepressants  
 Antimicrobial agents  
 Antiosteoporotic agents  
 Antiparkinsonian agents  
 Calcium channel blockers  
 Central nervous system agents  
 Cholinergic antagonists  
 Cyclooxygenase 1 inhibitors  
 Cyclooxygenase 2 inhibitors  
 Dopamine agonists  
 Enzyme inhibitors  
 HMG-CoA reductase inhibitors  
 Hypolipemic agents  
 Immunomodulators  
 Leukotriene antagonists  
 Nicotinic antagonists  
 Platelet aggregation inhibitors  
 Uricosuric agents  
 $\beta$ -Adrenoceptor antagonists  
 (codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Corticosteroids, biological studies  
 Fibrates  
 Growth hormone secretagogues  
 Interferons  
 Platelet-derived growth factors  
 Transforming growth factor  $\beta$   
 Tumor necrosis factors  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease  
(complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Central nervous system, disease  
Peripheral nervous system, disease  
(complications of malignant, infectious, or autoimmune disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease  
Inflammation  
(conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis  
(contact; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eosinophilia  
Lymphoma  
(cutaneous; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bladder, disease  
Inflammation  
(cystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm  
(cytokine-transfected tumor cell lines as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nerve, disease  
(degeneration; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mental and behavioral disorders  
(dementia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus erythematosus  
(discoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Penis  
(disease, Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Oviduct  
(disease, salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Urethra  
(disease, urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Joint, anatomical  
(disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (down regulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
 (dysplasia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
 (eosinophilic paschiitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
 (epidermolysis bullosa; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reproductive system, disease  
 (epididymitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Esophagus, disease  
 Inflammation  
 (esophagitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Amyloidosis  
 (familial Mediterranean fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fever and Hyperthermia  
 (familial Mediterranean; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease  
 (farmer's lung; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Heart, disease  
 (fibrosis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy  
 (gene-directed enzyme prodrug therapy, as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gingiva, disease  
 Inflammation  
 (gingivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
 Kidney, disease  
 (glomerulonephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
 Tongue, disease  
 (glossitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis



(herpetiformis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy  
Inflammation  
Lung, disease  
(hypersensitivity pneumonitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Purpura (disease)  
(idiopathic thrombocytopenic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sexual disorders  
(impotence; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Growth factor receptors  
Growth factors, animal  
Urokinase-type plasminogen activator receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Hepatocyte growth factor  
Platelet-derived growth factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cell adhesion molecules  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reperfusion  
(injury; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pneumonia  
(interstitial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatoid arthritis  
(juvenile; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mouth, disease  
Skin, disease  
(lichen planus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sclerosis  
(lichen sclerosis et atrophica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant and Transplantation  
(lung, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia

(male pattern; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interleukin 4  
Interleukin 5  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(modulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(modulators, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoclonal, anti-TNF, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Erythema  
(multiforme; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
Kidney, disease  
(nephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, neoplasm  
(non-melanoma; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pharmacokinetics  
(of indole compds.; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Ovary, disease  
(oophoritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease  
Inflammation  
(ophthalmitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
Pancreas, disease  
(pancreatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal  
(panniculitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm  
(paraneoplastic syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
(pemphigoid; preparation of indole compds. having CRTH2 antagonist activity

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
(pemphigus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
Pericardium  
(pericarditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
Vein, disease  
(phlebitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
(photodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis  
(phytodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatic diseases  
(polymyalgia rheumatica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nose, neoplasm  
(polyp; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT AIDS (disease)

Acne

Addison's disease

Allergy

Allergy inhibitors

Alzheimer's disease

Analgesics

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antidiabetic agents

Antifibrotic agents

Antiphospholipid syndrome

Antirheumatic agents

Antitumor agents

Antitussives

Antilulcer agents

Antiviral agents

Asthma

Atherosclerosis

Autoimmune disease

Behcet's syndrome

Bone, disease

Cardiomyopathy

Cardiovascular agents

Celiac disease

Cirrhosis  
 Connective tissue, disease  
 Cough  
 Cystic fibrosis  
 Dermatological agents  
 Diabetes mellitus  
 Drug delivery systems  
 Eczema  
 Emphysema  
 Endocarditis  
 Fibrosis  
 Food allergy  
 Gastrointestinal agents  
 Graves' disease  
 Hepatitis  
 Human  
 Inflammatory bowel disease  
 Ischemia  
 Leprosy  
 Mastocytosis  
 Multiple sclerosis  
 Myasthenia gravis  
 Myocarditis  
 Myositis  
 Nasal drug delivery systems  
 Neoplasm  
 Nervous system agents  
 Oral drug delivery systems  
 Osteoarthritis  
 Pain  
 Parenteral drug delivery systems  
 Periodontitis  
 Proctitis  
 Psoriasis  
 Rectal drug delivery systems  
 Retinal disease  
 Rheumatic fever  
 Rheumatoid arthritis  
 Sarcoidosis  
 Scleroderma  
 Seborrhea  
 Sezary syndrome  
 Sjogren syndrome  
 Thrombosis  
 Topical drug delivery systems  
 Urticaria  
 Uveitis  
 Vaginal drug delivery systems  
 Vascular restenosis  
 Vasculitis

(preparation of indole compds. having CRTH2 antagonist activity for  
 treating allergic diseases, asthma, inflammatory conditions,  
 and other diseases)

- IT Wound healing
- Wound healing promoters
- (promotion of healing without fibrotic scarring; preparation of indole  
 compds. having CRTH2 antagonist activity for treating  
 allergic diseases, asthma, inflammatory conditions, and other diseases)

- IT Inflammation
- Prostate gland, disease
- (prostatitis; preparation of indole compds. having CRTH2 antagonist activity

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pruritus  
(pruritus ani; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis  
(psoriatic arthritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihypertensives  
Hypertension  
(pulmonary; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
(pyoderma, pyoderma gangrenosum; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis  
(reactive; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Injury  
(reperfusion; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
Nose, disease  
(rhinitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
(salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease  
(sarcoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis  
(septic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Spinal column, disease  
(spondyloarthropathy, undifferentiated spondarthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mast cell  
(stabilizers as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis  
Synovial membrane, disease  
(synovitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus erythematosus  
(systemic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Erythema  
(toxic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Animal cell  
(transfected immune cells as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung  
(transplant, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interleukin 2  
Interleukin 4  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor cell transfection with interleukins as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Prostanoid receptors  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(type DP2; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tachykinin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type NK1, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tachykinin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type NK3, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammatory bowel disease  
(ulcerative colitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Colitis  
(ulcerative; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation  
(urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Heart, disease  
(valvulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Drugs  
(vascular damaging agents as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease  
(vasculitic and thrombotic disorders; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alkaloids, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)  
(vinca, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Infection  
(viral; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Vagina, disease  
(vulvovaginitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha\beta3$ , inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha4\beta1$ , antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interferons  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ , codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT  $\beta$ -Adrenoceptor agonists  
( $\beta4$ , as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 141579-87-5  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Abbott 79175, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 65154-06-5, Platelet activating factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-33-9, Phenylbutazone, biological studies 50-76-0, Dactinomycin 50-78-2, Aspirin 51-21-8, 5-Fluorouracil 52-67-5, D-Penicillamine 53-86-1, Indomethacin 55-86-7, Nitrogen mustard 55-98-1, Busulfan 57-22-7, Vincristine 58-55-9, Theophylline, biological studies 59-05-2, Methotrexate 59-42-7, Phenylephrine 61-68-7 90-82-4, Pseudoephedrine 101-40-6, Propylhexedrine 113-92-8 118-42-3, Hydroxychloroquine 127-07-1, Hydroxyurea 147-94-4, Cytosine arabinoside 148-82-3, Melphalan 305-03-3, Chlorambucil 317-34-0, Aminophylline 427-51-0, Cyproterone acetate 446-86-6, Azathioprine 522-48-5, Tetrahydrozoline hydrochloride 550-99-2, Naphazoline hydrochloride 586-06-1, Metaproterenol 595-33-5, Megestrol acetate 865-21-4, Vinblastine 1218-35-5, Xylometazoline hydrochloride 2315-02-8, Oxymetazoline hydrochloride 3198-07-0 5104-49-4, Flurbiprofen 6569-51-3, Borazole 6990-06-3, Fusidic acid 7683-59-2, Isoproterenol 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13311-84-7, Flutamide 13539-59-8, Apazone 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen

15826-37-6, Sodium cromoglycate 17902-23-7, Tegafur 18378-89-7  
 18559-94-9, Albuterol 20830-81-3, Daunomycin 22071-15-4, Ketoprofen  
 22204-53-1, Naproxen 23031-25-6, Terbutaline 23214-92-8, Doxorubicin  
 23593-75-1, Clotrimazole 25316-40-9, Adriamycin 29679-58-1, Fenoprofen  
 29767-20-2, Teniposide 30392-41-7, Bitolterol mesylate 30516-87-1, AZT  
 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34031-32-8, Auranofin  
 36322-90-4, Piroxicam 38194-50-2, Sulindac 38677-81-5, Pirbuterol  
 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53123-88-9, Rapamycin  
 53643-48-4, Vindesine 53714-56-0, Leuporelin 56420-45-2, Epirubicin  
 57982-77-1, Buserelin 58581-89-8, Azelastine 58957-92-9, Idarubicin  
 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 63612-50-0, Nilutamide  
 63798-73-2, Cyclosporin E 65807-02-5, Goserelin 68844-77-9, Astemizole  
 71125-38-7, Meloxicam 71486-22-1, Vinorelbine 73573-87-2, Formoterol  
 75706-12-6, Leflunomide 79794-75-5, Loratidine 82413-20-5, Droloxifene  
 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 89365-50-4, Salmeterol  
 89778-26-7, Toremifene 90357-06-5, Bicalutamide 94055-76-2, Suplatast  
 tosylate 95058-81-4, Gemcitabine 98319-26-7, Finasteride 100643-71-8  
 104227-87-4 104987-11-3, Tacrolimus 107868-30-4, Exemestane  
 112809-51-5, Letrozole 112887-68-0, Raltitrexed 114977-28-5, Taxotere  
 116057-75-1 117048-59-6, Combretastatin A4 120511-73-1 123948-87-8,  
 Topotecan 126544-47-6, Ciclesonide 129453-61-8, Fulvestrant  
 137071-32-0, Pimecrolimus 154039-60-8, Marimastat 159989-65-8,  
 Viracept 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 180288-69-1,  
 Trastuzumab 181695-72-7, Valdecoxib 202409-33-4, Etoricoxib  
 205923-56-4, Cetuximab 242138-07-4, Omalizumab

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(codrug; preparation of indole compds. having CRTH2 antagonist activity for  
 treating allergic diseases, asthma, inflammatory conditions,  
 and other diseases)

IT 50-24-8, Prednisolone 53-03-2, Prednisone 57-66-9, Probenecid  
 57-96-5, Sulfapyrazone 59-92-7, biological studies 64-86-8,  
 Colchicine 76-25-5, Triamcinolone acetonide 315-30-0, Allopurinol  
 321-64-2, Tacrine 404-86-4, Capsaicin 2323-36-6, Deprenyl 3385-03-3,  
 Flunisolide 3562-84-3, Benzbromarone 5534-09-8, Beclomethasone  
 dipropionate 7440-57-5D, Gold, compds. 9004-08-4, Cathepsin  
 9004-61-9, Synvisc 9067-32-7, Hyalgan 14611-51-9, Selegiline  
 22254-24-6, Ipratropium bromide 28797-61-7, Pirenzepine 30286-75-0,  
 Oxitropium bromide 51333-22-3, Budesonide 55242-55-2, Propentofylline  
 62031-54-3, Fibroblast growth factor 79617-96-2, Sertraline  
 80474-14-2, Fluticasone propionate 80880-90-6, Telenzepine 83869-56-1,  
 Colony-stimulating factor 2 83919-23-7, Mometasone furoate 80488-42-6,  
 Linomide 84449-90-1 91374-20-8, Requip 93211-49-5, L-651392  
 96566-25-5, Ablukast 103177-37-3, Pranlukast 103475-41-8, Tepoxalin  
 106096-93-9, Basic fibroblast growth factor 107753-78-6, Zafirlukast  
 111406-87-2, Zileuton 118414-82-7, MK-886 120014-06-4, Donepezil  
 120128-20-3, RG-12525 120443-16-5, Verlukast 122320-73-4,  
 Rosiglitazone 128312-51-6, Ro-24-5913 129318-43-0, Fosamax  
 134308-13-7, Tasmar 136236-51-6, Rasagiline 136310-93-5, Tiotropium  
 bromide 140841-32-3, ZD2138 141579-54-6, Fenleuton 143538-27-6, BAY  
 x 7195 147030-01-1, MK-591 147398-01-4, CGS-25019c 147432-77-7,  
 Ontazolast 151581-24-7, Iralukast 153259-65-5, Cilomilast  
 154355-76-7, ABT-761 158930-07-5, L-739010 158966-92-8, Montelukast  
 162750-10-9, SB-210661 168154-07-2, L-746530 171964-73-1, ZD-0892  
 174636-32-9, Talnetant 180916-16-9, Lasofoxifene 183321-74-6,  
 Erlotinib 184475-35-2, Gefitinib 188039-54-5, Palivizumab  
 191217-81-9, Mirapex 204974-93-6, BIL 284/260 216974-75-3,  
 Bevacizumab 257892-34-5, D-4418 289499-45-2, CI 1033 350610-64-9,  
 NKP 608C 446023-33-2, UT 77

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)



- (codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 1004293-19-9P, 2-[5-Fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1H-indol-1-yl]acetic acid 1004293-21-3P, 2-[3-[2-(4-Chlorophenylsulfonyl)benzyl]-5-fluoro-2-methyl-1H-indol-1-yl]acetic acid 1004293-24-6P, 2-[5-Fluoro-3-[2-(4-fluorophenylsulfonyl)benzyl]-2-methyl-1H-indol-1-yl]acetic acid  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9025-82-5, Phosphodiesterase 9026-43-1 9036-21-9, PDE4 62229-50-9, Epidermal growth factor 79079-06-4, EGF receptor tyrosine kinase 80449-02-1 131384-38-8, Farnesyl transferase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9004-06-2, Elastase 9081-34-9, 5α Reductase 80449-01-0, Topoisomerase 80619-02-9, 5-Lipoxygenase 81669-70-7 86090-08-6, Angiotensin 151769-16-3, TACE 501433-35-8, INOS 506430-87-1, Neuronal nitric oxide synthase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9001-66-5 9012-25-3, Catechol methyltransferase 141907-41-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9039-48-9, Aromatase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9001-40-5, Glucose-6-phosphate dehydrogenase 9002-17-9, Xanthine oxidase 9015-82-1 9028-35-7 9028-93-7, Inosine monophosphate dehydrogenase 97501-93-4, Tryptase 122191-40-6, Interleukin converting enzyme 142243-02-5 329900-75-6 329967-85-3  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 67763-96-6, Insulin-like growth factor I  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mimetics as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 9034-40-6, Luteinizing hormone-releasing factor  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (modulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT 41598-07-6, Prostaglandin D2  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 371-42-6, 4-Fluorobenzenethiol 446-52-6, 2-Fluorobenzaldehyde 873-55-2, Benzenesulfinic acid sodium salt 107572-07-6, 2-(4-Chlorophenylthio)benzaldehyde 646515-46-0, 2-(5-Fluoro-2-methyl-1H-indol-1-yl)acetic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 126076-76-4P, 2-(Phenylsulfonyl)benzaldehyde 643763-14-8P, 2-(4-Fluorophenylthio)benzaldehyde 1004293-20-2P 1004293-22-4P, 2-(4-Chlorophenylsulfonyl)benzaldehyde 1004293-23-5P, Ethyl 2-[3-[[2-(4-chlorophenylsulfonyl)phenyl]methyl]-5-fluoro-2-methyl-1H-indol-1-yl]acetate 1004293-25-7P 1004293-26-8P, 1-(Dimethoxymethyl)-2-(4-fluorophenylsulfonyl)benzene 1004293-27-9P, 2-(4-Fluorophenylsulfonyl)benzaldehyde 1004293-28-0P, Ethyl 2-[5-fluoro-3-[[2-(4-fluorophenylsulfonyl)phenyl]methyl]-2-methyl-1H-indol-1-yl]acetate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 51-61-6, Dopamine, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (reuptake inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bach Nicholas J; US 5641800 A 1997 CAPLUS

(2) Boyd; WO 2005044260 A 2005 CAPLUS

(3) Shionogi & Co; EP 1505061 A1 2005 CAPLUS

L32 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 129318-43-0, Fosamax

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(integrin-binding small mols. for treatment of diseases and combination with other agents)

RN 129318-43-0 CAPLUS

CN Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1) (CA INDEX NAME)



● Na

ACCESSION NUMBER: 2007:563324 CAPLUS

DOCUMENT NUMBER: 147:2055

TITLE: Integrin-binding small molecules

INVENTOR(S): Neamati, Nouri; Dayam, Raveendra  
 PATENT ASSIGNEE(S): University of Southern California, USA  
 SOURCE: PCT Int. Appl., 112pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059195	A1	20070524	WO 2006-US44305	20061114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20070155750	A1	20070705	US 2006-559857	20061114
PRIORITY APPLN. INFO.:			US 2005-736780P	P 20051114
OTHER SOURCE(S):	MARPAT 147:2055			

AN 2007:563324 CAPLUS  
 DN 147:2055  
 ED Entered STN: 24 May 2007  
 TI Integrin-binding small molecules  
 IN Neamati, Nouri; Dayam, Raveendra  
 PA University of Southern California, USA  
 SO PCT Int. Appl., 112pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 CC 1-12 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059195	A1	20070524	WO 2006-US44305	20061114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20070155750	A1	20070705	US 2006-559857	20061114
PRAI US 2005-736780P	P	20051114		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007059195	IPCI	A61K0031-52 [I,A]; A61K0031-519 [I,C*]; A61K0031-517 [I,A]

IPCR A61K0031-519 [I,C]; A61K0031-52 [I,A]; A61K0031-517  
 [I,C]; A61K0031-517 [I,A]  
 US 20070155750 IPCI A61K0031-519 [I,A]; A61K0031-525 [I,A]  
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-525  
 [I,A]  
 NCL 514/249.000; 514/251.000; 514/264.100  
 OS MARPAT 147:2055  
 AB The present invention relates in general to integrin-binding small mols.  
 More specifically, the invention provides novel compns. and methods of  
 using these compns. for treating various diseases. Accordingly,  
 in one aspect, the invention features a composition comprising a compound, or a  
 pharmaceutically or cosmeceutically acceptable salt, solvate, or hydrate  
 thereof, wherein the compound comprises one H-bond donor (HBD), one H-bond  
 acceptor (HBA), two hydrophobic aromatic groups (HAR1 and HAR2), and one neg.  
 ionizable group (NI).  
 ST integrin binding mol disease treatment  
 IT Inflammatory bowel disease  
 (Crohn's disease; integrin-binding small mols. for treatment  
 of diseases and combination with other agents)  
 IT Bone, disease  
 (Paget's; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Blood vessel, disease  
 (adhesion; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Respiratory distress syndrome  
 (adult; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Retinal disease  
 (age-related macular degeneration; integrin-binding small mols. for  
 treatment of diseases and combination with other agents)  
 IT Thrombosis  
 (arterial; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Disease, animal  
 (arthropathy, hemophilic; integrin-binding small mols. for  
 treatment of diseases and combination with other agents)  
 IT Dermatitis  
 (atopic; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Cardiovascular system  
 Immune system  
 Inflammation  
 Vascular endothelium  
 (cells, integrins of; integrin-binding small mols. for  
 treatment of diseases and combination with other agents)  
 IT Thrombosis  
 (cerebral artery; integrin-binding small mols. for treatment  
 of diseases and combination with other agents)  
 IT Ischemia  
 (cerebral; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Gastroenteritis  
 (chronic; integrin-binding small mols. for treatment of  
 diseases and combination with other agents)  
 IT Estrogens  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (conjugated, Premarin; integrin-binding small mols. for  
 treatment of diseases and combination with other agents)  
 IT Dermatitis

(contact; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Transplant and Transplantation  
(cornea, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye  
(cornea, transplant, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Radiation  
(damage, dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis  
(dermatitis exfoliativa neonatorum; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Cosmetics and personal care products  
IR radiation  
Ionizing radiation  
UV radiation  
(dermatitis from; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Toxicity  
(dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease  
(diabetic retinopathy, proliferative; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Joint, anatomical  
(disease, hemophilic; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Mucous membrane  
(disease, inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Lung, disease  
(embolism; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Hyperplasia  
(endometrial; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease  
(endometriosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease  
(endometrium, hyperplasia; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease  
(erythematous squamous dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Gingiva, disease  
Inflammation  
(gingivitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Wound  
(granulation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease  
(hemorrhage; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis  
(herpetiformis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Muscle, disease

(idiopathic inflammatory myopathy; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Blood vessel  
(imaging agents for; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Radionuclides, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(imaging agents; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Platelet activation  
(inappropriate; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adenoviridae  
Bunyaviridae  
Foot-and-mouth disease virus  
Hantavirus  
Human coxsackievirus  
Human echovirus  
Human immunodeficiency virus 1  
Human parechovirus  
Picornaviridae  
Reoviridae  
Retroviridae  
Rotavirus  
(infection, integrins in; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Vascular restenosis  
(inhibitors; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adhesion, biological  
Allergy  
Allergy inhibitors  
Angiogenesis  
Angiogenesis inhibitors  
Angioplasty  
Animalia  
Animals  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiartherosclerotics  
Antiarthritics  
Antiasthmatics  
Anticoagulants  
Antiosteoporotic agents  
Antirheumatic agents  
Antitumor agents  
Arterial occlusion  
Arteriosclerosis  
Asthma  
Atherectomy  
Autoimmune disease  
Blood vessel, disease  
Combination chemotherapy  
Coronary artery disease  
Coronary bypass surgery  
Coronary thrombosis  
Cosmetics and personal care products  
Dermatitis  
Dermatomyositis  
Drug screening

Duodenitis  
 Eczema  
 Embolism  
 Erythema  
 Eye, neoplasm  
 Gastritis  
 Hemangioma  
 Hematopoietic neoplasm  
 Hodgkin's disease  
 Human  
 Imaging agents  
 Immune disease  
 Inflammation  
 Inflammatory bowel disease  
 Ischemia  
 Keloid  
 Leukemia  
 Mucosal drug delivery systems  
 Multiple myeloma  
 Multiple sclerosis  
 Myeloproliferative disorders  
 Myocardial infarction  
 Myocardial ischemia  
 Neoplasm  
 Non-Hodgkin lymphoma  
 Oral drug delivery systems  
 Osteoporosis  
 Parenteral drug delivery systems  
 Pharmaceutical carriers  
 Preeclampsia  
 Psoriasis  
 Radiopharmaceuticals  
 Rectal drug delivery systems  
 Rheumatoid arthritis  
 Seborrhea  
 Stroke  
 Sunburn  
 Telangiectasia  
 Thrombosis  
 Transdermal drug delivery systems  
 Transplant rejection  
 Uveitis  
 Wart

(integrin-binding small mols. for treatment of diseases and  
 combination with other agents)

IT Integrins

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,  
 unclassified); BIOL (Biological study)

(integrin-binding small mols. for treatment of diseases and  
 combination with other agents)

IT Thrombospondins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(integrin-binding small mols. for treatment of diseases and  
 combination with other agents)

IT Tumor necrosis factors

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(integrin-binding small mols. for treatment of diseases and  
 combination with other agents)

IT Structure-activity relationship

(integrin-binding; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Animal cell  
Dendritic cell  
Leukocyte  
Macrophage  
Osteoclast  
Stromal cell  
Vascular smooth muscle  
(integrins of; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Erythema  
(intertrigo; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Drug delivery systems  
(intradermal; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease  
(iris erythema; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Brain, disease  
(ischemia, transient; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Brain, disease  
Lung, disease  
(ischemia; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Hemophilia  
(joint disease; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis  
(juvenile; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease  
(lichen planus; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease  
(macular degeneration; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Bone, neoplasm  
(metastasis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Inflammation  
(mucous membrane; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Erythema  
(multiforme; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Myeloproliferative disorders  
(myelofibrosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease  
(neovascularization, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angiogenesis  
(neovascularization, eye, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angiogenesis  
(neovascularization, heart; integrin-binding small mols. for treatment of diseases and combination with other agents)



IT Heart, disease  
(neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis  
(neurodermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease  
Inflammation  
(ophthalmitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Keratosis  
(parakeratosis, variegate; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Bone, disease  
(pathol. resorption; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Allergy  
(photoallergic contact dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis  
(photoallergic contact; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Myositis  
(polymyositis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease  
(prematurity-associated; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Arthritis  
(psoriatic arthritis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Embolism  
Ischemia  
(pulmonary; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Granuloma  
(pyogenic; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease  
(rosacea; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Pharmaceutical injections  
(s.c. injections; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Connective tissue, disease  
(s.c., inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Neoplasm  
(solid; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease  
(staphylococcal scalded-skin syndrome; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Medical goods  
(stents, placement; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease  
(subcorneal pustular dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Surgery  
(thrombosis in; integrin-binding small mols. for treatment of

diseases and combination with other agents)

IT Ischemia  
(transient cerebral; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Blood vessel, disease  
(transplant vasculopathy; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Inflammatory bowel disease  
(ulcerative colitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Colitis  
(ulcerative; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angina pectoris  
(unstable; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adhesion, biological  
(vascular; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Thrombosis  
(venous; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Infection  
(viral, integrins in; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Granulation  
(wound; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Integrins  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha v\beta 3$ ; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 9002-64-6, Parathormone  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(hypercalcemia mediated by; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 7440-70-2, Calcium, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(hypercalcemia, parathormone-mediated; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 50-18-0, Cyclophosphamide 50-28-2, Climara, biological studies  
50-35-1, Thalidomide 57-22-7, Vincristine 362-07-2, 2-Methoxyestradiol 1084-65-7, Arresten 3275-78-3 4323-02-8 7414-83-7, Didronel 8015-12-1, Femhrt 9007-12-9, Calcitonin 10098-06-3 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 24045-19-0 33069-62-4, Paclitaxel 47931-85-1, Miacalcin 57248-88-1, Aredia 77728-33-7, Combipatch 82640-04-8, Evista 82855-09-2, Combretastatin 86090-08-6, Angiostatin 115436-72-1, Actonel 123948-87-8, Topotecan 129318-43-0, Fosamax 134461-48-6, Prefest 135843-32-2, Prempro 181427-78-1, NM-3 187888-07-9, Endostatin 216974-75-3, Bevacizumab 232927-14-9 292034-65-2 309732-80-7 309949-29-9 311795-57-0 312747-18-5 326906-42-7 328130-39-8 353774-36-4 354125-43-2 354144-06-2 364623-94-9 385398-46-9 425664-72-8 439946-76-6 442150-15-4 443876-79-7 500261-75-6 500577-98-0 501108-10-7 501347-80-4 593274-97-6 642000-26-8 670240-89-8 675168-61-3 850544-78-4, Tumstatin 851717-89-0 892553-42-3, Vitaxin 905811-52-1 906449-76-1, Canstatin 937237-42-8 937237-43-9 937237-44-0  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)  
(integrin-binding small mols. for treatment of diseases and  
combination with other agents)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Baell; Journal of Computer-Aided Molecular Design 2002, V16, P245 CAPLUS  
(2) Genentech Inc; WO 9845331 A2 1998 CAPLUS  
(3) Lee; Journal of Medicinal Chemistry 1974, V17(3), P326 CAPLUS

L32 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 301166-54-1, Protein, PTEN

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

RN 301166-54-1 CAPLUS

CN Phosphatase, gene PTEN (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2007:357681 CAPLUS

DOCUMENT NUMBER: 146:357244

TITLE: Dual variable domain immunoglobulins and multispecific  
derivatives for treating acute and chronic  
inflammation, cancer and other diseases

INVENTOR(S): Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.;  
Salfeld, Jochen G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 126pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070071675	A1	20070329	US 2006-507050	20060818
WO 2008024188	A2	20080228	WO 2007-US17340	20070803
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:  
US 2005-709911P P 20050819  
US 2005-732892P P 20051102  
US 2006-507050 A 20060818

AN 2007:357681 CAPLUS

DN 146:357244

ED Entered STN: 30 Mar 2007

TI Dual variable domain immunoglobulins and multispecific derivatives for  
treating acute and chronic inflammation, cancer and other diseases

IN Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G.

PA USA

SO U.S. Pat. Appl. Publ., 126pp.

CODEN: USXXCO  
 DT Patent  
 LA English  
 INCL 424001490; 530388800; 530391100; 530388220; 424155100; 424178100;  
 435069100; 435326000; 435252300; 435254210  
 CC 15-3 (Immunochemistry)  
 Section cross-reference(s): 1, 2, 3, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070071675	A1	20070329	US 2006-507050	20060818
	WO 2008024188	A2	20080228	WO 2007-US17340	20070803
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-70991P	P	20050819		
	US 2005-732892P	P	20051102		
	US 2006-507050	A	20060818		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 20070071675	INCL	424001490; 530388800; 530391100; 530388220; 424155100; 424178100; 435069100; 435326000; 435252300; 435254210
		IPCI	A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A]; C12N0001-18 [I,A]; C12N0005-06 [I,A]
		IPCR	A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C]; C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]
		NCL	424/001.490; 424/155.100; 424/178.100; 435/069.100; 435/252.300; 435/254.210; 435/326.000; 435/348.000; 530/388.220; 530/388.800; 530/391.100; 536/023.530
		ECLA	K61K; M07K; M07K; M07K
	WO 2008024188	IPCI	A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A]; C12N0001-18 [I,A]; C12N0005-06 [I,A]
		IPCR	A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C]; C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]
AB	The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.		
ST	dual variable domain humanized chimeric multispecific antibody inflammation cancer		
IT	Gram-negative bacteria (-caused sepsis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and		

other diseases)

IT Drugs  
 (-induced interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (-mediated cytotoxicity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (130; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 Keratins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (19; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Keratins  
 Syndecans  
 Thrombospondins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (20; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (21; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (22  $\alpha$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (22; dual variable domain Igs and multispecific derivs. for treating

acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (22a2; dual variable domain Igs and multispecific derivs  
 . for treating acute and chronic inflammation, cancer and  
 other diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (25; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (26; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (27; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (27w; C19orf10; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (28B; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (28c; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (29; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Thrombospondins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (2; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Keratins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (2A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (30; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Metallothioneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (3; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Thrombospondins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (4; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (5; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cyclins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (A1CDA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 10 receptors  
 Interleukin 11 receptors  
 Interleukin 12  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ABCF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ACVR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ACVR1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ACVR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ACVR2B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ACVRL1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADAM8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADORA2A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AGR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AIF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AIG1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AKAP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AKAP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AMH; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (AMHR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPT2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPTL3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPTL4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins



RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ANPEP; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Interleukin 1 receptors  
Interleukin 18 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(AP; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Interleukin 1 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(APL1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(APL2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(APOC1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(AR; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(AZGP1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Interleukin 12 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and  
other diseases)

IT Interleukin 12 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Interleukin 10 receptors  
Interleukin 12  
Interleukin 17  
Lipophilins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Cytokines  
Cytokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(BAFF; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Bcl2-associated athanogene proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(BAG-1; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BA11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BCA-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLNK (B-cell linker); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 18  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRAK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRCA1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BTNO2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bad; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bcl-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BlyS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (C-X-C, GCP-2 (granulocyte chemotactic protein 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (C/EBP- $\beta$  (CCAAT box/enhancer element-binding protein  $\beta$ ); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Complement receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (C5R1; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CANT1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CAP (catabolite gene activator protein); dual variable domain Igs  
 and multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CAV1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCBP2 (chemokine-binding protein 2); dual variable domain Igs and  
 multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCBP2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL1 (C-C motif ligand 1); dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation,  
 cancer and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL16 (C-C motif ligand 16); dual variable domain Igs and  
 multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Chemokines  
 Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL17 (C-C motif ligand 17); dual variable domain Igs and  
 multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL25 (C-C motif ligand 25); dual variable domain Igs and  
 multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL27 (C-C motif ligand 27); dual variable domain Igs and  
 multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCL28 (C-C motif ligand 28); dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCNA2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCND1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCNE1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCNE2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and  
 other diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR1; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
 Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
 Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR5; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other  
 diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR8; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CCR; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CCRL1 (chemokine (C-C motif) receptor-like 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCRL2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD164; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD1 (antigen)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD1c; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD200; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD27; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD30 ligand; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD37; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD40-L (antigen CD40 ligand); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD52; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD70; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CD72; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD79a; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD83; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 Proteins  
 Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CER1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHGA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHGB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line  
 (CHO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHST10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL25; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CLN3 (ceroid-lipofuscinosis, neuronal 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKOR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CNR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL18A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(COL1A1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(COL4A3; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(COL6A1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Animal cell line  
(COS; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and  
other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CSPG; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CX3CR1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCL16; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and  
other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR3; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR4; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXCR6; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CYB5; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and  
other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CYC1; dual variable domain Igs and multispecific derivs. for



treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYSLTR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cln3 (cyclinlike 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease  
Prion diseases  
(Creutzfeldt-Jakob; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cripto; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammatory bowel disease  
(Crohn's disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DAB2IP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DARC (Duffy antigen receptor for chemokines); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DES; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DKFZp451J0118; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNCL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DPP4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (E2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sphingosine-1-phosphate receptors

Sphingosine-1-phosphate receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EDG-1; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer  
and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EFNA1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EFNA3; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and  
other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EFNB2; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ENA-78; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ENG; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ENO1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ENO2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ENO3; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EREG; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ERK8; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ESR1; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ESR2; dual variable domain Igs and multispecific derivs. for treating  
acute and chronic inflammation, cancer and other diseases)

IT EphB receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphB4; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other

diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Prostaglandins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (F; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FADD (Fas-associated death domain protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FASN; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCER1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCER2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCGR3A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FLI1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FLJ12584; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FLJ25530; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FRA-1 (fos-related antigen 1); dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Nervous system, disease  
 (Friedreich's ataxia; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT GABA receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GABAA; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GAGEB1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GAGEC1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GALNAC4S-6ST; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GF-11; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (GGT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNAS1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNRH1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRCC10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP (glucose-regulated protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP44; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP81; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GSTP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Kidney, disease  
(Goodpasture's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (H1F1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (HAVCR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Keratins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HB6; hair-specific type II; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HDAC4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HDAC5; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HDAC7A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HDAC9; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HIP1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Histocompatibility antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HLA-A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Histocompatibility antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HLA-DR, A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HM74; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HMOX1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HSP 75; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HUMCYT2A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukin 1  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HY1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Brain, disease  
 (Hallervorden-Spatz disease; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Purpura (disease)  
 (Henoch-Schoenlein; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Heart  
 (His bundle, arrhythmia; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Nervous system, disease  
 (Huntington's chorea; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (I-TAC; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ICE-BERG; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ICOS (inducible co-stimulator), ligand; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ID2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IF-3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGBP1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGFBP-2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGFBP-3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukin 17  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IL-17C; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ILK; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (INH4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (INH4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (INSL3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (INSL4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Antibodies and Immunoglobulins  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study,  
 unclassified); BIOL (Biological study)  
 (IgA, disease; linear; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (JAG1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Gene, animal  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Jun, protein product; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KITLG; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLF5; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLF6 (Kruppel-like factor 6); dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)



IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK10; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK12; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK13; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK14; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK15; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK5; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLK9; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Sarcoma  
 (Kaposi's; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukin 1 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (L1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Interleukin 1 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(L2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (LAMAS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-Troy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-p75; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDC (macrophage-derived chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MS4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MSMB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MTSSL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mucins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Mig (monokine induced by interferon- $\gamma$ ); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (MyD88 (myeloid differentiation primary response protein 88); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (N; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NCK, 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB1 (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB2 (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells, 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NME1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease  
 (NOS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NOX5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NPPB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR0B1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR0B2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(NR1D1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1D2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2FG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR6A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NT5E; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NTN4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NgR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Nogo, A; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Nogo, NgR-Lingo; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Nogo, NgR-Troy; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Nogo, NgR-nogo66; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Nogo, NgR-p75; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (OPZ1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (OMGP (oligodendrocyte myelin glycoprotein), p; dual variable domain  
 Igs and multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (OPRD1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (P2RX7; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PAP (pancreatitis-associated protein); dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PART1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PATE; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAWR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PCA3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cell adhesion molecules  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PECAM-1 (platelet-endothelial cell adhesion mol. 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PED2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PGR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIAS2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIK3CG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLXDC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
 (POEMS syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PPID; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(PR-1 (pathogenesis-related, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKCQ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKD1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROC; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROK2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSAP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSCA (prostate stem cell antigen); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (PTAFR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RARβ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGM A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS (regulator of G protein signaling), 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-1 (regulator of G protein signaling 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-3 (regulator of G protein signaling 3); dual variable domain Igs



and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNF110; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ROBO (Roundabout), 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis  
 (Reiter's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (S100A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SBP (sex steroid-binding protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCYE1; endothelial monocyte-activating; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SDF-1 (stromal-derived factor-1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line  
 (SF9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Histocompatibility antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLA (swine leukocyte antigen), class II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
 Chemokines  
 Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC (secondary lymphoid tissue chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic

inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SLC2A2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SLC33A1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SLC43A1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Lung, disease  
 (SLE-associated; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SLIT2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SPP1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SPRR1B; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SPRR2A (small proline-rich protein 2A); dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SPRR2B; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ST6GAL1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (STAB1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factor STAT  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (STAT6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (STEAP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (STEAP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (STRL33; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease  
(Schmidt's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAC2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAPA-1 (target of antiproliferative antibody, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TB4R2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TBX21; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TCP10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TH1L; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TH1P0; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TIMP3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TLR-7; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TLR-8; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Toll-like receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TLR-9; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFAIP2 (tumor necrosis factor  $\alpha$ -induced protein 2); dual  
 variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFAIP3 (tumor necrosis factor  $\alpha$ -induced protein 3); dual  
 variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFRSF21; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFRSF5; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFRSF8; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFRSF9; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Cytokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNFSF7 (tumor necrosis factor superfamily member 7); dual variable  
 domain Igs and multispecific derivs. for treating acute and  
 chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TOLLIP; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TPM1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TPM2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRADD (tumor necrosis factor receptor 1-associated death domain); dual  
 variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF3; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF4; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF5; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Tumor necrosis factor receptor-associated factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAF6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); dual  
 variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TREM1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TREM2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRPC6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TSLP; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TWEAK; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Blood vessel, disease  
(Takayasu's disease; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Te38; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Tyrosine kinase receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Tie-1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Tyrosine kinase receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Tie-2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(VHL C5; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Granulomatous disease  
(Wegener's granulomatosis; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer  
and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(XCR1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ZFPM2; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Hyperlipoproteinemia  
(abeta-; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Skin, disease  
(acanthosis nigricans; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer  
and other diseases)

IT Antibodies and Immunoglobulins  
(acquired hypogammaglobulinemia; dual variable domain Igs and  
multispecific derivs. for treating acute and chronic  
inflammation, cancer and other diseases)

IT Pain  
(acute and chronic; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases)

IT Immune disease  
(acute or chronic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Pancreas, disease  
(acute pancreatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease  
Rheumatic fever  
(acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma  
(adenocarcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Endocrine system  
(adrenal-hypothalamus-pituitary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Respiratory distress syndrome  
(adult; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Gonadotropin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(agonist; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cirrhosis  
(alc.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy  
(allergic asthma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy  
Eye, disease  
Inflammation  
(allergic conjunctivitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy  
(allergic contact dermatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dermatitis  
(allergic contact; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy  
Inflammation  
Nose, disease  
(allergic rhinitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)



IT Asthma  
(allergic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant rejection  
(allotransplant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormones, animal, biological studies  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anabolic steroids; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Spinal column, disease  
(ankylosing spondylitis, lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal cord  
(anterior horn, cell degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Psoriasis  
(anti-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxicity  
(antibody-mediated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxic agents  
(antimetabolites; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery  
(aorta, dissection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease  
(aorta, occlusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
(aorta; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aneurysm  
(aortic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Alopecia  
(areata; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
(arthropathy, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chlamydia  
Disease, animal

Salmonella  
Yersinia  
    (arthropathy; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Disease, animal  
    (asthenia; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Nervous system, disease  
Spinal column, disease  
    (ataxia; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Allergy  
    (atopy; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Hypothyroidism  
    (atrophic autoimmune; dual variable domain Igs and multispecific  
    derivs. for treating acute and chronic inflammation, cancer  
    and other diseases)

IT Anemia (disease)  
Autoimmune disease  
    (autoimmune hemolytic anemia; dual variable domain Igs and  
    multispecific derivs. for treating acute and chronic  
    inflammation, cancer and other diseases)

IT Autoimmune disease  
    (autoimmune thrombocytopenia; dual variable domain Igs and  
    multispecific derivs. for treating acute and chronic  
    inflammation, cancer and other diseases)

IT Autoimmune disease  
Inflammation  
Thyroid gland, disease  
    (autoimmune thyroiditis; dual variable domain Igs and multispecific  
    derivs. for treating acute and chronic inflammation, cancer  
    and other diseases)

IT Hypoglycemia  
Thyroid gland, disease  
    (autoimmune; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Sperm  
    (autoimmunity; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Infection  
    (bacterial; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Brain  
    (basal ganglia, disease; dual variable domain Igs and multispecific  
    derivs. for treating acute and chronic inflammation, cancer  
    and other diseases)

IT Luminescent substances  
    (bioluminescent; dual variable domain Igs and multispecific derivs. for  
    treating acute and chronic inflammation, cancer and other  
    diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)  
 (bispecific; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Oral drug delivery systems  
 (bolus drug delivery systems; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
 (bone marrow, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
 (bone, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bronchi, disease  
 (bronchiolitis obliterans syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease  
 (bullous, autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart, disease  
 (bundle branch block; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (c-jun; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pancreas, neoplasm  
 (carcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm  
 (cardiac; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Shock (circulatory collapse)  
 (cardiogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
 (cardiopulmonary bypass; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aves  
 Birds  
 Insecta  
 Protista  
 (cell; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain  
 (cerebellar cortex, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

(cerebellar; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease  
(cerebellum, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tachycardia  
(chaotic or multifocal atrial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chimeric; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease  
(cholestasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease  
(chorea, senile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Viral hepatitis  
(chronic active; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fatigue, biological  
Fatigue, biological  
(chronic fatigue syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Newborn  
(chronic lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Candidiasis  
(chronic mucocutaneous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(chronic obstructive pulmonary disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(chronic, neonatal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease  
(chronic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(claudin-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(claudin-7; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(co-stimulation mol.; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer  
and other diseases)

IT Intestine, neoplasm  
(colon; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Intestine, neoplasm  
(colorectal carcinoma; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer  
and other diseases)

IT Carcinoma  
(colorectal; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(conjugates; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(conjugates; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Eye, disease  
Inflammation  
(conjunctivitis; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Dermatitis  
(contact; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Heart, disease  
(cor pulmonale; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Nervous system  
(corticospinal tract, disease; dual variable domain Igs and  
multispecific derivs. for treating acute and chronic  
inflammation, cancer and other diseases)

IT Autoimmune hepatitis  
(cryptogenic; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(crystallized; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Sepsis

- (culture-neg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Disease, animal  
(cyanosis, acro-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Nervous system, disease  
(degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Disease, animal  
(degenerative, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Mental and behavioral disorders  
(dementia, AIDS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Mental and behavioral disorders  
(dementia, pugilistica; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Nerve, disease  
(demyelination; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Infection  
(dengue; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Mental and behavioral disorders  
(depression; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Arteriosclerosis  
(diabetic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Mental and behavioral disorders  
(diffuse Lewy body disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Cardiomyopathy  
(dilated congestive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Cardiomyopathy  
(dilated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Lupus erythematosus  
(discoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Platelet (blood)  
(disease, autoimmune thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Reticuloendothelial system  
(disease, histiocytosis, malignant; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mitochondria  
(disease, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Joint, anatomical  
(disease, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Platelet (blood)  
(disease, thrombocytopenia, idiopathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemotherapy  
Joint, anatomical  
(disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Blood coagulation disorders  
(disseminated intravascular coagulation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT AIDS (disease)  
Acute lymphocytic leukemia  
Acute myeloid leukemia  
Addison's disease  
Alkylating agents, biological  
Allergy  
Alopecia  
Alzheimer's disease  
Analgesics  
Anaphylaxis  
Anemia (disease)  
Anesthetics  
Angina pectoris  
Angiogenesis inhibitors  
Animal cell  
Antiasthmatics  
Antibiotics  
Antimicrobial agents  
Antiphospholipid syndrome  
Antirheumatic agents  
Arterial occlusion  
Arteriosclerosis  
Arteriosclerosis  
Asthma  
Asthma  
Atherosclerosis  
Atherosclerosis  
Atrial fibrillation  
Atrial flutter  
B-cell lymphoma  
Bladder, neoplasm  
Buccal drug delivery systems  
Burkitt lymphoma

Burn  
Cachexia  
Cardiac arrhythmia  
Cardiac arrhythmia  
Cardiomyopathy  
Cardiopulmonary bypass  
Chronic lymphocytic leukemia  
Chronic myeloid leukemia  
Connective tissue, disease  
Controlled-release drug delivery systems  
Coronary artery disease  
Cystic fibrosis  
Cytotoxic agents  
DNA sequences  
Dermatitis  
Dermatitis  
Diabetes mellitus  
Dissociation constant  
Down's syndrome  
Drug delivery systems  
Drugs  
Eczema  
Encephalomyelitis  
Endocarditis  
Endocrine system, disease  
Escherichia coli  
Eukaryota  
Fibrosis  
Fungi  
Genetic vectors  
Gout  
Granuloma  
Graves' disease  
Hairy cell leukemia  
Hay fever  
    Heart block  
    Heart failure  
    Heart failure  
Hematopoietic neoplasm  
Hemochromatosis  
Hemodialysis  
Hemorrhage  
Hemorrhage  
Hepatitis  
Hepatitis  
Hepatitis A  
Hepatitis B  
Hepatitis C  
Hodgkin's disease  
Human  
Human immunodeficiency virus  
Hypertension  
Hypertension  
Hyperthyroidism  
Hypnotics and Sedatives  
Hypoparathyroidism  
Imaging agents  
Immunosuppressants  
Indicators  
Infection  
Inflammatory bowel disease



Influenza  
Inhalation drug delivery systems  
Intestine, disease  
Intragastric drug delivery systems  
Ischemia  
Kawasaki disease  
Kidney, disease  
Legionella  
Leprosy  
Leukemia  
Leukemia  
Linking agents  
Lung, neoplasm  
Lyme disease  
Lymphoma  
Malaria  
Mammary gland, neoplasm  
Melanoma  
Meningitis  
Mental and behavioral disorders  
Metabolic disorders  
Molecular cloning  
Mouse  
Movement disorders  
Multiple myeloma  
Multiple sclerosis  
Mus musculus  
Muscle relaxants  
Myasthenia gravis  
Mycobacterium avium  
Mycobacterium tuberculosis  
Mycosis  
Myelodysplastic syndromes  
Myocardial infarction  
Myocardial ischemia  
Narcotics  
Neoplasm  
Nervous system stimulants  
Neuromuscular blocking agents  
Non-Hodgkin lymphoma  
Nonsteroidal anti-inflammatory drugs  
Osteoarthritis  
Osteoarthritis  
Osteoporosis  
Ovary, neoplasm  
Pancreas, neoplasm  
Parasite  
Parkinson's disease  
Pharmaceutical carriers  
Plant cell  
Preeclampsia  
Prokaryota  
Prostate gland, neoplasm  
Protein sequences  
Radiotherapy  
Raynaud disease  
Refsum disease  
Rheumatoid arthritis  
Rodentia  
Saccharomyces cerevisiae  
Sarcoidosis

Sarcoma  
 Schizophrenia  
 Scleroderma  
 Scleroderma  
 Sepsis  
 Shock (circulatory collapse)  
 Sickle cell anemia  
 Skin, disease  
 Stomach, neoplasm  
 Streptococcus group B  
 Stroke  
 Stroke  
 Sublingual drug delivery systems  
 Surface plasmon resonance  
 Syphilis  
 Telangiectasia  
 Transdermal drug delivery systems  
 Transplant rejection  
 Urticaria  
 Uveitis  
 Vaccines  
 Vaginal drug delivery systems  
 Valvular heart disease  
 Varicose vein  
 Vasculitis  
 Vein, disease  
 Ventricular fibrillation  
 Vitiligo  
 Wernicke-Korsakoff syndrome  
 Wilson's disease  
 Yeast  
 $\beta$ -Adrenoceptor agonists  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

- IT Antibodies and Immunoglobulins
- Nucleic acids
- RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)
- (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)
- IT APC protein
- Aggrecans
- Antigens
- Bone morphogenetic protein 1
- Bone morphogenetic protein 2
- Bone morphogenetic protein 4
- Bone morphogenetic protein 6
- Bone morphogenetic protein 8
- Brain-derived neurotrophic factors
- CD19 (antigen)
- CD20 (antigen)
- CD22 (antigen)
- CD28 (antigen)
- CD3 (antigen)
- CD38 (antigen)
- CD4 (antigen)
- CD40 (antigen)
- CD44 (antigen)

CD45RB (antigen)  
CD69 (antigen)  
CD8 (antigen)  
CD80 (antigen)  
CD80 (antigen)  
CD86 (antigen)  
CD86 (antigen)  
CTLA-4 (antigen)  
Cell adhesion molecules  
Chemokines  
Clusterin  
Clusterin  
Cytokines  
Enzymes, biological studies  
Eotaxin 1  
Eotaxin 2  
Eotaxin 3  
Epidermal growth factor receptors  
Fas antigen  
Fas ligand  
Fibronectins  
Gelsolin  
Hepatocyte growth factor  
Histamine receptors  
Insulin-like growth factor I receptors  
Integrins  
Interleukin 1  
Interleukin 10  
Interleukin 11  
Interleukin 12  
Interleukin 13  
Interleukin 14  
Interleukin 15  
Interleukin 16  
Interleukin 17  
Interleukin 17 receptors  
Interleukin 18  
Interleukin 18 receptors  
Interleukin 19  
Interleukin 1 $\alpha$   
Interleukin 1 $\beta$   
Interleukin 2  
Interleukin 20  
Interleukin 22  
Interleukin 23  
Interleukin 24  
Interleukin 3  
Interleukin 4  
Interleukin 5  
Interleukin 6  
Interleukin 6 receptors  
Interleukin 7  
Interleukin 8  
Interleukin 9  
Interleukin 9 receptors  
Invariant chain (class II antigen)  
Ki-67 antigen  
Lipopolysaccharides  
Lymphokine receptors  
Lymphokines  
Lymphotoxin

Macrophage inflammatory protein 2  
 Macrophage inflammatory protein 2 $\alpha$   
 Macrophage inflammatory protein 2 $\beta$   
 Macrophage inflammatory protein 3 $\alpha$   
 Macrophage inflammatory protein 3 $\beta$   
 Macrophage inflammatory protein 4  
 Macrophage inflammatory protein 5  
 Melanoma growth-stimulating activity- $\alpha$   
 Midkines  
 Monocyte chemoattractant protein-1  
 Monocyte chemoattractant protein-2  
 Monocyte chemoattractant protein-3  
 Monocyte chemoattractant protein-4  
 Monokines  
 Nerve growth factor receptors  
 Neutrophil-activating peptide-2  
 Proliferating cell nuclear antigen  
 RANTES (chemokine)  
 Receptors  
 Toll-like receptors  
 Transforming growth factor  $\beta$   
 Tumor necrosis factors  
 Tumor necrosis factors  
 Versicans  
 neu (receptor)  
 neu (receptor)  
 p53 (protein)

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Anthracyclines  
 Growth factors, animal  
 Radionuclides, biological studies  
 Toxins  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Corticosteroids, biological studies  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT CD3 (antigen)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (e; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Lung, disease  
 (eosinophilia; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Epididymis  
 (epididymitis; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Respiratory system, disease  
 (epiglottitis; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
(erythromelalgia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease  
(extrapyramidal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease  
(failure, acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease  
Ovary, disease  
(failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
(familial hemophagocytic lymphohistiocytosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders  
(female; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Embryo, animal  
(fetus, thymus implant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(fibrosis, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
Radiation  
(fibrosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
(fistula, arteriovenous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(fos; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(fractalkines; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fragments; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD3 (antigen)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (g; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Necrosis  
 (gas gangrene; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Ulcer  
 (gastric; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene B29; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene BCL6; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene ELAC2; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene KAI1; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Arteritis  
 (giant cell; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Inflammation  
 Inflammation  
 Kidney, disease  
 Kidney, disease  
 (glomerulonephritis; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Transplant and Transplantation  
 (graft-vs.-host reaction; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Transplant and Transplantation  
 (heart; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Antibodies and Immunoglobulins  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (heavy chain; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Anemia (disease)  
 (hemolytic, Coombs-pos.; dual variable domain Igs and multispecific

derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Kidney, disease  
 (hemolytic-uremic syndrome; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Anemia (disease)  
 (hemolytic; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Injury  
 (hepatic, alc.-induced; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Disease, animal  
 (histiocytosis, malignant; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Antibodies and Immunoglobulins  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (humanized; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Allergy  
 (hypersensitivity; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Pharmaceutical injections  
 (i.m. injections; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Pharmaceutical injections  
 (i.p. injections; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Pharmaceutical injections  
 (i.v. injections; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Blood, disease  
 (idiopathic thrombocytopenia; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Leukocytopenia  
 (idiopathic; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Antibodies and Immunoglobulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (immunoadhesins; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Thymus gland  
 (implant rejection; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Human herpesvirus 4  
 Neisseria meningitidis  
 (infection; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Apoptosis  
Mitosis  
(inhibitors; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease  
(injury, aic.-induced; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Reperfusion  
(injury; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease  
(insulin-dependent diabetes mellitus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Diabetes mellitus  
(insulin-dependent; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(interferon  $\gamma$ -inducible protein-10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Lung, disease  
(interstitial pneumonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(interstitial, connective tissue disease-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(interstitial, post-inflammatory; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(interstitial, rheumatoid arthritis-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nasal drug delivery systems  
Rectal drug delivery systems  
(intra-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intraabdominal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intraarticular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intrabronchial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)



- diseases)
- IT Drug delivery systems  
(intracapsular; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracartilaginous; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracavitary; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracellular; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracerebellar; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracerebroventricular; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer  
and other diseases)
- IT Drug delivery systems  
(intracervical; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intracolic; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intrahepatic; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intramyocardial; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intraosteal; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intrapelvic; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intrapleural; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intraprostatic; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)
- IT Drug delivery systems  
(intrapulmonary; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Drug delivery systems  
(intrarenal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intraretinal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intraspinal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intrasynovial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intrathoracic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intrauterine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(intravesical; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Eye, disease  
Inflammation  
(iridocyclitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Rheumatoid arthritis  
Rheumatoid arthritis  
Rheumatoid arthritis  
(juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (k6HF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
(kidney, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fluorescent substances  
Luminescent substances  
Magnetic materials  
(label; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(labeled; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection  
(leishmaniasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(leukotriene B4, LTB4R2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(leukotriene B4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(light chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Peptides, biological studies  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(linker; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
(liver, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anesthetics  
(local; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sjogren syndrome  
(lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Edema  
(lymph-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease  
(lymphocytic infiltrative; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(lymphotactin, XCL2 or SCM-1b; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(lymphotactin; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders  
(male; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lymphoma  
(malignant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell  
(mammalian; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease  
(microscopic vasculitis of; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Vasculitis  
(microscopic; of kidney; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Headache  
(migraine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
(mitochondrial, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Connective tissue, disease  
(mixed connective tissue disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(monoclonal gammopathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoclonal, therapy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monoclonal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(monokine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(myc; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Spinal cord, disease  
(myelitis, acute transverse; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT    Edema  
       Hypothyroidism  
       (myxedema; dual variable domain Igs and multispecific derivs. for  
       treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Carcinoma  
       (nasopharyngeal; dual variable domain Igs and multispecific derivs. for  
       treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Pharynx, neoplasm  
       (nasopharynx, carcinoma; dual variable domain Igs and multispecific  
       derivs. for treating acute and chronic inflammation, cancer  
       and other diseases)

IT    Heart, disease  
       (neoplasm; dual variable domain Igs and multispecific derivs. for  
       treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Inflammation  
       Kidney, disease  
       (nephritis; dual variable domain Igs and multispecific derivs. for  
       treating acute and chronic inflammation, cancer and  
       other diseases)

IT    Kidney, disease  
       (nephrotic syndrome; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Proteoglycans, biological studies  
       RL: BSU (Biological study, unclassified); BIOL (Biological study)  
       (neurocan; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Muscular dystrophy  
       (neurogenic I; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Nerve, disease  
       (neuropathy, HIV; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Agranulocytosis  
       (neutropenia, autoimmune; dual variable domain Igs and multispecific  
       derivs. for treating acute and chronic inflammation, cancer  
       and other diseases)

IT    Fever and Hyperthermia  
       (neutropenic; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Steatohepatitis  
       (nonalc.; dual variable domain Igs and multispecific derivs. for  
       treating acute and chronic inflammation, cancer and other  
       diseases)

IT    Eye, disease  
       (ophthalmia, sympathetic; dual variable domain Igs and multispecific  
       derivs. for treating acute and chronic inflammation, cancer  
       and other diseases)

IT    Inflammation  
       Nerve, disease  
       (optic neuritis; dual variable domain Igs and multispecific derivs.  
       for treating acute and chronic inflammation, cancer  
       and other diseases)

IT    Inflammation

Testis, disease  
 (orchitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Immune disease  
 (organ transplant-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal  
 (organomegaly; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cyclin dependent kinase inhibitors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (p57/KIP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pBJ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pBV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pEF6TOPO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pEFBOS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pJV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pTT3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pTT; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
 (pancreas, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma  
 (pancreatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm  
 (paraneoplastic syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pcDNA3.1TOPO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors  
 (pcDNA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Body, anatomical  
 (pelvis, inflammation; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease  
(pemphigoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease  
(pemphigus foliaceus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease  
(pemphigus vulgaris; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease  
Inflammation  
(periarteritis nodosa, pulmonary manifestation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems  
(pericardiac; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal organ  
(pericardial, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Peritoneum, disease  
(peritonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)  
(pernicious anemia, acquired or juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Uveitis  
(phacogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(phosphacan; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(plectins; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease  
Endocrine system, disease  
(polyglandular syndrome, type I and II deficiency; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormone receptors  
Hormones, animal, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(polypeptide; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection  
(postinfectious interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Ovary, disease  
(premature failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease  
(primary biliary cirrhosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hepatitis  
(primary sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Paralysis  
(pseudobulbar, progressive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis  
(psoriatic arthritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis  
(pulmonary, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis  
Hypertension  
(pulmonary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis  
(reactive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Intestine, neoplasm  
(rectum; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury  
(reperfusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation  
Nose, disease  
(rhinitis, perianal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections  
(s.c. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease  
Inflammation  
(sclerosing cholangitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis  
Shock (circulatory collapse)



- (septic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Mucins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin MUC-24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transplant and Transplantation  
(skin, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transplant and Transplantation  
(small intestine, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Inflammation  
Spinal column, disease  
(spondylitis, rheumatoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Spinal column, disease  
Spinal column, disease  
(spondyloarthropathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Myositis  
(streptococcal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Encephalitis  
(subacute sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 14; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (superfamily 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (surface; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Brain, disease  
(syncope; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Arthritis  
Synovial membrane, disease  
(synovitis, enteropathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Lupus erythematosus  
(systemic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Cytokines  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapy-associated disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Thrombosis  
(thromboangiitis obliterans; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Purpura (disease)  
(thrombocytopenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Autoimmune disease  
(thyroid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Inflammation  
Thyroid gland, disease  
(thyroiditis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Shock (circulatory collapse)  
(toxic shock syndrome; dual variable domain Igs and multispecific

derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cartilage

Parathyroid gland  
 (transplant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone

Bone marrow  
 Kidney  
 Liver  
 Pancreas  
 Skin  
 Small intestine  
 (transplant, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart  
 (transplant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury  
 (trauma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Psoriasis  
 (type 1 and 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 1, TNFRSFB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Complement receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibroblast growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune hepatitis  
 (type I and II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal muscular atrophy  
 (type I; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type I; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type IA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type IB; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors  
 Interleukin 1 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type II; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic inflammation,  
 cancer and other diseases)

IT Spinal muscular atrophy  
 (type III; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other diseases)

IT Vascular endothelial growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type VEGFR-1; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Vascular endothelial growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type VEGFR-2; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Stomach, disease  
 (ulcer; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammatory bowel disease  
 (ulcerative colitis, arthropathy; dual variable domain Igs  
 and multispecific derivs. for treating acute and chronic inflammation,  
 cancer and other diseases)

IT Inflammatory bowel disease  
 (ulcerative colitis; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic inflammation,  
 cancer and other diseases)

IT Colitis  
 (ulcerative, arthropathy; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT Colitis  
 (ulcerative; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)

IT Sepsis  
 (uro-; dual variable domain Igs and multispecific derivs. for treating  
 acute and chronic inflammation, cancer and other diseases)

IT Growth inhibitors, animal  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (vascular endothelial growth inhibitor; dual variable domain Igs  
 and multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Lung, disease  
 (vasculitic diffuse; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT Surgery  
 Vas deferens  
 (vasectomy, orchitis; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT Thrombosis  
 (venous; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Infection  
(viral; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation  
(xenotransplant, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD3 (antigen)  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (z; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$  chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Amyotrophic lateral sclerosis  
( $\alpha$ 1-antitrypsin-deficient; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
Interleukin 13 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
Interleukin 13 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
Interleukin 15 receptors  
Interleukin 3 receptors  
Interleukin 4 receptors  
Interleukin 5 receptors  
Interleukin 7 receptors

Interleukin 8 receptors  
Platelet-derived growth factors  
IT RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer  
and other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(αv; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α1, ITGA1; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α2, ITGA2; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α3, ITGA3; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α4β1; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer and  
other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(α6, ITGA6; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer and other  
diseases)

IT Interleukin 2 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(β chain; dual variable domain Igs and multispecific  
derivs. for treating acute and chronic inflammation, cancer and  
other diseases)

IT Catenins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(β-; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(β1; dual variable domain Igs and multispecific derivs. for  
treating acute and chronic inflammation, cancer and other  
diseases)

IT Interleukin 8 receptors  
Lymphotoxin  
Platelet-derived growth factors  
IT RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(β; dual variable domain Igs and multispecific derivs.  
for treating acute and chronic inflammation, cancer  
and other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(β3; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Integrins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (β4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ω, 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 203874-76-4, Fibroblast growth factor 12  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 37205-61-1, Proteinase inhibitor  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SERPIN F 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 930324-46-2P 930324-47-3P 930324-48-4P 930324-49-5P 930324-50-8P  
930324-51-9P 930324-52-0P 930324-53-1P 930324-54-2P 930324-55-3P  
930324-56-4P 930324-57-5P 930324-58-6P 930324-59-7P 930324-60-0P  
930324-61-1P 930324-62-2P 930324-63-3P 930324-64-4P 930324-65-5P  
930324-66-6P 930324-67-7P 930324-68-8P 930324-69-9P 930324-70-2P  
930324-71-3P 930324-72-4P 930324-73-5P 930324-74-6P 930324-75-7P  
930324-76-8P 930324-77-9P  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 69-72-7, Salicylic acid, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (chronic intoxication; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 51-43-4D, Epinephrine, analogs 51-45-6, Histamine, biological studies 9001-06-3, Chitinase 9001-92-7, Protease 9002-07-7, PTN 9002-62-4, PRL, biological studies 9035-58-9, Blood-coagulation factor III 9041-92-3, SERPIN A 1 9047-22-7, Cathepsin B 9061-61-4, NGF 11096-26-7, EPO 62031-54-3, FGF 62229-50-9, EGF 67763-96-6, IGF-1 67763-97-7, IGF-2 80295-41-6, Complement C3 80295-49-4, Complement C4a 80295-53-0, Complement C5 81627-83-0, M-CSF 83869-56-1, GM-CSF 88232-92-2, SDF 2 106096-92-8, FGF 1 106096-93-9, FGF 2 122191-40-6, CASP-1 123584-45-2, FGF 4 127464-60-2, VEGF 129653-64-1, FGF 5 130939-41-2, FGF 6 140208-23-7, SERPIN E 1 141176-92-3, SERPIN A 3

141349-86-2, CDK-2 kinase 143011-72-7, G-CSF 146480-35-5, Mmp 2  
 146480-36-6, Mmp 9 147014-96-8, CDK-5 kinase 147014-97-9, CDK-4 kinase  
 148348-14-5, FGF 3 148348-15-6, FGF 7 151185-16-9, FGF 9  
 152478-56-3, JAK1 kinase 153190-71-7, CDK-3 kinase 157482-36-5, JAK3  
 kinase 157857-21-1, SERPIN B 5 164003-41-2, FGF 8 167397-96-8,  
 IRAK-1 kinase 169494-85-3, Leptin 171758-70-6, Fibroblast growth  
 factor 10 182762-08-9, CASP-4 182938-13-2, CDK-9 kinase 185915-21-3,  
 FGF 11 185915-22-4, FGF 13 185915-23-5, Fibroblast growth factor 14  
 188417-84-7, VEGFC 192662-83-2, Vascular endothelial growth factor B  
 193363-12-1, VEGFD 193830-08-9, GDF-5 200578-48-9, IRAK-2 kinase  
 204719-95-9, Fibroblast growth factor 16 214210-47-6, Neuropilin 1  
 223121-69-5, Fibroblast growth factor 19 227018-38-4, Neuropilin 2  
 245480-69-7, Fibroblast growth factor 20 271597-13-8, GDF-10  
 301166-54-1, Protein, PTEN 303014-92-8, CDK-6 kinase  
 314026-96-5, Fibroblast growth factor 23 322637-17-2, Fibroblast growth  
 factor 17 322637-18-3, FGF 18 329900-75-6, Cox-2 330197-29-0, CDK-7  
 kinase 335217-23-7, Fibroblast growth factor 22 341970-61-4,  
 Fibroblast growth factor 21 372092-80-3, Protein kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)  
 IT 58-85-5, Biotin  
 RL: BSU (Biological study, unclassified); BUU (Biological use,  
 unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)  
 IT 59-05-2, Methotrexate 10028-17-8, Hydrogen-3, biological studies  
 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90,  
 biological studies 13967-65-2, Holmium-166, biological studies  
 14133-76-7, Technetium-99, biological studies 14158-31-7, Iodine-125,  
 biological studies 14265-75-9, Lutetium-177, biological studies  
 14762-75-5, Carbon-14, biological studies 15117-53-0, Sulfur-35,  
 biological studies 15750-15-9, Indium-111, biological studies  
 15766-00-4, Samarium-153, biological studies 53123-88-9, Rapamycin  
 79217-60-0, Cyclosporin 104987-11-3, FK 506  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)  
 IT 7439-89-6, Iron, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hemosiderosis, lung disease; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)  
 IT 122024-47-9 500995-49-3 500995-50-6 532391-75-6 669774-82-7  
 865864-24-0 865864-26-2 923954-87-4 930288-78-1 930288-80-5  
 930288-82-7 930288-91-8 930288-96-3 930289-05-7 930289-14-8  
 930289-22-8 930289-25-1 930289-43-3  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (linker; dual variable domain Igs and multispecific derivs. for  
 treating acute and chronic inflammation, cancer and other  
 diseases)  
 IT 930324-92-8 930324-93-9 930324-94-0 930324-95-1 930324-96-2  
 930324-97-3 930324-98-4 930324-99-5 930325-00-1 930325-01-2  
 930325-02-3 930325-03-4 930325-04-5 930325-05-6 930325-06-7  
 930325-07-8 930325-08-9 930325-09-0 930325-10-3 930325-11-4  
 930325-14-7 930325-15-8 930325-16-9 930325-17-0 930325-18-1



930325-19-2 930325-20-5 930325-21-6 930325-22-7 930325-23-8  
 930325-24-9 930325-25-0 930325-26-1 930325-27-2 930325-28-3  
 930325-29-4 930325-30-7 930325-31-8 930325-32-9 930325-33-0  
 930325-34-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; dual variable domain Igs and  
 multispecific derivs. for treating acute and chronic  
 inflammation, cancer and other diseases)

IT 930324-80-4 930324-81-5 930324-82-6 930324-83-7 930324-84-8  
 930324-85-9 930324-86-0 930324-87-1 930324-88-2 930324-89-3  
 930324-90-6 930324-91-7 930325-12-5 930325-13-6 930325-35-2  
 930325-36-3 930325-37-4 930325-38-5 930325-39-6 930325-40-9  
 930325-41-0 930325-42-1 930325-43-2 930325-44-3 930325-45-4  
 930325-46-5 930325-47-6 930325-48-7 930325-49-8 930325-50-1  
 930325-51-2 930325-52-3

RL: PRP (Properties)

(unclaimed protein sequence; dual variable domain Igs and multispecific  
 derivs. for treating acute and chronic inflammation, cancer  
 and other diseases)

IT 362526-53-2 609338-75-2 930288-59-8 930288-63-4 930288-65-6  
 930288-67-8 930288-69-0 930288-71-4 930288-73-6 930288-75-8

RL: PRP (Properties)

(unclaimed sequence; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

IT 142805-56-9

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (α, α; dual variable domain Igs and multispecific derivs.  
 for treating acute and chronic inflammation, cancer and other  
 diseases)

L32 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 115926-52-8, Phosphoinositide-3-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2007:284115 CAPLUS

DOCUMENT NUMBER: 146:352574

TITLE: Double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases

INVENTOR(S): Chajut, Ayelet; Pinner, Elhanan

PATENT ASSIGNEE(S): Quark Biotech, Inc., USA

SOURCE: PCT Int. Appl., 145pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029249	A2	20070315	WO 2006-IL1036	20060906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,			

RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2005-715414P P 20050909  
 US 2005-732188P P 20051031

AN 2007:284115 CAPLUS

DN 146:352574

ED Entered STN: 16 Mar 2007

TI Double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases

IN Chajut, Ayelet; Pinner, Elhanan

PA Quark Biotech, Inc., USA

SO PCT Int. Appl., 145pp.

CODEN: PIXXD2

DT Patent

LA English

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029249	A2	20070315	WO 2006-IL1036	20060906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-715414P P 20050909

US 2005-732188P P 20051031

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007029249	IPCI	A61K0048-00 [I,A]; C07H0021-02 [I,A]; C07H0021-00 [I,C*]
	IPCR	A61K0048-00 [I,C]; A61K0048-00 [I,A]; C07H0021-00 [I,C]; C07H0021-02 [I,A]

AB The invention relates to a double-stranded compound, such as siRNAs, which down-regulates the expression of one or more cardiovascular-related gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a cardiovascular disorder or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically ED so as to thereby treat the patient.

ST siRNA cardiovascular disease treatment

IT Hemoglobins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Z; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (105kDa/110kDa, 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (13; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cadherins  
 Keratins  
 Kinesins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (14; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (162; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Keratins  
 Nexins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (17; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Keratins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (18; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Keratins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (19; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Ankyrins  
 Calmodulins  
 Calponin  
 Fibrillins  
 Thrombospondins  
 Tropomyosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Kinesins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (18; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Metallothioneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (1K; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Nexins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (24; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (27kDa protein 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (27kDa protein 3; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Calmodulins

Fibrillins  
 Kinesins  
 Presenilins  
 Tropomyosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (2; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Metallothioneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (2A; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (2B; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Ankyrins  
 Calponin  
 Nexins  
 Synaptobrevins  
 Tropomyosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (3; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Splicing factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (3a, subunit 3, 60kDa; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (3b, subunit 2, 145kDa; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Connexins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (43, 43kDa; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Syndecans  
 Tropomyosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (4; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (5; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Kinesins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (5B; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (70kDa protein 14; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (70kDa protein 4; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Heat-shock proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (70kDa protein 5; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Keratins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(8; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Heat-shock proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(90kDa protein 1, alpha; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Heat-shock proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(90kDa protein 1, beta; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Transcription elongation factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(A-like 8; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(A/B; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(A3; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ADF (actin-depolymg. factor); double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ADP-ribosylation factor-like 2 binding protein; double-stranded RNAs  
and their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ADP-ribosylation factor-like 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ADP-ribosylation factor-like 6 interacting protein; double-stranded  
RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ADP-ribosylation-like factor 6 interacting protein 5; double-stranded  
RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(A11-associated protein 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Clathrin adaptor proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(AP-1 (adaptor protein complex 1); double-stranded RNAs and their use  
for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(APC (anaphase-promoting complex); double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases  
)

IT ADP ribosylation factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ARF-3; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT ADP ribosylation factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ARF-4; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT ADP ribosylation factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ARF-5; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ASK interacting protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(AR2 domain containing 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ATF-3 (activating transcription factor 3); double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ATF-4 (activating transcription factor 4); double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Phosphoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Anp32b (acidic nuclear phosphoprotein 32 family member B);  
double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Phosphoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Anp32e (acidic nuclear phosphoprotein 32 family member E);  
double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Actin-related proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Arp2; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Actin-related proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Arp3; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B and B1; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Cyclins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B1; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Cyclins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(B2; double-stranded RNAs and their use for downregulating genes and

treating cardiovascular diseases)

IT Nexins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (B; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Bf1 interacting corepressor; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (BP-like protein 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (BPAG1 (bullous pemphigoid antigen 1); double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (C/EBP (CCAAT box/enhancer element-binding protein); double-stranded  
 RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CBL; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD151; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD24; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD31; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD56; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD63; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD72; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CD9; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cell cycle regulatory proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CDC20; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cell cycle regulatory proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDC2; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDC42 effector protein 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT G proteins (guanine nucleotide-binding proteins)

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDC42; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDC44; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDC45 cell division cycle 45-like; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDK2-associated protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDK2-associated protein 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDK5 regulatory subunit associated protein 1; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CDK5 regulatory subunit associated protein 3; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CENP-E (centromere protein E); double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CL2-antagonist of cell death; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CL2-associated X protein; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CL2-related protein A1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CL2/adenovirus E1B 19kDa interacting protein 2; double-stranded RNAs



and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CL2/adenovirus E1B 19kDa interacting protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(COMM domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(COMM domain containing 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CR4-NOT transcription complex, subunit 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cellular retinol-binding proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CRBP-I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collapsin response mediator proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CRMP-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Colony stimulating factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CSF2RB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CXXC finger 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Cbp/p300-interacting transactivator 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ClC-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ClC-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Crip1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(D-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cyclins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(D1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (D2, 165kDa; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (D2-associated; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Cyclins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (D2; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (D3, 18kDa; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Cyclins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (D3; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DAZ associated protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 17; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 39; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 41; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 47; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 48; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 51; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 5; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAD box protein 6; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular

diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAH box protein 30; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DEAH box protein 9; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DNA fragmentation factor DFF35; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DNA helicase, homolog; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DNA methyltransferase 1 associated protein 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DNase I-like 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DP (docking protein); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DRP (dystrophin-related protein); double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DTW domain containing 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DiGeorge syndrome critical region gene 6-like; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Molecular chaperones  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (DnaJ, homolog; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Down syndrome cell adhesion mol. like 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Down syndrome critical region gene 1-like 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Down syndrome critical region gene 5; double-stranded RNAs and their use  
for downregulating genes and treating  
cardiovascular diseases)

IT Cyclins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(E; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Sphingosine-1-phosphate receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EDG-1; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Lysophosphatidic acid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EDG-7; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Translation elongation factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EF-1γ; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Translation elongation factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EF-Tu; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EF-hand domain family, member D2; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EGF-like-domain, multiple 7; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ES130-related protein; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Egr-1; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT EphB receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphB3; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(F-box protein 16; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(F-box protein 21; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(F-box protein 30; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (F-box protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (F-box protein FBX29; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FABP3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FBP-interacting repressor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FERM domain containing 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 10, 65 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 1A, 12kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 2, 13kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FK506 binding protein 9, 63 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FKRP (fukutin-related protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FLYWCH-type zinc finger 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FOXO1 (forkhead box M1); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FP291; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (FYXD domain containing ion transport regulator 5; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Fanconi anemia, complementation group L; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Fas apoptotic inhibitory mol. 2; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (G protein pathway suppressor 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (G protein  $\beta 1/\gamma 2$  subunit-interacting factor 3;  
 double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (G protein-coupled receptor kinase interactor 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Cyclins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (G1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Cyclins  
 Small nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (G; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GAB1 (GRB2-associated binder 1); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GADD153; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GAS6 (growth arrest-specific 6); double-stranded RNAs and their use  
 for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-1; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-2; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-2A; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GATA-6; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GC-rich promoter binding protein 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GDI-1 (GDP dissociation inhibitor-1); double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GDI-2 (GDP dissociation inhibitor-2); double-stranded RNAs and their use  
 for downregulating genes and treating  
 cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GEM, associated protein 7; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GKLF (gut-enriched Kruppel-like factor); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GLI pathogenesis-related 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GTP cyclohydrolase I feedback regulator; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Gi (adenylate cyclase-inhibiting); double-stranded RNAs and their  
 use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (H-rev0107-like protein 5; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HCLS1 associated protein X-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HIRA interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HIV-1 enhancer binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-B associated transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-DRB1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HMG-box transcription factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HMG14; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HMG2 like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HMP19; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HOXB9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HSPC038; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HSPC244; double-stranded RNAs and their use for downregulating genes



and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HT-1080; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Huntingtin interacting protein K; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Fibronectins  
 Profilins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (I; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGFBP-4; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGFBP-5; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IGFBP-7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Annexins  
 Profilins  
 Secretogranins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (II; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IQ motif containing F3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IQ motif containing GTPase activating protein 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ISGF-2 (interferon-stimulated gene factor 2); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Myosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (IXB; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Voltage-gated potassium channels  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Isk-related family, member 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Molecular chaperones  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (J-type co-chaperone HSC20; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (JAB1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Jagged 1; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Jumonji AT rich interactive domain 1B; double-stranded RNAs and their  
 use for downregulating genes and treating  
 cardiovascular diseases)

IT Blood-group substances  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (K (Kell); double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KDEL endoplasmic reticulum protein retention, receptor 2;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLF2 (Kruppel-like factor 2); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLF3 (Kruppel-like factor 3); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (KLF9 (Kruppel-like factor 9); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (L; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LIM and senescent cell antigen-like domains 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LIM domain binding 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LIM domain-containing; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LMO4 (LIM domain only 4); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LSM3 homolog, U6 small nuclear RNA associated; double-stranded RNAs and  
 their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LSM4 homolog, U6 small nuclear RNA associated; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LSM5 homolog, U6 small nuclear RNA associated; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LSM7 homolog, U6 small nuclear RNA associated; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (LTBP2 (latent transforming growth factor  $\beta$ -binding protein 2);  
 double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (M; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MAD2L1 binding protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Microtubule-associated proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MAP1, light chain 3a; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Microtubule-associated proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MAP1B; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MARCKS-like 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MASL1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MBC3205; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MCM6 (minichromosome maintenance deficient 6); double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MDC9 (metalloprotease-disintegrin-cysteine-rich); double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT P-glycoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MDR3; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MID1 interacting protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MLAA-37; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MLAA-3; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MMSA-10; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Phosphoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MPP4; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MSH6; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MTERF domain containing 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Meisl, myeloid ecotropic viral integration site 1 homolog;  
double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Mov010, Moloney leukemia virus 10, homolog; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Ionotropic glutamate receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(N-Me D-aspartate-like 1A; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(N-acylsphingosine amidohydrolase 3-like; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NAD(P) dependent steroid dehydrogenase-like; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Cell adhesion molecules  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NCAM (neural cell adhesion mol.); double-stranded RNAs and their use  
for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NDRG2 (N-myc downstream-regulated gene 2); double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NECAP endocytosis associated 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NEKB-interacting Ras-like 2; double-stranded RNAs and their use  
for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NOL1/NOP2/Sun domain family 2; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Atrial natriuretic peptide receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NPR-A; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NS5ATP13TP2; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Voltage-gated sodium channels

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Nav1.1; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Nedd4 family interacting protein 1; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Ninjurin 1; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(OAZ1 (ornithine decarboxylase antizyme 1); double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(P381P; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PAI-1 binding protein; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PAK1 interacting protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PBX/knotted 1 homeobox 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PCOLCE (procollagen C-proteinase enhancer); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PDGFA associated protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PDZ and LIM domain 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PDZ and LIM domain 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PDZ and LIM domain 7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Cell adhesion molecules  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PECAM-1 (platelet-endothelial cell adhesion mol. 1); double-stranded  
 RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PED; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PEST-containing nuclear protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PHD finger protein 5A; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PIN2-interacting protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PKCq-interacting protein PICOT; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PPAR binding protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (PRAL domain family 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (PRP19PSO4 pre-mRNA processing factor 19 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PRP39 pre-mRNA processing factor 39 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Splicing factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PSF (PTB-associated splicing factor); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PTK9L protein tyrosine kinase 9-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PWP2 periodic tryptophan protein homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PWWP domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Quiescin Q6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(R; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAB18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAB1A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAB3A-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAB7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAB11 family interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAD23 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAD9 homolog A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAG-1 (recombination-activating gene, 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAG-2 (recombination-activating gene, 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAN binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAN binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAN; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAT1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAVER; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(REX2, RNA exonuclease 2 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Translation termination factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RF-1 (release factor 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RFP (ret finger protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(R13 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RING1 and YY1 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RNA binding motif protein 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RNA binding motif protein 8A; double-stranded RNAs and their use for



downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA binding protein, autoantigenic; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA helicase DDX3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding region containing 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, 1,; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, S1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, cold shock domain containing E1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, poly(A) binding protein, C1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, poly(A) binding protein, nuclear 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, poly(rC) binding protein 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RNA-binding, synaptotagmin-binding; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RP42 homolog; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Microtubule-associated proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RPEB family, member 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (RRN3, homolog; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(RUN and SH3 domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RUNX2 (runt-related transcription factor 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RWD domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rab acceptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rac; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras association domain family 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras-GTPase activating protein SH3 domain-binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras-related GTP binding C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RasGEF domain family 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RelA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-GDI $\alpha$  (Rho-specific GDP dissociation inhibitor  $\alpha$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-GDI $\gamma$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT GTPase-activating protein  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RhoGAP (Rho GTPase-activating protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT GTPase-activating protein  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (RhoGAP 22 (Rho GTPase-activating protein 22); double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Rtf1, Paf1/RNA polymerase II complex component, homolog;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT S-100 proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (S-100A10; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT S-100 proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (S-100C; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SAA1 (serum amyloid A1); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SAM and SH3 domain containing 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SAM domain and HD domain 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SCP65 (synaptonemal complex protein 65); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SCP2 (sterol carrier protein 2); double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SEC31-like 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SECIS-binding protein 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SFRP1 (secreted frizzled-related protein 1); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SG2NA; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SH2 domain binding protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (SH3 domain binding glutamic acid-rich; double-stranded RNAs and their

use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SIN3 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SM-11044 binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SMT3 suppressor of mif two 3 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Nexins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SNX22; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SOCS-2 (suppressor of cytokine signaling-2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRP14 (signal recognition particle 14 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRP9 (signal recognition particle 9 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRY-box 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRY-box 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins, specific or class  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SSB (single-stranded DNA-binding), 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT3-interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT5A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(STEAP family member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SUB1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SUMO-1 activating; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sec61; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sipl; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sjogren syndrome B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Spl; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (T-rich interactive domain 5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TACC3 (transforming acidic coiled-coil 3); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAF9 RNA polymerase II, TATA box binding protein-associated factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAPA-1 (target of antiproliferative antibody, 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAR; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TBC1 domain family, member 8; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TCF-4 (T-cell factor 4); double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TEA domain family member 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TERA; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TFIIIC (transcription factor IIIC), polypeptide 3, 102kDa;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TGF- $\beta$  induced apoptosis protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TGF $\beta$ -induced factor; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TGF $\beta$ -inducible nuclear protein 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Transforming growth factor  $\beta$   
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TGF $\beta$ 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (THAP domain containing 7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (THRSP (thyroid hormone-responsive protein); double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TIP47; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TM2 domain containing 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TNF receptor-associated factor 7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TNF receptor-associated protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TPMsk3; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TPRD1; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT DNA-binding proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TRF1 (telomeric repeat-binding factor 1); double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Transient receptor potential cation channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TRPM7; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TSC22 domain family, member 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TSPY-like 4; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Tax1 binding protein 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Tax1 binding protein 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(U2 small nuclear RNA auxiliary factor 2; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(U2 small nuclear RNA-associated; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(UBX domain containing 5; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Annexins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(V; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Voltage-dependent anion channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(VDAC1; double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Voltage-dependent anion channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(VDAC2; double-stranded RNAs and their use for downregulating genes and

treating cardiovascular diseases)

IT Voltage-dependent anion channels  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (VDAC3; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (WD repeat domain 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (WD repeat domain 26; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (WNT1 inducible signaling pathway protein 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (WW domain binding protein 5; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Williams-Beuren syndrome chromosome region 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Wilms tumor 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (X-ray repair complementing defective repair in Chinese hamster cells  
 1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (XPA binding protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Y box binding protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (YEATS domain containing 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (YPL1; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Zic family member 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (abhydrolase domain containing 11; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins



RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(abhydrolase domain containing 6; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Transforming proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(acidic coiled-coil containing protein 1; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin filament-associated; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-capping, gelsolin-like; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-capping, muscle Z-line,  $\alpha 1$ ; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-capping, muscle Z-line,  $\alpha 2$ ; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-capping, muscle Z-line,  $\beta$ ; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-like 6A; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(actin-related protein 23; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(acyl-CoA binding domain containing 5; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(adenylate cyclase-associated protein 1; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(adhesion regulating mol. 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(adiponectin, 1; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(adipophilin; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (afamin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (alanine-glyoxylate aminotransferase 2-like 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (amphiphysin; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (amyloid beta precursor protein binding protein 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (amyloid beta precursor-like protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (angiopoietin-like 7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat and SOCS box-containing 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat and SOCS box-containing 4; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat domain 13; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat domain 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat domain 37; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ankyrin repeat, family A, 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (anterior pharynx defective 1 homolog A; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antioxidant protein ATX1 homolog; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(aquarius homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine-glutamic acid dipeptide repeats; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine-rich, mutated in early stage tumors; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine/serine-rich 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine/serine-rich 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine/serine-rich 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine/serine-rich 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arginine/serine-rich coiled-coil 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arrestin domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(astrotactin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ataxin 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ataxin 2-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(autoantigens, NOR-90; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (autoantigens, SjogrenNULLs syndrome nuclear autoantigen 1;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (autoantigens, calcium binding atopy-related autoantigen 1;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (autophagy 12-like protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (autophagy 7-like protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (baculoviral IAP repeat-containing 6; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (barren homolog; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (barrier to autointegration factor 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (basic leucine zipper and W2 domains 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (basic leucine zipper nuclear factor 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (basic leucine zipper transcription factor 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (basic transcription factor 3-like 4; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain abundant, membrane attached signal protein 1; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain expressed, X-linked 1; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain protein 13; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain protein 44-like; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain protein 44; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain-specific angiogenesis inhibitor 2;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain-specific; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (breast carcinoma-associated, isoform I; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (brix domain containing 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (bromodomain and WD repeat domain containing 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (bromodomain containing 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (bromodomain containing 8; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Growth factors, animal  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (c-fos induced; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cAMP responsive element binding protein-like 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cAMP responsive element binding protein-like 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Chloride channels  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (calcium activated, family member 3; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (calcyclin binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Calcium-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (calcyclins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (calseinilin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (calsyntenin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (carbon catabolite repression 4-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Troponin T  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (cardiac, TNNT2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (carnitine deficiency-associated, expressed in ventricle 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (catenins  $\alpha 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cell cycle regulatory proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (cell division cycle 2-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cell cycle regulatory proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (cell division cycle associated 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (centaurin,  $\gamma 3$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (contractin  $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (contractin  $\beta$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (centrosome-associated protein 350; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cereblon; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cervical cancer oncogene 9; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromatin accessibility complex 1; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromatin modifying 2A; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromobox homolog 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromobox homolog 5; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromodomain helicase DNA binding 9; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 106; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 119; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 122; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 58; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 75; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 8; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (chromosome 1 open reading frame 91; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 1 open reading frame 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 10 open reading frame 119; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 10 open reading frame 56; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 10 open reading frame 88; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 11 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 11 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 12 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 12 open reading frame 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 13 open reading frame 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 14 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 14 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chromosome 14 open reading frame 166; double-stranded RNAs and their



use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 16 open reading frame 53; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 25; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 35; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 37; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 18 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 19 open reading frame 27; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 2 open reading frame 18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 116; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 149; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 47; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 20 open reading frame 67; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 22 open reading frame 13; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 22 open reading frame 16; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 22 open reading frame 9; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 4 open reading frame 9; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 106; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 111; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 62; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 82; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 85; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 6 open reading frame 93; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 7 open reading frame 21; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular

diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 7 open reading frame 30; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 9 open reading frame 10; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 9 open reading frame 24; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 9 open reading frame 58; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 9 open reading frame 88; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chromosome 9 open reading frame 89; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cingulin-like 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cingulins; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Claudins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (claudin-15; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Claudins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (claudin-7; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cleavage stimulation factor; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coated vesicle membrane protein; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coatamer, subunit alpha; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coatamer, subunit beta; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coatamer, subunit zeta 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coenzyme Q7 homolog, ubiquinone; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cofilin, 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cofilin, 2; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coiled-coil domain containing 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coiled-coil domain containing 80; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coiled-coil-helix domain containing 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coiled-coil-helix domain containing 2; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coiled-coil-helix domain containing 3; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cold shock domain protein A; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (containing TCF1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (copine I; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (copine III; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (copper metabolism domain containing 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cornichon homolog 4; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coronin, actin binding protein, 1B; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coronin, actin binding protein, 1C; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (coronin, actin binding protein, 2B; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cortactins; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cross-immune reaction antigen PCIA1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cyclin D-binding myb-like, 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cysteine and glycine-rich protein 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cysteine and glycine-rich protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cysteine and glycine-rich protein 3; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cysteine-rich, angiogenic inducer, 61; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cytoglobin; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cytokine induced apoptosis inhibitor 1; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cytoskeleton-associated protein 4; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(damage-specific, 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Guanine nucleotide exchange factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(deafness locus-associated; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(death-associated; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(defender against cell death 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dendritic cell; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dermokine; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dickkopf homolog 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(differential display and activated by p53; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dihydropyrimidinase-like 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dihydrouridine synthase 1-like; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(disintegrin and metalloproteinase, domain 32; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(disks large homolog-associated protein 4; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(dispatched homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (disrupted in renal carcinoma 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (docking protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cardiac arrest  
 Cardiac arrhythmia  
 Cardiovascular system, disease  
 Coronary artery disease  
 Coronary thrombosis  
 DNA sequences  
 Human  
 Myocardial infarction  
 Myocardial ischemia  
 Stroke  
 Valvular heart disease  
 cDNA sequences  
 (double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins  
 Albumins, biological studies  
 Amyloid precursor proteins  
 Benzodiazepine receptors  
 Biglycans  
 Bone morphogenetic protein 1  
 Bone morphogenetic protein 2  
 Bone morphogenetic protein 4  
 C-reactive protein  
 CD19 (antigen)  
 CD3 (antigen)  
 CD34 (antigen)  
 CD4 (antigen)  
 Caldesmon  
 Calnexin  
 Calreticulin  
 Clusterin  
 DNA formation factors  
 DNA-binding proteins  
 Decorins  
 Desmins  
 Desmoplakins  
 Endothelin ETA receptors  
 Ephrin-A2  
 Ephrin-B1  
 Ephrin-B3  
 Epidermal growth factor receptors  
 Erythropoietin receptors  
 Ferritins  
 Fibromodulins  
 Filamin  
 G protein-coupled receptors  
 G proteins (guanine nucleotide-binding proteins)  
 Gelsolin  
 Glypicans  
 Heat-shock proteins  
 Insulin-like growth factor II receptors

Interleukin 7 receptors  
 Leptin receptors  
 Leukemia inhibitory factor receptors  
 Lumicans  
 Macrophage inflammatory protein 1 $\beta$   
 Macrophage migration inhibitory factor  
 Mdm2 protein  
 Midkines  
 Monocyte chemoattractant protein-5  
 Nicotinic receptors  
 Osteonectin  
 Platelet-derived growth factor receptors  
 Pleiotrophins  
 Prion proteins  
 Protamines  
 Proteins  
 Proteins  
 Signal sequence receptors  
 Stem cell factor  
 Synaptophysin  
 Thrombomodulin  
 Thyroid hormone receptors  
 Transferrin receptors  
 Transferrins  
 Translation initiation factors  
 Troponin C  
 Troponin I  
 Troponin I  
 Troponin T  
 Vimentins  
 Vinculin  
 Vitronectin  
 p53 (protein)  
 $\alpha$ -Actins  
 $\beta$ -Actins  
 $\beta$ 1-Adrenoceptors  
 $\beta$ 2-Adrenoceptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

- IT Proteins
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (down-regulated by Ctnnb1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (down-regulator of transcription 1, TBP-binding; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)
- IT Proteins
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dpy-30-like; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)
- IT Proteins
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dysferlin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)
- IT Proteins
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dystonin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)



IT Translation elongation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eEF-1 $\alpha$ ; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Translation elongation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eEF-2; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-1A; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-2B; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-3; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-4A; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-4B; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-4E-BP1 (eIF-4E-binding protein 1); double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-4E; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-4G; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-5; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-5A; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Translation initiation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eIF-5B; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (echinoderm microtubule associated protein like 4; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (egl nine homolog 2; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (elastin microfibril interfacer 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (elastin microfibril interfacer 2; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Flavoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (electron transfer flavoprotein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (emopamil binding protein-like; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (enabled, homolog; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (endophilin, B1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (endothelial differentiation-related factor 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (endozepine-like protein type 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (enhancer of rudimentary, homolog; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (epithelial membrane protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (epithelial membrane protein 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (epithelial membrane protein 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (erythrocyte membrane protein band 41-like 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(essential meiotic endonuclease 1 homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (eukaryotic initiation factor-2-associated, p67; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Organelle  
 (exosome (exonuclease complex), components 5 and 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (far upstream element binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fascin homolog 1, actin-bundling protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fibrinogen-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fibulin, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fibulin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (filamin A interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (flightless I homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (follistatin-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (forty-two-three domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (four and a half LIM domains 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fracture callus 1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fragile X mental retardation, autosomal homolog 1; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (frizzled homolog 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (frizzled homolog 4; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (frizzled homolog 6; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (fumarylacetoacetate hydrolase domain containing 2A; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (galactose-binding, soluble, 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (galactose-binding, soluble, 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (galactose-binding, soluble, 4; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (galactose-binding, soluble, 8; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (galectin-3; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gap junction-specific,  $\alpha 7$ , 45kDa; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene B29; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene HGFL; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene KAL1; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(gene RAB10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB14; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB20; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB22A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB40C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB4A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB5C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB8A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene RAB9A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene SCL; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (glioma tumor suppressor candidate region gene 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (glycerophosphodiester phosphodiesterase domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (glycine cleavage system protein H; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (glycosyltransferase 25 domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (golgi complex, 6; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (golgi complex, 8; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (golgi reassembly stacking protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (growth arrest and DNA-damage-inducible, gamma; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (growth arrest-specific 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (growth factor receptor-bound protein 10; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (growth factor receptor-bound protein 14; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (growth factor receptor-bound protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (heart and neural crest derivs. expressed 1; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (heat shock, 2; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Myosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (heavy chain 11, smooth muscle; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Clathrin  
 Dyneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (heavy chain; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hematopoietic stem progenitor cells 176; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteoglycans, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (heparitin sulfate-containing; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Growth factors, animal  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hepatoma-derived; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (high mobility group AT-hook 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (high-mobility group box 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (high-mobility group box 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (high-mobility group nucleosomal binding domain 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (high-risk human papilloma viruses E6 oncoproteins targeted protein  
 B6TP1a; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP A1; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP A2/B1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP C; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP F; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP H; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP K; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hnRNP U; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (homeodomain-containing, iroquois homeobox protein 3; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (homeodomain-containing, iroquois homeobox protein 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(homeodomain-containing, msh homeo box homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(homeodomain-containing, msh homeo box homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Ras proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(huntingtin interacting protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hypoxia up-regulated 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(immature colon carcinoma transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(immediate early response 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(influenza virus NSIA binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitor of DNA binding 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitor of DNA binding 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitor of growth family, member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(insulin-induced gene 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)



IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (integrin  $\beta$ 1 binding protein 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (integrin  $\beta$ 1 binding protein 2; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (integrin  $\beta$ 1 binding protein 3; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (integrin  $\beta$ 4 binding protein; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Post-transcriptional processing  
 (interference; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (interferon-induced transmembrane protein 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (interferon-induced transmembrane protein 3; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (interferon-related developmental regulator 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (interferon-stimulated transcription factor 3,  $\gamma$  48kDa;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (interleukin 6 signal transducer; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Dyneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (intermediate chain; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (intersectin 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (jagunal homolog 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(jumonji, AT-rich interactive domain 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(junB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(junD; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(kelch domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(keratin associated protein 6-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(keratinocyte associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(kinase anchor protein 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(kinase anchor protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(kinase anchor protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(kinase insert domain receptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(lamin AC; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Calcium-activated potassium channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(large-conductance, subfamily M, beta member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(late cornified envelope 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(latent transforming growth factor  $\beta$  binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(latrophilin, 3; double-stranded RNAs and their use for downregulating

genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine rich repeat containing 10; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine rich repeat containing 45; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine rich repeat containing 8B; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine zipper protein 5; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine-rich PPR-motif containing; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leucine-rich repeats and Ig-like domains 3; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (leukocyte Ig-like receptor, subfamily A, member 2; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Myosins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (light chain, 1 slow a; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Clathrin  
 Dyneins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (light chain; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (low d. lipoprotein receptor adaptor protein 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (lymphocyte cytosolic protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (lymphocyte-specific protein 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (lysyl oxidase-like 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (lysyl oxidase-like 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (major facilitator superfamily domain containing 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (major nuclear matrix protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (major vault protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (makorin, ring finger protein, 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (male-enhanced antigen 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Mannose receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mannose 6-phosphate; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mannose phosphate-dolichol utilization defect 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mannose-binding, 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (melanoma antigen family D, 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (melanoma antigen family D, 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, 2A; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, integral membrane protein 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, integral membrane protein 2B; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, lysosomal-associated membrane protein 1; double-stranded RNAs  
 and their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, lysosomal-associated membrane protein 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, lysosomal-associated protein transmembrane 4a;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, palmitoylated 1, 55kDa; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, vesicle-associated, 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane, vesicle-associated, 8; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (membrane-associated ring finger 7; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mesoderm specific transcript homolog; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (metaxin 1; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (metaxin 2; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (meteorin-like; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (meteorin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (methyl-CpG binding domain protein 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (microfibrillar-associated protein 2; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (microfibrillar-associated protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(microfibrillar-associated protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(midnolin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(milk fat globule-EGF factor 8 protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(modulator of estrogen induced transcription; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(monocyte to macrophage differentiation-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mortality factor 4 like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mucolipin 1, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mucolipin 1, 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(muscleblind-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(myc target 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(myelin gene expression factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(myelin protein zero-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(myeloblastosis viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myeloid leukemia factor 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myeloid-associated differentiation marker-like; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myeloid/lymphoid or mixed-lineage leukemia; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myogenic factor 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myotubularin related protein 9; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (myristoylated alanine-rich protein kinase C substrate; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nasal embryonic LHRH factor; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nasopharyngeal carcinoma-related; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (necdin, homolog; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nerve growth factor receptor-associated protein 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (neural precursor cell expressed, developmentally down-regulated  
 4-like; double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (neural precursor cell expressed, developmentally down-regulated 4;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (neural precursor cell expressed, developmentally down-regulated 8;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neural proliferation, differentiation and control, 1; double-stranded  
RNAs and their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuralized-like 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuroblastoma RAS viral oncogene homolog; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neurofibromin 2; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Cytoskeleton  
(neurofilament, light polypeptide 68kDa; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Cytoskeleton  
(neurofilament; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuroligin 3; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuronatin; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neurotrimin; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neutrophil cytosolic factor 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nexilin; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nidogen 1; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nuclear VCP-like; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nuclear casein kinase and cyclin-dependent kinase substrate 1;  
double-stranded RNAs and their use for downregulating genes and  
treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nuclear factor I; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)



IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear factor of activated T-cells 5, tonicity-responsive;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear factor, interleukin 3 regulated; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear factor-like 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear protein E3-3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Nuclear receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear receptor subfamily 1, group D, member 1; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Nuclear receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear receptor subfamily 1, group H, member 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Nuclear receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nuclear receptor subfamily 2, group F, member 2; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleic acid-binding, polypyrimidine tract binding protein 1;  
 double-stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleobindin 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleolar complex associated 2, homolog; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleolar protein 11; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleolar protein 5A; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (nucleolar protein family A, member 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleolar protein family A, member 3; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleolar protein with MIF4G domain 1; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleophosmin; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleoporin, 54 and 205kDa; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleosome assembly protein 1-like 1; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleotide binding protein 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(olfactomedin-like 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(optic atrophy 3; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(outer dense fiber of sperm tails 1; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(oxidase assembly 1-like; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p19INK4D; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p21CIP1; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p27/KIP1; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p53 and DNA damage regulated 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (p53-inducible nuclear protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p53-inducible nuclear protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclin dependent kinase inhibitors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(p57/KIP2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(paired box gene 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(partitioning defective 6 homolog alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(patatin-like phospholipase domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(pentatricopeptide repeat domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(peptide/histidine transporter 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(peripheral myelin protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(pern-like domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Peroxins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(peroxin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(peroxisomal membrane protein 2, 22kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(peroxisome biogenesis factor 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(pescadillo homolog 1, containing BRCT domain; double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (phosphatidylinositol transfer protein, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Glycophospholipids  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (phosphatidylinositol-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (phosphofurin acidic cluster sorting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (phospholemman; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pim-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pinin, desmosome associated protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pleckstrin homol. domain containing, family B member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pleckstrin homol. domain containing, family C, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pleckstrin homol.-like domain, family A, member 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pleckstrin homol.-like domain, family B, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (plectins, intermediate filament binding protein 500kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (poly binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (poly polymerase family, member 6; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (polycomb group ring finger 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (popeye domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (popeye domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (postsynaptic protein CRIPT; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pre-B-cell leukemia transcription factor interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prefoldin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prefoldin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prefoldin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (programmed cell death 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (programmed cell death 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proliferation-associated 2G4, 38kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proline-, glutamic acid-, leucine-rich protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prosaposins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prostaglandin F2 receptor neg. regulator; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prostatains; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protein inhibitor of activated STAT, 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protein regulator of cytokinesis I; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protein tyrosine phosphatase domain containing 1; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proteolipid protein 2; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 10; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 11; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 12; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 3; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 4; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(protocadherin, gamma subfamily A, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily A, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily B, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily B, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily B, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily B, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily B, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily C, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (protocadherin, gamma subfamily C, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pseudogene, UBBP4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pseudogene, UOX; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pseudogene, cytochrome c processed; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

diseases)

IT Gene  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pseudogene, thioredoxin 1 pseudogene 5; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pxl9-like protein; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (quaking homolog, KH domain RNA binding; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT G proteins (guanine nucleotide-binding proteins)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (rap1B; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ras homolog gene family, member A; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ras homolog gene family, member J; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ras-related C3 botulinum toxin substrate 1; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ras-related C3 botulinum toxin substrate 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (regulator of chromosome condensation 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT DNA formation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (replication factor C 2, 40kDa; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT DNA formation factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (replication protein A3, 14kDa; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (restin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (reticulocalbin 3; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins



RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(reticulin 1; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(reticulin 3; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(reticulin 4a; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinitis pigmentosa GTPase regulator interacting protein 1;  
double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinoblastoma binding protein 2 homolog 1; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinoblastoma binding protein 4; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinoblastoma binding protein 7; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular  
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinoblastoma-like 1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinoblastoma-like 2; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(retinol binding protein 4; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ribophorin I; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ribophorin II; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ring finger protein 128; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ring finger protein 149; double-stranded RNAs and their use  
for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ring finger protein 185; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ring finger protein CKBBP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(runt-related transcription factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sarcolemma-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sarcoma antigen NY-SAR-77; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenium-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenium-containing, K; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenium-containing, P, plasma, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenium-containing, X, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenium-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(selenocysteine-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sepin 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sepins, 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sepins, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sepins, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(serine/arginine repetitive matrix 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/arginine repetitive matrix 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/threonine kinase receptor-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (seven in absentia homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (sex comb on midleg homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (shroom; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Mucins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (signal transducing adaptor mol. 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (sin3-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 Proteins, specific or class  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (single-stranded DNA-binding, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (small EDRK-rich factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (small acidic; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Double stranded RNA  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (small interfering; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (small muscle, X-linked; double-stranded RNAs and their use for

- downregulating genes and treating cardiovascular diseases)
- IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (small nuclear RNA auxiliary factor 1-like 2; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Ribonucleoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (snRNP (small nucleolar ribonucleoprotein), UTP1-like, U3;  
 double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)
- IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (soc-2 suppressor of clear homolog; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 12, member 7; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 16, member 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 2, member 1; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 2, member 3; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 20, member 1; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 22, member 3; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 23, member 1; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 24, member 5; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)
- IT Transport proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (solute carrier family 25, member 13; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 35, member A4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 36, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 36, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 37, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 39, member 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 39, member 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 6, member 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 9, isoform 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sortilin-related VPS10 domain-containing receptor 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sparcaneonectin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (spen homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sperm associated antigen 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (spermatogenesis associated 16; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (spermatogenesis associated 21; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (spinster; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (split handfoot malformation type 1; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (sprouty-related, EVH1 domain containing 2; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (stabilin 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (stannin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (stathmin-like 2; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (stathmin; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (steroid 5 alpha-reductase 2-like; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (steroid sensitive gene 1; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (sterol regulatory element binding, 2; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular  
 diseases)

IT Enzymes, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (sterol-C4-Me oxidase-like; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (stomatin-like 1; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(stress-induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (stromal cell derived factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (stromal cell derived factor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (structure-specific recognition protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated potassium channels  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (subfamily H, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (suppressor of *S. cerevisiae* gcr2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (suppressor of Ty 16 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (surfeit 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (sushi domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptopodin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptoporin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptotagmin IV; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (syncollin, intermediate filament 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (syndecan-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (syntaxin 16; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (t-complex-associated-testis-expressed 1-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (t-complex-associated-testis-expressed 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tafazzin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (talin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tankyrase 1 binding protein 1, 182kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (taxilin  $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tensin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (testis-expressed sequence 261; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tetraspan NET-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tetratricopeptide repeat domain 7B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thioredoxin domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thioredoxin-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thyroid hormone receptor interactor 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)



(thyroid hormone receptor interactor 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thyroid hormone receptor interactor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thyrotrophic embryonic factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tight junction protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (timeless-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (toll-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (torsin, family 1, member A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (trafficking protein particle complex 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transcript release factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transformer-2 $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transforming growth factor  $\beta$ -induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transforming growth factor  $\beta$ 1-induced transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transgelin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transgelin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(translocation protein-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane trafficking; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 30A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 38A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 49; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 64; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, BAX inhibitor motif containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, channel-like 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, emp24 protein transport domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, emp24 protein transport domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, growth hormone-inducible; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, prostate androgen-induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (transportin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tribbles homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tripartite motif-containing 23; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tripartite motif-containing 28; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tripartite motif-containing 41; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tripartite motif-containing 55; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tripartite motif-containing 65; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tripartite motif-containing 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (triple functional domain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tristetraprolin, C3H type, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tristetraprolin, C3H type-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Glycoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (trophoblast; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tubulin-specific,  $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tubulointerstitial nephritis antigen-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tumor necrosis factor receptor superfamily, member 12A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tumor necrosis factor receptor superfamily, member 5 isoform 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (tumor necrosis factor  $\alpha$ -induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor necrosis factor  $\alpha$ -induced, 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein D52; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein, translationally-controlled 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor rejection antigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor suppressor candidate 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor susceptibility gene 101; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type FP; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type I,  $\alpha$ 1(I)-chain, collagens,  $\alpha$ 1(I); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Bone morphogenetic protein receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Activin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IIA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Voltage-gated sodium channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Voltage-gated sodium channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IX,  $\alpha$  subunit; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(tyrosine ligase-like family, member 4; double-stranded RNAs and their  
use for downregulating genes and treating cardiovascular  
diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ubiquitin; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ubiquitin-cytochrome c reductase binding protein; double-stranded RNAs  
and their use for downregulating genes and treating  
cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ubiquitin-activating; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ubiquitin-conjugating; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ubiquitin-like 3; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(unc-5 homolog B; double-stranded RNAs and their use for downregulating  
genes and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(unc-93 homolog B1; double-stranded RNAs and their use for  
downregulating genes and treating cardiovascular diseases)

IT Angina pectoris  
(unstable; double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(upregulated during skeletal muscle growth 5; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(upstream transcription factor 2, c-fos interacting; double-stranded  
RNAs and their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(v-erb-b2 erythroblastic leukemia viral oncogene homolog 2;  
double-stranded RNAs and their use for downregulating genes  
and treating cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(v-fos FBJ murine osteosarcoma viral oncogene homolog; double-stranded  
RNAs and their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(v-jun sarcoma virus 17 oncogene homolog; double-stranded RNAs and  
their use for downregulating genes and treating  
cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;  
 double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (v-myb myeloblastosis viral oncogene homolog; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (v-raf-1 murine leukemia viral oncogene homolog 1; double-  
 stranded RNAs and their use for downregulating genes and  
 treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (v-ral simian leukemia viral oncogene homolog B; double-stranded RNAs  
 and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (vacuolar protein sorting 25; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (vacuolar protein sorting 29; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (vacuolar protein sorting 4A; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (wingless-type MMTV integration site family, member 7B; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (yeast INO80 protein homolog; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (yrdC domain-containing; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 11B; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 161; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 205; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 23; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 336; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 445; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 574; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 605; double-stranded RNAs and their  
 use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 662; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 670; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 91, homolog; double-stranded RNAs and their use  
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, 9; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, BTB domain containing 16; double-stranded  
 RNAs and their use for downregulating genes and treating cardiovascular  
 diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, CCCH-type containing 11A; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, CCHC domain containing 9; double-stranded  
 RNAs and their use for downregulating genes and treating  
 cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, CSL-type containing 2; double-stranded RNAs and  
 their use for downregulating genes and treating  
 cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, Chk2-interacting; double-stranded RNAs and  
 their use for downregulating genes and treating cardiovascular  
 diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, FYVE domain containing 9; double-stranded  
 RNAs and their use for downregulating genes and treating

cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, GLIS family zinc finger 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zinc finger proteins, matrin type 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (zyxin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antibodies and Immunoglobulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\kappa$ -chain, VJ region; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Laminins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$  subunit,  $\alpha 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Karyopherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ ,  $\alpha 3$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -, SPTAN1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -, non-erythrocytic 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Hemoglobins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Tubulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -, double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Actinins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -actinin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Actinins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ -actinin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha 1$ (I1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha 1$ (IV); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)



( $\alpha 1(V)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1(VIII)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1(XI)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1(XV)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1(XVIII)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT  $\alpha$ -Actins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2(I)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2(IV)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2(V)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2(VI)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT  $\alpha$ -Actins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 3(VI)$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Platelet-derived growth factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Crystallins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha B-$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Microglobulins  
 Tubulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1-$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Macroglobulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

( $\alpha 2$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$  chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Karyopherins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ ,  $\beta 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -, non-erythrocytic 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -, non-erythrocytic 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Tubulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -chimaerin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -galactosidase protective protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta 5$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$  chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT  $\gamma$ -Actins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma 1$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Laminins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(γ1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT γ-Actins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ2-; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Hemoglobins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ε-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Crystallins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (μ-; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 71427-00-4, Ribonuclease P  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (14kDa subunit; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 37205-61-1, Proteinase inhibitor  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (16; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9026-23-7, Carbamoyl-phosphate synthetase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9025-77-8, Phosphatidic acid phosphatase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (2B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 433940-25-1, MRNA splicing endonuclease  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (34 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 109136-49-4, Ubiquitin specific protease  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 95076-93-0, Peptidylprolyl isomerase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (A, B and C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9024-52-6 9054-75-5, Guanylate cyclase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9032-58-0, Farnesyltransferase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CAAX box, β-; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9013-93-8, Phospholipase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (D3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9082-72-8, Branched-chain keto acid dehydrogenase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (E1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9000-83-3, ATPase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (H+, Ca2+, or Na+/K+-transporting; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT 9014-24-8  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (I, II and III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9001-85-8, Lysophospholipase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (II or 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 80449-02-1  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ig-like and EGF-like domains-containing, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 866261-76-9  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MX; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9068-67-1, Sulfatase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SULF-2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9031-98-5, Carboxypeptidase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (X; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 96282-35-8, Serpin  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (clade A, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 139691-92-2, Serine proteinase inhibitor  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (clade G member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9025-42-7  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (class 2A, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9000-86-6, Glutamic-pyruvate transaminase 9000-95-7, Ectonucleoside triphosphate diphosphohydrolase 9000-96-8, Arginase 9001-15-4, Creatine kinase 9001-16-5, Cytochrome c oxidase 9001-26-7, Coagulation factor II 9001-42-7,  $\alpha$ -Glucosidase 9001-52-9, Fructose-1,6-bisphosphatase 9001-58-5, Isocitrate dehydrogenase 9001-59-6, Pyruvate kinase 9001-60-9, Lactate dehydrogenase 9001-62-1, Lipase A 9001-63-2, Lysozyme 9001-64-3, Malate dehydrogenase 9001-77-8, Acid phosphatase 9001-78-9, Alkaline phosphatase 9001-80-3, Phosphofructokinase 9001-82-5, Phosphogluconate dehydrogenase 9001-88-1, Phosphorylase kinase 9004-02-8, Lipoprotein lipase 9012-34-4, Acylphosphatase 9012-42-4, Adenylate cyclase 9012-49-1, Aspartate transcarbamylase 9012-52-6, Methionine adenosyltransferase 9013-02-9, Adenylate kinase 9013-10-9, Glucosamine-6-phosphate deaminase 9013-18-7, Acyl-CoA synthetase 9013-66-5, Glutathione peroxidase 9014-08-8, Enolase 9014-20-4, Pyruvate dehydrogenase 9014-34-0, Fatty acid desaturase 9016-12-0, Hypoxanthine phosphoribosyltransferase 9023-44-3, Tryptophanyl-tRNA synthetase 9023-47-6, Valyl-tRNA synthetase 9023-53-4, Phosphoribosylaminoimidazole synthetase 9023-58-9, Argininosuccinate synthetase 9023-66-9, Formyltetrahydrofolate synthetase 9023-70-5, Glutamate-ammonia ligase 9023-78-3, Triosephosphate isomerase 9023-93-2, Acetyl-Coenzyme A carboxylase 9024-25-3, Aconitase 9024-60-6, Ornithine decarboxylase 9024-93-5,

Dihydroorotase 9025-26-7, Cathepsin D 9025-32-5 9025-54-1,  
 S-Adenosylhomocysteine hydrolase 9025-83-6, 3'(2'),5'-Bisphosphate  
 nucleotidase 9026-39-5, Uridine-cytidine kinase 9026-43-1 9026-46-4,  
 Phosphomevalonate kinase 9026-59-9, Guanylate kinase 9027-03-6,  
 Ubiquinol-cytochrome c reductase 9027-13-8, Enoyl Coenzyme A hydratase  
 9027-33-2 9027-63-8, Sterol acyltransferase 9027-80-9, Adenine  
 phosphoribosyltransferase 9027-81-0, Adenylosuccinate lyase 9027-95-6,  
 ATP citrate lyase 9027-97-8, Methenyltetrahydrofolate cyclohydrolase  
 9028-04-0, NADH dehydrogenase 9028-06-2 9028-39-1,  
 3-Hydroxyisobutyrate dehydrogenase 9028-40-4, 3-Hydroxyacyl-Coenzyme A  
 dehydrogenase 9028-86-8, Aldehyde dehydrogenase 9028-93-7, IMP  
 dehydrogenase 9029-12-3, Glutamate dehydrogenase 1 9029-14-5,  
 Methylenetetrahydrofolate dehydrogenase 9029-32-7, Guanosine  
 monophosphate reductase 9029-72-5, p-Hydroxyphenylpyruvate dioxygenase  
 9029-73-6, Phenylalanine hydroxylase 9029-78-1, Betaine-homocysteine  
 methyltransferase 9030-08-4, UDP glucuronosyltransferase 9030-66-4,  
 Glycerol kinase 9030-96-0, Isoleucine-tRNA synthetase 9031-19-0,  
 Saccharopine dehydrogenase 9031-26-9, Lysyl-tRNA synthetase 9031-37-2,  
 Ceruloplasmin 9031-50-9, Nucleotidyltransferase 9031-68-9,  
 Galactosyltransferase 9031-71-4, Alanine-tRNA synthetase 9031-82-7,  
 Phosphoribosyl pyrophosphate amidotransferase 9031-86-1, Aspartoacylase  
 9031-99-6, Dipeptidase 9032-01-3 9032-02-4, Phosphoribosylglycinamide  
 formyltransferase 9032-25-1, Cytochrome b5 reductase 9032-59-1,  
 Fumarylacetoacetate hydrolase 9032-62-6, Phosphoglycerate mutase  
 9032-68-2, Cathepsin C 9032-95-5 9033-53-8, Retinol dehydrogenase  
 9033-55-0, Saccharopine dehydrogenase 9036-20-8, Adenosylmethionine  
 decarboxylase 9036-37-7,  $\delta$ -Aminolevulinic acid dehydratase  
 9037-14-3,  $\delta$ -Aminolevulinic acid synthase 9037-42-7, DNA  
 methyltransferase 9037-62-1, Glycyl-tRNA synthetase 9037-65-4,  
 $\alpha$ -L-Fucosidase 9046-67-7, Serine carboxypeptidase 9047-22-7,  
 Cathepsin B 9048-63-9, Epoxide hydrolase 9054-44-8,  
 Acetylglucosaminyltransferase 9054-89-1, Superoxide dismutase  
 9055-65-6, Prostaglandin synthase 9055-67-8, Tankyrase 9055-72-5,  
 Pyridoxine-5'-phosphate oxidase 9059-22-7, Heme oxygenase 9059-25-0,  
 Lysyl oxidase 9073-96-5, Saccharopine dehydrogenase 9074-01-5,  
 Pyruvate dehydrogenase kinase 9074-14-0, Thioredoxin reductase  
 9074-83-3, Aspartyl aminopeptidase 9074-87-7, Glutamate carboxypeptidase  
 9075-21-2, Pyroglutamyl-peptidase I 9075-29-0, Phosphoglycerate  
 dehydrogenase 9075-59-6, Glutaminyl-tRNA synthetase 9075-64-3,  
 Prolylcarboxypeptidase 9077-14-9, Farnesyl diphosphate  
 farnesyltransferase 9080-21-1, 7-Dehydrocholesterol reductase  
 37228-72-1, Glycine N-methyltransferase 37256-26-1, Saccharopine  
 dehydrogenase 37256-59-0, Cysteine dioxygenase 37256-73-8,  
 Flavin-containing monooxygenase 37270-94-3, Platelet factor 4  
 37278-25-4, Ribonuclease T2 37288-40-7, N-Acetyl- $\alpha$ -glucosaminidase  
 37289-06-8, N-Acylsphingosine amidohydrolase 37318-49-3, Protein  
 disulfide isomerase 37341-57-4 39391-18-9, Prostaglandin-endoperoxide  
 synthase 50812-36-7, Farnesyl diphosphate synthase 50812-37-8,  
 Glutathione S-transferase 52227-79-9, Prostaglandin E synthase  
 52660-18-1, Casein kinase 1 53096-17-6, Bleomycin hydrolase  
 55963-40-1, Vitamin K epoxide reductase 55976-95-9 60382-71-0,  
 Diacylglycerol kinase 60571-91-7, Hydroxysteroid dehydrogenase 7  
 60748-73-4, Cathepsin H 62213-44-9, Dolichyl-phosphate  
 mannosyltransferase 62213-50-7, Serine palmitoyltransferase  
 65979-36-4, Signal peptidase 67763-97-7, IGF-II 71124-51-1,  
 $\beta$ -Galactoside  $\alpha$ -2,3-sialyltransferase 71965-46-3, Cathepsin S  
 74506-58-4, Heparan 2-O-sulfotransferase 74812-43-4, Spermine synthase  
 74812-49-0, E3 Ubiquitin protein ligase 76901-00-3, Platelet-activating  
 factor acetylhydrolase 77114-08-0, Serine racemase 77642-24-1,  
 Thymosin  $\beta$ 4 78689-77-7, 6-Phosphofructo-2-kinase 80146-85-6,  
 Transglutaminase 80295-41-6, Complement C3 80295-50-7, Complement C4b

81611-75-8, Fructose-2,6-bisphosphatase 81627-83-0, Colony-stimulating factor 1 83268-44-4 83380-83-0 86480-67-3, Ubiquitin carboxyl-terminal hydrolase 87397-91-9, Thymosin  $\beta$ 10 89964-14-7, Prothymosin, alpha 90597-47-0, Peptidylglycine  $\alpha$ -amidating monooxygenase 95328-48-6, Parathymosin 98668-52-1, ADP ribosylarginine hydrolase 106283-10-7, Inositol 1,4,5-trisphosphate 3-kinase 106640-75-9, Aldo-keto reductase 108658-39-5, Myosin phosphatase 109319-16-6, Von Willebrand factor 115926-52-8, Phosphoinositide-3-kinase 116283-83-1, Elongation factor-2 kinase 117444-13-0, tRNA splicing endonuclease 120178-12-3, Telomerase reverse transcriptase 124861-55-8 127464-60-2, Vascular endothelial growth factor 130731-20-3, Prenylcysteine carboxymethyltransferase 137632-07-6, Protein kinase ERK1 137632-08-7, Mitogen-activated protein kinase 1 139316-54-4, Epithelin 141349-86-2, Cyclin-dependent kinase 2 141436-78-4, Protein kinase C 142008-29-5, CAMP-dependent protein kinase 143375-65-9, CDC2 protein 145809-21-8, Tissue inhibitor of metalloproteinase 3 146480-35-5, Matrix metalloproteinase 2 146480-36-6, Matrix metalloproteinase 9 146702-84-3, Mitogen-activated protein kinase kinase kinase 147014-97-9, Cyclin-dependent kinase 4 149371-18-6, Legumain 149885-84-7 151125-25-6, Selenophosphate synthetase 151662-36-1, Tripeptidyl peptidase I 151821-61-3, Ubiquitin B 151821-62-4, Ubiquitin C 152478-57-4, Janus kinase 2 153190-63-7, AXL receptor tyrosine kinase 154531-34-7, Heparin-binding EGF-like growth factor 156681-44-6,  $\alpha$ -Methylacyl-CoA racemase 165245-96-5, Mitogen-activated protein kinase 14 167397-96-8, Interleukin-1 receptor-associated kinase 1 169277-44-5, Sphingosine-1-phosphate phosphatase 171715-12-1, Cathepsin Z 172308-13-3, Mitogen-activated protein kinase kinase 3 178037-70-2, Serum- and glucocorticoid-regulated protein kinase 180189-96-2, Caspase 9 183257-54-7, Heparan sulfate 3-O-sulfotransferase 186270-49-5, Angiopoietin 1 186359-58-0, Protein kinase ZAK 189460-40-0, Connective tissue growth factor 190396-38-4, Carboxypeptidase Z 192140-83-3, p21-Activated kinase 2 192662-83-2, Vascular endothelial growth factor B 204719-95-9, Fibroblast growth factor 16 207137-51-7, Peroxiredoxin 207137-52-8, Nemo like kinase 214210-47-6, Neuropilin 1 220983-94-8, Sorbitol dehydrogenase 252901-98-7, Tousled-like kinase 1 271597-11-6, Growth differentiation factor 3 271597-13-8, Growth differentiation factor 10 300855-77-0, Protein tyrosine phosphatase, non-receptor type 6 300857-36-7, Protein tyrosine phosphatase, receptor type, D 302355-25-5, Receptor protein tyrosine phosphatase N 302355-88-0 336874-97-6, Cytochrome P 450 3A5 353498-78-9, Mitogen-activated protein kinase 6 370088-29-2, Mitogen-activated protein kinase kinase kinase 4 372092-80-3, Protein kinase 372170-33-7, Apelin 400653-73-8, Dual specificity phosphatase 5 403648-87-3, Protein kinase Cdc28 403652-37-9, Cyclin-dependent kinase 8 423124-77-0, Inter- $\alpha$  trypsin inhibitor 4 438496-81-2, Sirtuin 443900-95-6, Glycogen synthase kinase 3 $\beta$  644991-16-2, Peroxiredoxin 6 676145-27-0, Protein tyrosine phosphatase, non-receptor type 18

RL: BSU (Biological study, unclassified); BIOL (Biological study) (double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 689772-77-8, Calpain 7 710319-61-2, Sestrin 2 859235-38-4, WNK kinase 905848-61-5, Cytochrome P 450 2A01

RL: BSU (Biological study, unclassified); BIOL (Biological study) (double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 929740-27-2 929740-28-3 929740-29-4 929740-30-7 929740-31-8  
 929740-32-9 929740-33-0 929740-34-1 929740-35-2 929740-36-3  
 929740-37-4 929740-38-5 929740-39-6 929740-40-9 929740-41-0  
 929740-42-1 929740-43-2 929740-44-3 929740-45-4 929740-46-5  
 929740-47-6 929740-48-7 929740-49-8 929740-50-1 929740-51-2

929740-52-3	929740-53-4	929740-54-5	929740-55-6	929740-56-7
929740-57-8	929740-58-9	929740-59-0	929740-60-3	929740-61-4
929740-62-5	929740-63-6	929740-64-7	929740-65-8	929740-66-9
929740-67-0	929740-68-1	929740-69-2	929740-70-5	929740-71-6
929740-72-7	929740-73-8	929740-74-9	929740-75-0	929740-76-1
929740-77-2	929740-78-3	929740-79-4	929740-80-7	929740-81-8
929740-82-9	929740-83-0	929740-84-1	929740-85-2	929740-86-3
929740-87-4	929740-88-5	929740-89-6	929740-90-9	929740-91-0
929740-92-1	929740-93-2	929740-94-3	929740-95-4	929740-96-5
929740-97-6	929740-98-7	929740-99-8	929741-00-4	929741-01-5
929741-02-6	929741-03-7	929741-04-8	929741-05-9	929741-06-0
929741-07-1	929741-08-2	929741-09-3	929741-10-6	929741-11-7
929741-12-8	929741-13-9	929741-14-0	929741-15-1	929741-16-2
929741-17-3	929741-18-4	929741-19-5	929741-20-8	929741-21-9
929741-22-0	929741-23-1	929741-24-2	929741-25-3	929741-26-4
929741-27-5	929741-28-6	929741-29-7	929741-30-0	929741-31-1
929741-32-2	929741-33-3	929741-34-4	929741-35-5	929741-36-6
929741-37-7	929741-38-8	929741-39-9	929741-40-2	929741-41-3
929741-42-4	929741-43-5	929741-44-6	929741-45-7	929741-46-8
929741-47-9	929741-48-0	929741-49-1	929741-50-4	929741-51-5
929741-52-6	929741-53-7	929741-54-8	929741-55-9	929741-56-0
929741-57-1	929741-58-2	929741-59-3	929741-60-6	929741-61-7
929741-62-8	929741-63-9	929741-64-0	929741-65-1	929741-66-2
929741-67-3	929741-68-4	929741-69-5	929741-70-8	929741-71-9
929741-72-0	929741-73-1	929741-74-2	929741-75-3	929741-76-4
929741-77-5	929741-78-6	929741-79-7	929741-80-0	929741-81-1
929741-82-2	929741-83-3	929741-84-4	929741-85-5	929741-86-6
929741-87-7	929741-88-8	929741-89-9	929741-90-2	929741-91-3
929741-92-4	929741-93-5	929741-94-6	929741-95-7	929741-96-8
929741-97-9	929741-98-0	929741-99-1	929742-00-7	929742-01-8
929742-02-9	929742-03-0	929742-04-1	929742-05-2	929742-06-3
929742-07-4	929742-08-5	929742-09-6	929742-10-9	929742-11-0
929742-12-1	929742-13-2	929742-14-3	929742-15-4	929742-16-5
929742-17-6	929742-18-7	929742-19-8	929742-20-1	929742-21-2
929742-22-3	929742-23-4	929742-24-5	929742-25-6	929742-26-7
929742-27-8	929742-28-9	929742-29-0	929742-30-3	929742-31-4
929742-32-5	929742-33-6	929742-34-7	929742-35-8	929742-36-9
929742-37-0	929742-38-1	929742-39-2	929742-40-5	929742-41-6
929742-42-7	929742-43-8	929742-44-9	929742-45-0	929742-46-1
929742-47-2	929742-48-3	929742-49-4	929742-50-7	929742-51-8
929742-52-9	929742-53-0	929742-54-1	929742-55-2	929742-56-3
929742-57-4	929742-58-5	929742-59-6	929742-60-9	929742-61-0
929742-62-1				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene CTIN-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929742-63-2	929742-64-3	929742-65-4	929742-66-5	929742-67-6
	929742-68-7	929742-69-8	929742-70-1	929742-71-2	929742-72-3
	929742-73-4	929742-74-5	929742-75-6	929742-76-7	929742-77-8
	929742-78-9	929742-79-0	929742-80-3	929742-81-4	929742-82-5
	929742-83-6	929742-84-7	929742-85-8	929742-86-9	929742-87-0
	929742-88-1	929742-89-2	929742-90-5	929742-91-6	929742-92-7
	929742-93-8	929742-94-9	929742-95-0	929742-96-1	929742-97-2
	929742-98-3	929742-99-4	929743-00-0	929743-01-1	929743-02-2
	929743-03-3	929743-04-4	929743-05-5	929743-06-6	929743-07-7
	929743-08-8	929743-09-9	929743-10-2	929743-11-3	929743-12-4
	929743-13-5	929743-14-6	929743-15-7	929743-16-8	929743-17-9
	929743-18-0	929743-19-1	929743-20-4	929743-21-5	929743-22-6
	929743-23-7	929743-24-8	929743-25-9	929743-26-0	929743-27-1
	929743-28-2	929743-29-3	929743-30-6	929743-31-7	929743-32-8

929743-33-9	929743-34-0	929743-35-1	929743-36-2	929743-37-3
929743-38-4	929743-39-5	929743-40-8	929743-41-9	929743-42-0
929743-43-1	929743-44-2	929743-45-3	929743-46-4	929743-47-5
929743-48-6	929743-49-7	929743-50-0	929743-51-1	929743-52-2
929743-53-3	929743-54-4	929743-55-5	929743-56-6	929743-57-7
929743-58-8	929743-59-9	929743-60-2	929743-61-3	929743-62-4
929743-63-5	929743-64-6	929743-65-7	929743-66-8	929743-67-9
929743-68-0				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene CTIN-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929743-69-1	929743-70-4	929743-71-5	929743-72-6	929743-73-7
	929743-74-8	929743-75-9	929743-76-0	929743-77-1	929743-78-2
	929743-79-3	929743-80-6	929743-81-7	929743-82-8	929743-83-9
	929743-84-0	929743-85-1	929743-86-2	929743-87-3	929743-88-4
	929743-89-5	929743-90-8	929743-91-9	929743-92-0	929743-93-1
	929743-94-2	929743-95-3	929743-96-4	929743-97-5	929743-98-6
	929743-99-7	929744-00-3	929744-01-4	929744-02-5	929744-03-6
	929744-04-7	929744-05-8	929744-06-9	929744-07-0	929744-08-1
	929744-09-2	929744-10-5	929744-11-6	929744-12-7	929744-13-8
	929744-14-9	929744-15-0	929744-16-1	929744-17-2	929744-18-3
	929744-19-4	929744-20-7	929744-21-8	929744-22-9	929744-23-0
	929744-24-1	929744-25-2	929744-26-3	929744-27-4	929744-28-5
	929744-29-6	929744-30-9	929744-31-0	929744-32-1	929744-33-2
	929744-34-3	929744-35-4	929744-36-5	929744-37-6	929744-38-7
	929744-39-8	929744-40-1	929744-41-2	929744-42-3	929744-43-4
	929744-44-5	929744-45-6	929744-46-7	929744-47-8	929744-48-9
	929744-49-0	929744-50-3	929744-51-4	929744-52-5	929744-53-6
	929744-54-7	929744-55-8	929744-56-9	929744-57-0	929744-58-1
	929744-59-2	929744-60-5	929744-61-6	929744-62-7	929744-63-8
	929744-64-9	929744-65-0	929744-66-1	929744-67-2	929744-68-3
	929744-69-4	929744-70-7	929744-71-8	929744-72-9	929744-73-0
	929744-74-1	929744-75-2	929744-76-3	929744-77-4	929744-78-5
	929744-79-6	929744-80-9	929744-81-0	929744-82-1	929744-83-2
	929744-84-3	929744-85-4	929744-86-5	929744-87-6	929744-88-7
	929744-89-8	929744-90-1	929744-91-2	929744-92-3	929744-93-4
	929744-94-5	929744-95-6	929744-96-7	929744-97-8	929744-98-9
	929744-99-0	929745-00-6	929745-01-7	929745-02-8	929745-03-9
	929745-04-0	929745-05-1	929745-06-2	929745-07-3	929745-08-4
	929745-09-5	929745-10-8	929745-11-9	929745-12-0	929745-13-1
	929745-14-2	929745-15-3	929745-16-4	929745-17-5	929745-18-6
	929745-19-7	929745-20-0	929745-21-1	929745-22-2	929745-23-3
	929745-24-4	929745-25-5	929745-26-6	929745-27-7	929745-28-8
	929745-29-9	929745-30-2	929745-31-3	929745-32-4	929745-33-5
	929745-34-6	929745-35-7	929745-36-8	929745-37-9	929745-38-0
	929745-39-1	929745-40-4	929745-41-5	929745-42-6	929745-43-7
	929745-44-8	929745-45-9	929745-46-0	929745-47-1	929745-48-2
	929745-49-3	929745-50-6	929745-51-7	929745-52-8	929745-53-9
	929745-54-0	929745-55-1	929745-56-2	929745-57-3	929745-58-4
	929745-59-5	929745-60-8	929745-61-9	929745-62-0	929745-63-1
	929745-64-2	929745-65-3	929745-66-4	929745-67-5	929745-68-6

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene FXYD5-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929745-69-7	929745-70-0	929745-71-1	929745-72-2	929745-73-3
	929745-74-4	929745-75-5	929745-76-6	929745-77-7	929745-78-8
	929745-79-9	929745-80-2	929745-81-3	929745-82-4	929745-83-5
	929745-84-6	929745-85-7	929745-86-8	929745-87-9	929745-88-0
	929745-89-1	929745-90-4	929745-91-5	929745-92-6	929745-93-7



929745-94-8	929745-95-9	929745-96-0	929745-97-1	929745-98-2
929745-99-3	929746-00-9	929746-01-0	929746-02-1	929746-03-2
929746-04-3	929746-05-4	929746-06-5	929746-07-6	929746-08-7
929746-09-8	929746-10-1	929746-11-2	929746-12-3	929746-13-4
929746-14-5	929746-15-6	929746-16-7	929746-17-8	929746-18-9
929746-19-0	929746-20-3	929746-21-4	929746-22-5	929746-23-6
929746-24-7	929746-25-8	929746-26-9	929746-27-0	929746-28-1
929746-29-2	929746-30-5	929746-31-6	929746-32-7	929746-33-8
929746-34-9	929746-35-0	929746-36-1	929746-37-2	929746-38-3
929746-39-4	929746-40-7	929746-41-8	929746-42-9	929746-43-0
929746-44-1	929746-45-2	929746-46-3	929746-47-4	929746-48-5
929746-49-6	929746-50-9	929746-51-0	929746-52-1	929746-53-2
929746-54-3	929746-55-4	929746-56-5	929746-57-6	929746-58-7
929746-59-8	929746-60-1	929746-61-2	929746-62-3	929746-63-4
929746-64-5	929746-65-6	929746-66-7	929746-67-8	929746-68-9
929746-69-0	929746-70-3	929746-71-4	929746-72-5	929746-73-6
929746-74-7	929746-75-8	929746-76-9	929746-77-0	929746-78-1
929746-79-2	929746-80-5	929746-81-6	929746-82-7	929746-83-8
929746-84-9	929746-85-0	929746-86-1	929746-87-2	929746-88-3
929746-89-4	929746-90-7	929746-91-8	929746-92-9	929746-93-0
929746-94-1	929746-95-2	929746-96-3	929746-97-4	929746-98-5
929746-99-6	929747-00-2	929747-01-3	929747-02-4	929747-03-5
929747-04-6	929747-05-7	929747-06-8	929747-07-9	929747-08-0
929747-09-1	929747-10-4	929747-11-5	929747-12-6	929747-13-7
929747-14-8	929747-15-9	929747-16-0	929747-17-1	929747-18-2
929747-19-3	929747-20-6	929747-21-7	929747-22-8	929747-23-9
929747-24-0	929747-25-1	929747-26-2	929747-27-3	929747-28-4
929747-29-5	929747-30-8	929747-31-9	929747-32-0	929747-33-1
929747-34-2	929747-35-3	929747-36-4	929747-37-5	929747-38-6
929747-39-7	929747-40-0	929747-41-1	929747-42-2	929747-43-3
929747-44-4	929747-45-5	929747-46-6	929747-47-7	929747-48-8
929747-49-9	929747-50-2	929747-51-3	929747-52-4	929747-53-5
929747-54-6	929747-55-7	929747-56-8	929747-57-9	929747-58-0
929747-59-1	929747-60-4	929747-61-5	929747-62-6	929747-63-7
929747-64-8	929747-65-9	929747-66-0	929747-67-1	929747-68-2
929747-69-3	929747-70-6	929747-71-7	929747-72-8	929747-73-9
929747-74-0	929747-75-1	929747-76-2	929747-77-3	929747-78-4
929747-79-5	929747-80-8	929747-81-9	929747-82-0	929747-83-1
929747-84-2	929747-85-3	929747-86-4	929747-87-5	929747-88-6
929747-89-7	929747-90-0	929747-91-1	929747-92-2	929747-93-3

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene HBEGF-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929747-94-4	929747-95-5	929747-96-6	929747-97-7	929747-98-8
	929747-99-9	929748-00-5	929748-01-6	929748-02-7	929748-03-8
	929748-04-9	929748-05-0	929748-06-1	929748-07-2	929748-08-3
	929748-09-4	929748-10-7	929748-11-8	929748-12-9	929748-13-0
	929748-14-1	929748-15-2	929748-16-3	929748-17-4	929748-18-5
	929748-19-6	929748-20-9	929748-21-0	929748-22-1	929748-23-2
	929748-24-3	929748-25-4	929748-26-5	929748-27-6	929748-28-7
	929748-29-8	929748-30-1	929748-31-2	929748-32-3	929748-33-4
	929748-34-5	929748-35-6	929748-36-7	929748-37-8	929748-38-9
	929748-39-0	929748-40-3	929748-41-4	929748-42-5	929748-43-6
	929748-44-7	929748-45-8	929748-46-9	929748-47-0	929748-48-1
	929748-49-2	929748-50-5	929748-51-6	929748-52-7	929748-53-8
	929748-54-9	929748-55-0	929748-56-1	929748-57-2	929748-58-3
	929748-59-4	929748-60-7	929748-61-8	929748-62-9	929748-63-0
	929748-64-1	929748-65-2	929748-66-3	929748-67-4	929748-68-5
	929748-69-6	929748-70-9	929748-71-0	929748-72-1	929748-73-2
	929748-74-3	929748-75-4	929748-76-5	929748-77-6	929748-78-7

929748-79-8	929748-80-1	929748-81-2	929748-82-3	929748-83-4
929748-84-5	929748-85-6	929748-86-7	929748-87-8	929748-88-9
929748-89-0	929748-90-3	929748-91-4	929748-92-5	929748-93-6
929748-94-7	929748-95-8	929748-96-9	929748-97-0	929748-98-1
929748-99-2	929749-00-8	929749-01-9	929749-02-0	929749-03-1
929749-04-2	929749-05-3	929749-06-4	929749-07-5	929749-08-6
929749-09-7	929749-10-0	929749-11-1	929749-12-2	929749-13-3
929749-14-4	929749-15-5	929749-16-6	929749-17-7	929749-18-8
929749-19-9	929749-20-2	929749-21-3	929749-22-4	929749-23-5
929749-24-6	929749-25-7	929749-26-8	929749-27-9	929749-28-0
929749-29-1	929749-30-4	929749-31-5	929749-32-6	929749-33-7
929749-34-8	929749-35-9	929749-36-0	929749-37-1	929749-38-2
929749-39-3	929749-40-6	929749-41-7	929749-42-8	929749-43-9
929749-44-0	929749-45-1	929749-46-2	929749-47-3	929749-48-4
929749-49-5	929749-50-8	929749-51-9	929749-52-0	929749-53-1
929749-54-2	929749-55-3	929749-56-4	929749-57-5	929749-58-6
929749-59-7	929749-60-0	929749-61-1	929749-62-2	929749-63-3
929749-64-4	929749-65-5	929749-66-6	929749-67-7	929749-68-8
929749-69-9	929749-70-2	929749-71-3	929749-72-4	929749-73-5
929749-74-6	929749-75-7	929749-76-8	929749-77-9	929749-78-0
929749-79-1	929749-80-4	929749-81-5	929749-82-6	929749-83-7
929749-84-8	929749-85-9	929749-86-0	929749-87-1	929749-88-2
929749-89-3	929749-90-6	929749-91-7	929749-92-8	929749-93-9
929749-94-0	929749-95-1	929749-96-2	929749-97-3	929749-98-4
929749-99-5	929750-00-5	929750-01-6	929750-02-7	929750-03-8
929750-04-9	929750-05-0	929750-06-1	929750-07-2	929750-08-3
929750-09-4	929750-10-7	929750-11-8	929750-12-9	929750-13-0
929750-14-1	929750-15-2	929750-16-3	929750-17-4	929750-18-5
929750-19-6	929750-20-9	929750-21-0	929750-22-1	929750-23-2
929750-24-3	929750-25-4	929750-26-5	929750-27-6	929750-28-7
929750-29-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929750-30-1	929750-31-2	929750-32-3	929750-33-4	929750-34-5
	929750-35-6	929750-36-7	929750-37-8	929750-38-9	929750-39-0
	929750-40-3	929750-41-4	929750-42-5	929750-43-6	929750-44-7
	929750-45-8	929750-46-9	929750-47-0	929750-48-1	929750-49-2
	929750-50-5	929750-51-6	929750-52-7	929750-53-8	929750-54-9
	929750-55-0	929750-56-1	929750-57-2	929750-58-3	929750-59-4
	929750-60-7	929750-61-8	929750-62-9	929750-63-0	929750-64-1
	929750-65-2	929750-66-3	929750-67-4	929750-68-5	929750-69-6
	929750-70-9	929750-71-0	929750-72-1	929750-73-2	929750-74-3
	929750-75-4	929750-76-5	929750-77-6	929750-78-7	929750-79-8
	929750-80-1	929750-81-2	929750-82-3	929750-83-4	929750-84-5
	929750-85-6	929750-86-7	929750-87-8	929750-88-9	929750-89-0
	929750-90-3	929750-91-4	929750-92-5	929750-93-6	929750-94-7
	929750-95-8	929750-96-9	929750-97-0	929750-98-1	929750-99-2
	929751-00-8	929751-01-9	929751-02-0	929751-03-1	929751-04-2
	929751-05-3	929751-06-4	929751-07-5	929751-08-6	929751-09-7
	929751-10-0	929751-11-1	929751-12-2	929751-13-3	929751-14-4
	929751-15-5	929751-16-6	929751-17-7	929751-18-8	929751-19-9
	929751-20-2	929751-21-3	929751-22-4	929751-23-5	929751-24-6
	929751-25-7	929751-26-8	929751-27-9	929751-28-0	929751-29-1
	929751-30-4	929751-31-5	929751-32-6	929751-33-7	929751-34-8
	929751-35-9	929751-36-0	929751-37-1	929751-38-2	929751-39-3
	929751-40-6	929751-41-7	929751-42-8	929751-43-9	929751-44-0
	929751-45-1	929751-46-2	929751-47-3	929751-48-4	929751-49-5
	929751-50-8	929751-51-9	929751-52-0	929751-53-1	929751-54-2
	929751-55-3	929751-56-4	929751-57-5	929751-58-6	929751-59-7

929751-60-0	929751-61-1	929751-62-2	929751-63-3	929751-64-4
929751-65-5	929751-66-6	929751-67-7	929751-68-8	929751-69-9
929751-70-2	929751-71-3	929751-72-4	929751-73-5	929751-74-6
929751-75-7	929751-76-8	929751-77-9	929751-78-0	929751-79-1
929751-80-4	929751-81-5	929751-82-6	929751-83-7	929751-84-8
929751-85-9	929751-86-0	929751-87-1	929751-88-2	929751-89-3
929751-90-6	929751-91-7	929751-92-8	929751-93-9	929751-94-0
929751-95-1	929751-96-2	929751-97-3	929751-98-4	929751-99-5
929752-00-1	929752-01-2	929752-02-3	929752-03-4	929752-04-5
929752-05-6	929752-06-7	929752-07-8	929752-08-9	929752-09-0
929752-10-3	929752-11-4	929752-12-5	929752-13-6	929752-14-7
929752-15-8	929752-16-9	929752-17-0	929752-18-1	929752-19-2
929752-20-5	929752-21-6	929752-22-7	929752-23-8	929752-24-9
929752-25-0	929752-26-1	929752-27-2	929752-28-3	929752-29-4
929752-30-7	929752-31-8	929752-32-9	929752-33-0	929752-34-1
929752-35-2	929752-36-3	929752-37-4	929752-38-5	929752-39-6
929752-40-9	929752-41-0	929752-42-1	929752-43-2	929752-44-3
929752-45-4	929752-46-5	929752-47-6	929752-48-7	929752-49-8
929752-50-1	929752-51-2	929752-52-3	929752-53-4	929752-54-5
929752-55-6	929752-56-7	929752-57-8	929752-58-9	929752-59-0
929752-60-3	929752-61-4	929752-62-5	929752-63-6	929752-64-7
929752-65-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929752-66-9	929752-67-0	929752-68-1	929752-69-2	929752-70-5
	929752-71-6	929752-72-7	929752-73-8	929752-74-9	929752-75-0
	929752-76-1	929752-77-2	929752-78-3	929752-79-4	929752-80-7
	929752-81-8	929752-82-9	929752-83-0	929752-84-1	929752-85-2
	929752-86-3	929752-87-4	929752-88-5	929752-89-6	929752-90-9
	929752-91-0	929752-92-1	929752-93-2	929752-94-3	929752-95-4
	929752-96-5	929752-97-6	929752-98-7	929752-99-8	929753-00-4
	929753-01-5	929753-02-6	929753-03-7	929753-04-8	929753-05-9

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929753-06-0	929753-07-1	929753-08-2	929753-09-3	929753-10-6
	929753-11-7	929753-12-8	929753-13-9	929753-14-0	929753-15-1
	929753-16-2	929753-17-3	929753-18-4	929753-19-5	929753-20-8
	929753-21-9	929753-22-0	929753-23-1	929753-24-2	929753-25-3
	929753-26-4	929753-27-5	929753-28-6	929753-29-7	929753-30-0
	929753-31-1	929753-32-2	929753-33-3	929753-34-4	929753-35-5
	929753-36-6	929753-37-7	929753-38-8	929753-39-9	929753-40-2
	929753-41-3	929753-42-4	929753-43-5	929753-44-6	929753-45-7
	929753-46-8	929753-47-9	929753-48-0	929753-49-1	929753-50-4
	929753-51-5	929753-52-6	929753-53-7	929753-54-8	929753-55-9
	929753-56-0	929753-57-1	929753-58-2	929753-59-3	929753-60-6
	929753-61-7	929753-62-8	929753-63-9	929753-64-0	929753-65-1
	929753-66-2	929753-67-3	929753-68-4	929753-69-5	929753-70-8
	929753-71-9	929753-72-0	929753-73-1	929753-74-2	929753-75-3
	929753-76-4	929753-77-5	929753-78-6	929753-79-7	929753-80-0
	929753-81-1	929753-82-2	929753-83-3	929753-84-4	929753-85-5
	929753-86-6	929753-87-7	929753-88-8	929753-89-9	929753-90-2
	929753-91-3	929753-92-4	929753-93-5	929753-94-6	929753-95-7
	929753-96-8	929753-97-9	929753-98-0	929753-99-1	929754-00-7
	929754-01-8	929754-02-9	929754-03-0	929754-04-1	929754-05-2
	929754-06-3	929754-07-4	929754-08-5	929754-09-6	929754-10-9
	929754-11-0	929754-12-1	929754-13-2	929754-14-3	929754-15-4
	929754-16-5	929754-17-6	929754-18-7	929754-19-8	929754-20-1

929754-21-2	929754-22-3	929754-23-4	929754-24-5	929754-25-6
929754-26-7	929754-27-8	929754-28-9	929754-29-0	929754-30-3
929754-31-4	929754-32-5	929754-33-6	929754-34-7	929754-35-8
929754-36-9	929754-37-0	929754-38-1	929754-39-2	929754-40-5
929754-41-6	929754-42-7	929754-43-8	929754-44-9	929754-45-0
929754-46-1	929754-47-2	929754-48-3	929754-49-4	929754-50-7
929754-51-8	929754-52-9	929754-53-0	929754-54-1	929754-55-2
929754-56-3	929754-57-4	929754-58-5	929754-59-6	929754-60-9
929754-61-0	929754-62-1	929754-63-2	929754-64-3	929754-65-4
929754-66-5	929754-67-6	929754-68-7	929754-69-8	929754-70-1
929754-71-2	929754-72-3	929754-73-4	929754-74-5	929754-75-6
929754-76-7	929754-77-8	929754-78-9	929754-79-0	929754-80-3
929754-81-4	929754-82-5	929754-83-6	929754-84-7	929754-85-8
929754-86-9	929754-87-0	929754-88-1	929754-89-2	929754-90-5
929754-91-6	929754-92-7	929754-93-8	929754-94-9	929754-95-0
929754-96-1	929754-97-2	929754-98-3	929754-99-4	929755-00-0
929755-01-1	929755-02-2	929755-03-3	929755-04-4	929755-05-5
929755-06-6	929755-07-7	929755-08-8	929755-09-9	929755-10-2
929755-11-3	929755-12-4	929755-13-5	929755-14-6	929755-15-7
929755-16-8	929755-17-9	929755-18-0	929755-19-1	929755-20-4
929755-21-5	929755-22-6	929755-23-7	929755-24-8	929755-25-9
929755-26-0	929755-27-1	929755-28-2	929755-29-3	929755-30-6
929755-31-7	929755-32-8	929755-33-9	929755-34-0	929755-35-1
929755-36-2	929755-37-3	929755-38-4	929755-39-5	929755-40-8
929755-41-9				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene ODC1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929755-42-0	929755-43-1	929755-44-2	929755-45-3	929755-46-4
	929755-47-5	929755-48-6	929755-49-7	929755-50-0	929755-51-1
	929755-52-2	929755-53-3	929755-54-4	929755-55-5	929755-56-6
	929755-57-7	929755-58-8	929755-59-9	929755-60-2	929755-61-3
	929755-62-4	929755-63-5	929755-64-6	929755-65-7	929755-66-8
	929755-67-9	929755-68-0	929755-69-1	929755-70-4	929755-71-5
	929755-72-6	929755-73-7	929755-74-8	929755-75-9	929755-76-0
	929755-77-1	929755-78-2	929755-79-3	929755-80-6	929755-81-7
	929755-82-8	929755-83-9	929755-84-0	929755-85-1	929755-86-2
	929755-87-3	929755-88-4	929755-89-5		

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene ODC1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929755-90-8	929755-91-9	929755-92-0	929755-93-1	929755-94-2
	929755-95-3	929755-96-4	929755-97-5	929755-98-6	929755-99-7
	929756-00-3	929756-01-4	929756-02-5	929756-03-6	929756-04-7
	929756-05-8	929756-06-9	929756-07-0	929756-08-1	929756-09-2
	929756-10-5	929756-11-6	929756-12-7	929756-13-8	929756-14-9
	929756-15-0	929756-16-1	929756-17-2	929756-18-3	929756-19-4
	929756-20-7	929756-21-8	929756-22-9	929756-23-0	929756-24-1
	929756-25-2	929756-26-3	929756-27-4	929756-28-5	929756-29-6
	929756-30-9	929756-31-0	929756-32-1	929756-33-2	929756-34-3
	929756-35-4	929756-36-5	929756-37-6	929756-38-7	929756-39-8
	929756-40-1	929756-41-2	929756-42-3	929756-43-4	929756-44-5
	929756-45-6	929756-46-7	929756-47-8	929756-48-9	929756-49-0
	929756-50-3	929756-51-4	929756-52-5	929756-53-6	929756-54-7
	929756-55-8	929756-56-9	929756-57-0	929756-58-1	929756-59-2
	929756-60-5	929756-61-6	929756-62-7	929756-63-8	929756-64-9
	929756-65-0	929756-66-1	929756-67-2	929756-68-3	929756-69-4
	929756-70-7	929756-71-8	929756-72-9	929756-73-0	929756-74-1
	929756-75-2	929756-76-3	929756-77-4	929756-78-5	929756-79-6

929756-80-9	929756-81-0	929756-82-1	929756-83-2	929756-84-3
929756-85-4	929756-86-5	929756-87-6	929756-88-7	929756-89-8
929756-90-1	929756-91-2	929756-92-3	929756-93-4	929756-94-5
929756-95-6	929756-96-7	929756-97-8	929756-98-9	929756-99-0
929757-00-6	929757-01-7	929757-02-8	929757-03-9	929757-04-0
929757-05-1	929757-06-2	929757-07-3	929757-08-4	929757-09-5
929757-10-8	929757-11-9	929757-12-0	929757-13-1	929757-14-2
929757-15-3	929757-16-4	929757-17-5	929757-18-6	929757-19-7
929757-20-0	929757-21-1	929757-22-2	929757-23-3	929757-24-4
929757-25-5	929757-26-6	929757-27-7	929757-28-8	929757-29-9
929757-30-2	929757-31-3	929757-32-4	929757-33-5	929757-34-6
929757-35-7	929757-36-8	929757-37-9	929757-38-0	929757-39-1
929757-40-4	929757-41-5	929757-42-6	929757-43-7	929757-44-8
929757-45-9	929757-46-0	929757-47-1	929757-48-2	929757-49-3
929757-50-6	929757-51-7	929757-52-8	929757-53-9	929757-54-0
929757-55-1	929757-56-2	929757-57-3	929757-58-4	929757-59-5
929757-60-8	929757-61-9	929757-62-0	929757-63-1	929757-64-2
929757-65-3	929757-66-4	929757-67-5	929757-68-6	929757-69-7
929757-70-0	929757-71-1	929757-72-2	929757-73-3	929757-74-4
929757-75-5	929757-76-6	929757-77-7	929757-78-8	929757-79-9
929757-80-2	929757-81-3	929757-82-4	929757-83-5	929757-84-6
929757-85-7	929757-86-8	929757-87-9	929945-16-4	929945-17-5
929945-18-6	929945-19-7	929945-20-0	929945-21-1	929945-22-2
929945-23-3	929945-24-4	929945-25-5	929945-26-6	929945-27-7
929945-28-8	929945-29-9	929945-30-2	929945-31-3	929945-32-4
929945-33-5	929945-34-6	929945-35-7	929945-36-8	929945-37-9
929945-38-0	929945-39-1	929945-40-4	929945-41-5	

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene PIM1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929757-88-0	929757-89-1	929757-90-4	929757-91-5	929757-92-6
	929757-93-7	929757-94-8	929757-95-9	929757-96-0	929757-97-1
	929757-98-2	929757-99-3	929758-00-9	929758-01-0	929758-02-1
	929758-03-2	929758-04-3	929758-05-4	929758-06-5	929758-07-6
	929758-08-7	929758-09-8	929758-10-1	929758-11-2	929758-12-3
	929758-13-4	929758-14-5	929758-15-6	929758-16-7	929758-17-8
	929758-18-9	929758-19-0	929758-20-3	929758-21-4	929758-22-5
	929758-23-6	929758-24-7	929758-25-8	929758-26-9	929758-27-0
	929758-28-1	929758-29-2	929758-30-5	929758-31-6	929758-32-7
	929758-33-8	929758-34-9	929758-35-0	929758-36-1	929758-37-2
	929758-38-3	929758-39-4	929758-40-7	929758-41-8	929758-42-9
	929758-43-0	929758-44-1	929758-45-2	929758-46-3	929758-47-4
	929758-48-5	929758-49-6	929758-50-9	929758-51-0	929758-52-1
	929758-53-2	929758-54-3	929758-55-4	929758-56-5	929758-57-6
	929758-58-7	929758-59-8	929758-60-1	929758-61-2	929758-62-3
	929758-63-4	929758-64-5	929758-65-6	929758-66-7	929758-67-8
	929758-68-9	929758-69-0	929758-70-3	929758-71-4	929758-72-5
	929758-73-6	929758-74-7	929758-75-8	929758-76-9	929758-77-0
	929758-78-1	929758-79-2	929758-80-5	929758-81-6	929758-82-7
	929758-83-8	929758-84-9	929758-85-0	929758-86-1	929758-87-2
	929758-88-3	929758-89-4	929758-90-7	929758-91-8	929758-92-9
	929758-93-0	929758-94-1	929758-95-2	929758-96-3	929758-97-4
	929758-98-5	929758-99-6	929759-00-2	929759-01-3	929759-02-4
	929759-03-5	929759-04-6	929759-05-7	929759-06-8	929759-07-9
	929759-08-0	929759-09-1	929759-10-4	929759-11-5	929759-12-6
	929759-13-7	929759-14-8	929759-15-9	929759-16-0	929759-17-1
	929759-18-2	929759-19-3	929759-20-6	929759-21-7	929759-22-8
	929759-23-9	929759-24-0	929759-25-1	929759-26-2	929759-27-3
	929759-28-4	929759-29-5	929759-30-8	929759-31-9	929759-32-0
	929759-33-1	929759-34-2	929759-35-3	929759-36-4	929759-37-5

929759-38-6	929759-39-7	929759-40-0	929759-41-1	929759-42-2
929759-43-3	929759-44-4	929759-45-5	929759-46-6	929759-47-7
929759-48-8	929759-49-9	929759-50-2	929759-51-3	929759-52-4
929759-53-5	929759-54-6	929759-55-7	929759-56-8	929759-57-9
929759-58-0	929759-59-1	929759-60-4	929759-61-5	929759-62-6
929759-63-7	929759-64-8	929759-65-9	929759-66-0	929759-67-1
929759-68-2	929759-69-3	929759-70-6	929759-71-7	929759-72-8
929759-73-9	929759-74-0	929759-75-1	929759-76-2	929759-77-3
929759-78-4	929759-79-5	929759-80-8	929759-81-9	929759-82-0
929759-83-1	929759-84-2	929759-85-3	929759-86-4	929759-87-5
929759-88-6	929759-89-7	929759-90-0	929759-91-1	929759-92-2
929759-93-3	929759-94-4	929759-95-5	929759-96-6	929759-97-7
929759-98-8	929759-99-9	929760-00-9	929760-01-0	929760-02-1
929760-03-2	929760-04-3	929760-05-4	929760-06-5	929760-07-6
929760-08-7	929760-09-8	929760-10-1	929760-11-2	929760-12-3
929760-13-4	929760-14-5	929760-15-6	929760-16-7	929760-17-8
929760-18-9	929760-19-0	929760-20-3	929760-21-4	929760-22-5
929760-23-6				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

	(gene SGPP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)			
IT	929760-24-7	929760-25-8	929760-26-9	929760-27-0
	929760-29-2	929760-30-5	929760-31-6	929760-32-7
	929760-34-9	929760-35-0	929760-36-1	929760-37-2
	929760-39-4	929760-40-7	929760-41-8	929760-42-9
	929760-44-1	929760-45-2	929760-46-3	929760-47-4
	929760-49-6	929760-50-9	929760-51-0	929760-52-1
	929760-54-3	929760-55-4	929760-56-5	929760-57-6
	929760-59-8	929760-60-1	929760-61-2	929760-62-3
	929760-64-5			

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

	(gene SGPP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)			
IT	929760-65-6	929760-66-7	929760-67-8	929760-68-9
	929760-70-3	929760-71-4	929760-72-5	929760-73-6
	929760-75-8	929760-76-9	929760-77-0	929760-78-1
	929760-80-5	929760-81-6	929760-82-7	929760-83-8
	929760-85-0	929760-86-1	929760-87-2	929760-88-3
	929760-90-7	929760-91-8	929760-92-9	929760-93-0
	929760-95-2	929760-96-3	929760-97-4	929760-98-5
	929761-00-2	929761-01-3	929761-02-4	929761-03-5
	929761-05-7	929761-06-8	929761-07-9	929761-08-0
	929761-10-4	929761-11-5	929761-12-6	929761-13-7
	929761-15-9	929761-16-0	929761-17-1	929761-18-2
	929761-20-6	929761-21-7	929761-22-8	929761-23-9
	929761-25-1	929761-26-2	929761-27-3	929761-28-4
	929761-30-8	929761-31-9	929761-32-0	929761-33-1
	929761-35-3	929761-36-4	929761-37-5	929761-38-6
	929761-40-0	929761-41-1	929761-42-2	929761-43-3
	929761-45-5	929761-46-6	929761-47-7	929761-48-8
	929761-50-2	929761-51-3	929761-52-4	929761-53-5
	929761-55-7	929761-56-8	929761-57-9	929761-58-0
	929761-60-4	929761-61-5	929761-62-6	929761-63-7
	929761-65-9	929761-66-0	929761-67-1	929761-68-2
	929761-70-6	929761-71-7	929761-72-8	929761-73-9
	929761-75-1	929761-76-2	929761-77-3	929761-78-4
	929761-80-8	929761-81-9	929761-82-0	929761-83-1
	929761-85-3	929761-86-4	929761-87-5	929761-88-6
	929761-90-0	929761-91-1	929761-92-2	929761-93-3

929761-95-5	929761-96-6	929761-97-7	929761-98-8	929761-99-9
929762-00-5	929762-01-6	929762-02-7	929762-03-8	929762-04-9
929762-05-0	929762-06-1	929762-07-2	929762-08-3	929762-09-4
929762-10-7	929762-11-8	929762-12-9	929762-13-0	929762-14-1
929762-15-2	929762-16-3	929762-17-4	929762-18-5	929762-19-6
929762-20-9	929762-21-0	929762-22-1	929762-23-2	929762-24-3
929762-25-4	929762-26-5	929762-27-6	929762-28-7	929762-29-8
929762-30-1	929762-31-2	929762-32-3	929762-33-4	929762-34-5
929762-35-6	929762-36-7	929762-37-8	929762-38-9	929762-39-0
929762-40-3	929762-41-4	929762-42-5	929762-43-6	929762-44-7
929762-45-8	929762-46-9	929762-47-0	929762-48-1	929762-49-2
929762-50-5	929762-51-6	929762-52-7	929762-53-8	929762-54-9
929762-55-0	929762-56-1	929762-57-2	929762-58-3	929762-59-4
929762-60-7	929762-61-8	929762-62-9	929762-63-0	929762-64-1
929762-65-2	929762-66-3	929762-67-4	929762-68-5	929762-69-6
929762-70-9	929762-71-0	929762-72-1	929762-73-2	929762-74-3
929762-75-4	929762-76-5	929762-77-6	929762-78-7	929762-79-8
929762-80-1	929762-81-2	929762-82-3	929762-83-4	929762-84-5
929762-85-6	929762-86-7	929762-87-8	929762-88-9	929762-89-0
929762-90-3	929762-91-4	929762-92-5	929762-93-6	929762-94-7
929762-95-8	929762-96-9	929762-97-0	929762-98-1	929762-99-2
929763-00-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929763-01-9	929763-02-0	929763-03-1	929763-04-2	929763-05-3
	929763-06-4	929763-07-5	929763-08-6	929763-09-7	929763-10-0
	929763-11-1	929763-12-2	929763-13-3	929763-14-4	929763-15-5
	929763-16-6	929763-17-7	929763-18-8	929763-19-9	929763-20-2
	929763-21-3	929763-22-4	929763-23-5	929763-24-6	929763-25-7
	929763-26-8	929763-27-9	929763-28-0	929763-29-1	929763-30-4
	929763-31-5	929763-32-6	929763-33-7	929763-34-8	929763-35-9
	929763-36-0	929763-37-1	929763-38-2	929763-39-3	929763-40-6
	929763-41-7	929763-42-8	929763-43-9	929763-44-0	929763-45-1
	929763-46-2	929763-47-3	929763-48-4	929763-49-5	929763-50-8
	929763-51-9	929763-52-0	929763-53-1	929763-54-2	929763-55-3
	929763-56-4	929763-57-5	929763-58-6	929763-59-7	929763-60-0
	929763-61-1	929763-62-2	929763-63-3	929763-64-4	929763-65-5
	929763-66-6	929763-67-7	929763-68-8	929763-69-9	929763-70-2
	929763-71-3	929763-72-4	929763-73-5	929763-74-6	929763-75-7
	929763-76-8	929763-77-9	929763-78-0	929763-79-1	929763-80-4
	929763-81-5	929763-82-6	929763-83-7	929763-84-8	929763-85-9
	929763-86-0	929763-87-1	929763-88-2	929763-89-3	929763-90-6
	929763-91-7	929763-92-8	929763-93-9	929763-94-0	929763-95-1
	929763-96-2	929763-97-3	929763-98-4	929763-99-5	929764-00-1
	929764-01-2	929764-02-3	929764-03-4	929764-04-5	929764-05-6
	929764-06-7	929764-07-8	929764-08-9	929764-09-0	929764-10-3
	929764-11-4	929764-12-5	929764-13-6	929764-14-7	929764-15-8
	929764-16-9	929764-17-0	929764-18-1	929764-19-2	929764-20-5
	929764-21-6	929764-22-7	929764-23-8	929764-24-9	929764-25-0
	929764-26-1	929764-27-2	929764-28-3	929764-29-4	929764-30-7
	929764-31-8	929764-32-9	929764-33-0	929764-34-1	

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929764-35-2	929764-36-3	929764-37-4	929764-38-5	929764-39-6
	929764-40-9	929764-41-0	929764-42-1	929764-43-2	929764-44-3
	929764-45-4	929764-46-5	929764-47-6	929764-48-7	929764-49-8
	929764-50-1	929764-51-2	929764-52-3	929764-53-4	929764-54-5

929764-55-6	929764-56-7	929764-57-8	929764-58-9	929764-59-0
929764-60-3	929764-61-4	929764-62-5	929764-63-6	929764-64-7
929764-65-8	929764-66-9	929764-67-0	929764-74-9	929764-75-0
929764-76-1	929764-77-2	929764-78-3	929764-79-4	929764-80-7
929764-81-8	929764-82-9	929764-83-0	929764-84-1	929764-85-2
929764-86-3	929764-87-4	929764-88-5	929764-89-6	929764-90-9
929764-91-0	929764-92-1	929764-93-2	929764-94-3	929764-95-4
929764-96-5	929764-97-6	929764-98-7	929764-99-8	929765-00-4
929765-01-5	929765-02-6	929765-03-7	929765-04-8	929765-05-9
929765-06-0	929765-07-1	929765-08-2	929765-09-3	929765-10-6
929765-11-7	929765-12-8	929765-13-9	929765-14-0	929765-15-1
929765-16-2	929765-17-3	929765-18-4	929765-19-5	929765-20-8
929765-21-9	929765-22-0	929765-23-1	929765-24-2	929765-25-3
929765-26-4	929765-27-5	929765-28-6	929765-29-7	929765-30-0
929765-31-1	929765-32-2	929765-33-3	929765-34-4	929765-36-6
929765-37-7	929765-38-8	929765-39-9	929765-40-2	929765-41-3
929765-42-4	929765-43-5	929765-44-6	929765-46-8	929765-47-9
929765-48-0	929765-49-1	929765-50-4	929765-51-5	929765-52-6
929765-53-7	929765-54-8	929765-55-9	929765-56-0	929765-57-1
929765-58-2	929765-59-3	929765-60-6	929765-61-7	929765-62-8
929765-63-9	929765-64-0	929765-65-1	929765-66-2	929765-67-3
929765-68-4	929765-69-5	929765-70-8	929765-71-9	929765-72-0
929765-73-1	929765-74-2	929765-75-3	929765-76-4	929765-78-6
929765-79-7	929765-80-0	929765-81-1	929765-82-2	929765-83-3
929765-84-4	929765-85-5	929765-86-6	929765-87-7	929765-88-8
929765-89-9	929765-90-2	929765-92-4	929765-93-5	929765-94-6
929765-95-7	929765-96-8	929765-97-9	929765-98-0	929765-99-1
929766-00-7	929766-01-8	929766-02-9	929766-03-0	929766-05-2
929766-06-3	929766-07-4	929766-08-5	929766-09-6	929766-10-9
929766-11-0	929766-12-1	929766-13-2	929766-14-3	929766-15-4
929766-16-5	929766-17-6	929766-19-8	929766-20-1	929766-21-2
929766-22-3	929766-23-4	929766-24-5	929766-25-6	929766-26-7
929766-27-8	929766-28-9	929766-29-0	929766-31-4	929766-32-5
929766-33-6	929766-34-7	929766-35-8	929766-36-9	929766-37-0
929766-38-1	929766-39-2	929766-41-6	929766-42-7	929766-43-8
929766-44-9	929766-45-0	929766-46-1	929766-47-2	929766-48-3
929766-49-4	929766-50-7	929766-52-9	929766-53-0	929766-54-1
929766-55-2	929766-56-3	929766-57-4	929766-58-5	929766-59-6
929766-60-9	929766-61-0	929766-63-2	929766-64-3	929766-65-4
929766-66-5	929766-67-6	929766-68-7	929766-69-8	929766-70-1
929766-71-2	929766-72-3	929766-73-4	929766-74-5	929766-75-6
929766-76-7	929766-77-8	929766-78-9	929766-79-0	929766-80-3
929766-81-4	929766-82-5	929766-83-6	929766-84-7	929766-85-8
929766-86-9				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SSAT-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929766-87-0	929766-88-1	929766-89-2	929766-90-5	929766-91-6
	929766-92-7	929766-93-8	929766-94-9	929766-95-0	929766-96-1
	929766-97-2	929766-98-3	929766-99-4	929767-00-0	929767-01-1
	929767-02-2	929767-03-3	929767-04-4	929767-05-5	929767-06-6
	929767-07-7	929767-08-8	929767-09-9	929767-10-2	929767-11-3
	929767-12-4	929767-13-5	929767-14-6	929767-15-7	929767-16-8
	929767-17-9	929767-18-0	929767-19-1	929767-20-4	929767-21-5
	929767-22-6	929767-23-7	929767-24-8	929767-25-9	929767-26-0
	929767-27-1	929767-28-2	929767-29-3	929767-30-6	929767-31-7
	929767-32-8	929767-33-9	929767-34-0	929767-35-1	929767-36-2
	929767-37-3	929767-38-4	929767-39-5	929767-40-8	929767-41-9
	929767-43-1	929767-44-2	929767-45-3	929767-46-4	929767-47-5
	929767-48-6	929767-49-7	929767-50-0	929767-51-1	929767-52-2



929767-53-3 929767-54-4 929767-55-5 929767-56-6 929767-57-7  
 929767-58-8 929767-59-9 929767-61-3 929767-62-4 929767-63-5  
 929767-64-6 929767-65-7 929767-66-8 929767-67-9 929767-68-0  
 929767-69-1 929767-71-5 929767-72-6 929767-73-7 929767-74-8  
 929767-75-9 929767-76-0 929767-77-1 929767-78-2 929767-80-6  
 929767-81-7 929767-82-8 929767-83-9 929767-84-0 929767-85-1  
 929767-86-2 929767-87-3 929767-89-5 929767-90-8 929767-91-9  
 929767-92-0 929767-93-1 929767-94-2 929767-95-3 929767-96-4  
 929767-97-5 929767-99-7 929768-00-3 929768-01-4 929768-02-5  
 929768-03-6 929768-04-7 929768-05-8 929768-06-9 929768-07-0  
 929768-08-1 929768-09-2 929768-10-5 929768-12-7 929768-13-8  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)

(gene SSAT-targeting siRNA; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT	929768-14-9	929768-15-0	929768-16-1	929768-17-2	929768-18-3
	929768-19-4	929768-20-7	929768-21-8	929768-22-9	929768-24-1
	929768-25-2	929768-26-3	929768-27-4	929768-28-5	929768-29-6
	929768-30-9	929768-31-0	929768-32-1	929768-33-2	929768-35-4
	929768-36-5	929768-37-6	929768-38-7	929768-39-8	929768-40-1
	929768-41-2	929768-42-3	929768-44-5	929768-45-6	929768-46-7
	929768-47-8	929768-48-9	929768-49-0	929768-50-3	929768-51-4
	929768-52-5	929768-54-7	929768-55-8	929768-56-9	929768-57-0
	929768-58-1	929768-59-2	929768-60-5	929768-61-6	929768-62-7
	929768-63-8	929768-65-0	929768-66-1	929768-67-2	929768-68-3
	929768-69-4	929768-70-7	929768-71-8	929768-72-9	929768-73-0
	929768-74-1	929768-76-3	929768-77-4	929768-78-5	929768-79-6
	929768-80-9	929768-81-0	929768-82-1	929768-83-2	929768-84-3
	929768-85-4	929768-86-5	929768-88-7	929768-89-8	929768-90-1
	929768-91-2	929768-92-3	929768-93-4	929768-94-5	929768-95-6
	929768-96-7	929768-97-8	929768-99-0	929769-00-6	929769-01-7
	929769-02-8	929769-03-9	929769-04-0	929769-05-1	929769-06-2
	929769-07-3	929769-08-4	929769-09-5	929769-11-9	929769-12-0
	929769-13-1	929769-14-2	929769-15-3	929769-16-4	929769-17-5
	929769-18-6	929769-20-0	929769-21-1	929769-22-2	929769-23-3
	929769-24-4	929769-25-5	929769-26-6	929769-27-7	929769-28-8
	929769-29-9	929769-30-2	929769-31-3	929769-32-4	929769-33-5
	929769-34-6	929769-35-7	929769-36-8	929769-37-9	929769-38-0
	929769-39-1	929769-40-4	929769-42-6	929769-43-7	929769-44-8
	929769-45-9	929769-46-0	929769-47-1	929769-48-2	929769-49-3
	929769-51-7	929769-52-8	929769-53-9	929769-54-0	929769-55-1
	929769-56-2	929769-57-3	929769-58-4	929769-59-5	929769-60-8
	929769-61-9	929769-62-0	929769-63-1	929769-64-2	929769-65-3
	929769-66-4	929769-67-5	929769-68-6	929769-69-7	929769-70-0
	929769-72-2	929769-73-3	929769-74-4	929769-75-5	929769-76-6
	929769-77-7	929769-78-8	929769-79-9	929769-80-2	929769-81-3
	929769-83-5	929769-84-6	929769-85-7	929769-86-8	929769-87-9
	929769-88-0	929769-89-1	929769-90-4	929769-91-5	929769-92-6
	929769-93-7	929769-95-9	929769-96-0	929769-97-1	929769-98-2
	929769-99-3	929770-00-3	929770-01-4	929770-02-5	929770-03-6
	929770-04-7	929770-05-8	929770-06-9	929770-07-0	929770-08-1
	929770-09-2	929770-10-5	929770-11-6	929770-12-7	929770-13-8
	929770-14-9	929770-15-0	929770-16-1	929770-17-2	929770-18-3
	929770-19-4	929770-20-7	929770-21-8	929770-22-9	929770-23-0
	929770-24-1	929770-25-2	929770-26-3	929770-27-4	929770-28-5
	929770-29-6	929770-30-9	929770-31-0	929770-32-1	929770-33-2
	929770-34-3	929770-35-4	929770-36-5	929770-37-6	929770-38-7
	929770-39-8	929770-40-1	929770-41-2	929770-42-3	929770-43-4
	929770-44-5	929770-45-6	929770-46-7	929770-47-8	929770-48-9
	929770-49-0	929770-50-3	929770-51-4	929770-52-5	929770-53-6
	929770-54-7	929770-55-8	929770-56-9	929770-57-0	929770-58-1

929770-59-2 929770-60-5 929770-61-6 929770-62-7 929770-63-8  
 929770-64-9  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)

(gene SSG1-targeting siRNA; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT 929770-65-0 929770-66-1 929770-67-2 929770-68-3 929770-69-4  
 929770-70-7 929770-71-8 929770-72-9 929770-73-0 929770-74-1  
 929770-75-2 929770-76-3 929770-77-4 929770-78-5 929770-79-6  
 929770-80-9 929770-81-0 929770-82-1 929770-83-2 929770-84-3  
 929770-85-4 929770-86-5 929770-87-6 929770-88-7 929770-89-8  
 929770-90-1 929770-91-2 929770-92-3 929770-93-4 929770-94-5  
 929770-95-6 929770-96-7 929770-97-8 929770-98-9 929770-99-0  
 929771-00-6 929771-01-7 929771-02-8 929771-03-9 929771-04-0  
 929771-05-1 929771-06-2 929771-07-3 929771-08-4 929771-09-5  
 929771-10-8 929771-11-9 929771-12-0 929771-13-1 929771-14-2  
 929771-15-3 929771-16-4 929771-17-5 929771-18-6 929771-19-7  
 929771-20-0 929771-21-1 929771-22-2 929771-23-3 929771-24-4

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)

(gene SSG1-targeting siRNA; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT 929771-25-5 929771-26-6 929771-27-7 929771-28-8 929771-29-9  
 929771-30-2 929771-31-3 929771-32-4 929771-33-5 929771-34-6  
 929771-35-7 929771-36-8 929771-37-9 929771-38-0 929771-39-1  
 929771-40-4 929771-41-5 929771-42-6 929771-43-7 929771-44-8  
 929771-45-9 929771-46-0 929771-47-1 929771-48-2 929771-49-3  
 929771-50-6 929771-51-7 929771-52-8 929771-53-9 929771-54-0  
 929771-55-1 929771-56-2 929771-57-3 929771-58-4 929771-59-5  
 929771-60-8 929771-61-9 929771-62-0 929771-63-1 929771-64-2  
 929771-65-3 929771-66-4 929771-67-5 929771-68-6 929771-69-7  
 929771-70-0 929771-71-1 929771-72-2 929771-73-3 929771-74-4  
 929771-75-5 929771-76-6 929771-77-7 929771-78-8 929771-79-9  
 929771-80-2 929771-81-3 929771-82-4 929771-83-5 929771-84-6  
 929771-85-7 929771-86-8 929771-87-9 929771-88-0 929771-89-1  
 929771-90-4 929771-91-5 929771-92-6 929771-93-7 929771-94-8  
 929771-95-9 929771-96-0 929771-97-1 929771-98-2 929771-99-3  
 929772-00-9 929772-01-0 929772-02-1 929772-03-2 929772-04-3  
 929772-05-4 929772-06-5 929772-07-6 929772-08-7 929772-09-8  
 929772-10-1 929772-11-2 929772-12-3 929772-13-4 929772-14-5  
 929772-15-6 929772-16-7 929772-17-8 929772-18-9 929772-19-0  
 929772-20-3 929772-21-4 929772-22-5 929772-23-6 929772-24-7  
 929772-25-8 929772-26-9 929772-27-0 929772-28-1 929772-29-2  
 929772-30-5 929772-31-6 929772-32-7 929772-33-8 929772-34-9  
 929772-35-0 929772-36-1 929772-37-2 929772-38-3 929772-39-4  
 929772-40-7 929772-41-8 929772-42-9 929772-43-0 929772-44-1  
 929772-45-2 929772-46-3 929772-47-4 929772-48-5 929772-49-6  
 929772-50-9 929772-51-0 929772-52-1 929772-53-2 929772-54-3  
 929772-55-4 929772-56-5 929772-57-6 929772-58-7 929772-59-8  
 929772-60-1 929772-61-2 929772-62-3 929772-63-4 929772-64-5  
 929772-65-6 929772-66-7 929772-67-8 929772-68-9 929772-69-0  
 929772-70-3 929772-71-4 929772-72-5 929772-73-6 929772-74-7  
 929772-75-8 929772-76-9 929772-77-0 929772-78-1 929772-79-2  
 929772-80-5 929772-81-6 929772-82-7 929772-83-8 929772-84-9  
 929772-85-0 929772-86-1 929772-87-2 929772-88-3 929772-89-4  
 929772-90-7 929772-91-8 929772-92-9 929772-93-0 929772-94-1  
 929772-95-2 929772-96-3 929772-97-4 929772-98-5 929772-99-6  
 929773-00-2 929773-01-3 929773-02-4 929773-03-5 929773-04-6  
 929773-05-7 929773-06-8 929773-07-9 929773-08-0 929773-09-1  
 929773-10-4 929773-11-5 929773-12-6 929773-13-7 929773-14-8  
 929773-15-9 929773-16-0 929773-17-1 929773-18-2 929773-19-3

929773-20-6 929773-21-7 929773-22-8 929773-23-9 929773-24-0  
 929773-25-1 929773-26-2 929773-27-3 929773-28-4 929773-29-5  
 929773-30-8 929773-31-9 929773-32-0 929773-33-1 929773-34-2  
 929773-35-3 929773-36-4 929773-37-5 929773-38-6 929773-39-7  
 929773-40-0 929773-41-1 929773-42-2 929773-43-3 929773-44-4  
 929773-45-5 929773-46-6 929773-47-7 929773-48-8 929773-49-9  
 929773-50-2 929773-51-3 929773-52-4 929773-53-5 929773-54-6  
 929773-55-7 929773-56-8 929773-57-9 929773-58-0 929773-59-1  
 929773-60-4

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 929773-61-5

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 97002-67-0, Mak3 N-acetyltransferase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 301167-57-7, Protein tyrosine phosphatase, type IVA

RL: BSU (Biological study, unclassified); BIOL (Biological study) (member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 139805-02-0, GenBank M22878 139811-39-5, DNA (human clone 137.)  
 139812-87-6, GenBank X07499 139841-85-3, DNA (human clone 5 gene flg cDNA) 145405-49-8 150835-03-3, DNA (human cell line CEPH 134702)  
 150946-39-7 151315-20-7, DNA (human gene CSF1 cDNA) 156132-00-2  
 161072-70-4 161073-44-5 161784-22-1 164244-73-9 170178-96-8  
 170896-07-8 172247-21-1, DNA (human myosin isoform Ixb cDNA)  
 174518-29-7 177308-82-6 183100-56-3 183818-28-2 184892-27-1  
 185082-45-5 190047-47-3 191307-27-4, DNA (human clone 2QTEL001)  
 191307-34-3 197840-86-1 199496-62-3 200768-39-4 204565-11-7  
 206630-64-0 209999-07-5 210466-21-0 213076-75-6 216296-73-0  
 220500-43-6 226540-81-4, DNA (human gene P38IP cDNA) 227447-51-0  
 228685-95-8, DNA (human gene PIF1 cDNA) 241463-12-7 253570-31-9, DNA (human gene FIR cDNA) 256189-00-1 256630-24-7, DNA (human clone ADKA01901 cDNA) 259479-03-3 261330-04-5, DNA (human clone LCHN cDNA)  
 266667-92-9 268185-97-3 273904-51-1 274670-41-6 280739-08-2  
 283089-44-1 288708-52-1, DNA (human reticulon 4a) 292553-67-4, DNA (human clone HRC10233 cDNA) 292555-59-0, DNA (human clone HST07791 cDNA)  
 292558-35-1 292564-53-5, DNA (human clone LNG09301 cDNA) 312679-19-9, DNA (human DC44 cDNA) 326661-72-7 326664-67-9 326673-49-8  
 326682-96-6 329305-57-9 336774-53-9 336774-78-8 344977-30-6  
 346015-95-0, DNA (human clone IMAGE:3544244 cDNA) 346026-13-9  
 350730-14-2 354192-22-6 355890-95-8 361976-35-4, DNA (human gene MDM2 cDNA) 362583-35-5 364650-10-2 366408-13-1 366422-30-2  
 366425-45-8 366426-57-5 366429-37-0, DNA (human clone PLACE5000058 cDNA) 366431-18-7, DNA (human clone PROST2003563 cDNA) 366434-69-7, DNA (human clone TESTI1000131 cDNA) 366435-27-0, DNA (human clone TESTI2001099 cDNA) 366437-44-7, DNA (human clone TESTI2007951 cDNA)  
 366442-40-2, DNA (human clone STM06043 cDNA) 375317-70-7 375323-40-3, DNA (human clone IMAGE:4500659 cDNA) 378180-53-1 381471-54-1, DNA (Hepatitis B virus gene OG23) 381982-42-9, GenBank AF456479  
 381987-16-2 384432-32-0 384455-81-6 384515-64-4 384569-79-3, DNA (human gene APFR cDNA) 384599-49-9 384749-58-0 384976-50-5  
 385263-69-4 385727-26-4, DNA (human gene FBX29 cDNA) 385733-36-8  
 386194-13-4 389180-82-9 389184-31-0 389184-37-6 389185-71-1, GenBank M30496 389203-01-4, DNA (human binding protein cDNA)

390095-19-9 390125-31-2 390129-38-1, DNA (human cell line U937 gene  
 G16 cDNA) 390136-69-3, DNA (human gene G7b cDNA) 390250-30-3  
 390259-86-6 390329-02-9, DNA (human clone PLACE1005876 cDNA)  
 390330-80-0, DNA (human clone PLACE2000216 cDNA) 390333-13-8  
 390632-01-6 390636-37-0, DNA (human clone HEMBB1002600 cDNA)  
 391532-75-5 391542-33-9, DNA (human PLC a1fa cDNA) 391542-59-9  
 391552-32-2 391812-63-8 391831-71-3 391831-89-3, DNA (human gene  
 HTP-1 cDNA) 391837-44-8, DNA (human myosin I beta cDNA) 391849-15-3  
 392039-63-3 392049-86-4 392053-57-5 392059-27-7 392065-27-9  
 392074-84-9 392079-85-5, DNA (human gene RBBP2H1 cDNA) 392084-92-3  
 392093-04-8 392111-57-8 398399-18-3, DNA (human clone IMAGE:3508235  
 cDNA) 398425-79-1, GenBank M15841 407526-89-0, DNA (human gene TPM3  
 cDNA) 411873-71-7, DNA (human clone IMAGE:4339438 cDNA) 417979-99-8  
 418524-58-0 423687-63-2, DNA (human pseudogene Uox exon 8) 424470-24-6  
 427276-40-2 427276-44-6 438080-29-6 438080-63-8 439658-66-9  
 439774-65-9, DNA (human clone DKFZp451C066 cDNA) 439778-78-6, DNA (human  
 clone DKFZp686I1727 cDNA) 439779-47-2 439779-78-9 439781-74-5  
 439787-71-0, DNA (human clone DKFZp667K0520 cDNA) 440393-98-6  
 441606-54-8, DNA (human clone KIDNE2008403 cDNA) 441626-81-9, DNA (human  
 clone TRACH2015243 cDNA) 441628-70-2, DNA (human  
 clone) 441633-37-0, DNA (human clone BRAMY2010441 cDNA) 441642-14-4,  
 DNA (human clone D9OST2001433 cDNA) 441642-50-8, DNA (human clone  
 FCBBF1000053 cDNA) 441646-38-4, DNA (human clone  
 441646-90-8, DNA (human clone HEART2006195 cDNA) 441650-05-1  
 441654-43-9, DNA (human clone PEBLM2006049 cDNA) 441655-85-2, DNA (human  
 clone PROST2017617 cDNA) 441657-18-7, DNA (human clone SMINT2003386  
 cDNA) 441658-14-6, DNA (human clone SMINT2016313 cDNA) 441664-41-1,  
 DNA (human clone TESTI2034718 cDNA) 441665-98-1, DNA (human clone  
 TESTI2046786 cDNA) 441668-54-8, DNA (human clone  
 441669-68-7, DNA (human clone UTERU20101024 cDNA) 444477-92-3  
 450510-87-9 453089-64-0, DNA (human clone PLACE1005539 cDNA)  
 453090-79-4, DNA (human clone THYRO1001457 cDNA) 453091-04-8  
 455220-38-9, DNA (human clone IMAGE:5263531 cDNA) 456953-20-1, DNA  
 (human clone IMAGE:5241630 cDNA) 456954-22-6, DNA (human clone  
 IMAGE:5288990 cDNA) 492991-19-2 493096-18-7, DNA (human clone  
 IMAGE:5787152 cDNA) 493356-90-4, DNA (human clone IMAGE:4400215 cDNA)  
 494346-55-3 494365-08-1 494455-40-2 494509-13-6, DNA (human clone  
 IMAGE:5277710 cDNA) 494509-88-5 495663-69-9 495690-84-1, DNA (human  
 clone IMAGE:4820027 cDNA) 496323-48-9, DNA (human clone CS0DF038Y005  
 cDNA) 496401-61-7 496417-48-2, DNA (human clone CS0DF007YN24 cDNA)  
 503763-48-2 503986-53-6 505903-25-3 514986-90-4 520897-62-5  
 520900-32-7 520902-26-5 528328-40-7 537435-71-5, DNA (human clone  
 DKFZp779B0244 cDNA) 525234-13-1 556761-35-4 577611-74-6  
 577612-50-1, DNA (human clone DKFZp686O10247 cDNA) 577668-65-6, DNA  
 (human clone DKFZp686K02111 cDNA) 577675-09-3, DNA (human clone  
 DKFZp686N2252 cDNA) 577678-62-7, DNA (human clone DKFZp686I16170 cDNA)  
 577679-80-2, DNA (human clone DKFZp686C20269 cDNA) 577679-94-8, DNA  
 (human clone DKFZp686K17155 cDNA) 577680-64-9 577683-33-1, DNA (human  
 clone DKFZp686A06190 cDNA) 577686-80-7 581048-25-1 582931-34-8, DNA  
 (human clone TLIVE2007016 cDNA) 582934-76-7, DNA (human clone  
 SYNNOV4009298 cDNA) 582935-07-7, DNA (human clone TESTI4014553 cDNA)  
 582935-98-6, DNA (human clone ASTRO1000009 cDNA) 582954-59-4, DNA (human  
 clone BRACE3002508 cDNA) 582957-67-3, DNA (human clone BRAWH3004530  
 cDNA) 582958-06-3, DNA (human clone BRCAN2002562 cDNA) 582964-77-0  
 582965-11-5 582967-69-9, DNA (human clone PLACE6015211 cDNA)  
 582968-81-8, DNA (human clone SPLEN2016480 cDNA) 582972-11-0, DNA (human  
 clone TESTI4006407 cDNA) 582972-75-6, DNA (human  
 clone) 582979-35-9, DNA (human clone TRACH3008902 cDNA) 582981-36-0,  
 DNA (human clone UTERU3005205 cDNA) 582986-75-2, DNA (human clone  
 BRAMY3015549 cDNA) 582987-73-3, DNA (human clone BRAWH3011623 cDNA)  
 582990-54-3, DNA (human clone BRCAN2006051 cDNA) 583000-39-9, DNA (human

clone PLACE7000266 cDNA) 583004-17-5, DNA (human clone TESTI4010979 cDNA) 583879-62-3, GenBank AY225123 626095-42-9 633183-54-7, DNA (human FP291 cDNA)  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 633234-90-9, DNA (human LP4947 cDNA) 635266-00-1 638122-93-7  
 645887-63-4, GenBank AY288946 645888-06-8, GenBank AY288979  
 663533-87-7, DNA (human unknown cDNA) 664946-03-6 668088-69-5, DNA (human clone IMAGE:30343220 cDNA) 673849-79-1, DNA (human clone IMAGE:5193590 cDNA) 680961-30-2, DNA (human clone CTONG2004000 cDNA) 680965-75-7, DNA (human clone TESTI4029528 cDNA) 686696-63-9  
 689699-30-7 695137-68-9 700666-63-3 700734-94-7 716907-04-9, DNA (human clone CS0CAP003YE18 cDNA) 716907-58-3, DNA (human clone CS0DI002YD21 cDNA) 716918-63-7, DNA (human clone CS0DI086YE21 cDNA) 716923-06-7, DNA (human clone CS0DI063YH06 cDNA) 716924-53-7, DNA (human clone CS0DI085YB07 cDNA) 716926-59-9, DNA (human clone CS0DI076YI17 cDNA) 716926-73-7, DNA (human clone CS0DC026YCI15 cDNA) 716931-74-7, DNA (human clone CS0DF037YF09 cDNA) 716937-10-9, DNA (human clone CS0DI031YC12 cDNA) 716938-18-0, DNA (human clone CS0DI011YP01 cDNA) 716952-87-3, DNA (human clone CS0DI045YB05 cDNA) 716957-76-5, DNA (human clone CS0DF005YK21 cDNA) 716959-00-1, DNA (human clone CS0DK001YMI17 cDNA) 716963-73-4, DNA (human clone CS0DF005YMI18 cDNA) 716965-60-5, DNA (human clone CS0DI044YL08 cDNA) 716967-17-8, DNA (human clone CS0DD007YL12 cDNA) 716967-57-6, DNA (human clone CS0DH004YL21 cDNA) 716970-46-6, DNA (human clone CS0DI066YB16 cDNA) 716973-09-0, DNA (human clone CS0DI022YG21 cDNA) 716975-10-9, DNA (human clone CS0DB001YH18 cDNA) 716979-70-3, DNA (human clone CS0DC001YH18 cDNA) 716983-78-7, DNA (human clone CS0DI084YG07 cDNA) 716993-15-6, DNA (human clone CS0DF036YG02 cDNA) 716994-30-8, DNA (human clone CS0DK008YI13 cDNA) 717004-61-0, DNA (human clone CS0DM011YK19 cDNA) 717007-19-7, DNA (human clone CS0DI053YB05 cDNA) 717018-01-4, DNA (human clone CS0DI057YMI10 cDNA) 717025-51-9, DNA (human clone CS0DE006YB21 cDNA) 717028-42-7, DNA (human clone CS0DF006YB20 cDNA) 717028-86-9, DNA (human clone CL0BA006ZC10 cDNA) 717029-38-4, DNA (human clone CS0DB001YD10 cDNA) 717035-20-6, DNA (human clone CS0DL006YG09 cDNA) 717035-58-0, DNA (human clone CS0DJ005YD11 cDNA) 717035-87-5, DNA (human clone CS0DC017YA10 cDNA) 717042-47-2, DNA (human clone CS0DA010YE20 cDNA) 717043-26-0, DNA (human clone CS0DH001YN15 cDNA) 717053-08-2, DNA (human clone CS0DF018YJ11 cDNA) 717053-16-2, DNA (human clone CS0DI027YE21 cDNA) 717054-62-1, DNA (human clone CS0DI036YF07 cDNA) 717059-74-0, DNA (human clone CS0DC005YH06 cDNA) 717064-83-0, DNA (human clone CS0DF032YB12 cDNA) 717071-34-6, DNA (human clone CS0DF018YK19 cDNA) 717073-42-2, DNA (human clone CS0DI010YH14 cDNA) 717077-18-4, DNA (human clone CS0DL011YN12 cDNA) 717077-35-5, DNA (human clone CS0DB001YA17 cDNA) 717080-53-0, DNA (human clone CS0DI031YE19 cDNA) 717085-18-2, DNA (human clone CS0DD007YD16 cDNA) 717086-07-2, DNA (human clone CS0DI034YG17 cDNA) 717614-74-9, DNA (human clone CS0DJ015YL04 cDNA) 717615-19-5, DNA (human clone CS0DI020Y004 cDNA) 717617-67-9, DNA (human clone CS0DF028Y007 cDNA) 717619-51-7, DNA (human clone CS0DI016YM08 cDNA) 717622-23-6, DNA (human clone CS0DI059YF19 cDNA) 717623-43-3, DNA (human clone CS0CAP007YI09 cDNA) 717624-10-7, DNA (human clone CL0BA012ZA08 cDNA) 717627-50-4, DNA (human clone CS0DI060YJ19 cDNA) 717632-37-6, DNA (human clone CS0DJ002YN19 cDNA) 717632-77-4, DNA (human clone CS0DI019XI14 cDNA) 717644-46-7, DNA (human clone CS0DB004Y023 cDNA) 717650-67-4, DNA (human clone CS0DI013YH09 cDNA) 717653-98-0, DNA (human clone CS0DG007YD04 cDNA) 717658-48-5, DNA (human clone CS0DF008YL18 cDNA) 717661-22-8, DNA (human clone CS0DE002YP03 cDNA) 717670-75-2, DNA (human clone CS0DJ001YD15 cDNA)

717679-39-5, DNA (human clone CL0BA009ZC04 cDNA) 717680-82-5, DNA (human clone CS0DB008YA09 cDNA) 717682-06-9, DNA (human clone) 717685-75-1, DNA (human clone CS0DC017YN21 cDNA) 717686-17-4, DNA (human clone CS0DI077YN15 cDNA) 717691-81-1, DNA (human clone CS0DC004YN01 cDNA) 717693-04-4, DNA (human clone) 717695-93-7, DNA (human clone CS0DC023YC13 cDNA) 717704-82-0, DNA (human clone CS0DF011YP12 cDNA) 717711-45-0, DNA (human clone) 717717-03-8, DNA (human clone CS0DK012YC18 cDNA) 717719-05-6, DNA (human clone CS0DC014YC18 cDNA) 717732-34-8, DNA (human clone CS0DI056YJ24 cDNA) 717734-75-3, DNA (human clone) 717735-42-7, DNA (human clone CS0DC003YK02 cDNA) 717741-89-4, DNA (human clone CS0DL004YL07 cDNA) 717747-53-0, DNA (human clone) 717752-64-2, DNA (human clone CS0DJ009YD01 cDNA) 717752-98-2, DNA (human clone CS0DI044YP06 cDNA) 717755-07-2, CS0DJ006YC05 cDNA) 717755-58-3, DNA (human clone) 717756-80-4, DNA (human clone CS0DI019YM04 cDNA) 717758-31-1, DNA (human clone CS0DH006YI09 cDNA) 717771-77-2, DNA (human clone) 717775-74-1, DNA (human clone CL0BB019ZH12 cDNA) 717786-50-0, DNA (human clone CS0DI036YF21 cDNA) 717794-26-8, DNA (human clone CS0DF010YL22 cDNA) 717795-17-0, DNA (human clone) 717796-45-7, DNA (human clone CS0DF034YK23 cDNA) 717798-79-3, DNA (human clone CS0DE009YF20 cDNA) 721296-60-2, GenBank AY044853 757860-59-6 770642-77-8 838051-94-8, DNA (human clone DKFZp686M208 cDNA) 838052-91-8, DNA (human clone DKFZp686G0883 cDNA) 838053-45-5, DNA (human clone DKFZp686P12164 cDNA) 929579-52-2 929579-54-4 929579-56-6 929579-58-8 929579-60-2, GenBank AY954500 929579-61-3 929579-63-5 929579-65-7 929579-67-9 929579-69-1 929579-71-5 929579-73-7 929579-75-9 929579-77-1 929579-79-3 929579-81-7 929579-83-9 929579-85-1 929579-87-3 929579-89-5 929579-91-9, DNA (human gene SMAP2 cDNA) 929579-93-1 929579-97-5 929579-99-7 929580-00-7 929580-02-9, DNA (human clone IMAGE:30529503 cDNA) 929580-03-0 929580-05-2 929871-85-2, GenBank F87463  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
 (nucleotide sequence; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)  
 IT 929739-88-8 929739-89-9 929739-90-2 929739-91-3 929739-92-4 929739-93-5 929739-94-6 929739-95-7 929739-96-8 929739-97-9 929739-98-0 929739-99-1 929740-00-1 929740-01-2 929740-02-3 929740-03-4 929740-04-5 929740-05-6 929740-06-7 929740-07-8 929740-08-9 929740-09-0 929740-10-3 929740-11-4 929740-12-5 929740-13-6 929740-14-7 929740-15-8 929740-16-9 929740-17-0 929740-18-1 929740-19-2 929740-20-5 929740-21-6 929740-22-7 929740-23-8 929740-24-9 929740-25-0 929740-26-1  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)  
 IT 9002-02-2, Succinate dehydrogenase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (subunit B, iron sulfur; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)  
 IT 140879-24-9, 26S Proteasome 172522-01-9, AMP-activated protein kinase 362479-32-1, Protein phosphatase 1 362674-81-5, Protein phosphatase 2 364367-46-4, Protein phosphatase 4  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (subunits; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)  
 IT 9013-05-2, Phosphatase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tensin-like C1 domain containing; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT 104645-76-3, Phosphatidylinositol-4-phosphate 5-kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type II, alpha; double-stranded RNAs and their use for downregulating  
 genes and treating cardiovascular diseases)

IT 9001-86-9, Phospholipase C  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (alpha and gamma; double-stranded RNAs and their use for  
 downregulating genes and treating cardiovascular diseases)

IT 9026-30-6, Poly(A) polymerase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (alpha; double-stranded RNAs and their use for downregulating genes  
 and treating cardiovascular diseases)

L32 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 115926-52-8, Phosphoinositide 3-kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in  
 treatment and prophylaxis of diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2007:220269 CAPLUS

DOCUMENT NUMBER: 146:295955

TITLE: Preparation of pyrazine derivatives, particularly  
 N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as  
 PI3K inhibitors

INVENTOR(S): Gaillard, Pascale; Quattropiani, Anna; Pomel, Vincent;  
 Rueckle, Thomas; Klicic, Jasna; Church, Dennis

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.  
 Antilles

SOURCE: PCT Int. Appl., 170pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023186	A1	20070301	WO 2006-EP65688	20060825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006283846	A1	20070301	AU 2006-283846	20060825
CA 2618479	A1	20070301	CA 2006-2618479	20060825
EP 1917252	A1	20080507	EP 2006-793019	20060825
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2008049767	A	20080604	KR 2008-707158	20080325

PRIORITY APPLN. INFO.:

EP 2005-107838 A 20050826  
US 2005-711873P P 20050826  
WO 2006-EP65688 W 20060825

OTHER SOURCE(S): MARPAT 146:295955

AN 2007:220269 CAPLUS

DN 146:295955

ED Entered STN: 01 Mar 2007

TI Preparation of pyrazine derivatives, particularly N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K inhibitors  
IN Gaillard, Pascale; Quattropani, Anna; Pomel, Vincent; Rueckle, Thomas; Klicic, Jasna; Church, Dennis

PA Applied Research Systems Ars Holding N.V., Neth. Antilles

SO PCT Int. Appl., 170pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007023186	A1	20070301	WO 2006-EP65688	20060825
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006283846	A1	20070301	AU 2006-283846	20060825
	CA 2618479	A1	20070301	CA 2006-2618479	20060825
	EP 1917252	A1	20080507	EP 2006-793019	20060825
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
	KR 2008049767	A	20080604	KR 2008-707158	20080325
PRAI	EP 2005-107838	A	20050826		
	US 2005-711873P	P	20050826		
	WO 2006-EP65688	W	20060825		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007023186	IPCI	C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
	IPCR	C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A]
	ECLA	C07D241/44; C07D401/12; C07D403/12; C07D405/12;



		C07D409/12; C07D413/12; C07D417/12
AU 2006283846	IPCI	C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A]
	ECLA	C07D241/44; C07D401/12; C07D403/12; C07D405/12; C07D409/12; C07D413/12; C07D417/12
CA 2618479	IPCI	A61K0031-498 [I,A]; A61P0035-00 [I,A]; C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]
EP 1917252	IPCI	C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
KR 2008049767	IPCI	C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
OS	MARPAT	146:295955
GI		



AB Title compds. I [A, B, D, E = independently C, N, such that the ring R is an aromatic ring; R<sup>1</sup> = H, halo, NO<sub>2</sub>, alk(en/yn)yl; R<sup>2</sup> = H, alk(en/yn)yl; R<sup>3</sup> = H, halo, alk(en/yn)yl, alkoxy, aryl, heteroaryl; R<sup>4</sup> = alk(en/yn)yl, aryl, heteroaryl, arylalkenyl, cycloalkylalkyl, etc.; n = 0-4; and their geometrical isomers, their optically active forms as enantiomers,

diastereomers, tautomers, racemates, and their pharmaceutically acceptable salts] were prepared as phosphoinositide 3-kinase (PI3K) inhibitors for use as a drug. Thus, treatment of 2,3-dichloroquinoxaline with ammonium carbonate in DMF, amination of the chloride with 2,5-dimethoxyaniline, and reaction of the amine 1-methylimidazole-4-sulfonyl chloride gave quinoxaline II. II inhibited PI3K induced-lipid phosphorylation with IC50 = 0.08  $\mu$ M. II inhibited IgM-induced Akt phosphorylation with IC50 = 0.03  $\mu$ M. Selected I inhibited stem cell factor-induced PKB/Akt phosphorylation in mast cells with IC50 ranging from 0.09  $\mu$ M to 1.22  $\mu$ M. I are useful for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

- ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PIK3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PIK3K inhibitor
- IT Nervous system, disease  
(Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Sarcoma  
(Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung, disease  
(airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Muscle, disease  
(atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection  
(bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection  
(bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection  
(bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung, disease  
(chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Nervous system, disease  
(degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Erythrocyte  
(disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Sperm motility  
(diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Blood vessel, disease  
(endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung  
(epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Blood, disease

(erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease  
(fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease  
(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease  
(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease  
Reperfusion  
(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm  
(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy  
(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
Pancreas, disease  
(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease  
(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
Lung, disease  
(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy  
Allergy inhibitors  
Alzheimer's disease  
Anaphylaxis  
Angiogenesis  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Antibacterial agents  
Antifibrotic agents  
Antihypertensives  
Antirheumatic agents  
Antitumor agents  
Antiviral agents  
Asthma  
Atherosclerosis  
Autoimmune disease  
B cell (lymphocyte)  
Bone marrow  
Cardiac hypertrophy  
Cardiovascular agents  
Cardiovascular system, disease  
Central nervous system agents

Encephalitis  
 Fibrosis  
 Glomerulosclerosis  
 Heart, disease  
 Human  
 Hypertension  
 Immunomodulators  
 Immunosuppressants  
 Inflammation  
 Inflammatory bowel disease  
 Ischemia  
 Kidney, disease  
 Mast cell  
 Melanoma  
 Meningitis  
 Multiple organ failure  
 Multiple sclerosis  
 Neoplasm  
 Neuroprotective agents  
 Pharmaceutical carriers  
 Pharmaceutical excipients  
 Platelet activation  
 Platelet aggregation  
 Platelet aggregation inhibitors  
 Prophylaxis  
 Psoriasis  
 Rheumatoid arthritis  
 Sepsis  
 Stroke  
 Thrombolytics  
 Thrombosis  
 Transplant and Transplantation  
 Transplant rejection  
 Vasoconstriction  
 Vasodilators

(preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

- IT Epithelium
  - (pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
  - (pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Leukocyte
  - (recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Fibrosis
  - (renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
  - (reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lupus erythematosus
  - (systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Central nervous system, disease
  - (trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
  - (vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Endothelium  
(vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
(viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
(viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
(viral; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 331723-61-6P, N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372091-52-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 577998-70-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714245-33-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714282-93-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 714917-87-0P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714932-70-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide 843630-52-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928139-93-9P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928140-00-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3-sulfonamide 928140-31-2P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-32-3P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-36-7P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-38-9P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-39-0P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-50-5P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-52-7P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-71-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-

yl]benzenesulfonamide 928140-75-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-77-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-83-4P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-85-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonamide 928140-87-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-96-9P, Methyl 3-[4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate 928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-00-8P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-11-1P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-13-3P, Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928141-14-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-22-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-26-8P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-30-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide 928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928141-35-9P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide 928141-37-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-39-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxy pyridine-3-sulfonamide 928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-47-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide 928141-51-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-56-4P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-58-6P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-59-7P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylate 928141-62-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928141-75-7P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylic acid 928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide

928141-81-5P, 4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-88-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-90-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide 928141-93-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesulfonamide 928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-02-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-07-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide 928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714924-49-9P, 3-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-02-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(morpholin-4-yl)pyridine-3-sulfonamide 928140-07-2P, N-[3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-10-7P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-sulfonamide 928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-12-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-14-1P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-15-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-16-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-18-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(methylsulfonyl)benzenesulfonamide 928140-20-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-21-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamide 928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzothiadiazole-4-sulfonamide 928140-23-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzoxadiazole-4-sulfonamide 928140-25-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide

928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-27-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-30-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-sulfonamide 928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-35-6P, 2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-37-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-41-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-44-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-45-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-47-0P, N-[3-[(5-Methoxy-2-(1H-pyrrol-1-yl)phenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-55-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928140-59-4P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-62-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide potassium salt 928140-63-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928140-64-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-65-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-67-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-69-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928140-72-1P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-74-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-78-7P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-81-2P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-84-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonami



de potassium salt 928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-88-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-94-7P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928140-99-2P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928141-03-1P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide potassium salt 928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, N-[2-[(2,5-Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide 928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928141-12-2P 928141-16-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-17-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-25-7P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-27-9P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-29-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide potassium salt 928141-31-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide hydrochloride 928141-33-7P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-34-8P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide potassium salt 928141-36-0P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-38-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide potassium salt 928141-40-6P 928141-41-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt 928141-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-55-3P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-57-5P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-60-0P, N-[3-[(2-Bromo-5-methoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt 928141-63-3P, 3-[(3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-

yl)sulfamoyl]benzoic acid 928141-65-5P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-67-7P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-69-9P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-70-2P, 3-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoic acid 928141-71-3P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylic acid 928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt 928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt 928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide dihydrochloride 928141-80-4P 928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(hydroxymethyl)benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide hydrochloride 928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-94-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-96-2P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide sodium salt 928141-97-3P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide sodium salt 928141-98-4P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-(3-methoxypropyl)benzamide 928141-99-5P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide hydrochloride 928142-01-2P 928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide potassium salt 928142-05-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(morpholin-4-yl)carbonyl]pyridine-3-sulfonamide 928142-06-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide potassium salt 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide 928142-09-0P 928142-14-7P, N-[6-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928142-15-8P, N-[3-[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-nitroquinoxalin-2-yl]benzenesulfonamide 928142-17-0P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid 928142-18-1P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid 928142-19-2P, 4-[[[3-[(3,5-

Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]benzamide  
 928142-20-5P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 98-10-2P, Benzenesulfonamide 636-76-0P, 3-(Aminosulfonyl)benzoic acid 825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide 2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione 2922-45-4P, 3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-yl)-4-methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide 6684-39-5P, 6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl 4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide 25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl 5-(aminosulfonyl)pyridine-2-carboxylate 34082-13-8P, 6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine 35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione 35251-99-1P, 2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P, 6-Chloropyridine-3-sulfonamide 53595-65-6P, 5-Bromothiophene-2-sulfonamide 59777-67-2P, Methyl 3-(aminosulfonyl)benzoate 63555-50-0P, Methyl 3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine 166271-34-7P, N-(3-Chloro-2-quinoxalinyl)benzenesulfonamide 199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide 256353-34-1P, 4,5-Dichlorothiophene-2-sulfonamide 478264-00-5P, 6-Methylpyridine-3-sulfonyl chloride 488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-fluorobenzenesulfonamide 522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 848052-87-9P, N-(3-Chloroquinoxalin-2-yl)thiophene-2-sulfonamide 856955-32-3P, 6-Methoxypyridine-3-sulfonamide 859491-30-8P, 5-[(1,3-Dioxo-1,3-dihydro-2H-isindol-2-yl)methyl]thiophene-2-sulfonamide 883057-32-7P, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928139-26-8P, N-(3,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-27-9P, N-(2,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-28-0P, Methyl 3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl 5-(aminosulfonyl)-4-methylthiophene-2-carboxylate 928139-30-4P, 3-Cyano-4-fluorobenzenesulfonamide 928139-31-5P, 6-Cyanopyridine-3-sulfonyl chloride 928139-32-6P, 6-Cyanopyridine-3-sulfonamide 928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide 928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide 928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide 928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide 928139-37-1P, Methyl 4-[(3-chloroquinoxalin-2-yl)amino)sulfonyl]butanoate 928139-39-3P, Methyl 4-[(3-chloroquinoxalin-2-yl)amino)sulfonyl]benzoate 928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide 928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide 928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide 928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide 928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide 928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide 928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide 928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928139-62-2P, 4-Acetyl-N-(3-

chloroquinoxalin-2-yl)benzenesulfonamide 928139-63-3P, Methyl  
 3-[4-[(3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate  
 928139-64-4P, 5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide  
 928139-66-6P, N-(3,6-Dichloroquinoxalin-2-yl)benzenesulfonamide  
 928139-67-7P, Methyl 5-[(3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-  
 methylthiophene-2-carboxylate 928139-70-2P, 5-[(3-Chloroquinoxalin-2-  
 yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester  
 928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-  
 fluorobenzenesulfonamide 928139-74-6P, N-(3-Chloroquinoxalin-2-yl)-5-  
 [(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide  
 928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-  
 fluorobenzenesulfonamide 928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-  
 yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-  
 (dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-  
 Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide  
 928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide  
 928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide  
 928139-87-1P, Methyl 5-[(3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-  
 2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-yl)-3-[(morpholin-4-  
 yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-  
 1-methyl-1H-imidazole-4-sulfonamide 928139-90-6P, N-(2-Chloropyrido[3,4-  
 b]pyrazin-3-yl)benzenesulfonamide 928139-91-7P, N-(3-Chloropyrido[2,3-  
 b]pyrazin-2-yl)benzenesulfonamide 928139-92-8P, N-[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-  
 yl)carbonyl]benzenesulfonamide 928139-94-0P, N-[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-  
 yl)carbonyl]benzenesulfonamide 928139-95-1P, 4-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-  
 dimethylbenzamide 928139-96-2P, 3-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-  
 dimethylbenzamide 928139-98-4P, 6-(Chloromethyl)-N-[3-[(3,5-  
 dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide  
 928140-01-6P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928142-21-6P,  
 N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine 928142-22-7P,  
 N-[5-Methoxy-2-(pyrrol-1-yl)phenyl]quinoxaline-2,3-diamine 928142-23-8P,  
 N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine 928142-24-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in  
 treatment and prophylaxis of diseases)  
 IT 115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in  
 treatment and prophylaxis of diseases)  
 IT 928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-  
 yl]benzenesulfonamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in  
 treatment and prophylaxis of diseases)  
 IT 54-96-6, 3,4-Diaminopyridine 70-55-3, p-Toluenesulfonamide 98-09-9,  
 Benzenesulfonyl chloride 98-61-3, Pipsyl chloride 98-64-6,  
 4-Chlorobenzenesulfonamide 102-56-7, 2,5-Dimethoxyaniline 109-01-3,  
 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 138-41-0,  
 4-(Aminosulfonyl)benzoic acid 402-46-0, 4-Fluorobenzenesulfonamide  
 452-58-4, 2,3-Diaminopyridine 536-90-3, m-Anisidine 701-34-8,  
 4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamid  
 e 1129-26-6, 4-Methoxybenzenesulfonamide 1524-40-9,  
 3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzenesulfonyl chloride

1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline  
 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl  
 chloride 2958-87-4, 2,3,6-Trichloroquinoxaline 3119-02-6,  
 4-Cyanobenzenesulfonamide 3430-14-6, 3-Amino-6-methylpyridine  
 4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4808-69-9,  
 6-Methylpyridine-3-sulfonic acid 5332-73-0, 3-Methoxypropylamine  
 5335-40-0, 3-(Methylsulfonyl)benzenesulfonyl chloride 5350-93-6,  
 5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide  
 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1,  
 1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline  
 16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl  
 chloride 17260-71-8, 3-Chlorobenzenesulfonamide 23905-46-6,  
 3-Acetylamino benzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-  
 methylaniline 51175-71-4, 3-Thiophenesulfonyl chloride 55338-73-3,  
 5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-sulfonyl chloride  
 56542-67-7, 3-Cyanobenzenesulfonyl chloride 59194-26-2,  
 5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl  
 3-(chlorosulfonyl)thiophene-2-carboxylate 59557-92-5,  
 2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl  
 chloride 73713-79-8 82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl  
 chloride 85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride  
 88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride  
 89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 111124-90-4,  
 1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-  
 sulfonyl chloride 126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride  
 137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9,  
 4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4,  
 Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-  
 methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-  
 sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-  
 yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6 351003-23-1,  
 4-Fluoro-3-cyanobenzenesulfonyl chloride 374537-95-8, Methyl  
 3-(4-chlorosulfonylphenyl)propionate 423768-46-1, Methyl  
 5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate 847744-22-3,  
 N-(3-Chloroquinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide  
 849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride 878682-97-4,  
 3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride  
 882564-09-2 928140-28-7 928141-10-0, N-(3,7-Dichloroquinoxalin-2-  
 yl)benzenesulfonamide 928142-10-3, N-[3-[(1,3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-  
 isoindol-2-yl)methyl]thiophene-2-sulfonamide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in  
 treatment and prophylaxis of diseases)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; Ambinter Stock Screening Collection 2005

(2) Anon; DATABASE CHEMCATS 2005

(3) Icos Corporation; WO 03035075 A 2003

L32 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 98-59-9, 4-Methylphenylsulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase  
 inhibitors useful in treatment of diseases)

RN 98-59-9 CAPLUS

CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 2007:11341 CAPLUS  
 DOCUMENT NUMBER: 146:121941  
 TITLE: Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases  
 INVENTOR(S): Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua  
 PATENT ASSIGNEE(S): Plexxikon, Inc., USA  
 SOURCE: PCT Int. Appl., 631 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002433	A1	20070104	WO 2006-US24524	20060621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006261993	A1	20070104	AU 2006-261993	20060621
CA 2613015	A1	20070104	CA 2006-2613015	20060621
EP 1893612	A1	20080305	EP 2006-773861	20060621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, YU				
PRIORITY APPLN. INFO.:			US 2005-692960P	P 20050622
			US 2005-731528P	P 20051028
			WO 2006-US24524	W 20060621

OTHER SOURCE(S): MARPAT 146:121941  
 AN 2007:11341 CAPLUS  
 DN 146:121941  
 ED Entered STN: 04 Jan 2007  
 TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases  
 IN Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang;

Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua

PA Plexxikon, Inc., USA  
SO PCT Int. Appl., 631 pp.  
CODEN: PIXXD2

DT Patent  
LA English

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007002433	A1	20070104	WO 2006-US24524	20060621
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006261993	A1	20070104	AU 2006-261993	20060621
	CA 2613015	A1	20070104	CA 2006-2613015	20060621
	EP 1893612	A1	20080305	EP 2006-773861	20060621
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, YU			
PRAI	US 2005-692960P	P	20050622		
	US 2005-731528P	P	20051028		
	WO 2006-US24524	W	20060621		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007002433	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; A61P0035-00 [I,A]	
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]	
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D	
AU 2006261993	IPCI	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]	
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]	
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D	
CA 2613015	IPCI	A61K0031-435 [I,A]; A61P0035-00 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-00 [I,C*]	

IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]


EP 1893612 IPCI C07D0471-04 [I,A]; C07D0471-00 [I,C\*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C\*]; A61P0035-00 [I,A]

IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]


ECLA C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D

OS MARPAT 146:121941

GI



I



II

AB Compds. of formula I which are active on protein kinases are described, as well as methods of using such compds. to treat diseases and conditions associated with aberrant activity of protein kinases. Compds. of formula I wherein Q is (un)substituted aryl, (un)substituted indole, (un)substituted heteroaryl, etc.; A is O, S, (un)substituted methylene, NH and derivs., CO, CS, SO and SO<sub>2</sub>; R<sub>4</sub> - R<sub>6</sub> is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted alkynyl, (un)substituted (hetero)cycloalkyl, and (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrogenation to give the corresponding benzoic acid, which underwent chlorination, to give the corresponding acid chloride, which underwent reaction with 5-bromo-7-azaindole to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. Several of the tested compds. exhibited good protein kinase inhibitory activity against several kinases.

ST pyrrolopyridine prepn protein kinase inhibitory activity

IT Diabetes mellitus  
(-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus  
(-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation



(CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease  
(Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease  
Teratogenesis  
(Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphA1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, disease  
(Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease  
(Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Gene, animal  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Granulomatous disease  
(Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antibodies and Immunoglobulins  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
 Respiratory distress syndrome  
 (acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease  
 (age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy  
 Inflammation  
 Nose, disease  
 (allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antiarteriosclerotics  
 (antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm  
 (astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Dermatitis  
 (atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease  
 Inflammation  
 Thyroid gland, disease  
 (autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection  
 (bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Prostate gland, disease  
 (benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hyperplasia  
 (benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bronchi, disease  
 Inflammation  
 (bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm  
 Mammary gland, neoplasm  
 Pancreas, neoplasm  
 (carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (cardio-faciocutaneous, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia  
(cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia  
(chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease  
(chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
(chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
(chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm  
(colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
Intestine, neoplasm  
(colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm  
(complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders  
(dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders  
(dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease  
(dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease  
(diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease  
(endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm  
(endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(faciocutaneoskeletal, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of

diseases)

IT Reproductive system  
(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease  
(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm  
(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation  
(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury  
(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia  
(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm  
(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma  
(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders  
(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori  
Influenza virus  
(infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
(inflammatory pain, treatment of; preparation of pyrrolopyridine

derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Head and Neck, disease  
 Reperfusion  
 Spinal cord, disease  
 (injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Autoimmune disease  
 (insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Diabetes mellitus  
 (insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Inflammation  
 Kidney, disease  
 (interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Liver, disease  
 (ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Myoma  
 Sarcoma  
 (leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Disease, animal  
 (leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Inflammation  
 Kidney, disease  
 (lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Edema  
 (lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Carcinoma  
 (mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Metabolic disorders  
 (metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Bone, neoplasm  
 (metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Blood vessel, disease  
 (microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Headache  
 (migraine, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 IT Bone formation  
 (mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Oviduct  
(neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Astrocyte  
(neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Schwann cell  
(neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Kidney, disease  
(nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nerve, neoplasm  
(neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
(neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus  
(non-insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm  
(non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sarcoma  
(of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant rejection  
(organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(pancreatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Pancreas, disease  
(pancreatitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(polycystic, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases)

IT Allergy inhibitors  
 Analgesics  
 Angiogenesis inhibitors  
 Anti-Alzheimer's agents  
 Anti-infective agents  
 Anti-inflammatory agents  
 Anti-ischemic agents  
 Antiarthritics  
 Antiasthmatics  
 Antibacterial agents  
 Antidiabetic agents  
 Antifibrotic agents  
 Antimigraine agents  
 Antiobesity agents  
 Antiosteoporotic agents  
 Antiparkinsonian agents  
 Antipyretics  
 Antirheumatic agents  
 Antitumor agents  
 Antiviral agents  
 Canidae  
 Cardiovascular agents  
 Combination chemotherapy  
 Human  
 Immunostimulants  
 Immunosuppressants  
 Lipolysis  
 Nervous system agents  
 Pharmaceutical carriers  
 Prodrugs  
 Respiratory system agents  
 Thrombolytics  
 Transplant and Transplantation  
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful  
 in treatment of diseases)

IT c-Kit (protein)  
 neu (receptor)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful  
 in treatment of diseases)

IT Carcinoma  
 (pulmonary non-small-cell, treatment of; preparation of  
 pyrrolopyridine derivs. as protein kinase inhibitors useful in  
 treatment of diseases)

IT Carcinoma  
 (pulmonary small-cell, treatment of; preparation of  
 pyrrolopyridine derivs. as protein kinase inhibitors useful in  
 treatment of diseases)

IT Carcinoma  
 Fibrosis  
 (pulmonary, treatment of; preparation of pyrrolopyridine derivs.  
 as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, neoplasm  
 (renal cell carcinoma, treatment of; preparation of  
 pyrrolopyridine derivs. as protein kinase inhibitors useful in  
 treatment of diseases)

IT Carcinoma  
 (renal cell, treatment of; preparation of pyrrolopyridine derivs.  
 as protein kinase inhibitors useful in treatment of diseases)

IT Injury

(reperfusion, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, neoplasm  
(schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT T lymphocyte  
(selective defect of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Immunodeficiency  
(severe combined, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm  
(small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury  
(spinal cord, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(squamous cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Digestive tract, neoplasm  
(stroma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus  
(systemic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(tissue scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Acute lymphocytic leukemia  
Acute myeloid leukemia  
Aging, animal  
Allergy  
Alopecia  
Alzheimer's disease  
Amyotrophic lateral sclerosis  
Asthma  
Atherosclerosis  
Bladder, neoplasm  
Bone, disease  
Bone, neoplasm  
Brain, neoplasm  
Cardiac hypertrophy  
Cardiovascular system, disease  
Central nervous system, neoplasm  
Chronic lymphocytic leukemia  
Chronic myeloid leukemia  
Diabetic nephropathy  
Digestive tract, neoplasm  
Emphysema  
Endocrine system, disease  
Eosinophilia  
Fever and Hyperthermia  
Fibrosis  
Graves' disease  
Hair, disease  
Heart failure



Hepatic steatosis  
Hepatitis  
Hyperglycemia  
Immunodeficiency  
Infection  
Inflammation  
Inflammatory bowel disease  
Intestine, disease  
Ischemia  
Kidney, disease  
Leukemia  
Liver, neoplasm  
Lung, disease  
Lung, neoplasm  
Lymphoma  
Mammary gland, neoplasm  
Mastocytoma  
Mastocytosis  
Melanoma  
Multiple myeloma  
Multiple sclerosis  
Mutation  
Myasthenia gravis  
Myelodysplastic syndromes  
Neoplasm  
Neurofibromatosis 1  
Neuroglia, neoplasm  
Non-Hodgkin lymphoma  
Obesity  
Osteoarthritis  
Osteoporosis  
Ovary, neoplasm  
Pancreas, neoplasm  
Parkinson's disease  
Prostate gland, disease  
Prostate gland, neoplasm  
Psoriasis  
Rheumatoid arthritis  
Sarcoma  
Scleroderma  
Sepsis  
Sjogren syndrome  
Skeleton, disease  
Skin, disease  
Skin, neoplasm  
Stroke  
Systemic mastocytosis  
Testis, neoplasm  
Thrombosis  
Thyroid gland, neoplasm  
Tuberous sclerosis  
Vascular restenosis

(treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Necrosis

(tubular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Angiogenesis

(tumor, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT Fibroblast growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT Fibroblast growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT Fibroblast growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT Inflammatory bowel disease  
 (ulcerative colitis, treatment of; preparation of pyrrolopyridine  
 derivs. as protein kinase inhibitors useful in treatment of  
 diseases)

IT Colitis  
 (ulcerative, treatment of; preparation of pyrrolopyridine derivs.  
 as protein kinase inhibitors useful in treatment of diseases)

IT Infection  
 (viral, treatment of; preparation of pyrrolopyridine derivs. as  
 protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ ; preparation of pyrrolopyridine derivs. as protein kinase  
 inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\beta$ ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT 142805-58-1  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT 50-99-7, D-Glucose, biological studies  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study,  
 unclassified); BIOL (Biological study)  
 (blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors  
 useful in treatment of diseases)

IT 858118-20-4P 918504-27-5P 918506-28-2P 918506-62-4P 918507-15-0P  
 918507-82-1P 918507-83-2P 918507-84-3P 918507-86-5P 918507-89-8P  
 918508-05-1P 918508-18-6P 918508-21-1P 918508-33-5P 918509-12-3P  
 918509-57-6P 918509-58-7P 918509-59-8P 918510-12-0P 918510-89-1P  
 918510-93-7P 918510-98-2P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate and intermediate; preparation of pyrrolopyridine derivs. as  
 protein kinase inhibitors useful in treatment of diseases)

IT 4649-09-6P 55052-24-9P 55052-28-3P 74420-15-8P 183208-35-7P  
 611204-98-9P 611205-38-0P 757978-25-9P 849067-96-5P 849068-05-9P  
 858116-85-5P 858118-15-7P 866319-00-8P 866546-07-8P 918504-28-6P  
 918504-29-7P 918504-31-1P 918504-32-2P 918504-33-3P 918504-36-6P  
 918504-37-7P 918504-38-8P 918504-39-9P 918505-66-5P 918505-72-3P  
 918506-47-5P 918506-48-6P 918506-97-5P 918507-50-3P 918507-53-6P  
 918507-54-7P 918507-55-8P 918507-56-9P 918507-67-2P 918510-14-2P  
 918510-28-8P 918510-95-9P 918511-92-9P 918512-43-3P 918514-97-3P  
 918516-12-8P 918516-27-5P 918517-04-1P 918519-14-9P 918519-37-6P

918519-69-4P 918520-82-8P 918521-31-0P 918522-25-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	23612-48-8P	23616-63-9P	27663-72-5P	27663-73-6P	65623-46-3P
	74420-00-1P, 1H-Pyrrolo[2,3-b]pyridin-4-amine	116168-44-6P			
	122379-64-0P	145934-58-3P	151098-60-1P	161225-76-9P	183208-54-0P
	226085-70-7P	344327-11-3P, 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile			
	344454-28-0P	348640-06-2P	348640-54-0P	351438-96-5P	351439-00-4P
	351439-01-5P	394223-03-1P	460053-58-1P	479552-75-5P	611204-94-5P
	611205-04-0P	611205-10-8P	611205-12-0P	611205-16-4P	611205-18-6P
	611205-34-6P	633303-87-4P	633303-90-9P	675840-52-5P	754214-42-1P
	850014-39-0P	850014-40-3P	858116-60-6P	858116-61-7P	858116-65-1P
	858116-68-4P	858116-69-5P	858116-70-8P	858116-73-1P	858116-74-2P
	858116-75-3P	858116-76-4P	858116-77-5P	858116-78-6P	858116-82-2P
	858116-87-7P	858116-89-9P	858116-90-2P	858116-91-3P	858116-93-5P
	858116-97-9P	858116-98-0P	858116-99-1P	858117-01-8P	858117-07-4P
	858117-12-1P	858117-13-2P	858117-14-3P	858117-15-4P	858117-16-5P
	858117-19-8P	858117-20-1P	858117-21-2P	858117-22-3P	858117-23-4P
	858117-24-5P	858117-25-6P	858117-26-7P	858117-27-8P	858117-28-9P
	858117-29-0P	858117-30-3P	858117-33-6P	858117-34-7P	858117-35-8P
	858117-36-9P	858117-37-0P	858117-38-1P	858117-39-2P	858117-40-5P
	858117-41-6P	858117-42-7P	858117-43-8P	858117-44-9P	858117-45-0P
	858117-46-1P	858117-47-2P	858117-48-3P	858117-49-4P	858117-50-7P
	858117-51-8P	858117-52-9P	858117-53-0P	858117-54-1P	858117-55-2P
	858117-56-3P	858117-57-4P	858117-58-5P	858117-59-6P	858117-60-9P
	858117-61-0P	858117-62-1P	858117-63-2P	858117-64-3P	858117-65-4P
	858117-66-5P	858117-67-6P	858117-68-7P	858117-69-8P	858117-70-1P
	858117-71-2P	858117-72-3P	858117-73-4P	858117-74-5P	858117-76-7P
	858117-77-8P	858117-78-9P	858117-79-0P	858117-80-3P	858117-81-4P
	858117-82-5P	858117-83-6P	858117-84-7P	858117-85-8P	858117-86-9P
	858117-87-0P	858117-88-1P	858117-89-2P	858117-90-5P	858117-91-6P
	858117-92-7P	858117-93-8P	858117-94-9P	858117-95-0P	858117-96-1P
	858117-97-2P	858117-98-3P	858117-99-4P	858118-00-0P	858118-01-1P
	858118-02-2P	858118-03-3P	858118-04-4P	858118-05-5P	858118-06-6P
	858118-07-7P	858118-08-8P	858118-09-9P	858118-10-2P	858118-11-3P
	858118-12-4P	858118-13-5P	858118-14-6P	858118-17-9P	858118-18-0P
	858118-19-1P	858118-21-5P	858118-22-6P	858118-23-7P	858118-24-8P
	858118-25-9P	858118-26-0P	858118-27-1P	858118-28-2P	858118-29-3P
	858118-30-6P	858118-31-7P	858118-32-8P	858118-33-9P	858118-34-0P
	858118-35-1P	858118-36-2P	858118-37-3P	858118-38-4P	858118-39-5P
	858118-40-8P	858118-41-9P	858118-42-0P	858118-43-1P	858118-44-2P
	858118-45-3P	858118-46-4P	858118-47-5P	858118-48-6P	858118-49-7P
	858118-50-0P	858118-51-1P	858118-52-2P	858118-53-3P	858118-54-4P
	858118-55-5P	858118-56-6P	858118-57-7P	858118-58-8P	858118-59-9P
	858118-60-2P	858118-61-3P	858118-62-4P	858118-63-5P	858118-64-6P
	858118-65-7P	858118-66-8P	858118-67-9P	858118-68-0P	858118-69-1P
	858118-70-4P	858118-71-5P	858118-72-6P	858118-73-7P	858118-74-8P
	858118-75-9P	858118-76-0P	858118-77-1P	858118-78-2P	858118-79-3P
	858118-80-6P	858118-81-7P	858118-82-8P	858118-83-9P	858118-84-0P
	858118-85-1P	858118-86-2P	858118-87-3P	858118-88-4P	858118-89-5P
	858118-90-8P	858118-91-9P	858118-92-0P	858118-93-1P	858118-94-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	858118-95-3P	858118-96-4P	858118-97-5P	858118-98-6P	858118-99-7P
	858119-00-3P	858119-01-4P	858119-02-5P	858119-03-6P	858119-04-7P

858119-05-8P	858119-06-9P	858119-07-0P	858119-08-1P	858119-09-2P
858119-10-5P	858119-11-6P	858119-12-7P	858119-13-8P	858119-14-9P
858119-15-0P	858119-16-1P	858119-17-2P	858119-18-3P	858119-19-4P
858119-20-7P	858119-21-8P	858119-22-9P	858119-23-0P	858119-24-1P
858119-25-2P	858119-26-3P	858119-27-4P	858119-28-5P	858119-29-6P
858119-30-9P	858119-31-0P	858119-32-1P	858119-33-2P	858119-34-3P
858119-35-4P	858119-36-5P	858119-37-6P	858119-38-7P	858119-39-8P
866545-86-0P	866545-87-1P	873786-06-2P	873786-08-4P	873786-10-8P
873786-11-9P	873786-12-0P	873786-16-4P	873786-17-5P	873786-19-7P
880770-36-5P	880770-84-3P	880770-85-4P	880770-86-5P	880771-30-2P
880771-31-3P	880771-32-4P	880771-34-6P	880771-35-7P	916172-49-1P
916173-07-4P	916173-12-1P	916173-13-2P	916173-16-5P	916173-34-7P
916174-24-8P	916174-48-6P	916174-49-7P	918504-30-0P	918504-34-4P
918504-35-5P	918504-40-2P	918504-41-3P	918504-42-4P	918504-43-5P
918504-44-6P	918504-45-7P	918504-46-8P	918504-47-9P	918504-48-0P
918504-49-1P	918504-50-4P	918504-51-5P	918504-52-6P	918504-53-7P
918504-54-8P	918504-55-9P	918504-56-0P	918504-57-1P	918504-58-2P
918504-59-3P	918504-60-6P	918504-61-7P	918504-62-8P	918504-63-9P
918504-64-0P	918504-65-1P	918504-66-2P	918504-67-3P	918504-68-4P
918504-69-5P	918504-70-8P	918504-71-9P	918504-72-0P	918504-73-1P
918504-74-2P	918504-75-3P	918504-76-4P	918504-77-5P	918504-78-6P
918504-79-7P	918504-80-0P	918504-81-1P	918504-82-2P	918504-83-3P
918504-84-4P	918504-85-5P	918504-86-6P	918504-87-7P	918504-88-8P
918504-89-9P	918504-90-2P	918504-91-3P	918504-92-4P	918504-93-5P
918504-94-6P	918504-95-7P	918504-96-8P	918504-97-9P	918504-98-0P
918504-99-1P	918505-00-7P	918505-01-8P	918505-02-9P	918505-03-0P
918505-04-1P	918505-05-2P	918505-07-4P	918505-08-5P	918505-09-6P
918505-10-9P	918505-11-0P	918505-12-1P	918505-13-2P	918505-14-3P
918505-15-4P	918505-16-5P	918505-17-6P	918505-18-7P	918505-19-8P
918505-20-1P	918505-21-2P	918505-22-3P	918505-23-4P	918505-24-5P
918505-25-6P	918505-26-7P	918505-27-8P	918505-28-9P	918505-29-0P
918505-30-3P	918505-31-4P	918505-32-5P	918505-33-6P	918505-34-7P
918505-35-8P	918505-36-9P	918505-37-0P	918505-38-1P	918505-39-2P
918505-40-5P	918505-41-6P	918505-42-7P	918505-43-8P	918505-44-9P
918505-45-0P	918505-46-1P	918505-47-2P	918505-48-3P	918505-49-4P
918505-50-7P	918505-51-8P	918505-52-9P	918505-53-0P	918505-54-1P
918505-55-2P	918505-56-3P	918505-57-4P	918505-58-5P	918505-59-6P
918505-60-9P	918505-61-0P	918505-62-1P	918505-63-2P	918505-64-3P
918505-65-4P	918505-67-6P	918505-68-7P	918505-69-8P	918505-70-1P
918505-71-2P	918505-73-4P	918505-74-5P	918505-75-6P	918505-76-7P
918505-77-8P	918505-78-9P	918505-79-0P	918505-80-3P	918505-81-4P
918505-82-5P	918505-83-6P	918505-84-7P	918505-85-8P	918505-86-9P
918505-87-0P	918505-88-1P	918505-89-2P	918505-90-5P	918505-91-6P
918505-92-7P	918505-93-8P	918505-94-9P	918505-95-0P	918505-96-1P
918505-97-2P	918505-98-3P	918505-99-4P	918506-00-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918506-01-1P	918506-02-2P	918506-03-3P	918506-04-4P	918506-05-5P
	918506-06-6P	918506-07-7P	918506-08-8P	918506-09-9P	918506-10-2P
	918506-11-3P	918506-12-4P	918506-13-5P	918506-14-6P	918506-15-7P
	918506-16-8P	918506-17-9P	918506-18-0P	918506-19-1P	918506-20-4P
	918506-21-5P	918506-22-6P	918506-23-7P	918506-24-8P	918506-25-9P
	918506-26-0P	918506-27-1P	918506-29-3P	918506-30-6P	918506-31-7P
	918506-32-8P	918506-33-9P	918506-34-0P	918506-35-1P	918506-36-2P
	918506-37-3P	918506-38-4P	918506-39-5P	918506-40-8P	918506-41-9P
	918506-42-0P	918506-43-1P	918506-44-2P	918506-45-3P	918506-46-4P
	918506-49-7P	918506-50-0P	918506-51-1P	918506-52-2P	918506-53-3P
	918506-54-4P	918506-55-5P	918506-56-6P	918506-57-7P	918506-58-8P

918506-59-9P	918506-60-2P	918506-61-3P	918506-63-5P	918506-64-6P
918506-65-7P	918506-66-8P	918506-67-9P	918506-68-0P	918506-69-1P
918506-70-4P	918506-71-5P	918506-72-6P	918506-73-7P	918506-74-8P
918506-75-9P	918506-76-0P	918506-77-1P	918506-78-2P	918506-79-3P
918506-80-6P	918506-81-7P	918506-82-8P	918506-83-9P	918506-84-0P
918506-85-1P	918506-86-2P	918506-87-3P	918506-88-4P	918506-89-5P
918506-90-8P	918506-91-9P	918506-92-0P	918506-93-1P	918506-94-2P
918506-95-3P	918506-96-4P	918506-98-6P	918506-99-7P	918507-00-3P
918507-01-4P	918507-02-5P	918507-03-6P	918507-04-7P	918507-05-8P
918507-06-9P	918507-07-0P	918507-08-1P	918507-09-2P	918507-10-5P
918507-11-6P	918507-12-7P	918507-13-8P	918507-14-9P	918507-16-1P
918507-17-2P	918507-18-3P	918507-19-4P	918507-20-7P	918507-21-8P
918507-22-9P	918507-23-0P	918507-24-1P	918507-25-2P	918507-26-3P
918507-27-4P	918507-28-5P	918507-29-6P	918507-30-9P	918507-31-0P
918507-32-1P	918507-33-2P	918507-34-3P	918507-35-4P	918507-36-5P
918507-37-6P	918507-38-7P	918507-40-1P	918507-47-8P	918507-49-0P
918507-51-4P	918507-52-5P	918507-57-0P	918507-58-1P	918507-59-2P
918507-60-5P	918507-61-6P	918507-62-7P	918507-63-8P	918507-64-9P
918507-65-0P	918507-66-1P	918507-68-3P	918507-70-7P	918507-71-8P
918507-72-9P	918507-73-0P	918507-74-1P	918507-75-2P	918507-76-3P
918507-77-4P	918507-78-5P	918507-79-6P	918507-80-9P	918507-81-0P
918507-85-4P	918507-87-6P	918507-88-7P	918507-90-1P	918507-91-2P
918507-92-3P	918507-93-4P	918507-94-5P	918507-95-6P	918507-96-7P
918507-97-8P	918507-98-9P	918507-99-0P	918508-00-6P	918508-01-7P
918508-02-8P	918508-03-9P	918508-04-0P	918508-06-2P	918508-07-3P
918508-08-4P	918508-09-5P	918508-10-8P	918508-11-9P	918508-12-0P
918508-13-1P	918508-14-2P	918508-15-3P	918508-16-4P	918508-17-5P
918508-19-7P	918508-20-0P	918508-22-2P	918508-23-3P	918508-24-4P
918508-25-5P	918508-26-6P	918508-27-7P	918508-28-8P	918508-29-9P
918508-30-2P	918508-31-3P	918508-32-4P	918508-34-6P	918508-35-7P
918508-36-8P	918508-37-9P	918508-38-0P	918508-39-1P	918508-40-4P
918508-41-5P	918508-42-6P	918508-43-7P	918508-44-8P	918508-45-9P
918508-46-0P	918508-47-1P	918508-48-2P	918508-49-3P	918508-50-6P
918508-51-7P	918508-52-8P	918508-53-9P	918508-54-0P	918508-55-1P
918508-56-2P	918508-57-3P	918508-58-4P	918508-59-5P	918508-60-8P
918508-61-9P	918508-62-0P	918508-63-1P	918508-64-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918508-65-3P	918508-66-4P	918508-67-5P	918508-68-6P	918508-69-7P
	918508-70-0P	918508-71-1P	918508-72-2P	918508-73-3P	918508-74-4P
	918508-75-5P	918508-76-6P	918508-77-7P	918508-78-8P	918508-79-9P
	918508-80-2P	918508-81-3P	918508-82-4P	918508-83-5P	918508-84-6P
	918508-85-7P	918508-86-8P	918508-87-9P	918508-88-0P	918508-89-1P
	918508-90-4P	918508-91-5P	918508-92-6P	918508-93-7P	918508-94-8P
	918508-95-9P	918508-96-0P	918508-97-1P	918508-98-2P	918508-99-3P
	918509-00-9P	918509-01-0P	918509-02-1P	918509-03-2P	918509-04-3P
	918509-05-4P	918509-06-5P	918509-07-6P	918509-08-7P	918509-09-8P
	918509-10-1P	918509-11-2P	918509-13-4P	918509-14-5P	918509-15-6P
	918509-16-7P	918509-17-8P	918509-18-9P	918509-19-0P	918509-20-3P
	918509-21-4P	918509-22-5P	918509-23-6P	918509-24-7P	918509-25-8P
	918509-26-9P	918509-27-0P	918509-28-1P	918509-29-2P	918509-30-5P
	918509-31-6P	918509-32-7P	918509-33-8P	918509-34-9P	918509-35-0P
	918509-36-1P	918509-37-2P	918509-38-3P	918509-39-4P	918509-40-7P
	918509-41-8P	918509-42-9P	918509-43-0P	918509-44-1P	918509-45-2P
	918509-46-3P	918509-47-4P	918509-48-5P	918509-49-6P	918509-50-9P
	918509-51-0P	918509-52-1P	918509-53-2P	918509-54-3P	918509-55-4P
	918509-56-5P	918509-60-1P	918509-61-2P	918509-62-3P	918509-63-4P
	918509-64-5P	918509-65-6P	918509-66-7P	918509-67-8P	918509-68-9P

918509-69-0P	918509-70-3P	918509-71-4P	918509-72-5P	918509-73-6P
918509-74-7P	918509-75-8P	918509-76-9P	918509-77-0P	918509-78-1P
918509-79-2P	918509-80-5P	918509-81-6P	918509-82-7P	918509-83-8P
918509-84-9P	918509-85-0P	918509-86-1P	918509-87-2P	918509-88-3P
918509-89-4P	918509-90-7P	918509-91-8P	918509-92-9P	918509-93-0P
918509-94-1P	918509-95-2P	918509-96-3P	918509-97-4P	918509-98-5P
918509-99-6P	918510-00-6P	918510-01-7P	918510-02-8P	918510-03-9P
918510-04-0P	918510-05-1P	918510-06-2P	918510-07-3P	918510-08-4P
918510-09-5P	918510-10-8P	918510-11-9P	918510-13-1P	918510-15-3P
918510-16-4P	918510-17-5P	918510-18-6P	918510-19-7P	918510-20-0P
918510-21-1P	918510-22-2P	918510-23-3P	918510-24-4P	918510-25-5P
918510-26-6P	918510-27-7P	918510-29-9P	918510-30-2P	918510-31-3P
918510-32-4P	918510-33-5P	918510-34-6P	918510-36-8P	918510-38-0P
918510-40-4P	918510-41-5P	918510-42-6P	918510-44-8P	918510-46-0P
918510-48-2P	918510-50-6P	918510-52-8P	918510-53-9P	918510-54-0P
918510-55-1P	918510-56-2P	918510-57-3P	918510-58-4P	918510-59-5P
918510-60-8P	918510-61-9P	918510-62-0P	918510-63-1P	918510-64-2P
918510-65-3P	918510-66-4P	918510-67-5P	918510-68-6P	918510-69-7P
918510-70-0P	918510-71-1P	918510-72-2P	918510-73-3P	918510-74-4P
918510-75-5P	918510-76-6P	918510-77-7P	918510-78-8P	918510-79-9P
918510-80-2P	918510-81-3P	918510-82-4P	918510-83-5P	918510-84-6P
918510-85-7P	918510-86-8P	918510-87-9P	918510-88-0P	918510-90-4P
918510-91-5P	918510-92-6P	918510-94-8P	918510-96-0P	918510-97-1P
918510-99-3P	918511-00-9P	918511-01-0P	918511-02-1P	918511-03-2P
918511-04-3P	918511-05-4P	918511-06-5P	918511-07-6P	918511-08-7P
918511-09-8P	918511-10-1P	918511-11-2P	918511-12-3P	918511-13-4P
918511-14-5P	918511-15-6P	918511-16-7P	918511-17-8P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918511-18-9P	918511-19-0P	918511-20-3P	918511-21-4P	918511-22-5P
	918511-23-6P	918511-24-7P	918511-25-8P	918511-26-9P	918511-27-0P
	918511-28-1P	918511-29-2P	918511-30-5P	918511-31-6P	918511-32-7P
	918511-33-8P	918511-34-9P	918511-35-0P	918511-36-1P	918511-37-2P
	918511-38-3P	918511-39-4P	918511-40-7P	918511-41-8P	918511-42-9P
	918511-43-0P	918511-44-1P	918511-45-2P	918511-46-3P	918511-47-4P
	918511-48-5P	918511-49-6P	918511-50-9P	918511-51-0P	918511-52-1P
	918511-53-2P	918511-54-3P	918511-55-4P	918511-56-5P	918511-57-6P
	918511-58-7P	918511-59-8P	918511-60-1P	918511-61-2P	918511-62-3P
	918511-63-4P	918511-64-5P	918511-65-6P	918511-66-7P	918511-67-8P
	918511-68-9P	918511-69-0P	918511-70-3P	918511-71-4P	918511-72-5P
	918511-73-6P	918511-74-7P	918511-75-8P	918511-76-9P	918511-77-0P
	918511-78-1P	918511-79-2P	918511-80-5P	918511-81-6P	918511-82-7P
	918511-83-8P	918511-84-9P	918511-85-0P	918511-86-1P	918511-87-2P
	918511-88-3P	918511-89-4P	918511-90-7P	918511-91-8P	918511-93-0P
	918511-94-1P	918511-95-2P	918511-96-3P	918511-97-4P	918511-98-5P
	918511-99-6P	918512-00-2P	918512-01-3P	918512-03-5P	918512-04-6P
	918512-05-7P	918512-06-8P	918512-07-9P	918512-08-0P	918512-09-1P
	918512-10-4P	918512-11-5P	918512-12-6P	918512-13-7P	918512-14-8P
	918512-15-9P	918512-16-0P	918512-17-1P	918512-18-2P	918512-19-3P
	918512-20-6P	918512-21-7P	918512-22-8P	918512-23-9P	918512-24-0P
	918512-25-1P	918512-26-2P	918512-27-3P	918512-28-4P	918512-29-5P
	918512-30-8P	918512-31-9P	918512-32-0P	918512-33-1P	918512-34-2P
	918512-35-3P	918512-36-4P	918512-37-5P	918512-38-6P	918512-39-7P
	918512-40-0P	918512-41-1P	918512-42-2P	918512-44-4P	918512-45-5P
	918512-46-6P	918512-47-7P	918512-48-8P	918512-49-9P	918512-50-2P
	918512-51-3P	918512-52-4P	918512-53-5P	918512-54-6P	918512-55-7P
	918512-56-8P	918512-57-9P	918512-58-0P	918512-59-1P	918512-60-4P
	918512-61-5P	918512-62-6P	918512-63-7P	918512-64-8P	918512-65-9P

918512-66-0P	918512-67-1P	918512-68-2P	918512-69-3P	918512-70-6P
918512-71-7P	918512-72-8P	918512-73-9P	918512-74-0P	918512-75-1P
918512-76-2P	918512-77-3P	918512-78-4P	918512-79-5P	918512-80-8P
918512-81-9P	918512-82-0P	918512-83-1P	918512-84-2P	918512-85-3P
918512-86-4P	918512-87-5P	918512-88-6P	918512-89-7P	918512-90-0P
918512-91-1P	918512-92-2P	918512-93-3P	918512-94-4P	918512-95-5P
918512-96-6P	918512-97-7P	918512-98-8P	918512-99-9P	918513-00-5P
918513-01-6P	918513-02-7P	918513-03-8P	918513-04-9P	918513-05-0P
918513-06-1P	918513-07-2P	918513-08-3P	918513-09-4P	918513-10-7P
918513-11-8P	918513-12-9P	918513-13-0P	918513-14-1P	918513-15-2P
918513-16-3P	918513-17-4P	918513-18-5P	918513-19-6P	918513-20-9P
918513-21-0P	918513-22-1P	918513-23-2P	918513-24-3P	918513-25-4P
918513-26-5P	918513-27-6P	918513-28-7P	918513-29-8P	918513-30-1P
918513-31-2P	918513-32-3P	918513-33-4P	918513-34-5P	918513-35-6P
918513-36-7P	918513-37-8P	918513-38-9P	918513-39-0P	918513-40-3P
918513-41-4P	918513-42-5P	918513-43-6P	918513-44-7P	918513-45-8P
918513-46-9P	918513-47-0P	918513-48-1P	918513-49-2P	918513-50-5P
918513-51-6P	918513-52-7P	918513-53-8P	918513-54-9P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918513-55-0P	918513-56-1P	918513-57-2P	918513-58-3P	918513-59-4P
	918513-60-7P	918513-61-8P	918513-62-9P	918513-63-0P	918513-64-1P
	918513-65-2P	918513-66-3P	918513-67-4P	918513-68-5P	918513-69-6P
	918513-70-9P	918513-71-0P	918513-72-1P	918513-73-2P	918513-74-3P
	918513-75-4P	918513-76-5P	918513-77-6P	918513-78-7P	918513-79-8P
	918513-80-1P	918513-81-2P	918513-82-3P	918513-83-4P	918513-84-5P
	918513-85-6P	918513-86-7P	918513-87-8P	918513-88-9P	918513-89-0P
	918513-90-3P	918513-91-4P	918513-92-5P	918513-93-6P	918513-94-7P
	918513-95-8P	918513-96-9P	918513-97-0P	918513-98-1P	918513-99-2P
	918514-00-8P	918514-01-9P	918514-02-0P	918514-03-1P	918514-04-2P
	918514-05-3P	918514-06-4P	918514-07-5P	918514-08-6P	918514-09-7P
	918514-10-0P	918514-11-1P	918514-12-2P	918514-13-3P	918514-14-4P
	918514-15-5P	918514-16-6P	918514-17-7P	918514-18-8P	918514-19-9P
	918514-20-2P	918514-21-3P	918514-22-4P	918514-23-5P	918514-24-6P
	918514-25-7P	918514-26-8P	918514-27-9P	918514-28-0P	918514-29-1P
	918514-30-4P	918514-31-5P	918514-32-6P	918514-33-7P	918514-34-8P
	918514-35-9P	918514-36-0P	918514-37-1P	918514-38-2P	918514-39-3P
	918514-40-6P	918514-41-7P	918514-42-8P	918514-43-9P	918514-44-0P
	918514-45-1P	918514-46-2P	918514-47-3P	918514-48-4P	918514-49-5P
	918514-50-8P	918514-51-9P	918514-52-0P	918514-53-1P	918514-54-2P
	918514-55-3P	918514-56-4P	918514-57-5P	918514-58-6P	918514-59-7P
	918514-60-0P	918514-61-1P	918514-62-2P	918514-63-3P	918514-64-4P
	918514-65-5P	918514-66-6P	918514-67-7P	918514-68-8P	918514-69-9P
	918514-70-2P	918514-71-3P	918514-72-4P	918514-73-5P	918514-74-6P
	918514-75-7P	918514-76-8P	918514-77-9P	918514-78-0P	918514-79-1P
	918514-80-4P	918514-81-5P	918514-82-6P	918514-83-7P	918514-84-8P
	918514-85-9P	918514-86-0P	918514-87-1P	918514-88-2P	918514-89-3P
	918514-90-6P	918514-91-7P	918514-92-8P	918514-93-9P	918514-94-0P
	918514-95-1P	918514-96-2P	918514-98-4P	918514-99-5P	918515-00-1P
	918515-01-2P	918515-02-3P	918515-03-4P	918515-04-5P	918515-05-6P
	918515-06-7P	918515-07-8P	918515-08-9P	918515-09-0P	918515-10-3P
	918515-11-4P	918515-12-5P	918515-13-6P	918515-14-7P	918515-15-8P
	918515-16-9P	918515-17-0P	918515-18-1P	918515-19-2P	918515-20-5P
	918515-21-6P	918515-22-7P	918515-23-8P	918515-24-9P	918515-25-0P
	918515-26-1P	918515-27-2P	918515-28-3P	918515-29-4P	918515-30-7P
	918515-31-8P	918515-32-9P	918515-33-0P	918515-34-1P	918515-35-2P
	918515-36-3P	918515-37-4P	918515-38-5P	918515-39-6P	918515-40-9P
	918515-41-0P	918515-42-1P	918515-43-2P	918515-44-3P	918515-45-4P

918515-46-5P	918515-47-6P	918515-48-7P	918515-49-8P	918515-50-1P
918515-51-2P	918515-52-3P	918515-53-4P	918515-54-5P	918515-55-6P
918515-56-7P	918515-57-8P	918515-58-9P	918515-59-0P	918515-60-3P
918515-61-4P	918515-62-5P	918515-63-6P	918515-64-7P	918515-65-8P
918515-66-9P	918515-67-0P	918515-68-1P	918515-69-2P	918515-70-5P
918515-71-6P	918515-72-7P	918515-73-8P	918515-74-9P	918515-75-0P
918515-76-1P	918515-77-2P	918515-78-3P	918515-79-4P	918515-80-7P
918515-81-8P	918515-82-9P	918515-83-0P	918515-84-1P	918515-85-2P
918515-86-3P	918515-87-4P	918515-88-5P	918515-89-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918515-90-9P	918515-91-0P	918515-92-1P	918515-93-2P	918515-94-3P
	918515-95-4P	918515-96-5P	918515-97-6P	918515-98-7P	918515-99-8P
	918516-00-4P	918516-01-5P	918516-02-6P	918516-03-7P	918516-04-8P
	918516-05-9P	918516-06-0P	918516-07-1P	918516-08-2P	918516-09-3P
	918516-10-6P	918516-11-7P	918516-13-9P	918516-14-0P	918516-15-1P
	918516-16-2P	918516-17-3P	918516-18-4P	918516-19-5P	918516-20-8P
	918516-21-9P	918516-22-0P	918516-23-1P	918516-24-2P	918516-25-3P
	918516-26-4P	918516-28-6P	918516-29-7P	918516-30-0P	918516-31-1P
	918516-32-2P	918516-33-3P	918516-34-4P	918516-35-5P	918516-36-6P
	918516-37-7P	918516-38-8P	918516-39-9P	918516-40-2P	918516-41-3P
	918516-42-4P	918516-43-5P	918516-44-6P	918516-45-7P	918516-46-8P
	918516-47-9P	918516-48-0P	918516-49-1P	918516-50-4P	918516-51-5P
	918516-52-6P	918516-53-7P	918516-54-8P	918516-55-9P	918516-56-0P
	918516-57-1P	918516-58-2P	918516-59-3P	918516-60-6P	918516-61-7P
	918516-62-8P	918516-63-9P	918516-64-0P	918516-65-1P	918516-66-2P
	918516-67-3P	918516-68-4P	918516-69-5P	918516-70-8P	918516-71-9P
	918516-72-0P	918516-73-1P	918516-74-2P	918516-75-3P	918516-76-4P
	918516-77-5P	918516-78-6P	918516-79-7P	918516-80-0P	918516-81-1P
	918516-82-2P	918516-83-3P	918516-84-4P	918516-85-5P	918516-86-6P
	918516-87-7P	918516-88-8P	918516-89-9P	918516-90-2P	918516-91-3P
	918516-92-4P	918516-93-5P	918516-94-6P	918516-95-7P	918516-96-8P
	918516-97-9P	918516-98-0P	918516-99-1P	918517-00-7P	918517-01-8P
	918517-02-9P	918517-06-3P	918517-08-5P	918517-10-9P	918517-12-1P
	918517-14-3P	918517-16-5P	918517-18-7P	918517-20-1P	918517-22-3P
	918517-24-5P	918517-26-7P	918517-28-9P	918517-29-0P	918517-31-4P
	918517-33-6P	918517-35-8P	918517-37-0P	918517-39-2P	918517-41-6P
	918517-43-8P	918517-45-0P	918517-47-2P	918517-49-4P	918517-51-8P
	918517-53-0P	918517-55-2P	918517-57-4P	918517-59-6P	918517-61-0P
	918517-63-2P	918517-65-4P	918517-67-6P	918517-71-2P	918517-73-4P
	918517-75-6P	918517-77-8P	918517-79-0P	918517-82-5P	918517-84-7P
	918517-86-9P	918517-88-1P	918517-90-5P	918517-92-7P	918517-94-9P
	918517-96-1P	918517-98-3P	918518-00-0P	918518-02-2P	918518-04-4P
	918518-07-7P	918518-09-9P	918518-14-6P	918518-16-8P	918518-19-1P
	918518-21-5P	918518-23-7P	918518-25-9P	918518-27-1P	918518-30-6P
	918518-32-8P	918518-34-0P	918518-39-5P	918518-42-0P	918518-45-3P
	918518-48-6P	918518-50-0P	918518-53-3P	918518-55-5P	918518-57-7P
	918518-59-9P	918518-61-3P	918518-63-5P	918518-65-7P	918518-67-9P
	918518-69-1P	918518-71-5P	918518-73-7P	918518-75-9P	918518-77-1P
	918518-78-2P	918518-80-6P	918518-82-8P	918518-84-0P	918518-85-1P
	918518-86-2P	918518-87-3P	918518-88-4P	918518-90-8P	918518-92-0P
	918518-93-1P	918518-96-4P	918518-98-6P	918519-01-4P	918519-04-7P
	918519-05-8P	918519-06-9P	918519-26-3P	918519-32-1P	918519-33-2P
	918519-35-4P	918519-40-1P	918519-42-3P	918519-44-5P	918519-46-7P
	918519-47-8P	918519-48-9P	918519-50-3P	918519-51-4P	918519-52-5P
	918519-53-6P	918519-54-7P	918519-55-8P	918519-56-9P	918519-57-0P
	918519-58-1P	918519-59-2P	918519-60-5P	918519-61-6P	918519-62-7P
	918519-63-8P	918519-64-9P	918519-65-0P	918519-66-1P	



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase  
inhibitors useful in treatment of diseases)

IT	918519-67-2P	918519-68-3P	918519-70-7P	918519-71-8P	918519-72-9P
	918519-73-0P	918519-74-1P	918519-75-2P	918519-76-3P	918519-77-4P
	918519-79-6P	918519-80-9P	918519-81-0P	918519-82-1P	918519-83-2P
	918519-84-3P	918519-85-4P	918519-86-5P	918519-87-6P	918519-88-7P
	918519-89-8P	918519-90-1P	918519-91-2P	918519-92-3P	918519-93-4P
	918519-94-5P	918519-95-6P	918519-96-7P	918519-97-8P	918519-98-9P
	918519-99-0P	918520-00-0P	918520-01-1P	918520-02-2P	918520-03-3P
	918520-04-4P	918520-05-5P	918520-06-6P	918520-07-7P	918520-08-8P
	918520-09-9P	918520-10-2P	918520-11-3P	918520-12-4P	918520-13-5P
	918520-14-6P	918520-15-7P	918520-16-8P	918520-17-9P	918520-18-0P
	918520-19-1P	918520-20-4P	918520-21-5P	918520-22-6P	918520-23-7P
	918520-24-8P	918520-25-9P	918520-26-0P	918520-27-1P	918520-28-2P
	918520-29-3P	918520-30-6P	918520-31-7P	918520-32-8P	918520-33-9P
	918520-34-0P	918520-35-1P	918520-36-2P	918520-37-3P	918520-38-4P
	918520-39-5P	918520-40-8P	918520-41-9P	918520-42-0P	918520-43-1P
	918520-44-2P	918520-45-3P	918520-46-4P	918520-47-5P	918520-48-6P
	918520-49-7P	918520-50-0P	918520-51-1P	918520-52-2P	918520-53-3P
	918520-54-4P	918520-55-5P	918520-56-6P	918520-57-7P	918520-58-8P
	918520-59-9P	918520-60-2P	918520-61-3P	918520-62-4P	918520-63-5P
	918520-64-6P	918520-65-7P	918520-66-8P	918520-67-9P	918520-68-0P
	918520-69-1P	918520-70-4P	918520-71-5P	918520-72-6P	918520-73-7P
	918520-74-8P	918520-75-9P	918520-76-0P	918520-77-1P	918520-78-2P
	918520-79-3P	918520-80-6P	918520-81-7P	918520-83-9P	918520-84-0P
	918520-85-1P	918520-86-2P	918520-87-3P	918520-88-4P	918520-89-5P
	918520-90-8P	918520-91-9P	918520-92-0P	918520-93-1P	918520-94-2P
	918520-95-3P	918520-96-4P	918520-97-5P	918520-98-6P	918520-99-7P
	918521-00-3P	918521-01-4P	918521-02-5P	918521-03-6P	918521-04-7P
	918521-05-8P	918521-06-9P	918521-07-0P	918521-08-1P	918521-09-2P
	918521-10-5P	918521-11-6P	918521-12-7P	918521-13-8P	918521-14-9P
	918521-15-0P	918521-16-1P	918521-17-2P	918521-18-3P	918521-19-4P
	918521-20-7P	918521-21-8P	918521-22-9P	918521-23-0P	918521-24-1P
	918521-25-2P	918521-26-3P	918521-27-4P	918521-28-5P	918521-29-6P
	918521-30-9P	918521-32-1P	918521-33-2P	918521-34-3P	918521-35-4P
	918521-36-5P	918521-37-6P	918521-38-7P	918521-39-8P	918521-40-1P
	918521-41-2P	918521-42-3P	918521-43-4P	918521-44-5P	918521-45-6P
	918521-46-7P	918521-47-8P	918521-48-9P	918521-49-0P	918521-50-3P
	918521-51-4P	918521-52-5P	918521-53-6P	918521-54-7P	918521-55-8P
	918521-56-9P	918521-57-0P	918521-58-1P	918521-59-2P	918521-60-5P
	918521-61-6P	918521-62-7P	918521-63-8P	918521-64-9P	918521-65-0P
	918521-66-1P	918521-67-2P	918521-68-3P	918521-69-4P	918521-70-7P
	918521-71-8P	918521-72-9P	918521-73-0P	918521-74-1P	918521-75-2P
	918521-76-3P	918521-77-4P	918521-78-5P	918521-79-6P	918521-80-9P
	918521-81-0P	918521-82-1P	918521-83-2P	918521-84-3P	918521-85-4P
	918521-86-5P	918521-87-6P	918521-88-7P	918521-89-8P	918521-90-1P
	918521-91-2P	918521-92-3P	918521-93-4P	918521-94-5P	918521-95-6P
	918521-96-7P	918521-97-8P	918521-98-9P	918521-99-0P	918522-00-6P
	918522-01-7P	918522-02-8P	918522-03-9P	918522-04-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase  
inhibitors useful in treatment of diseases)

IT	918522-05-1P	918522-06-2P	918522-07-3P	918522-08-4P	918522-09-5P
	918522-10-8P	918522-11-9P	918522-12-0P	918522-13-1P	918522-14-2P
	918522-15-3P	918522-16-4P	918522-17-5P	918522-18-6P	918522-19-7P
	918522-20-0P	918522-21-1P	918522-22-2P	918522-23-3P	918522-24-4P

918522-26-6P	918522-27-7P	918522-28-8P	918522-29-9P	918522-30-2P
918522-31-3P	918522-32-4P	918522-33-5P	918522-34-6P	918522-35-7P
918522-36-8P	918522-37-9P	918522-38-0P	918522-39-1P	918522-40-4P
918522-41-5P	918522-43-7P	918522-45-9P	918522-46-0P	918522-48-2P
918522-49-3P	918522-51-7P	918522-53-9P	918522-55-1P	918522-56-2P
918522-57-3P	918522-59-5P	918522-61-9P	918522-63-1P	918522-65-3P
918522-67-5P	918522-69-7P	918522-71-1P	918522-73-3P	918522-75-5P
918522-77-7P	918522-79-9P	918522-81-3P	918522-83-5P	918522-85-7P
918522-87-9P	918522-89-1P	918522-91-5P	918522-93-7P	918522-95-9P
918522-97-1P	918522-99-3P	918523-01-0P	918523-02-1P	918523-03-2P
918523-05-4P	918523-06-5P	918523-07-6P	918523-08-7P	918523-09-8P
918523-10-1P	918523-11-2P	918523-12-3P	918523-13-4P	918523-14-5P
918523-15-6P	918523-16-7P	918523-17-8P	918523-18-9P	918523-19-0P
918523-20-3P	918523-21-4P	918523-22-5P	918523-23-6P	918523-24-7P
918523-25-8P	918523-26-9P	918523-27-0P	918523-28-1P	918523-29-2P
918523-30-5P	918523-31-6P	918523-32-7P	918523-33-8P	918523-34-9P
918523-35-0P	918523-36-1P	918523-37-2P	918523-38-3P	918523-39-4P
918523-40-7P	918523-41-8P	918523-42-9P	918523-43-0P	918523-50-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 824-52-2P 5654-92-2P 39255-23-7P 56741-33-4P 70205-04-8P

76588-84-6P	79418-72-7P	79418-77-2P	112434-18-1P	132303-32-3P
143468-13-7P	152434-86-1P	152434-87-2P	152434-88-3P	183208-36-8P
209866-50-9P	269072-20-0P	43124-79-6P	486424-36-6P	849409-81-0P
849409-82-1P	858116-59-3P	858116-66-2P	858116-86-6P	858117-08-5P
901238-24-2P	902458-30-4P	913983-25-2P	918523-44-1P	918523-45-2P
918523-46-3P	918523-47-4P	918523-48-5P	918523-49-6P	918523-51-0P
918523-52-1P	918523-53-2P	918523-54-3P	918523-55-4P	918523-56-5P
918523-57-6P	918523-58-7P	918523-59-8P	918523-60-1P	918523-61-2P
918523-62-3P	918523-63-4P	918523-64-5P	918523-65-6P	918523-66-7P
918523-67-8P	918523-68-9P	918523-69-0P	918523-70-3P	918523-71-4P
918523-72-5P	918523-73-6P	918523-74-7P	918523-75-8P	918523-76-9P
918523-77-0P	918523-78-1P	918523-79-2P	918523-80-5P	918523-81-6P
918523-82-7P	918523-83-8P	918523-84-9P	918523-85-0P	918523-86-1P
918523-87-2P	918523-88-3P	918523-89-4P	918523-90-7P	918523-91-8P
918523-92-9P	918523-93-0P	918523-94-1P	918523-95-2P	918523-96-3P
918523-97-4P	918523-98-5P	918523-99-6P	918524-00-2P	918524-01-3P
918524-02-4P	918524-03-5P	918524-04-6P	918524-05-7P	918524-06-8P
918524-07-9P	918524-08-0P	918524-09-1P	918524-10-4P	918524-11-5P
918524-12-6P	918524-13-7P	918524-14-8P	918524-15-9P	918524-16-0P
918524-17-1P	918524-18-2P	918524-19-3P	918524-20-6P	918524-21-7P
918524-22-8P	918524-23-9P	918524-24-0P	918524-25-1P	918524-26-2P
918524-27-3P	918524-28-4P	918524-29-5P	918524-30-8P	918524-31-9P
918524-32-0P	918524-33-1P	918524-34-2P	918524-35-3P	918524-36-4P
918524-37-5P	918524-38-6P	918524-39-7P	918524-40-0P	918524-41-1P
918524-42-2P	918524-43-3P	918524-44-4P	918524-45-5P	918524-46-6P
918524-47-7P	918524-48-8P	918524-49-9P	918524-50-2P	918524-51-3P
918524-52-4P	918524-53-5P	918524-54-6P	918524-55-7P	918524-56-8P
918524-57-9P	918524-58-0P	918524-59-1P	918524-60-4P	918524-61-5P
918524-62-6P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolopyridine derivs. as protein kinase

- inhibitors useful in treatment of diseases)
- IT 7782-44-7, Oxygen, biological studies  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
- IT 79079-06-4, EGFR kinase 98037-52-6, Abl protein kinase 103843-29-4, IGF1R kinase 108891-60-7 11694-09-8 114051-78-4, LCK kinase 136396-12-8 137632-03-2, Met kinase 137632-06-5, Csk kinase 137632-08-7, Erk2 kinase 137632-09-8, Erbb2 kinase 138399-29-2, c-KIT kinase 138674-26-7, Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes protein kinase 141350-03-0, Ftl1 kinase 141436-78-4, Protein kinase C $\beta$  144114-16-9, Fak kinase 144376-45-4, Pim1 kinase 144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK kinase 146279-92-7, Ret kinase 146838-30-4, MAPKAPK2 147014-96-8, CDK5 kinase 147014-97-9, CDK4 kinase 147230-71-5, Flt3 kinase 148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7 150316-14-6, Mitogen-activated protein kinase kinase 2 150977-45-0, Erkr kinase 151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38 Kinase 165245-99-8, Polo like kinase 1 166433-56-3, Anaplastic lymphoma kinase 170780-46-8, Pyk2 kinase 176023-60-2, Akt2 kinase 182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1 182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase 191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4, Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase 289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3 kinase 303014-92-8, CDK6 kinase 362517-43-9, IKK- $\beta$  kinase 370088-29-2, Mitogen-activated protein kinase kinase kinase 4 372092-80-3 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase 443900-95-6, Glycogen synthase kinase 3 $\beta$  458560-40-2, Protein kinase Stk6 553648-93-4, Glycogen synthase kinase 3 $\alpha$
- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
- IT 9004-10-8, Insulin, biological studies  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (resistance; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
- IT 62-53-3, Aniline, reactions 83-38-5, 2,6-Dichlorobenzaldehyde 89-97-4, 2-Chlorobenzylamine 90-04-0, 2-Methoxyaniline 94-99-5, 2,4-Dichlorobenzyl chloride 95-51-2, 2-Chloroaniline 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl chloride 98-16-8, 3-Trifluoromethylaniline 98-18-0, 3-Aminobenzenesulfonamide 98-31-7, 3,4-Dichlorophenylsulfonyl chloride 98-59-9, 4-Methylphenylsulfonyl chloride 98-60-2, 4-Chlorophenylsulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6, Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 99-98-9, 4-Dimethylaminobenzylamine 100-07-2, 4-Methoxybenzoic acid chloride 100-37-8, 2-(Diethylamino)ethanol 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 100-61-8, N-Methylaniline, reactions 100-81-2, 3-Methylbenzylamine 103-71-9, Phenyl isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 104-94-9, 4-Methoxyaniline 106-41-2, 4-Bromophenol 106-47-8, 4-Chloroaniline, reactions 106-49-0, 4-Methylaniline, reactions 107-10-8,

1-Propanamine, reactions 108-42-9, 3-Chloroaniline 108-91-8,  
 Aminocyclohexane, reactions 109-01-3 109-73-9, 1-Butanamine, reactions  
 109-86-4, 2-Methoxyethanol 110-68-9, N-Methyl-1-butanamine 110-91-8,  
 Morpholine, reactions 111-36-4, Butyl isocyanate 121-32-4,  
 3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-methoxybenzaldehyde  
 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-  
 (Acetylamino)benzenesulfonyl chloride 123-08-0, 4-Hydroxybenzaldehyde  
 133-59-5, 2-Methylbenzenesulfonyl chloride 139-59-3, 4-Phenoxyaniline  
 140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole 303-38-8,  
 2,3-Dihydroxybenzoic acid 327-78-6, 4-Chloro-3-trifluoromethylphenyl  
 isocyanate 349-88-2, 4-Fluorophenylsulfonyl chloride 367-25-9,  
 2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol 371-40-4,  
 4-Fluoroaniline 399-95-1, 2-Fluoro-4-hydroxyaniline 404-71-7,  
 3-Fluorophenyl isocyanate 405-05-0, 3-Fluoro-4-hydroxybenzaldehyde  
 437-81-0, 2,6-Difluorobenzaldehyde 445-05-6, 5-Fluoro-2-  
 methylbenzenesulfonyl chloride 445-26-1, 1-(2-Fluorophenyl)ethanol  
 446-31-1, 4-Amino-2-fluorobenzoic acid 446-51-5, 2-Fluorobenzyl alcohol  
 454-89-7, 3-Trifluoromethylbenzaldehyde 459-59-6, N-Methyl-4-  
 fluoroaniline 461-82-5, 4-Trifluoromethoxyaniline 462-08-8,  
 3-Aminopyridine 501-30-4 501-53-1, Benzyl chloroformate 536-90-3,  
 3-Methoxyaniline 582-33-2, Ethyl 3-aminobenzoate 586-95-8,  
 4-Pyridinemethanol 586-98-1, 2-Pyridinemethanol 589-87-7,  
 1-Bromo-4-iodobenzene 603-80-5, 3-Hydroxy-2-methylbenzoic acid  
 614-68-6, 2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate  
 621-59-0, 3-Hydroxy-4-methoxybenzaldehyde 622-40-2, N-(2-  
 Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl isocyanate 622-95-7,  
 4-Chlorobenzyl bromide 623-24-5, 1,4-Bis(bromomethyl)benzene 626-43-7,  
 3,5-Dichloroaniline 626-58-4, 4-Methylpiperidine 656-42-8,  
 3,4-(Difluoromethylenedioxy)benzaldehyde 696-44-6 701-27-9,  
 3-Fluorobenzenesulfonyl chloride 701-34-8, 4-Bromobenzenesulfonamide  
 766-00-7, 2-Cyclopentylethanol 766-80-3, 3-Chlorobenzyl bromide  
 767-05-5, 3-Cyclopropylpropanol 768-35-4, 3-Fluorophenylboronic acid  
 777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride 824-94-2,  
 4-Methoxybenzyl chloride 932-96-7, N-Methyl-4-chloroaniline 1003-03-8,  
 Aminocyclopentane 1072-67-9, 3-Amino-5-methylisoxazole 1074-86-8,  
 4-Indolecarboxaldehyde 1122-71-0, 6-Methylpyridine-2-methanol  
 1123-56-4, 2,6-Dimethylbenzaldehyde 1138-56-3, 4-Butoxyphenylsulfonyl  
 chloride 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3,  
 3-Trifluoromethylphenylboronic acid 1483-28-9, 2,5-  
 Dimethoxybenzenesulfonyl chloride 1535-73-5, 3-Trifluoromethoxyaniline  
 1548-13-6, 4-Trifluoromethylphenyl isocyanate 1679-18-1,  
 4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic acid  
 1692-25-7, Pyridin-3-ylboronic acid 1765-93-1, 4-Fluorophenylboronic  
 acid 1777-82-8, 2,4-Dichlorobenzyl alcohol 1899-93-0,  
 3-Methylbenzenesulfonyl chloride 1978-37-6, N-Methyl-3-fluoroaniline  
 1996-41-4, 2-Chloro-4-fluorophenol 2038-03-1, N-(2-Aminoethyl)morpholine  
 2124-55-2, 4-Indolecarboxylic acid 2359-60-6, 4-(Piperidin-1-yl)aniline  
 2386-60-9, 1-Butanesulfonyl chloride 2393-23-9, 4-Methoxybenzylamine  
 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 2426-87-1,  
 4-Benzoyloxy-3-methoxybenzaldehyde 2516-47-4, Cyclopropylmethylamine  
 2524-67-6, 4-(Morpholin-4-yl)aniline 2688-84-8, 2-Phenoxyaniline  
 2713-31-7, 2,5-Difluorophenol 2740-83-2, 3-Trifluoromethylbenzylamine  
 2836-04-6, 3-Dimethylaminoaniline 2905-21-7, 2-Fluorobenzenesulfonyl  
 chloride 2909-38-8, 3-Chlorophenyl isocyanate 2987-49-7,  
 2-Methylsulfonylaniline 2991-42-6, 4-Trifluoromethylphenylsulfonyl  
 chloride 3048-01-9, 2-Trifluoromethylbenzylamine 3173-56-6, Benzyl  
 isocyanate 3218-02-8, Cyclohexanemethanamine 3300-51-4,  
 4-Trifluoromethylbenzylamine 3355-28-0, 1-Bromo-2-butene 3445-11-2,  
 N-(2-Hydroxyethyl)pyrrolidin-2-one 3586-12-7, 3-Phenoxyaniline  
 3587-60-8, Benzoyloxymethyl chloride 3731-51-9, Pyridine-2-methylamine  
 3731-52-0, 3-Pyridinemethanamine 3954-13-0, Pentyl isocyanate

4152-90-3, 3-Chlorobenzylamine 4393-16-2, 4-Methylsulfonylbenzylamine  
 4441-30-9, N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine  
 5071-96-5, 3-Methoxybenzylamine 5180-79-0 5345-54-0,  
 3-Chloro-4-methoxyaniline 5369-19-7, 3-tert-Butylaniline 5416-93-3,  
 4-Methoxyphenyl isocyanate 5470-49-5, 4-Methylsulfonylaniline  
 5585-33-1, 2-Morpholinoaniline 5720-07-0, 4-Methoxyphenylboronic acid  
 5779-95-3, 3,5-Dimethylbenzaldehyde 5961-59-1, N-Methyl-4-methoxyaniline  
 6165-68-0, Thiophene-2-boronic acid 6482-24-2, 1-Bromo-2-methoxyethane  
 7006-52-2, N-Methyl-3-chloroaniline 7304-32-7, 2-Fluoro-5-nitrobenzoic  
 acid 10130-74-2, 3-Methoxyphenylsulfonyl chloride 10147-36-1,  
 1-Propanesulfonyl chloride 10147-37-2, 2-Propanesulfonyl chloride  
 10203-08-4, 3,5-Dichlorobenzaldehyde 10272-07-8, 3,5-Dimethoxyaniline  
 10365-98-7, 3-Methoxyphenylboronic acid 10541-83-0, 4-Methylaminobenzoic  
 acid 13358-73-1, Dibutyl carbamoyl chloride 13360-63-9,  
 N-Ethyl-1-butanamine 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride  
 13952-84-6, 2-Butanamine 14318-66-2, N-Methyl-3-methoxyaniline  
 15268-31-2, 3-Isocyanatopyridine 15854-87-2, 4-Iodopyridine  
 16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9,  
 2-Thiophenesulfonyl chloride 16712-69-9, 4-Ethylphenylsulfonyl chloride  
 17334-08-6, 1-Methylimidazole-2-methanol 18278-34-7,  
 4-Hydroxy-2-methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate  
 20012-63-9, 2-Benzyloxyaniline 20443-98-5, 2,6-Dichlorobenzyl bromide  
 20984-81-0, 3-(Diethylamino)pyrrolidine 21626-70-0 22184-97-0  
 23095-31-0, 3,4-Dimethoxyphenylsulfonyl chloride 23616-57-1  
 26153-38-8, 3,5-Dihydroxybenzaldehyde 27086-19-7, Dipropylcarbamoyl  
 chloride 28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4,  
 4-Dimethylaminophenylboronic acid 29668-44-8, 3,4-  
 Ethylenedioxybenzaldehyde 30418-59-8, 3-Aminophenylboronic acid  
 35216-39-8, 3-Methylsulfonylaniline 35856-62-3, 1-Piperidinesulfonyl  
 chloride 37045-73-1 37527-66-5, 3,4-Dimethoxyphenyl isocyanate  
 38041-19-9, 4-Amino-tetrahydropyran 38070-73-4 39893-50-0,  
 3-Chloro-4-trifluoromethylphenyl isocyanate 39989-43-0,  
 3,5-Dichlorobenzylamine 40750-59-2, N-Methyl-3,4-dichloroaniline  
 41419-59-4, N-Methyl-4-trifluoromethoxyaniline 41483-74-3 41838-46-4,  
 4-Amino-1-methylpiperidine 42170-95-6, 2-Methoxyethyl isocyanate  
 42601-04-7, 3,4-Difluorophenyl isocyanate 49584-26-1,  
 4-Cyanophenylsulfonyl chloride 50382-32-6, 2,4-Dimethylthiazole-5-  
 methanol 50528-86-4, 2-Chloro-5-trifluoromethylphenyl isocyanate  
 51175-71-4, 3-Thiophenesulfonyl chloride 51488-22-3,  
 2-Chloro-4-trifluoromethylphenyl isocyanate 52130-17-3,  
 3-Amino-2-methylbenzoic acid 52771-21-8, 3-Trifluoromethoxybenzaldehyde  
 53104-95-3, 4-Hydroxy-3-trifluoromethoxybenzaldehyde 54751-01-8,  
 4-Bromomethylpyridine 54997-90-9, 4-Isopropylbenzenesulfonyl chloride  
 56456-47-4, 2,4-Difluorobenzylalcohol 56456-49-6, 4-Chloro-2-  
 fluorobenzyl alcohol 56542-67-7, 3-Cyanobenzenesulfonyl chloride  
 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 57012-20-1 57678-46-3,  
 3-Dimethylaminobenzylamine 57946-56-2, 4-Chloro-2-fluoroaniline  
 61424-26-8, 3-Benzylaniline 61672-75-1, Isoxazol-3-yl isocyanate  
 63503-60-6, 3-Chlorophenylboronic acid 63624-28-2 63758-12-3  
 69360-26-5, 2-Cyanobenzenesulfonyl chloride 69816-05-3 70067-45-7  
 71189-18-9 71916-82-0, 4-Chloro-2-fluorobenzyl bromide 71924-62-4  
 72975-46-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase  
 inhibitors useful in treatment of diseases)

II 78887-39-5, 3-(Acetylmino)phenylboronic acid 79418-78-3,  
 3-Fluoro-4-hydroxy-5-methoxybenzaldehyde 80466-80-4 85345-76-2,  
 3-Chloro-2-fluorobenzoyl chloride 85684-61-3, 3-  
 Difluoromethoxybenzaldehyde 86718-08-3 89599-01-9,  
 3-Bromobenzenesulfonamide 90001-64-2, Benzothiophene-2-sulfonyl chloride  
 90260-13-2, 3-Fluoro-4-methylbenzenesulfonyl chloride 93071-75-1,

3-Trifluoromethoxybenzylamine 93919-56-3, 4-Trifluoromethoxybenzylamine 97272-04-3, 2,5-Dimethylthiophene-3-sulfonyl chloride 98437-24-2, 2-Benzofuranboronic acid 103438-86-4 103438-88-6, 2-Fluoro-3-methoxybenzaldehyde 104451-70-9, 2,3,6-Trifluorobenzaldehyde 108679-71-6, 3-Amino-2-chlorobenzoic acid 109299-78-7, Pyrimidine-5-boronic acid 119895-68-0 123088-59-5, 4-(Aminocarbonyl)phenylboronic acid 126747-14-6, 4-Cyanophenylboronic acid 128796-39-4, 4-Trifluoromethylphenylboronic acid 137049-02-6 137654-20-7, 2-Fluoro-3-methoxybenzoic acid 138564-16-6, N-Methyl-2,4-difluoroaniline 148355-75-3, 3-(Methylsulfonylamino)phenylboronic acid 151411-98-2, 2,4,6-Trifluorobenzyl bromide 151858-64-9, 5-(2-Pyridinyl)thiophene-2-sulfonyl chloride 153912-60-8, 1,5-Dimethyl-1H-pyrazole-3-methanol 156545-07-2, 3,5-Difluorophenylboronic acid 163105-89-3, 2-Methoxypyridin-5-ylboronic acid 166964-26-7, 2,5-Dimethylfuran-3-sulfonyl chloride 167678-46-8, Acetic acid 3-chlorocarbonyl-2-methylphenyl ester 168899-43-2 175205-64-8, 2-Trifluoromethoxybenzylamine 179113-90-7, 3-Trifluoromethoxyphenylboronic acid 180200-86-6 181124-40-3, 6-Benzothiazolesulfonyl chloride 188815-30-7, 3-Fluoro-5-trifluoromethylbenzaldehyde 190774-52-8, 2-Fluoro-3-trifluoromethylphenyl isocyanate 197239-49-9, 2-Fluoro-4-trifluoromethylbenzyl alcohol 208186-84-9, 2-Chloro-4-fluorobenzyl alcohol 210532-25-5, 3,5-Difluorobenzenesulfonyl chloride 216144-91-1 252928-74-8 306936-35-6 321309-40-4 337508-66-4, 4-(Oxazol-5-yl)benzenesulfonyl chloride 351003-34-4, 4-Difluoromethoxybenzenesulfonyl chloride 351422-73-6, 3-(Aminocarbonyl)phenylboronic acid 364794-80-9 373384-18-0, 3-(Methylsulfonyl)phenylboronic acid 380430-52-4 386704-04-7 388088-73-1 389621-84-5 405520-68-5 423151-49-9 445264-61-9 485799-04-0 532967-21-8, 2,6-Difluoro-4-hydroxybenzaldehyde 451930-53-1 628692-15-9 690632-68-9 701269-22-9 754214-56-7 761446-44-0 785785-59-3 852180-61-1 852227-95-3 858116-95-7 909501-40-2 911210-53-2, 4-Cyano-3,5-dimethylphenylboronic acid 918524-63-7 918524-64-8 918524-65-9 918524-66-0 918524-67-1 918524-68-2 918524-69-3 918524-70-6 918524-71-7 918524-72-8 918524-73-9 918524-74-0 918524-75-1 918524-76-2 918524-77-3 918524-78-4 918524-80-8 918524-83-1 918524-85-3 918524-86-4 918524-87-5 918524-88-6 918524-89-7 918524-90-0 918524-91-1 918524-92-2 918524-93-3 918524-94-4 918524-95-5 918524-96-6 918524-97-7 918524-98-8 918524-99-9 918525-00-5 918525-01-6 918525-02-7 918525-03-8 918525-04-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918724-49-9 918724-53-5 918724-54-6 918724-55-7 918724-56-8  
918724-57-9 918724-58-0 918724-59-1 918724-61-5 918724-62-6  
918724-63-7

RL: PRP (Properties)

(unclaimed nucleotide sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

IT 918724-60-4 918724-64-8

RL: PRP (Properties)

(unclaimed protein sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

IT 918724-35-3 918724-36-4 918724-37-5 918724-38-6 918724-39-7  
918724-40-0 918724-41-1 918724-42-2 918724-43-3 918724-44-4  
918724-45-5 918724-46-6 918724-47-7 918724-48-8 918724-50-2  
918724-51-3 918724-52-4 918724-65-9 918724-66-0 918724-67-1  
918724-68-2 918724-69-3 918724-70-6 918724-71-7 918724-72-8

918724-73-9	918724-74-0	918724-75-1	918724-76-2	918724-77-3
918724-78-4	918724-79-5	918724-80-8	918724-81-9	918724-82-0
918724-83-1	918724-84-2	918724-85-3	918724-86-4	918724-87-5
918724-88-6	918724-89-7	918724-90-0	918724-91-1	918724-92-2
918724-93-3	918724-94-4	918724-95-5	918724-96-6	918724-97-7
918724-98-8	918724-99-9	918725-00-5	918725-01-6	918725-02-7
918725-03-8	918725-04-9	918725-05-0	918725-06-1	918725-07-2
918725-08-3	918725-09-4	918725-10-7	918725-11-8	918725-12-9
918725-13-0	918725-14-1	918725-15-2	918725-16-3	918725-17-4
918725-18-5	918725-19-6	918725-20-9	918725-21-0	918725-22-1
918725-23-2	918725-24-3	918725-25-4	918725-26-5	918725-27-6
918725-28-7	918725-29-8	918725-30-1	918725-31-2	918725-32-3
918725-33-4	918725-34-5	918725-35-6	918725-36-7	918725-37-8
918725-38-9	918725-39-0	918725-40-3	918725-41-4	918725-42-5
918725-43-6	918725-44-7	918725-45-8	918725-46-9	918725-47-0
918725-48-1	918725-49-2	918725-50-5	918725-51-6	918725-52-7
918725-53-8	918725-54-9	918725-55-0	918725-56-1	918725-57-2
918725-58-3				

RL: PRP (Properties)

(unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aadal, N; WO 2004016610 A 2004 CAPLUS
- (2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS
- (3) Bayer Ag; DE 2413258 A1 1975 CAPLUS
- (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS
- (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS
- (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS
- (7) Normington, J; US 2234705 A 1941 CAPLUS
- (8) Pierce; J AM CHEM SOC 1942, V64, P1691

L32 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 98-59-9, 4-Methylbenzenesulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

RN 98-59-9 CAPLUS

CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 2007:11300 CAPLUS

DOCUMENT NUMBER: 146:142627

TITLE: Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao;

PATENT ASSIGNEE(S): Shi, Shenghua  
 SOURCE: Plexxikon, Inc., USA  
 PCT Int. Appl., 291 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002325	A1	20070104	WO 2006-US24361	20060621
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
KR 2008030619	A	20080404	KR 2008-701659	20080121
PRIORITY APPLN. INFO.:			US 2005-692960P	P 20050622
			US 2005-731528P	P 20051028
			WO 2006-US24361	W 20060621

OTHER SOURCE(S): MARPAT 146:142627

AN 2007:11300 CAPLUS

DN 146:142627

ED Entered STN: 04 Jan 2007

TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Ibrahim, Prabhba N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao; Shi, Shenghua

PA Plexxikon, Inc., USA

SO PCT Int. Appl., 291 pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002325	A1	20070104	WO 2006-US24361	20060621
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			





	KG, KZ, MD, RU, TJ, TM		
KR	2008030619	A	20080404
PRAI	US 2005-692960P	P	20050622
	US 2005-731528P	P	20051028
	WO 2006-US24361	W	20060621

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007002325	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; A61P0035-00 [I,A]
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]
KR 2008030619	IPCI	

OS MARPAT 146:142627  
GI



AB Compds. of formula I which are active on protein kinases are described, as well as methods of using such compds. to treat diseases and conditions associated with aberrant activity of protein kinases. Compds. of formula I wherein Q is (un)substituted (hetero)aryl, and (un)substituted indole; A is O, S, (un)substituted methylene, NH and derivs., CO, CS, SO and SO2; R4 - R6 are independently H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts, prodrugs, tautomer, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrolysis to give the corresponding benzoic acid, which underwent chlorination and coupling with 5-bromo-7-azaindole to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. Several of the invention compds. exhibited good inhibitory activity against various protein kinases.

ST pyrrolopyridine prepn protein kinase inhibitor

IT Diabetes mellitus

(-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus  
 (-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
 (CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease  
 (Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease  
 Teratogenesis  
 (Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (EphA1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, disease  
 (Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease  
 (Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Gene, animal  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases)

IT Granulomatous disease  
(Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antibodies and Immunoglobulins  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
Respiratory distress syndrome  
(acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease  
(age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy  
Inflammation  
Nose, disease  
(allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm  
(astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Dermatitis  
(atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease  
Inflammation  
Thyroid gland, disease  
(autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection  
(bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Prostate gland, disease  
(benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hyperplasia  
(benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bronchi, disease  
Inflammation  
(bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm  
Mammary gland, neoplasm

Pancreas, neoplasm  
 (carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (cardio-faciocutaneous, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia  
 (cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia  
 (chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease  
 (chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
 (chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
 (chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm  
 (colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
 Intestine, neoplasm  
 (colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm  
 (complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders  
 (dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders  
 (dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease  
 (dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease  
 (diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease  
 (endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm  
 (endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (faciocutaneoskeletal, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Reproductive system  
(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease  
(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease  
(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm  
(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation  
(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury  
(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia  
(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm  
(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma  
(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders  
(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori

Influenza virus  
 (infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
 (inflammatory pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Head and Neck, disease  
 Reperfusion  
 Spinal cord, disease  
 (injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease  
 (insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus  
 (insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
 Kidney, disease  
 (interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, disease  
 (ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Myoma  
 Sarcoma  
 (leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
 (leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
 Kidney, disease  
 (lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Edema  
 (lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
 (mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Metabolic disorders  
 (metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, neoplasm  
 (metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Blood vessel, disease  
 (microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Headache  
 (migraine, treatment of; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT Bone formation  
(mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Oviduct  
(neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Astrocyte  
(neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Schwann cell  
(neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Kidney, disease  
(nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nerve, neoplasm  
(neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain  
(neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus  
(non-insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm  
(non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sarcoma  
(of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant rejection  
(organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(pancreatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation  
Pancreas, disease

(pancreatitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease  
(polycystic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy inhibitors

Analgesics

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-infective agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antibacterial agents

Antidiabetic agents

Antifibrotic agents

Antimigraine agents

Antiobesity agents

Antiosteoporotic agents

Antiparkinsonian agents

Antipyretics

Antirheumatic agents

Antitumor agents

Antiviral agents

Canidae

Cardiovascular agents

Combination chemotherapy

Human

Immunostimulants

Immunosuppressants

Lipolysis

Nervous system agents

Pharmaceutical carriers

Prodrugs

Respiratory system agents

Thrombolytics

Transplant and Transplantation  
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT c-Kit (protein)

neu (receptor)

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(pulmonary non-small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(pulmonary small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

Fibrosis  
(pulmonary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, neoplasm  
(renal cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in



treatment of diseases)

IT Carcinoma  
(renal cell, treatment of; preparation of pyrrolopyridine derivs.  
as protein kinase inhibitors useful in treatment of diseases)

IT Injury  
(reperfusion, treatment of; preparation of pyrrolopyridine derivs.  
as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, neoplasm  
(schwannoma, treatment of; preparation of pyrrolopyridine derivs.  
as protein kinase inhibitors useful in treatment of diseases)

IT T lymphocyte  
(selective defect of; preparation of pyrrolopyridine derivs. as protein  
kinase inhibitors useful in treatment of diseases)

IT Immunodeficiency  
(severe combined, treatment of; preparation of pyrrolopyridine  
derivs. as protein kinase inhibitors useful in treatment of  
diseases)

IT Lung, neoplasm  
(small-cell carcinoma, treatment of; preparation of  
pyrrolopyridine derivs. as protein kinase inhibitors useful in  
treatment of diseases)

IT Injury  
(spinal cord, treatment of; preparation of pyrrolopyridine derivs.  
as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma  
(squamous cell, treatment of; preparation of pyrrolopyridine  
derivs. as protein kinase inhibitors useful in treatment of  
diseases)

IT Digestive tract, neoplasm  
(stroma, treatment of; preparation of pyrrolopyridine derivs. as  
protein kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus  
(systemic, treatment of; preparation of pyrrolopyridine derivs. as  
protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal  
(tissue scarring, treatment of; preparation of pyrrolopyridine  
derivs. as protein kinase inhibitors useful in treatment of  
diseases)

IT Acute lymphocytic leukemia  
Acute myeloid leukemia  
Aging, animal  
Allergy  
Alopecia  
Alzheimer's disease  
Amyotrophic lateral sclerosis  
Asthma  
Atherosclerosis  
Bladder, neoplasm  
Bone, disease  
Bone, neoplasm  
Brain, neoplasm  
Cardiac hypertrophy  
Cardiovascular system, disease  
Central nervous system, neoplasm  
Chronic lymphocytic leukemia  
Chronic myeloid leukemia  
Diabetic nephropathy  
Digestive tract, neoplasm  
Emphysema  
Endocrine system, disease  
Eosinophilia

Fever and Hyperthermia  
 Fibrosis  
 Graves' disease  
 Hair, disease  
     Heart failure  
 Hepatic steatosis  
 Hepatitis  
 Hyperglycemia  
 Immunodeficiency  
 Infection  
 Inflammation  
 Inflammatory bowel disease  
 Intestine, disease  
     Ischemia  
 Kidney, disease  
 Leukemia  
 Liver, neoplasm  
 Lung, disease  
 Lung, neoplasm  
 Lymphoma  
 Mammary gland, neoplasm  
 Mastocytoma  
 Mastocytosis  
 Melanoma  
 Multiple myeloma  
 Multiple sclerosis  
 Mutation  
 Myasthenia gravis  
 Myelodysplastic syndromes  
 Neoplasm  
 Neurofibromatosis 1  
 Neuroglia, neoplasm  
 Non-Hodgkin lymphoma  
 Obesity  
 Osteoarthritis  
 Osteoporosis  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Parkinson's disease  
 Prostate gland, disease  
 Prostate gland, neoplasm  
 Psoriasis  
 Rheumatoid arthritis  
 Sarcoma  
 Scleroderma  
 Sepsis  
 Sjogren syndrome  
 Skeleton, disease  
 Skin, disease  
 Skin, neoplasm  
 Stroke  
 Systemic mastocytosis  
 Testis, neoplasm  
 Thrombosis  
 Thyroid gland, neoplasm  
 Tuberous sclerosis  
 Vascular restenosis  
     (treatment of; preparation of pyrrolopyridine derivs. as protein  
     kinase inhibitors useful in treatment of diseases)  
 IT Necrosis  
     (tubular, treatment of; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT Angiogenesis  
(tumor, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease  
(ulcerative colitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Colitis  
(ulcerative, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection  
(viral, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 142805-58-1  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 50-99-7, D-Glucose, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918504-27-5P 918506-28-2P 918507-15-0P 918507-82-1P 918507-83-2P  
918507-84-3P 918507-88-7P 918508-05-1P 918508-21-1P 918508-33-5P  
918509-12-3P 918509-57-6P 918509-58-7P 918509-59-8P 918510-89-1P  
918511-00-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate and intermediate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918504-32-2P 918504-33-3P 918504-39-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase

inhibitors useful in treatment of diseases)					
IT	918504-31-1P	918504-34-4P	918504-35-5P	918504-40-2P	918504-41-3P
	918504-42-4P	918504-43-5P	918504-61-7P	918504-62-8P	918504-63-9P
	918504-64-0P	918504-65-1P	918504-66-2P	918504-67-3P	918504-68-4P
	918504-69-5P	918504-70-8P	918504-71-9P	918504-72-0P	918504-75-3P
	918504-76-4P	918504-77-5P	918504-78-6P	918504-79-7P	918504-80-0P
	918504-81-1P	918504-82-2P	918504-83-3P	918504-84-4P	918504-85-5P
	918504-86-6P	918504-87-7P	918504-88-8P	918504-89-9P	918504-90-2P
	918504-91-3P	918504-92-4P	918504-93-5P	918504-94-6P	918504-95-7P
	918504-96-8P	918504-97-9P	918505-58-5P	918505-61-0P	918505-62-1P
	918505-63-2P	918505-69-8P	918505-70-1P	918505-71-2P	918505-73-4P
	918505-74-5P	918505-75-6P	918505-76-7P	918505-77-8P	918505-78-9P
	918505-79-0P	918505-80-3P	918505-81-4P	918505-82-5P	918505-83-6P
	918505-84-7P	918505-85-8P	918505-86-9P	918505-87-0P	918505-88-1P
	918505-90-5P	918505-91-6P	918505-92-7P	918505-93-8P	918505-94-9P
	918505-95-0P	918505-96-1P	918505-97-2P	918505-98-3P	918505-99-4P
	918506-00-0P	918506-01-1P	918506-02-2P	918506-03-3P	918506-04-4P
	918506-05-5P	918506-06-6P	918506-07-7P	918506-08-8P	918506-09-9P
	918506-10-2P	918506-11-3P	918506-12-4P	918506-13-5P	918506-14-6P
	918506-15-7P	918506-16-8P	918506-17-9P	918506-18-0P	918506-19-1P
	918506-20-4P	918506-21-5P	918506-26-0P	918506-27-1P	918506-29-3P
	918506-35-1P	918506-36-2P	918506-37-3P	918506-38-4P	918506-39-5P
	918506-40-8P	918506-42-0P	918506-43-1P	918506-44-2P	918506-45-3P
	918506-49-7P	918506-50-0P	918506-51-1P	918506-52-2P	918506-53-3P
	918506-54-4P	918506-55-5P	918506-56-6P	918506-57-7P	918506-58-8P
	918506-59-9P	918506-60-2P	918506-61-3P	918506-62-4P	918506-63-5P
	918506-64-6P	918506-65-7P	918506-66-8P	918506-67-9P	918506-68-0P
	918506-70-4P	918506-71-5P	918506-72-6P	918506-73-7P	918506-74-8P
	918506-75-9P	918506-76-0P	918506-77-1P	918506-78-2P	918506-79-3P
	918506-80-6P	918506-81-7P	918506-82-8P	918506-83-9P	918506-84-0P
	918506-85-1P	918506-86-2P	918506-87-3P	918506-88-4P	918506-89-5P
	918506-90-8P	918506-92-0P	918506-93-1P	918506-94-2P	918506-95-3P
	918506-96-4P	918506-97-5P	918506-98-6P	918506-99-7P	918507-00-3P
	918507-01-4P	918507-02-5P	918507-03-6P	918507-04-7P	918507-05-8P
	918507-06-9P	918507-07-0P	918507-08-1P	918507-09-2P	918507-10-5P
	918507-11-6P	918507-12-7P	918507-13-8P	918507-14-9P	918507-16-1P
	918507-17-2P	918507-20-7P	918507-21-8P	918507-22-9P	918507-23-0P
	918507-24-1P	918507-28-5P	918507-29-6P	918507-30-9P	918507-31-0P
	918507-32-1P	918507-33-2P	918507-34-3P	918507-38-7P	918507-40-1P
	918507-47-8P	918507-49-0P	918507-51-4P	918507-57-0P	918507-58-1P
	918507-59-2P	918507-60-5P	918507-61-6P	918507-62-7P	918507-63-8P
	918507-64-9P	918507-65-0P	918507-66-1P	918507-67-2P	918507-68-3P
	918507-78-5P	918507-79-6P	918507-85-4P	918507-86-5P	918507-87-6P
	918507-89-8P	918507-90-1P	918507-91-2P	918507-92-3P	918507-93-4P
	918507-94-5P	918507-95-6P	918507-96-7P	918507-97-8P	918507-98-9P
	918507-99-0P	918508-00-6P	918508-01-7P	918508-02-8P	918508-03-9P
	918508-04-0P	918508-06-2P	918508-07-3P	918508-08-4P	918508-09-5P
	918508-10-8P	918508-11-9P	918508-12-0P	918508-13-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)					
IT	918508-14-2P	918508-15-3P	918508-16-4P	918508-17-5P	918508-18-6P
	918508-19-7P	918508-20-0P	918508-22-2P	918508-23-3P	918508-25-5P
	918508-26-6P	918508-27-7P	918508-28-8P	918508-29-9P	918508-30-2P
	918508-31-3P	918508-32-4P	918508-34-6P	918508-35-7P	918508-36-8P
	918508-37-9P	918508-38-0P	918508-39-1P	918508-40-4P	918508-41-5P
	918508-42-6P	918508-43-7P	918508-44-8P	918508-45-9P	918508-46-0P
	918508-47-1P	918508-48-2P	918508-49-3P	918508-50-6P	918508-51-7P
	918508-52-8P	918508-53-9P	918508-54-0P	918508-55-1P	918508-56-2P

918508-57-3P	918508-58-4P	918508-59-5P	918508-60-8P	918508-61-9P
918508-62-0P	918508-63-1P	918508-64-2P	918508-65-3P	918508-66-4P
918508-67-5P	918508-68-6P	918508-69-7P	918508-70-0P	918508-71-1P
918508-72-2P	918508-73-3P	918508-74-4P	918508-75-5P	918508-76-6P
918508-77-7P	918508-78-8P	918508-79-9P	918508-80-2P	918508-81-3P
918508-82-4P	918508-83-5P	918508-84-6P	918508-85-7P	918508-86-8P
918508-87-9P	918508-88-0P	918508-89-1P	918508-90-4P	918508-91-5P
918508-92-6P	918508-93-7P	918508-94-8P	918508-95-9P	918508-96-0P
918508-97-1P	918508-98-2P	918508-99-3P	918509-00-9P	918509-01-0P
918509-02-1P	918509-03-2P	918509-04-3P	918509-05-4P	918509-06-5P
918509-07-6P	918509-08-7P	918509-09-8P	918509-10-1P	918509-11-2P
918509-13-4P	918509-14-5P	918509-15-6P	918509-16-7P	918509-17-8P
918509-18-9P	918509-19-0P	918509-20-3P	918509-21-4P	918509-22-5P
918509-23-6P	918509-24-7P	918509-25-8P	918509-26-9P	918509-27-0P
918509-28-1P	918509-29-2P	918509-30-5P	918509-31-6P	918509-32-7P
918509-33-8P	918509-34-9P	918509-35-0P	918509-36-1P	918509-37-2P
918509-38-3P	918509-39-4P	918509-41-8P	918509-42-9P	918509-43-0P
918509-44-1P	918509-45-2P	918509-46-3P	918509-47-4P	918509-48-5P
918509-49-6P	918509-50-9P	918509-51-0P	918509-52-1P	918509-53-2P
918509-54-3P	918509-55-4P	918509-56-5P	918509-60-1P	918509-61-2P
918509-62-3P	918509-63-4P	918509-64-5P	918509-65-6P	918509-66-7P
918509-67-8P	918509-68-9P	918509-69-0P	918509-70-3P	918509-71-4P
918509-72-5P	918509-73-6P	918509-74-7P	918509-75-8P	918509-76-9P
918509-77-0P	918509-78-1P	918509-79-2P	918509-80-5P	918509-81-6P
918509-82-7P	918509-83-8P	918509-84-9P	918509-85-0P	918509-86-1P
918509-87-2P	918509-88-3P	918509-89-4P	918509-90-7P	918509-91-8P
918509-92-9P	918509-93-0P	918509-94-1P	918509-95-2P	918509-96-3P
918509-97-4P	918509-98-5P	918509-99-6P	918510-00-6P	918510-01-7P
918510-02-8P	918510-03-9P	918510-04-0P	918510-05-1P	918510-06-2P
918510-07-3P	918510-08-4P	918510-09-5P	918510-10-8P	918510-11-9P
918510-90-4P	918510-91-5P	918510-92-6P	918511-01-0P	918511-33-8P
918511-34-9P	918511-35-0P	918511-36-1P	918511-89-4P	918511-94-1P
918512-65-9P	918513-93-6P	918515-13-6P	918516-21-9P	918516-54-8P
918517-29-0P	918517-39-2P	918517-41-6P	918518-09-9P	918519-06-9P
918520-58-8P	918520-62-4P	918520-75-9P	918520-76-0P	918520-85-1P
918521-03-6P	918521-04-7P	918521-05-8P	918521-06-9P	918521-09-2P
918521-38-7P	918521-56-9P	918521-57-0P	918521-58-1P	918521-59-2P
918521-68-3P	918521-73-0P	918521-74-1P	918521-87-6P	918521-92-3P
918521-93-4P	918521-94-5P	918521-95-6P	918521-99-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918522-00-6P 918522-24-4P 918522-27-7P 918522-83-5P 918522-97-1P  
918803-06-2P 918803-08-4P 918803-09-5P 918803-10-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918517-04-1P 918520-82-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate, drug candidate; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT 824-52-2P 4649-09-6P 39255-23-7P 79418-72-7P 112434-18-1P  
152434-86-1P 152434-87-2P 183208-36-8P 208986-50-9P 269072-20-0P  
443124-79-6P 486424-36-6P, 4-Bromo-2,5-difluorophenol 611204-98-9P  
611205-38-0P 849067-96-5P 849068-05-9P 849409-81-0P 849409-82-1P  
858116-66-2P 858116-85-5P 858116-86-6P 858117-08-5P 866319-00-8P  
866546-07-8P 901238-24-2P 913983-25-2P 918507-52-5P 918511-92-9P  
918516-27-5P 918519-14-9P 918519-37-6P 918522-25-5P 918523-44-1P  
918523-45-2P 918523-46-3P 918523-47-4P 918523-48-5P 918523-49-6P  
918523-51-0P 918523-52-1P 918523-53-2P 918523-54-3P 918523-56-5P  
918523-57-6P 918523-58-7P 918523-59-8P 918523-60-1P 918523-61-2P  
918523-62-3P 918523-63-4P 918523-64-5P 918523-65-6P 918523-66-7P  
918523-67-8P 918523-68-9P 918523-70-3P 918523-71-4P 918523-72-5P  
918523-73-6P 918523-76-9P 918523-77-0P 918523-78-1P 918523-79-2P  
918523-80-5P 918523-81-6P 918523-82-7P 918523-83-8P 918523-84-9P  
918523-85-0P 918523-86-1P 918523-87-2P 918523-88-3P 918523-89-4P  
918523-90-7P 918523-91-8P 918523-92-9P 918523-93-0P 918523-94-1P  
918523-95-2P 918523-96-3P 918523-98-5P 918523-99-6P 918524-01-3P  
918524-02-4P 918524-03-5P 918524-04-6P 918524-05-7P 918524-06-8P  
918524-07-9P 918524-08-0P 918524-09-1P 918524-11-5P 918524-12-6P  
918524-13-7P 918524-14-8P 918524-15-9P 918524-16-0P 918524-17-1P  
918524-18-2P 918524-19-3P 918524-20-6P 918524-21-7P 918524-22-8P  
918524-23-9P 918524-24-0P 918524-25-1P 918524-26-2P 918524-27-3P  
918524-28-4P 918524-31-9P 918524-32-0P 918524-33-1P 918524-37-5P  
918524-44-4P 918524-45-5P 918524-46-6P 918524-50-2P 918524-52-4P  
918524-53-5P 918524-54-6P 918524-55-7P 918524-56-8P 918524-57-9P  
918524-58-0P 918524-59-1P 918524-60-4P 918524-61-5P 918524-62-6P  
918803-34-6P 918803-35-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 7782-44-7, Oxygen, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 79079-06-4, EGFR kinase 98037-52-6, Abl protein kinase 103843-29-4, IGF1R kinase 108891-60-7 111694-09-8 114051-78-4, LCK kinase 136396-12-8 137632-03-2, Met kinase 137632-06-5, Csk kinase 137632-08-7, Erk2 kinase 138359-29-2, c-KIT kinase 138674-26-7, Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes protein kinase 141350-03-0, Flt1 kinase 141436-78-4, Protein kinase CP 144114-16-9, Fak kinase 144376-45-4, Pim1 kinase 144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK kinase 146279-92-7, Ret kinase 146838-30-4, MAPKAPK2 147014-96-8, CDK5 kinase 147014-97-9, CDK4 kinase 147230-71-5, Flt3 kinase 148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7 150316-14-6, Mitogen-activated protein kinase kinase 2 150977-45-0, Kdr kinase 151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38 Kinase 165245-99-8, Polo like kinase 1 166433-56-3, Anaplastic lymphoma kinase 170780-46-8, Pyk2 kinase 176023-60-2, Akt2 kinase 182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1 182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase 191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4, Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase 289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3

kinase 303014-92-8, CDK6 kinase 362517-43-9, IKK- $\beta$  kinase 370088-29-2, Mitogen-activated protein kinase kinase kinase 4 372092-80-3 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase 443900-95-6, Glycogen synthase kinase 3 $\beta$  458560-40-2, Protein kinase Stk6 553648-93-4, Glycogen synthase kinase 3 $\alpha$

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 348-62-9, 4-Chloro-2-fluorophenol 13358-73-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 9004-10-8, Insulin, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(resistance; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918505-72-3P 918511-37-2P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(starting material, drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 56741-33-4P 70205-04-8P 79418-77-2P 918523-55-4P 918523-69-0P 918523-74-7P 918523-75-8P 918523-97-4P 918524-00-2P 918524-30-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(starting material, intermediate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 62-53-3, Aniline, reactions 94-99-5, 2,4-Dichlorobenzyl chloride 96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6, Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 100-37-8, 2-(Diethylamino)ethanol 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 103-71-9, Phenyl isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 106-41-2, 4-Bromophenol 107-10-8, 1-Propanamine, reactions 109-01-3 109-73-9, 1-Butanamine, reactions 109-85-3, 2-Methoxyethylamine 109-86-4, 2-Methoxyethanol 110-68-9, N-Methylbutanamine 110-91-8, Morpholine, reactions 111-36-4, Butyl isocyanate 120-83-2, 2,4-Dichlorophenol 121-32-4, 3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-methoxybenzaldehyde 121-60-8, 4-(Acetylamino)phenylsulfonyl chloride 123-08-0, 4-Hydroxybenzaldehyde 133-59-5, 2-Methylbenzenesulfonyl chloride 140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole 327-78-6, 4-Chloro-3-trifluoromethylphenyl isocyanate 329-01-1, 3-Trifluoromethylphenyl isocyanate 349-88-2, 4-Fluorobenzenesulfonyl chloride 367-25-9, 2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol 371-40-4, 4-Fluoroaniline 402-49-3, 1-Bromomethyl-4-(trifluoromethyl)benzene 404-71-7, 3-Fluorophenyl isocyanate 405-05-0, 3-Fluoro-4-hydroxybenzaldehyde 444-30-4, 2-(Trifluoromethyl)phenol 445-05-6, 5-Fluoro-2-methylbenzenesulfonyl chloride 445-26-1, 1-(2-Fluorophenyl)ethanol 446-51-5, 2-Fluorobenzyl alcohol 501-30-4 501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 582-33-2, Ethyl 3-aminobenzoate 586-95-8, 4-Pyridinemethanol 586-98-1, 2-Pyridinemethanol 603-80-5, 3-Hydroxy-2-methylbenzoic acid 614-68-6, 2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate 622-40-2, N-(2-Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl isocyanate 622-95-7 623-24-5, 1,4-Bis(bromomethyl)benzene 626-58-4, 4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride

701-34-8, 4-Bromobenzenesulfonamide 766-00-7, 2-Cyclopentylethanol  
 766-80-3, 3-Chlorobenzyl bromide 767-05-5, 3-Cyclopentylpropanol  
 768-35-4, 3-Fluorophenylboronic acid 777-44-6, 3-  
 Trifluoromethylphenylsulfonfyl chloride 824-94-2, 4-Methoxybenzyl  
 chloride 1003-03-8, Aminocyclopentane 1074-86-8, Indole-4-  
 carboxaldehyde 1122-71-0, 6-Methylpyridine-2-methanol 1138-56-3,  
 4-Butoxybenzenesulfonfyl chloride 1195-45-5, 4-Fluorophenylisocyanate  
 1483-28-9, 2,5-Dimethoxybenzenesulfonfyl chloride 1548-13-6,  
 4-Trifluoromethylphenyl isocyanate 1679-18-1, 4-Chlorophenylboronic acid  
 1692-15-5, Pyridine-4-boronic acid 1692-25-7, Pyridine-3-boronic acid  
 1765-93-1, 4-Fluorophenylboronic acid 1777-82-8, 2,4-Dichlorobenzyl  
 alcohol 1899-93-0, 3-Methylbenzenesulfonfyl chloride 1996-41-4,  
 2-Chloro-4-Fluorophenol 2038-03-1, N-(2-Aminoethyl)morpholine  
 2124-55-2, Indole-4-carboxylic acid 2386-60-9, Butanesulfonfyl chloride  
 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 2426-87-1,  
 4-Benzoyloxy-3-methoxybenzaldehyde 2516-47-4, Cyclopropylmethylamine  
 2713-31-7, 2,5-Difluorophenol 2905-21-7, 2-Fluorobenzenesulfonfyl  
 chloride 2909-38-8, 3-Chlorophenyl isocyanate 2991-42-6,  
 4-Trifluoromethylbenzenesulfonfyl chloride 3173-56-6, Benzyl isocyanate  
 3391-10-4, 1-(4-Chlorophenyl)ethanol 3445-11-2, N-(2-  
 Hydroxyethyl)pyrrolidin-2-one 3954-13-0, Pentyl isocyanate 4441-30-9,  
 N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine 4747-71-1,  
 Isocyanatocyclopentane 4857-04-9, 2-Chloromethyl-1H-benzimidazole  
 5180-79-0, 3-Isocyanatobenzoyl chloride 5345-54-0, 3-Chloro-4-  
 methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate 5720-07-0,  
 4-Methoxyphenylboronic acid 6482-24-2, 1-Bromo-2-methoxyethane  
 7304-32-7, 2-Fluoro-5-nitrobenzoic acid 10130-74-2, 3-  
 Methoxybenzenesulfonfyl chloride 10147-36-1, 1-Propanesulfonfyl chloride  
 10147-37-2, 2-Propanesulfonfyl chloride 10365-98-7, 3-  
 Methoxyphenylboronic acid 13360-63-9, N-Ethylbutanamine 13918-92-8,  
 2,4-Difluorobenzenesulfonfyl chloride 13952-84-6, 2-Butanamine  
 15268-31-2, Pyridin-3-yl isocyanate 15854-87-2, 4-Iodopyridine  
 16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9,  
 2-Thiophenesulfonfyl chloride 16712-69-9, 4-Ethylbenzenesulfonfyl chloride  
 17334-08-6, 1-Methylimidazole-2-methanol 17739-45-6,  
 2-(2-Bromoethoxy)tetrahydropyran 18278-34-7, 4-Hydroxy-2-  
 methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate 19463-48-0,  
 3-Chloro-4-hydroxy-5-methoxybenzaldehyde 20443-98-5, 2,6-Dichlorobenzyl  
 bromide 20984-81-0, 3-(Diethylamino)pyrrolidine 23095-31-0,  
 3,4-Dimethoxybenzenesulfonfyl chloride 23616-57-1, 3-Iodo-7-azaindole  
 24677-78-9, 2,3-Dihydroxybenzaldehyde 27086-19-7, Dipropyl carbamoyl  
 chloride 28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4,  
 4-Dimethylaminophenylboronic acid 35856-62-3, 1-Piperidinesulfonfyl  
 chloride 37527-66-5, 3,4-Dimethoxyphenyl isocyanate 38070-73-4  
 39893-50-0, 3-Chloro-4-trifluoromethylphenyl isocyanate 42170-95-6,  
 2-Methoxyethyl isocyanate 42601-04-7, 3,4-Difluorophenyl isocyanate  
 49584-26-1, 4-Cyanophenylsulfonfyl chloride 50382-32-6,  
 2,4-Dimethylthiazole-5-methanol 50528-86-4, 2-Chloro-5-  
 trifluoromethylphenyl isocyanate 50824-04-9, 4-Bromo-2-  
 (trifluoromethyl)phenol 51175-71-4, 3-Thiophenesulfonfyl chloride  
 51488-22-3, 2-Chloro-4-trifluoromethylphenyl isocyanate 52130-17-3,  
 3-Amino-2-methylbenzoic acid 53104-95-3, 4-Hydroxy-3-  
 (trifluoromethoxy)benzaldehyde 54751-01-8, 4-Bromomethylpyridine  
 54997-90-9, 4-Isopropylbenzenesulfonfyl chloride 55052-28-3,  
 4-Chloro-7-azaindole 56456-47-4, 2,4-Difluorobenzyl alcohol  
 56456-49-6, 4-Chloro-2-fluorobenzyl alcohol 56542-67-7,  
 3-Cyanobenzenesulfonfyl chloride 56962-11-9, 2-Chloro-4-  
 hydroxybenzaldehyde 57012-20-1 57946-56-2, 4-Chloro-2-fluoroaniline  
 61672-75-1 63503-60-6, 3-Chlorophenylboronic acid 63624-28-2,  
 2,4-Dimethoxybenzenesulfonfyl chloride 63758-12-3 69360-26-5,  
 2-Cyanobenzenesulfonfyl chloride 69816-05-3 70067-45-7 71189-18-9



71916-82-0, 4-Chloro-2-fluorobenzyl bromide 71924-62-4 72975-46-3  
 79418-78-3, 3-Fluoro-4-hydroxy-5-methoxybenzaldehyde 80466-80-4  
 86718-08-3 89599-01-9, 3-Bromobenzenesulfonamide 90001-64-2,  
 Benzothiophene-2-sulfonyl chloride 90260-13-2, 3-Fluoro-4-  
 methylbenzenesulfonyl chloride 97272-04-3, 2,5-Dimethylthiophene-3-  
 sulfonyl chloride 108679-71-6, 3-Amino-2-chlorobenzoic acid  
 123088-59-5, 4-Aminocarbonylphenylboronic acid 128796-39-4,  
 4-Trifluoromethylphenylboronic acid 137049-02-6 151411-98-2,  
 2,4,6-Trifluorobenzyl bromide 151858-64-9 152434-88-3 153912-60-8,  
 1,5-Dimethylpyrazole-3-methanol 163105-89-3, 2-Methoxyppyridine-5-boronic  
 acid 166964-26-7, 2,5-Dimethylfuran-3-sulfonyl chloride 168899-43-2  
 179113-90-7, 3-Trifluoromethoxyphenylboronic acid 180200-86-6  
 181124-40-3, 6-Benzothiazolesulfonyl chloride 183208-35-7,  
 5-Bromo-7-azaindole 190774-52-8, 2-Fluoro-3-trifluoromethylphenyl  
 isocyanate 197239-49-9, 2-Fluoro-4-trifluoromethylbenzyl alcohol  
 208186-84-9, 2-Chloro-4-fluorobenzyl alcohol 210532-25-5,  
 3,5-Difluorobenzenesulfonyl chloride 306936-35-6 321309-40-4  
 337508-66-4 351003-34-4, 4-Difluoromethoxybenzenesulfonyl chloride  
 351422-73-6, 3-Aminocarbonylphenylboronic acid 364794-80-9  
 373384-18-0, 3-(Methylsulfonyl)phenylboronic acid 380430-52-4  
 386704-04-7 388088-73-1 389621-84-5 405520-68-5 423151-49-9  
 445264-61-9 485799-04-0 551930-53-1 628692-15-9 690632-68-9  
 754214-56-7 757978-25-9 761446-44-0 785785-59-3 852180-61-1  
 852227-95-3 858116-95-7 909501-40-2 911210-53-2,  
 4-Cyano-3,5-dimethylphenylboronic acid 918519-69-4 918523-07-6  
 918524-34-2 918524-63-7 918524-64-8 918524-65-9 918524-70-6  
 918524-71-7 918524-72-8 918524-73-9 918524-74-0 918524-75-1  
 918524-76-2 918524-77-3 918524-78-4 918524-83-1 918524-85-3  
 918524-86-4 918524-87-5 918524-88-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of pyrrolopyridine derivs. as protein kinase  
 inhibitors useful in treatment of diseases)

IT 918524-89-7 918524-90-0 918524-91-1 918524-92-2 918524-93-3,  
 4-Benzoyloxy-2,6-difluorobenzaldehyde 918524-94-4 918524-95-5  
 918524-96-6 918524-97-7 918524-99-9 918525-00-5 918525-01-6  
 918525-03-8 918525-04-9 918803-36-8 918803-37-9 918803-38-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of pyrrolopyridine derivs. as protein kinase  
 inhibitors useful in treatment of diseases)

IT 918919-61-6 918919-62-7 918919-63-8 918919-64-9 918919-65-0  
 918919-66-1 918919-67-2 918919-68-3 918919-69-4 918919-70-7  
 918919-71-8 918919-72-9 918919-73-0 918919-74-1 918919-75-2  
 918919-76-3 918919-77-4 918919-78-5 918919-79-6 918919-80-9  
 918919-81-0 918919-82-1 918919-83-2 918919-84-3 918919-85-4  
 918919-86-5 918919-87-6 918919-88-7 918919-89-8 918919-90-1  
 918919-91-2 918919-92-3 918919-93-4 918919-94-5 918919-95-6  
 918919-96-7 918919-97-8 918919-98-9 918919-99-0 918920-00-0  
 918920-01-1 918920-02-2 918920-03-3 918920-04-4 918920-05-5  
 918920-06-6 918920-07-7 918920-08-8 918920-09-9 918920-10-2  
 918920-11-3 918920-12-4 918920-13-5 918920-14-6 918920-15-7  
 918920-16-8 918920-17-9 918920-18-0 918920-19-1 918920-20-4  
 918920-21-5 918920-22-6 918920-23-7 918920-24-8 918920-25-9  
 918920-26-0 918920-27-1 918920-28-2 918920-29-3 918920-30-6  
 918920-31-7 918920-32-8 918920-33-9

RL: PRP (Properties)  
 (unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase  
 inhibitors and their preparation, pharmaceutical compns. and use in the  
 treatment of diseases)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

(1) Aadal, N; WO 2004016610 A 2004 CAPLUS

(2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS  
 (3) Bayer Ag; DE 2413258 A1 1975 CAPLUS  
 (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS  
 (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS  
 (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS  
 (7) Normington, J; US 2234705 A 1941 CAPLUS  
 (8) Pierce; J AM CHEM SOC 1942, V64, P1691

L32 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole  
 derivs. as PI3 kinase inhibitors with therapeutic uses)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2006:1252615 CAPLUS

DOCUMENT NUMBER: 146:7952

TITLE: Preparation of 4,5'-bithiazole and  
 4-(oxazol-5-yl)thiazole derivatives as  
 phosphoinositide-3 kinase inhibitors with therapeutic  
 uses

INVENTOR(S): Quattropiani, Anna; Dorbais, Jerome; Covini, David;  
 Desforges, Gwenaelle; Rueckle, Thomas

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N. V., Neth.  
 Antilles

SOURCE: PCT Int. Appl., 149pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125805	A1	20061130	WO 2006-EP62595	20060524
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006251159	A1	20061130	AU 2006-251159	20060524
CA 2607385	A1	20061130	CA 2006-2607385	20060524
EP 1888546	A1	20080220	EP 2006-777240	20060524
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
MX 200714883	A	20080215	MX 2007-14883	20071126
NO 2007006557	A	20071219	NO 2007-6557	20071219
KR 2008015119	A	20080218	KR 2007-729932	20071221
PRIORITY APPLN. INFO.:			EP 2005-104394	A 20050524
			US 2005-686270P	P 20050601
			WO 2006-EP62595	W 20060524

OTHER SOURCE(S): MARPAT 146:7952

AN 2006:1252615 CAPLUS

DN 146:7952

ED Entered STN: 01 Dec 2006

TI Preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivatives as phosphoinositide-3 kinase inhibitors with therapeutic uses

IN Quattropani, Anna; Dorbais, Jerome; Covini, David; Desforages, Gwenaelle; Rueckle, Thomas

PA Applied Research Systems Ars Holding N. V., Neth. Antilles

SO PCT Int. Appl., 149pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125805	A1	20061130	WO 2006-EP62595	20060524
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006251159	A1	20061130	AU 2006-251159	20060524
	CA 2607385	A1	20061130	CA 2006-2607385	20060524
	EP 1888546	A1	20080220	EP 2006-777240	20060524
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	MX 200714883	A	20080215	MX 2007-14883	20071126
	NO 2007006557	A	20071219	NO 2007-6557	20071219
	KR 2008015119	A	20080218	KR 2007-729932	20071221
PRAI	EP 2005-104394	A	20050524		
	US 2005-686270P	P	20050601		
	WO 2006-EP62595	W	20060524		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2006125805	IPCI	C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];

		A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	ECLA	C07D277/46; C07D277/48; C07D417/14; C07D491/10+317B+221B; C07D498/04+317C+265C
AU 2006251159	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	ECLA	C07D277/46; C07D277/48; C07D417/14; C07D491/10+317B+221B; C07D498/04+317C+265C
CA 2607385	IPCI	A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]; C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
EP 1888546	IPCI	C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427

[I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];  
A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454  
[I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];  
A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375  
[I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];  
A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00  
[I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];  
C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00  
[I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];  
C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]  
C07D0277-46 [I,A]; A61K0031-427 [I,A]; A61K0031-433  
[I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965  
[I,C\*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C\*];  
A61K0031-553 [I,A]; A61P0025-00 [I,A]; A61P0009-00  
[I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A];  
C07D0277-00 [I,C\*]; C07D0417-14 [I,A]; C07D0417-00  
[I,C\*]; C07D0491-10 [I,A]; C07D0491-00 [I,C\*];  
C07D0493-08 [I,A]; C07D0493-00 [I,C\*]  
NO 2007006557 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]  
IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]  
ECLA C07D277/46; C07D277/48; C07D417/14;  
C07D491/10+317B+221B; C07D498/04+317C+265C  
KR 2008015119 IPCI C07D0417-04 [I,A]; C07D0417-14 [I,A]; C07D0417-00  
[I,C\*]; C07D0491-10 [I,A]; C07D0491-00 [I,C\*]  
OS MARPAT 146:7952  
GI



AB The present invention is related to thiazole derivs. (shown as I; variables defined below; e.g. Et 2'-(acetyl amino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate) as well as geometrical isomers, optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries (no data). Although the methods of preparation are not claimed, preps. and/or characterization data for .apprx.80 examples of I are included. For example, Et 2'-(acetyl amino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate was prepared in 46 % yield by cyclizing N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (preparation given) with Et thiooxamate in dioxane. For I: R1 = -C(O)R5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl C1-C6-alkyl, heteroaryl C1-C6-alkyl, C3-C8 cycloalkyl C1-C6-alkyl and heterocycloalkyl C1-C6-alkyl; R2 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl and C2-C6-alkynyl; R3 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl and C2-C6-alkynyl; R4 = -C(O)R6, aryl, heteroaryl, heterocycloalkyl and C3-C8 cycloalkyl; R5 = H, hydroxy, alkoxy, amino, aryl, heteroaryl, C3-C8 cycloalkyl and heterocycloalkyl; R6 = H, C1-C6-alkyl, C2-C6-alkenyl,

C2-C6-alkynyl, aryl C1-C6-alkyl, heteroaryl C1-C6-alkyl and amino; X = S and O. IC50 values for inhibition of PI3K $\gamma$ -induced lipid and/or PI3K-induced Akt/PKB phosphorylation are tabulated for 12 examples of 1-thiazole deriv prepn PI3 kinase inhibitor therapeutic use; bithiazole oxazolylthiazole prepn PI3 kinase inhibitor therapeutic use

ST Nervous system, disease  
(Huntington's chorea; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Sarcoma  
(Kaposi's; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PI3 kinase  $\gamma$ , inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Fibrosis  
(anaphylactic shock; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Muscle, disease  
(atrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Infection  
(bacterial; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease  
(chronic obstructive pulmonary disease; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Nervous system, disease  
(degeneration; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Nervous system agents  
(degenerative; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Erythrocyte  
(disease, deficiency; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease  
(endothelial and epithelial injuries; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Blood, disease  
(erythrocyte, deficiency; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Kidney, disease  
(fibrosis, progressive; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Muscle, disease

(hypertrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Brain, disease  
(infection; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease  
Reperfusion  
(injury; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Neoplasm  
(metastasis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Hypertrophy  
(muscular; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Heart, disease  
(myocyte dysfunction; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Inflammation  
Lung, disease  
(pneumonitis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Allergy  
Allergy inhibitors  
Alzheimer's disease  
Angiogenesis  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Antibacterial agents  
Antifibrotic agents  
Antihypertensives  
Antirheumatic agents  
Antitumor agents  
Antiviral agents  
Asthma  
Atherosclerosis  
Autoimmune disease  
Cardiac hypertrophy  
Cardiovascular agents  
Cardiovascular system, disease  
Encephalitis  
Glomerulosclerosis  
Human  
Hypertension  
Immunomodulators  
Inflammation  
Inflammatory bowel disease  
Ischemia  
Kidney, disease  
Melanoma  
Meningitis  
Multiple sclerosis  
Neoplasm  
Platelet aggregation  
Platelet aggregation inhibitors  
Psoriasis  
Respiratory system, disease

Respiratory system agents

Rheumatoid arthritis

Sepsis

Stroke

Thrombolytics

Thrombosis

Transplant and Transplantation

Transplant rejection

Vasoconstriction

(preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Injury

(pulmonary; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Fibrosis

(renal, progressive; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Injury

(reperfusion; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lupus erythematosus

(systemic; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Central nervous system, disease

(trauma; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Infection

(viral; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT

915702-31-7P, Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 915702-33-9P, N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-34-0P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid 915702-64-6P, 5-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid 915702-68-0P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide 915702-70-4P, N-[4'-Methyl-2-[(2H-tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-74-8P, 1-[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-4-carboxylic acid 915702-88-4P, 2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-92-0P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid 915702-94-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-fluorobenzoic acid 915702-96-4P, 2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-98-6P, 2'-(Acetylamino)-N-[4-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915703-28-5P, tert-Butyl 4-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-4-oxobutanoate 915703-29-6P, Methyl 5-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-oxopentanoate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT

915702-32-8P, 2'-(Acetylamino)-N-allyl-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-35-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid potassium salt 915702-36-2P, 2'-(Acetylamino)-N-(2-methoxyethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-37-3P, 2'-(Acetylamino)-4'-methyl-N-(tetrahydrofuran-



2-ylmethyl)-4,5'-bi-1,3-thiazole-2-carboxamide 915702-38-4P,  
 2'-(Acetylamino)-N-[2-(dimethylamino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-39-5P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-40-8P, N-[4'-Methyl-2-[(4-methylpiperazin-1-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-41-9P, N-[4'-Methyl-2-[(4-methylpiperazin-1-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide mono(trifluoroacetate) 915702-42-0P, 2'-(Acetylamino)-N-[3-(dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-43-1P, 2'-(Acetylamino)-N-[3-(dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide mono(trifluoroacetate) 915702-44-2P, 2'-(Acetylamino)-N-(2-hydroxyethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-45-3P, 2'-(Acetylamino)-N-(2-cyanoethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-46-4P, 2'-(Acetylamino)-4'-methyl-N-(1H-tetrazol-5-yl)-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-48-6P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid potassium salt 915702-49-7P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid potassium salt 915702-50-0P, 2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-51-1P, 2'-(Acetylamino)-N-benzyl-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-52-2P, 2'-(Acetylamino)-4'-methyl-N-propyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-53-3P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-56-6P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid potassium salt 915702-58-8P, 1-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-3-carboxylic acid 915702-60-2P, 5-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid potassium salt 915702-66-8P, N-[4'-Methyl-2-[(2H-tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide potassium salt 915702-72-6P, 1-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-4-carboxylic acid potassium salt 915702-76-0P, 2'-(Acetylamino)-N-[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-78-2P, N-[2-[(3-Hydroxypiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-80-6P, N-[2-[[4-(Hydroxymethyl)piperidin-1-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-82-8P, N-[2-[[4-(2-Hydroxyethyl)piperidin-1-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-84-0P, N-[2-[(4-Hydroxypiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-86-2P, 2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-90-8P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid potassium salt 915702-93-1P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-fluorobenzoic acid potassium salt 915702-95-3P, 2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-97-5P, 2'-(Acetylamino)-N-[4-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-99-7P, N-[2-(Hydroxymethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-00-3P, 1-(2-Methoxyethyl)-3-[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea 915703-02-5P, Ethyl N-[[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-β-alaninate 915703-03-6P, N-[2-[(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-04-7P, 2'-(Acetylamino)-N-(2,3-dihydroxypropyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915703-05-8P, 1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea 915703-06-9P, N-[4'-Methyl-2-[(3-oxopiperazin-1-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-07-0P, N-[4'-Methyl-2-[(4-oxopiperidin-1-

yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-08-1P,  
N-[2-[(3-Hydroxypyrrrolidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]acetamide 915703-09-2P, 2'-(Acetylamino)-4'-methyl-N-(2-propyn-1-yl)-  
4,5'-bi-1,3-thiazole-2-carboxamide 915703-10-5P, N-[2-[(4-  
Acetyl)piperazin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]acetamide 915703-11-6P, N,N-Dimethyl-N'-[[[4'-methyl-2-[(morpholin-4-  
yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]glycinamide  
915703-12-7P, N-[[[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-  
thiazol-2'-yl]amino]carbonyl]-β-alanine 915703-13-8P,  
N-[2-[(4-Fluoropiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]acetamide 915703-14-9P, N-[2-[(15S,5S,7S)-7-(Hydroxymethyl)-6,8-dioxo-3-  
azabicyclo[3.2.1]oct-3-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]acetamide 915703-15-0P, Ethyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-  
1,3-thiazol-2'-yl]amino]carbonyl]-β-alanine 915703-17-2P,  
N-[2-[(1R,5R,7R)-7-(Hydroxymethyl)-6,8-dioxo-3-azabicyclo[3.2.1]oct-3-  
yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-19-4P,  
tert-Butyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]amino]carbonyl]-β-alanine 915703-20-7P, [4'-Methyl-2'-  
[(pyrazin-2-yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetoneitrile  
915703-22-9P, Ethyl 4'-methyl-2'-[(pyrazin-2-yl)amino]-4,5'-bi-1,3-  
thiazole-2-carboxylate 915703-23-0P, [4'-Methyl-2'-[(1H-pyrazol-3-  
yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetoneitrile 915703-25-2P,  
N-[4'-Methyl-2-[(2-(morpholin-4-yl)-2-oxoethyl)-4,5'-bi-1,3-thiazol-2'-  
yl]acetamide 915703-27-4P 915703-30-9P, Methyl 6-[[[2-(cyanomethyl)-4'-  
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-6-oxohexanoate 915703-31-0P,  
2'-(Acetylamino)-N,N,4'-trimethyl-4,5'-bi-1,3-thiazole-2-carboxamide  
915703-32-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-  
carboxamide 915703-33-2P, 4-[[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-  
thiazol-2'-yl]amino]-4-oxobutanoic acid 915703-34-3P,  
5-[[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-  
oxopentanoic acid 915703-35-4P, tert-Butyl N-[[[2-(cyanomethyl)-4'-  
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]glycinate 915703-36-5P,  
tert-Butyl 4-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]amino]carbonyl]amino]butanoate 915703-37-6P, N'-[[[2-(Cyanomethyl)-4'-  
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-dimethylglycinamide  
915703-38-7P, tert-Butyl N-[[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-  
bi-1,3-thiazol-2'-yl]amino]carbonyl]-β-alanine 915703-39-8P,  
1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-  
(morpholin-4-yl)-2-oxoethyl]urea 915703-40-1P, 1-[2-(Cyanomethyl)-4'-  
methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-(morpholin-4-yl)-2-oxoethyl]urea  
915703-41-2P, Methyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]amino]carbonyl]-β-alanine 915703-42-3P, N'-[[[2-(Cyanomethyl)-  
4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-diisopropyl-β-  
alaninamide 915703-43-4P, N'-[[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-  
thiazol-2'-yl]amino]carbonyl]-N-(2-hydroxy-1,1-dimethylethyl)-β-  
alaninamide 915703-44-5P, N-(tert-Butyl)-N'-[[[2-(cyanomethyl)-4'-methyl-  
4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-β-alaninamide  
915703-45-6P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-  
(2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]urea 915703-46-7P,  
1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-  
1,3-oxazolidin-3-yl)-3-oxopropyl]urea 915703-47-8P, N'-[[[2-  
(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N-(2,2-  
dimethylpropyl)glycinamide 915703-50-3P, 1-[3-(Azocan-1-yl)-3-oxopropyl]-  
3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]urea  
915703-52-5P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-  
(1-isopropyl-1H-imidazol-4-yl)ethyl]urea 915703-54-7P,  
1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-(1-ethyl-1H-  
imidazol-4-yl)ethyl]urea 915703-55-8P, 1-[2-(5-tert-Butyl-1,2,4-  
oxadiazol-3-yl)ethyl]-3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
yl]urea 915703-56-9P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-  
2'-yl]-3-[2-(5-isopropyl-1,2,4-oxadiazol-3-yl)ethyl]urea 915703-57-0P,

N-[4'-Methyl-2-[[5-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-58-1P, 2'-(Acetylamino)-4'-methyl-N-(1H-tetrazol-5-yl)-4,5'-bi-1,3-thiazole-2-carboxamide 915703-59-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid 915703-60-5P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid 915703-61-6P, 2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide 915703-62-7P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 51-45-6, 2-(1H-Imidazol-4-yl)ethanamine, reactions 62-23-7, 4-Nitrobenzoic acid 75-30-9, 2-Iodopropane 75-64-9, tert-Butylamine, reactions 96-97-9, 2-Hydroxy-5-nitrobenzoic acid 97-72-3, Isobutyric anhydride 99-05-8, 3-Aminobenzoic acid 100-46-9, Benzylamine, reactions 107-10-8, N-Propylamine, reactions 107-11-9, Allylamine 107-95-9,  $\beta$ -Alanine 108-00-9, 2-Dimethylaminoethylamine 108-18-9, Diisopropylamine 109-01-3, 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions 121-92-6, 3-Nitrobenzoic acid 124-68-5, 2-Amino-2-methyl-1-propanol 133-10-8, Sodium p-aminosalicylate 150-13-0, 4-Aminobenzoic acid 151-18-8, N-(2-Cyanoethyl)amine 177-11-7, 1,4-Dioxo-8-azaspiro[4.5]decane 446-31-1, 4-Amino-2-fluorobenzoic acid 498-94-2, Isonipecotic acid 498-95-3, Nipeccotic acid 501-53-1, Benzyl chloroformate 570-23-0, 3-Aminosalicylic acid 622-26-4, 4-Piperidineethanol 627-91-8 1121-92-2, Heptamethylenimine 1501-27-5 1694-29-7, 3-Chloro-2,4-pentanedione 1820-80-0, 3-Aminopyrazole 2237-30-1, 3-Aminobenzonitrile 2450-71-7, Propargylamine 3196-73-4 3282-30-2, Trimethylacetate chloride 3303-84-2, N-Boc- $\beta$ -alanine 3325-11-9, 5-Aminobenzotriazole 4418-61-5, 5-Aminotetrazole 4530-20-5, Boc-glycine 4795-29-3, Tetrahydrofurfurylamine 5049-61-6, 2-Aminopyrazine 5100-34-5, Ethyl 3-isocyanatopropionate 5382-16-1, 4-Hydroxypiperidine 5625-67-2, Piperazin-2-one 5813-64-9, Neopentylamine 6456-74-2 6457-49-4, 4-(Hydroxymethyl)piperidine 6859-99-0, 3-Hydroxypiperidine 7357-70-2, 2-Cyanothioacetamide 13794-28-0, Ethyl 2-isocyanatopropionate 13889-98-0, 1-Acetylpiperazine 15026-17-2, Succinic acid mono-tert-butyl ester 16982-21-1, Ethyl thioacetate 19351-18-9, 2,2-Dimethylthiazolidine 22195-47-7, 2,2-Dimethyl-1,3-dioxolane-4-methanamine 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 40499-83-0, 3-Pyrrolidinol 41979-39-9, 4-Piperidone hydrochloride 51200-87-4, 4,4-Dimethylloxazolidine 53588-95-7, tert-Butyl N-(2-cyanoethyl)carbamate 56414-96-1, 2-Amino-1-(morpholin-4-yl)ethanone 58620-93-2,  $\beta$ -Alanine tert-butyl ester hydrochloride 58640-01-0, tert-Butyl 4-aminobutanate hydrochloride 68947-43-3, N-Methyl-4-piperidinecarboxylic acid 72410-06-1, 2-Thiocarbamoylacetamide 73732-51-1, 5-(3-Aminophenyl)tetrazole 78197-27-0, 4-Fluoropiperidine 200634-33-9, Glycine dimethylamide acetate 250137-96-3, (1S,5S,7S)-6,8-Dioxo-3-azabicyclo[3.2.1]oct-7-yl)methanol 915702-54-4, 4-(2H-Tetrazol-5-yl)aniline hydrochloride 915703-18-3, (1R,5R,7R)-6,8-Dioxo-3-azabicyclo[3.2.1]oct-7-yl)methanol 915703-26-3, 3-(Morpholin-4-yl)-3-thioxopropionamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3

kinase inhibitors with therapeutic uses)

IT 618-94-0P, 3-Nitrobenzohydrazide 618-95-1P, Methyl 3-nitrobenzoate  
619-50-1P, Methyl 4-nitrobenzoate 636-97-5P, 4-Nitrobenzohydrazide  
6935-15-5P, 4-[[[(Benzyloxy)carbonyl]amino]-2-hydroxybenzoic acid  
14509-66-1P, 7,8-Dihydroimidazo[1,5-c]pyrimidin-5(6H)-one 31437-04-4P,  
N-[[[(Pyrazin-2-yl)amino]carbonothioyl]benzamide 31437-05-5P,  
1-(Pyrazin-2-yl)thiourea 32519-74-7P, N-[5-(Bromoacetyl)-4-methyl-1,3-  
thiazol-2-yl]acetamide 32519-75-8P, N-[5-(Bromoacetyl)-4-methyl-1,3-  
thiazol-2-yl]acetamide hydrobromide 34683-41-5P, N-[[[(1H-Pyrazol-3-  
yl)amino]carbonothioyl]benzamide 39884-12-3P, N-(5-Acetyl-4-methyl-1,3-  
thiazol-2-yl)acetamide 41125-77-3P, 5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-  
ol 71274-46-9P, N,N-Diisopropyl-β-alaninamide 83725-80-8P,  
5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 94284-80-7P, 1-(2-Amino-4-methyl-  
1,3-thiazol-5-yl)-2-bromoethanone hydrobromide 98804-62-7P,  
7-(N-Cbz-amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one 113118-47-1P,  
5-(4-Aminophenyl)-1,3,4-oxadiazol-2-ol 115082-05-8P,  
5-(3-Aminophenyl)-1,3,4-oxadiazol-2-ol 209467-48-1P,  
N-(tert-Butyl)-β-alaninamide 299171-15-6P, (2'-Amino-4'-methyl-4,5'-  
bi-1,3-thiazol-2-yl)acetoneitrile 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-  
thiadiazol-2-amine 479408-49-6P, 2-(1-Ethyl-1H-imidazol-4-yl)ethanamine  
479408-51-0P, 2-(1-Isopropyl-1H-imidazol-4-yl)ethanamine 758715-91-2P,  
1-(1H-Pyrazol-3-yl)thiourea 842137-44-4P, 7-Amino-2,4-dimethyl-4H-1,3-  
benzodioxin-4-one 842137-46-6P, 6-Amino-2,2-dimethyl-4H-1,3-benzodioxin-  
4-one 847789-44-0P, N'-(tert-Butoxycarbonyl)-N-(tert-butyl)-β-  
alaninamide 915702-00-0P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2-yl)amino]-  
1,3-thiazol-5-yl]ethanone hydrobromide 915702-01-1P,  
1-[4-Methyl-2-[(pyrazin-2-yl)amino]-1,3-thiazol-5-yl]ethanone  
hydrochloride 915702-02-2P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-  
(pyrazin-2-yl)acetamide 915702-03-3P, 1-[2-[(1-Acetyl-1H-pyrazol-3-  
yl)amino]-4-methyl-1,3-thiazol-5-yl]-2-bromoethanone hydrobromide  
915702-04-4P, 1-[4-Methyl-2-[(1H-pyrazol-3-yl)amino]-1,3-thiazol-5-  
yl]ethanone 915702-05-5P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-(1-  
acetyl-1H-pyrazol-3-yl)acetamide 915702-06-6P,  
N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-1H-imidazole-1-  
carboxamide 915702-07-7P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-  
bi-1,3-thiazol-2'-yl]-1H-imidazole-1-carboxamide 915702-08-8P, Ethyl  
2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 915702-10-2P,  
4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-amine  
mono(trifluoroacetate) 915702-11-3P, 6-[Hydroxy(oxido)amino]-2,2-  
dimethyl-4H-1,3-benzodioxin-4-one 915702-14-6P, N3-(tert-Butoxycarbonyl)-  
N1,N1-diisopropyl-β-alaninamide 915702-15-7P, N1-(2-Hydroxy-1,1-  
dimethylethyl)-β-alaninamide 915702-16-8P, N3-(tert-Butoxycarbonyl)-  
N1-(2-Hydroxy-1,1-dimethylethyl)-β-alaninamide 915702-17-9P,  
3-(2,2-Dimethyl-1,3-thiazolidin-3-yl)-3-oxopropan-1-amine 915702-18-0P,  
tert-Butyl [3-(2,2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]carbamate  
915702-19-1P, 3-(4,4-Dimethyl-1,3-oxazolidin-3-yl)-3-oxopropan-1-amine  
915702-20-4P, tert-Butyl [3-(4,4-dimethyl-1,3-oxazolidin-3-yl)-3-  
oxopropyl]carbamate 915702-21-5P, N-(2,2-Dimethylpropyl)glycinamide  
915702-22-6P, tert-Butyl [2-[(2,2-dimethylpropyl)amino]-2-  
oxoethyl]carbamate 915702-23-7P, 3-(Azocan-1-yl)-3-oxopropan-1-amine  
915702-24-8P, tert-Butyl [3-(azocan-1-yl)-3-oxopropyl]carbamate  
915702-25-9P, 2-Isopropyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-  
2-ium iodide 915702-26-0P, 2-Ethyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-  
c]pyrimidin-2-ium bromide 915702-27-1P, 2-(5-tert-Butyl-1,2,4-oxadiazol-  
3-yl)ethanamine 915702-28-2P, tert-Butyl [2-(5-tert-Butyl-1,2,4-  
oxadiazol-3-yl)ethyl]carbamate 915702-29-3P, 2-(5-Isopropyl-1,2,4-  
oxadiazol-3-yl)ethanamine 915702-30-6P, tert-Butyl [2-(5-isopropyl-1,2,4-  
oxadiazol-3-yl)ethyl]carbamate 915702-47-5P, 2'-Acetylamino-4'-methyl-  
4,5'-bithiazole-2-carbonyl chloride 915702-62-4P, 2'-(Acetylamino)-N-  
(2,2-dimethyl-4-oxo-4H-1,3-benzodioxin-6-yl)-4'-methyl-4,5'-bi-1,3-  
thiazole-2-carboxamide 915702-91-9P, 2'-(Acetylamino)-N-(2,2-dimethyl-4-

oxo-4H-1,3-benzodioxin-7-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide  
 915703-01-4P, Ethyl 2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate  
 monohydrobromide 915703-21-8P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2-  
 yl)amino]-1,3-thiazol-5-yl]ethanone 915703-24-1P, 1-[2-[(1-Acetyl-1H-  
 pyrazol-3-yl)amino]-4-methyl-1,3-thiazol-5-yl]-2-bromoethanone  
 915710-94-0P, tert-Butyl [(3E)-3-amino-3-(hydroxyimino)propyl]carbamate  
 915710-95-1P, tert-Butyl [(3Z)-3-amino-3-[(2,2-  
 dimethylpropanoyl)oxy]imino]propyl]carbamate 915710-96-2P,  
 N-[2-[(2E)-2-Amino-2-(hydroxyimino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-  
 yl]acetamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3  
 kinase inhibitors with therapeutic uses)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Agouron Pharmaceuticals Inc; WO 0075120 A 2000 CAPLUS
- (2) Bloomfield, G; WO 2004078754 A 2004 CAPLUS
- (3) Bruce, I; WO 03072557 A 2003 CAPLUS
- (4) Bruce, I; WO 2004096797 A 2004 CAPLUS
- (5) Fujisawa Pharmaceutical Co Ltd; EP 0117082 A 1984 CAPLUS
- (6) Sawhney, S; INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL  
 MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE 1976, V14B(7), P552  
 CAPLUS

L32 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, Phosphoinositide-3-kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of vasculostatic agents and use for treatment of  
 disorders associated with compromised vasculostasis)

RN 115926-52-8 CAPLUS


CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 91-56-5, Isatin  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of vasculostatic agents and use for  
 treatment of disorders associated with compromised vasculostasis)

RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2005:1335074 CAPLUS

DOCUMENT NUMBER: 144:69859

TITLE: Indoles, pteridines, pyridopyrazines, and  
 benzotriazines as vasculostatic agents, their  
 preparation, pharmaceutical compositions and use in  
 therapy

INVENTOR(S): Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor;  
 Noronha, Glenn; Hood, John D.; Dneprovskaja, Elena;  
 Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning  
 Targen, Inc., USA

PATENT ASSIGNEE(S):  
 SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S.  
 Ser. No. 679,209.

DOCUMENT TYPE: CODEN: USXXCO  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 2 English  
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050282814	A1	20051222	US 2005-105845	20050413
US 20040167198	A1	20040826	US 2003-679209	20031002
US 7208493	B2	20070424		
ZA 2005002328	A	20060927	ZA 2005-2328	20050318
US 20070208019	A1	20070906	US 2007-653190	20070111
PRIORITY APPLN. INFO.:			US 2002-415981P	P 20021003
			US 2003-440234P	P 20030114
			US 2003-443752P	P 20030129
			US 2003-463818P	P 20030417
			US 2003-466983P	P 20030430
			US 2003-479295P	P 20030617
			US 2003-679209	A2 20031002

OTHER SOURCE(S): CASREACT 144:69859; MARPAT 144:69859  
 AN 2005:1335074 CAPLUS  
 DN 144:69859  
 ED Entered STN: 23 Dec 2005  
 TI Indoles, pteridines, pyridopyrazines, and benzotriazines as vasculostatic agents, their preparation, pharmaceutical compositions and use in therapy  
 IN Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaya, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning  
 PA Targen, Inc., USA  
 SO U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 679,209.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-525  
 ICS A61K031-724  
 INCL 514251000; 514058000  
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050282814	A1	20051222	US 2005-105845	20050413
US 20040167198	A1	20040826	US 2003-679209	20031002
US 7208493	B2	20070424		
ZA 2005002328	A	20060927	ZA 2005-2328	20050318
US 20070208019	A1	20070906	US 2007-653190	20070111
PRAI US 2002-415981P	P	20021003		
US 2003-440234P	P	20030114		
US 2003-443752P	P	20030129		
US 2003-463818P	P	20030417		
US 2003-466983P	P	20030430		
US 2003-479295P	P	20030617		
US 2003-679209	A2	20031002		

CLASS  
 PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES  
 US 20050282814 ICM A61K031-525  
 ICS A61K031-724  
 INCL 514251000; 514058000  
 IPCI A61K0031-525 [ICM, 7]; A61K0031-519 [ICM, 7, C\*];

A61K0031-724 [ICS,7]; A61K0031-716 [ICS,7,C\*]  
 IPCR A61K0031-403 [I,C\*]; A61K0031-405 [I,A]; A61K0031-519 [I,C\*]; A61K0031-525 [I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A]; C07D0209-00 [I,C\*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C\*]; C07D0241-42 [I,A]; C07D0253-00 [I,C\*]; C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
 NCL 514/251.000; 514/058.000  
 US 20040167198 IPCI A61K0031-4985 [I,A]; C07D0471-02 [I,A]; C07D0471-00 [I,C\*]  
 IPCR A61K0031-403 [I,C\*]; A61K0031-405 [I,A]; A61K0031-519 [I,C\*]; A61K0031-525 [I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A]; C07D0209-00 [I,C\*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C\*]; C07D0241-42 [I,A]; C07D0253-00 [I,C\*]; C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
 NCL 514/414.000; 514/415.000; 548/465.000; 548/511.000; 514/249.000; 544/256.000  
 ZA 2005002328 IPCI A61K [N,S]; C07D [N,S]  
 US 20070208019 IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C\*]; A61K0031-525 [I,A]; A61K0031-519 [I,C\*]; A61K0039-395 [I,A]; A61K0031-704 [I,A]; A61K0031-7028 [I,C\*]; A61K0031-7048 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-337 [I,A]; A61K0031-404 [I,A]; A61K0031-403 [I,C\*]  
 IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-337 [I,C]; A61K0031-337 [I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A]; A61K0031-519 [I,C]; A61K0031-525 [I,A]; A61K0031-7028 [I,C]; A61K0031-704 [I,A]; A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0039-395 [I,C]; A61K0039-395 [I,A]  
 NCL 514/234.500; 424/155.100; 424/649.000; 514/027.000; 514/034.000; 514/251.000; 514/414.000; 514/449.000; 514/492.000  
 OS CASREACT 144:69859; MARPAT 144:69859  
 GI



- AB The invention relates to nitrogen heterocyclic compds. of formula I, which are useful for treating disorders associated with compromised vasculostasis. In compds. I, each of A, B, W, X, Y, and Z is independently selected from C, C(O), N, and NR3, where R3 is H or (un)substituted alkyl; each R1 is independently halo, OR4, N(R4)2, or SR4, where R4 is H, lower alkyl, aryl, heteroaryl, etc.; each R2 is independently halo, OR5, N(R5)2, SR5, OPO3H2, (un)substituted alkyl, (un)substituted aryl, (un)substituted heteroaryl, where R5 is H, lower alkyl, aryl, heteroaryl, etc.; and each of m and n is independently an integer from 1 to 4. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of a variety of disorders including stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Cyclocondensation of 3,3'-dihydroxybenzil with 2,4,5,6-tetraaminopyrimidine sulfate results in the formation of diaminopteridine II. Compound II expresses an IC50 value of 83 nM in an assay for the inhibition of the human p120γ subunit of PI3 kinase and results in 65% reduction of myocardial infarction in rats.
- ST indolyl phenyl carboxamide prepn vasculostatic; pteridine prepn vasculostatic; pyridopyrazine prepn vasculostatic; quinazoline prepn vasculostatic; benzotriazine prepn vasculostatic
- IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (HER2; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Respiratory distress syndrome  
 (acute; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Respiratory distress syndrome  
 (adult; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Antibiotics  
 (anthracycline; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Cytotoxic agents  
 (antimetabolites; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)



IT Disease, animal  
(arthropathy; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Disease, animal  
(associated with compromised vasculostasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibiotics  
(bleomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Muscle, disease  
(cancer; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Drug delivery systems  
(carriers; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Intestine, neoplasm  
(colon; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT DNA  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(crosslinking agents; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Joint, anatomical  
(disease; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Heart, disease  
(failure; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Heart, disease  
(infarction; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Drug delivery systems  
(injections; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Reperfusion  
(injury; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Capillary vessel, disease  
(leakage syndrome; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye, disease  
(macula, degeneration; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Lung, neoplasm  
(metastasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibiotics  
(mitomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Blood vessel  
(permeability; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Biological transport  
(permeation, vascular; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Alkylating agents, biological  
Angiogenesis  
Angiogenesis inhibitors  
Anti-inflammatory agents

Anti-ischemic agents  
Antiarthritics  
Antitumor agents  
Arthritis  
Autoimmune disease  
Bladder, neoplasm  
Bone, neoplasm  
Brain, neoplasm  
Burn  
Cardiovascular agents  
Combination chemotherapy  
Digestive tract, neoplasm  
Edema  
Human  
Immunomodulators  
Inflammation  
Kidney, neoplasm  
Leukemia  
Liver, neoplasm  
Lung, neoplasm  
Lymphoma  
Mammary gland, neoplasm  
Melanoma  
Microtubule  
Neoplasm  
Ovary, neoplasm  
Prostate gland, neoplasm  
Skin, neoplasm  
Spleen  
T cell (lymphocyte)

Transplant rejection  
(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Growth factor receptors  
Growth factors, animal  
Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Interleukin 2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Injury

(reperfusion; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye, disease

(retinopathy, vitreo-; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye, disease

(retinopathy; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Brain, disease

(stroke; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Drug interactions

(synergistic; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)  
 (therapeutic; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Cardiovascular agents  
 (vasculostatics; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Alkaloids, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vinca; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye  
 (vitreous humor, vitreoretinal disease; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 677297-15-3P, N-[2-(1H-Indol-2-yl)-phenyl]-2-(2-methoxyphenyl)acetamide  
 677297-25-5P, N-[2-(1H-Indol-2-yl)-phenyl]phthalamic acid 677297-30-2P,  
 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine 677297-48-2P,  
 4-(4-Aminopteridin-7-yl)-phenol 677297-51-7P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4,-diamine 677297-58-4P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine 677297-61-9P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine sulfate 677297-63-1P,  
 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-65-3P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine  
 677297-75-5P 677297-77-7P 677297-90-4P, 7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-ylamine 677298-01-0P,  
 N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-phenylamine 677298-27-0P,  
 6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 14892-98-9P 102704-20-1P, N-[2-(1H-Indol-2-yl)-phenyl]-2-phenylacetamide  
 128076-13-1P, 6-Phenylpteridin-4-ylamine 278799-97-6P,  
 6-(Benzylaminomethyl)-2,4-pteridinediamine 677297-11-9P,  
 2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-12-0P,  
 4-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-13-1P,  
 3,4-Dihydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-14-2P,  
 2-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-16-4P,  
 2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-17-5P,  
 2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide  
 677297-18-6P, 2-[1,3-Benzodioxol-5-yl]-N-[2-(1H-indol-2-yl)-phenyl]-acetamide 677297-19-7P, N-[2-(1H-Indol-2-yl)-phenyl]-3-phenylpropionamide 677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propionamide 677297-21-1P, N-[2-(1H-Indol-2-yl)-phenyl]-3-(2-methoxyphenyl)propionamide 677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propionamide 677297-23-3P, 2-(4-Hydroxyphenoxy)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-26-6P, 2-[2-(1H-Indol-2-yl)-phenyl]carbamoyl]nicotinic acid 677297-27-7P, 3,4,5-Trihydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-28-8P 677297-29-9P,  
 6,7-Bis-(4-hydroxyphenyl)pteridin-4-yl-(3-(morpholin-4-yl)propyl)amine hydrochloride 677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-aminopteridin-6-yl]-phenyl ester 677297-32-4P, Acetic acid  
 4-[2-(4-acetoxyphenyl)-6-aminopyrido[2,3-b]pyrazin-3-yl]-phenyl ester 677297-35-7P, (3,4-Dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-36-8P, (3-Chloro-4,6-dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-37-9P, (3-Hydroxy-4-methoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-38-0P, (4-Hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-39-1P, (2,5-Dimethyl-4-hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-40-4P, 2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid

677297-41-5P, 2-Diethylaminomethyl-4-(6-phenylpteridin-4-ylamino)phenol  
 677297-44-8P, Benzyl-(6-phenylpteridin-4-yl)-amine 677297-45-9P,  
 4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol 677297-46-0P,  
 Indan-2-yl-(6-phenylpteridin-4-yl)-amine 677297-47-1P,  
 2-(3,4-Dimethoxyphenyl)ethyl-(6-phenylpteridin-4-yl)-amine  
 677297-49-3P, 4-(4-Benzylaminopteridin-7-yl)-phenol 677297-53-9P,  
 6-Pyridin-2-yl-7-pyridin-3-ylpteridin-4-amine sulfate 677297-54-0P,  
 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol 677297-55-1P,  
 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride  
 677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine  
 methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-  
 diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-  
 ylamine hydrochloride 677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-  
 ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-  
 dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-  
 dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-66-4P,  
 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate  
 677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P,  
 2,3-Diphenylpyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-69-7P,  
 2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride  
 677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine  
 hydrochloride 677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-  
 8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-  
 b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-  
 hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride  
 677297-76-6P 677297-78-8P 677297-79-9P, 4-(4-Aminopteridin-7-yl)-  
 benzene-1,2-diol 677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)-benzene-1,2-  
 diol 677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)-phenol 677297-82-4P,  
 4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol 677297-83-5P,  
 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride  
 677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride  
 677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride  
 677297-86-8P, 2,3-Bis(3,4-dihydroxyphenyl)quinoxalin-6-ylamine  
 dihydrochloride 677297-89-1P, [7-(1,3-Benzodioxol-5-  
 yl)benzo[1,2,4]triazin-3-yl]amine 677297-91-5P, 7-(4-  
 Phenoxypheyl)benzo[1,2,4]triazin-3-ylamine 677297-92-6P,  
 7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-ylamine 677297-93-7P,  
 7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-ylamine 677297-94-8P,  
 7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-ylamine 677297-95-9P,  
 7-Biphenyl-4-ylbenzo[1,2,4]triazin-3-ylamine 677297-96-0P,  
 7-Benzofuran-2-ylbenzo[1,2,4]triazin-3-ylamine 677297-97-1P,  
 7-Dibenzofuran-4-ylbenzo[1,2,4]triazin-3-ylamine 677297-98-2P,  
 7-Naphthalen-1-ylbenzo[1,2,4]triazin-3-ylamine 677297-99-3P,  
 3-(3-Aminobenzo[1,2,4]triazin-7-yl)-phenol 677298-00-9P,  
 N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine  
 677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-[3-(4-  
 methylpiperazin-1-yl)-propyl]amine 677298-03-2P, N-[5-Methyl-7-(2,4,6-  
 trimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine 677298-04-3P,  
 N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-  
 phenylamine 677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-  
 methylbenzo[1,2,4]triazin-3-yl]-phenylamine 677298-06-5P,  
 N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-phenylamine  
 677298-07-6P, 7-Naphthalen-2-ylbenzo[1,2,4]triazin-3-ylamine-1-oxide  
 677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-  
 hydroxyphenyl)propionic acid tert-butyl ester 677298-09-8P,  
 6-[(Pyridin-2-ylmethyl)amino]methyl-2,4-pteridinediamine 677298-10-1P,  
 6-[(Naphthalen-1-ylmethyl)amino]methyl-2,4-pteridinediamine  
 677298-11-2P, 6-[(Adamantan-1-ylmethyl)amino]methyl-2,4-pteridinediamine  
 677298-13-4P, 6-[2-(2-Dimethylpropylamino)methyl]-2,4-pteridinediamine  
 677298-14-5P, 6-[[2-(3,4-Dimethoxyphenyl)ethylamino]methyl]-2,4-  
 pteridinediamine 677298-15-6P, 6-[[2-(3,4-Dihydroxyphenyl)ethylamino]met

hyl)-2,4-pteridinediamine 677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P 677298-18-9P, 3-(4-tert-Butoxyphenyl)-2-[(2,4-diaminopteridin-6-ylmethyl)amino]propionic acid tert-butyl ester 677298-19-0P, 1-[[Bis-(2,4-Diaminopteridin-6-ylmethyl)]-amino]methyl]naphthalene 677298-20-3P, 6-(2,6-Dimethylphenyl)-3H-quinazolin-4-one 677298-21-4P, 6-(2,6-Dimethoxyphenyl)-3H-quinazolin-4-one 677298-22-5P, 6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one 677298-23-6P, 6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one 677298-24-7P, 6-(Naphthalen-1-yl)-3H-quinazolin-4-one 677298-25-8P, 6-(Naphthalen-2-yl)-3H-quinazolin-4-one 677298-26-9P, 6-(4-Phenoxyphenyl)-3H-quinazolin-4-one 677298-28-1P, 6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one 677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one 677298-31-6P, 8-Bromo-4-[3-(4-methylpiperazin-1-yl)-propylamino]-6-nitroquinazolin-2-ol 677298-32-7P, (6,7-Diphenylpteridin-4-yl)-[3-(4-methylpiperazin-1-yl)-propyl]amine 677298-33-8P 677298-34-9P 8/1590-51-1P, (S)-2-Acetylamino-3-(4-hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propanamide 871590-52-2P, 5-(6-Phenylpteridin-4-ylamino)quinolin-8-ol hydrochloride 871590-53-3P, 6-(3,4-Dimethoxybenzylamino)methyl)-2,4-pteridinediamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 6298-38-0P, 7-Bromobenzo[1,2,4]triazin-3-ylamine-1-oxide 32084-59-6P, 6-Bromo-3H-quinazolin-4-one 52853-40-4P, 6-Bromomethyl-2,4-pteridinediamine hydrobromide 59368-16-0P, 6-Bromomethyl-2,4-pteridinediamine 677297-74-4P 677297-87-9P 677297-88-0P, [7-(1,3-Benzodioxol-5-yl)-1-oxo-benzo[1,2,4]triazin-3-yl]amine 677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 115926-52-8, Phosphoinositide-3-kinase 127464-60-2, VEGF 141349-89-5, Src kinase 141349-91-9, Yes kinase 143180-75-0 144114-16-9, Protein tyrosine kinase 2 148640-14-6, Akt kinase 372092-80-3, Protein kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 50-76-0, Dactinomycin 59-05-2, Methotrexate 64-86-8, Colchicine 477-30-5, Demecolcine 1605-68-1, Taxane 7585-39-9,  $\beta$ -Cyclodextrin 12619-70-4, Cyclodextrin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin 42077-25-8, Adriamycin-14-octanoate 50935-04-1 56420-45-2, Epirubicin 58957-92-9, Idarubicin 59367-03-2, Adriamycin-14-benzoate 64161-91-7, Adriamycin-14-naphthaleneacetate 65271-80-9, Mitoxantrone 79466-09-4, 13-Deoxydaunorubicin 84325-15-5, 11-Deoxydaunorubicin 114977-28-5, Taxotere 154447-36-6, LY294002 180288-69-1, Trastuzumab 183319-69-9, OSI-774 194615-04-8, Captisol 216974-75-3, Bevacizumab 677298-35-0, 6,7-Bis-(3-hydroxyphenyl)pteridine-2,4-diamine sulfate 892553-42-3, Vitamin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 77-92-9, Citric acid, biological studies 1404-00-8, Mitomycin 11056-06-7, Bleomycin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 51-61-6, 2-(3,4-Dihydroxyphenyl)ethylamine, reactions 62-31-7, 3-Hydroxytyramine hydrochloride 62-53-3, Aniline, reactions 69-72-7, Salicylic acid, reactions 85-44-9, Phthalic anhydride 91-56-5, Isatin 93-25-4, 2-Methoxyphenylacetic acid 97-50-7, (3-Chloro-4,6-dimethoxyphenyl)amine 99-50-3, 3,4-Dihydroxybenzoic acid 99-96-7, 4-Hydroxybenzoic acid, reactions 100-46-9, Benzylamine, reactions 102-32-9, 3,4-Dihydroxyphenylacetic acid 103-82-2, Phenylacetic acid, reactions 118-31-0, 1-Aminomethylnaphthalene 118-70-7, 4,5,6-Triaminopyrimidine 120-20-7, 2-(3,4-Dimethoxyphenyl)ethylamine 123-00-2, N-(3-Aminopropyl)morpholine 123-30-8, (4-Hydroxyphenyl)amine 134-81-6, Benzil 149-91-7, Gallic acid, reactions 156-38-7, 4-Hydroxyphenylacetic acid 501-52-0, Hydrocinnamic acid 501-97-3, 3-(4-Hydroxyphenyl)propionic acid 537-55-3, N-Acetyl-L-tyrosine 615-47-4 635-85-8, 2-(3,4-Dimethoxyphenyl)ethylamine hydrochloride 699-98-9, 2,3-Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride 875-51-4, 4-Bromo-2-nitrophenylamine 1004-74-6, 2,4,5,6-Tetraaminopyrimidine 1078-61-1, 3,4-Dihydroxyhydrocinnamic acid 1124-40-9, 3,4-Dihydroxybenzylamine hydrochloride 1423-27-4, 2-Trifluoromethyl phenylboronic acid 1687-53-2, (3-Hydroxy-4-methoxyphenyl)amine 1878-84-8, (4-Hydroxyphenoxy)acetic acid 2835-04-3, 2-Hydroxy-5-aminobenzenesulfonic acid 2861-28-1, 3,4-(Methylenedioxy)phenylacetic acid 2975-41-9, Indan-2-ylamine 3096-71-7, (2,5-Dimethyl-4-hydroxyphenyl)amine 3731-51-9, 2-(Aminomethyl)pyridine 4572-03-6, 3-(4-Methylpiperazin-1-yl)-propylamine 5122-94-1, 4-Biphenylboronic acid 5763-61-1, 3,4-Dimethoxybenzylamine 5794-88-7, 2-Amino-5-Bromobenzoic acid 5813-64-9, 2,2-Dimethylpropylamine 5980-97-2, 2,4,6-Trimethylphenylboronic acid 5993-91-9, 2-Aminomethylbenzimidazole dihydrochloride 6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6315-89-5, (3,4-Dimethoxyphenyl)amine 6342-77-4, 3-(2-Methoxyphenyl)propionic acid 13207-66-4, 5-(Amino)quinolin-8-ol 13922-41-3, 1-Naphthylboronic acid 16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4, 2-Amino-3-bromo-5-nitrobenzonitrile 17768-41-1, 1-Aminomethyl adamantane 20284-90-6, 2,3,6-Triaminopyridine dihydrochloride 21454-19-3 23112-96-1, 2,6-Dimethoxyphenylboronic acid 24645-80-5, 4-Hydroxyphenylglyoxal 24850-02-0, 6,7-Diphenylpteridin-4-ylamine 29477-55-2, 3,4-Dihydroxyphenylglyoxal 32316-92-0, 2-Naphthylboronic acid 32566-01-1, 2-(2-Aminophenyl)indole 33288-79-8, 4,4'-Dihydroxybenzil 37491-68-2, 4-[(Amino)methyl]benzene-1,2-diol 42965-55-9, 5,6-Diamino-2,4-dihydroxypyrimidine sulfate 49647-58-7, 2,4,5,6-Tetraaminopyrimidine sulfate 49721-45-1, 4,5,6-Triaminopyrimidine sulfate 51067-38-0, 4-Phenoxyphenylboronic acid 51387-92-9, 2-Diethylaminomethyl-4-(amino)phenol 63192-57-4, 3,3'-Dihydroxybenzil 76145-91-0, (2,4-Diaminopteridin-6-yl)-methanol hydrobromide 77712-97-1, 3,4,5-Triaminopyridine hydrochloride 77811-44-0, 4-Bromo-2-methyl-6-nitrophenylamine 78495-63-3, 2-Fluoro-6-methoxyphenylboronic acid 87199-18-6, 3-Hydroxyphenylboronic acid 88878-78-8, 2-Amino-3-(4-hydroxyphenyl)propionic acid tert-butyl ester 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 95195-43-0, 2,3'-Pyridil 98437-24-2, 2-Benzofuranboronic acid 100124-06-9, 4-Dibenzofuranboronic acid 100379-00-8, 2,6-Dimethylphenylboronic acid 123324-71-0, 4-tert-Butylphenylboronic acid 385370-80-9, 2-Chloro-6-methoxyphenylboronic acid 545390-26-9, 2-Amino-3-(4-tert-butoxyphenyl)propionic acid tert-butyl ester hydrochloride 677297-33-5, 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine 677297-34-6, N'-(3-Cyano-5-phenylpyrazin-2-yl)-N,N-dimethylformamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

L32 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of thiazole derivs. as modulators of the phosphoinositide  
3-kinases (PI3Ks))

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2005:673279 CAPLUS

DOCUMENT NUMBER: 143:172865

TITLE: Preparation of thiazole derivatives as modulators of  
the phosphoinositide 3-kinases (PI3Ks)

INVENTOR(S): Quattropiani, Anna; Rueckle, Thomas; Schwarz, Matthias;  
Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe;  
Desforges, Gwenaelle

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N. V., Neth.  
Antilles

SOURCE: PCT Int. Appl., 212 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068444	A2	20050728	WO 2005-EP50102	20050111
WO 2005068444	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005205201	A1	20050728	AU 2005-205201	20050111
CA 2551415	A1	20050728	CA 2005-2551415	20050111
EP 1709019	A2	20061011	EP 2005-701490	20050111
EP 1709019	B1	20070808		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN 1926121	A	20070307	CN 2005-80006639	20050111
BR 2005006749	A	20070522	BR 2005-6749	20050111
JP 2007517835	T	20070705	JP 2006-548315	20050111
AT 369349	T	20070815	AT 2005-701490	20050111
ES 2287896	T3	20071216	ES 2005-701490	20050111
IN 2006DN03731	A	20070420	IN 2006-DN3731	20060629
MX 2006PA07934	A	20060914	MX 2006-PA7934	20060711
NO 2006003606	A	20061012	NO 2006-3606	20060809
PRIORITY APPLN. INFO.:			EP 2004-100083	A 20040112
			WO 2005-EP50102	W 20050111

OTHER SOURCE(S): CASREACT 143:172865; MARPAT 143:172865

AN 2005:673279 CAPLUS

DN 143:172865

ED Entered STN: 29 Jul 2005  
 TI Preparation of thiazole derivatives as modulators of the phosphoinositide 3-kinases (PI3Ks)  
 IN Quattropiani, Anna; Rueckle, Thomas; Schwarz, Matthias; Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe; Desforges, Gwenaelle  
 PA Applied Research Systems ARS Holding N. V., Neth. Antilles  
 SO PCT Int. Appl., 212 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D277-46  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005068444	A2	20050728	WO 2005-EP50102	20050111
	WO 2005068444	A3	20050909		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005205201	A1	20050728	AU 2005-205201	20050111
	CA 2551415	A1	20050728	CA 2005-2551415	20050111
	EP 1709019	A2	20061011	EP 2005-701490	20050111
	EP 1709019	B1	20070808		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
	CN 1926121	A	20070307	CN 2005-80006639	20050111
	BR 2005006749	A	20070522	BR 2005-6749	20050111
	JP 2007517835	T	20070705	JP 2006-548315	20050111
	AT 369349	T	20070815	AT 2005-701490	20050111
	ES 2287896	T3	20071216	ES 2005-701490	20050111
	IN 2006DN03731	A	20070420	IN 2006-DN3731	20060629
	MX 2006PA07934	A	20060914	MX 2006-PA7934	20060711
	NO 2006003606	A	20061012	NO 2006-3606	20060809
PRAI	EP 2004-100083	A	20040112		
	WO 2005-EP50102	W	20050111		



CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005068444	ICM	C07D277-46
	IPCI	C07D0277-46 [ICM,7]; C07D0277-00 [ICM,7,C*]
	IPCR	C07D0277-00 [I,C*]; C07D0277-46 [I,A]; C07D0417-00 [I,C*]; C07D0417-14 [I,A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
AU 2005205201	IPCI	C07D0277-00 [I,C*]; C07D0417-00 [I,C*]; C07D0277-46 [I,A]; C07D0417-14 [I,A]
CA 2551415	IPCI	A61K0031-427 [I,A]; C07D0277-46 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]



	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
EP 1709019	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
CN 1926121	IPCI	C07D0277-46 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; A61K0031-427 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00 [I,C*]; C07D0417-14 [I,A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
BR 2005006749	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
JP 2007517835	IPCI	C07D0277-20 [I,A]; C07D0277-46 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0277-48 [I,A]; C07D0277-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-496 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-433 [I,A]; A61K0031-4709 [I,A]; A61P0025-28 [I,A]; A61P0025-14 [I,A]; A61P0025-00 [I,A]; A61P0043-00 [I,A]; A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0017-06 [I,A]; A61P0017-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61P0037-02 [I,A]; A61P0001-04 [I,A]; A61P0001-00 [I,C*]; A61P0011-00 [I,A]; A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0031-00 [I,A]; A61P0029-00 [I,A]; A61P0009-12 [I,A]; A61P0009-08 [I,A]; A61P0037-08 [I,A]; A61P0011-06 [I,A]; A61P0021-02 [I,A]; A61P0021-00 [I,C*]; A61P0035-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0037-06 [I,A]; A61P0037-00 [I,C*]; A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0015-08 [I,A]; A61P0015-00 [I,C*]
	IPCR	C07D0277-00 [I,C]; C07D0277-20 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-08 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-08 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0021-00 [I,C]; A61P0021-02 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];

A61P0025-14 [I,A]; A61P0025-28 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C]; A61P0031-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0037-06 [I,A]; A61P0037-08 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B  
 FTERM 4C033/AD04; 4C033/AD07; 4C033/AD15; 4C033/AD16; 4C033/AD17; 4C033/AD20; 4C063/AA03; 4C063/BB02; 4C063/BB07; 4C063/BB09; 4C063/CC62; 4C063/CC67; 4C063/CC73; 4C063/CC76; 4C063/CC94; 4C063/DD03; 4C063/DD04; 4C063/DD10; 4C063/DD12; 4C063/DD14; 4C063/DD47; 4C063/DD51; 4C063/DD52; 4C063/DD58; 4C063/DD62; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC82; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA10; 4C086/GA12; 4C086/MA01; 4C086/MA02; 4C086/MA04; 4C086/MA05; 4C086/NA14; 4C086/NA15; 4C086/ZA02; 4C086/ZA16; 4C086/ZA22; 4C086/ZA23; 4C086/ZA36; 4C086/ZA39; 4C086/ZA42; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59; 4C086/ZA66; 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB05; 4C086/ZB08; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB21; 4C086/ZB26; 4C086/ZB32; 4C086/ZB33; 4C086/ZB35; 4C086/ZC19; 4C086/ZC20  
 AT 369349 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B  
 ES 2287896 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B  
 IN 2006DN03731 IPCI C07D0277-46 [I,C]; C07D0277-00 [I,C]; C07D0277-00 [I,C]  
 MX 2006PA07934 IPCI A61K0031-427 [I,C]; C07D0277-46 [I,C]; C07D0277-00 [I,C]; C07D0417-14 [I,C]; C07D0417-00 [I,C]; C07D0417-00 [I,C]  
 NO 2006003606 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]  
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]  
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B  
 OS CASREACT 143:172865; MARPAT 143:172865



- AB The title compds. I [R1 = NR5R6; R2, R3, R5 = H, alkyl, alkenyl, alkynyl; R4 = H, alkyl, alkenyl, alkynyl, NR8R9 (wherein R8, R9 = H, alkyl, alkenyl, etc.); R6 = alkyl, aryl, heteroaryl, etc.], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 3-[(aminocarbonothioyl)amino]benzoic acid with N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (preparation given) afforded II.HBr which showed IC50 of 10 nM against PI3Ky.
- ST thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator
- IT Nervous system, disease  
(Huntington's chorea, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Sarcoma  
(Kaposi's, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Muscle, disease  
(atrophy, treating or preventing skeletal muscle atrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Infection  
(bacterial, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Muscle  
(cardiac, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Hypertrophy  
(cardiac, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Lung, disease

(chronic obstructive pulmonary disease, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Nervous system, disease  
(degeneration, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease  
(fibrosis, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Kidney, disease  
(glomerulonephritis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease  
(glomerulosclerosis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease  
(hypertrophy, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart, disease  
(hypertrophy, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease  
(infection, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Intestine, disease  
(inflammatory, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease  
Reperfusion  
(injury, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Neoplasm  
(metastasis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy  
(muscular, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart  
(myocardium, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Lung, disease  
(pneumonitis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy inhibitors  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Antibacterial agents  
Anticoagulants  
Antihypertensives  
Antirheumatic agents

- Antitumor agents
- Antiviral agents
- Cardiovascular agents
- Human
- Immunosuppressants
- Platelet aggregation inhibitors
  - (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Injury
  - (pulmonary, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Fibrosis
  - (renal, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Injury
  - (perfusion, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Brain, disease
  - (stroke, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Lupus erythematosus
  - (systemic, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Central nervous system, disease
  - (trauma, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Leukocyte
  - (treating or preventing leukocyte recruitment in cancer tissue; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Allergy
- Alzheimer's disease
- Anaphylaxis
- Angiogenesis
- Asthma
- Atherosclerosis
- Autoimmune disease
- Cardiovascular system, disease
- Encephalitis
- Fibrosis
- Hypertension
- Inflammation
  - Ischemia
- Kidney, disease
- Melanoma
- Meningitis
- Multiple sclerosis
- Neoplasm
- Platelet aggregation
- Psoriasis
- Rheumatoid arthritis
- Sepsis
- Thrombosis
- Transplant and Transplantation
- Transplant rejection
- Vasoconstriction
  - (treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Infection
  - (viral, treating or preventing; preparation of thiazole derivs. as

modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 860619-22-3P 860619-39-2P 860619-58-5P 860619-75-6P 860620-37-7P  
 860620-38-8P 860620-39-9P 860620-40-2P 860620-42-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 32558-17-1P 307343-36-8P 315704-54-2P 315705-71-6P 315705-72-7P  
 315705-74-9P 315705-75-0P 315705-76-1P 315705-77-2P 315705-78-3P  
 315705-79-4P 315705-80-7P 315705-81-8P 315705-82-9P 315705-83-0P  
 315705-86-3P 315705-87-4P 315705-90-9P 315705-91-0P 315705-92-1P  
 315705-94-3P 315705-95-4P 333746-52-4P 333746-55-7P 333746-64-8P  
 333746-84-2P 412919-76-7P 421580-61-2P 428836-20-8P 443747-65-7P  
 472980-88-4P 860619-23-4P 860619-24-5P 860619-25-6P 860619-26-7P  
 860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P 860619-31-4P  
 860619-32-5P 860619-33-6P 860619-34-7P 860619-35-8P 860619-36-9P  
 860619-37-0P 860619-38-1P 860619-40-5P 860619-41-6P 860619-42-7P  
 860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P 860619-47-2P  
 860619-48-3P 860619-49-4P 860619-50-7P 860619-51-8P 860619-52-9P  
 860619-53-0P 860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P  
 860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P 860619-63-2P  
 860619-64-3P 860619-65-4P 860619-66-5P 860619-67-6P 860619-68-7P  
 860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P 860619-73-4P  
 860619-74-5P 860619-76-7P 860619-77-8P 860619-78-9P 860619-79-0P  
 860619-80-3P 860619-81-4P 860619-82-5P 860619-83-6P 860619-84-7P  
 860619-85-8P 860619-86-9P 860619-87-0P 860619-88-1P 860619-89-2P  
 860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P 860619-94-9P  
 860619-95-0P 860619-96-1P 860619-98-3P 860620-00-4P 860620-02-6P  
 860620-03-7P 860620-04-8P 860620-05-9P 860620-06-0P 860620-07-1P  
 860620-08-2P 860620-09-3P 860620-10-6P 860620-11-7P 860620-12-8P  
 860620-13-9P 860620-14-0P 860620-15-1P 860620-16-2P 860620-17-3P  
 860620-18-4P 860620-19-5P 860620-20-8P 860620-21-9P 860620-22-0P  
 860620-23-1P 860620-24-2P 860620-25-3P 860620-26-4P 860620-27-5P  
 860620-28-6P 860620-29-7P 860620-30-0P 860620-31-1P 860620-32-2P  
 860620-33-3P 860620-34-4P 860620-35-5P 860620-36-6P 860620-41-3P  
 860620-43-5P 860620-44-6P 860620-45-7P 860620-46-8P 860620-47-9P  
 860620-48-0P 860620-49-1P 860620-50-4P 860620-51-5P 860620-52-6P  
 860620-53-7P 860620-70-8P 860620-75-3P 860620-76-4P 860620-77-5P  
 860620-78-6P 860620-83-3P 860620-84-4P 860620-86-6P 860620-87-7P  
 860620-88-8P 860620-89-9P 860621-18-7P 860621-19-8P 860621-20-1P  
 860621-21-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9,  $\beta$ -Alanine 109-57-9, N-Allylthiourea 109-94-4, Ethyl formate 121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 621-83-0, N-Benzylthiourea 709-72-8 1516-33-2, N-Isobutylthiourea 1516-37-6, N-(2-Methoxyphenyl)thiourea 1520-26-9 1520-27-0, N-(4-Hydroxyphenyl)thiourea 2237-30-1, 3-Aminobenzonitrile 2293-07-4, N-(4-Methoxyphenyl)thiourea 2295-31-0, 2,4-Thiazolidinedione 3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-Cyanophenyl)thiourea 3696-22-8, N-(4-Nitrophenyl)thiourea 3696-23-9,

N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea  
 5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate  
 5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9,  
 N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea 7204-48-0,  
 N-(tert-Butyl)thiourea 7366-56-5 14294-09-8, 1-  
 Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide  
 14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3 25343-29-7,  
 N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9,  
 N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea  
 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5,  
 4-Methylpiperazine-1-carbothioamide 37014-08-7 37182-75-5  
 40398-36-5, 1-Pyrrolidinecarbothioamide 51039-84-0 52992-37-7  
 55130-40-0 56541-14-1, N-Cyclopropylthiourea 61451-94-3,  
 N-(2,3-Dihydro-1H-inden-2-yl)thiourea 63467-61-8, N-(2,2-  
 Diethoxyethyl)thiourea 66892-01-1 66892-25-9, N-(Tetrahydrofuran-2-  
 ylmethyl)thiourea 72806-58-7 73161-70-3, N-(Pyridin-3-  
 ylmethyl)thiourea 73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea  
 74764-61-7 86114-63-8 99115-47-6 102353-42-4, N-(2-  
 Methoxyethyl)thiourea 102936-57-2, N-Cyclopentylthiourea 111538-46-6,  
 N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-  
 yl)ethyl)thiourea 125117-97-7, N-(6-Chloropyridin-3-yl)thiourea  
 140899-50-9 171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea  
 179927-28-7 196809-80-0 206761-87-7, N-(2-(Piperidin-1-  
 yl)ethyl)thiourea 227932-43-6 237385-80-7, N-(3-  
 (Hydroxymethyl)phenyl)thiourea 282715-65-5, N-(Pyridin-4-  
 ylmethyl)thiourea 342626-46-4 420130-44-5, N-(6-Methoxypyridin-3-  
 yl)thiourea 473706-96-6 473706-97-7 500865-55-4 572889-33-9,  
 N-Cyclobutylthiourea 618913-44-3, N-(Cyclopropylmethyl)thiourea  
 659741-74-9 659741-75-0 763887-70-3 850164-09-9  
 N-(3-Cyanophenyl)thiourea 859786-81-5 860615-45-8,  
 N-(Benzofuran-5-yl)thiourea 860617-18-1, N-(2-Chloropyridin-4-  
 yl)thiourea 860620-65-1 860620-66-2 860620-67-3 860620-68-4,  
 3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-  
 yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,  
 N-(2-Chloropyridin-3-yl)thiourea 860620-73-1, N-[3-(1,3-Oxazol-5-  
 yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea  
 860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea  
 860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]thiourea  
 860620-91-3 860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea  
 860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea 860620-94-6  
 860620-95-7 860620-96-8 860620-97-9 860620-98-0 860620-99-1  
 860621-00-7 860621-01-8 860621-02-9 860621-03-0 860621-04-1  
 860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4  
 860621-08-5 860621-09-6 860621-10-9 860621-11-0 860621-12-1  
 860621-13-2 860621-14-3 860621-15-4 860621-16-5 860621-17-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide  
 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P,  
 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate  
 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P,  
 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P, 5-(3-Nitrophenyl)-  
 1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl  
 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P 167405-28-9P,  
 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P,  
 1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P,  
 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-8P  
 860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-  
 oxazol-2-yl)acetamide 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-  
 thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-  
 (trifluoromethyl)-1,3-thiazol-2-yl]acetamide 860620-60-6P

860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate  
 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-  
 [1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoro-acetamide 860620-81-1P  
 860620-82-2P 860620-85-5P 860620-90-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide  
 3-kinases (PI3Ks))

L32 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; VEGF receptor inhibitor combination with other agents for  
 therapeutic use)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2005:283364 CAPLUS

DOCUMENT NUMBER: 142:349102

TITLE: Combinations of a VEGF receptor inhibitor with other  
 agents for therapeutic use

INVENTOR(S): Bold, Guido; Bruegggen, Josef Bernhard; Huang, Jerry  
 Min-Jian; Kinder, Frederick Ray; Lane, Heidi; Latour,  
 Elisabeth Jeanne; Manley, Paul William; Wood, Jeanette  
 Marjorie

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027973	A2	20050331	WO 2004-EP10701	20040923
WO 2005027973	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004273619	A1	20050331	AU 2004-273619	20040923
CA 2539230	A1	20050331	CA 2004-2539230	20040923
EP 1667721	A2	20060614	EP 2004-765555	20040923
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1856326	A	20061101	CN 2004-80027535	20040923
BR 2004014604	A	20061107	BR 2004-14604	20040923
JP 2007505939	T	20070315	JP 2006-527355	20040923
MX 2006PA03164	A	20060605	MX 2006-PA3164	20060320
PRIORITY APPLN. INFO.:			US 2003-505255P	P 20030923
			WO 2004-EP10701	W 20040923

OTHER SOURCE(S): MARPAT 142:349102



AN 2005:283364 CAPLUS  
 DN 142:349102  
 ED Entered STN: 01 Apr 2005  
 TI Combinations of a VEGF receptor inhibitor with other agents for  
 therapeutic use  
 IN Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry Min-Jian; Kinder,  
 Frederick Ray; Lane, Heidi; Latour, Elisabeth Jeanne; Manley, Paul  
 William; Wood, Jeanette Marjorie  
 PA Novartis Ag, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K045-06  
 ICS A61P035-00; A61P027-00; A61P009-00; A61P003-00  
 CC 1-12 (Pharmacology)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027973	A2	20050331	WO 2004-EP10701	20040923
	WO 2005027973	A3	20050909		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004273619	A1	20050331	AU 2004-273619	20040923
	CA 2539230	A1	20050331	CA 2004-2539230	20040923
	EP 1667721	A2	20060614	EP 2004-765555	20040923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1856326	A	20061101	CN 2004-80027535	20040923
	BR 2004014604	A	20061107	BR 2004-14604	20040923
	JP 2007505939	T	20070315	JP 2006-527355	20040923
	MX 2006PA03164	A	20060605	MX 2006-PA3164	20060320
PRAI	US 2003-505255P	P	20030923		
	WO 2004-EP10701	W	20040923		

CLASS	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2005027973	ICM	A61K045-06
		ICS	A61P035-00; A61P027-00; A61P009-00; A61P003-00
		IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61P0035-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0003-00 [ICS,7]
		IPCR	A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
		ECLA	A61K045/06
	AU 2004273619	IPCI	A61K0045-00 [I,C]; A61P0003-00 [I,C]; A61P0009-00 [I,C]; A61P0027-00 [I,C]; A61P0035-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00 [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
		IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00

		[I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
CA 2539230	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00 [I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
EP 1667721	ECLA	A61K045/06
	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61P0035-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0003-00 [ICS,7]
	IPCR	A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
	ECLA	A61K045/06
CN 1856326	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0035-00 [I,A]; A61P0027-00 [I,A]; A61P0009-00 [I,A]; A61P0003-00 [I,A]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
	ECLA	A61K045/06
BR 2004014604	IPCI	A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0003-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0035-00 [ICS,7]
	IPCR	A61K0045-00 [I,C*]; A61P0003-00 [I,C*]; A61P0009-00 [I,C*]; A61P0027-00 [I,C*]; A61P0035-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
	ECLA	A61K045/06
JP 2007505939	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61K0031-502 [I,A]; A61P0017-06 [I,A]; A61P0009-10 [I,A]; A61P0015-00 [I,A]; A61P0001-04 [I,A]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,A]; A61P0009-14 [I,A]; A61P0009-00 [I,C*]; A61P0027-02 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*]; A61P0027-06 [I,A]; A61P0041-00 [I,A]; A61P0027-10 [I,A]; A61P0027-00 [I,C*]; A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0037-06 [I,A]; A61P0037-00 [I,C*]; A61P0001-16 [I,A]; A61P0001-00 [I,C*]; A61P0025-00 [I,A]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0011-06 [I,A]; A61P0011-00 [I,A]; A61P0043-00 [I,A]; C07D0401-06 [N,A]; C07D0401-00 [N,C*]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0031-502 [I,C]; A61K0031-502 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C]; A61P0003-00 [I,A]; A61P0003-10 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00

[I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C];  
A61P0025-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00  
[I,A]; A61P0027-02 [I,A]; A61P0027-06 [I,A];  
A61P0027-10 [I,A]; A61P0029-00 [I,C]; A61P0029-00  
[I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];  
A61P0037-00 [I,C]; A61P0037-06 [I,A]; A61P0041-00  
[I,C]; A61P0041-00 [I,A]; A61P0043-00 [I,C];  
A61P0043-00 [I,A]; C07D0401-00 [N,C]; C07D0401-06 [N,A]

FTERM 4C063/AA01; 4C063/BB03; 4C063/CC28; 4C063/DD12;  
4C063/EE01; 4C084/AA19; 4C084/AA20; 4C084/MA02;  
4C084/NA05; 4C084/NA14; 4C084/ZA011; 4C084/ZA331;  
4C084/ZA361; 4C084/ZA441; 4C084/ZA451; 4C084/ZA541;  
4C084/ZA591; 4C084/ZA661; 4C084/ZA681; 4C084/ZA751;  
4C084/ZA811; 4C084/ZA891; 4C084/ZA961; 4C084/ZB071;  
4C084/ZB081; 4C084/ZB111; 4C084/ZB151; 4C084/ZB261;  
4C084/ZC021; 4C084/ZC351; 4C084/ZC751; 4C086/AA01;  
4C086/AA02; 4C086/BC41; 4C086/MA02; 4C086/MA04;  
4C086/NA05; 4C086/NA14; 4C086/ZA01; 4C086/ZA33;  
4C086/ZA36; 4C086/ZA44; 4C086/ZA45; 4C086/ZA54;  
4C086/ZA59; 4C086/ZA66; 4C086/ZA68; 4C086/ZA75;  
4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB07;  
4C086/ZB08; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26;  
4C086/ZC02; 4C086/ZC35; 4C086/ZC75

MX 2006PA03164 IPCI A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C\*];  
A61P0027-00 [ICS,7]; A61P0003-00 [ICS,7]; A61P0035-00  
[ICS,7]; A61P0009-00 [ICS,7]  
A61K045/06

ECLA

OS MARPAT 142:349102

AB The invention discloses a combination therapy for treating  
patients suffering from diseases characterized by cell proliferation and  
infiltration of inflammatory cells, coronary diseases, hypertension, renal  
diseases, diabetes, or ocular diseases and conditions. The patient is  
treated with a combination of a VEGF inhibitor compound and one or more  
second therapeutic agents selected from angiostatic steroids,  
photosensitizers, implants containing corticosteroids, AT1 receptor  
antagonists, ACE inhibitors, cyclooxygenase inhibitors, IGF-IR inhibitors,  
mTOR kinase inhibitors, somatostatin receptor antagonists, P13K  
inhibitors, Raf kinase inhibitors, PKC inhibitors; xiii. integrin  
antagonists, endogenous anti-angiogenic mols., and PEDF (pigment  
epithelium-derived factor) and analogs.

ST VEGF receptor inhibitor combination therapeutic; cell proliferation  
inflammatory cell infiltration VEGF receptor inhibitor combination;  
coronary renal disease hypertension VEGF receptor inhibitor combination  
therapeutic; diabetes eye disease VEGF receptor inhibitor combination  
therapeutic

IT Inflammation  
(Crohn's disease; VEGF receptor inhibitor combination with other agents  
for therapeutic use)

IT Intestine, disease  
(Crohn's; VEGF receptor inhibitor combination with other agents for  
therapeutic use)

IT Angiogenesis inhibitors  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiarteriosclerotics  
Antiarthritics  
Antiasthmatics  
Anticoagulants  
Antidiabetic agents  
Antiglaucoma agents  
Antihypertensives

Antirheumatic agents  
Antitumor agents  
Arteriosclerosis  
Arthritis  
Asthma  
Cardiovascular agents  
Cell proliferation  
Cirrhosis  
Combination chemotherapy  
Cytotoxic agents  
Diabetes mellitus  
Drug delivery systems  
Eye, disease  
Fibrosis  
Gastrointestinal agents  
Heart, disease  
Human  
Hypertension  
Immunosuppressants  
Inflammation  
Kidney, disease  
Nervous system agents  
Photosensitizers, pharmaceutical  
Prophylaxis  
Rheumatoid arthritis  
Thrombosis  
Transplant rejection  
Wound

Wound healing promoters

(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Corticosteroids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Aging, animal

(age spots; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, neoplasm

(angiofibroma; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Steroids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(angiostatic; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiotensin AT1 receptors

Integrins

Somatostatin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel

(artificial; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Bronchi, disease

Inflammation  
(chronic bronchitis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Dermatitis  
(contact; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation  
(cornea, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye  
(cornea, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye  
(cornea, transplant, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(cystoid macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(diabetic macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease  
(diabetic nephropathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(diabetic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Uterus, disease  
(endometriosis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease  
(glomerulus; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, neoplasm  
(hemangioma; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Drug delivery systems  
(implants, corticosteroid-containing; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Insulin-like growth factor I receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Nerve, disease  
(injury; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye  
(iris, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Ischemia  
(ischemic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation  
(kidney; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(macula, senile degeneration; VEGF receptor inhibitor combination with

other agents for therapeutic use)

IT Eye, disease  
(macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Medical goods  
(mech. devices for holding vessels open; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney  
(mesangium, proliferative disease; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease  
(microangiopathy, thrombotic microangiopathic syndrome; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vision disorders  
(myopia, pathol.; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Glaucoma (disease)  
(neovascular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis  
(neovascularization, ocular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis  
(neovascularization, retinal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease  
(nephrosclerosis, malignant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Injury  
(neuronal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vein, disease  
(occlusion, central vein occlusion; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease  
(occlusion, re-occlusion after balloon catheter treatment; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Histoplasma capsulatum  
(ocular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Disease, animal  
(proliferative; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angioplasty  
(re-occlusion after; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Artery, disease  
(restenosis, stent-induced; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(retina, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(retinopathy, ischemic; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease  
(retrolental fibroplasia; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Wound healing  
(scar-free; VEGF receptor inhibitor combination with other agents for

therapeutic use)

IT Medical goods  
(stents, restenosis induced by; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney  
(transplant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 127464-60-2, VEGF 386705-49-3, Vascular endothelial growth factor receptor kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 50-02-2, Dexamethasone 124-94-7, Triamcinolone 807-38-5, Fluocinolone 7753-60-8, Anecortave 83150-76-9, Octreotide 86541-75-5, Benazepril 129497-78-5, BPD-MA 137862-53-4, Valsartan 159351-69-6, Everolimus 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 197980-93-1, Pigment epithelium-derived factor 197980-93-1D, Pigment epithelium-derived factor, analogs 212141-54-3 220991-20-8, Lumiracoxib 396091-73-9, SOM230  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(VEGF receptor inhibitor combination with other agents for therapeutic use)


IT 9015-82-1 39391-18-9, Cyclooxygenase 103843-29-4, IGF-1 receptor tyrosine kinase 115926-52-8, PI3 kinase 139691-76-2, Raf kinase 141436-78-4, Protein kinase C 171715-28-9, MTOR kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

L32 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 39755-95-8, 5-Methoxy isatin  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

RN 39755-95-8 CAPLUS

CN 1H-Indole-2,3-dione, 5-methoxy- (CA INDEX NAME)



ACCESSION NUMBER: 2005:238947 CAPLUS  
DOCUMENT NUMBER: 142:316831  
TITLE: Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun

PATENT ASSIGNEE(S): Kemia, Inc., USA  
SOURCE: PCT Int. Appl., 316 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004270733	A1	20050317	AU 2004-270733	20040910
CA 2538820	A1	20050317	CA 2004-2538820	20040910
US 20050107399	A1	20050519	US 2004-939324	20040910
EP 1670787	A2	20060621	EP 2004-809707	20040910
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014313	A	20061107	BR 2004-14313	20040910
CN 1878769	A	20061213	CN 2004-80033055	20040910
JP 2007505127	T	20070308	JP 2006-526272	20040910
KR 2007020370	A	20070221	KR 2006-705055	20060310
MX 2006PA02853	A	20060614	MX 2006-PA2853	20060313
IN 2006KN00791	A	20080215	IN 2006-KN791	20060331
PRIORITY APPLN. INFO.:			US 2003-502569P	P 20030911
			US 2003-531234P	P 20031218
			US 2004-575704P	P 20040528
			US 2004-585012P	P 20040702
			WO 2004-US29372	W 20040910

OTHER SOURCE(S): CASREACT 142:316831; MARPAT 142:316831

AN 2005:238947 CAPLUS

DN 142:316831

ED Entered STN: 18 Mar 2005

TI Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases

IN Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun

PA Kemia, Inc., USA

SO PCT Int. Appl., 316 pp.  
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004270733 A1 20050317 AU 2004-270733 20040910  
 CA 2538820 A1 20050317 CA 2004-2538820 20040910  
 US 20050107399 A1 20050519 US 2004-939324 20040910  
 EP 1670787 A2 20060621 EP 2004-809707 20040910

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004014313 A 20061107 BR 2004-14313 20040910  
 CN 1878769 A 20061213 CN 2004-80033055 20040910  
 JP 2007505127 T 20070308 JP 2006-526272 20040910  
 KR 2007020370 A 20070221 KR 2006-705055 20060310  
 MX 2006PA02853 A 20060614 MX 2006-PA2853 20060313  
 IN 2006KN00791 A 20080215 IN 2006-KN791 20060331

PRAI US 2003-502569P P 20030911  
 US 2003-531234P P 20031218  
 US 2004-575704P P 20040528  
 US 2004-585012P P 20040702  
 WO 2004-US29372 W 20040910



# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2005023761	ICM ICPI IPCR	C07D C07D [ICM,7] A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]
AU 2004270733	ICPI IPCR	C07D0403-00 [I,C*]; A61K0031-416 [I,C*]; C07D0403-12 [I,A]; A61K0031-416 [I,A] C07D0403-00 [I,C*]; C07D0403-12 [I,A]; A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]
CA 2538820	ICPI IPCR	A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00 [I,C*] C07D0403-00 [I,C]; C07D0403-12 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A]; C07D [I,S]
US 20050107399	ICPI IPCR NCL	A61K0031-4965 [ICM,7] A61K0031-4965 [I,C*]; A61K0031-4965 [I,A] 514/255.060; 514/356.000; 514/617.000
EP 1670787	ICPI IPCR	C07D0403-12 [ICM,7]; C07D0403-00 [ICM,7,C*]; A61K0031-416 [ICS,7] A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]
BR 2004014313	ICPI IPCR	C07D0403-12 [ICS,7]; C07D0403-00 [ICS,7,C*]; A61K0031-416 [ICS,7] A61K0031-416 [I,C*]; C07D0403-00 [I,C*]; A61K0031-416 [I,A]; C07D0403-12 [I,A]
CN 1878769	ICPI IPCR	C07D0403-12 [I,A]; C07D0403-00 [I,C*]; A61K0031-416 [I,A] C07D0403-00 [I,C]; C07D0403-12 [I,A]
JP 2007505127	ICPI	C07D0207-40 [I,A]; C07D0207-00 [I,C*]; C07D0231-38 [I,A]; C07D0231-00 [I,C*]; C07D0239-47 [I,A]; C07D0239-00 [I,C*]; C07D0249-12 [I,A]; C07D0249-00 [I,C*]; C07D0253-06 [I,A]; C07D0253-00 [I,C*]; C07D0295-08 [I,A]; C07D0295-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]; A61K0031-415 [I,A]; A61K0031-437

[I,A]; A61K0031-4353 [I,C\*]; A61K0031-5375 [I,A];  
 A61K0031-5377 [I,A]; A61P0001-02 [I,A]; A61P0001-04  
 [I,A]; A61P0001-14 [I,A]; A61P0001-18 [I,A];  
 A61P0001-00 [I,C\*]; A61P0003-00 [I,A]; A61P0003-04  
 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];  
 A61P0005-48 [I,A]; A61P0005-00 [I,C\*]; A61P0007-00  
 [I,A]; A61P0007-02 [I,A]; A61P0009-00 [I,A];  
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0009-14  
 [I,A]; A61P0011-00 [I,A]; A61P0011-02 [I,A];  
 A61P0011-06 [I,A]; A61P0011-10 [I,A]; A61P0013-02  
 [I,A]; A61P0013-12 [I,A]; A61P0013-00 [I,C\*];  
 A61P0015-00 [I,A]; A61P0017-00 [I,A]; A61P0017-02  
 [I,A]; A61P0017-06 [I,A]; A61P0017-10 [I,A];  
 A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-10  
 [I,A]; A61P0019-00 [I,C\*]; A61P0021-00 [I,A];  
 A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-08  
 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A];  
 A61P0025-18 [I,A]; A61P0025-22 [I,A]; A61P0025-24  
 [I,A]; A61P0025-28 [I,A]; A61P0025-30 [I,A];  
 A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0027-14  
 [I,A]; A61P0027-00 [I,C\*]; A61P0029-00 [I,A];  
 A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12  
 [I,A]; A61P0031-18 [I,A]; A61P0031-00 [I,C\*];  
 A61P0033-06 [I,A]; A61P0033-00 [I,C\*]; A61P0035-00  
 [I,A]; A61P0037-00 [I,A]; A61P0037-02 [I,A];  
 A61P0039-00 [I,A]; A61P0043-00 [I,A]  
 IPCR C07D0207-00 [I,C]; C07D0207-40 [I,A]; A61K0031-415  
 [I,C]; A61K0031-415 [I,A]; A61K0031-416 [I,C\*];  
 A61K0031-416 [I,A]; A61K0031-4353 [I,C]; A61K0031-437  
 [I,A]; A61K0031-5375 [I,C]; A61K0031-5375 [I,A];  
 A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-02  
 [I,A]; A61P0001-04 [I,A]; A61P0001-14 [I,A];  
 A61P0001-18 [I,A]; A61P0003-00 [I,C]; A61P0003-00  
 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];  
 A61P0003-10 [I,A]; A61P0005-00 [I,C]; A61P0005-48  
 [I,A]; A61P0007-00 [I,C]; A61P0007-00 [I,A];  
 A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00  
 [I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A];  
 A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00  
 [I,A]; A61P0011-02 [I,A]; A61P0011-06 [I,A];  
 A61P0011-10 [I,A]; A61P0013-00 [I,C]; A61P0013-02  
 [I,A]; A61P0013-12 [I,A]; A61P0015-00 [I,C];  
 A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00  
 [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A];  
 A61P0017-10 [I,A]; A61P0019-00 [I,C]; A61P0019-02  
 [I,A]; A61P0019-06 [I,A]; A61P0019-10 [I,A];  
 A61P0021-00 [I,C]; A61P0021-00 [I,A]; A61P0025-00  
 [I,C]; A61P0025-00 [I,A]; A61P0025-04 [I,A];  
 A61P0025-08 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
 [I,A]; A61P0025-18 [I,A]; A61P0025-22 [I,A];  
 A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0025-30  
 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];  
 A61P0027-06 [I,A]; A61P0027-14 [I,A]; A61P0029-00  
 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];  
 A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12  
 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C];  
 A61P0033-06 [I,A]; A61P0035-00 [I,C]; A61P0035-00  
 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A];  
 A61P0037-02 [I,A]; A61P0039-00 [I,C]; A61P0039-00  
 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D  
 [I,S]; C07D0231-00 [I,C]; C07D0231-38 [I,A];

C07D0239-00 [I,C]; C07D0239-47 [I,A]; C07D0249-00 [I,C]; C07D0249-12 [I,A]; C07D0253-00 [I,C]; C07D0253-06 [I,A]; C07D0295-00 [I,C]; C07D0295-08 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]  
 FTERM 4C050/AA01; 4C050/BB05; 4C050/CC05; 4C050/EE04; 4C050/FF02; 4C050/FF05; 4C050/GG01; 4C050/HH04; 4C065/AA04; 4C065/BB06; 4C065/CC01; 4C065/DD03; 4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK09; 4C065/LL04; 4C065/PP03; 4C065/PP04; 4C069/AC32; 4C069/BB08; 4C069/BB16; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC36; 4C086/BC73; 4C086/CB03; 4C086/CB05; 4C086/GA07; 4C086/GA12; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA06; 4C086/ZA08; 4C086/ZA12; 4C086/ZA16; 4C086/ZA18; 4C086/ZA21; 4C086/ZA22; 4C086/ZA29; 4C086/ZA33; 4C086/ZA34; 4C086/ZA36; 4C086/ZA44; 4C086/ZA45; 4C086/ZA51; 4C086/ZA54; 4C086/ZA59; 4C086/ZA63; 4C086/ZA66; 4C086/ZA68; 4C086/ZA69; 4C086/ZA70; 4C086/ZA75; 4C086/ZA81; 4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97; 4C086/ZB01; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB21; 4C086/ZB26; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZC01; 4C086/ZC31; 4C086/ZC33; 4C086/ZC35; 4C086/ZC37; 4C086/ZC39; 4C086/ZC41; 4C086/ZC54; 4C086/ZC55  
 KR 2007020370 IPCI A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00 [I,C\*]; A61K0031-4965 [I,A]  
 MX 2006PA02853 IPCI A61K0031-416 [ICM,7]; C07D0403-12 [ICS,7]; C07D0403-00 [ICS,7,C\*]  
 IN 2006KN00791 IPCI C07D0403-12 [ICM,7]; C07D0403-00 [ICM,7,C\*]; A61K0031-416 [ICS,7]  
 OS CASREACT 142:316831; MARPAT 142:316831  
 GI



AB Title compds., such as I and II (four Markush structures are claimed), wherein X = C(O), C(S) or CH<sub>2</sub>; G = (un)substituted carbocyclyl or heterocyclyl; Ar = indazolyl, indolyl, pyrazolyl, alkyl, etc.; L = covalent bond or (un)substituted carbon chain; Q = H, (un)substituted amino, cycloalkyl, heterocyclyl, alkoxy or sulfonyl; with some limitations and exclusions, and stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, were prepared as cytokine inhibitors. For instance, cyclization of p-tolylhydrazine hydrochloride with 4,4-dimethyl-3-oxopentananitrile to the corresponding pyrazolamine

(92% yield) followed by EDC-mediated coupling with indazole-3-carboxylic acid gave indazolopyrazole III (40% yield). I were found to have activity in the TNFa ELISA assay, with some compds. having IC50 < 10 µM. Therefore, I and their pharmaceutical compns. are useful in preventing or treating conditions mediated by cytokines, such as arthritis and inflammatory diseases.

- ST pyrazolamine aniline amide prepn cytokine TNF inhibitor antiinflammatory agent
- IT AIDS (disease)
  - (AIDS dementia complex, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Mental and behavioral disorders
  - (AIDS dementia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Lymph node, disease
  - (Castleman's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Inflammation
  - (Crohn's disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Intestine, disease
  - (Crohn's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Selectins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (E-, compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
  - (Gilles de la Tourette syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Nervous system, disease
  - (Guillain-Barre syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Nervous system, disease
  - (Huntington's chorea, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
  - (MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Muscle, disease
  - (MERRF (myoclonic epilepsy associated with ragged-red muscle fibers), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Arthritis
  - (Reiter's syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
  - (Rett syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Anti-infective agents
  - (SARS; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Pain
  - (acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Respiratory distress syndrome
  - (adult, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Allergy

Eye, disease  
 Inflammation  
 (allergic conjunctivitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Allergy  
 Inflammation  
 Nose, disease  
 (allergic rhinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Transplant rejection  
 (allotransplant; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Nervous system, disease  
 (amyotrophic lateral sclerosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Nervous system agents  
 (amyotrophic lateral sclerosis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Antiarteriosclerotics  
 (antiatherosclerotics; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Artery, disease  
 Inflammation  
 (arteritis, Takayasu, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Disease, animal  
 (arthropathy, bursitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Animal tissue  
 (artificial, phantom, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Infection  
 (aseptic meningitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Meningitis  
 (aseptic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Dermatitis  
 (atopic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Meningitis  
 (bacterial, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Bronchi, disease  
 Inflammation  
 (bronchitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Medical goods  
 (cannulas; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Ischemia  
 (cardiac, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Heart, disease  
 (cardiomyopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Inflammation  
 (carditis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)  
 IT Lung, disease

(chronic obstructive pulmonary disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
Lung, disease  
(chronic pneumonitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain  
(chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Headache  
(cluster, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, neoplasm  
(colon, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Adhesion, biological  
(comps. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Angiogenesis inhibitors  
Anticoagulants  
Cytotoxic agents  
Immunomodulators  
Immunosuppressants  
(comps. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT CTLA-4 (antigen)  
Glucocorticoids  
Interleukin 1 receptor antagonist  
LFA-1 (antigen)  
Macrolides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(comps. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Dermatitis  
(contact, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease  
(coronary, occlusion, acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease  
(coronary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Ulcer  
(cutaneous, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
(decreased cardiac output, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Muscle, disease  
(degeneration, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease  
(demyelination, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Mental and behavioral disorders  
(depression, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Kidney, disease

(diabetic nephropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
(diabetic retinopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease  
(diminished lung compliance, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Toxins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(diphtheria, DAB389, compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Joint, anatomical  
(disease, bursitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Viscera  
(disease, pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tendon  
(disease, tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tendon  
(disease, tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Platelet (blood)  
(disease, thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood coagulation disorders  
(disseminated intravascular coagulation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis  
(during pregnancy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease  
(embolism, massive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease  
(embolism, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Uterus, disease  
(endometriosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
Kidney, disease  
(failure, chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
(failure, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Muscle, disease  
(fibromyalgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Kidney, disease  
(fibrosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Meningitis  
(fulminant meningococcemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

Kidney, disease  
 (glomerulonephritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Transplant and Transplantation  
 (graft-vs.-host reaction; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease  
 (hepatic encephalopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
 (hereditary optic atrophy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inborn errors of metabolism  
 (homocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders  
 (hydroxybutyric aminoaciduria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inborn errors of metabolism  
 (hyperhomocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders  
 (hyperprolinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Mucus  
 (hypersecretion, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
 (infarction, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis  
 (infectious, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Respiratory system, disease  
 (inflammation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, disease  
 (inflammatory, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tumor necrosis factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
 (injury, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Reperfusion  
 Spinal cord, disease  
 (injury, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Spinal column, disease  
 (intervertebral disk syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, disease  
 (irritable bowel syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
 (ischemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)



IT Brain, disease  
(lead, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Infection  
(leishmaniasis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Headache  
(migraine, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
Inflammation  
(myocarditis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Skin, disease  
(necrosis, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease  
Pain  
(neuralgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
Nerve, disease  
(neuritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease  
(neuropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lymphoma  
(nodular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lymphoma  
(non-Hodgkin's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
(non-articular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders  
(nonketotic hyperglycinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Anti-inflammatory agents  
(nonsteroidal, comps. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease  
(occlusion, acute peripheral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Injury  
(ocular, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain  
(osteo-traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
Pancreas, disease  
(pancreatitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
(periretinal proliferation, trauma-induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease  
 (polyneuropathy, treatment of; preparation of amides of  
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Allergy inhibitors  
 Analgesics  
 Anti-AIDS agents  
 Anti-Alzheimer's agents  
 Anti-inflammatory agents  
 Antiarthritics  
 Antiasthmatics  
 Anticonvulsants  
 Antidepressants  
 Antidiabetic agents  
 Antiglaucoma agents  
 Antimalarials  
 Antimigraine agents  
 Antiobesity agents  
 Antiparkinsonian agents  
 Antipsychotics  
 Antirheumatic agents  
 Antitumor agents  
 Anxiolytics  
 Drug tolerance  
 Fibrinolytics  
 Hematopoietic precursor cell  
 Human  
 Parturition  
 Rheumatoid arthritis  
 Surgery  
 Vascular resistance  
 (preparation of amides of pyrazolamines and anilines as well as analogs as  
 cytokine inhibitors)

IT Arthritis  
 (psoriatic arthritis, treatment of; preparation of amides of  
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Embolism  
 (pulmonary, massive, treatment of; preparation of amides of  
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Embolism  
 (pulmonary, treatment of; preparation of amides of pyrazolamines  
 and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease  
 (reflex sympathetic dystrophy, treatment of; preparation of amides  
 of pyrazolamines and anilines as well as analogs as cytokine  
 inhibitors)

IT Fibrosis  
 (renal, treatment of; preparation of amides of pyrazolamines and  
 anilines as well as analogs as cytokine inhibitors)

IT Injury  
 (reperfusion, treatment of; preparation of amides of pyrazolamines  
 and anilines as well as analogs as cytokine inhibitors)

IT Bone, disease  
 (resorption, treatment of; preparation of amides of pyrazolamines  
 and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
 (respiratory tract, treatment of; preparation of amides of  
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease  
 (restenosis, treatment of; preparation of amides of pyrazolamines  
 and anilines as well as analogs as cytokine inhibitors)

IT Cardiovascular agents

(restenosis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
(retinal ischemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Ischemia  
(retinal, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal  
(sciatica, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Necrosis  
(skin, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Injury  
(spinal cord, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease  
(spinocerebellar ataxia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis  
(spondylarthritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
Spinal column, disease  
(spondylitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease  
(stroke, acute thrombotic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease  
(stroke, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis  
Synovial membrane, disease  
(synovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lupus erythematosus  
(systemic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
(tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
(tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood, disease  
(thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Shock (circulatory collapse)  
(toxic shock syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Central nervous system, disease  
Injury  
(trauma, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis  
(traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Hepatitis C virus

Human immunodeficiency virus  
(treatment of infection from; preparation of amides of  
pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT AIDS (disease)  
Acne  
Acute myeloid leukemia  
Alcoholism  
Alzheimer's disease  
Aneurysm  
Angiogenesis  
Anorexia  
Anxiety  
Asthma  
Atherosclerosis  
Blood coagulation  
Bulimia  
Cachexia  
Convulsion  
Diabetes insipidus  
Diabetes mellitus  
Drug dependence  
Drug resistance  
Eczema  
Emphysema  
Endotoxemia  
Epilepsy  
Familial hypercholesterolemia  
Fibrinolytic disorders  
Glaucoma (disease)  
Gout  
Hypercholesterolemia  
Hypotension  
Infection  
Leprosy  
Leukocytopenia  
Lung, neoplasm  
Lyme disease  
Malaria  
Mammary gland, neoplasm  
Multiple myeloma  
Multiple sclerosis  
Musculoskeletal diseases  
Myelodysplastic syndromes  
Neoplasm  
Obesity  
Osteoarthritis  
Osteoporosis  
Pain  
Parkinson's disease  
Prostate gland, neoplasm  
Psoriasis  
Rubella  
Schizophrenia  
Seizures  
Sepsis  
Silicosis  
Thrombosis  
Thrombus  
Wernicke-Korsakoff syndrome  
(treatment of; preparation of amides of pyrazolamines and anilines  
as well as analogs as cytokine inhibitors)

IT Skin, disease  
(ulcer, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation  
Intestine, disease  
(ulcerative colitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease  
Inflammation  
(uveitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease  
(valve, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood vessel, disease  
Inflammation  
(vasculitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Liver, disease  
(venoocclusive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis  
(venous, axillary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis  
(venous, massive iliofemoral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis  
(venous, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal  
(visceral pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain  
(visceral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\alpha$ , compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 80449-02-1  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 127464-60-2, VEGF  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(compns. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-35-1, Thalidomide 50-78-2, Aspirin 52-67-5, D-Penicillamine 53-86-1, Indomethacin 54-21-7, Sodium salicylate 58-32-2, Dipyridamole 59-05-2, Methotrexate 61-68-7, Mefenamic acid 67-73-2, Fluocinolone acetonide 67-97-0, Vitamin D3 76-25-5, Triamcinolone acetonide 77-86-1, Tromethamine 80-08-0, Dapsone 83-43-2, Methylprednisolone 89-57-6, 5-ASA 91-64-5, Coumarin 103-90-2, Acetaminophen 118-42-3, Hydroxychloroquine 127-07-1, Hydroxyurea 154-42-7, 6-Thioguanine 305-03-3, Chlorambucil 356-12-7, Fluciclonide 378-44-9, Betamethasone 446-86-6, Azathioprine 552-94-3, Salsalate 599-79-1, Sulfasalazine 2016-36-6, Choline salicylate 2607-06-9, Diflucortolone 3615-24-5, Ramifenazone

5104-49-4, Flurbiprofen 6385-02-0, Meclofenamate sodium 6493-05-6  
 9002-01-1, Streptokinase 9005-49-6, Heparin, biological studies  
 9039-53-6, Urokinase 10118-90-8, Minocycline 12244-57-4, Gold sodium  
 thiomalate 14484-47-0, Deflazacort 15307-86-5, Diclofenac  
 15687-27-1, Ibuprofen 18917-89-0, Magnesium salicylate 21256-18-8,  
 Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4,  
 Diflunisal 23187-87-3, Choline magnesium salicylate 26171-23-3,  
 Tolmetin 31441-78-8, Mercaptopurine 31842-01-0, Indoprofen  
 32222-06-3, 1a,25-Dihydroxyvitamin D3 33005-95-7, Tiaprofenic acid  
 33069-62-4, Taxol 34031-32-8, Auranoftin 34597-40-5, Fenopropfen calcium  
 36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac  
 42924-53-8, Nabumetone 51333-22-3, Budesonide 51803-78-2, Nimesulide  
 53123-88-9, Sirolimus 53716-49-7, Carprofen 54063-32-0, Clobetasone  
 55142-85-3, Ticlopidine 57333-96-7, Tacalcitol 59865-13-3,  
 Cyclosporine A 63798-73-2, Cyclosporine 70374-27-5, Lomoxicam  
 70374-39-9, Lornoxicam 71125-38-7, Meloxicam 74103-06-3, Ketorolac  
 75706-12-6, Leflunomide 80937-31-1, Flosulide 82657-92-9, Pro-UK  
 87653-67-6, Aggrenox 90566-53-3, Fluticasone 98651-66-2, Halobetasol  
 103370-86-1, Parathyroid hormone-related peptide 103909-75-7,  
 Maxacalcitol 104987-11-3, Tacrolimus 104987-12-4, Ascomycin  
 105102-22-5, Mometasone 105913-11-9, Plasminogen activator  
 106362-32-7, Peptide T 112965-21-6, Calcipotriol 113665-84-2,  
 Clopidogrel 128794-94-5, Mycophenolate mofetil 137071-32-0,  
 Pimecrolimus 143090-92-0, Anakinra 143653-53-6, Abciximab  
 144494-65-5, Aggrastat 145155-23-3, Interferon beta-1B 152923-56-3,  
 Daclizumab 162011-90-7, Rofecoxib 169590-42-5, Celecoxib  
 170277-31-3, Infliximab 173146-27-5, DAB389 IL-2 179045-86-4,  
 Basiliximab 181695-72-7, Valdecoxib 185243-69-0, Etanercept  
 186627-80-7, Integrilin 202409-33-4, Etoricoxib 214745-43-4,  
 Efalizumab 222535-22-0, Alefacept 331731-18-1, Adalimumab  
 679809-58-6, Enoxaparin sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. comprising of; preparation of amides of pyrazolamines and anilines  
 as well as analogs as cytokine inhibitors)

IT 9029-38-3, Sulfite oxidase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (deficiency, treatment of; preparation of amides of pyrazolamines  
 and anilines as well as analogs as cytokine inhibitors)

IT 848144-15-0P 848144-45-6P 848144-49-0P 848144-84-3P 848144-85-4P  
 848145-00-6P 848145-02-8P 848150-50-5P

RL: RCT (Pharmacological activity); PCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (inhibitor; preparation of amides of pyrazolamines and anilines as well as  
 analogs as cytokine inhibitors)

IT 105438-50-4P 763089-51-6P 848144-05-8P 848144-09-2P 848144-12-7P  
 848144-14-9P 848144-21-8P 848144-26-3P 848144-31-0P 848144-32-1P  
 848144-34-3P 848144-35-4P 848144-39-8P 848144-42-3P 848144-47-8P  
 848144-48-9P 848144-50-3P 848144-64-9P 848144-77-4P 848144-78-5P  
 848144-89-8P 848144-90-1P 848144-91-2P 848144-92-3P 848144-94-5P  
 848144-96-7P 848144-98-9P 848145-01-7P 848145-05-1P 848145-07-3P  
 848145-08-4P 848145-09-5P 848145-10-8P 848145-11-9P 848145-12-0P  
 848145-13-1P 848145-14-2P 848145-15-3P 848145-16-4P 848145-17-5P  
 848145-18-6P 848145-19-7P 848145-20-0P 848145-21-1P 848145-22-2P  
 848145-23-3P 848145-24-4P 848145-25-5P 848145-26-6P 848145-27-7P  
 848145-28-8P 848145-29-9P 848145-30-2P 848145-31-3P 848145-32-4P  
 848145-33-5P 848145-34-6P 848145-35-7P 848145-36-8P 848145-37-9P  
 848145-38-0P 848145-39-1P 848145-40-4P 848145-41-5P 848145-42-6P  
 848145-43-7P 848145-44-8P 848145-45-9P 848145-46-0P 848145-47-1P  
 848145-48-2P 848145-49-3P 848145-50-6P 848145-51-7P 848145-52-8P  
 848145-53-9P 848145-54-0P 848145-55-1P 848145-56-2P 848145-57-3P

848145-58-4P	848145-59-5P	848145-60-8P	848145-61-9P	848145-62-0P
848145-63-1P	848145-64-2P	848145-65-3P	848145-66-4P	848145-67-5P
848145-68-6P	848145-69-7P	848145-71-1P	848145-72-2P	848145-73-3P
848145-74-4P	848145-75-5P	848145-76-6P	848145-77-7P	848145-78-8P
848145-79-9P	848145-80-2P	848145-81-3P	848145-82-4P	848145-83-5P
848145-84-6P	848145-85-7P	848145-86-8P	848145-87-9P	848145-88-0P
848145-89-1P	848145-90-4P	848145-91-5P	848145-92-6P	848145-93-7P
848145-94-8P	848145-95-9P	848145-96-0P	848145-97-1P	848145-98-2P
848145-99-3P	848146-00-9P	848146-01-0P	848146-02-1P	848146-03-2P
848146-04-3P	848146-05-4P	848146-06-5P	848146-07-6P	848146-08-7P
848146-09-8P	848146-10-1P	848146-11-2P	848146-12-3P	848146-13-4P
848146-14-5P	848146-15-6P	848146-16-7P	848146-17-8P	848146-18-9P
848146-19-0P	848146-20-3P	848146-21-4P	848146-22-5P	848146-23-6P
848146-24-7P	848146-25-8P	848146-26-9P	848146-27-0P	848146-28-1P
848146-29-2P	848146-30-5P	848146-31-6P	848146-32-7P	848146-33-8P
848146-34-9P	848146-35-0P	848146-36-1P	848146-37-2P	848146-38-3P
848146-39-4P	848146-40-7P	848146-41-8P	848146-42-9P	848146-43-0P
848146-44-1P	848146-45-2P	848146-46-3P	848146-47-4P	848146-48-5P
848146-49-6P	848146-50-9P	848146-51-0P	848146-52-1P	848146-53-2P
848146-54-3P	848146-55-4P	848146-56-5P	848146-57-6P	848146-58-7P
848146-59-8P	848146-60-1P	848146-61-2P	848146-62-3P	848146-63-4P
848146-64-5P	848146-65-6P	848146-66-7P	848146-67-8P	848146-68-9P
848146-69-0P	848146-70-3P	848146-71-4P	848146-72-5P	848146-73-6P
848146-75-8P	848146-77-0P	848146-79-2P	848146-81-6P	848146-82-7P
848146-83-8P	848146-84-9P	848146-85-0P	848146-86-1P	848146-87-2P
848146-88-3P	848146-89-4P	848146-90-7P	848146-91-8P	848146-92-9P
848146-93-0P	848146-94-1P	848146-95-2P	848146-96-3P	848146-97-4P
848146-98-5P	848146-99-6P	848147-00-2P	848147-01-3P	848147-02-4P
848147-03-5P	848147-04-6P	848147-05-7P	848147-06-8P	848147-07-9P
848147-08-0P	848147-09-1P	848147-10-4P	848147-11-5P	848147-12-6P
848147-13-7P	848147-14-8P	848147-15-9P	848147-16-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	848147-17-1P	848147-18-2P	848147-19-3P	848147-20-6P	848147-21-7P
	848147-22-8P	848147-23-9P	848147-24-0P	848147-25-1P	848147-26-2P
	848147-27-3P	848147-28-4P	848147-29-5P	848147-30-8P	848147-31-9P
	848147-32-0P	848147-33-1P	848147-34-2P	848147-35-3P	848147-36-4P
	848147-37-5P	848147-38-6P	848147-39-7P	848147-40-0P	848147-41-1P
	848147-42-2P	848147-43-3P	848147-44-4P	848147-45-5P	848147-46-6P
	848147-47-7P	848147-48-8P	848147-49-9P	848147-50-2P	848147-51-3P
	848147-52-4P	848147-53-5P	848147-54-6P	848147-55-7P	848147-56-8P
	848147-57-9P	848147-58-0P	848147-59-1P	848147-60-4P	848147-61-5P
	848147-62-6P	848147-63-7P	848147-64-8P	848147-65-9P	848147-66-0P
	848147-67-1P	848147-68-2P	848147-69-3P	848147-70-6P	848147-71-7P
	848147-72-8P	848147-73-9P	848147-74-0P	848147-75-1P	848147-76-2P
	848147-77-3P	848147-78-4P	848147-79-5P	848147-80-8P	848147-81-9P
	848147-82-0P	848147-83-1P	848147-84-2P	848147-85-3P	848147-86-4P
	848147-87-5P	848147-88-6P	848147-89-7P	848147-90-0P	848147-91-1P
	848147-92-2P	848147-93-3P	848147-94-4P	848147-95-5P	848147-96-6P
	848147-97-7P	848147-99-9P	848148-00-5P	848148-01-6P	848148-02-7P
	848148-03-8P	848148-04-9P	848148-05-0P	848148-06-1P	848148-07-2P
	848148-08-3P	848148-09-4P	848148-10-7P	848148-11-8P	848148-12-9P
	848148-13-0P	848148-14-1P	848148-15-2P	848148-16-3P	848148-17-4P
	848148-18-5P	848148-19-6P	848148-20-9P	848148-21-0P	848148-22-1P
	848148-23-2P	848148-24-3P	848148-25-4P	848148-26-5P	848148-27-6P
	848148-28-7P	848148-29-8P	848148-30-1P	848148-31-2P	848148-32-3P
	848148-33-4P	848148-34-5P	848148-35-6P	848148-36-7P	848148-37-8P
	848148-38-9P	848148-39-0P	848148-40-3P	848148-41-4P	848148-42-5P

848148-43-6P	848148-44-7P	848148-45-8P	848148-46-9P	848148-47-0P
848148-48-1P	848148-49-2P	848148-50-5P	848148-51-6P	848148-52-7P
848148-53-8P	848148-54-9P	848148-55-0P	848148-56-1P	848148-57-2P
848148-58-3P	848148-59-4P	848148-60-7P	848148-61-8P	848148-62-9P
848148-63-0P	848148-64-1P	848148-65-2P	848148-66-3P	848148-67-4P
848148-68-5P	848148-69-6P	848148-70-9P	848148-71-0P	848148-72-1P
848148-73-2P	848148-74-3P	848148-75-4P	848148-76-5P	848148-77-6P
848148-78-7P	848148-79-8P	848148-80-1P	848148-81-2P	848148-82-3P
848148-83-4P	848148-84-5P	848148-85-6P	848148-86-7P	848148-87-8P
848148-88-9P	848148-89-0P	848148-91-4P	848148-92-5P	848148-93-6P
848148-94-7P	848148-95-8P	848148-96-9P	848148-97-0P	848148-98-1P
848148-99-2P	848149-00-8P	848149-01-9P	848149-02-0P	848149-03-1P
848149-04-2P	848149-05-3P	848149-06-4P	848149-07-5P	848149-08-6P
848149-09-7P	848149-10-0P	848149-11-1P	848149-12-2P	848149-13-3P
848149-14-4P	848149-15-5P	848149-16-6P	848149-17-7P	848149-18-8P
848149-19-9P	848149-20-2P	848149-21-3P	848149-22-4P	848149-23-5P
848149-24-6P	848149-25-7P	848149-26-8P	848149-27-9P	848149-28-0P
848149-29-1P	848149-30-4P	848149-31-5P	848149-32-6P	848149-33-7P
848149-34-8P	848149-35-9P	848149-36-0P	848149-37-1P	848149-38-2P
848149-39-3P	848149-40-6P	848149-42-8P	848149-44-0P	848149-46-2P
848149-48-4P	848149-50-8P	848149-51-9P	848149-52-0P	848149-53-1P
848149-55-3P	848149-56-4P	848149-57-5P	848149-58-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	848149-59-7P	848149-60-0P	848149-61-1P	848149-62-2P	848149-63-3P
	848149-64-4P	848149-65-5P	848149-66-6P	848149-67-7P	848149-68-8P
	848149-69-9P	848149-70-2P	848149-71-3P	848149-72-4P	848149-73-5P
	848149-74-6P	848149-75-7P	848149-76-8P	848149-77-9P	848149-78-0P
	848149-79-1P	848149-80-4P	848149-81-5P	848149-82-6P	848149-83-7P
	848149-84-8P	848149-85-9P	848149-86-0P	848149-87-1P	848149-88-2P
	848149-89-3P	848149-90-6P	848149-91-7P	848149-92-8P	848149-93-9P
	848149-94-0P	848149-95-1P	848149-96-2P	848149-97-3P	848149-98-4P
	848149-99-5P	848150-00-5P	848150-01-6P	848150-02-7P	848150-03-8P
	848150-04-9P	848150-05-0P	848150-06-1P	848150-07-2P	848150-08-3P
	848150-09-4P	848150-10-7P	848150-11-8P	848150-12-9P	848150-13-0P
	848150-14-1P	848150-15-2P	848150-16-3P	848150-17-4P	848150-18-5P
	848150-19-6P	848150-20-9P	848150-21-0P	848150-22-1P	848150-23-2P
	848150-24-3P	848150-25-4P	848150-26-5P	848150-27-6P	848150-28-7P
	848150-29-8P	848150-30-1P	848150-31-2P	848150-32-3P	848150-33-4P
	848150-34-5P	848150-35-6P	848150-36-7P	848150-37-8P	848150-38-9P
	848150-39-0P	848150-40-3P	848150-41-4P	848150-42-5P	848150-43-6P
	848150-44-7P	848150-45-8P	848150-46-9P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 848150-47-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(insulinitis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 3993-78-0P, 4-Chloro-2-pyrimidinamine 848144-76-3P 848144-86-5P  
RL: BYP (Byproduct); PREP (Preparation)



(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 62-53-3, Aniline, reactions 90-11-9, 1-Bromonaphthalene 90-15-3, 1-Naphthalenol 98-09-9, Benzenesulfonyl chloride 98-27-1, 4-tert-Butyl-2-methylphenol 98-54-4, 4-tert-Butylphenol 106-49-0, (p-Methylphenyl)amine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 134-32-7, 1-Naphthylamine 135-19-3, 2-Hydroxynaphthalene, reactions 444-30-4, 2-Trifluoromethylphenol 637-60-5, p-Tolylhydrazine hydrochloride 765-30-0, Cyclopropylamine 1774-47-6, Trimethylsulfoxonium iodide 2534-77-2, exo-2-Bromonorbornane 2605-67-6 3240-94-6, 4-(2-Chloroethyl)morpholine 3279-07-0, 4-tert-Butyl-2-nitrophenol 3647-69-6, N-(2-Chloroethyl)morpholine hydrochloride 3934-20-1, 2,4-Dichloropyrimidine 4114-31-2, Ethyl hydrazinecarboxylate 4498-67-3, Indazole-3-carboxylic acid 5369-19-7, 3-tert-Butylaniline 5720-05-8, (p-Methylphenyl)boronic acid 5781-53-3, Methyl chloroglyoxylate 7677-24-9, Trimethylsilyl cyanide 7770-45-8, 4-Hydroxy-1-naphthaldehyde 16013-85-7, 2,6-Dichloro-3-nitropyridine 16640-68-9, (Triphenylphosphoranylidene)acetonitrile 23056-36-2, 2-Chloro-4-nitropyridine 23894-12-4, 6-Amino-1-naphthalenol 26867-21-0 36082-50-5, 5-Bromo-2,4-dichloropyrimidine 39755-95-8, 5-Methoxy isatin 59997-51-2, 4,4-Dimethyl-3-oxopentenenitrile 73469-54-2, 5-tert-Butyl-2-methoxybenzoic acid 74124-79-1 82560-12-1, (5-tert-Butyl-1H-pyrazol-3-yl)amine 83405-70-3 88139-91-7, (5-Bromopyridin-2-yl)methanol 118430-73-2 175137-04-9 285984-25-0 285984-50-1 306937-27-9, 3-tert-Butylphenylhydrazine hydrochloride 317806-90-9 473269-70-4, 5-tert-Butyl-2-methoxybenzene-1,3-diamine 725686-47-5 848144-33-2 848144-81-0, 2,6-Dichloro-3-nitropyrimidine 848144-88-7 848144-99-0 855304-89-1 929011-97-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 98-28-2P, 4-tert-Butyl-2-chlorophenol 7461-50-9P, 2-Chloro-4-pyrimidinamine 14593-28-3P, 4-tert-Butyl-2-chloro-6-nitrophenol 18215-94-6P, [2-(Morpholin-4-yl)pyrimidin-4-yl]amine 20294-44-4P, 4-tert-Butyl-2-methyl-6-nitrophenol 21660-76-4P, N-Naphthalen-1-ylloxalamic acid 26867-13-0P 32569-82-7P 33353-61-6P 33353-66-1P 35980-77-9P, [2-(Morpholin-4-yl)pyridin-4-yl]amine 55304-16-0P 57477-80-2P, 4-tert-Butyl-2-trifluoromethylphenol 90417-53-1P, 5-Methoxy-1H-indazole-3-carboxylic acid 157130-34-2P 254751-07-0P 294851-95-9P, 4-(5-Bromopyridin-2-ylmethyl)morpholine 294851-97-1P 404010-35-1P, N-(3-Amino-5-tert-butyl-2-methoxyphenyl)methanesulfonamide 848144-06-9P 848144-07-0P 848144-08-1P 848144-10-5P 848144-11-6P 848144-13-8P 848144-16-1P 848144-17-2P 848144-18-3P 848144-19-4P 848144-20-7P 848144-22-9P 848144-23-0P 848144-24-1P 848144-25-2P 848144-27-4P, 4-(4-Nitropyridin-2-yl)morpholine 848144-28-5P 848144-29-6P 848144-30-9P 848144-36-5P 848144-37-6P 848144-38-7P 848144-40-1P 848144-41-2P 848144-43-4P 848144-44-5P 848144-46-7P 848144-51-4P 848144-52-5P 848144-54-7P 848144-56-9P 848144-59-2P 848144-61-6P 848144-68-3P 848144-69-4P 848144-70-7P 848144-71-8P, 6-(Boc-amino)naphthalen-1-ol 848144-72-9P 848144-73-0P 848144-74-1P 848144-75-2P 848144-79-6P 848144-80-9P 848144-82-1P 848144-83-2P 848144-87-6P 848144-93-4P 848144-95-6P 848144-97-8P 848145-03-9P 848145-04-0P 848145-06-2P 848150-48-1P 848150-49-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

L32 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylozoles as PI3 kinase inhibitors)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2005:120737 CAPLUS

DOCUMENT NUMBER: 142:219270

TITLE: Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylozoles as PI3 kinase inhibitors  
Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011686	A1	20050210	WO 2004-EP51625	20040727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260836	A1	20050210	AU 2004-260836	20040727
CA 2531140	A1	20050210	CA 2004-2531140	20040727
EP 1648452	A1	20060426	EP 2004-766335	20040727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007500171	T	20070111	JP 2006-521581	20040727
US 20070021447	A1	20070125	US 2004-565976	20040727
NO 2006000573	A	20060203	NO 2006-573	20060203
PRIORITY APPLN. INFO.:			EP 2003-102313	A 20030728
			WO 2004-EP51625	W 20040727

OTHER SOURCE(S): CASREACT 142:219270; MARPAT 142:219270

AN 2005:120737 CAPLUS

DN 142:219270

ED Entered STN: 11 Feb 2005

TI Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylozoles as PI3 kinase inhibitors

IN Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David

PA Applied Research Systems Ars Holding N.V., Neth.

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-427

ICS A61P037-00; A61P029-00; C07D417-06; C07D417-14

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011686	A1	20050210	WO 2004-EP51625	20040727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260836	A1	20050210	AU 2004-260836	20040727
	CA 2531140	A1	20050210	CA 2004-2531140	20040727
	EP 1648452	A1	20060426	EP 2004-766335	20040727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007500171	T	20070111	JP 2006-521581	20040727
	US 20070021447	A1	20070125	US 2004-565976	20040727
	NO 2006000573	A	20060203	NO 2006-573	20060203
PRAI	EP 2003-102313	A	20030728		
	WO 2004-EP51625	W	20040727		

# CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO	2005011686	ICM	A61K031-427
		ICS	A61P037-00; A61P029-00; C07D417-06; C07D417-14
		IPCI	A61K0031-427 [ICM,7]; A61P0037-00 [ICS,7]; A61P0029-00 [ICS,7]; C07D0417-06 [ICS,7]; C07D0417-14 [ICS,7]; C07D0417-00 [ICS,7,C*]
		IPCR	A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0417-00 [I,C*]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
		ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
AU	2004260836	IPCI	A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0037-00 [I,C]; C07D0417-00 [I,C]; A61K0031-427 [I,A]; A61P0029-00 [I,A]; A61P0037-00 [I,A]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
		IPCR	A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
CA	2531140	IPCI	A61K0031-427 [I,A]; A61P0029-00 [I,A]; A61P0037-00 [I,A]; C07D0417-06 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]
		IPCR	A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
		ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
EP	1648452	IPCI	A61K0031-427 [ICM,7]; A61P0037-00 [ICS,7]; A61P0029-00

JP 2007500171 IPCI [ICS,7]; C07D0417-06 [ICS,7]; C07D0417-14 [ICS,7];  
 C07D0417-00 [ICS,7,C\*]  
 C07D0417-06 [I,A]; A61K0031-427 [I,A]; C07D0417-14  
 [I,A]; C07D0417-00 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4709 [I,A]; A61K0031-498  
 [I,A]; A61K0031-517 [I,A]; A61P0037-06 [I,A];  
 A61P0037-00 [I,C\*]; A61P0029-00 [I,A]; A61P0009-00  
 [I,A]; A61P0025-00 [I,A]; A61P0007-02 [I,A];  
 A61P0007-00 [I,C\*]; A61P0035-00 [I,A]; A61P0011-00  
 [I,A]; C07B0061-00 [N,A]  
 IPCR C07D0417-00 [I,C]; C07D0417-06 [I,A]; A61K0031-427  
 [I,C]; A61K0031-427 [I,A]; A61K0031-4427 [I,C];  
 A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709  
 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];  
 A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61P0007-00  
 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C];  
 A61P0009-00 [I,A]; A61P0011-00 [I,C]; A61P0011-00  
 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];  
 A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00  
 [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C];  
 A61P0037-00 [I,A]; A61P0037-06 [I,A]; C07B0061-00  
 [N,C]; C07B0061-00 [N,A]; C07D0417-14 [I,A]  
 FTERM 4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB08;  
 4C063/CC81; 4C063/CC92; 4C063/DD14; 4C063/DD31;  
 4C063/DD34; 4C063/DD62; 4C063/EE01; 4C086/AA01;  
 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC82;  
 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08;  
 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14;  
 4C086/ZA02; 4C086/ZA36; 4C086/ZA54; 4C086/ZA59;  
 4C086/ZB08; 4C086/ZB11; 4C086/ZB26; 4H039/CA80;  
 4H039/CD20  
 US 20070021447 IPCI A61K0031-517 [I,A]; A61K0031-4709 [I,A]; A61K0031-427  
 [I,A]; A61K0031-422 [I,A]; A61K0031-4178 [I,A];  
 A61K0031-4164 [I,C\*]; C07D0417-02 [I,A]; C07D0417-00  
 [I,C\*]; C07D0413-02 [I,A]; C07D0413-00 [I,C\*]  
 NCL 514/266.230; 514/317.000; 514/369.000; 514/376.000;  
 514/388.000; 544/284.000; 546/159.000; 548/181.000;  
 548/225.000; 548/311.100  
 ECLA C07D417/06+277B+215; C07D417/06+277B+239;  
 C07D417/06+277B+241; C07D417/06+317+277B;  
 C07D417/14+317+277B+213; C07D417/14+317+277B+215;  
 C07D417/14+317+277B+231; C07D417/14+333B+277B+215;  
 C07D417/14+333B+317+277B  
 NO 2006000573 IPCI C07D0413-00 [I,C]; A61K0031-427 [I,C]; C07D0413-06  
 [I,A]; A61K0031-427 [I,A]  
 IPCR C07D0413-00 [I,C]; C07D0413-06 [I,A]; A61K0031-427  
 [I,C]; A61K0031-427 [I,A]; A61P0029-00 [I,C\*];  
 A61P0029-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-00  
 [I,A]; C07D0417-00 [I,C\*]; C07D0417-06 [I,A];  
 C07D0417-14 [I,A]  
 ECLA C07D417/06+277B+215; C07D417/06+277B+239;  
 C07D417/06+277B+241; C07D417/06+317+277B;  
 C07D417/14+317+277B+213; C07D417/14+317+277B+215;  
 C07D417/14+317+277B+231; C07D417/14+333B+277B+215;  
 C07D417/14+333B+317+277B



- AB The title compds. I [A = 5-8 membered heterocyclic or carbocyclic group which may be fused with an aryl, heteroaryl, cycloalkyl or heterocycloalkyl; X = S, O, NR<sub>3</sub>, Y = S, O; R<sub>1</sub> = H, CN, CO<sub>2</sub>H, acyl, etc.; R<sub>2</sub> = H, halo, acyl, NH<sub>2</sub>, etc.; G = alkoxy, alkyl, CN, etc.; R<sub>3</sub> = H, alkyl; with provisos], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 5-benzo[1,3]dioxol-5-ylmethylene-2-iminothiazolidin-4-one (preparation given) with 2-chlorobenzenesulfonyl chloride afforded 17% II. The tested compds. I showed IC<sub>50</sub> of < 10 μM with regard to PI3Ky.
- ST iminothioxopolycyclovinyllazoline prepn PI3 kinase inhibitor; thiazolidine benzodioxolylmethylene quinoxalinylmethylene quinolinylmethylene prepn PI3 kinase inhibitor
- IT Nervous system, disease  
(Huntington's chorea, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Sarcoma  
(Kaposi's, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Muscle, disease  
(atrophy, treating skeletal muscle atrophy/hypertrophy; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Muscle  
(cardiac, treating cardiac myocyte dysfunction; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Hypertrophy  
(cardiac, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Lung, disease  
(chronic obstructive pulmonary disease, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Nervous system, disease  
(degeneration, treating; preparation of 2-imino-4-(thio)oxo-5-

polycyclovinyllazolines as PI3 kinase inhibitors)

IT Kidney, disease  
(fibrosis, treating progressive renal fibrosis; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Inflammation  
Kidney, disease  
(glomerulonephritis, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Kidney, disease  
(glomerulosclerosis, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Muscle, disease  
(hypertrophy, treating skeletal muscle atrophy/hypertrophy; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Heart, disease  
(hypertrophy, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Intestine, disease  
(inflammatory, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Lung, disease  
Reperfusion  
(injury, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Leukocyte  
(leukocyte recruitment in cancer tissue; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Neoplasm  
(metastasis, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Hypertrophy  
(muscular, treating skeletal muscle atrophy/hypertrophy; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Heart  
(myocardium, treating cardiac myocyte dysfunction; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Inflammation  
Lung, disease  
(pneumonitis, treatment; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Allergy inhibitors  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Anticoagulants  
Antihypertensives  
Antirheumatic agents  
Antitumor agents  
Cardiovascular agents  
Human  
Immunomodulators  
Immunosuppressants  
Nervous system agents  
Platelet aggregation inhibitors  
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Injury

(pulmonary, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Fibrosis  
(renal, treating progressive renal fibrosis; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Injury  
(reperfusion, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Brain, disease  
(stroke, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Lupus erythematosus  
(systemic, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Central nervous system, disease  
(trauma, treating CNS trauma; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Brain, disease  
Encephalitis  
Meningitis  
(treating brain infection/inflammation; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Allergy  
Alzheimer's disease  
Anaphylaxis  
Angiogenesis  
Asthma  
Atherosclerosis  
Autoimmune disease  
Cardiovascular system, disease  
Hypertension  
Inflammation  
Ischemia  
Kidney, disease  
Melanoma  
Multiple sclerosis  
Neoplasm  
Platelet aggregation  
Psoriasis  
Rheumatoid arthritis  
Sepsis  
Thrombosis  
Transplant rejection  
(treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 115926-52-8, PI3 kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 843641-13-4P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 176529-68-3P 326093-91-8P 419552-35-5P 843641-09-8P 843641-10-1P  
843641-11-2P 843641-12-3P 843641-14-5P 843641-15-6P 843641-16-7P  
843641-17-8P 843641-18-9P 843641-19-0P 843641-20-3P 843641-21-4P  
843641-22-5P 843641-23-6P 843641-24-7P 843641-25-8P 843641-26-9P  
843641-27-0P 843641-28-1P 843641-29-2P 843641-30-5P 888948-67-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 100-46-9, Benzylamine, reactions 120-57-0, Piperonal 656-42-8, 2,2-Difluoro-1,3-benzodioxole-5-carboxaldehyde 2688-90-6, [1,1'-Biphenyl]-2-sulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 3113-71-1, 3-Methyl-4-nitrobenzoic acid 4113-04-6, 6-Quinolinelcarboxaldehyde 130345-50-5, 6-Quinoxalinecarboxaldehyde 412311-41-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 4315-09-7P 28824-66-0P 33890-03-8P 33986-75-3P 152536-17-9P 152536-21-5P 300829-97-4P 304645-61-2P 648449-05-2P 648449-06-3P 648449-09-6P 648449-81-4P 648450-30-0P 719286-35-8P 843641-32-7P 843641-33-8P 843641-34-9P 843641-35-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Fujimoto Pharmaceutical Co Ltd; EP 0697410 A 1996 CAPLUS

(2) Roue, N; TETRAHEDRON 1999, V55(51), P14729 CAPLUS

L32 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 91-56-5, Isatin

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)

RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2004:308364 CAPLUS

DOCUMENT NUMBER: 140:321386

TITLE: Preparation of vasculostatic agents and methods of use

INVENTOR(S): Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaja, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

PATENT ASSIGNEE(S): Targeen, Inc., USA

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004030635	A2	20040415	WO 2003-US31721	20031002
WO 2004030635	A3	20040812		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,			



GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RR: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500727 A1 20040415 CA 2003-2500727 20031002  
AU 2003282726 A1 20040423 AU 2003-282726 20031002  
EP 1549614 A2 20050706 EP 2003-774610 20031002

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003015053 A 20050809 BR 2003-15053 20031002  
CN 1720224 A 20060111 CN 2003-80104711 20031002  
JP 2006515317 T 20060525 JP 2005-500378 20031002  
IN 2005DN01020 A 20070316 IN 2005-DN1020 20050316  
ZA 2005002328 A 20060927 ZA 2005-2328 20050318  
MX 2005PA03477 A 20050722 MX 2005-PA3477 20050401

PRIORITY APPLN. INFO.:  
US 2002-415981P P 20021003  
US 2003-440234P P 20030114  
US 2003-443752P P 20030129  
US 2003-463818P P 20030417  
US 2003-466983P P 20030430  
US 2003-479295P P 20030617  
WO 2003-US31721 W 20031002

OTHER SOURCE(S): MARPAT 140:321386  
AN 2004:308364 CAPLUS  
DN 140:321386  
ED Entered STN: 15 Apr 2004  
TI Preparation of vasculostatic agents and methods of use  
IN Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaia, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning  
PA Targegen, Inc., USA  
SO PCT Int. Appl., 230 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K  
CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004030635	A2	20040415	WO 2003-US31721	20031002
	WO 2004030635	A3	20040812		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2500727	A1	20040415	CA 2003-2500727	20031002
	AU 2003282726	A1	20040423	AU 2003-282726	20031002
	EP 1549614	A2	20050706	EP 2003-774610	20031002
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR	2003015053	A	20050809	BR 2003-15053 20031002
CN	1720224	A	20060111	CN 2003-80104711 20031002
JP	2006515317	T	20060525	JP 2005-500378 20031002
IN	2005DN01020	A	20070316	IN 2005-DN1020 20050316
ZA	2005002328	A	20060927	ZA 2005-2328 20050318
MX	2005PA03477	A	20050722	MX 2005-PA3477 20050401
PRAI	US 2002-415981P	P	20021003	
	US 2003-440234P	P	20030114	
	US 2003-443752P	P	20030129	
	US 2003-463818P	P	20030417	
	US 2003-466983P	P	20030430	
	US 2003-479295P	P	20030617	
	WO 2003-US31721	W	20031002	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004030635	ICM	A61K
	IPCI	A61K [ICM]
	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00; M07D; M07D
CA 2500727	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]
	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00
AU 2003282726	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]

IPCR A61K0031-403 [I,C\*]; A61K0031-405 [I,A]; A61K0031-519 [I,C\*]; A61K0031-525 [I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A]; C07D0209-00 [I,C\*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C\*]; C07D0241-42 [I,A]; C07D0253-00 [I,C\*]; C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]

EP 1549614 IPCI C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C\*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C\*]; A61K0031-495 [ICS,7]

IPCR C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A]; A61K0031-405 [I,A]; A61K0031-495 [I,C]; A61K0031-495 [I,A]; A61K0031-519 [I,C\*]; A61K0031-525 [I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C\*]; C07D0241-42 [I,A]; C07D0253-00 [I,C\*]; C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]

ECLA C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00; M07D; M07D

BR 2003015053 IPCI C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C\*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C\*]; A61K0031-495 [ICS,7]

IPCR A61K0031-403 [I,C\*]; A61K0031-405 [I,A]; A61K0031-519 [I,C\*]; A61K0031-525 [I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A]; C07D0209-00 [I,C\*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C\*]; C07D0241-42 [I,A]; C07D0253-00 [I,C\*]; C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A]

ECLA C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00

CN 1720224 IPCI C07D0209-04 [I,A]; C07D0209-00 [I,C\*]; A61K0031-404 [I,A]; A61K0031-403 [I,C\*]; A61K0031-495 [I,A]

JP 2006515317 IPCI C07D0209-00 [I,C]; C07D0209-04 [I,A]

IPCR C07D0209-00 [I,C]; C07D0209-04 [I,A]

IPCI C07D0209-14 [I,A]; A61K0031-404 [I,A]; A61K0031-403

[I,C\*]; C07D0209-48 [I,A]; C07D0209-00 [I,C\*];  
A61K0031-4439 [I,A]; A61K0031-4427 [I,C\*]; C07D0475-08  
[I,A]; C07D0519-00 [I,A]; C07D0471-04 [I,A];  
C07D0471-00 [I,C\*]; A61K0031-4985 [I,A]; C07D0253-08  
[I,A]; C07D0253-00 [I,C\*]; A61K0031-53 [I,A];  
C07D0487-04 [I,A]; C07D0487-00 [I,C\*]; C07D0475-02  
[I,A]; C07D0475-06 [I,A]; C07D0475-00 [I,C\*];  
A61K0031-519 [I,A]; C07D0241-44 [I,A]; C07D0241-00  
[I,C\*]; A61K0031-498 [I,A]; A61P0009-00 [I,A];  
A61P0009-10 [I,A]; A61P0035-00 [I,A]; A61P0019-02  
[I,A]; A61P0019-00 [I,C\*]; A61P0027-02 [I,A];  
A61P0027-00 [I,C\*]; A61P0037-06 [I,A]; A61P0037-00  
[I,C\*]; A61P0029-00 [I,A]; A61P0017-02 [I,A];  
A61P0017-00 [I,C\*]; A61P0011-00 [I,A]; A61P0043-00  
[I,A]; A61K0031-704 [I,A]; A61K0031-7028 [I,C\*];  
A61K0031-337 [I,A]; A61K0038-00 [I,A]; A61K0039-395  
[I,A]; A61K0031-661 [I,A]; C07D0405-04 [I,A];  
A61J0001-05 [I,A]; A61J0003-00 [I,A]; A61K0031-5377  
[I,A]; A61K0031-5375 [I,C\*]; C07D0405-12 [I,A];  
C07D0405-00 [I,C\*]  
IPC R C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61J0001-05  
[I,C]; A61J0001-05 [I,A]; A61J0003-00 [I,C];  
A61J0003-00 [I,A]; A61K0031-337 [I,C]; A61K0031-337  
[I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A];  
A61K0031-405 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439  
[I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];  
A61K0031-4985 [I,C]; A61K0031-4985 [I,A]; A61K0031-519  
[I,C]; A61K0031-519 [I,A]; A61K0031-525 [I,A];  
A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-5375  
[I,C]; A61K0031-5377 [I,A]; A61K0031-661 [I,C];  
A61K0031-661 [I,A]; A61K0031-7028 [I,C]; A61K0031-704  
[I,A]; A61K0031-716 [I,C\*]; A61K0031-724 [I,A];  
A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K0039-395  
[I,C]; A61K0039-395 [I,A]; A61P0009-00 [I,C];  
A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
[I,C]; A61P0011-00 [I,A]; A61P0017-00 [I,C];  
A61P0017-02 [I,A]; A61P0019-00 [I,C]; A61P0019-02  
[I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];  
A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00  
[I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C];  
A61P0037-06 [I,A]; A61P0043-00 [I,C]; A61P0043-00  
[I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A];  
C07D0209-48 [I,A]; C07D0239-00 [I,C\*]; C07D0239-88  
[I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];  
C07D0241-00 [I,C]; C07D0241-42 [I,A]; C07D0241-44  
[I,A]; C07D0253-00 [I,C]; C07D0253-08 [I,A];  
C07D0253-10 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12  
[I,A]; C07D0403-00 [I,C\*]; C07D0403-12 [I,A];  
C07D0405-00 [I,C]; C07D0405-04 [I,A]; C07D0405-12  
[I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A];  
C07D0475-00 [I,C]; C07D0475-02 [I,A]; C07D0475-06  
[I,A]; C07D0475-08 [I,A]; C07D0487-00 [I,C];  
C07D0487-04 [I,A]; C07D0519-00 [I,C]; C07D0519-00 [I,A]  
F TERM 4C050/AA01; 4C050/BB08; 4C050/CC12; 4C050/EE04;  
4C050/FF05; 4C050/GG04; 4C050/HH01; 4C063/AA01;  
4C063/BB01; 4C063/BB09; 4C063/CC12; 4C063/CC76;  
4C063/CC81; 4C063/DD06; 4C063/DD44; 4C063/EE01;  
4C065/AA04; 4C065/BB12; 4C065/CC01; 4C065/DD03;  
4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK04;  
4C065/LL01; 4C065/PP03; 4C072/MM02; 4C084/AA02;  
4C084/BA44; 4C084/DB52; 4C084/MA02; 4C084/NA05;

4C084/NA14; 4C084/ZA331; 4C084/ZA332; 4C084/ZA361;  
 4C084/ZA362; 4C084/ZA891; 4C084/ZA892; 4C084/ZA961;  
 4C084/ZA962; 4C084/ZB081; 4C084/ZB082; 4C084/ZB111;  
 4C084/ZB112; 4C084/ZB261; 4C084/ZB262; 4C084/ZC751;  
 4C085/AA13; 4C085/EE03; 4C086/AA01; 4C086/AA02;  
 4C086/AA03; 4C086/BA02; 4C086/BC13; 4C086/BC17;  
 4C086/BC52; 4C086/BC64; 4C086/CB09; 4C086/CB14;  
 4C086/DA34; 4C086/EA10; 4C086/GA02; 4C086/GA07;  
 4C086/GA08; 4C086/MA01; 4C086/MA02; 4C086/MA04;  
 4C086/NA05; 4C086/NA14; 4C086/ZA33; 4C086/ZA36;  
 4C086/ZA89; 4C086/ZA96; 4C086/ZB08; 4C086/ZB11;  
 4C086/ZB26; 4C086/ZC75; 4C204/BB01; 4C204/CB03;  
 4C204/CB04; 4C204/DB03; 4C204/DB30; 4C204/EB02;  
 4C204/EB03; 4C204/FB01; 4C204/FB16; 4C204/GB01  
 IN 2005DN01020 IPCI C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C\*]  
 ZA 2005002328 IPCI A61K [N,S]; C07D [N,S]  
 MX 2005PA03477 IPCI A61K [ICM,7]; A61K0031-404 [ICS,7]; A61K0031-403  
 [ICS,7,C\*]; A61K0031-495 [ICS,7]; C07D0209-04 [ICS,7];  
 C07D0209-00 [ICS,7,C\*]  
 OS MARPAT 140:321386  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Compds. (2 Markush structures shown as I and II; others are described in the claims and disclosure; variables defined below; e.g. III and IV) and methods are provided for treating disorders associated with compromised vasculostasis. Invention methods and compns. are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Although the methods of preparation are not claimed, many example preps. are included. For example, III was prepared (75 %) from 2-(2-aminophenyl)indole and 4-hydroxyphenylacetic acid. Various expts. are described that show the use of the claimed compds. along with chemotherapeutic agents for cancer treatment. The claimed compds. also show inhibition of vascular leak induced by interleukin 2. Inhibition of VEGF-induced edema, reduction of myocardial infarction and inhibition of c-Src and Yes kinases were demonstrated for some of the claimed compds. For I: each R0 = -H, -COOH, -OR', -SO3H, wherein R' is -H or lower alkyl, or when x = 2, each R0 is taken together to form a 1,3-dioxolyl ring, or each R0 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocyclic, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted alkylaryl, (un)substituted arylalkyl, (un)substituted arylalkenyl, (un)substituted arylalkynyl, halogen, amino, amido, nitro, or thioalkyl. R1 and R2 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocyclic, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted alkylaryl, (un)substituted arylalkyl, (un)substituted arylalkenyl, (un)substituted arylalkynyl; G is NH, O, S, or (CR'')p, wherein R'' is -H, lower alkyl, or acetamido, and wherein p = 0-3; Ar is aryl or heteroaryl, and x and y = 1-4. For II: Z1-Z6 = C, -C(O, N, or NRA, wherein Ra is -H, (un)substituted alkyl, wherein said substituents are halogen, hydroxy, oxo, or amino; each X = halogen, -ORb, -NRb2, or -SRb, wherein Rb is -H

lower alkyl, -(CH<sub>2</sub>)<sub>2</sub>NHET, -(CH<sub>2</sub>)<sub>3</sub>morpholin-1-yl, -(CH<sub>2</sub>)<sub>3</sub>-(N-methylpiperazin-1-yl), aryl, heteroaryl, -(NH-NH-Rc), -(N:N-NH-Rc), wherein Rc is H or lower alkyl. Each Y = -ORd, -NRd<sub>2</sub>, -SRd, or -OPO<sub>3</sub>H<sub>2</sub> wherein Rd is H, lower alkyl, aryl, heteroaryl, -(CH<sub>2</sub>)<sub>2</sub>NHET, -(CH<sub>2</sub>)<sub>3</sub>morpholin-1-yl, or (CH<sub>2</sub>)<sub>3</sub>-(N-methylpiperazin-1-yl); or each Y = (un)substituted alkyl, (un)substituted aryl, (un)substituted heteroaryl, or halogen, wherein said substituents = halogen, -ORE, -NRe<sub>2</sub>, -SRe, -P(O)(OH)<sub>2</sub>, wherein Re is -H, lower alkyl, aryl, or heteroaryl; or each Y = CH<sub>2</sub>glycyl, CH<sub>2</sub>NHethoxy, CH<sub>2</sub>NHCH<sub>2</sub>alkyl, CH<sub>2</sub>NHCH<sub>2</sub>t-Bu, CH<sub>2</sub>NHCH<sub>2</sub>aryl, CH<sub>2</sub>NHCH<sub>2</sub>substituted aryl, CH<sub>2</sub>NHCH<sub>2</sub>heteroaryl, CH<sub>2</sub>NHCH<sub>2</sub>substituted heteroaryl; or when n is 2, each Y is taken together to form a fused aromatic or heteroarom. ring system; and m and n = 1 to 4, wherein when Z<sub>1</sub>, Z<sub>3</sub>, Z<sub>5</sub>, and Z<sub>6</sub> are each N, X is NH<sub>2</sub>, and m = n = 2, Y is not Ph or 4-hydroxyphenyl.

- ST indolylphenyl carboxamide prepn vasculostatic agent compn; pteridine prepn vasculostatic agent compn; quinoxaline prepn vasculostatic agent compn; quinazoline prepn vasculostatic agent compn; benzotriazine prepn vasculostatic agent compn; vasculostasis treatment fused nitrogen heterocycle prepn
- IT Respiratory distress syndrome  
(acute; preparation of vasculostatic agents and methods of use)
- IT Respiratory distress syndrome  
(adult; preparation of vasculostatic agents and methods of use)
- IT Alkylation  
(agents, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Antibiotics  
(anthracycline, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Antitumor agents  
(antifolates, codrugs; preparation of vasculostatic agents and methods of use)
- IT Cytotoxic agents  
(antimetabolites, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Disease, animal  
(arthropathy; preparation of vasculostatic agents and methods of use)
- IT Antibodies and Immunoglobulins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(binding to HER2 protein, growth factors or growth factor receptors, or integrin receptors; codrugs; preparation of vasculostatic agents and methods of use)
- IT Antibiotics  
(bleomycin- and mitomycin-type, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Interleukin 2  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrug; preparation of vasculostatic agents and methods of use)
- IT Taxanes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Intestine, neoplasm  
(colon; preparation of vasculostatic agents and methods of use)
- IT Joint, anatomical  
(disease; preparation of vasculostatic agents and methods of use)
- IT Heart, disease  
(failure; preparation of vasculostatic agents and methods of use)
- IT Crosslinking agents  
(for DNA, as codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Heart, disease

(infarction; preparation of vasculostatic agents and methods of use)

IT Microtubule  
(inhibitors, codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT Reperfusion  
(injury; preparation of vasculostatic agents and methods of use)

IT Capillary vessel, disease  
(leakage syndrome; preparation of vasculostatic agents and methods of use)

IT Eye, disease  
(macula, degeneration; preparation of vasculostatic agents and methods of use)

IT Angiogenesis inhibitors  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiarthritics  
Antitumor agents  
Arthritis  
Autoimmune disease  
Bladder, neoplasm  
Blood vessel, disease  
Bone, neoplasm  
Brain, neoplasm  
Burn  
Cardiovascular agents  
Digestive tract, neoplasm  
Diuretics  
Drug delivery systems  
Edema  
Human  
Immunomodulators  
Inflammation  
Ischemia  
Kidney, neoplasm  
Leukemia  
Liver, neoplasm  
Lung, neoplasm  
Lymphoma  
Mammary gland, neoplasm  
Myoma  
Neoplasm  
Ovary, neoplasm  
Packaging materials  
Prostate gland, neoplasm  
Skin, neoplasm  
Transplant rejection  
(preparation of vasculostatic agents and methods of use)

IT Injury  
(reperfusion; preparation of vasculostatic agents and methods of use)

IT Eye, disease  
(retinopathy; preparation of vasculostatic agents and methods of use)

IT Brain, disease  
(stroke; preparation of vasculostatic agents and methods of use)

IT Alkaloids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(vinca, codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT Eye, disease  
(vitreoretinal; preparation of vasculostatic agents and methods of use)

IT 180288-69-1, Trastuzumab 183319-69-9, OSI-774 216974-75-3, Bevacizumab 892553-42-3, Vitaxin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug for cancer; preparation of vasculostatic agents and methods of use)

IT 50-76-0, Dactinomycin 59-05-2, Methotrexate 64-86-8, Colchicine 477-30-5, Demecolcine 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 39472-31-6, Carminomycin 41575-94-4, Carboplatin 42077-25-8, Adriamycin-14-octanoate 56420-45-2, Epirubicin 58957-92-9, Idarubicin 59367-03-2, Adriamycin-14-benzoate 64161-91-7, Adriamycin-14-naphthaleneacetate 65271-80-9, Mitoxantrone 79466-09-4, 13-Deoxydaunorubicin 84325-15-5, 11-Deoxydaunorubicin 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT 24850-02-0P 677297-15-3P, N-[2-(1H-Indol-2-yl)phenyl]-2-(2-methoxyphenyl)acetamide 677297-25-5P, N-[2-(1H-Indol-2-yl)phenyl]phthalamic acid 677297-30-2P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine 677297-48-2P, 4-(4-Aminopteridin-7-yl)phenol 677297-51-7P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine 677297-58-4P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine 677297-61-9P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine sulfate 677297-63-1P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-75-5P 677297-77-7P 677297-99-3P, 3-(3-Aminobenzol[1,2,4]triazin-7-yl)phenol 677298-01-0P, N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)phenylamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of vasculostatic agents and methods of use)

IT 14892-98-9P, 6,7-Diphenylpteridine-2,4-diol 18181-93-6P, 6,7-Diphenylpteridine-2,4-diamine 24863-39-6P, 6,7-Diphenylpteridin-4-ol 32044-95-4P, 2,3-Diphenylquinoxalin-5-amine 73384-11-9P, 7-Phenylpteridin-4-amine 102554-55-2P, 2,3-Diphenylquinoxalin-5-ol 102704-20-1P, N-[2-(1H-Indol-2-yl)phenyl]-2-phenylacetamide 126988-00-9P, 3-Phenylquinoxalin-5-amine 128076-13-1P, (6-Phenylpteridin-4-yl)amine 278799-97-6P, 6-[(Benzylamino)methyl]-2,4-pteridinediamine 677297-11-9P, 2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-12-0P, 4-Hydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-13-1P, 3,4-Dihydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-14-2P, 2-Hydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-16-4P, 2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-17-5P, 2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-18-6P, 2-(Benzodioxol-5-yl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-19-7P, N-[2-(1H-Indol-2-yl)phenyl]-3-phenylpropionamide 677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-21-1P, N-[2-(1H-Indol-2-yl)phenyl]-3-(2-methoxyphenyl)propionamide 677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-23-3P, 2-(4-Hydroxyphenoxy)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-24-4P, 2-Acetylamin-3-(4-hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-26-6P, 2-[[2-(1H-Indol-2-yl)phenyl]carbonyl]nicotinic acid 677297-27-7P, 3,4,5-Trihydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-28-8P, 2-(2-Phthalimidophenyl)-1H-indole 677297-29-9P, [6,7-Bis(4-hydroxyphenyl)pteridin-4-yl][3-(morpholin-4-yl)propyl]amine hydrochloride 677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-aminopteridin-6-yl]phenyl ester 677297-32-4P, Acetic acid 4-[2-(4-acetoxyphenyl)-6-aminopyrido[2,3-b]pyrazin-3-yl]phenyl ester 677297-35-7P, (3,4-Dimethoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-36-8P, (3-Chloro-4,6-dimethoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-37-9P, (3-Hydroxy-4-methoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-38-0P, (4-Hydroxyphenyl)(6-phenylpteridin-4-yl)amine 677297-39-1P, (2,5-Dimethyl-4-hydroxyphenyl)(6-phenylpteridin-4-yl)amine 677297-40-4P, 2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid



677297-41-5P, 2-[(Diethylamino)methyl]-4-(6-phenylpteridin-4-ylamino)phenol 677297-42-6P, 5-(6-Phenylpteridin-4-ylamino)quinolin-8-ol dihydrochloride 677297-44-8P, Benzyl(6-phenylpteridin-4-yl)amine 677297-45-9P, 4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol 677297-46-0P, (Indan-2-yl)(6-phenylpteridin-4-yl)amine 677297-47-1P, [2-(3,4-Dimethoxyphenyl)ethyl](6-phenylpteridin-4-yl)amine 677297-49-3P, 4-(4-Benzylaminopteridin-7-yl)phenol 677297-50-6P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine monohydrochloride 677297-52-8P, 6-(Pyridin-2-yl)-7-(pyridin-3-yl)pteridin-4-amine 677297-53-9P, 6-(Pyridin-2-yl)-7-(pyridin-3-yl)pteridin-4-amine sulfate 677297-54-0P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol 677297-55-1P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-65-3P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine 677297-66-4P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate 677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P, (2,3-Diphenylpyrido[3,4-b]pyrazin-8-yl)amine hydrochloride 677297-69-7P, 2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-76-6P 677297-78-8P 4-(4-Aminopteridin-7-yl)benzene-1,2-diol 677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)benzene-1,2-diol 677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)phenol 677297-82-4P, 4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol 677297-83-5P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-86-8P, 2,3-Bis(3,4-dihydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-94-8P, [7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-yl]amine 677297-98-2P, [7-(Naphthalen-1-yl)benzo[1,2,4]triazin-3-yl]amine 677298-00-9P, N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine 677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)[3-(4-methylpiperazin-1-yl)propyl]amine 677298-03-2P, N-[5-Methyl-7-(2,4,6-trimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine 677298-04-3P, N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-06-5P, N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-hydroxyphenyl)propionic acid tert-butyl ester 677298-09-8P, 6-[[[Pyridin-2-ylmethyl]amino]methyl]-2,4-pteridinediamine 677298-10-1P, 6-[[[Naphthalen-1-ylmethyl]amino]methyl]-2,4-pteridinediamine 677298-11-2P, 6-[[[Adamantan-1-ylmethyl]amino]methyl]-2,4-pteridinediamine 677298-12-3P, 6-[[[3,4-Dimethoxybenzyl]amino]-2,4-pteridinediamine 677298-13-4P, 6-[[[2,6-Dimethylpropylamino]methyl]-2,4-pteridinediamine 677298-14-5P, 6-[[[2-(3,4-Dimethoxyphenyl)ethyl]amino]methyl]-2,4-pteridinediamine 677298-15-6P, 6-[[[2-(3,4-Dihydroxyphenyl)ethyl]amino]methyl]-2,4-pteridinediamine 677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P, 6-[[[3,4-Dihydroxybenzyl]amino]methyl]-2,4-pteridinediamine 677298-18-9P, 3-(4-tert-Butoxyphenyl)-2-[[[2,4-diaminopteridin-6-

yl)methyl]amino]propionic acid tert-butyl ester 677298-19-0P,  
1-[[Bis(2,4-diaminopteridin-6-ylmethyl)amino]methyl]naphthalene  
677298-20-3P, 6-(2,6-Dimethylphenyl)-3H-quinazolin-4-one 677298-21-4P,  
6-(2,6-Dimethoxyphenyl)-3H-quinazolin-4-one 677298-22-5P,  
6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one 677298-23-6P,  
6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one 677298-24-7P,  
6-(Naphthalen-1-yl)-3H-quinazolin-4-one 677298-25-8P,  
6-(Naphthalen-2-yl)-3H-quinazolin-4-one 677298-26-9P,  
6-(4-Phenoxyphenyl)-3H-quinazolin-4-one 677298-28-1P,  
6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one  
677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-  
quinazolin-4-one 677298-32-7P, (6,7-Diphenylpteridin-4-yl)[3-(4-  
methylpiperazin-1-yl)propyl]amine 677298-33-8P 677298-34-9P,  
3-[[Bis(2,4-diaminopteridin-6-ylmethyl)amino]-1H-indolin-2-one 677298-35-0P,  
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine sulfate 677298-36-1P,  
4-(2,4-Diaminopteridin-6-yl)phenol sulfate 677298-37-2P,  
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diol 677298-38-3P,  
N-[2-(2,3-Dihydro-1H-indol-2-yl)phenyl]-2-hydroxybenzamide 677298-39-4P,  
3-[[2-(1H-Indol-2-yl)phenyl]carbonyl]pyridine-2-carboxylic acid  
677298-40-7P, 6-[[Bis(2,4-diaminopteridin-6-ylmethyl)amino]methyl]pteridine-2,4-  
diamine 677298-42-9P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-  
ylamine 677298-46-3P, 3,4,5-Trihydroxy-N-(1H-indol-2-yl)benzamide  
677298-47-4P, 6,7-Bis(pyridin-2-yl)pteridin-4-ylamine 677298-48-5P,  
6,7-Bis(3-hydroxyphenyl)pteridin-2-amine 677298-49-6P,  
6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine hydrobromide 677298-50-9P,  
2-Phenylquinoxalin-5-amine 677298-51-0P, 6-(Pyridin-2-yl)-7-(pyridin-3-  
yl)pteridine-2,4-diol 677298-53-2P, 6-(Pyridin-3-yl)-7-(pyridin-2-  
yl)pteridin-4-amine 677298-54-3P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-  
b]pyrazin-6-ylamine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(drug candidate; preparation of vasculostatic agents and methods of use)  
IT 677298-52-1  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(drug candidate; preparation of vasculostatic agents and methods of use)  
IT 143180-75-0  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, codrugs for cancer; preparation of vasculostatic agents and  
methods of use)  
IT 372092-80-3, Protein kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, codrugs; preparation of vasculostatic agents and methods of  
use)  
IT 9026-43-1, Serine kinase 9031-44-1, Kinase 80449-02-1, Tyrosine kinase  
141349-89-5, Src kinase 141349-91-9, Yes kinase 144697-17-6, c-Src  
kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; preparation of vasculostatic agents and methods of use)  
IT 51-61-6, 2-(3,4-Dihydroxyphenyl)ethylamine, reactions 62-31-7,  
3-Hydroxytyramine hydrochloride 62-53-3, Aniline, reactions 69-72-7,  
Salicylic acid, reactions 85-44-9, Phthalic anhydride 91-56-5,  
Isatin 93-25-4, 2-Methoxyphenylacetic acid 99-50-3,  
3,4-Dihydroxybenzoic acid 99-96-7, 4-Hydroxybenzoic acid, reactions  
100-46-9, Benzylamine, reactions 102-32-9, 3,4-Dihydroxyphenylacetic  
acid 103-82-2, Phenylacetic acid, reactions 118-31-0,  
1-Aminomethylnaphthalene 123-00-2, N-(3-Aminopropyl)morpholine  
134-81-6, Benzil 149-91-7, Gallic acid, reactions 156-38-7,  
4-Hydroxyphenylacetic acid 501-52-0, Hydrocinnamic acid 501-97-3,  
3-(4-Hydroxyphenyl)propionic acid 537-55-3, N-Acetyl-L-tyrosine

615-47-4, 1,2,4-Benzenetriamine dihydrochloride 635-85-8,  
 2-(3,4-Dimethoxyphenyl)ethylamine hydrochloride 699-98-9,  
 2,3-Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride  
 875-51-4, (4-Bromo-2-nitrophenyl)amine 1078-61-1, 3,4-  
 Dihydroxyhydrocinnamic acid 1124-40-9, (3,4-Dihydroxybenzyl)amine  
 hydrochloride 1423-27-4, 2-Trifluoromethylphenylboronic acid  
 1878-84-8, (4-Hydroxyphenoxy)acetic acid 2861-28-1, 3,4-  
 (Methylenedioxy)phenylacetic acid 3731-51-9, 2-(Aminomethyl)pyridine  
 4572-03-6, 3-(4-Methylpiperazin-1-yl)propylamine 5122-94-1,  
 (4-Biphenyl)boronic acid 5763-61-1, 3,4-Dimethoxybenzylamine  
 5794-88-7, 2-Amino-5-Bromobenzoic acid 5813-64-9, 2,2-  
 Dimethylpropylamine 5980-97-2, 2,4,6-Trimethylphenylboronic acid  
 6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6342-77-4, 3-(2-  
 Methoxyphenyl)propionic acid 7757-21-3 13922-41-3, (1-Naphthyl)boronic  
 acid 16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4,  
 2-Amino-3-bromo-5-nitrobenzonitrile 17768-41-1, 1-Aminomethyladamantane  
 20284-90-6, 2,3,6-Triaminopyridine dihydrochloride 21454-19-3,  
 Bis[4-(1,2-dioxo-2-phenylethyl)phenyl] ether 23112-96-1,  
 2,6-Dimethoxyphenylboronic acid 24645-80-5, 4-Hydroxyphenylglyoxal  
 32316-92-0, (2-Naphthyl)boronic acid 32566-01-1, 2-(2-Aminophenyl)indole  
 33288-79-8, 4,4'-Dihydroxybenzil 42965-55-9, 5,6-Diamino-2,4-  
 dihydroxypyrimidine sulfate 49647-58-7, 2,4,5,6-Tetraaminopyrimidine  
 sulfate 49721-45-1, 4,5,6-Triaminopyrimidine sulfate 51067-38-0,  
 4-Phenoxymethylboronic acid 52853-40-4, 6-Bromomethyl-2,4-  
 pteridinediamine hydrobromide 63192-57-4, 3,3'-Dihydroxybenzil  
 76145-91-0, (2,4-Diaminopteridin-6-yl)methanol hydrobromide 77712-97-1,  
 3,4,5-Triaminopyridine hydrochloride 77811-44-0, (4-Bromo-2-methyl-6-  
 nitrophenyl)amine 78495-63-3, 2-Fluoro-6-methoxyphenylboronic acid  
 87199-18-6, 3-Hydroxyphenylboronic acid 88878-78-8, 2-Amino-3-(4-  
 hydroxyphenyl)propionic acid tert-butyl ester 94839-07-3,  
 3,4-(Methylenedioxy)phenylboronic acid 95195-43-0, 2,3'-Pyridil  
 98437-24-2, 2-Benzofuranboronic acid 100124-06-9, 4-Dibenzofuranboronic  
 acid 100379-00-8, 2,6-Dimethylphenylboronic acid 123324-71-0,  
 4-tert-Butylphenylboronic acid 385370-80-9, 2-Chloro-6-  
 methoxyphenylboronic acid 545390-26-9, 2-Amino-3-(4-tert-  
 butoxyphenyl)propionic acid tert-butyl ester hydrochloride 677297-33-5,  
 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine 677297-34-6,  
 N'-(3-Cyano-5-phenylpyrazin-2-yl)-N,N-dimethylformamidine  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)  
 IT 6298-38-0P, (7-Bromobenzo[1,2,4]triazin-3-yl)amine 1-oxide 32084-59-6P,  
 6-Bromo-3H-quinazolin-4-one 59368-16-0P, 6-Bromomethyl-2,4-  
 pteridinediamine 677297-74-4P 677297-87-9P 677297-88-0P,  
 [7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide  
 677297-89-1P, [7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine  
 677297-90-4P, [7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]amine  
 677297-91-5P, [7-(4-Phenoxyphenyl)benzo[1,2,4]triazin-3-yl]amine  
 677297-92-6P, [7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-yl]amine  
 677297-93-7P, [7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-yl]amine  
 677297-95-9P, [7-(Biphenyl-4-yl)benzo[1,2,4]triazin-3-yl]amine  
 677297-96-0P, [7-(Benzofuran-2-yl)benzo[1,2,4]triazin-3-yl]amine  
 677297-97-1P, [7-(Dibenzofuran-4-yl)benzo[1,2,4]triazin-3-yl]amine  
 677298-27-0P, 6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one  
 677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol 677298-31-6P,  
 8-Bromo-4-[[3-(4-methylpiperazin-1-yl)propyl]amino]-6-nitroquinazolin-2-ol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)  
 IT 677298-07-6P, [7-(Naphthalen-2-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of vasculostatic agents and methods of use)

L32 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 1072-84-0, 4-Imidazolecarboxylic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyridinones as modulators of p38 MAP kinase for  
 treatment of inflammatory conditions, ischemia, viral  
 infections, autoimmune diseases, and other conditions)  
 RN 1072-84-0 CAPLUS  
 CN 1H-Imidazole-5-carboxylic acid (CA INDEX NAME)



ACCESSION NUMBER: 2003:656582 CAPLUS  
 DOCUMENT NUMBER: 139:1973/1  
 TITLE: Preparation of substituted pyridinones as modulators  
 of p38 MAP kinase  
 INVENTOR(S): Devadas, Balekudru; Walker, John; Selness, Shaun R.;  
 Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh;  
 Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.;  
 Madsen, Heather M.; Alvira, Edgardo; Promo, Michele  
 A.; Blevis-Bal, Radhika M.; Marrufo, Laura D.;  
 Hitchcock, Jeff; Owen, Thomas; Naing, Win; King, Li;  
 Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott,  
 Ian L.; McGee, Kevin F.  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: PCT Int. Appl., 1052 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068230	A1	20030821	WO 2003-US4634	20030214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476012	A1	20030821	CA 2003-2476012	20030214
AU 2003217433	A1	20030904	AU 2003-217433	20030214
US 20040058964	A1	20040325	US 2003-367987	20030214
US 7067540	B2	20060627		
BR 2003007631	A	20041221	BR 2003-7631	20030214
EP 1490064	A1	20041229	EP 2003-713478	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1646125	A	20050727	CN 2003-808042	20030214
JP 2005531501	T	20051020	JP 2003-567412	20030214
NZ 534395	A	20061027	NZ 2003-534395	20030214

IN 2004DN02150	A	20050401	IN 2004-DN2150	20040723
MX 2004PA07470	A	20041110	MX 2004-PA7470	20040802
ZA 2004006275	A	20051004	ZA 2004-6275	20040805
NO 2004003820	A	20041109	NO 2004-3820	20040913
US 20060211694	A1	20060921	US 2005-226556	20050914
US 20070088033	A1	20070419	US 2006-531492	20060913
JP 2007023053	A	20070201	JP 2006-263778	20060928
KR 2007017443	A	20070209	KR 2007-701895	20070125
AU 2007202607	A1	20070628	AU 2007-202607	20070607
PRIORITY APPLN. INFO.:			US 2002-357029P	P 20020214
			US 2002-436915P	P 20021230
			AU 2003-217433	A3 20030214
			JP 2003-567412	A3 20030214
			US 2003-367987	A1 20030214
			WO 2003-US4634	W 20030214
			KR 2004-712622	A3 20040813
			US 2005-226556	A3 20050914

OTHER SOURCE(S): MARPAT 139:197371

AN 2003:656582 CAPLUS

DN 139:197371

ED Entered STN: 22 Aug 2003

TI Preparation of substituted pyridinones as modulators of p38 MAP kinase

IN Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.;  
 Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.;  
 Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.;  
 Blevis-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas;  
 Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang;  
 Scott, Ian L.; McGee, Kevin F.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 1052 pp.

CODEN: P1XXD2

DT Patent

LA English

IC ICM A61K031-4412

ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70;  
 C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10;  
 C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79;  
 C07D401-04; C07D405-04; C07D413-10; C07D215-22

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068230	A1	20030821	WO 2003-US4634	20030214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
	CA 2476012	A1	20030821	CA 2003-2476012	20030214
	AU 2003217433	A1	20030904	AU 2003-217433	20030214
	US 20040058964	A1	20040325	US 2003-367987	20030214
	US 7067540	B2	20060627		
	BR 2003007631	A	20041221	BR 2003-7631	20030214
	EP 1490064	A1	20041229	EP 2003-713478	20030214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

		IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	CN	1646125	A	20050727
	JP	2005531501	T	20051020
	NZ	534395	A	20061027
	IN	2004DN02150	A	20050401
	MX	2004PA07470	A	20041110
	ZA	2004006275	A	20051004
	NO	2004003820	A	20041109
	US	20060211694	A1	20060921
	US	20070088033	A1	20070419
	JP	2007023053	A	20070201
	KR	2007017443	A	20070209
	AU	2007202607	A1	20070628
PRAI	US	2002-357029P	P	20020214
	US	2002-436915P	P	20021230
	AU	2003-217433	A3	20030214
	JP	2003-567412	A3	20030214
	US	2003-367987	A1	20030214
	WO	2003-US4634	W	20030214
	KR	2004-712622	A3	20040813
	US	2005-226556	A3	20050914
	CN	2003-808042		20030214
	JP	2003-567412		20030214
	NZ	2003-534395		20030214
	IN	2004-DN2150		20040723
	MX	2004-PA7470		20040802
	ZA	2004-6275		20040805
	NO	2004-3820		20040913
	US	2005-226556		20050914
	US	2006-531492		20060913
	JP	2006-263778		20060928
	KR	2007-701895		20070125
	AU	2007-202607		20070607

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003068230	ICM	A61K031-4412
	ICS	A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70; C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10; C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79; C07D401-04; C07D405-04; C07D413-10; C07D215-22
	IPCI	A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7]; C07D401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]
	IPCR	A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];

		<p> A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+239B+213; C07D401/04+231+213; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+213+209C; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+233+213; C07D401/10+231+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213 </p>
ECLA		
CA 2476012	IPCI	<p> A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0401-04 [ICS,7]; C07D0405-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0405-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0401-12 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0213-64 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*] </p>
	IPCR	<p> A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*]; </p>

A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00 [I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213  
 AU 2003217433 IPCI A61K0031-4412 [ICM,7]; C07D0409-14 [ICS,7]; C07D0213-85 [ICS,7]; A61P0029-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0409-00 [ICS,7,C\*]; C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-00 [ICS,7,C\*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C\*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C\*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C\*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C\*]  
 IPCR A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472 [I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497



[I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
 A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
 [I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
 A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
 [I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
 [I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
 A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
 [I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
 [I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
 [I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
 A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
 A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
 [I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
 C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];  
 C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06  
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];  
 C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14  
 [I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]  
 A61K0031-44 [I,A]; C07D0213-02 [I,A]; C07D0213-00  
 [I,C\*]; C07D0401-02 [I,A]; C07D0401-00 [I,C\*]  
 A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; C07D0213-00  
 [I,C\*]; C07D0213-64 [I,A]; C07D0213-69 [I,A];  
 C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75  
 [I,A]; C07D0213-79 [I,A]; C07D0213-84 [I,A];  
 C07D0213-85 [I,A]; C07D0215-00 [I,C\*]; C07D0215-22  
 [I,A]; C07D0401-00 [I,C\*]; C07D0401-04 [I,A];  
 C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12  
 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C\*];  
 C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12  
 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C\*];  
 C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00  
 [I,C\*]; C07D0413-10 [I,A]  
 NCL 514/340.000; 514/344.000; 514/345.000; 546/268.100;  
 546/288.000; 546/290.000; 514/348.000; 514/256.000;  
 514/336.000; 544/333.000; 546/283.400; 546/296.000  
 ECLA C07D213/64A; C07D401/14+239B+213+211;  
 C07D405/04+307B+213; C07D405/06+307B+213;  
 C07D405/06+317+213; C07D405/12+307B+213;  
 C07D405/14+307B+307B+213; C07D409/06+333B+213;  
 C07D409/14+333B+333B+213; C07D413/10+261+213;  
 C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C;  
 C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85;  
 C07D215/22D; C07D401/04+213+211; C07D401/04+231+213;  
 C07D401/04+239B+213; C07D401/06+213+209C;  
 C07D401/06+217+213; C07D401/06+213+211;  
 C07D401/06+239B+213; C07D401/06+231+213;

BR 2003007631

IPCI

C07D401/06+241B+213; C07D401/10+213+211;  
C07D401/10+231+213; C07D401/10+233+213;  
C07D401/12+213+207; C07D401/12+233+213  
A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69  
[ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];  
C07D0409-00 [ICS,7,C\*]; C07D0213-70 [ICS,7];  
C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-84  
[ICS,7]; C07D0405-06 [ICS,7]; C07D0401-10 [ICS,7];  
C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75  
[ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7];  
C07D0213-00 [ICS,7,C\*]; C07D0401-04 [ICS,7];  
C07D0401-00 [ICS,7,C\*]; C07D0405-04 [ICS,7];  
C07D0405-00 [ICS,7,C\*]; C07D0413-10 [ICS,7];  
C07D0413-00 [ICS,7,C\*]

IPCR

A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444  
[I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A];  
A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
[I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
[I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
[I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
[I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
[I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
[I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
[I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
[I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
[I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
[I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
[I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
[I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];  
C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06  
[I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];  
C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14  
[I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A];  
ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;  
C07D213/74C; C07D213/75B; C07D213/79E2; C07D213/84E;  
C07D213/85; C07D215/22D; C07D401/04+213+211;  
C07D401/04+231+213; C07D401/04+239B+213;  
C07D401/06+213+209C; C07D401/06+213+211;  
C07D401/06+217+213; C07D401/06+231+213;  
C07D401/06+239B+213; C07D401/06+241B+213;

EP 1490064

IPCI

C07D401/10+213+211; C07D401/10+231+213;  
C07D401/10+233+213; C07D401/12+213+207;  
C07D401/12+233+213; C07D401/14+239B+213+211;  
C07D405/04+307B+213; C07D405/06+307B+213;  
C07D405/06+317+213; C07D405/12+307B+213;  
C07D405/14+307B+307B+213; C07D409/06+333B+213;  
C07D409/14+333B+333B+213; C07D413/10+261+213  
A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69  
[ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];  
C07D0409-00 [ICS,7,C\*]; C07D0213-70 [ICS,7];  
C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06  
[ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7];  
C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75  
[ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7];  
C07D0213-00 [ICS,7,C\*]; C07D0401-04 [ICS,7];  
C07D0401-00 [ICS,7,C\*]; C07D0405-04 [ICS,7];  
C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C\*];  
C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C\*];  
C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C\*]

IPCR

A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444  
[I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A];  
A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
[I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
[I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
[I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
[I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
[I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
[I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
[I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
[I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
[I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
[I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
[I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
[I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];  
C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06  
[I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];  
C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14  
[I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]

ECLA

C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;  
C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;

CN 1646125

IPCI

C07D213/85; C07D215/22D; C07D401/04+213+211;  
C07D401/04+231+213; C07D401/04+239B+213;  
C07D401/06+213+209C; C07D401/06+213+211;  
C07D401/06+217+213; C07D401/06+231+213;  
C07D401/06+239B+213; C07D401/06+241B+213;  
C07D401/10+213+211; C07D401/10+231+213;  
C07D401/10+233+213; C07D401/12+213+207;  
C07D401/12+233+213; C07D401/14+239B+213+211;  
C07D405/04+307B+213; C07D405/06+307B+213;  
C07D405/06+317+213; C07D405/12+307B+213;  
C07D405/14+307B+307B+213; C07D409/06+333B+213;  
C07D409/14+333B+333B+213; C07D413/10+261+213  
A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69  
[ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];  
C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74  
[ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7];  
C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12  
[ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7];  
C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00  
[ICS,7,C\*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7];  
C07D0413-00 [ICS,7,C\*]; C07D0215-22 [ICS,7];  
C07D0215-00 [ICS,7,C\*]; C07D0405-14 [ICS,7];  
C07D0405-00 [ICS,7,C\*]; C07D0409-14 [ICS,7];  
C07D0409-00 [ICS,7,C\*]; C07D0213-85 [ICS,7];  
C07D0213-00 [ICS,7,C\*]

IPCR

A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444  
[I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A];  
A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
[I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
[I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
[I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
[I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
[I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
[I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
[I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
[I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
[I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
[I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
[I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
[I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];

		<p> C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213 </p>
JP 2005531501	IPCI	<p> C07D0213-64 [ICM,7]; A61K0031-4412 [ICS,7]; A61K0031-4418 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-4545 [ICS,7]; A61K0031-4523 [ICS,7,C*]; A61K0031-455 [ICS,7]; A61K0031-4725 [ICS,7]; A61K0031-472 [ICS,7,C*]; A61K0031-496 [ICS,7]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61K0031-506 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61P0001-04 [ICS,7]; A61P0001-16 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-10 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0007-02 [ICS,7]; A61P0007-00 [ICS,7,C*]; A61P0009-04 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61P0011-00 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-12 [ICS,7]; A61P0013-00 [ICS,7,C*]; A61P0015-08 [ICS,7]; A61P0015-00 [ICS,7,C*]; A61P0017-02 [ICS,7]; A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*]; A61P0019-02 [ICS,7]; A61P0019-06 [ICS,7]; A61P0019-08 [ICS,7]; A61P0019-10 [ICS,7]; A61P0019-00 [ICS,7,C*]; A61P0025-00 [ICS,7]; A61P0025-02 [ICS,7]; A61P0025-04 [ICS,7]; A61P0025-14 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-28 [ICS,7]; A61P0027-02 [ICS,7]; A61P0027-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0033-02 [ICS,7]; A61P0033-06 [ICS,7]; A61P0033-00 [ICS,7,C*]; A61P0035-00 [ICS,7]; A61P0037-06 [ICS,7]; A61P0037-00 [ICS,7,C*]; A61P0043-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-80 [ICS,7]; C07D0213-82 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-12 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*] </p>
	IPCR	<p> A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; </p>

A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
 [I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
 A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
 A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
 [I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
 A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
 [I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
 [I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
 A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
 [I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
 [I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
 [I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
 A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
 A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
 [I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
 C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];  
 C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06  
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];  
 C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14  
 [I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]  
 FTERM 4C031/EA15; 4C031/EA17; 4C055/AA03; 4C055/AA06;  
 4C055/AA09; 4C055/AA10; 4C055/BA02; 4C055/BA42;  
 4C055/CA01; 4C055/CA02; 4C055/CA39; 4C055/DA08;  
 4C055/DA42; 4C055/DA47; 4C055/DA52; 4C055/DB01;  
 4C055/DB04; 4C055/DB06; 4C055/DB08; 4C055/DB10;  
 4C055/DB16; 4C055/FA03; 4C063/AA01; 4C063/AA03;  
 4C063/BB01; 4C063/BB03; 4C063/BB04; 4C063/BB06;  
 4C063/BB08; 4C063/BB09; 4C063/CC12; 4C063/CC15;  
 4C063/CC22; 4C063/CC25; 4C063/CC29; 4C063/CC34;  
 4C063/CC51; 4C063/CC71; 4C063/CC75; 4C063/CC92;  
 4C063/DD03; 4C063/DD06; 4C063/DD10; 4C063/DD12;  
 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;  
 4C086/BC17; 4C086/BC21; 4C086/BC30; 4C086/BC36;  
 4C086/BC37; 4C086/BC38; 4C086/BC42; 4C086/BC47;  
 4C086/BC48; 4C086/BC67; 4C086/BC73; 4C086/GA02;  
 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09;  
 4C086/GA12; 4C086/GA13; 4C086/MA01; 4C086/NA14;  
 4C086/ZA02; 4C086/ZA08; 4C086/ZA33; 4C086/ZA36;  
 4C086/ZA40; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59;  
 4C086/ZA66; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81;  
 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB08;  
 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26;  
 4C086/ZB33; 4C086/ZB35; 4C086/ZB38; 4C086/ZC10;  
 4C086/ZC11; 4C086/ZC31; 4C086/ZC35; 4C086/ZC55  
 A61K0031-4412 [ICS,7]; A61K0029-00 [ICS,7]; C07D0213-64

[ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7];  
C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79  
[ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7];  
C07D0213-00 [ICS,7,C\*]; C07D0215-22 [ICS,7];  
C07D0215-00 [ICS,7,C\*]; C07D0401-04 [ICS,7];  
C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12  
[ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C\*];  
C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12  
[ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C\*];  
C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00  
[ICS,7,C\*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C\*]

IPCR A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444  
[I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A];  
A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
[I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
[I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
[I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
[I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
[I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
[I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
[I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
[I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
[I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
[I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
[I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64  
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];  
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79  
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];  
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00  
[I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*];  
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10  
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];  
C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06  
[I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];  
C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14  
[I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]

ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;  
C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;  
C07D213/85; C07D215/22D; C07D401/04+213+211;  
C07D401/04+231+213; C07D401/04+239B+213;  
C07D401/06+213+209C; C07D401/06+213+211;  
C07D401/06+217+213; C07D401/06+231+213;  
C07D401/06+239B+213; C07D401/06+241B+213;  
C07D401/10+213+211; C07D401/10+231+213;  
C07D401/10+233+213; C07D401/12+213+207;  
C07D401/12+233+213; C07D401/14+239B+213+211;

		C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213
IN 2004DN02150	IPCI	A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]
MX 2004PA07470	IPCI	A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]
ZA 2004006275	IPCI	A61K [ICM,7]; A61P [ICS,7]; C07D [ICS,7]
NO 2004003820	IPCI	C07D0213-64 [ICM,7]; C07D0213-00 [ICM,7,C*]
	IPCR	A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];



		C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213
US 20060211694	IPCI	A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-498 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-501 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4747 [I,A]; A61K0031-4709 [I,A]; A61K0031-4412 [I,A]
	IPCR	A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4412 [I,C]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-4747 [I,C]; A61K0031-4747 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61K0031-501 [I,C]; A61K0031-501 [I,A]; A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
	NCL	514/241.000; 514/252.030; 514/255.050; 514/256.000; 514/307.000; 514/338.000; 514/340.000; 514/341.000; 514/344.000; 514/345.000; 544/209.000; 544/238.000; 544/333.000; 544/405.000; 546/015.000; 546/148.000; 546/256.000; 546/272.700; 546/275.400; 546/276.400; 546/284.400; 546/288.000; 546/290.000
	ECLA	C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213;

C07D401/10+213+211; C07D401/10+231+213;  
 C07D401/10+233+213; C07D401/12+213+207;  
 C07D401/12+233+213; C07D401/14+239B+213+211;  
 C07D405/04+307B+213; C07D405/06+307B+213;  
 C07D405/06+317+213; C07D405/12+307B+213;  
 C07D405/14+307B+307B+213; C07D409/06+333B+213;  
 C07D409/14+333B+333B+213; C07D413/10+261+213  
 US 20070088033 IPCI A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-497  
 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4545 [I,A];  
 A61K0031-4523 [I,C\*]; A61K0031-4709 [I,A]; C07D0417-02  
 [I,A]; C07D0417-00 [I,C\*]; C07D0403-02 [I,A];  
 C07D0403-00 [I,C\*]; C07D0401-02 [I,A]; C07D0401-00  
 [I,C\*]  
 IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4427  
 [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C];  
 A61K0031-4545 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709  
 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A];  
 A61K0031-506 [I,C]; A61K0031-506 [I,A]; C07D0401-00  
 [I,C]; C07D0401-02 [I,A]; C07D0403-00 [I,C];  
 C07D0403-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]  
 NCL 514/241.000; 514/255.050; 514/256.000; 514/310.000;  
 514/314.000; 514/318.000; 514/340.000; 514/341.000;  
 544/209.000; 544/333.000; 544/405.000; 546/148.000;  
 546/169.000; 546/194.000; 546/268.400; 546/269.700;  
 546/272.700; 546/273.100; 546/275.100  
 JP 2007023053 IPCI C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0401-06  
 [I,A]; C07D0409-06 [I,A]; C07D0213-70 [I,A];  
 C07D0213-74 [I,A]; C07D0405-04 [I,A]; C07D0401-10  
 [I,A]; C07D0213-75 [I,A]; C07D0405-12 [I,A];  
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0401-00  
 [I,C\*]; C07D0213-80 [I,A]; C07D0213-00 [I,C\*];  
 C07D0405-06 [I,A]; C07D0405-14 [I,A]; C07D0405-00  
 [I,C\*]; C07D0409-14 [I,A]; C07D0409-00 [I,C\*];  
 A61K0031-4412 [I,A]; A61K0031-4545 [I,A]; A61K0031-4535  
 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-4418 [I,A];  
 A61K0031-4725 [I,A]; A61K0031-472 [I,C\*]; A61K0031-4439  
 [I,A]; A61K0031-443 [I,A]; A61K0031-5377 [I,A];  
 A61K0031-5375 [I,C\*]; A61K0031-497 [I,A]; A61K0031-4965  
 [I,C\*]; A61K0031-506 [I,A]; A61K0031-444 [I,A];  
 A61K0031-4427 [I,A]; A61K0031-4436 [I,A]; A61P0043-00  
 [I,A]; A61P0029-00 [I,A]; A61P0019-02 [I,A];  
 A61P0019-06 [I,A]; A61P0037-02 [I,A]; A61P0025-00  
 [I,A]; A61P0037-08 [I,A]; A61P0037-00 [I,C\*];  
 A61P0011-00 [I,A]; A61P0035-00 [I,A]; A61P0011-06  
 [I,A]; A61P0009-10 [I,A]; A61P0007-02 [I,A];  
 A61P0007-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-12  
 [I,A]; A61P0009-00 [I,C\*]; A61P0013-12 [I,A];  
 A61P0013-00 [I,C\*]; A61P0017-02 [I,A]; A61P0001-16  
 [I,A]; A61P0001-04 [I,A]; A61P0027-02 [I,A];  
 A61P0027-06 [I,A]; A61P0027-00 [I,C\*]; A61P0001-02  
 [I,A]; A61P0001-00 [I,C\*]; A61P0003-10 [I,A];  
 A61P0003-00 [I,C\*]; A61P0017-00 [I,A]; A61P0017-06  
 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A];  
 A61P0033-06 [I,A]; A61P0033-00 [I,C\*]; A61P0031-18  
 [I,A]; A61P0031-22 [I,A]; A61P0031-16 [I,A];  
 A61P0031-00 [I,C\*]; A61P0019-10 [I,A]; A61P0015-08  
 [I,A]; A61P0015-00 [I,C\*]; A61P0019-08 [I,A];  
 A61P0019-00 [I,C\*]; A61P0035-02 [I,A]; A61P0025-28  
 [I,A]; A61P0025-16 [I,A]; A61P0025-14 [I,A];  
 A61P0021-04 [I,A]; A61P0021-00 [I,C\*]; A61P0025-02

IPCR [I,A]; C07D0413-10 [I,A]; C07D0413-00 [I,C\*]  
C07D0213-00 [I,C]; C07D0213-64 [I,A]; A61K0031-4412 [I,C]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C]; A61K0031-4427 [I,A]; A61K0031-443 [I,A]; A61K0031-4436 [I,A]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C]; A61K0031-4535 [I,A]; A61K0031-4545 [I,A]; A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472 [I,C]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-02 [I,A]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C]; A61P0003-10 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-08 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0021-00 [I,C]; A61P0021-04 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61P0031-18 [I,A]; A61P0031-22 [I,A]; A61P0033-00 [I,C]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0037-06 [I,A]; A61P0037-08 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C]; C07D0413-10 [I,A]



ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213

FTERM 4C055/AA01; 4C055/AA03; 4C055/AA04; 4C055/AA05;  
 4C055/AA06; 4C055/AA09; 4C055/AA10; 4C055/AA12;  
 4C055/AA13; 4C055/BA01; 4C055/BA02; 4C055/BA03;  
 4C055/BA05; 4C055/BA06; 4C055/BA16; 4C055/BA25;  
 4C055/BA27; 4C055/BA42; 4C055/BA50; 4C055/BB02;  
 4C055/BB08; 4C055/CA01; 4C055/CA02; 4C055/CA05;  
 4C055/CA06; 4C055/CA13; 4C055/CA25; 4C055/CA39;  
 4C055/CA57; 4C055/CA59; 4C055/DA01; 4C055/DA05;  
 4C055/DA06; 4C055/DA22; 4C055/DA25; 4C055/DA47;  
 4C055/DA53; 4C055/DB01; 4C055/DB02; 4C055/DB07;  
 4C055/EA01; 4C063/AA01; 4C063/AA03; 4C063/BB02;  
 4C063/BB05; 4C063/BB06; 4C063/BB07; 4C063/BB08;  
 4C063/BB09; 4C063/CC12; 4C063/CC15; 4C063/CC22;  
 4C063/CC25; 4C063/CC29; 4C063/CC34; 4C063/CC73;  
 4C063/CC75; 4C063/CC92; 4C063/DD03; 4C063/DD06;  
 4C063/DD10; 4C063/DD12; 4C063/EE01; 4C086/AA01;  
 4C086/AA02; 4C086/AA03; 4C086/BC17; 4C086/BC21;  
 4C086/BC28; 4C086/BC30; 4C086/BC37; 4C086/BC38;  
 4C086/BC39; 4C086/BC42; 4C086/BC48; 4C086/BC50;  
 4C086/BC73; 4C086/GA02; 4C086/GA04; 4C086/GA07;  
 4C086/GA08; 4C086/MA01; 4C086/MA04; 4C086/NA14;  
 4C086/ZA01; 4C086/ZA02; 4C086/ZA07; 4C086/ZA08;  
 4C086/ZA15; 4C086/ZA16; 4C086/ZA18; 4C086/ZA20;  
 4C086/ZA33; 4C086/ZA34; 4C086/ZA36; 4C086/ZA37;  
 4C086/ZA40; 4C086/ZA45; 4C086/ZA53; 4C086/ZA59;  
 4C086/ZA67; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81;  
 4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97;  
 4C086/ZB05; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13;  
 4C086/ZB15; 4C086/ZB26; 4C086/ZB27; 4C086/ZB33;  
 4C086/ZB35; 4C086/ZB38; 4C086/ZC02; 4C086/ZC54;  
 4C086/ZC55

KR 2007017443 IPCI A61K0031-4412 [I,A]; A61P0029-00 [I,A]; C07D0401-06  
 [I,A]; C07D0401-00 [I,C\*]  
 AU 2007202607 IPCI A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
 A61K0031-4418 [I,C\*]; A61K0031-4418 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444  
 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-4545 [I,A];  
 A61K0031-455 [I,C\*]; A61K0031-455 [I,A]; A61K0031-472  
 [I,C\*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C\*];  
 A61K0031-496 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497  
 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
 A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61P0001-00  
 [I,C\*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];  
 A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0007-00  
 [I,C\*]; A61P0007-02 [I,A]; A61P0009-00 [I,C\*];  
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00  
 [I,C\*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];  
 A61P0013-00 [I,C\*]; A61P0013-12 [I,A]; A61P0015-00  
 [I,C\*]; A61P0015-08 [I,A]; A61P0017-00 [I,C\*];  
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00  
 [I,C\*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];  
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00  
 [I,C\*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];  
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16  
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*];  
 A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00  
 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00  
 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];  
 A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00  
 [I,C\*]; A61P0037-06 [I,A]; A61P0043-00 [I,C\*];

A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]

OS MARPAT 139:197371  
GI



AB Disclosed are title compds. I [wherein R1 = H, halo, NO2, CHO, CN, CO2H, or (un)substituted (halo)alkyl, (aryl)alkoxy, aryl(alkyl), alkenyl, (aryl)alkynyl, (aryl)alkanoyl, alkoxyalkyl, or haloalkoxy; R2 = H, OH, halo, NR8R9, CO2R, or (un)substituted OSO2-alkyl, OSO2-aryl, arylalkoxy, aryloxy(alkyl), arylthio(alkoxy), arylalkynyl, alkoxy(alkoxy), alkyl, alkynyl, OCONH(CH2)n-aryl, OCON(alkyl)(CH2)n-aryl, dialkylamino, (hetero)aryl(alkyl), arylalkenyl, or heterocycloalkyl(alkyl); R3 = H, halo, alkenyl, NR6R7, NR6R7-alkyl, alkyl, or (un)substituted (aryl)alkoxycarbonyl, aryloxy(alkoxy), arylalkyl, OCONH(CH2)n-aryl, arylalkoxy, OCON(alkyl)(CH2)n-aryl, aryloxy, arylthio, or (aryl)thioalkoxy; R4 = H or (un)substituted alkyl; R5 = H, aryl, aryl(thio)alkyl, NH2, alkoxycarbonyl, alkynyl, SO2-alkyl, (hetero)cycloalkyl(alkyl), heteroaryl, or (un)substituted alkyl, alkoxy(alkyl), or alkenyl; R6 and R7 = independently H, OH, or (un)substituted (aryl)alkyl, alkoxy(alkyl), alkanoyl(alkyl), arylalkoxy, SO2-alkyl, (aryl)alkoxycarbonyl, heteroarylalkyl, or arylalkanol; or NR6R7 = (un)substituted (thio)morpholinyl, pyrrolidinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R8 = independently H or (un)substituted (aryl)alkyl or (aryl)alkanoyl; R9 = H or (un)substituted (aryl)alkyl, (aryl)alkanoyl, cycloalkyl(alkyl), alkenyl, heteroaryl, (alkyl)aminoalkyl, SO2Ph, or aryl; R = independently H or (un)substituted alkyl; n = 0-6; and pharmaceutically acceptable salts thereof]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity, such as inflammation, ischemia, viral infections, and autoimmune diseases (no data). Pharmaceutical compds. containing I, methods of preparing them, and methods of treatment using the compds. are also disclosed. For example, reaction of 4-benzyloxy-2(1H)-pyridone with EtBr in the presence of K2CO3 in DMF gave II. The latter inhibited MKK6-activated human p38α kinase phosphorylation of a biotinylated substrate or human p38α-induced phosphorylation of EGFRP (epidermal growth factor receptor peptide) with an IC50 in the range of 1 μM to 25 μM.

ST pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic immunomodulator

- IT AIDS (disease)  
(-related complex, cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Lymphoma  
(B-cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Inflammation  
(Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease  
(Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Nervous system, disease  
(Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Carcinoma  
(adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Respiratory distress syndrome  
(adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Transplant rejection  
(allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Nervous system, disease  
(amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Blood vessel, neoplasm  
(angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Bone  
(avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Necrosis  
(avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Infection  
(bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Skin, neoplasm  
(basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma  
(basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT AIDS (disease)  
Human herpesvirus  
Pneumonia  
(cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease  
(cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Edema  
Ischemia  
(cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, neoplasm  
(cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Lung, disease  
(chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
(colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
(colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection  
(corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, disease  
(diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
(diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease  
(edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, disease  
(endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Heart, disease  
(failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Ulcer  
(gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Inflammation  
Stomach, disease  
(gastritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Transplant and Transplantation  
(graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Blood vessel, neoplasm  
(hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Heart, disease  
(infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease  
(inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Eye, disease  
Reperfusion  
Spinal cord, disease  
(injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease  
(irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Brain, disease  
(ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Rheumatoid arthritis  
(juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Neoplasm  
(metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Pharynx  
(nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions,



ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lip  
(neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Glaucoma (disease)  
(neovascular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis  
(neovascularization, eye; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis  
(neovascularization, retinal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
(neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Kidney, disease  
(nephritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
(neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nerve, disease  
(neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury  
(ocular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
(photophobia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Lung, disease  
(pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Alzheimer's disease  
Analgesics  
Angiogenesis  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiarteriosclerotics  
Antiarthritics  
Antiasthmatics

Antibacterial agents  
Anticoagulants  
Antidiabetic agents  
Antimalarials  
Antiparkinsonian agents  
Antipyretics  
Antirheumatic agents  
Antitumor agents  
Antitumor agents  
Antiviral agents  
Arteriosclerosis  
Arthritis  
Asthma  
Autoimmune disease  
Bladder, neoplasm  
Bone, neoplasm  
Bone resorption  
Bone resorption inhibitors  
Brain, neoplasm  
Burn  
Cachexia  
Carcinoma  
Cardiovascular agents  
Cardiovascular system, disease  
Dermatitis  
Diabetes insipidus  
Diabetes mellitus  
Digestive tract, disease  
Digestive tract, neoplasm  
Drug delivery systems  
Eczema  
Esophagus, neoplasm  
Eye, disease  
Fever and Hyperthermia  
Gastrointestinal agents  
Gout  
Granulation tissue  
Human  
Immunomodulators  
Inflammation  
Influenza  
Ischemia  
Keloid  
Leukemia  
Lip  
Liver, disease  
Liver, neoplasm  
Lung, disease  
Lung, neoplasm  
Lymphoma  
Malaria  
Mammary gland, neoplasm  
Meningitis  
Mouth, neoplasm  
Multiple sclerosis  
Neoplasm  
Nervous system agents  
Osteoarthritis  
Osteoporosis  
Ovary, neoplasm  
Pain

Pancreas, neoplasm  
Parkinson's disease  
Phosphorylation, biological  
Prostate gland, neoplasm  
Psoriasis  
Reproduction disorders  
Rheumatoid arthritis  
Sepsis  
Silicosis  
Skin, disease  
Skin, neoplasm  
Solid phase synthesis  
Stomach, neoplasm  
Thrombosis

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Sarcoidosis

(pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, neoplasm

(renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma

(renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart

Kidney

(reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury

(reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lung, disease

(sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)  
(septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
(small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury  
(spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Spinal column, disease  
(spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease  
(stroke; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lupus erythematosus  
(systemic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)  
(toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease  
(trauma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Stomach, disease  
(ulcer; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Intestine, disease  
(ulcerative colitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
Inflammation  
(uveitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection  
(viral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Central nervous system, disease  
(with inflammatory or apoptotic component; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl

3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile 3446-91-1P, 4-Bromomethyl-N,N-dimethylbenzenesulfonamide 3749-51-7P, 4-Hydroxy-6-methyl-2(1H)-pyridone 13737-35-4P, (2-Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-yl]methanol 21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one 21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 24812-90-6P, Methyl 3-amino-4-methoxybenzoate 26576-93-2P, 3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one 33524-79-7P, 1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one 38275-41-1P, Methyl 2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-Chloromethylpyrazine 41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate 49668-89-5P 49668-90-8P, Methyl 6-(chloromethyl)nicotinate 68432-92-8P, Methyl 3-cyanomethylbenzoate 76518-57-5P, Isoquinoline-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol 119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester 123226-36-8P, (3-Bromomethylphenyl)acetonitrile 135645-63-5P, 4-(Bromomethyl)-2-(methylthio)pyrimidine 140215-42-5P, Ethyl (3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-fluorobenzoate 177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile 185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P, 3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 186551-70-2P, 3-Methylpyrazole-1-carboxylic acid tert-butyl ester 217661-27-3P, 2-(Bromomethyl)-5-fluorobenzoitrile 220364-34-1P, [3-(Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P 226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester 227609-86-1P, (3-Amino-4-fluorophenyl)methanol 391957-11-2P, 3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P, 4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 586373-04-8P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate 586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P, 1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P, 3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586373-26-4P, 4-(Benzoyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-one 586373-29-7P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl N-methyl-N-phenylcarbamate 586373-31-1P, 4-(Benzoyloxy)-1-(3-fluorobenzyl)-3-iodopyridin-2(1H)-one 586373-32-2P, 4-(Benzoyloxy)-1-(3-fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one 586373-34-4P, 1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P, (Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-37-7P, 4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide 586373-38-8P, 4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one 586373-39-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one 586373-51-5P, 3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile 586373-57-1P, 4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide 586373-58-2P, 4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one 586373-59-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P, 3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-70-8P, 1-Chloromethyl-3-(methanesulfonyl)benzene 586373-73-1P, Methyl 4-[(3-chloro-4-(2,4-difluorobenzyl)oxy)-2-oxo-2H-pyridin-1-yl]methylbenzoate 586373-76-4P, 5-Bromomethylisoquinoline hydrobromide 586373-79-7P, [5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester 586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester 586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester 586373-82-2P, [5-[(3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]indol-1-yl]carbamic acid tert-butyl ester 586373-93-5P,

4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one  
 586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-04-1P, Methyl  
 2-fluoro-3-methylbenzoate 586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-29-0P, Methyl 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methylphenylacetate 586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 586374-40-5P, Methyl 1-cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate 586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-carboxylic acid tert-butyl ester 586374-45-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P, 4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-14-6P, 1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P, 4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-16-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1(2H)-yl]benzoate 586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586375-22-6P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586375-29-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzaldehyde 586375-31-7P, 1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586375-35-1P, 4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-93-1P 586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-25-2P, 1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-52-5P, 3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-56-9P, 4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-58-1P, 4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride 586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-80-9P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-methylbenzoate 586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate 586377-10-8P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-32-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-38-0P, tert-Butyl 4-[3-chloro-4-[(2,4-

difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate  
 586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]methyl)carbamate 586377-41-5P,  
 tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]cyclopropylmethyl)carbamate 586377-43-7P,  
 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzamide 586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile 586377-46-0P,  
 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile potassium salt 586377-58-4P, 1-(3-Fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-59-5P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-60-8P,  
 3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P,  
 1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-67-5P, 3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-79-9P,  
 3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P,  
 3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586378-02-1P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P,  
 3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate 586378-34-9P, 3-Bromo-1-[[5-(chloromethyl)pyrazin-2-yl]methyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P,  
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylic acid 586378-50-9P, 1-(3-Fluorobenzyl)-4-hydroxy-3-iodopyridin-2(1H)-one 586378-55-4P, 4-Amino-1-(3-fluorobenzyl)pyridin-2(1H)-one 586378-56-5P, 4-Fluoro-N-[1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide 586378-58-7P,  
 3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one 586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-68-9P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-69-0P  
 586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P,  
 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-99-6P, 3-Chloro-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-10-4P,  
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylic acid 586379-14-8P, 1-Allyl-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-16-0P,  
 1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586379-19-3P,  
 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one 586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxaldehyde 586379-27-3P, 4-[(2,4-

Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-methylbenzoate 586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-methylbenzoate 586379-43-3P, 1-(4-Bromo-2-methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586379-44-4P, 1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-45-5P, 4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-48-8P, Methyl 4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-49-9P, Methyl 3-(4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-52-4P, 4-Hydroxy-1-[5-(hydroxymethyl)-4-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586379-53-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-56-8P, 1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde 586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methylbenzoate 586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-70-6P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-77-3P, 4-[(2,4-Difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-82-0P, 4-[(2,4-Difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-86-4P, 4-[(2,4-Difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-89-7P, 3-[(4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzonitrile 586379-90-0P, 3-[4-[(2,4-Difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-94-4P, 1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-95-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586379-97-7P, Methyl 4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-14-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate 586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-49-6P 586380-51-0P, 4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586380-53-2P 586380-54-3P, 6-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]nicotinic acid 586380-58-7P, 4-Hydroxy-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-59-8P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-65-6P, 4-(Benzoyloxy)-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-83-8P 586380-84-9P 586380-85-0P 586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid



586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-12-6P, 1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-13-7P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-oxoethyl acetate 586381-16-0P, tert-Butyl 4-[1-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]carbamate 586381-33-1P, 4-Bromomethyl-N-(2-hydroxyethyl)benzenesulfonamide 586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-39-7P, 3-[1-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-carboxylic acid tert-butyl ester 586381-41-1P, 5-[1-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586381-42-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-yl)methyl-1H-pyridin-2-one 586381-44-4P, 5-[1-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-3,3-dibromo-1H-indol-2-one 586381-53-5P 586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-59-1P, Methyl 3-[4-[(2-cyano-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-61-5P, Methyl 3-[4-[(2-(aminomethyl)-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate trifluoroacetate 586381-62-6P 586381-63-7P, 3-[4-[(4-Fluoro-2-[(methoxycarbonyl)amino]methyl]benzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-64-8P, 3-[3-Bromo-4-[(4-fluoro-2-[(methoxycarbonyl)amino]methyl]benzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-72-8P, Methyl 3-[4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-73-9P, 3-[4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl 3-[4-[[2-[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P, 3-[4-[[2-[(Cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-79-5P, Ethyl (5-fluoro-2-methylphenoxy)acetate 586381-80-8P, Ethyl [2-(bromomethyl)-5-fluorophenoxy]acetate 586381-81-9P, Ethyl [2-[[1-[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P, [2-[[1-[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P, 3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate RL: RCT (Reactant); SPN (Synthetic preparation); PRBP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-93-3P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenic acid 586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid 586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-14-1P, [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-

difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate  
 586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine 586382-19-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2-(methylthio)pyrimidin-5-  
 yl)methyl]pyridin-2(1H)-one trifluoroacetate 586382-21-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2-  
 (methylsulfonyl)pyrimidin-5-yl)methyl]pyridin-2(1H)-one trifluoroacetate  
 586382-26-5P, Ethyl 3-[3-(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-  
 oxo-2H-pyridin-1-yl)-4-methylphenyl]-3-oxopropanoate 586382-30-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one 586382-31-2P,  
 Methyl 4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-  
 yl)methyl]benzoate 586382-33-4P, 5-[(3-Bromo-4-[(2,4-difluorobenzyl)oxy]-  
 6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-2-furoic acid 586382-35-6P,  
 Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate  
 586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-  
 2H-pyridin-1-yl]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid  
 586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-  
 yl)isophthalate 586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-  
 oxo-2H-pyridin-1-yl)isophthalate 586382-41-4P, Dimethyl  
 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]isophthalate 586382-42-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl  
 [3-(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-4-  
 fluorophenyl]carbamate 586382-50-5P, 2-[(3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-4-fluorophenyl]amino]-  
 2-oxoethyl acetate 586382-52-7P, 2-[(3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-4-fluorophenyl]amino]-  
 1,1-dimethyl-2-oxoethyl acetate 586382-54-9P, 4-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of pyridinones as modulators of p38 MAP kinase  
 for treatment of inflammatory conditions, ischemia,  
 viral infections, autoimmune diseases, and other conditions)  
 IT 586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-  
 [(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (p38 kinase inhibitor; hydrochloride)  
 IT 586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-  
 [(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one  
 586380-87-2P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]-3-chlorobenzamide  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical  
 process); PYP (Physical process); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC  
 (Process); USES (Uses)  
 (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP  
 kinase for treatment of inflammatory conditions,  
 ischemia, viral infections, autoimmune diseases, and other  
 conditions)  
 IT 586414-48-4P 586414-49-5P  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP  
 kinase for treatment of inflammatory conditions,  
 ischemia, viral infections, autoimmune diseases, and other  
 conditions)  
 IT 108379-95-9P 571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-

one 586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one  
 586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one  
 586372-73-8P, 4-(Benzyloxy)-3-bromo-1-[(3-fluorophenyl)methyl]pyridin-  
 2(1H)-one 586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one  
 586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-  
 one 586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-  
 one 586372-82-9P 586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-  
 2(1H)-one hydrobromide 586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-  
 methylpyridin-2(1H)-one 586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-  
 methylpyridin-2(1H)-one 586373-06-0P, 1-Benzyl-4-[(2,6-  
 dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-14-0P, 1-Benzyl-4-  
 (benzyloxy)-3-vinylpyridin-2(1H)-one 586373-20-8P, 1-Benzyl-3-bromo-2-  
 oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586373-50-4P  
 586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-  
 (hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P,  
 [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-  
 yl]methyl]benzyl]carbamic acid tert-butyl ester 586373-75-3P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-  
 pyridin-2-one trifluoroacetate 586373-78-6P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one  
 586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-  
 indol-5-yl)methyl]pyridin-2(1H)-one 586373-95-7P, 2-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile  
 586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-  
 pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate  
 586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-  
 fluorobenzyl)pyridin-2(1H)-one 586374-28-9P, 2-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide  
 586374-30-3P, Ethyl 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-  
 pyridin-1-yl]methyl]phenyl]acetate 586374-34-7P, 4-[(2,4-  
 Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-  
 carbonitrile 586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-  
 dimethylpyridin-2(1H)-one 586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-  
 2H-pyridin-1-yl]methyl]benzonitrile 586374-47-2P, 2-[[4-(Benzyloxy)-3-  
 bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586374-55-2P,  
 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile  
 586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]benzonitrile 586374-61-0P, 3-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile  
 586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]benzonitrile 586374-63-2P, 4-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide  
 586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-  
 oxo-2H-pyridin-1-yl]methyl]benzoate 586374-70-1P, 3-Bromo-1-[4-  
 (bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,  
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]benzoic acid 586375-08-8P, Methyl 4-[(benzyloxy)-3-bromo-2-  
 oxo-2H-pyridin-1-yl]benzoate 586375-10-2P, 4-[[4-(Benzyloxy)-3-bromo-2-  
 oxo-2H-pyridin-1-yl]benzoic acid 586375-20-4P, Methyl  
 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzoate 586375-23-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-25-9P,  
 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]benzoic acid 586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-  
 1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-30-6P,  
 4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one  
 586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-  
 methylpyridin-2(1H)-one 586375-66-8P, 3-Bromo-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-71-5P, Methyl 4-[(3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzoate 586375-97-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-20-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-64-9P, 1-[4-Bromo-2,6-difluorophenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-66-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-70-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586377-80-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586377-88-0P, 2-[[[13-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586377-90-4P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-1-[3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-13-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-15-6P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-carbonitrile trifluoroacetate 586378-29-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-31-6P, Ethyl 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586378-38-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586378-49-6P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-iodopyridin-2(1H)-one 586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586379-25-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-30-8P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxaldehyde 586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-51-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate 586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid 586380-11-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid 586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoic acid 586380-19-0P, 1-[5-(Aminomethyl)-2-fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-

methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile  
 586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methyl-5-vinylpyridin-2(1H)-one 586380-61-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxyethyl)-6-methylpyridin-2(1H)-one 586380-62-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-methylpyridin-2(1H)-one 586380-63-4P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxaldehyde 586380-64-5P, 4-(Benzyloxy)-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-67-8P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P, 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P, Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-07-9P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid 586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586381-58-0P, Methyl 2-[[[3-bromo-6-methyl-1-[(2-methyl-5-(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-78-4P, 3-[3-Bromo-4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-89-7P 586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate 586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-2(1H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

II 4241-21-8P, 2-Oxo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile 39883-43-7P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carbonitrile 43083-13-2P, 2-Oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile 53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one 54923-34-1P, 4-Benzyloxy-3-methyl-1H-pyridin-2-one 56304-43-9P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-[(2-bromobenzyl)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-one 242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)carbonyl]hydrazinecarbothioamide 338774-98-4P, N-[5-Acetyl-1-(4-chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-4-chlorobenzamide 338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 338978-39-5P 338981-04-7P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-dimethylaminopropyl)amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-

oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide  
 339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-  
 carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P,  
 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 N-(4-chlorophenyl)amide 339008-63-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-  
 dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide  
 339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-  
 carboxylic acid N-(4-trifluoromethoxyphenyl)amide 339008-65-0P,  
 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 benzylamide 339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-  
 dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide  
 339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-  
 carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P,  
 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic  
 acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-  
 dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide  
 339024-00-9P 400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-  
 dihydropyridine-3-carboxylate 477852-96-3P, 1-Benzyl-5-[5-[(3,4-  
 dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one  
 477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-  
 yl]-1H-pyridin-2-one 477864-11-2P, N'-[[[(1-Benzyl-6-oxo-1,6-  
 dihydropyridin-3-yl)carbonyl]oxy]pyridine-4-carboximidamide  
 478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 N-[2-(morpholin-4-yl)ethyl]amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-  
 oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide  
 478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one  
 565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[12-  
 (hydroxymethyl)benzyl]oxypyridazin-3(2H)-one 565157-26-8P,  
 4-Bromo-2-(2,6-dichlorophenyl)-5-[12-(2,4-difluorobenzyl)oxy]pyridazin-3(2H)-  
 one 586372-66-9P, 4-(Benzyloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-  
 one 586372-68-1P, 4-(Benzyloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-  
 one 586372-69-2P, 4-(Benzyloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-  
 2(1H)-one 586372-70-5P, 4-(Benzyloxy)-1-[(4-chlorophenyl)methyl]pyridin-  
 2(1H)-one 586372-71-6P, 4-(Benzyloxy)-3-bromo-1-[(4-  
 chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzyloxy)-1-[(2-  
 fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzyloxy)-3-  
 bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-78-3P,  
 4-(Benzyloxy)-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one  
 586372-79-4P, 4-(Benzyloxy)-3-bromo-1-[[4-(methoxycarbonyl)phenyl]methyl]p-  
 yridin-2(1H)-one 586372-80-7P, 4-(Benzyloxy)-3-bromo-1-[(4-  
 carboxyphenyl)methyl]pyridin-2(1H)-one 586372-83-0P,  
 4-(Benzyloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one  
 586372-84-1P, 4-(Benzyloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-  
 2(1H)-one 586372-85-2P, 4-(Benzyloxy)-3-bromo-1-ethylpyridin-2(1H)-one  
 586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one  
 586372-88-5P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one  
 586372-89-6P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-  
 hydroxybenzenecarboximidamide 586372-90-9P, 4-(Benzyloxy)-3-bromo-1-  
 (piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-91-0P,  
 4-(Benzyloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one  
 586372-92-1P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-  
 2(1H)-one 586372-93-2P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-  
 ylmethyl)pyridin-2(1H)-one hydrochloride 586372-94-3P,  
 4-(Benzyloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one  
 586372-95-4P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-  
 one 586372-96-5P, 4-(Benzyloxy)-3-bromo-1-[3-  
 (trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-97-6P,  
 4-(Benzyloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one  
 586372-98-7P, 4-(Benzyloxy)-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-  
 one 586372-99-8P, 4-(Benzyloxy)-3-bromo-1-[4-  
 (trifluoromethoxy)benzyl]pyridin-2(1H)-one 586373-01-5P,

1-Benzyl-4-(benzyloxy)-3-bromo-6-methylpyridin-2(1H)-one 586373-02-6P,  
 1-Benzyl-4-(benzyloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one  
 586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-  
 2(1H)-one 586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-  
 dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-08-2P, 1-Benzyl-4-[(2-  
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-  
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-10-6P, 1-Benzyl-3-bromo-4-[(4-  
 methylbenzyl)oxy]pyridin-2(1H)-one 586373-11-7P, 1-Benzyl-4-[(3-  
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-12-8P,  
 1-Benzyl-4-(benzylthio)-3-bromopyridin-2(1H)-one 586373-13-9P,  
 1-Benzyl-3-bromo-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one  
 586373-15-1P, 1-Benzyl-4-(benzyloxy)-3-ethylpyridin-2(1H)-one  
 586373-16-2P, 3-Acetyl-4-(benzyloxy)-1-(2-chlorophenyl)-6-methylpyridin-  
 2(1H)-one 586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-  
 one 586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-  
 phenylethyl)pyridin-2(1H)-one 586373-23-1P, 4-(Benzyloxy)-3-bromo-1-(2,6-  
 dichlorophenyl)-6-methylpyridin-2(1H)-one 586373-27-5P,  
 3-Bromo-1-(3-fluorobenzyl)-4-(2-phenylethyl)pyridin-2(1H)-one  
 586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl  
 N-methyl-N-phenylcarbamate 586373-30-0P, 4-(Benzyloxy)-3-ethynyl-1-(3-  
 fluorobenzyl)pyridin-2(1H)-one 586373-33-3P, 4-(Benzylamino)-3-bromo-1-  
 (3-fluorobenzyl)pyridin-2(1H)-one 586373-36-6P, 3-Bromo-1-  
 (cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one  
 586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-  
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-  
 yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-42-4P,  
 3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one  
 586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-  
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-  
 yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-45-7P,  
 3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one  
 586373-46-8P 586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-  
 (trifluoromethyl)benzyl]pyridin-2(1H)-one 586373-48-0P,  
 3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one  
 586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-  
 2(1H)-one 586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-  
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-53-7P, 1-(3-Aminomethylbenzyl)-  
 3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate  
 (1:1.125) 586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-  
 2H-pyridin-1-yl)methyl]benzoate 586373-56-0P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one  
 586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-  
 [(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-62-8P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-  
 pyridin-2-one 586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-  
 [(methylamino)methyl]benzyl]-1H-pyridin-2-one 586373-65-1P,  
 1-[(3-Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-  
 one 586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-  
 [(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-69-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-  
 pyridin-2-one 586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-  
 (methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-72-0P,  
 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-  
 yl)methyl]benzamide 586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-  
 [(1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one  
 586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]pyridin-2(1H)-one 586373-85-5P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one  
 586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-  
 ylmethyl)pyridin-2(1H)-one 586373-87-7P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one

586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-89-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one 586373-90-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(benzodioxol-5-yl)methylpyridine-2(1H)-one 586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-fluorobenzyl)pyridin-2(1H)-one 586373-92-4P, 3-Bromo-1-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-94-6P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetoneitrile 586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-98-0P, Methyl 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzamide 586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P 586374-11-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-15-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-16-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-butylbenzyl)oxy]-1H-pyridin-2-one 586374-20-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one 586374-21-2P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586374-22-3P 586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P 586374-25-6P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[[2-(hydroxymethyl)benzyl]oxy]pyridin-2(1H)-one 586374-31-4P, 2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586374-33-6P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one 586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-4-yl)methyl)-1H-pyridin-2-one 586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-49-4P, 1-[3-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-54-1P, Methyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile 586374-57-4P, [4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetic acid 586374-58-5P 586374-64-3P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-67-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-69-8P, 3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-73-4P,



1-[3-[(Morpholin-4-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-76-7P, 1-[3-[(Piperidin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-77-8P, 1-[3-[(2-Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-78-9P, 1-[3-[[Bis(2-hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-79-0P, 1-[3-[(Piperazin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one 586374-82-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-83-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-84-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyacetyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-85-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-86-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)methyl]benzyl]pyridin-2(1H)-one 586374-87-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-yl)methyl]benzyl]pyridin-2(1H)-one 586374-88-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-2(1H)-one 586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-90-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-91-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-hydroxyethyl]amino]methyl]benzyl]pyridin-2(1H)-one 586374-92-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-93-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[methoxycarbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586374-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one 586374-95-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[methylsulfonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586374-96-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[aminocarbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586374-97-2P, 4-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoyl]piperazine-1-carboxamide 586374-99-4P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-00-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)methyl]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-01-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-methylethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-02-2P, 586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(aminomethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(hydroxymethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(acetylamino)methyl]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-06-6P, 1-[4-[(4-Acetyl)piperazin-1-yl]carbonyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-07-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-[(methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one

586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide  
 586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-  
 one 586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-  
 2H-pyridin-1-yl]benzoate 586375-17-9P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one  
 586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-  
 2(1H)-one 586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-  
 hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-28-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(methylamino)methyl]benzyl]pyridin-2(1H)-one 586375-33-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-  
 2(1H)-one 586375-34-0P 586375-36-2P, 4-[13-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl-N-(2-hydroxy-2-  
 methylpropyl)benzamide 586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-  
 1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl]-6-methylpyridin-2(1H)-one  
 586375-38-4P, 4-[13-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl-N-(2-hydroxyethyl)benzamide 586375-39-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(piperazino)carbonyl]benzyl]pyridin-2(1H)-one 586375-40-8P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-  
 aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-41-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-  
 aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-42-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-43-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(methylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-44-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-45-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(morpholino)carbonyl]benzyl]pyridin-2(1H)-one 586375-46-4P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(bis(2-  
 hydroxyethyl)amino)carbonyl]benzyl]pyridin-2(1H)-one 586375-47-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-48-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-49-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(1-  
 pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one 586375-50-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-  
 methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one 586375-51-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-  
 (dimethylamino)ethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one  
 586375-52-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-  
 methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-53-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-hydroxyethyl)-N-  
 methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-54-4P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-methoxyethyl)-N-  
 methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-55-5P,  
 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-  
 (2-hydroxyethyl)benzamide 586375-56-6P  
 , 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(piperazinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-57-7P,  
 N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]benzamide hydrochloride 586375-58-8P, N-(3-Aminopropyl)-4-  
 [3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzamide hydrochloride 586375-59-9P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]phenyl]pyridin-  
 2(1H)-one hydrochloride 586375-60-2P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]phenyl]pyridin-  
 2(1H)-one hydrochloride 586375-61-3P, 3-Bromo-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-62-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-64-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-67-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586375-68-0P, 4-(Benzylloxy)-3-bromo-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586375-69-1P, 4-(Benzylloxy)-3-bromo-1-[4-(piperazin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-70-4P, 4-[4-(Benzylloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586375-73-7P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylbenzamide 586375-74-8P 586375-75-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(hydroxymethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-87-3P 586375-88-4P 586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide hydrochloride 586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide 586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586375-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[piperazinocarbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[methylamino]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[morpholinocarbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-

6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-02-5P,  
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-dimethylaminoethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-hydroxyethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-methoxyethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586376-22-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586376-26-3P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]methanesulfonamide 586376-27-4P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide 586376-28-5P 586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide 586376-30-9P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-acetoxyacetamide hydrochloride 586376-31-0P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P, N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea 586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one 586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]urea 586376-38-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-41-2P, N-[4-[4-(Benzoyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzyl]acetamide 586376-44-5P, N-[4-[4-(Benzoyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586376-45-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-

yl)ethyl]pyridin-2(1H)-one 586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-48-9P, Methyl 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-50-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-difluorobenzamide 586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-68-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-72-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-78-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-82-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide 586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-[(4-fluoro-2-(hydroxymethyl)benzyl)oxy]-6-methylpyridin-2(1H)-one 586377-04-0P, 3-Chloro-1-(2,6-difluorophenyl)-4-[(4-fluoro-2-(hydroxymethyl)benzyl)oxy]-6-methylpyridin-2(1H)-one 586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide 586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methoxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-17-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-19-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-hydroxyethyl)-N-methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-21-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-methoxyethyl)-N-methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-26-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-28-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide 586377-33-5P 586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide 586377-35-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzamide 586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one hydrochloride 586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide 586377-44-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-

difluorobenzyl]oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea  
 586377-48-2P, 2-[[[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate  
 586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]acetamide 586377-50-6P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-methoxyacetamide 586377-51-7P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide 586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide 586377-53-9P  
 586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-3-hydroxy-3-methylbutanamide 586377-55-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1-hydroxycyclopropanecarboxamide 586377-56-2P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-phenylethoxy)pyridin-2(1H)-one 586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(E)-2-(4-fluorophenyl)ethenyl]pyridin-2(1H)-one 586377-64-2P, 4-(Benzoyloxy)-3-bromo-1-[(6-fluoropyridin-3-yl)methyl]pyridin-2(1H)-one 586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P, 3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-78-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-dichlorobenzenesulfonamide 586377-83-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]urea 586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586378-07-6P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)methyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-11-2P 586378-17-8P 586378-19-0P, Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-carboxylate trifluoroacetate 586378-21-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1-(2-hydroxypyrimidin-4-yl)methyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-23-6P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-

carboxamide trifluoroacetate 586378-24-7P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-yl]methylcarbamate 586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-28-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-ylmethyl)pyridin-2(1H)-one 586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-hydroxyethyl)(methyl)amino]methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-37-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586378-41-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide 586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide 586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide 586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(2-methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-46-3P, Carbamic acid 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester 586378-48-5P, 4-(Benzoyloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-2(1H)-one 586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide 586378-57-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one 586378-61-2P, 3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586378-65-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one 586378-71-4P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one 586378-72-5P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one 586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-74-7P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-76-9P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-78-1P, 3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-79-2P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one 586378-81-6P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one 586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one 586378-83-8P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-86-1P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one 586378-87-2P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one  
 586378-91-8P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one trifluoroacetate  
 586378-93-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-methyl-4-(methyldimino)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate  
 586378-95-2P 586378-97-4P 586378-98-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(methyldimino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylpyrazine-2-carboxamide 586379-05-7P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylpyrazine-2-carboxamide 586379-06-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-07-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide 586379-08-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-(morpholin-4-ylcarbonyl)pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-09-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(4-hydroxypiperidin-1-yl)carbonyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-11-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide 586379-12-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide 586379-13-7P, 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-15-9P, 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-17-1P, Methyl (2E)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586379-18-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one 586379-21-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-24-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-29-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-31-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-ylmethyl)pyridin-2(1H)-one 586379-33-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[[2-(methoxyethyl)amino]methyl]pyridin-2(1H)-one 586379-34-2P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid 586379-35-3P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoate 586379-38-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-carboxyphenyl)pyridin-2(1H)-one 586379-39-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-(hydroxymethyl)phenyl]pyridin-2(1H)-one 586379-40-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[[2-(methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586379-41-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(methyldimino)carbonyl]phenyl]pyridin-2(1H)-one 586379-46-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-47-7P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoate 586379-50-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoic acid 586379-54-6P,



3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-57-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-59-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-60-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586379-65-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(2-methoxyethyl)amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-67-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-68-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-69-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(methyl-2-methylphenyl)-6-methylpyridin-2(1H)-one 586379-71-7P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-76-2P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-78-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-80-8P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-83-1P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P, 3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one 586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-03-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one 586380-04-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586380-05-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-06-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[3-(hydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-08-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2,3-dihydroxypropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-09-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxy-1,1-dimethylethyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one 586380-17-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N-methylbenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP

kinase for treatment of inflammatory conditions,  
ischemia, viral infections, autoimmune diseases, and other  
conditions)

IT 586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N,N-dimethylbenzamide 586380-21-4P,  
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 586380-22-5P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[acetyl(amino)methyl]phenyl]pyridin-2(1H)-one 586380-23-6P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[methoxyacetyl(amino)methyl]phenyl]pyridin-2(1H)-one 586380-24-7P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-25-8P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-27-0P,  
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methoxycarbonyl)amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-28-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(trifluoromethyl)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-29-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(isopropoxycarbonyl)amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-30-5P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(ethylamino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-31-6P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tetrahydrofuran-3-yloxy)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-32-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propoxycarbonyl)amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-33-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(allyloxy)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-34-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propargyloxy)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-35-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tert-butoxy)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-36-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tert-butyl)amino]carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-37-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propylsulfonyl)amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-38-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(ethylsulfonyl)amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-39-4P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(isopropylamino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-40-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methoxymethyl)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-41-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methylanino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-42-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[N-methyl-N-(tert-butyl)amino]carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-43-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(cyclopropylamino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-44-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(2,2,2-trifluoroethyl)amino]carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-45-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(cyclopropylmethyl)amino]carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-46-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(2,2-dimethylpropylamino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-47-4P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(dimethylamino)carbonyl]amino)methyl]benzyl]oxy]pyridin-2(1H)-one 586380-48-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[15-(1-hydroxy-1-methylthethyl)pyridin-2-yl]methyl-6-methylpyridin-2(1H)-one 586380-50-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[15-(hydroxymethyl)pyridin-2-yl]methyl-6-methylpyridin-2(1H)-one

586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide  
 586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide 586380-56-5P,  
 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylnicotinamide 586380-57-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester 586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 586380-69-0P,  
 4-(Benzoyloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one 586380-71-4P,  
 4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methyl-5-(E)-2-phenylethenylpyridin-2(1H)-one 586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one 586380-77-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(thien-2-ylmethyl)pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one 586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide 586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586380-91-8P 586380-92-9P,  
 N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-dimethylurea 586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide 586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide 586380-96-3P 586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-98-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N,N-dimethylbenzamide 586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one 586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxy-2-methylpropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586381-10-4P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide 586381-11-5P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586381-14-8P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586381-17-1P, 1-[3-Aminobenzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-18-2P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide

586381-19-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide 586381-20-6P,  
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-acetoxyacetamide 586381-21-7P 586381-22-8P,  
 N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-23-9P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-methylurea 586381-24-0P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxy-2-methylpropyl)urea 586381-25-1P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperidine-1-carboxamide 586381-26-2P,  
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P,  
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P,  
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,  
 N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-4-hydroxypiperidine-1-carboxamide 586381-31-9P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzenesulfonamide 586381-35-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[[2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydroindol-2-one 586381-45-5P,  
 N-[[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl]-N-methylmethanesulfonamide 586381-46-6P,  
 Methyl 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl(methyl)carbamate 586381-47-7P  
 586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide 586381-50-2P, 1-[(5-Aminopyrazin-2-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586381-52-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(3-methyl-1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate 586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-65-9P, Methyl 2-[[[3-bromo-1-[5-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-66-0P, Methyl 2-[[[3-bromo-1-[5-[(2-hydroxy-2-methylpropyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-67-1P,  
 Methyl 2-[[[3-bromo-1-[5-[(2-methoxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-68-2P, O-Methyl 2-[[[1-[5-(aminocarbonyl)-2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-69-3P, N-2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-N'-phenylurea 586381-70-6P, (Thien-3-yl)methyl 2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-71-7P, Ethyl 2-[[[3-bromo-6-methyl-1-[2-methyl-5-[(methylanino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-75-1P 586381-83-1P, Methyl 3-[6-(acetyloxy)methyl]-3-bromo-4-

[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate  
 586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-88-6P,  
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586381-90-0P,  
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methyl-2-butenamide 586381-97-7P 586381-98-8P 586381-99-9P 586382-00-5P 586382-01-6P, Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester 586382-06-1P, Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl ester 586382-07-2P, N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl ester 586382-11-8P, (S)-2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1-methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-(Aminocarbonyl)phenyl]-5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl 2-[[[3-bromo-1-[5-[[2-(2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586382-24-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586382-27-6P 586382-28-7P 586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl]methyl]benzoate 586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furamide 586382-34-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furamide 586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-43-6P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalamide 586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586382-47-0P, 1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586382-49-2P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxyacetamide 586382-51-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-dimethylbenzamide 586382-55-0P 586382-56-1P, 3-Chloro-4-[[2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methylpyridin-2(1H)-one 586382-57-2P, 3-Chloro-4-[[2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methylpyridin-2(1H)-one 586382-58-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylindoline-1-carboxamide 586382-59-4P 586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-

2,3-dihydro-1H-indol-5-yl)methyl]pyridin-2(1H)-one 586382-61-8P,  
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylindoline-1-carboxamide 586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586382-64-1P, 4-(Benzyloxy)-3-bromo-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-65-2P, 4-(Benzyloxy)-3-bromo-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586382-66-3P, 1-Benzyl-4-(benzyloxy)-3-chloropyridin-2(1H)-one 586382-67-4P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-(phenylthio)ethyl]pyridin-2(1H)-one 586382-71-0P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one 586382-72-1P 586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-carboxaldehyde 586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P, 1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one 586382-77-6P, 3-Bromo-1-(4-methylbenzyl)-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one 586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586382-80-1P, 5-Bromo-1-(2-chloro-6-fluorobenzyl)-3-methylpyridin-2(1H)-one 586382-81-2P, 1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde 586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde 586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxaldehyde 586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-2(1H)-one 586382-85-6P, 4-(Benzyloxy)-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one 586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one 586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one 586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one 586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one 586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate 586382-92-5P, 6-(Benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 586382-93-6P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one 586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one 586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one 586382-96-9P, 4-Amino-1-benzylpyridin-2(1H)-one 586382-97-0P, 4-[(2,6-Dichlorobenzyl)oxy]pyridine-1-oxide 586382-98-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P 586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-dihydro-1H-indol-5-yl]pyridin-2(1H)-one 586383-03-1P 586383-04-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]indoline-1-carboxamide 586383-06-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-yl]pyridin-2(1H)-one 586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-08-6P 586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-11-1P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-carboxamide 586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-15-5P, 1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-16-6P 586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-18-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P 586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-30-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-32-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P 586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-39-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-40-6P, 1-(1-Acetyl-1H-benzimidazol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-41-7P 586383-42-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-43-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-44-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-47-3P,

5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1-carboxamide 586383-48-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-50-8P 586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-52-0P, 1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-53-1P, 1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-55-3P, 3-Acetyl-5-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586383-56-4P 586383-57-5P 586383-58-6P 586383-59-7P 586383-60-0P  
 586383-61-1P 586383-62-2P 586383-63-3P 586383-64-4P,  
 1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-69-9P,  
 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-72-4P 586383-73-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-76-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-80-4P 586383-81-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-



(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-84-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-87-1P, 1-[Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P 586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-90-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-98-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586384-00-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-02-3P 586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-04-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-07-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-08-9P, 1-[1,3-Bis(3-methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-09-0P, 1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-10-3P, 1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-

methylpyridin-2(1H)-one 586384-11-4P 586384-12-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-  
 pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-13-6P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-  
 pyrrol-3-yl]pyridin-2(1H)-one 586384-14-7P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-  
 methylpyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrrol-3-yl]-6-  
 methylpyridin-2(1H)-one 586384-16-9P, 3-[3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-  
 carboxamide 586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-18-1P,  
 1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-  
 methylpyridin-2(1H)-one 586384-19-2P 586384-20-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-  
 imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-21-6P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-  
 imidazol-4-yl]pyridin-2(1H)-one 586384-22-7P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-  
 methylpyridin-2(1H)-one 586384-23-8P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-  
 methylpyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-  
 carboxamide 586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[1-(methylsulfonyl)-1H-imidazol-4-yl]pyridin-2(1H)-one 586384-26-1P,  
 1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-  
 methylpyridin-2(1H)-one 586384-27-2P 586384-28-3P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-  
 pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-29-4P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-  
 pyrazol-4-yl]pyridin-2(1H)-one 586384-30-7P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-  
 methylpyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-  
 methylpyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-  
 carboxamide 586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-  
 2(1H)-one 586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-  
 (isoquinolin-6-yl)methylpyridin-2(1H)-one 586384-36-3P,  
 5-[(3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-  
 dihydro-2H-indol-2-one 586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-  
 yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one  
 586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-  
 methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one  
 586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(N-methylglycyl)-  
 2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-40-9P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-  
 dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-41-0P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-  
 2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-42-1P,  
 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-  
 yl]methylindoline-1-carboxamide 586384-43-2P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-  
 yl]methylpyridin-2(1H)-one 586384-44-3P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-  
 one 586384-45-4P, 1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-  
 chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-46-5P  
 586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-  
 methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methylpyridin-2(1H)-one

586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-49-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-50-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-51-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide 586384-52-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-53-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-54-5P, 1-[[2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-55-6P 586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-58-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-59-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-61-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-62-5P, 1-[[2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-63-6P 586384-64-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-66-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-67-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-69-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-70-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-71-6P, 1-[[1-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-72-7P 586384-73-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-74-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-75-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-76-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-77-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-78-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-79-4P, 1-[[3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-80-7P, 3-Chloro-1-[(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-81-8P 586384-82-9P, 1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-

yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one  
 586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one  
 586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-86-3P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazol-1-carboxamide 586384-87-4P, 1-[[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-88-5P 586384-89-6P  
 586384-90-9P 586384-91-0P 586384-92-1P 586384-93-2P 586384-94-3P 586384-95-4P 586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-98-7P 586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-00-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-01-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-03-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-1-carboxamide 586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P 586385-08-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-09-3P, 1-[[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-11-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-12-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-1-carboxamide 586385-13-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-14-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-16-2P 586385-17-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-18-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-19-5P, 1-[[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-

[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-20-8P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-22-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-23-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-24-2P, 1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-25-3P 586385-26-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-27-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-28-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-29-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-30-0P, 1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-32-2P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-33-3P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-34-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-38-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-40-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-41-3P, 1-[[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P 586385-43-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-46-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-47-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one

586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-50-4P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-51-5P 586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P, 1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-60-6P 586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-64-0P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-67-3P 586385-68-4P 586385-69-5P 586385-70-8P 586385-71-9P 586385-72-0P 586385-73-1P 586385-74-2P 586385-75-3P 586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-78-6P 586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-80-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-82-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-83-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-

yl)methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-85-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-86-6P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-87-7P, 586385-88-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-89-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-90-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-91-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-96-8P, 586385-97-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-99-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-00-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-01-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-02-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-05-2P, 586386-06-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-07-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-10-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-13-2P, 586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-

oxo-2H-pyridin-1-yl|methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-15-4P,  
 6-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-16-5P, 6-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-17-6P, 6-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-18-7P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-2-oxo-1H-benzimidazole-1,3(2H)-dicarboxamide 586386-19-8P, 6-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-20-1P, 6-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-21-2P, 1-Acetyl-5-[[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-22-3P 586386-23-4P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-24-5P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1-(N-methylglycyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-25-6P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-26-7P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-27-8P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-28-9P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl|methyl]-1,3-bis(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[[4-fluorophenyl]ethyl]-6-methylpyridin-2(1H)-one 586386-31-4P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde 586386-32-5P, 4-[[2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586386-33-6P, 4-[[2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586386-34-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-methoxyphenyl]-6-methylpyridin-2(1H)-one 586386-35-8P, 3-Bromo-4-[[2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]phenyl]pyridin-2(1H)-one 586386-36-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]benzamide 586386-37-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)benzamide 586386-38-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 586386-39-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(2-hydroxyethyl)-N-methylbenzamide 586386-40-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-methylbenzamide 586386-41-6P, 4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P, Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy|methyl]-3,5-difluorobenzyl]carbamate 586386-43-8P, 3-Bromo-4-[[2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-44-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluorophenyl]-6-[[ethoxycarbonyl]methyl]pyridin-2(1H)-one 586386-45-0P, N-(3-Aminopropyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl|methyl]benzamide hydrochloride 586386-46-1P, 3-Bromo-4-[[2,4-difluorobenzyl)oxy]-1-(1H-



indazol-5-ylmethyl)pyridin-2(1H)-one 586386-47-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586386-51-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586386-52-9P 586386-53-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-55-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-bis(2-hydroxyethyl)benzamide 586386-56-3P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-hydroxybenzamide 586386-57-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one 586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P, 3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586386-63-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586386-65-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-isopropylbenzamide 586386-68-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-70-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586386-71-2P, 4-(Benzylamino)-1-(3-fluorobenzyl)-6-methyl-3-nitropyridin-2(1H)-one 586386-72-3P, tert-Butyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-carboxylate 586386-73-4P, Ethyl 4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]acetate 586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzenesulfonamide 586386-75-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-phenylmethanesulfonamide 586386-76-7P, 3-Bromo-4-[(2,4-difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-77-8P, 4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P, Methyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]amino]benzoate 586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-trimethoxyphenyl)amino]pyridin-2(1H)-one 586386-80-3P, 3-Bromo-1-(3-fluorobenzyl)pyridin-4-[(4-fluorophenyl)piperazin-1-yl]pyridin-2(1H)-one 586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)pyridin-2(1H)-one trifluoroacetate 586386-83-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,5-difluorobenzamide 586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,4-difluorobenzamide 586386-85-8P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid 586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-N'-(2,4-difluorophenyl)urea 586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide 586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-

(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one 586386-89-2P,  
N-(3-Aminopropyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride  
586386-91-6P, 4-(Benzyloxy)-3-bromo-1-[2-(morpholin-4-yl)ethyl]pyridin-2(1H)-one 586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-93-8P,  
[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic acid 586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-95-0P,  
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate  
586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-diethoxyethyl)pyridin-2(1H)-one 586386-99-4P 586387-00-0P  
586387-01-1P 586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-one 586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-methylimidazolidine-2,4-dione 586387-04-4P, Ethyl [4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]acetate 586387-05-5P, 2-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]acetamide 586387-06-6P, 4-(Benzyloxy)-1-ethylpyridin-2(1H)-one 586387-07-7P, tert-Butyl 3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-08-8P, 1,3-Dibenzyl-4-hydroxy-6-methylpyridin-2(1H)-one 586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate 586387-10-2P, 1-Benzyl-4-(naphthyl-1-ylmethoxy)pyridin-2(1H)-one 586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-dibromopyridin-2(1H)-one 586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-4-(benzyloxy)pyridin-2(1H)-one 586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-[[2-cyclohexylethyl]amino]methyl]pyridin-2(1H)-one 586387-14-6P,  
1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P,  
1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate 586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586387-17-9P,  
1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate 586387-18-0P, 4-Phenoxy-1-[[2-(trimethylsilyl)ethoxy]methyl]pyridin-2(1H)-one 586387-19-1P,  
1-Benzyl-4-phenoxypyridin-2(1H)-one 586387-20-4P 586387-21-5P,  
3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride 586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one 586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)acetate 586387-24-8P, Methyl (2E)-4-[[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586387-25-9P, tert-Butyl 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-26-0P, 1-Benzyl-4-[[4-methylbenzyl]oxy]pyridin-2(1H)-one 586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-28-2P,  
tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-[methanesulfonyl]-1H-pyridin-2-one 586387-30-6P, tert-Butyl 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate 586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-methyl-4-methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one 586387-33-9P,  
4-(Benzyloxy)-1-[4-(methanesulfonyl)benzyl]pyridin-2(1H)-one 586387-34-0P, 4-Phenoxy-1H-pyridin-2-one 586387-35-1P,  
4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P,  
4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride 586387-39-5P, 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one

586387-40-8P, 4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-one 586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[(pyridin-3-ylmethyl)amino]-1H-pyridin-2-one 586387-42-0P, 2-Chloro-N-[1-(2,6-dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-fluorobenzamide 586387-43-1P, N-[1-(2,6-Dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide 586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-one 586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-pyridin-2-one 586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-[3,4']bipyridinyl-2'-one 586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-(3-fluorobenzyl)-1H-pyridin-2-one 586387-48-6P, 3-Bromo-1-(3-fluorobenzyl)-4-(thiophen-3-yl)-1H-pyridin-2-one 586387-49-7P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one 586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-one 586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-pyridin-2-one 586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-pyridin-2-one 586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one 586387-54-4P, 2-[[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-55-5P, 2-(2-Chloro-4-hydroxyphenyl)-4-[1-(2,4-difluorobenzyl)oxy]-6-methyl-1H-pyridin-2-one 586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-vinyl-1H-pyridin-2-one 586387-57-7P 586387-58-8P, 1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-indazol-5-ylamino)-6-methylpyridin-2(1H)-one 586387-61-3P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[2-(2,4-difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde 586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]pyrimidine-2-carbonitrile 586387-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-yl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-[1,2']bipyridinyl-3'-carbonitrile 586387-66-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid methylamide 586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-hydroxyethyl)amide 586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-methoxyethyl)amide 586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-methylbenzyl)-1H-pyridin-2-one 586387-70-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-6-methylpyridin-2(1H)-one 586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-72-6P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile trifluoroacetate 586387-74-8P 586387-75-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586387-76-0P  
 , 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-77-1P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586387-78-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-2(1H)-one 586387-79-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586387-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-81-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-bis(2-hydroxyethyl)benzamide 586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one trifluoroacetate 586387-84-0P,

3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-85-1P 586387-86-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-87-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one 586387-88-4P  
 586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586387-90-8P,  
 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586387-92-0P, 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-93-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methyl-1H-pyridin-2-one 586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-yl)methyl-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-[(cyclopropylmethyl)amino]methyl]-2,6-difluorophenyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586396-39-6P,  
 N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P  
 586397-63-9P 586397-73-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 165245-96-5, p38 $\alpha$  MAP kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586374-26-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 56-37-1, Benzyltriethylammonium chloride 75-31-0, Isopropylamine, reactions 79-44-7, Dimethylcarbonyl chloride 86-95-3, 4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline 88-17-5, 2-(Trifluoromethyl)aniline 95-02-3, 4-Amino-5-aminomethyl-2-methylpyrimidine 96-33-3, Methyl acrylate 98-00-0, Furfuryl alcohol 98-58-8, 4-Bromobenzenesulfonyl chloride 98-79-3 99-27-4, Dimethyl 5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine 103-64-0,  $\beta$ -Bromostyrene 103-71-9, Phenyl isocyanate, reactions 104-81-4, 4-Methylbenzyl bromide 105-36-2, Ethyl bromoacetate 106-96-7, Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine 109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3, 2-Methoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 315-14-0, 2,4,6-Trifluoronitrobenzene 315-31-1, 2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline 402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl chloride 405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol 453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic acid 456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide 459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride 536-74-3, Phenylacetylene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl

chloroformate 582-33-2, Ethyl 3-aminobenzoate 585-71-7,  
 (1-Bromoethyl)benzene 594-61-6, 2-Hydroxyisobutyric acid 616-30-8,  
 3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan 619-45-4,  
 Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid 626-03-9,  
 2,4-Dihydropyridine 626-15-3,  $\alpha,\alpha'$ -Dibromo-m-xylene  
 674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one  
 765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene  
 867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl  
 indole-5-carboxylate 1071-46-1, Monoethyl malonate 1072-84-0,  
 4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate  
 1121-76-2, 4-Chloropyridine 1-oxide 1124-33-0, 4-Nitropyridine N-oxide  
 1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile  
 1453-58-3, 3-Methyl-1H-pyrazole 1465-76-5, 1-tert-Butyl-4-oxopiperidine  
 1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine  
 2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl  
 4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate  
 2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-  
 propanol 3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,  
 2-Chlorophenyl isocyanate 3544-24-9, 3-Aminobenzamide 3731-51-9,  
 2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,  
 4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid  
 4285-42-1, N-Methyl-N-phenylcarbamoyl chloride 4385-35-7,  
 Isochroman-3-one 4412-91-3, 3-Furylmethanol 4518-10-9, Methyl  
 3-aminobenzoate 4530-20-5, Boc-glycine 5345-27-7, 3-  
 (Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine 5394-63-8,  
 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl 6-methylnicotinate  
 5509-65-9, 2,6-Difluoroaniline 5521-55-1, 5-Methylpyrazine-2-carboxylic  
 acid 5571-03-9, Methyl 2-methyl-5-pyrimidinecarboxylate 6482-24-2,  
 2-Methoxyethyl bromide 6723-30-4, [(Tetrahydro-2H-pyran-2-yl)oxylamine  
 7051-34-5, Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole  
 7693-46-1, 4-Nitrophenyl chloroformate 10406-24-3, 3-  
 (Aminomethyl)benzonitrile 13737-36-5, 4-(Bromomethyl)phenylacetic acid  
 13831-30-6, Acetoxyacetic acid 13831-31-7, Acetoxyacetyl chloride  
 14001-63-9, 4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic  
 acid bis(2,4,6-trichlorophenyl) ester 17201-43-3,  $\alpha$ -Bromo-p-  
 toluenitrile 17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid  
 18063-02-0, 2,6-Difluorobenzoyl chloride 18583-89-6, Methyl  
 3-amino-2-methylbenzoate 18595-18-1, Methyl 3-amino-4-methylbenzoate  
 19335-11-6, 5-Aminoindazole 20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol  
 22115-41-9,  $\alpha$ -Bromo-o-tolunitrile 22134-75-4 22600-30-2, Methyl  
 2-amino-5-furoate 23063-36-7,  $\alpha,\alpha$ -Dichloro-p-xylene  
 23915-07-3, 2,4-Difluorobenzyl bromide 24424-99-5, Di-tert-butyl  
 dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4,  
 2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-  
 propanol hydrochloride 36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride  
 38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl  
 isocyanate 40061-55-0, m-Tolylacetic acid ethyl ester 40635-66-3,  
 2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl  
 3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate  
 50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt  
 53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-  
 chlorobenzyl alcohol 56456-47-4, 2,4-Difluorobenzyl alcohol  
 57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,  
 3-(Cyclohexylamino)-2-butenic acid methyl ester 60728-41-8,  
 3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-  
 Bis(hydroxymethyl)-4-fluorobenzene 66176-39-4, 4-  
 (Bromomethyl)benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-  
 difluoroaniline 71637-34-8, Thien-3-ylmethanol 72235-52-0,  
 2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile  
 80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,  
 3-Amino-4-methylbenzyl alcohol 84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-

2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5, 5-Bromomethyl-2-fluoropyridine 114896-64-9, Methanesulfonic acid 2-(thiophen-3-yl)ethyl ester 120100-15-4, Methyl 3-amino-2-chlorobenzoate 132664-85-8, 5-Aminomethyl-2-methylpyrazine 134227-45-5, 3,4,5-Trifluorobenzonitrile 135394-68-2 161975-39-9, 4-(Methanesulfonyloxymethyl)-1-piperidine-1-carboxylic acid tert-butyl ester 162166-99-6, 3-[(Methanesulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester 192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one 586374-17-6, 1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one 586374-35-8 586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-2(1H)-one 586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one 586376-42-3, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one hydrochloride 586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586376-85-4, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586378-53-2, 1-Benzyl-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-62-3, 3-Bromo-1-(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-89-4, 4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-00-2, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[5-[(methylamino)methyl]pyrazin-2-yl]methylpyridin-2(1H)-one 586379-20-6, 4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-22-8, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 58804-19-6P 586378-47-4P 586381-34-2P 586381-37-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; CHEM BER 1956, V89, P876
- (2) Anon; COLLECT CZECH CHEM COMMUN 1993, V58(4), P947
- (3) Anon; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1 1986, P1289
- (4) Anon; LIEBIGS ANN, RECL 1997, V8, P1777
- (5) Crich, J; WO 0031063 A 2000 CAPLUS
- (6) Dorn, C; US 3715358 A 1973
- (7) Graham, P; US 3654291 A 1972 CAPLUS
- (8) Margolin, S; WO 9710712 A 1997 CAPLUS
- (9) Merck & Co Inc; GB 1289187 A 1972 CAPLUS
- (10) Sandoz Ag; WO 8601815 A 1986 CAPLUS
- (11) Witzel, B; US 3644626 A 1972 CAPLUS

L32 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 84-11-7, Phenanthrene-9,10-dione

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutics for chemokine-mediated diseases)

RN 84-11-7 CAPLUS

CN 9,10-Phenanthrenedione (CA INDEX NAME)



ACCESSION NUMBER: 2002:449493 CAPLUS  
 DOCUMENT NUMBER: 137:15782  
 TITLE: Therapeutics for chemokine-mediated diseases  
 INVENTOR(S): Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan  
 PATENT ASSIGNEE(S): Chemokine Therapeutics Corporation, Can.  
 SOURCE: PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045702	A2	20020613	WO 2001-CA1748	20011205
WO 2002045702	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW,			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2330350	A1	20020605	CA 2000-2330350	20001205
US 20030069265	A1	20030410	US 2001-767378	20010122
US 6706767	B2	20040316		
AU 2002015737	A5	20020618	AU 2002-15737	20011205
PRIORITY APPLN. INFO.:			CA 2000-2330350	A 20001205
			US 2001-767378	A 20010122
			WO 2001-CA1748	W 20011205

OTHER SOURCE(S): MARPAT 137:15782  
 AN 2002:449493 CAPLUS  
 DN 137:15782  
 ED Entered STN: 14 Jun 2002  
 TI Therapeutics for chemokine-mediated diseases  
 IN Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan  
 PA Chemokine Therapeutics Corporation, Can.  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-00  
 CC 1-7 (Pharmacology)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002045702	A2	20020613	WO 2001-CA1748	20011205
WO 2002045702	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA	2330350	A1 20020605 CA 2000-2330350 20001205
US	20030069265	A1 20030410 US 2001-767378 20010122
US	6706767	B2 20040316
AU	2002015737	A5 20020618 AU 2002-15737 20011205
PRAI	CA 2000-2330350	A 20001205
US	2001-767378	A 20010122
WO	2001-CA1748	W 20011205

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002045702	ICM	A61K031-00
	IPCI	A61K0031-00 [ICM,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*]; A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0025-00 [I,C*]; A61P0025-28 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-02 [I,A]; A61P0033-00 [I,C*]; A61P0033-06 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
CA 2330350	IPCI	A61K0031-122 [ICM,7]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*]; A61P0019-02 [ICS,7]; A61P0019-00 [ICS,7,C*]; A61P0001-04 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0011-06 [ICS,7]; A61P0011-00 [ICS,7,C*]; A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*]; A61P0037-06 [ICS,7]; A61P0037-00 [ICS,7,C*]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61K0031-11 [ICS,7]; A61K0031-473 [ICS,7]; A61K0031-66 [ICS,7]; A61K0031-695 [ICS,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*]; A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
US 20030069265	IPCI	A61K0031-473 [ICM,7]; A61K0031-122 [ICS,7]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,A]; A61K0031-11 [I,C*]; A61K0031-122 [I,A]; A61K0031-122 [I,C*]; A61K0031-473 [I,A]; A61K0031-473 [I,C*]
	NCL	514/290.000; 514/680.000; 514/765.000
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
AU 2002015737	IPCI	A61K0031-00 [ICM,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*];



A61K0031-11 [I,A]; A61K0031-122 [I,C\*]; A61K0031-122 [I,A]; A61K0031-473 [I,C\*]; A61K0031-473 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A]; A61P0011-00 [I,C\*]; A61P0011-00 [I,A]; A61P0017-00 [I,C\*]; A61P0017-06 [I,A]; A61P0019-00 [I,C\*]; A61P0019-02 [I,A]; A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-02 [I,A]; A61P0033-00 [I,C\*]; A61P0033-06 [I,A]; A61P0037-00 [I,C\*]; A61P0037-00 [I,A]

OS MARPAT 137:15782

AB The invention provides therapeutic and biol. uses of chemokine receptor-binding compds. (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as tricyclic phenanthrene derivs., including uses in the treatment of disease states mediated by chemokines or chemokine receptors. The relevant chemokines may be e.g. monocyte chemoattractant protein-1 (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may be e.g. corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). The invention also provides corresponding pharmaceutical compns. and therapeutic methods. In one aspect, for example, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.

ST chemokine mediated disease treatment chemokine receptor binding compd; tricyclic phenanthrene deriv chemokine mediated disease treatment; phenanthrenedione multiple sclerosis treatment

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR2; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR4; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR1; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR2; therapeutics for chemokine-mediated diseases)

IT Inflammation

(Crohn's disease; therapeutics for chemokine-mediated diseases)

IT Intestine, disease

(Crohn's; therapeutics for chemokine-mediated diseases)

IT Sepsis

(Gram-neg.; therapeutics for chemokine-mediated diseases)

IT Neutrophil

(activation; therapeutics for chemokine-mediated diseases)

IT Inflammation

(acute; therapeutics for chemokine-mediated diseases)

IT Respiratory distress syndrome

(adult; therapeutics for chemokine-mediated diseases)

IT Transplant rejection

(allotransplant; therapeutics for chemokine-mediated diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; therapeutics for chemokine-mediated diseases)

IT Dermatitis

(atopic; therapeutics for chemokine-mediated diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; therapeutics for chemokine-mediated diseases)

IT Inflammation

Transplant rejection

(chronic; therapeutics for chemokine-mediated diseases)

IT Autoimmune disease  
(exptl. autoimmune encephalomyelitis; therapeutics for chemokine-mediated diseases)

IT Encephalomyelitis  
(exptl. autoimmune; therapeutics for chemokine-mediated diseases)

IT Lung, disease  
(fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)

IT Ischemia  
(focal; therapeutics for chemokine-mediated diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; therapeutics for chemokine-mediated diseases)

IT Transplant and Transplantation  
(graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)

IT Intestine, disease  
(inflammatory; therapeutics for chemokine-mediated diseases)

IT Reperfusion  
(injury, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Lung, disease  
(injury, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Phagocyte  
(mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics for chemokine-mediated diseases)

IT Cell activation  
(neutrophil; therapeutics for chemokine-mediated diseases)

IT Arthritis  
(pseudogout, acute; therapeutics for chemokine-mediated diseases)

IT Fibrosis  
(pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)

IT Injury  
(pulmonary, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Heart, disease  
Kidney, disease  
(reperfusion injury; therapeutics for chemokine-mediated diseases)

IT Injury  
(reperfusion, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Artery, disease  
(restenosis; therapeutics for chemokine-mediated diseases)


IT Shock (circulatory collapse)  
(septic; therapeutics for chemokine-mediated diseases)

IT Brain, disease  
(stroke; therapeutics for chemokine-mediated diseases)

IT Multiple sclerosis  
(therapeutic agents; therapeutics for chemokine-mediated diseases)

IT Alzheimer's disease  
Angiogenesis  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiarthritics  
Antiasthmatics  
Anticoagulants  
Antimalarials  
Arthritis  
Asthma

Atherosclerosis  
 Cardiovascular agents  
 Drug delivery systems  
 Gastrointestinal agents  
 Gout  
 Inflammation  
 Malaria  
 Multiple sclerosis  
 Neutrophil  
 Psoriasis  
 Rheumatoid arthritis  
 Sarcoidosis  
 Thrombosis  
 (therapeutics for chemokine-mediated diseases)  
 IT Chemokine receptors  
 Chemokines  
 Interleukin 8  
 Monocyte chemoattractant protein-1  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (therapeutics for chemokine-mediated diseases)  
 IT Shock (circulatory collapse)  
 (toxic shock syndrome; therapeutics for chemokine-mediated diseases)  
 IT Inflammation  
 Intestine, disease  
 (ulcerative colitis; therapeutics for chemokine-mediated diseases)  
 IT Interleukin 8 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (α; therapeutics for chemokine-mediated diseases)  
 IT Interleukin 8 receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (β; therapeutics for chemokine-mediated diseases)  
 IT 7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (therapeutics for chemokine-mediated diseases)  
 IT 82-86-0, Acenaphthenequinone 83-32-9, Acenaphthene 84-11-7,  
 Phenanthrene-9,10-dione 1015-89-0, 6(5H)-Phenanthridinone 4707-71-5,  
 Phenanthrene-9-carboxaldehyde  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (therapeutics for chemokine-mediated diseases)  
 L32 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 98-59-9, p-Toluenesulfonyl chloride  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of novel multicyclic compds. and their amino acid derivs. as  
 inhibitors of enzymes for treatment of diseases related to  
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3  
 kinase)  
 RN 98-59-9 CAPLUS  
 CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 2001:833276 CAPLUS

DOCUMENT NUMBER: 135:371989  
 TITLE: Preparation of novel multicyclic compounds and their amino acid derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase  
 INVENTOR(S): Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar; Dunn, Derek; Hudkins, Robert L.  
 PATENT ASSIGNEE(S): Cephalon, Inc., USA  
 SOURCE: PCT Int. Appl., 209 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085686	A2	20011115	WO 2001-US14996	20010509
WO 2001085686	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028815	A1	20020307	US 2001-850858	20010508
US 7122679	B2	20061017		
CA 2409758	A1	20011115	CA 2001-2409758	20010509
EP 1294725	A2	20030326	EP 2001-935215	20010509
EP 1294725	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010993	A	20030624	BR 2001-10993	20010509
HU 2003002385	A2	20031229	HU 2003-2385	20010509
HU 2003002385	A3	20070328		
JP 2004501097	T	20040115	JP 2001-582287	20010509
NZ 522539	A	20040528	NZ 2001-522539	20010509
AT 315039	T	20060215	AT 2001-935215	20010509
ES 2256238	T3	20060716	ES 2001-935215	20010509
EP 1754707	A2	20070221	EP 2005-76862	20010509
EP 1754707	A3	20070228		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
MX 2002PA10977	A	20030714	MX 2002-PA10977	20021107
ZA 2002009065	A	20040209	ZA 2002-9065	20021107
NO 2002005376	A	20030108	NO 2002-5376	20021108
NO 324256	B1	20070917		
IN 2002CN01380	A	20050311	IN 2002-CN1380	20021108
KR 832602	B1	20080527	KR 2002-715062	20021109
BG 107355	A	20030731	BG 2002-107355	20021205
HK 1051369	A1	20060504	HK 2003-103639	20030522
PRIORITY APPLN. INFO.:			US 2000-202947P	P 20000509
			US 2001-850858	A 20010508
			EP 2001-935215	A3 20010509
			WO 2001-US14996	W 20010509
OTHER SOURCE(S):	MARPAT	135:371989		
AN 2001:833276	CAPLUS			
DN 135:371989				
ED Entered SIN: 16 Nov 2001				

TI Preparation of novel multicyclic compounds and their amino acid  
 derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase  
 IN Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar; Dunn, Derek; Hudkins,  
 Robert L.  
 PA Cephalon, Inc., USA  
 SO PCT Int. Appl., 209 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D209-00  
 CC 34-2 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1, 7, 28

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085686	A2	20011115	WO 2001-US14996	20010509
	WO 2001085686	A3	20020530		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 20020028815	A1	20020307	US 2001-850858	20010508
	US 7122679	B2	20061017		
	CA 2409758	A1	20011115	CA 2001-2409758	20010509
	EP 1294725	A2	20030326	EP 2001-935215	20010509
	EP 1294725	B1	20060104		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001010993	A	20030624	BR 2001-10993	20010509
	HU 2003002385	A2	20031229	HU 2003-2385	20010509
	HU 2003002385	A3	20070328		
	JP 2004501097	T	20040115	JP 2001-582287	20010509
	NZ 522539	A	20040528	NZ 2001-522539	20010509
	AT 315039	T	20060215	AT 2001-935215	20010509
	ES 2256238	T3	20060716	ES 2001-935215	20010509
	EP 1754707	A2	20070221	EP 2005-76862	20010509
	EP 1754707	A3	20070228		
	R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR			
	MX 2002PA10977	A	20030714	MX 2002-PA10977	20021107
	ZA 2002009065	A	20040209	ZA 2002-9065	20021107
	NO 2002005376	A	20030108	NO 2002-5376	20021108
	NO 324256	B1	20070917		
	IN 2002CN01380	A	20050311	IN 2002-CN1380	20021108
	KR 832602	B1	20080527	KR 2002-715062	20021109
	BG 107355	A	20030731	BG 2002-107355	20021205
	HK 1051369	A1	20060504	HK 2003-103639	20030522
PRAI	US 2000-202947P	P	20000509		
	US 2001-850858	A	20010508		
	EP 2001-935215	A3	20010509		
	WO 2001-US14996	W	20010509		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2001085686	ICM	C07D209-00
	IPCI	C07D209-00 [ICM, 7]

IPCR A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41  
 [I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*];  
 A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427  
 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A];  
 A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  
 [I,C\*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C\*];  
 A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10  
 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];  
 A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0017-00  
 [I,C\*]; A61P0017-06 [I,A]; A61P0025-00 [I,C\*];  
 A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28  
 [I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A];  
 A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00  
 [I,C\*]; A61P0035-00 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14  
 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A];  
 C07D0491-00 [I,C\*]; C07D0491-04 [I,A]; C07D0491-14  
 [I,A]; C07D0495-00 [I,C\*]; C07D0495-04 [I,A];  
 C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
 ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;  
 C07D487/04+235A+209A; C07D487/04+237A+209A;  
 C07D487/04+239A+209A; C07D491/04+307A+209A;  
 C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
 C07D519/00+487/00+487/00  
 US 20020028815 IPCI C07D0209-56 [I,A]; C07D0209-00 [I,C\*]; A61K0031-46  
 [I,A]  
 IPCR A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41  
 [I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*];  
 A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427  
 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A];  
 A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  
 [I,C\*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C\*];  
 A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10  
 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];  
 A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0017-00  
 [I,C\*]; A61P0017-06 [I,A]; A61P0025-00 [I,C\*];  
 A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28  
 [I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A];  
 A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00  
 [I,C\*]; A61P0035-00 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14  
 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A];  
 C07D0491-00 [I,C\*]; C07D0491-04 [I,A]; C07D0491-14  
 [I,A]; C07D0495-00 [I,C\*]; C07D0495-04 [I,A];  
 C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
 NCL 514/249.000; 514/290.000; 514/373.000; 514/411.000;  
 544/234.000; 546/079.000; 548/207.000; 548/427.000;  
 548/418.000; 548/416.000; 548/417.000; 548/420.000  
 ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;  
 C07D487/04+235A+209A; C07D487/04+237A+209A;  
 C07D487/04+239A+209A; C07D491/04+307A+209A;  
 C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
 C07D519/00+487/00+487/00  
 CA 2409758 IPCI C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C\*];  
 C07D0209-00 [ICS,7]; C07D0221-00 [ICS,7]; C07D0223-00

		[ICS,7]; C07D0243-00 [ICS,7]; C07D0307-00 [ICS,7]; C07D0519-00 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0491-14 [ICS,7]; C07D0491-00 [ICS,7,C*]; A61K0031-395 [ICS,7]
IPCR		A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
ECLA		C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
EP 1294725	IPCI	C07D0487-00 [I,C]; A61K0031-395 [I,C]; A61P0043-00 [I,C]; C07D0471-00 [I,C]; C07D0491-00 [I,C]; C07D0519-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395 [I,A]; A61P0043-00 [I,A]; C07D0471-14 [I,A]; C07D0491-14 [I,A]; C07D0519-00 [I,A]
	IPCR	C07D0487-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0471-00 [I,C]; C07D0471-14 [I,A]; C07D0491-00 [I,C]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A;

			C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
BR 2001010993	IPCI		C07D0209-00 [ICM,7]
	IPCR		A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
		ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
HU 2003002385	IPCI		C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*]
	IPCR		A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
		ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
JP 2004501097	IPCI		C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*]; A61K0031-407 [ICS,7]; A61K0031-41 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*]; A61K0031-4196 [ICS,7]; A61K0031-427 [ICS,7]; A61K0031-4412 [ICS,7]; A61K0031-4439 [ICS,7];





A61K0031-4427 [ICS,7,C\*]; A61K0031-4453 [ICS,7];  
 A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C\*];  
 A61K0031-501 [ICS,7]; A61K0031-5377 [ICS,7];  
 A61K0031-5375 [ICS,7,C\*]; A61P0003-10 [ICS,7];  
 A61P0003-00 [ICS,7,C\*]; A61P0009-10 [ICS,7];  
 A61P0009-00 [ICS,7,C\*]; A61P0015-00 [ICS,7];  
 A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C\*];  
 A61P0025-14 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-28  
 [ICS,7]; A61P0025-00 [ICS,7,C\*]; A61P0027-02 [ICS,7];  
 A61P0027-00 [ICS,7,C\*]; A61P0029-00 [ICS,7];  
 A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]  
 IPCR A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41  
 [I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*];  
 A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427  
 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A];  
 A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  
 [I,C\*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C\*];  
 A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10  
 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];  
 A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0017-00  
 [I,C\*]; A61P0017-06 [I,A]; A61P0025-00 [I,C\*];  
 A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28  
 [I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A];  
 A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00  
 [I,C\*]; A61P0035-00 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14  
 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A];  
 C07D0491-00 [I,C\*]; C07D0491-04 [I,A]; C07D0491-14  
 [I,A]; C07D0495-00 [I,C\*]; C07D0495-04 [I,A];  
 C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
 ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;  
 C07D487/04+235A+209A; C07D487/04+237A+209A;  
 C07D487/04+239A+209A; C07D491/04+307A+209A;  
 C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
 C07D519/00+487/00+487/00  
 FTERM 4C050/AA01; 4C050/AA07; 4C050/AA08; 4C050/BB04;  
 4C050/CC04; 4C050/DD10; 4C050/EE02; 4C050/FF01;  
 4C050/FF02; 4C050/FF05; 4C050/FF10; 4C050/GG03;  
 4C050/HH03; 4C050/HH04; 4C086/AA01; 4C086/AA02;  
 4C086/AA03; 4C086/CB03; 4C086/NA14; 4C086/ZA02;  
 4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA36;  
 4C086/ZA81; 4C086/ZA89; 4C086/ZB11; 4C086/ZB15;  
 4C086/ZB21; 4C086/ZB26; 4C086/ZC02; 4C086/ZC35  
 NZ 522539 IPCI C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C\*];  
 C07D0519-00 [ICS,7]; C07D0491-14 [ICS,7]; C07D0491-00  
 [ICS,7,C\*]; C07D0471-14 [ICS,7]; C07D0471-00  
 [ICS,7,C\*]; A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]  
 IPCR A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41  
 [I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*];  
 A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427  
 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A];  
 A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  
 [I,C\*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C\*];  
 A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10  
 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];

		A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
AT 315039	IPCI	C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]; A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0491-14 [ICS,7]; C07D0491-00 [ICS,7,C*]; C07D0519-00 [ICS,7]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
ES 2256238	IPCI	C07D0487-04 [ICS,4]; C07D0487-00 [ICS,4,C*]; A61K0031-395 [ICS,4]; C07D0471-14 [ICS,4]; C07D0471-00 [ICS,4,C*]; C07D0491-14 [ICS,4]; C07D0491-00 [ICS,4,C*]; C07D0519-00 [ICS,4]; A61P0043-00 [ICS,4]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]

		[I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
EP 1754707	IPCI	C07D0487-04 [I,A]; C07D0487-00 [I,C*]; A61K0031-395 [I,A]; A61P0043-00 [I,A]; C07D0519-00 [I,A]; C07D0491-04 [I,A]; C07D0491-00 [I,C*]; C07D0495-04 [I,A]; C07D0495-00 [I,C*]; C07D0209-00 [N,A]; C07D0243-00 [N,A]; C07D0223-00 [N,A]; C07D0307-00 [N,A]; C07D0221-00 [N,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
MX 2002PA10977	IPCI	C07D0209-00 [ICM,6]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
ZA 2002009065	IPCI	C07D [ICM,7]
NO 2002005376	IPCI	C07D0209-00 [ICM,7]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A;

C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
C07D519/00+487/00+487/00  
IN 2002CN01380 IPCI C07D0209-00 [ICM,7]  
KR 832602 IPCI C07D0487-04 [I,A]; C07D0487-00 [I,C\*]  
BG 107355 IPCI C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C\*];  
A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]; C07D0519-00  
[ICS,7]; C07D0491-14 [ICS,7]; C07D0491-00 [ICS,7,C\*];  
C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C\*]  
IPCR C07D0487-00 [I,C\*]; C07D0487-04 [I,A]  
ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;  
C07D487/04+235A+209A; C07D487/04+237A+209A;  
C07D487/04+239A+209A; C07D491/04+307A+209A;  
C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
C07D519/00+487/00+487/00  
HK 1051369 IPCI C07D [ICS,7]; A61K [ICS,7]; A61P [ICS,7]  
IPCR A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41  
[I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*];  
A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*];  
A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427  
[I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A];  
A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  
[I,C\*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C\*];  
A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10  
[I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];  
A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0017-00  
[I,C\*]; A61P0017-06 [I,A]; A61P0025-00 [I,C\*];  
A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28  
[I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A];  
A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00  
[I,C\*]; A61P0035-00 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14  
[I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A];  
C07D0491-00 [I,C\*]; C07D0491-04 [I,A]; C07D0491-14  
[I,A]; C07D0495-00 [I,C\*]; C07D0495-04 [I,A];  
C07D0519-00 [I,C\*]; C07D0519-00 [I,A]  
ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;  
C07D487/04+235A+209A; C07D487/04+237A+209A;  
C07D487/04+239A+209A; C07D491/04+307A+209A;  
C07D491/14+307A+209A+209A; C07D495/04+333A+209A;  
C07D519/00+487/00+487/00  
OS MARPAT 135:371989  
GI



AB The title compds. such as penta[a]pyrrolo[3,4-c]carbazole,  
hexano[a]pyrrolo[3,4-c]carbazole, pyrrolo[3,4-c]carbazole, and

furano[a-3,2]pyrrolo[3,4-c]carbazole derivs. [I; A, B = CO, CH(OR3), CH(SR3), CH2, CHR3, CHR3CHR4, CR3R4, COR3, N:CR3, SO, SO2 (wherein R3, R4 = H, optionally substituted lower alkyl or aryl); Y and Z, together with the carbon to which they are attached, form an (un)substituted mono- or bicyclic aryl or bicyclic heteroaryl, or C3-5 heteroaryl; E, F = lower alkyl or E and F, together with the carbon to which they are attached, form an (un)substituted C4-7 cycloalkyl, C3-6 heterocycloalkyl or heteroaryl, or an (un)substituted heterocycloalkyl endocyclically comprising at least one group G (wherein G = O, S, SO, SO2, NR2, NR2CO, NR2CONR3, NR2SO2, NR3SO2; R2 = H, optionally substituted lower alkyl or alkanoyl, CHO, acetyl, lower alkylsulfonyl, arylsulfonyl, an optionally protected amino acid)] are prepared. These compds. are effective in the treatment of diseases or disease states related to the activity of enzymes such as poly(ADP-ribose) polymerase (PARP), vascular endothelial growth factor receptor kinase (VEGFR2 kinase), and MLK3 kinase (a member of the mixed lineage kinase family), including, for example, traumatic central nervous system injuries, neurodegenerative diseases (in particular Parkinson's, Huntington's, or Alzheimer's disease), inflammation, cerebral or cardiac ischemia, endotoxic shock, diabetes, or cellular proliferative disorders (in particular cancer, solid tumors, diabetic retinopathy, intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, or endometriosis). They also suppress the formation of blood vessels (angiogenesis) and prevent neuronal degradation associated with traumatic central nervous system injuries. Thus, 2H-1,3,4,5,6,7-hexahydrocyclopenta[a]pyrrolo[3,4-c]carbazole-1,3-dione (II; R = H) (preparation given) was treated with NaH in DMF at room

temperature for

30 min and condensed with a stirred mixture of Boc-Lys(Boc)-OH dicyclohexylamine salt, TBTU, N-Methylmorpholine, and DMF at room temperature for 1 h, followed by treatment of the product with 4 N HCl in dioxane to give II (R = H-Lys). II (R = H-Lys) showed IC50 of µg/mL against of 22 nM against PARP.

ST clopentapyrrolocarbazole prepn inhibitor poly ADP ribose polymerase; PARP inhibitor multicyclic compd prepn; pyrrolocarbazole prepn inhibitor VEGFR2 kinase; furanopyrrolocarbazole prepn inhibitor VEGFR2 kinase; neurodegenerative disease treatment multicyclic compd prepn; inflammation treatment multicyclic compd prepn; ischemia treatment multicyclic compd prepn; MLK3 kinase inhibitor multicyclic compd prepn

IT Nervous system  
(Huntington's chorea; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amides, preparation  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system  
(central, injury; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system  
(degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,

- and MLK3 kinase)
- IT Eye, disease  
(diabetic retinopathy; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Cell proliferation  
(disorders; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Uterus, disease  
(endometriosis; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Eye, disease  
(intraocular neovascular syndromes; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Brain, disease  
Heart, disease  
(ischemia; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Eye, disease  
(macula, degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Heterocyclic compounds  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nitrogen, aromatic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Alzheimer's disease  
Angiogenesis inhibitors  
Anti-inflammatory agents  
Antidiabetic agents  
Antitumor agents  
Parkinson's disease  
Psoriasis  
Rheumatoid arthritis  
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT Amino acids, preparation  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Shock (circulatory collapse)

(septic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT	374069-00-8P	374069-03-1P	374069-12-2P	374069-14-4P	374069-19-9P
	374069-21-3P	374069-22-4P	374069-23-5P	374069-25-7P	374069-26-8P
	374069-31-5P	374069-33-7P	374069-35-9P	374069-36-0P	374069-43-9P
	374069-44-0P	374069-53-1P	374069-62-2P	374069-75-7P	374070-30-1P
	374070-33-4P	374070-38-9P	374070-39-0P	374070-57-2P	374070-59-4P
	374070-64-1P	374070-73-2P	374070-77-6P	374070-79-8P	374070-80-1P
	374070-83-4P	374070-95-8P	374070-96-9P	374071-01-9P	374071-12-2P
	374071-16-6P	374071-28-0P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT	154114-97-3P	374068-99-2P	374069-01-9P	374069-02-0P	374069-04-2P
	374069-05-3P	374069-06-4P	374069-07-5P	374069-08-6P	374069-09-7P
	374069-10-0P	374069-11-1P	374069-13-3P	374069-15-5P	374069-16-6P
	374069-17-7P	374069-18-8P	374069-20-2P	374069-24-6P	374069-27-9P
	374069-28-0P	374069-29-1P	374069-30-4P	374069-32-6P	374069-34-8P
	374069-37-1P	374069-38-2P	374069-39-3P	374069-40-6P	374069-41-7P
	374069-42-8P	374069-45-1P	374069-46-2P	374069-47-3P	374069-48-4P
	374069-49-5P	374069-50-8P	374069-51-9P	374069-52-0P	374069-54-2P
	374069-55-3P	374069-56-4P	374069-57-5P	374069-58-6P	374069-59-7P
	374069-60-0P	374069-61-1P	374069-63-3P	374069-64-4P	374069-65-5P
	374069-66-6P	374069-67-7P	374069-68-8P	374069-69-9P	374069-70-2P
	374069-71-3P	374069-72-4P	374069-73-5P	374069-74-6P	374069-76-8P
	374069-77-9P	374069-78-0P	374069-79-1P	374069-80-4P	374069-81-5P
	374069-82-6P	374069-83-7P	374069-84-8P	374069-85-9P	374069-87-1P
	374069-88-2P	374069-89-3P	374069-90-6P	374069-91-7P	374069-92-8P
	374069-93-9P	374069-94-0P	374069-95-1P	374069-96-2P	374069-97-3P
	374069-98-4P	374069-99-5P	374070-00-5P	374070-01-6P	374070-02-7P
	374070-03-8P	374070-04-9P	374070-05-0P	374070-06-1P	374070-07-2P
	374070-08-3P	374070-09-4P	374070-10-7P	374070-11-8P	374070-12-9P
	374070-13-0P	374070-14-1P	374070-15-2P	374070-16-3P	374070-17-4P
	374070-18-5P	374070-19-6P	374070-20-9P	374070-21-0P	374070-22-1P
	374070-23-2P	374070-24-3P	374070-25-4P	374070-26-5P	374070-27-6P
	374070-28-7P	374070-29-8P	374070-31-2P	374070-32-3P	374070-34-5P
	374070-35-6P	374070-36-7P	374070-37-8P	374070-40-3P	374070-41-4P
	374070-42-5P	374070-43-6P	374070-44-7P	374070-45-8P	374070-46-9P
	374070-47-0P	374070-48-1P	374070-49-2P	374070-50-5P	374070-51-6P
	374070-52-7P	374070-53-8P	374070-54-9P	374070-55-0P	374070-56-1P
	374070-58-3P	374070-60-7P	374070-62-9P	374070-63-0P	374070-65-2P
	374070-66-3P	374070-67-4P	374070-68-5P	374070-69-6P	374070-70-9P
	374070-71-0P	374070-72-1P	374070-74-3P	374070-75-4P	374070-76-5P
	374070-78-7P	374070-81-2P	374070-82-3P	374070-84-5P	374070-85-6P
	374070-86-7P	374070-87-8P	374070-88-9P	374070-89-0P	374070-90-3P
	374070-91-4P	374070-92-5P	374070-93-6P	374070-94-7P	374070-97-0P
	374070-98-1P	374070-99-2P	374071-00-8P	374071-02-0P	374071-03-1P
	374071-04-2P	374071-05-3P	374071-06-4P	374071-07-5P	374071-08-6P
	374071-09-7P	374071-10-0P	374071-11-1P	374071-13-3P	374071-14-4P
	374071-15-5P	374071-17-7P	374071-18-8P	374071-19-9P	374071-20-2P
	374071-21-3P	374071-22-4P	374071-23-5P	374071-24-6P	374071-25-7P
	374071-26-8P	374071-27-9P	374071-29-1P	374071-30-4P	374071-31-5P
	374071-32-6P	374071-33-7P	374071-34-8P	374071-35-9P	374071-36-0P

374071-37-1P 374071-38-2P 374071-39-3P 374071-40-6P 374071-41-7P  
 374071-42-8P 374071-43-9P 374071-44-0P 374071-45-1P 374071-46-2P  
 374071-47-3P 374071-48-4P 374071-49-5P 374071-50-8P 374071-51-9P  
 374071-52-0P 374071-53-1P 374071-54-2P 374071-55-3P 374071-56-4P  
 374071-57-5P 374071-58-6P 374072-29-4P 374553-23-8P 374553-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase 153190-46-6, MLK3 kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide 62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2, DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyl chloride 79-37-8, Oxalyl chloride 95-15-8, Benzothiophene 98-09-9, Phenylsulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric acid, reactions 108-00-9, N,N-Dimethylethylenediamine 108-12-3, Isovaleryl chloride 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4, 2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl isocyanate 109-97-7, Pyrrole 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 120-92-3, Cyclopentanone 123-75-1, Pyrrolidine, reactions 124-63-0, Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5, Ethanolamine, reactions 141-75-3, Butyl chloride 271-89-6, Benzofuran 288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluoroindole 541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide 591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0, Bromoacetyl bromide 598-52-7, N-Methylthiourea 614-96-0, 5-Methylindole 623-91-6, Diethyl fumarate 630-08-0, Carbon monoxide, reactions 638-29-9, Valeryl chloride 690-76-6, 2-(tert-Butoxycarbonyl)thioacetamide 762-42-5, Dimethyl acetylenedicarboxylate 933-67-5, 7-Methylindole 999-97-3, Hexamethyldisilazane 1121-92-2 1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl ester 2038-03-1, 4-(2-Aminoethyl)morpholine 2114-02-5 2133-40-6, L-Proline methyl ester hydrochloride 2812-46-6 3303-84-2, N-tert-Butoxycarbonyl- $\beta$ -alanine 3878-55-5, Succinic acid monomethyl ester 4023-34-1, Cyclopropanecarbonyl chloride 4377-33-7, 2-Picolyl chloride 4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5, N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-dione 5070-13-3, Bis(4-nitrophenyl) carbonate 5332-06-9, 4-Bromobutyronitrile 5332-26-3 5437-45-6, Benzyl bromoacetate 5699-40-1, N-Acetylguanidine 6940-76-7, 1-Chloro-3-iodopropane 6971-44-4, 4-(N-Methylaminomethyl)pyridine 7148-07-4, 1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolineamide 13154-24-0, Triisopropylsilyl chloride 15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1, Trimethylsilyldiazomethane 19099-93-5, Benzyl 4-oxo-1-piperidinecarboxylate 21035-59-6, 2-(N-Methylaminomethyl)pyridine 24424-99-5, Di-tert-butyl dicarbonate 40594-97-6 49548-40-5



53300-47-3, 2-(Methanesulfonyl)thioacetamide 53654-35-6, 2-Vinylindole  
 54663-78-4, 2-(Tributylstannyl)thiophene 57260-71-6 57260-73-8,  
 N-tert-Butoxycarbonyl ethylenediamine 57294-38-9, 4-(tert-  
 Butoxycarbonylamino)butyric acid 76822-35-0 86864-60-0,  
 (2-Bromoethoxy)-tert-butyl dimethylsilane 89031-84-5,  
 (3-Bromopropoxy)-tert-butyl dimethylsilane 98518-10-6 118486-97-8,  
 2-(Tributylstannyl)-1-methylpyrrole 124252-41-1, 4-  
 (Tributylstannyl)pyridine 133565-49-8 136088-69-2 138585-09-8,  
 p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,  
 3-(Furan-3-yl)indole 175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide  
 175334-72-2, 5-Isioxazolecarbothioamide 374071-64-4, 5-  
 (Triisopropylsilyloxy)-2-(1-hydroxycyclopentyl)indole 374071-66-6,  
 5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,  
 5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,  
 5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,  
 5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,  
 5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole 374071-71-3,  
 2-(tert-Butoxycarbonyloxy)thioacetamide 374071-77-9,  
 2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-  
 yl)indole 374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole 374071-92-8,  
 2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0 374071-96-2,  
 6-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-97-3,  
 4-Methoxy-2-(1-hydroxycyclopentyl)indole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as  
 inhibitors of enzymes for treatment of diseases related to  
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3  
 kinase)

II 90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole  
 118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P,  
 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole  
 374071-61-1P 374071-62-2P 374071-63-3P 374071-65-5P 374071-72-4P  
 374071-73-5P 374071-74-6P 374071-75-7P 374071-76-8P 374071-78-0P  
 374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole 374071-80-4P,  
 3-(Cyclopenten-1-yl)pyrrole 374071-81-5P, 2-(Cyclopenten-1-yl)-1-  
 (triisopropylsilyl)pyrrole 374071-82-6P 374071-83-7P 374071-84-8P  
 374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid  
 374071-86-0P 374071-88-2P 374071-89-3P 374071-95-1P 374071-98-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as  
 inhibitors of enzymes for treatment of diseases related to  
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3  
 kinase)

L32 ANSWER 19 OF 19 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights  
 reserved on STN

ACCESSION NUMBER: 1999036418 EMBASE  
 TITLE: Angiogenesis: Possibilities for therapeutic interventions.  
 AUTHOR: Wynendaele, W.; Van Oosterom, A.T.; Pawinski, A.; De  
 Bruijn, E.A., Dr. (correspondence)  
 CORPORATE SOURCE: Laboratory of Experimental Oncology, Herestraat 49, B-3000  
 Leuven, Belgium.  
 AUTHOR: De Bruijn, E.A., Dr. (correspondence); Maes, R.A.  
 CORPORATE SOURCE: Laboratory of Human Toxicology, Department of  
 Pharmaceutics, University of Utrecht, Sorbonnelaan 16, 3508  
 TB Utrecht, Netherlands.  
 AUTHOR: De Bruijn, E.A., Dr. (correspondence)  
 CORPORATE SOURCE: Patent Technology Lille France, P.O. Box 192, NL-4500 AD  
 Oostburg, Netherlands.  
 SOURCE: Pharmacy World and Science, (1998) Vol. 20, No. 6, pp.

225-235.

Refs: 131

ISSN: 0928-1231 CODEN: PWSCED

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 18 Feb 1999

Last Updated on STN: 18 Feb 1999

AN 1999036418 EMBASE

TI Angiogenesis: Possibilities for therapeutic interventions.

AU Wynendaale, W.; Van Oosterom, A.T.; Pawinski, A.; De Bruijn, E.A., Dr.  
(correspondence)

CS Laboratory of Experimental Oncology, Herestraat 49, B-3000 Leuven, Belgium  
.

AU De Bruijn, E.A., Dr. (correspondence); Maes, R.A.

CS Laboratory of Human Toxicology, Department of Pharmaceutics, University of  
Utrecht, Sorbonnelaan 16, 3508 TB Utrecht, Netherlands.

AU De Bruijn, E.A., Dr. (correspondence)

CS Patent Technology Lille France, P.O. Box 192, NL-4500 AD Oostburg,  
Netherlands.

SO Pharmacy World and Science, (1998) Vol. 20, No. 6, pp. 225-235.

Refs: 131

ISSN: 0928-1231 CODEN: PWSCED

CY Netherlands

DT Journal; General Review; (Review)

FS 030 Clinical and Experimental Pharmacology

037 Drug Literature Index

LA English

SL English

ED Entered STN: 18 Feb 1999

Last Updated on STN: 18 Feb 1999

AB Vascular proliferation normally occurs only during embryonic development,  
the female reproductive cycle and wound healing. Various pathological  
conditions such as diabetic retinopathy are characterized by persistent,  
uncontrolled angiogenesis. At the other hand, impaired development of new  
blood vessels has been found to be related with myocardial infarction. A  
series of anti-angiogenic drugs are currently included in experimental  
cancer treatment, whereas the failure of ulcers to heal may be  
limited by increased angiogenesis upon administration of growth factors.  
In the present review control mechanisms of the vasculature are summarized  
and therapeutic approaches discussed.

CT Medical Descriptors:

\*angiogenesis

cancer

cardiovascular disease

diabetic retinopathy

embryo development

endothelium

heart infarction

ischemia

ovary cycle

review

ulcer healing

wound healing

CT Drug Descriptors:

acidic fibroblast growth factor

alpha interferon

\*angiogenesis inhibitor

angiogenic factor  
 angiogenin  
 angiostatin  
 basic fibroblast growth factor  
 genistein  
 granulocyte colony stimulating factor  
 \*growth factor  
 herbimycin a  
 hyaluronic acid  
 \*interleukin 2  
 interleukin 8  
 lavendustin a  
 oleanolic acid  
 platelet derived endothelial cell growth factor  
 prolactin  
 proliferin  
 roquinimex  
 scatter factor  
 \*sialic acid derivative  
 suramin  
 thrombocyte factor 4  
 thrombospondin 1  
 tissue inhibitor of metalloproteinase 1  
 tissue inhibitor of metalloproteinase 2  
 tissue inhibitor of metalloproteinase 3  
 transforming growth factor alpha  
 transforming growth factor beta  
 ursolic acid  
 vasculotropin

RN (acidic fibroblast growth factor) 106096-92-8; (angiogenin) 97950-81-7;  
 (angiostatin) 172642-30-7, 86090-08-6; (basic fibroblast growth factor)  
 106096-93-9; (genistein) 446-72-0; (herbimycin A) 70563-58-5; (hyaluronic  
 acid) 31799-91-4, 9004-61-9, 9067-32-7; (interleukin 2) 85898-30-2;  
 (interleukin 8) 114308-91-7; (lavendustin A) 125697-92-9; (oleanolic acid)  
 508-02-1; (prolactin) 12585-34-1, 50647-00-2, 9002-62-4; (proliferin)  
 92769-12-5; (roquinimex) 84088-42-6; (scatter factor) 67256-21-7,  
 72980-71-3; (suramin) 129-46-4, 145-63-1; (thrombocyte factor 4)  
 37270-94-3, 69670-74-2; (thrombospondin 1) 343987-56-4; (tissue inhibitor  
 of metalloproteinase 1) 140208-24-8; (tissue inhibitor of  
 metalloproteinase 2) 124861-55-8; (tissue inhibitor of metalloproteinase  
 3) 145809-21-8, 164781-40-2; (ursolic acid) 77-52-1; (vasculotropin)  
 127464-60-2

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3  
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162  
 L3 22 S L2 AND DIONE  
 L4 0 S L2 AND PHENANTHROLINEDIONE  
 L5 2 S L2 AND PHENANTHROLINE  
 L6 0 S "SUBSTITUTED PHENANTHROLINE"

```

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
11 JUN 2008
L7      224329 S L2
L8      13877 S L3
L9      406 S L5
L10     224329 S L7 OR L8 OR L9
L11     3300 S 10 AND ANTIANGIOGENIC
L12     56 S L11 AND ISCHEMIA
L13     28 S L11 AND ("HEART DISEASE")
L14     2 S L13 AND L12
L15     7 S (L3 OR L5) AND ANTIANGIOGENIC
L16     587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17     4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008
L18     STR 27318-90-7
L19     1 S L18 FAM SAM
        SET SMA OFF
        SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
11 JUN 2008
L20     1303 S ("1,4-NAPHTHALENEDIONE?")
L21     129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22     0 S L21 AND ("HEART ATTACK")
L23     0 S L21 AND ("MYOCARDIAL INFARCTION")
L24     4 S L21 AND ISCHEMIA
L25     1 S L16 AND ("MYOCARDIAL INFARCTION")
L26     0 S L16 AND ("ANGIOGENESIS INHIBITOR?")
L27     552 S L2 AND ("ANGIOGENESIS INHIBITOR?")
L28     24 S L3 AND ("ANGIOGENESIS INHIBITOR?")
L29     2 S L5 AND ("ANGIOGENESIS INHIBITOR?")
L30     53 S (L27 OR L28 OR L29) AND HEART
L31     24 S L30 AND ISCHEMIA
L32     19 S L31 AND (TREAT OR TREATING OR TREATMENT)

=> s l32 and ("5,6-dione")
L33     0 L32 AND ("5,6-DIONE")

=> s l32 and ("1,10-phenanthrene")
L34     0 L32 AND ("1,10-PHENANTHRENE")

=> s l32 and dione
L35     5 L32 AND DIONE

=> dup rem l32 l35
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L35
L36     19 DUP REM L32 L35 (5 DUPLICATES REMOVED)
        ANSWERS '1-18' FROM FILE CAPLUS
        ANSWER '19' FROM FILE EMBASE

=> d scan l35

L35     5 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN
IC      ICM C07D277-46
CC      28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
        Section cross-reference(s): 1, 63
TI      Preparation of thiazole derivatives as modulators of the phosphoinositide

```

3-kinases (PI3Ks)

ST thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator

IT Nervous system, disease  
(Huntington's chorea, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Sarcoma  
(Kaposi's, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease  
(atrophy, treating or preventing skeletal muscle atrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Infection  
(bacterial, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle  
(cardiac, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy  
(cardiac, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease  
(chronic obstructive pulmonary disease, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Nervous system, disease  
(degeneration, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease  
(fibrosis, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Kidney, disease  
(glomerulonephritis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease  
(glomerulosclerosis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease  
(hypertrophy, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart, disease  
(hypertrophy, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease  
(infection, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Intestine, disease  
(inflammatory, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease  
Reperfusion

(injury, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Neoplasm  
(metastasis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy  
(muscular, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart  
(myocardium, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Lung, disease  
(pneumonitis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy inhibitors  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Antibacterial agents  
Anticoagulants  
Antihypertensives  
Antirheumatic agents  
Antitumor agents  
Antiviral agents  
Cardiovascular agents  
Human  
Immunosuppressants  
Platelet aggregation inhibitors  
(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Injury  
(pulmonary, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Fibrosis  
(renal, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Injury  
(reperfusion, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease  
(stroke, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lupus erythematosus  
(systemic, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Central nervous system, disease  
(trauma, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Leukocyte  
(treating or preventing leukocyte recruitment in cancer tissue; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy  
Alzheimer's disease  
Anaphylaxis

Angiogenesis  
 Asthma  
 Atherosclerosis  
 Autoimmune disease  
 Cardiovascular system, disease  
 Encephalitis  
 Fibrosis  
 Hypertension  
 Inflammation  
 Ischemia  
 Kidney, disease  
 Melanoma  
 Meningitis  
 Multiple sclerosis  
 Neoplasm  
 Platelet aggregation  
 Psoriasis  
 Rheumatoid arthritis  
 Sepsis  
 Thrombosis  
 Transplant and Transplantation  
 Transplant rejection  
 Vasoconstriction

(treating or preventing; preparation of thiazole derivs. as  
 modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Infection  
 (viral, treating or preventing; preparation of thiazole derivs. as  
 modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide  
 3-kinases (PI3Ks))

IT 860619-22-3P 860619-39-2P 860619-58-5P 860619-75-6P 860620-37-7P  
 860620-38-8P 860620-39-9P 860620-40-2P 860620-42-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of thiazole derivs. as modulators of the phosphoinositide  
 3-kinases (PI3Ks))

IT 32558-17-1P 307343-36-8P 315704-54-2P 315705-71-6P 315705-72-7P  
 315705-74-9P 315705-75-0P 315705-76-1P 315705-77-2P 315705-78-3P  
 315705-79-4P 315705-80-7P 315705-81-8P 315705-82-9P 315705-83-0P  
 315705-86-3P 315705-87-4P 315705-90-9P 315705-91-0P 315705-92-1P  
 315705-94-3P 315705-95-4P 333746-52-4P 333746-55-7P 333746-64-8P  
 333746-84-2P 412919-76-7P 421580-61-2P 428836-20-8P 443747-65-7P  
 472980-88-4P 860619-23-4P 860619-24-5P 860619-25-6P 860619-26-7P  
 860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P 860619-31-4P  
 860619-32-5P 860619-33-6P 860619-34-7P 860619-35-8P 860619-36-9P  
 860619-37-0P 860619-38-1P 860619-40-5P 860619-41-6P 860619-42-7P  
 860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P 860619-47-2P  
 860619-48-3P 860619-49-4P 860619-50-7P 860619-51-8P 860619-52-9P  
 860619-53-0P 860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P  
 860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P 860619-63-2P  
 860619-64-3P 860619-65-4P 860619-66-5P 860619-67-6P 860619-68-7P  
 860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P 860619-73-4P  
 860619-74-5P 860619-76-7P 860619-77-8P 860619-78-9P 860619-79-0P  
 860619-80-3P 860619-81-4P 860619-82-5P 860619-83-6P 860619-84-7P  
 860619-85-8P 860619-86-9P 860619-87-0P 860619-88-1P 860619-89-2P  
 860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P 860619-94-9P  
 860619-95-0P 860619-96-1P 860619-98-3P 860620-00-4P 860620-02-6P  
 860620-03-7P 860620-04-8P 860620-05-9P 860620-06-0P 860620-07-1P

860620-08-2P	860620-09-3P	860620-10-6P	860620-11-7P	860620-12-8P
860620-13-9P	860620-14-0P	860620-15-1P	860620-16-2P	860620-17-3P
860620-18-4P	860620-19-5P	860620-20-8P	860620-21-9P	860620-22-0P
860620-23-1P	860620-24-2P	860620-25-3P	860620-26-4P	860620-27-5P
860620-28-6P	860620-29-7P	860620-30-0P	860620-31-1P	860620-32-2P
860620-33-3P	860620-34-4P	860620-35-5P	860620-36-6P	860620-41-3P
860620-43-5P	860620-44-6P	860620-45-7P	860620-46-8P	860620-47-9P
860620-48-0P	860620-49-1P	860620-50-4P	860620-51-5P	860620-52-6P
860620-53-7P	860620-70-8P	860620-75-3P	860620-76-4P	860620-77-5P
860620-78-6P	860620-83-3P	860620-84-4P	860620-86-6P	860620-87-7P
860620-88-8P	860620-89-9P	860621-18-7P	860621-19-8P	860621-20-1P
860621-21-2P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9,  $\beta$ -Alanine 109-57-9, N-Allylthiourea 109-94-4, Ethyl formate 121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 621-83-0, N-Benzylthiourea 709-72-8 1516-33-2, N-Isobutylthiourea 1516-37-6, N-(2-Methoxyphenyl)thiourea 1520-26-9 1520-27-0, N-(4-Hydroxyphenyl)thiourea 2237-30-1, 3-Aminobenzonitrile 2293-07-4, N-(4-Methoxyphenyl)thiourea 2295-31-0, 2,4-Thiazolidinedione 3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-Cyanophenyl)thiourea 3696-22-8, N-(4-Nitrophenyl)thiourea 3696-23-9, N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea 5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate 5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9, N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea 7204-48-0, N-(tert-Butyl)thiourea 7366-56-5 14294-09-8, 1-Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide 14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3 25343-29-7, N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9, N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5, 4-Methylpiperazine-1-carbothioamide 37014-08-7 37182-75-5 40398-36-5, 1-Pyrrolidinecarbothioamide 51039-84-0 52992-37-7 55130-40-0 56541-14-1, N-Cyclopropylthiourea 61451-94-3, N-(2,3-Dihydro-1H-inden-2-yl)thiourea 63467-61-8, N-(2,2-Diethoxyethyl)thiourea 66892-01-1 66892-25-9, N-(Tetrahydrofuran-2-ylmethyl)thiourea 72806-58-7 73161-70-3, N-(Pyridin-3-ylmethyl)thiourea 73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea 74764-61-7 86114-63-8 99115-47-6 102353-42-4, N-(2-Methoxyethyl)thiourea 102936-57-2, N-Cyclopentylthiourea 111538-46-6, N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-yl)ethyl)thiourea 125117-97-7, N-(6-Chloropyridin-3-yl)thiourea 140899-50-9 171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea 179927-28-7 196809-80-0 206761-87-7, N-(2-(Piperidin-1-yl)ethyl)thiourea 227932-43-6 237385-80-7, N-[3-(Hydroxymethyl)phenyl]thiourea 282715-65-5, N-(Pyridin-4-ylmethyl)thiourea 342626-46-4 420130-44-5, N-(6-Methoxypyridin-3-yl)thiourea 473706-96-6 473706-97-7 500865-55-4 572889-33-9, N-Cyclobutylthiourea 618913-44-3, N-(Cyclopropylmethyl)thiourea 659741-74-9 659741-75-0 763887-70-3 850164-09-9 860615-45-8, N-(Benzofuran-5-yl)thiourea 860617-18-1, N-(2-Chloropyridin-4-yl)thiourea 860620-65-1 860620-66-2 860620-67-3 860620-68-4, 3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,



N-(2-Chloropyridin-3-yl)thiourea 860620-73-1, N-[3-(1,3-Oxazol-5-yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea 860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea 860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]thiourea 860620-91-3 860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea 860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea 860620-94-8 860620-95-7 860620-96-8 860620-97-9 860620-98-0 860620-99-1 860621-00-7 860621-01-8 860621-02-9 860621-03-0 860621-04-1 860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4 860621-08-5 860621-09-6 860621-10-9 860621-11-0 860621-12-1 860621-13-2 860621-14-3 860621-15-4 860621-16-5 860621-17-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P, 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P, 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P, 5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P 167405-28-9P, 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P, 1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-8P 860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-oxazol-2-yl)acetamide 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide 860620-60-6P 860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-2,2,2-trifluoroacetamide 860620-81-1P 860620-82-2P 860620-85-5P 860620-90-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
IC ICM A61K031-00  
CC 1-7 (Pharmacology)  
TI Therapeutics for chemokine-mediated diseases  
ST chemokine mediated disease treatment chemokine receptor binding compd; tricyclic phenanthrene deriv chemokine mediated disease treatment; phenanthrenedione multiple sclerosis treatment  
IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR2; therapeutics for chemokine-mediated diseases)  
IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR4; therapeutics for chemokine-mediated diseases)  
IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR1; therapeutics for chemokine-mediated diseases)  
IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR2; therapeutics for chemokine-mediated diseases)  
IT Inflammation  
(Crohn's disease; therapeutics for chemokine-mediated diseases)  
IT Intestine, disease  
(Crohn's; therapeutics for chemokine-mediated diseases)

IT Sepsis  
(Gram-neg.; therapeutics for chemokine-mediated diseases)

IT Neutrophil  
(activation; therapeutics for chemokine-mediated diseases)

IT Inflammation  
(acute; therapeutics for chemokine-mediated diseases)

IT Respiratory distress syndrome  
(adult; therapeutics for chemokine-mediated diseases)

IT Transplant rejection  
(allotransplant; therapeutics for chemokine-mediated diseases)

IT Antiarteriosclerotics  
(antiatherosclerotics; therapeutics for chemokine-mediated diseases)

IT Dermatitis  
(atopic; therapeutics for chemokine-mediated diseases)

IT Lung, disease  
(chronic obstructive pulmonary disease; therapeutics for chemokine-mediated diseases)

IT Inflammation  
Transplant rejection  
(chronic; therapeutics for chemokine-mediated diseases)

IT Autoimmune disease  
(exptl. autoimmune encephalomyelitis; therapeutics for chemokine-mediated diseases)

IT Encephalomyelitis  
(exptl. autoimmune; therapeutics for chemokine-mediated diseases)

IT Lung, disease  
(fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)

IT Ischemia  
(focal; therapeutics for chemokine-mediated diseases)

IT Inflammation  
Kidney, disease  
(glomerulonephritis; therapeutics for chemokine-mediated diseases)

IT Transplant and Transplantation  
(graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)

IT Intestine, disease  
(inflammatory; therapeutics for chemokine-mediated diseases)

IT Reperfusion  
(injury, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Lung, disease  
(injury, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Phagocyte  
(mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics for chemokine-mediated diseases)

IT Cell activation  
(neutrophil; therapeutics for chemokine-mediated diseases)

IT Arthritis  
(pseudogout, acute; therapeutics for chemokine-mediated diseases)

IT Fibrosis  
(pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)

IT Injury  
(pulmonary, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Heart, disease  
Kidney, disease  
(reperfusion injury; therapeutics for chemokine-mediated diseases)

IT Injury  
(reperfusion, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Artery, disease

(restenosis; therapeutics for chemokine-mediated diseases)

IT Shock (circulatory collapse)  
(septic; therapeutics for chemokine-mediated diseases)

IT Brain, disease  
(stroke; therapeutics for chemokine-mediated diseases)

IT Multiple sclerosis  
(therapeutic agents; therapeutics for chemokine-mediated diseases)

IT Alzheimer's disease

Angiogenesis  
Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Anticoagulants

Antimalarials

Arthritis

Asthma

Atherosclerosis

Cardiovascular agents

Drug delivery systems

Gastrointestinal agents

Gout

Inflammation

Malaria

Multiple sclerosis

Neutrophil

Psoriasis

Rheumatoid arthritis

Sarcoidosis

Thrombosis  
(therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

Chemokines

Interleukin 8

Monocyte chemoattractant protein-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(therapeutics for chemokine-mediated diseases)

IT Shock (circulatory collapse)  
(toxic shock syndrome; therapeutics for chemokine-mediated diseases)

IT Inflammation

Intestine, disease  
(ulcerative colitis; therapeutics for chemokine-mediated diseases)

IT Interleukin 8 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ ; therapeutics for chemokine-mediated diseases)

IT Interleukin 8 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ ; therapeutics for chemokine-mediated diseases)

IT 7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(therapeutics for chemokine-mediated diseases)

IT 82-86-0, Acenaphthenequinone 83-32-9, Acenaphthene 84-11-7,  
Phenanthrene-9,10-dione 1015-89-0, 6(5H)-Phenanthridinone  
4707-71-5, Phenanthrene-9-carboxaldehyde

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(therapeutics for chemokine-mediated diseases)

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

TI Preparation of pyrazine derivatives, particularly N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K inhibitors

ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PI3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PI3K inhibitor

IT Nervous system, disease  
 (Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sarcoma  
 (Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease  
 (airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Antiarteriosclerotics  
 (antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease  
 (atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
 (bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
 (bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection  
 (bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease  
 (chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Nervous system, disease  
 (degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Erythrocyte  
 (disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sperm motility  
 (diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood vessel, disease  
 (endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung  
 (epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood, disease  
 (erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease  
 (fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
 Kidney, disease  
 (glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease  
(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease  
Reperfusion  
(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm  
(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy  
(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
Pancreas, disease  
(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease  
(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation  
Lung, disease  
(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy  
Allergy inhibitors  
Alzheimer's disease  
Anaphylaxis  
Angiogenesis  
Angiogenesis inhibitors  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Anti-ischemic agents  
Antiasthmatics  
Antibacterial agents  
Antifibrotic agents  
Antihypertensives  
Antirheumatic agents  
Antitumor agents  
Antiviral agents  
Asthma  
Atherosclerosis  
Autoimmune disease  
B cell (lymphocyte)  
Bone marrow  
Cardiac hypertrophy  
Cardiovascular agents  
Cardiovascular system, disease  
Central nervous system agents  
Encephalitis  
Fibrosis  
Glomerulosclerosis  
Heart, disease  
Human  
Hypertension  
Immunomodulators  
Immunosuppressants  
Inflammation  
Inflammatory bowel disease

Ischemia  
 Kidney, disease  
 Mast cell  
 Melanoma  
 Meningitis  
 Multiple organ failure  
 Multiple sclerosis  
 Neoplasm  
 Neuroprotective agents  
 Pharmaceutical carriers  
 Pharmaceutical excipients  
 Platelet activation  
 Platelet aggregation  
 Platelet aggregation inhibitors  
 Prophylaxis  
 Psoriasis  
 Rheumatoid arthritis  
 Sepsis  
 Stroke  
 Thrombolytics  
 Thrombosis  
 Transplant and Transplantation  
 Transplant rejection  
 Vasoconstriction  
 Vasodilators

(preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Epithelium

(pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Injury

(pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Leukocyte

(recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Fibrosis

(renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Injury

(reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lupus erythematosus

(systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Central nervous system, disease

(trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Injury

(vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Endothelium

(vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(viral; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 331723-61-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372091-52-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 577998-70-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714245-33-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714282-93-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 714917-87-0P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714932-70-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide 843630-52-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928139-93-9P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928140-00-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3-sulfonamide 928140-31-2P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-32-3P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-36-7P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-38-9P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-39-0P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-50-5P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-52-7P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-71-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-75-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-77-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-83-4P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-85-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)benzenesulfonamide 928140-87-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-

iodobenzenesulfonamide 928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-96-9P, Methyl 3-[4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate 928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-00-8P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-11-1P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-13-3P, Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928141-14-4P, 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-22-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-26-8P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-30-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide 928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928141-35-9P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide 928141-37-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-39-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide 928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-47-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide 928141-51-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-56-4P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-58-6P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-59-7P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylate 928141-62-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928141-75-7P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylic acid 928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[[4-methylpiperazin-1-yl]methyl]benzenesulfonamide 928141-81-5P, 4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-88-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-90-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide 928141-93-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesul



fonamide 928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-02-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-07-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide 928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714924-49-9P, 3-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-02-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(morpholin-4-yl)pyridine-3-sulfonamide 928140-07-2P, N-[3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-10-7P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-sulfonamide 928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(pyrrolidin-1-yl)sulfonylbenzenesulfonamide 928140-12-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-14-1P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-15-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-16-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-18-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(methylsulfonyl)benzenesulfonamide 928140-20-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(pyrrolidin-1-yl)sulfonylbenzenesulfonamide 928140-21-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamide 928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzothiadiazole-4-sulfonamide 928140-23-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzoxadiazole-4-sulfonamide 928140-25-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-27-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-30-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-sulfonamide 928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-35-6P,

2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-37-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-41-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-44-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-45-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-47-0P, N-[3-[(5-Methoxy-2-(1H-pyrrol-1-yl)phenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-55-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928140-59-4P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-62-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide potassium salt 928140-63-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928140-64-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-65-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-67-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-69-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928140-72-1P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-74-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-78-7P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-81-2P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-84-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)benzenesulfonamide potassium salt 928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-88-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-94-7P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-

sulfonamide potassium salt 928140-99-2P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928141-03-1P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide potassium salt 928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, N-[2-[(2,5-Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide 928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928141-12-2P 928141-16-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-17-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-25-7P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-27-9P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-29-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide potassium salt 928141-31-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide hydrochloride 928141-33-7P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-34-8P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide potassium salt 928141-36-0P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-38-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxy-pyridine-3-sulfonamide potassium salt 928141-40-6P 928141-41-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt 928141-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-55-3P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-57-5P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-60-0P, N-[3-[(2-Bromo-5-methoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt 928141-63-3P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]sulfonyl]benzoic acid 928141-65-5P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-67-7P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-69-9P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-70-2P, 3-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-

yl]amino)sulfonyl]phenyl]propanoic acid 928141-71-3P,  
 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-4-  
 methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-4-methylthiophene-2-  
 carboxylic acid 928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxali-  
 n-2-yl]amino)sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium  
 salt 928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino)sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt  
 928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-  
 [(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-  
 yl)methyl]benzenesulfonamide dihydrochloride 928141-80-4P  
 928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-  
 (hydroxymethyl)benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-  
 [(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide  
 hydrochloride 928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-  
 2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-  
 yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-  
 yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-  
 [(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-94-0P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-  
 [(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-96-2P,  
 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino)sulfonyl]benzamide sodium salt 928141-97-3P,  
 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino)sulfonyl]benzamide sodium salt 928141-98-4P,  
 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-N-(3-  
 methoxypropyl)benzamide 928141-99-5P, 4-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-N-[3-  
 (dimethylamino)propyl]benzamide hydrochloride 928142-01-2P  
 928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino)sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-  
 yl)carbonyl]benzenesulfonamide potassium salt 928142-05-6P,  
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(morpholin-4-  
 yl)carbonyl]pyridine-3-sulfonamide 928142-06-7P, N-[3-[(3,5-  
 Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide  
 potassium salt 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-  
 2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide  
 928142-09-0P 928142-14-7P, N-[6-Chloro-3-[(3,5-  
 dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928142-15-8P,  
 N-[3-[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-  
 yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-  
 nitroquinoxalin-2-yl]benzenesulfonamide 928142-17-0P,  
 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-1-  
 methyl-1H-pyrrole-2-carboxylic acid 928142-18-1P, 5-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-1-methyl-1H-pyrrole-  
 2-carboxylic acid 928142-19-2P, 4-[[[3-[(3,5-  
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]benzamide  
 928142-20-5P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-  
 yl]amino)sulfonyl]benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful  
 in treatment and prophylaxis of diseases)

IT 98-10-2P, Benzenesulfonamide 636-76-0P, 3-(Aminosulfonyl)benzoic acid  
 825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-

Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide  
 2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione  
 2922-45-4P, 3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-yl)-4-methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide 6684-39-5P, 6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl 4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide 25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl 5-(aminosulfonyl)pyridine-2-carboxylate 34082-13-8P, 6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine 35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione 35251-99-1P, 2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P, 6-Chloropyridine-3-sulfonamide 53595-65-6P, 5-Bromothiophene-2-sulfonamide 59777-67-2P, Methyl 3-(aminosulfonyl)benzoate 63555-50-0P, Methyl 3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine 166271-34-7P, N-(3-Chloro-2-quinoxaliny)benzenesulfonamide 199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide 256353-34-1P, 4,5-Dichlorothiophene-2-sulfonamide 478264-00-5P, 6-Methylpyridine-3-sulfonyl chloride 488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-fluorobenzenesulfonamide 522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 848052-87-9P, N-(3-Chloroquinoxalin-2-yl)thiophene-2-sulfonamide 856955-32-3P, 6-Methoxypyridine-3-sulfonamide 859491-30-8P, 5-[[1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-carboxylic acid methyl ester 928139-26-8P, N-(3,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-27-9P, N-(2,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-28-0P, Methyl 3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl 5-(aminosulfonyl)-4-methylthiophene-2-carboxylate 928139-30-4P, 3-Cyano-4-fluorobenzenesulfonamide 928139-31-5P, 6-Cyanopyridine-3-sulfonyl chloride 928139-32-6P, 6-Cyanopyridine-3-sulfonamide 928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide 928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide 928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide 928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide 928139-37-1P, Methyl 4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]butanoate 928139-39-3P, Methyl 4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]benzoate 928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide 928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide 928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide 928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide 928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide 928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide 928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide 928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928139-62-2P, 4-Acetyl-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 928139-63-3P, Methyl 3-[4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate 928139-64-4P, 5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide 928139-66-6P, N-(3,6-Dichloroquinoxalin-2-yl)benzenesulfonamide 928139-67-7P, Methyl 5-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-methylthiophene-2-carboxylate 928139-70-2P, 5-[[[(3-Chloroquinoxalin-2-yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-fluorobenzenesulfonamide 928139-74-6P, N-(3-Chloroquinoxalin-2-yl)-5-[[1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide

928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-fluorobenzenesulfonamide 928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide 928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide 928139-87-1P, Methyl 5-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-yl)-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-1-methyl-1H-imidazole-4-sulfonamide 928139-90-6P, N-(2-Chloropyrido[3,4-b]pyrazin-3-yl)benzenesulfonamide 928139-91-7P, N-(3-Chloroquinoxalin-2-yl)-6-methylthiophene-2-carboxylate 928142-21-6P, N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine 928142-22-7P, N-(5-Methoxy-2-(pyrrol-1-yl)phenyl)quinoxaline-2,3-diamine 928142-23-8P, N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine 928142-24-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 54-96-6, 3,4-Diaminopyridine 70-55-3, p-Toluenesulfonamide 98-09-9, Benzenesulfonyl chloride 98-61-3, Pipsyl chloride 98-64-6, 4-Chlorobenzenesulfonamide 102-56-7, 2,5-Dimethoxyaniline 109-01-3, 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 138-41-0, 4-(Aminomethyl)benzoic acid 402-46-0, 4-Fluorobenzenesulfonamide 452-58-4, 2,3-Diaminopyridine 536-90-3, m-Anisidine 701-34-8, 4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamide 1129-26-6, 4-Methoxybenzenesulfonamide 1524-40-9, 3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzenesulfonyl chloride 1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2958-87-4, 2,3,6-Trichloroquinoxaline 3119-02-6, 4-Cyanobenzenesulfonamide 3430-14-6, 3-Amino-6-methylpyridine 4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4808-69-9, 6-Methylpyridine-3-sulfonic acid 5332-73-0, 3-Methoxypropylamine 5335-40-0, 3-(Methylsulfonyl)benzenesulfonyl chloride 5350-93-6, 5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline

16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl chloride 17260-71-8, 3-Chlorobenzenesulfonamide 23905-46-6, 3-Acetylamino benzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-methylaniline 51175-71-4, 3-Thiophenesulfonyl chloride 55338-73-3, 5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-sulfonyl chloride 56542-67-7, 3-Cyanobenzenesulfonyl chloride 59194-26-2, 5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl 3-(chlorosulfonyl)thiophene-2-carboxylate 59557-92-5, 2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl chloride 73173-79-8 82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl chloride 88598-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride 88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride 89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 111124-90-4, 1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride 137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9, 4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4, Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6 351003-23-1, 4-Fluoro-3-cyanobenzenesulfonyl chloride 374537-95-8, Methyl 3-(4-chlorosulfonylphenyl)propionate 423768-46-1, Methyl 5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate 847744-22-3, N-(3-Chloroquinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide 849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride 878682-97-4, 3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride 882564-09-2 928140-28-7 928141-10-0, N-(3,7-Dichloroquinoxalin-2-yl)benzenesulfonamide 928142-10-3, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

- L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
 IC ICM A61K031-4412  
 ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70;  
 C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10;  
 C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79;  
 C07D401-04; C07D405-04; C07D413-10; C07D215-22  
 CC 27-16 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 TI Preparation of substituted pyridinones as modulators of p38 MAP kinase  
 ST pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic immunomodulator  
 IT AIDS (disease)  
 (-related complex, cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)  
 IT Lymphoma  
 (B-cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)  
 IT Inflammation  
 (Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)  
 IT Intestine, disease  
 (Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for

- treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Nervous system, disease  
(Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Carcinoma  
(adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Respiratory distress syndrome  
(adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Transplant rejection  
(allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Nervous system, disease  
(amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Blood vessel, neoplasm  
(angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Bone  
(avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Necrosis  
(avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Infection  
(bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Skin, neoplasm  
(basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Carcinoma  
(basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT AIDS (disease)  
Human herpesvirus  
Pneumonia  
(cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Heart, disease  
(cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Edema



Ischemia  
(cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, neoplasm  
(cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Lung, disease  
(chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
(colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
(colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection  
(corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, disease  
(diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
(diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease  
(edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, disease  
(endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease  
(failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Ulcer  
(gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
Stomach, disease  
(gastritis; preparation of pyridinones as modulators of p38 MAP kinase for

- treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Transplant and Transplantation  
(graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Blood vessel, neoplasm  
(hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Heart, disease  
(infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease  
(inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Eye, disease  
Reperfusion  
Spinal cord, disease  
(injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease  
(irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Brain, disease  
(ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Rheumatoid arthritis  
(juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Neoplasm  
(metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Pharynx  
(nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Lip  
(neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Glaucoma (disease)  
(neovascular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Angiogenesis  
(neovascularization, eye; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis  
 (neovascularization, retinal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
 (neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
 Kidney, disease  
 (nephritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
 (neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nerve, disease  
 (neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury  
 (ocular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
 (photophobia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation  
 Lung, disease  
 (pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Alzheimer's disease  
 Analgesics  
 Angiogenesis  
 Angiogenesis inhibitors  
 Anti-Alzheimer's agents  
 Anti-inflammatory agents  
 Anti-ischemic agents  
 Antiartherosclerotics  
 Antiarthritics  
 Antiasthmatics  
 Antibacterial agents  
 Anticoagulants  
 Antidiabetic agents  
 Antimalarials  
 Antiparkinsonian agents  
 Antipyretics  
 Antirheumatic agents  
 Antitumor agents  
 Antiulcer agents  
 Antiviral agents  
 Arteriosclerosis  
 Arthritis  
 Asthma  
 Autoimmune disease  
 Bladder, neoplasia

Bone, neoplasm  
Bone resorption  
Bone resorption inhibitors  
Brain, neoplasm  
Burn  
Cachexia  
Carcinoma  
Cardiovascular agents  
Cardiovascular system, disease  
Dermatitis  
Diabetes insipidus  
Diabetes mellitus  
Digestive tract, disease  
Digestive tract, neoplasm  
Drug delivery systems  
Eczema  
Esophagus, neoplasm  
Eye, disease  
Fever and Hyperthermia  
Gastrointestinal agents  
Gout  
Granulation tissue  
Human  
Immunomodulators  
Inflammation  
Influenza  
Ischemia  
Keloid  
Leukemia  
Lip  
Liver, disease  
Liver, neoplasm  
Lung, disease  
Lung, neoplasm  
Lymphoma  
Malaria  
Mammary gland, neoplasm  
Meningitis  
Mouth, neoplasm  
Multiple sclerosis  
Neoplasm  
Nervous system agents  
Osteoarthritis  
Osteoporosis  
Ovary, neoplasm  
Pain  
Pancreas, neoplasm  
Parkinson's disease  
Phosphorylation, biological  
Prostate gland, neoplasm  
Psoriasis  
Reproduction disorders  
Rheumatoid arthritis  
Sepsis  
Silicosis  
Skin, disease  
Skin, neoplasm  
Solid phase synthesis  
Stomach, neoplasm  
Thrombosis  
(preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Tumor necrosis factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Sarcoidosis  
 (pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, neoplasm  
 (renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma  
 (renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart  
 Kidney  
 (reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury  
 (reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
 (retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
 (retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease  
 (retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lung, disease  
 (sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)  
 (septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm  
 (small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury  
 (spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Spinal column, disease

- (spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Brain, disease  
(stroke; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Lupus erythematosus  
(systemic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Shock (circulatory collapse)  
(toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Brain, disease  
(trauma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Stomach, disease  
(ulcer; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Inflammation  
Intestine, disease  
(ulcerative colitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Eye, disease  
Inflammation  
(uveitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Infection  
(viral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Central nervous system, disease  
(with inflammatory or apoptotic component; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT 329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl 3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile 3446-91-1P, 4-Bromomethyl-N,N-dimethylbenzenesulfonamide 3749-51-7P, 4-Hydroxy-6-methyl-2(1H)-pyridone 13737-35-4P, (2-Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-yl]methanol 21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one 21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 24812-90-6P, Methyl 3-amino-4-methoxybenzoate 26576-93-2P, 3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one 33524-79-7P, 1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one 38275-41-1P, Methyl 2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-Chloromethylpyrazine 41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate 49668-89-5P, 49668-90-8P, Methyl 6-(chloromethyl)nicotinate 68432-92-8P, Methyl 3-cyanomethylbenzoate 76518-57-5P, Isoquinolin-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol

119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-  
 one 121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester  
 123226-36-8P, (3-Bromomethylphenyl)acetonitrile 135645-63-5P,  
 4-(Bromomethyl)-2-(methylthio)pyrimidine 140215-42-5P, Ethyl  
 (3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-  
 fluorobenzoate 177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile  
 185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P,  
 3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 186551-70-2P,  
 3-Methylpyrazole-1-carboxylic acid tert-butyl ester 217661-27-3P,  
 2-(Bromomethyl)-5-fluorobenzonitrile 220364-34-1P, [3-  
 (Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P  
 226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester  
 227609-86-1P, (3-Amino-4-fluorophenyl)methanol 391957-11-2P,  
 3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P,  
 4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 586373-04-8P,  
 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate  
 586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P,  
 1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P,  
 3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one  
 586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one  
 586373-26-4P, 4-(Benzoyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-  
 one 586373-29-7P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl  
 N-methyl-N-phenylcarbamate 586373-31-1P, 4-(Benzoyloxy)-1-(3-  
 fluorobenzyl)-3-iodopyridin-2(1H)-one 586373-32-2P, 4-(Benzoyloxy)-1-(3-  
 fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one 586373-34-4P,  
 1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P,  
 4-(Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-37-7P,  
 4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide 586373-38-8P,  
 4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one 586373-39-9P,  
 3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one 586373-51-5P,  
 3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile 586373-57-1P,  
 4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide 586373-58-2P,  
 4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one 586373-59-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P,  
 3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-  
 one 586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one  
 586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-  
 difluorobenzyl)oxy]-1H-pyridin-2-one 586373-70-8P, 1-Chloromethyl-3-  
 (methanesulfonyl)benzene 586373-73-1P, Methyl 4-[(3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]benzoate 586373-76-4P,  
 5-Bromomethylisocoumarin hydrobromide 586373-79-7P,  
 [5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester  
 586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester  
 586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester  
 586373-82-2P, [5-[(3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-  
 yl)methyl]indol-1-yl]carbamic acid tert-butyl ester 586373-93-5P,  
 4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one  
 586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-  
 difluorobenzyl)oxy]-1H-pyridin-2-one 586374-04-1P, Methyl  
 2-fluoro-3-methylbenzoate 586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-  
 hydroxypyridin-2(1H)-one 586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-  
 fluorobenzyl)-1H-pyridin-2-one 586374-29-0P, Methyl 2-[(3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]phenylacetate  
 586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-  
 carbonitrile 586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-  
 dihydropyridine-3-carbonitrile 586374-40-5P, Methyl 1-cyclohexyl-4-  
 hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate  
 586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-  
 dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-  
 3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[(3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]pyrazole-1-

carboxylic acid tert-butyl ester 586374-45-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P, 4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-14-6P, 1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P, 4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-16-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1(2H)-yl]benzoate 586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586375-22-6P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586375-29-3P, 4-[1-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzaldehyde 586375-31-7P, 1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586375-35-1P, 4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-93-1P 586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-25-2P, 1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-52-5P, 3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-56-9P, 4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-58-1P, 4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride 586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-[(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-80-9P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-methylbenzoate 586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate 586377-10-8P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-32-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-38-0P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate 586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl](methyl)carbamate 586377-41-5P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl](cyclopropylmethyl)carbamate 586377-43-7P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzamide 586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile 586377-46-0P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile potassium salt 586377-58-4P, 1-(3-Fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-59-5P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-60-8P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P,



1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-67-5P,  
 3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one  
 586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-  
 2(1H)-one 586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-  
 methylpyridin-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-  
 methylphenyl)-6-methylpyridin-2(1H)-one 586377-79-9P,  
 3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-  
 yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-  
 hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-  
 dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-  
 difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P,  
 3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-  
 2(1H)-one 586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-  
 hydroxy-6-methylpyridin-2(1H)-one 586378-02-1P, 1-[(4-Amino-2-  
 methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one  
 586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-  
 hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-  
 methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P,  
 3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-  
 one 586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate  
 586378-34-9P, 3-Bromo-1-[5-(chloromethyl)pyrazin-2-yl]methyl-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P,  
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]pyrazine-2-carboxylic acid 586378-50-9P, 1-(3-Fluorobenzyl)-4-  
 hydroxy-3-iodopyridin-2(1H)-one 586378-55-4P, 4-Amino-1-(3-  
 fluorobenzyl)pyridin-2(1H)-one 586378-56-5P, 4-Fluoro-N-[1-(3-  
 fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide 586378-58-7P,  
 3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one  
 586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-  
 2(1H)-one 586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-  
 ylmethyl)pyridin-2(1H)-one 586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-  
 (pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-68-9P, 3-Bromo-4-hydroxy-6-  
 methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-69-0P  
 586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-  
 dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P,  
 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-  
 yl)methyl]pyridin-2(1H)-one 586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-  
 (pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-99-6P, 3-Chloro-4-hydroxy-6-  
 methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-10-4P,  
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]pyrazine-2-carboxylic acid 586379-14-8P, 1-Allyl-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-16-0P,  
 1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586379-19-3P,  
 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one  
 586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-  
 dihydropyridine-2-carboxaldehyde 586379-27-3P, 4-[(2,4-  
 Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-  
 one 586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-  
 methylbenzoate 586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-  
 2H-pyridin-1-yl)-3-methylbenzoate 586379-43-3P, 1-(4-Bromo-2-  
 methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586379-44-4P,  
 1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-  
 2(1H)-one 586379-45-5P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2-methyl-  
 4-vinylphenyl)pyridin-2(1H)-one 586379-48-8P, Methyl  
 4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate  
 586379-49-9P, Methyl 4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-  
 oxo-2H-pyridin-1-yl]benzoate 586379-52-4P, 4-Hydroxy-1-[5-  
 (hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-53-5P,  
 4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-  
 methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-  
 (hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-56-8P,

1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde 586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methylbenzoate 586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P, 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-70-6P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-77-3P, 4-[(2,4-difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-82-0P, 4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-86-4P, 4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-89-7P, 3-[4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl]methylbenzonitrile 586379-90-0P, 3-[4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methylbenzonitrile 586379-94-4P, 1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-95-5P, 4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586379-97-7P, Methyl 4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-14-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate 586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-49-6P 586380-51-0P, 4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)pyridin-2-yl]methyl-6-methylpyridin-2(1H)-one 586380-53-2P 586380-54-3P, 6-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methylnicotinic acid 586380-58-7P, 4-Hydroxy-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-59-8P, 4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-65-6P, 4-(Benzyloxy)-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-83-8P 586380-84-9P 586380-85-0P 586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-12-6P, 1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-13-7P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-oxoethyl acetate 586381-16-0P, tert-Butyl 4-[4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenylcarbamate 586381-33-1P, 4-Bromomethyl-N-(2-hydroxyethyl)benzenesulfonamide 586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-39-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methylpyrazole-1-carboxylic acid tert-butyl ester 586381-41-1P, 5-[1-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586381-42-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-

ylmethyl)-1H-pyridin-2-one 586381-44-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-3,3-dibromo-1H-indol-2-one 586381-53-5P 586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-59-1P, Methyl 3-[4-[(2-cyano-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-61-5P, Methyl 3-[4-[[2-(aminomethyl)-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate trifluoroacetate 586381-62-6P 586381-63-7P, 3-[4-[[4-Fluoro-2-[(methoxycarbonyl)amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-64-8P, 3-[3-Bromo-4-[[4-fluoro-2-[(methoxycarbonyl)amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-72-8P, Methyl 3-[4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-73-9P  
, 3-[4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl 3-[4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P, 3-[4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-79-5P, Ethyl (5-fluoro-2-methylphenoxy)acetate 586381-80-8P, Ethyl [2-(bromomethyl)-5-fluorophenoxy]acetate 586381-81-9P, Ethyl [2-[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P, [2-[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P, 3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)  
IT 586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-93-3P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenic acid 586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid 586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-14-1P, [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine 586382-19-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-21-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-26-5P, Ethyl 3-[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylphenyl]-3-oxopropanoate 586382-30-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one 586382-31-2P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl]methyl]benzoate 586382-33-4P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoic acid 586382-35-6P, Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate 586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid

586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-41-4P, Dimethyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalate 586382-42-5P, 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl [3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]carbamate 586382-50-5P, 2-[[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-2-oxoethyl acetate 586382-52-7P, 2-[[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-54-9P, 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; hydrochloride)

IT 586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586380-87-2P, 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzamide  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586414-48-4P 586414-49-5P  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 108379-95-9P 571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-one 586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one 586372-73-8P, 4-(Benzyloxy)-3-bromo-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one 586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one 586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-one 586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-one 586372-82-9P 586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one hydrobromide 586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-methylpyridin-2(1H)-one 586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586373-06-0P, 1-Benzyl-4-[(2,6-dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-14-0P, 1-Benzyl-4-(benzyloxy)-3-vinylpyridin-2(1H)-one 586373-20-8P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586373-50-4P 586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-(hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P, [3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-

yl)methyl]benzyl]carbamic acid tert-butyl ester 586373-75-3P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-  
 pyridin-2-one trifluoroacetate 586373-78-6P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-(1H-indol-5-yl)methyl)-1H-pyridin-2-one  
 586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-  
 indol-5-yl)methyl]pyridin-2(1H)-one 586373-95-7P, 2-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile  
 586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-  
 pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate  
 586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-  
 fluorobenzyl)pyridin-2(1H)-one 586374-28-9P, 2-[[2-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide  
 586374-30-3P, Ethyl 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-  
 pyridin-1-yl]methyl]phenyl]acetate 586374-34-7P, 4-[(2,4-  
 Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-  
 carbonitrile 586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-  
 dimethylpyridin-2(1H)-one 586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-  
 2H-pyridin-1-yl]methyl]benzonitrile 586374-47-2P, 2-[[4-(Benzyloxy)-3-  
 bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586374-55-2P,  
 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile  
 586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]benzonitrile 586374-61-0P, 3-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile  
 586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]benzonitrile 586374-63-2P, 4-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide  
 586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-  
 oxo-2H-pyridin-1-yl]methyl]benzoate 586374-70-1P, 3-Bromo-1-[4-  
 (bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,  
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]benzoic acid 586375-08-8P, Methyl 4-[[4-(benzyloxy)-3-bromo-2-  
 oxo-2H-pyridin-1-yl]benzoate 586375-10-2P, 4-[[4-(Benzyloxy)-3-bromo-2-  
 oxo-2H-pyridin-1-yl]benzoic acid 586375-20-4P, Methyl  
 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzoate 586375-23-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-25-9P,  
 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]benzoic acid 586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-  
 1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-30-6P,  
 4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one  
 586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-  
 methylpyridin-2(1H)-one 586375-66-8P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-  
 2(1H)-one hydrochloride 586375-71-5P, Methyl 4-[[3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate  
 586375-97-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[[4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate  
 586376-20-7P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-  
 bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586376-64-9P, 1-[4-Bromo-2,6-difluorophenyl]-4-[(2,4-difluorobenzyl)oxy]-6-  
 methylpyridin-2(1H)-one 586376-66-1P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one  
 586376-70-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-  
 trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[[3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile  
 586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-

difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586377-80-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-  
 2(1H)-one 586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-  
 difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586377-88-0P,  
 2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-  
 yl]oxy]methyl]-5-fluorobenzonitrile 586377-90-4P, 4-[[2-(Aminomethyl)-4-  
 fluorobenzyl]oxy]-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one  
 trifluoroacetate 586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-  
 chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate  
 586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate  
 586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride  
 586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate  
 586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-  
 (methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-13-4P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-  
 (methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-15-6P,  
 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]pyrimidine-2-carbonitrile trifluoroacetate 586378-29-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-  
 yl]methyl]-6-methylpyridin-2(1H)-one 586378-31-6P, Ethyl  
 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]pyrazine-2-carboxylate 586378-38-3P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-  
 yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate  
 586378-49-6P, 1-(3-Fluorobenzyl)-4-[[4-fluorobenzyl]oxy]-3-iodopyridin-  
 2(1H)-one 586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586379-25-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-  
 (hydroxymethyl)pyridin-2(1H)-one 586379-30-8P, 5-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-  
 carboxaldehyde 586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-51-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)-2-methylphenyl]-6-  
 methylpyridin-2(1H)-one 586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate  
 586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]-4-fluorobenzoic acid 586380-11-2P, 3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid  
 586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]-4-methoxybenzoic acid 586380-19-0P, 1-[5-(Aminomethyl)-2-  
 fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-  
 one hydrochloride 586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-  
 methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile  
 586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-  
 methyl-5-vinylpyridin-2(1H)-one 586380-61-2P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxyethyl)-6-  
 methylpyridin-2(1H)-one 586380-62-3P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-  
 methylpyridin-2(1H)-one 586380-63-4P, 5-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-  
 dihydropyridine-3-carboxaldehyde 586380-64-5P, 4-(Benzyloxy)-3-bromo-1-  
 (2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-67-8P,  
 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-  
 1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P,  
 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-  
 one 586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-  
 oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P,  
 Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-

yl]-3-fluorobenzoate 586381-07-9P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid 586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586381-58-0P, Methyl 2-[[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-78-4P, 3-[3-Bromo-4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-89-7P 586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate 586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-2(1H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 4241-21-8P, 2-Oxo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile 39883-43-7P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carbonitrile 43083-13-2P, 2-Oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile 53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one 54923-34-1P, 4-Benzoyloxy-3-methyl-1H-pyridin-2-one 56304-43-9P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-[(2-bromobenzyl)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-one 242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)carbonyl]hydrazinecarbothioamide 338774-98-4P, N-[5-Acetyl-1-(4-chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-4-chlorobenzamide 338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 338978-39-5P 338981-04-7P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-dimethylaminopropyl)amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide 339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-chlorophenyl)amide 339008-63-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide 339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-trifluoromethoxyphenyl)amide 339008-65-0P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide 339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide 339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide

339024-00-9P 400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylate 477852-96-3P, 1-Benzyl-5-[5-[(3,4-dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one 477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-1H-pyridin-2-one 477864-11-2P, N'-[(1-Benzyl-6-oxo-1,6-dihydropyridin-3-yl)carbonyl]oxylpyridine-4-carboximidamide 478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide 478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one 565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[2-(5-hydroxymethyl)benzyl]oxylpyridazin-3(2H)-one 565157-26-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[2-(2,4-difluorobenzyl)oxyl]pyridazin-3(2H)-one 586372-66-9P, 4-(Benzylloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-one 586372-68-1P, 4-(Benzylloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-one 586372-69-2P, 4-(Benzylloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-2(1H)-one 586372-70-5P, 4-(Benzylloxy)-1-[(4-chlorophenyl)methyl]pyridin-2(1H)-one 586372-71-6P, 4-(Benzylloxy)-3-bromo-1-[(4-chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzylloxy)-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzylloxy)-3-bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-78-3P, 4-(Benzylloxy)-1-[(4-methoxycarbonyl)phenyl]methylpyridin-2(1H)-one 586372-79-4P, 4-(Benzylloxy)-3-bromo-1-[(4-methoxycarbonyl)phenyl]methylpyridin-2(1H)-one 586372-80-7P, 4-(Benzylloxy)-3-bromo-1-[(4-carboxyphenyl)methyl]pyridin-2(1H)-one 586372-83-0P, 4-(Benzylloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one 586372-84-1P, 4-(Benzylloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one 586372-85-2P, 4-(Benzylloxy)-3-bromo-1-ethylpyridin-2(1H)-one 586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one 586372-88-5P, 4-(Benzylloxy)-3-bromo-1-methylpyridin-2(1H)-one 586372-89-6P, 4-[[4-(benzylloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-hydroxybenzenecarboximidamide 586372-90-9P, 4-(Benzylloxy)-3-bromo-1-(piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-91-0P, 4-(Benzylloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-92-1P, 4-(Benzylloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-93-2P, 4-(Benzylloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-94-3P, 4-(Benzylloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one 586372-95-4P, 4-(Benzylloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-one 586372-96-5P, 4-(Benzylloxy)-3-bromo-1-[3-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-97-6P, 4-(Benzylloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-98-7P, 4-(Benzylloxy)-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-one 586372-99-8P, 4-(Benzylloxy)-3-bromo-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-one 586373-01-5P, 1-Benzyl-4-(benzylloxy)-3-bromo-6-methylpyridin-2(1H)-one 586373-02-6P, 1-Benzyl-4-(benzylloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one 586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxyl]-6-methylpyridin-2(1H)-one 586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-dichlorobenzyl)oxyl]pyridin-2(1H)-one 586373-08-2P, 1-Benzyl-4-[(2-chlorobenzyl)oxyl]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-chlorobenzyl)oxyl]pyridin-2(1H)-one 586373-10-6P, 1-Benzyl-3-bromo-4-[(4-methylbenzyl)oxyl]pyridin-2(1H)-one 586373-11-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxyl]pyridin-2(1H)-one 586373-12-8P, 1-Benzyl-4-(benzylthio)-3-bromopyridin-2(1H)-one 586373-13-9P, 1-Benzyl-3-bromo-4-[[2-(trifluoromethyl)benzyl]oxyl]pyridin-2(1H)-one 586373-15-1P, 1-Benzyl-4-(benzylloxy)-3-ethylpyridin-2(1H)-one 586373-16-2P, 3-Acetyl-4-(benzylloxy)-1-(2-chlorophenyl)-6-methylpyridin-2(1H)-one 586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-one 586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-phenylethyl)pyridin-2(1H)-one 586373-23-1P, 4-(Benzylloxy)-3-bromo-1-(2,6-dichlorophenyl)-6-



methylpyridin-2(1H)-one 586373-27-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(2-phenylethyl)pyridin-2(1H)-one 586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl N-methyl-N-phenylcarbamate 586373-30-0P, 4-(Benzoyloxy)-3-ethynyl-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-33-3P, 4-(Benzylamino)-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-36-6P, 3-Bromo-1-(cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-42-4P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-45-7P, 3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-46-8P 586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586373-48-0P, 3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-53-7P, 1-(3-Aminomethylbenzyl)-3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate (1:1.125) 586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-56-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one 586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-62-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-pyridin-2-one 586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-[(methylamino)methyl]benzyl]-1H-pyridin-2-one 586373-65-1P, 1-[(3-Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-69-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-(methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-72-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-85-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586373-87-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one 586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-89-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one 586373-90-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(benzodioxol-5-yl)methylpyridine-2(1H)-one 586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-fluorobenzyl)pyridin-2(1H)-one 586373-92-4P, 3-Bromo-1-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-94-6P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetonitrile 586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-98-0P, Methyl 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-

fluorobenzamide 586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P 586374-11-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-15-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-16-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-butylbenzyl)oxy]-1H-pyridin-2-one 586374-20-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one 586374-21-2P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-(trifluoromethyl)benzyl)oxy]pyridin-2(1H)-one 586374-22-3P 586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P 586374-25-6P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-(hydroxymethyl)benzyl)oxy]pyridin-2(1H)-one 586374-31-4P, 2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586374-33-6P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one 586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-4-yl)methyl)-1H-pyridin-2-one 586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-49-4P, 1-[3-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-54-1P, Methyl 586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile 586374-57-4P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetic acid 586374-58-5P 586374-64-3P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-67-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-69-8P, 3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-73-4P, 1-[3-[(Morpholin-4-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-76-7P, 1-[3-[(Piperidin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-77-8P, 1-[3-[(2-Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-78-9P, 1-[3-[[Bis(2-Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-79-0P, 1-[3-[(Piperazin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one 586374-82-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-83-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-

[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-84-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-  
 hydroxyacetylaminomethyl]benzyl]pyridin-2(1H)-one 586374-85-8P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-  
 [(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-86-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(isopropylamino)methyl]benzyl]pyridin-2(1H)-one 586374-87-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-  
 yl)methyl]benzyl]pyridin-2(1H)-one 586374-88-1P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-  
 2(1H)-one 586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-  
 [4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-90-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-  
 hydroxyethyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-91-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-  
 hydroxyethyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-92-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazin-1-  
 yl)methyl]benzyl]pyridin-2(1H)-one 586374-93-8P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[[methoxycarbonyl]amino)methyl]benzyl]p  
 yridin-2(1H)-one 586374-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-1-[4-[(acetylaminomethyl]benzyl]pyridin-2(1H)-one 586374-95-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [[(methylsulfonyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-96-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [[(aminocarbonyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-97-2P,  
 4-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl)methyl]benzoyl]piperazine-1-carboxamide 586374-99-4P,  
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl)methyl]benzyl]-2-methoxyacetamide 586375-00-0P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)methyl]carbonyl]ami  
 no)methyl]benzyl]pyridin-2(1H)-one 586375-01-1P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-  
 methylethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one 586375-02-2P  
 586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [[[(aminomethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one  
 hydrochloride 586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[4-[[[(hydroxymethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one  
 586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [[[(acetylaminomethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one  
 586375-06-6P, 1-[4-[(4-Acetyl)piperazin-1-yl]carbonyl]benzyl]-3-bromo-4-  
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-07-7P  
 , 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-  
 (methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one  
 586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide  
 586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-  
 one 586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-  
 2H-pyridin-1-yl]benzoate 586375-17-9P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one  
 586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-  
 2(1H)-one 586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-  
 hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-28-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-  
 [(methylamino)methyl]benzyl]pyridin-2(1H)-one 586375-33-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-  
 2(1H)-one 586375-34-0P 586375-36-2P, 4-[[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-  
 methylpropyl)benzamide 586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-  
 1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl]-6-methylpyridin-2(1H)-one  
 586375-38-4P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586375-39-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-

[(piperazino)carbonyl]benzyl]pyridin-2(1H)-one 586375-40-8P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-41-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-42-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-43-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-44-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-45-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholino)carbonyl]benzyl]pyridin-2(1H)-one 586375-46-4P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-47-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-48-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-49-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(1-pyrrolidinyl)carbonyl]benzyl]pyridin-2(1H)-one 586375-50-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one 586375-51-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(2-dimethylamino)ethyl]amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-52-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(2-methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-53-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-54-4P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-methoxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-55-5P,  
 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586375-56-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-57-7P, N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride 586375-58-8P, N-(3-Aminopropyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride 586375-59-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-60-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-61-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-62-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-63-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-64-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-65-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-67-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586375-68-0P, 4-(Benzoyloxy)-3-bromo-1-[4-(morpholin-4-yl)carbonyl]phenyl]pyridin-2(1H)-one 586375-69-1P, 4-(Benzoyloxy)-3-bromo-1-[4-(piperazin-1-yl)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-70-4P, 4-[4-(Benzoyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586375-73-7P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylbenzamide 586375-74-8P 586375-75-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-aminoethyl)amino]carbonyl]benzyl]py

ridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride  
586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-87-3P  
586375-88-4P 586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide hydrochloride 586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide  
586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide  
586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586375-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[piperazinocarbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride  
586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(methylamino)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-02-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride

586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-  
 [(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
 586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-  
 [(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
 586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-  
 methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
 586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-  
 dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
 586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-  
 methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride  
 586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(N-(2-  
 dimethylaminoethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one  
 hydrochloride 586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[3-[(N-(2-hydroxyethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one  
 hydrochloride 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[3-[(N-(2-methoxyethyl)-N-methylamino)carbonyl]phenyl]pyridin-2(1H)-one  
 hydrochloride 586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]benzamide 586376-22-9P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-  
 methylpyridin-2(1H)-one 586376-26-3P, N-[3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzyl]methanesulfonamide 586376-27-4P, N-[3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide  
 586376-28-5P 586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide 586376-30-9P,  
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzyl]-2-acetoxyacetamide hydrochloride 586376-31-0P,  
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P,  
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P,  
 N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea  
 586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-  
 [(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one  
 586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]benzyl]urea 586376-38-7P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-  
 2(1H)-one 586376-41-2P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-  
 yl]benzyl]acetamide 586376-44-5P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-  
 pyridin-1-yl]benzyl]-2-hydroxyacetamide 586376-45-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-  
 yl)ethyl]pyridin-2(1H)-one 586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-  
 2-oxo-2H-pyridin-1-yl]propanoate 586376-48-9P, Methyl  
 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-50-3P,  
 N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-  
 difluorobenzamide 586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-  
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-68-3P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-  
 trifluorophenyl)pyridin-2(1H)-one 586376-72-9P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-  
 2(1H)-one 586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-  
 (hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-78-5P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-  
 yl)phenyl]-6-methylpyridin-2(1H)-one 586376-82-1P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-  
 methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-  
 methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-

methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide 586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-04-0P, 3-Chloro-1-(2,6-difluorophenyl)-4-[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide 586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methoxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-17-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-19-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-21-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[4-methylpiperazin-1-yl]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-methoxyethyl)-N-methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-26-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-28-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide 586377-33-5P 586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide 586377-35-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzamide 586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one hydrochloride 586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide 586377-44-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea 586377-48-2P, 2-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]acetamide 586377-50-6P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-methoxyacetamide 586377-51-7P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide 586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide 586377-53-9P 586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-3-hydroxy-3-methylbutanamide 586377-55-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1-hydroxycyclopropanecarboxamide 586377-56-2P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-

phenylethoxy)pyridin-2(1H)-one 586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(E)-2-(4-fluorobenzyl)ethenyl]pyridin-2(1H)-one 586377-64-2P, 4-(Benzoyloxy)-3-bromo-1-[(6-fluorobenzyl)-3-ylmethyl]pyridin-2(1H)-one 586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P, 3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-78-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-dichlorobenzenesulfonamide 586377-83-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]urea 586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586378-07-6P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-11-2P 586378-17-8P 586378-19-0P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-carboxylate trifluoroacetate 586378-21-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-hydroxypyrimidin-4-yl)methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-23-6P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-carboxamide trifluoroacetate 586378-24-7P, Methyl [4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-yl]methylcarbamate 586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-28-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-hydroxyethyl)(methyl)amino]methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-37-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586378-41-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide 586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide 586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide



586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one  
 586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one  
 586378-46-3P, Carbamic acid [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester  
 586378-48-5P, 4-(Benzylloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one  
 586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-2(1H)-one  
 586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide  
 586378-57-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one  
 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one  
 586378-61-2P, 3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
 586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one  
 586378-65-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one  
 586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one  
 586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one  
 586378-71-4P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one  
 586378-72-5P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one  
 586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-74-7P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-76-9P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-78-1P, 3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-79-2P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one  
 586378-81-6P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one  
 586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one  
 586378-83-8P, 3-Bromo-4-[(2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one  
 586378-86-1P, 3-Bromo-4-[(2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one  
 586378-87-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one  
 586378-91-8P  
 , 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one  
 trifluoroacetate 586378-93-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2-methyl-4-(methylamino)pyrimidin-5-yl)methyl]pyridin-2(1H)-one  
 trifluoroacetate 586378-95-2P, 586378-97-4P, 586378-98-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one  
 586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one  
 trifluoroacetate 586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one  
 586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylpyrazine-2-carboxamide  
 586379-05-7P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylpyrazine-2-carboxamide  
 586379-06-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one  
 586379-07-9P,

5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide 586379-08-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[5-(morpholin-4-ylcarbonyl)pyrazin-2-yl]methylpyridin-2(1H)-one 586379-09-1P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(4-hydroxypiperidin-1-yl)carbonyl]pyrazin-2-yl]methyl-6-methylpyridin-2(1H)-one 586379-11-5P,  
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide 586379-12-6P,  
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide 586379-13-7P,  
 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-15-9P,  
 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-17-1P,  
 Methyl 2E-4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586379-18-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one 586379-21-7P,  
 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-24-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-29-5P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-31-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-ylmethyl)pyridin-2(1H)-one 586379-33-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(2-methoxyethyl)amino]methylpyridin-2(1H)-one 586379-34-2P,  
 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid 586379-35-3P,  
 Methyl 4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoate 586379-38-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-carboxyphenyl)pyridin-2(1H)-one 586379-39-7P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-(hydroxymethyl)phenyl]pyridin-2(1H)-one 586379-40-0P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(2-methoxyethyl)amino]carbonyl]phenylpyridin-2(1H)-one 586379-41-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one 586379-46-6P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-47-7P,  
 Methyl 3-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoate 586379-50-2P,  
 3-[(3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-4-chlorobenzoic acid 586379-54-6P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-57-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-59-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-60-4P,  
 3-[(3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-N-(2-hydroxyethyl)-4-methylbenzamide 586379-65-9P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(2-methoxyethyl)amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-67-1P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-68-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-69-3P,  
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1-hydroxy-1-methylethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-71-7P,  
 Methyl 3-[(3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methylbenzoate 586379-76-2P,  
 3-Bromo-4-[(2,4-difluorobenzyl)amino]-

1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-78-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-80-8P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-83-1P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P, 3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one 586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-03-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-methylpiperazinyl)carbonyl]phenyl]pyridin-2(1H)-one 586380-04-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586380-05-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-06-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[3-(hydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-08-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2,3-dihydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-09-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxy-1,1-dimethylethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one 586380-17-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N-methylbenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N,N-dimethylbenzamide 586380-21-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 586380-22-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(acetylaminomethyl)phenyl]pyridin-2(1H)-one 586380-23-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methoxyacetylaminomethyl)phenyl]pyridin-2(1H)-one 586380-24-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-25-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-27-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[methoxycarbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one

586380-28-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[trifluoromethyl]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-29-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[(isopropoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-30-5P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[ethylanino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-31-6P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[tetrahydrofuran-3-yloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-  
 one 586380-32-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[(propoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-33-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[allyloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-34-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[propargyloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-35-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[tert-butoxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-36-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[tert-butyl]amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-37-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[(propylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-38-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[(ethylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-39-4P,  
 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[isopropylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-40-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[methoxymethyl]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-41-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[methylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one  
 586380-42-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-  
 [[[N-methyl-N-(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-  
 2(1H)-one 586380-43-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-  
 fluoro-2-[[[(cyclopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-  
 2(1H)-one 586380-44-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-  
 fluoro-2-[[[(2,2-trifluoroethyl)amino]carbonyl]amino]methyl]benzyl]oxy]  
 pyridin-2(1H)-one 586380-45-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-  
 4-[[4-fluoro-2-[[[(cyclopropylmethyl)amino]carbonyl]amino]methyl]benzyl]o  
 xy]pyridin-2(1H)-one 586380-46-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-  
 methyl-4-[[4-fluoro-2-[[[(2,2-dimethylpropylamino)carbonyl]amino]methyl]be  
 nzy]oxy]pyridin-2(1H)-one 586380-47-4P, 3-Chloro-1-(2,6-difluorophenyl)-6-  
 methyl-4-[[4-fluoro-2-[[[(dimethylamino)carbonyl]amino]methyl]benzyl]oxy]  
 pyridin-2(1H)-one 586380-48-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-  
 [[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-  
 one 586380-50-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-  
 (hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one  
 586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide  
 586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-  
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide 586380-56-5P,  
 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]methyl]-N,N-dimethylnicotinamide 586380-57-6P, 3-Bromo-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-  
 one 586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)oxy]-1-  
 (2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester  
 586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-  
 methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 586380-69-0P,  
 4-(Benzylloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-  
 one 586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-  
 difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one 586380-71-4P,  
 4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-  
 2(1H)-one 586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-  
 difluorophenyl)-6-methyl-5-((E)-2-phenylethenyl)pyridin-2(1H)-one

586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one 586380-77-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethyl)-6-methylpyridin-2(1H)-one 586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(thien-2-ylmethyl)pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one 586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide 586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586380-91-8P 586380-92-9P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-dimethylurea 586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide 586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide 586380-96-3P 586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-98-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N,N-dimethylbenzamide 586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one 586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(1-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxy-2-methylpropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586381-10-4P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide 586381-11-5P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586381-14-8P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586381-17-1P, 1-(3-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-18-2P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-19-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide 586381-20-6P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-acetoxyacetamide 586381-21-7P 586381-22-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-23-9P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-methylurea 586381-24-0P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxy-2-methylpropyl)urea 586381-25-1P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperidine-1-carboxamide 586381-26-2P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-

yl)methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,  
 N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-4-hydroxypiperidine-1-carboxamide 586381-31-9P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxyethyl)benzenesulfonamide 586381-35-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-1,3-dihydroindol-2-one 586381-45-5P, N-[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]pyrazin-2-yl)methyl]-N-methylmethanesulfonamide 586381-46-6P, Methyl [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]pyrazin-2-yl)methyl(methyl)carbamate 586381-47-7P  
 586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide 586381-50-2P, 1-[[5-Aminopyrazin-2-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586381-52-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(3-methyl-1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate 586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-65-9P, Methyl [2-[[[3-bromo-1-[5-[[[2-hydroxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-66-0P, Methyl [2-[[[3-bromo-1-[5-[[[2-hydroxy-2-methylpropyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-67-1P, Methyl [2-[[[3-bromo-1-[5-[[[2-methoxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-68-2P, O-Methyl [2-[[[1-[5-(aminocarbonyl)-2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-69-3P, N-[2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-N'-phenylurea 586381-70-6P, (Thien-3-yl)methyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-71-7P, Ethyl [2-[[[3-bromo-6-methyl-1-(2-methyl-5-[(methylamino)carbonyl]phenyl)-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-75-1P 586381-83-1P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-88-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586381-90-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methyl-5-[(methylamino)carbonyl]phenyl)-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate 586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methyl-2-butenamide 586381-97-7P 586381-98-8P 586381-99-9P 586382-00-5P 586382-01-6P, Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester 586382-06-1P, Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl ester 586382-07-2P, N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-

[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid  
 4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl ester 586382-11-8P, (S)-2-[[4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]phenyl]amino]-1-methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[(3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]phenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-(Aminocarbonyl)phenyl]-5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl)methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl [2-[[[(3-bromo-1-[5-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]methyl]-5-fluorobenzyl]carbamate 586382-24-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586382-27-6P 586382-28-7P 586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl)methyl]benzoate 586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-2-furamide 586382-34-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furamide 586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-43-6P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalamide 586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586382-47-0P, 1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586382-49-2P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxyacetamide 586382-51-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-dimethylbenzamide 586382-55-0P 586382-56-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl)methyl]-6-methylpyridin-2(1H)-one 586382-57-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl)methyl]-6-methylpyridin-2(1H)-one 586382-58-3P  
 , 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylindoline-1-carboxamide 586382-59-4P 586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl)methyl]pyridin-2(1H)-one 586382-61-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylindoline-1-carboxamide 586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586382-64-1P, 4-(Benzyloxy)-3-bromo-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-65-2P, 4-(Benzyloxy)-3-bromo-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586382-66-3P, 1-Benzyl-4-(benzyloxy)-3-chloropyridin-2(1H)-one 586382-67-4P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-(phenylthio)ethyl]pyridin-2(1H)-one 586382-71-0P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one 586382-72-1P 586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-carboxaldehyde 586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-

fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P,  
 1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one 586382-77-6P,  
 3-Bromo-1-(4-methylbenzyl)oxy]pyridin-2(1H)-one  
 586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-  
 2(1H)-one 586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-  
 fluorobenzyl)oxy]pyridin-2(1H)-one 586382-80-1P, 5-Bromo-1-(2-chloro-6-  
 fluorobenzyl)-3-methylpyridin-2(1H)-one 586382-81-2P,  
 1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde  
 586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde  
 586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-  
 carboxaldehyde 586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-  
 2(1H)-one 586382-85-6P, 4-(Benzylthio)-1-(4-fluorobenzyl)pyridin-2(1H)-  
 one 586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one  
 586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one  
 586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one  
 586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one  
 586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one  
 586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate  
 586382-92-5P, 6-(Benzylthio)-1-methyl-2-oxo-1,2-dihydropyridine-3-  
 carbonitrile 586382-93-6P, 3-Benzoyl-6-(benzyloxy)-1-methylpyridin-2(1H)-  
 one 586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one  
 586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one 586382-96-9P,  
 4-Amino-1-benzylpyridin-2(1H)-one 586382-97-0P, 4-[(2,6-  
 Dichlorobenzyl)oxy]pyridine-1-oxide 586382-98-1P, 3-Bromo-1-(3-  
 fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P  
 586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-  
 2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-  
 dihydro-1H-indol-5-yl]pyridin-2(1H)-one 586383-03-1P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-  
 1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-04-2P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-  
 dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-05-3P,  
 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-  
 yl]indoline-1-carboxamide 586383-06-4P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-  
 yl]pyridin-2(1H)-one 586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-  
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-08-6P  
 586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-  
 methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-  
 indol-5-yl]pyridin-2(1H)-one 586383-11-1P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-  
 methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-  
 methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-  
 carboxamide 586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-  
 1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-15-5P,  
 1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-  
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-16-6P  
 586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-  
 methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one  
 586383-18-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-  
 methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one  
 586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-  
 hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one  
 586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-  
 methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one



586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P 586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-30-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-32-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P 586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-39-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-40-6P, 1-(1-Acetyl-1H-benzimidazol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-41-7P 586383-42-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-43-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-44-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-47-3P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1-carboxamide 586383-48-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-50-8P 586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-52-0P, 1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-53-1P, 1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-55-3P, 3-Acetyl-5-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586383-56-4P 586383-57-5P 586383-58-6P 586383-59-7P 586383-60-0P  
586383-61-1P 586383-62-2P 586383-63-3P 586383-64-4P,  
1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one  
586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-69-9P,  
5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-72-4P 586383-73-5P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-76-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-80-4P 586383-81-5P,  
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-84-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-87-1P, 1-[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P  
586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-

benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-90-6P,  
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-98-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586384-00-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-02-3P 586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-04-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-07-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-08-9P, 1-[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-09-0P, 1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-10-3P, 1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-11-4P 586384-12-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-13-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-14-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-16-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-carboxamide 586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-18-1P, 1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-19-2P 586384-20-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-21-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-

imidazol-4-yl]pyridin-2(1H)-one 586384-22-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-23-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-carboxamide 586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-imidazol-4-yl]pyridin-2(1H)-one 586384-26-1P, 1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-27-2P 586384-28-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-29-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-30-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-carboxamide 586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-2(1H)-one 586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(isoquinolin-6-ylmethyl)pyridin-2(1H)-one 586384-36-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-indol-2-one 586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(N-methylglycyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-40-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-41-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-42-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]indoline-1-carboxamide 586384-43-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-44-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-45-4P, 1-[1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-46-5P 586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-49-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-50-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-51-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide 586384-52-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-53-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-54-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-55-6P 586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-

yl)methyl]pyridin-2(1H)-one 586384-58-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-59-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-61-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-62-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-63-6P 586384-64-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-66-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-67-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-69-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-70-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-71-6P, 1-[[1-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-72-7P 586384-73-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-74-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-75-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-76-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-77-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-78-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-79-4P, 1-[[3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-80-7P, 3-Chloro-1-[[2,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-81-8P 586384-82-9P, 1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-86-3P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-87-4P, 1-[[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-88-5P 586384-89-6P 586384-90-9P 586384-91-0P 586384-92-1P 586384-93-2P 586384-94-3P 586384-95-4P 586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]

pyridin-2(1H)-one 586384-98-7P 586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-00-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-01-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-03-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P 586385-08-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-09-3P, 1-[[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-11-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-12-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-13-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-14-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-16-2P 586385-17-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-18-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-19-5P, 1-[[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-20-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-22-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-23-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-24-2P, 1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-25-3P 586385-26-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-27-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-28-6P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-29-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-30-0P, 1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-32-2P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-33-3P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-34-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-38-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-40-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-41-3P, 1-[[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P 586385-43-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-46-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-47-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-50-4P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-51-5P 586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P,

1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-60-6P  
 586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-64-0P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-67-3P 586385-68-4P 586385-69-5P 586385-70-8P 586385-71-9P 586385-72-0P 586385-73-1P 586385-74-2P 586385-75-3P 586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-78-6P 586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-80-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-82-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-83-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-85-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-86-6P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-87-7P 586385-88-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-89-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-90-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-91-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P,



5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586385-96-8P 586385-97-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586385-99-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-00-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-01-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-02-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-05-2P 586386-06-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-07-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-10-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-13-2P 586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-15-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-16-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-17-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-18-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-1H-benzimidazole-1,3(2H)-dicarboxamide  
 586386-19-8P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide  
 586386-20-1P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-21-2P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one  
 586386-22-3P 586386-23-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-

oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-24-5P,  
 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-25-6P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-26-7P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-27-8P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-28-9P, 5-[[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[[4-fluorophenyl]ethynyl]-6-methylpyridin-2(1H)-one 586386-31-4P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde 586386-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586386-33-6P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586386-34-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-methoxyphenyl]-6-methylpyridin-2(1H)-one 586386-35-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]phenyl]pyridin-2(1H)-one 586386-36-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]benzamide 586386-37-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)benzamide 586386-38-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 586386-39-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-N-methylbenzamide 586386-40-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-methylbenzamide 586386-41-6P, 4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P, Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-3,5-difluorobenzyl]carbamate 586386-43-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-44-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluorophenyl]-6-[(ethoxycarbonyl)methyl]pyridin-2(1H)-one 586386-45-0P, N-[3-Aminopropyl]-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide hydrochloride 586386-46-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[1H-indazol-5-ylmethyl]pyridin-2(1H)-one 586386-47-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586386-51-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586386-52-9P 586386-53-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-55-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-bis(2-hydroxyethyl)benzamide 586386-56-3P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-hydroxybenzamide 586386-57-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one

586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P, 3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586386-63-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586386-65-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-isopropylbenzamide 586386-68-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-70-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586386-71-2P, 4-(Benzylamino)-1-(3-fluorobenzyl)-6-methyl-3-nitropyridin-2(1H)-one 586386-72-3P, tert-Butyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-carboxylate 586386-73-4P, Ethyl 4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-ylacetate 586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzenesulfonamide 586386-75-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-phenylmethanesulfonamide 586386-76-7P, 3-Bromo-4-[(2,4-difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-77-8P, 4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P, Methyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]aminobenzoate 586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-trimethoxyphenyl)amino]pyridin-2(1H)-one 586386-80-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-2(1H)-one 586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)pyridin-2(1H)-one trifluoroacetate 586386-83-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,5-difluorobenzamide 586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,4-difluorobenzamide 586386-85-8P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid 586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-N'-(2,4-difluorophenyl)urea 586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide 586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one 586386-89-2P, N-(3-Aminopropyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride 586386-91-6P, 4-(Benzyloxy)-3-bromo-1-[2-(morpholin-4-yl)ethyl]pyridin-2(1H)-one 586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-93-8P, [3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic acid 586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-95-0P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate 586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-diethoxyethyl)pyridin-2(1H)-one 586386-99-4P 586387-00-0P 586387-01-1P 586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-one 586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-

methylimidazolidine-2,4-dione 586387-04-4P, Ethyl  
 [4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]acetate 586387-05-5P,  
 2-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]acetamide 586387-06-6P,  
 4-(Benzyloxy)-1-ethylpyridin-2(1H)-one 586387-07-7P, tert-Butyl  
 3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate  
 586387-08-8P, 1,3-Dibenzyl-4-hydroxy-6-methylpyridin-2(1H)-one  
 586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl  
 methanesulfonate 586387-10-2P, 1-Benzyl-4-(naphthyl-1-ylmethoxy)pyridin-  
 2(1H)-one 586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-dibromopyridin-2(1H)-  
 one 586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-4-(benzyloxy)pyridin-  
 2(1H)-one 586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-[(2-  
 cyclohexylethyl)amino]methylpyridin-2(1H)-one 586387-14-6P,  
 1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P,  
 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate  
 586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-  
 (trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586387-17-9P,  
 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl  
 4-bromobenzenesulfonate 586387-18-0P, 4-Phenoxy-1-[[2-  
 (trimethylsilyl)ethoxymethyl]pyridin-2(1H)-one 586387-19-1P,  
 1-Benzyl-4-phenoxypyridin-2(1H)-one 586387-20-4P 586387-21-5P,  
 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride  
 586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-  
 one 586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-  
 yl)acetate 586387-24-8P, Methyl (2E)-4-[(2,4-difluorobenzyl)oxy]-6-  
 methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586387-25-9P, tert-Butyl  
 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-  
 carboxylate 586387-26-0P, 1-Benzyl-4-[[4-methylbenzyl]oxy]pyridin-2(1H)-  
 one 586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-  
 dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-28-2P,  
 tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-  
 yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-  
 (methanesulfonyl)-1H-pyridin-2-one 586387-30-6P, tert-Butyl  
 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate  
 586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one  
 586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[2-methyl-4-  
 methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one 586387-33-9P,  
 4-(Benzyloxy)-1-[4-(methylsulfonyl)benzyl]pyridin-2(1H)-one  
 586387-34-0P, 4-Phenoxy-1H-pyridin-2-one 586387-35-1P,  
 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-  
 one 586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one  
 586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-  
 (methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P,  
 4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride  
 586387-39-5P  
 , 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one 586387-40-8P,  
 4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-one  
 586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[[pyridin-3-  
 ylmethyl]amino]-1H-pyridin-2-one 586387-42-0P, 2-Chloro-N-[[1-(2,6-  
 dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-  
 fluorobenzamide 586387-43-1P, N-[1-(2,6-Dichlorobenzyl)-6-oxo-5-  
 trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide  
 586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-  
 one 586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-  
 pyridin-2-one 586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-  
 [3,4']bipyridinyl-2'-one 586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-  
 (3-fluorobenzyl)-1H-pyridin-2-one 586387-48-6P, 3-Bromo-1-(3-  
 fluorobenzyl)-4-thiophen-3-yl-1H-pyridin-2-one 586387-49-7P,  
 3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one  
 586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-  
 one 586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-  
 pyridin-2-one 586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-

pyridin-2-one 586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one 586387-54-4P, 2-[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-55-5P, 1-(2-Chloro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1H-pyridin-2-one 586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-vinyl-1H-pyridin-2-one 586387-57-7P 586387-58-8P, 1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-indazol-5-ylamino)-6-methylpyridin-2(1H)-one 586387-61-3P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[(2,4-difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde 586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]pyrimidine-2-carbonitrile 586387-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-yl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-[1,2']bipyridinyl-3'-carbonitrile 586387-66-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid methylamide 586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-hydroxyethyl)amide 586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-methoxyethyl)amide 586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-methylbenzyl)-1H-pyridin-2-one 586387-70-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-6-methylpyridin-2(1H)-one 586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-72-6P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile trifluoroacetate 586387-74-8P 586387-75-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586387-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-77-1P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586387-78-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-2(1H)-one 586387-79-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586387-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-81-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-bis(2-hydroxyethyl)benzamide 586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one trifluoroacetate 586387-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-85-1P 586387-86-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-87-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one 586387-88-4P 586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586387-90-8P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586387-92-0P, 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-93-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methyl-1H-pyridin-2-one 586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-[(cyclopropylmethyl)amino]methyl]-2,6-difluorophenyl]-4-[(2,4-

di(2-fluorobenzyl)oxy] pyridin-2(1H)-one hydrochloride 586396-39-6P,  
N-[3-[[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P  
586397-63-9P 586397-73-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 165245-96-5, p38 $\alpha$  MAP kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586374-26-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 56-37-1, Benzyltriethylammonium chloride 75-31-0, Isopropylamine, reactions 79-44-7, Dimethylcarbamylic chloride 86-95-3, 4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline 88-17-5, 2-(Trifluoromethyl)aniline 95-02-3, 4-Amino-5-aminomethyl-2-methylpyrimidine 96-33-3, Methyl acrylate 98-00-0, Furfuryl alcohol 98-58-8, 4-Bromobenzenesulfonyl chloride 98-79-3 99-27-4, Dimethyl 5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine 103-64-0,  $\beta$ -Bromostyrene 103-71-9, Phenyl isocyanate, reactions 104-81-4, 4-Methylbenzyl bromide 105-36-2, Ethyl bromoacetate 106-96-7, Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine 109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3, 2-Methoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 315-14-0, 2,4,6-Trifluoronitrobenzene 315-31-1, 2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline 402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl chloride 405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol 453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic acid 456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide 459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride 536-74-3, Phenylacetylene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 582-33-2, Ethyl 3-aminobenzoate 585-71-7, (1-Bromoethyl)benzene 594-61-6, 2-Hydroxyisobutyric acid 616-30-8, 3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan 619-45-4, Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid 626-03-9, 2,4-Dihydroxypyridine 626-15-3,  $\alpha,\alpha'$ -Dibromo-m-xylene 674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one 765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene 867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl indole-5-carboxylate 1071-46-1, Monoethyl malonate 1072-84-0, 4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate 1121-76-2, 4-Chloropyridine 1-oxide 1124-33-0, 4-Nitropyridine N-oxide 1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile 1453-58-3, 3-Methyl-1H-pyrazole 1465-76-5, 1-tert-Butyl-4-oxopiperidine 1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine 2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate 2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-

propanol 3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,  
 2-Chlorophenyl isocyanate 3544-24-9, 3-Aminobenzamide 3731-51-9,  
 2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,  
 4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid  
 4285-42-1, N-Methyl-N-phenylcarbamoyl chloride 4385-35-7,  
 Isochroman-3-one 4412-91-3, 3-Furylmethanol 4518-10-9, Methyl  
 3-aminobenzoate 4530-20-5, Boc-glycine 5345-27-7,  
 3-(Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine  
 5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl  
 6-methylnicotinate 5509-65-9, 2,6-Difluoroaniline 5521-55-1,  
 5-Methylpyrazine-2-carboxylic acid 5571-03-9, Methyl  
 2-methyl-5-pyrimidinocarboxylate 6482-24-2, 2-Methoxyethyl bromide  
 6723-30-4, [(Tetrahydro-2H-pyran-2-yl)oxy]amine 7051-34-5,  
 Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole 7693-46-1,  
 4-Nitrophenyl chloroformate 10406-24-3, 3-(Aminomethyl)benzonitrile  
 13737-36-5, 4-(Bromomethyl)phenylacetic acid 13831-30-6, Acetoxyacetic  
 acid 13831-31-7, Acetoxyacetyl chloride 14001-63-9,  
 4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic acid  
 bis(2,4,6-trichlorophenyl) ester 17201-43-3,  $\alpha$ -Bromo-p-tolunitrile  
 17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid 18063-02-0,  
 2,6-Difluorobenzoyl chloride 18583-89-6, Methyl 3-amino-2-methylbenzoate  
 18595-18-1, Methyl 3-amino-4-methylbenzoate 19335-11-6, 5-Aminoindazole  
 20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol 22115-41-9,  
 $\alpha$ -Bromo-o-tolunitrile 22134-75-4, 22600-30-2, Methyl  
 2-amino-5-furoate 23063-36-7,  $\alpha,\alpha$ -Dichloro-p-xylene  
 23915-07-3, 2,4-Difluorobenzyl bromide 24424-99-5, Di-tert-butyl  
 dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4,  
 2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-  
 propanol hydrochloride 36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride  
 38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl  
 isocyanate 40061-55-0, m-Tolylacetic acid ethyl ester 40635-66-3,  
 2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl  
 3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate  
 50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt  
 53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-  
 chlorobenzyl alcohol 56456-47-4, 2,4-Difluorobenzyl alcohol  
 57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,  
 3-(Cyclohexylamino)-2-butenic acid methyl ester 60728-41-8,  
 3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-  
 Bis(hydroxymethyl)-4-fluorobenzene 66176-39-4, 4-  
 (Bromomethyl)benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-  
 difluoroaniline 71637-34-8, Thien-3-ylmethanol 72235-52-0,  
 2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile  
 80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,  
 3-Amino-4-methylbenzyl alcohol 84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-  
 2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5,  
 5-Bromomethyl-2-fluoropyridine 114896-64-9, Methanesulfonic acid  
 2-(thiophen-3-yl)ethyl ester 120100-15-4, Methyl 3-amino-2-  
 chlorobenzoate 132664-85-8, 5-Aminomethyl-2-methylpyrazine  
 1342274-45-5, 3,4,5-Trifluorobenzonitrile 135394-68-2, 161975-39-9,  
 4-(Methanesulfonyloxymethyl)-1-piperidine-1-carboxylic acid tert-butyl  
 ester 162166-99-6, 3-[(Methanesulfonyloxy)methyl]piperidine-1-carboxylic  
 acid tert-butyl ester 192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-  
 pyran-2-yl)-1H-indazole 586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one  
 586374-17-6, 1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one  
 586374-35-8, 586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-  
 2(1H)-one 586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-  
 (piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one 586376-42-3,  
 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one  
 hydrochloride 586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-  
 dihydropyridin-4-yl trifluoromethanesulfonate 586376-85-4,

4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586378-53-2, 1-Benzyl-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-62-3, 3-Bromo-1-(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-89-4, 4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-00-2, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(methylamino)methyl]pyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-20-6, 4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-22-8, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 58804-19-6P 586378-47-4P 586381-34-2P 586381-37-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN

IC ICM C07D209-00

CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7, 28

TI Preparation of novel multicyclic compounds and their amino acid

derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase

ST cloptentapyrrololeucocarbazole prepn inhibitor poly ADP ribose polymerase; PARP

inhibitor multicyclic compd prepn; pyrrololeucocarbazole prepn inhibitor VEGFR2

kinase; furanopyrrololeucocarbazole prepn inhibitor VEGFR2 kinase;

neurodegenerative disease treatment multicyclic compd prepn;

inflammation treatment multicyclic compd prepn; ischemia

treatment multicyclic compd prepn; MLK3 kinase inhibitor

multicyclic compd prepn

IT Nervous system

(Huntington's chorea; preparation of novel multicyclic compds. and their

amino acid derivs. as inhibitors of enzymes for treatment of

diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2

kinase, and MLK3 kinase)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino; preparation of novel multicyclic compds. and their amino acid

derivs. as inhibitors of enzymes for treatment of diseases

related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,

and MLK3 kinase)

IT Nervous system

(central, injury; preparation of novel multicyclic compds. and their amino

acid derivs. as inhibitors of enzymes for treatment of

diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2

kinase, and MLK3 kinase)

IT Nervous system

(degeneration; preparation of novel multicyclic compds. and their amino acid

derivs. as inhibitors of enzymes for treatment of diseases

related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,

and MLK3 kinase)

IT Eye, disease

(diabetic retinopathy; preparation of novel multicyclic compds. and their

amino acid derivs. as inhibitors of enzymes for treatment of

diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2

kinase, and MLK3 kinase)



IT Cell proliferation  
(disorders; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Uterus, disease  
(endometriosis; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease  
(intraocular neovascular syndromes; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Brain, disease  
Heart, disease  
(ischemia; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease  
(macula, degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Heterocyclic compounds  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nitrogen, aromatic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Alzheimer's disease  
Angiogenesis inhibitors  
Anti-inflammatory agents  
Antidiabetic agents  
Antitumor agents  
Parkinson's disease  
Psoriasis  
Rheumatoid arthritis  
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amino acids, preparation  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Shock (circulatory collapse)  
(septic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 374069-00-8P 374069-03-1P 374069-12-2P 374069-14-4P 374069-19-9P

374069-21-3P	374069-22-4P	374069-23-5P	374069-25-7P	374069-26-8P
374069-31-5P	374069-33-7P	374069-35-9P	374069-36-0P	374069-43-9P
374069-44-0P	374069-53-1P	374069-62-2P	374069-75-7P	374070-30-1P
374070-33-4P	374070-38-9P	374070-39-0P	374070-57-2P	374070-59-4P
374070-64-1P	374070-73-2P	374070-77-6P	374070-79-8P	374070-80-1P
374070-83-4P	374070-95-8P	374070-96-9P	374071-01-9P	374071-12-2P
374071-16-6P	374071-28-0P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCI (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT	154114-97-3P	374068-99-2P	374069-01-9P	374069-02-0P	374069-04-2P
	374069-05-3P	374069-06-4P	374069-07-5P	374069-08-6P	374069-09-7P
	374069-10-0P	374069-11-1P	374069-13-3P	374069-15-5P	374069-16-6P
	374069-17-7P	374069-18-8P	374069-20-2P	374069-24-6P	374069-27-9P
	374069-28-0P	374069-29-1P	374069-30-4P	374069-32-6P	374069-34-8P
	374069-37-1P	374069-38-2P	374069-39-3P	374069-40-6P	374069-41-7P
	374069-42-8P	374069-45-1P	374069-46-2P	374069-47-3P	374069-48-4P
	374069-49-5P	374069-50-8P	374069-51-9P	374069-52-0P	374069-54-2P
	374069-55-3P	374069-56-4P	374069-57-5P	374069-58-6P	374069-59-7P
	374069-60-0P	374069-61-1P	374069-63-3P	374069-64-4P	374069-65-5P
	374069-66-6P	374069-67-7P	374069-68-8P	374069-69-9P	374069-70-2P
	374069-71-3P	374069-72-4P	374069-73-5P	374069-74-6P	374069-76-8P
	374069-77-9P	374069-78-0P	374069-79-1P	374069-80-4P	374069-81-5P
	374069-82-6P	374069-83-7P	374069-84-8P	374069-85-9P	374069-87-1P
	374069-88-2P	374069-89-3P	374069-90-6P	374069-91-7P	374069-92-8P
	374069-93-9P	374069-94-0P	374069-95-1P	374069-96-2P	374069-97-3P
	374069-98-4P	374069-99-5P	374070-00-5P	374070-01-6P	374070-02-7P
	374070-03-8P	374070-04-9P	374070-05-0P	374070-06-1P	374070-07-2P
	374070-08-3P	374070-09-4P	374070-10-7P	374070-11-8P	374070-12-9P
	374070-13-0P	374070-14-1P	374070-15-2P	374070-16-3P	374070-17-4P
	374070-18-5P	374070-19-6P	374070-20-9P	374070-21-0P	374070-22-1P
	374070-23-2P	374070-24-3P	374070-25-4P	374070-26-5P	374070-27-6P
	374070-28-7P	374070-29-8P	374070-31-2P	374070-32-3P	374070-34-5P
	374070-35-6P	374070-36-7P	374070-37-8P	374070-40-3P	374070-41-4P
	374070-42-5P	374070-43-6P	374070-44-7P	374070-45-8P	374070-46-9P
	374070-47-0P	374070-48-1P	374070-49-2P	374070-50-5P	374070-51-6P
	374070-52-7P	374070-53-8P	374070-54-9P	374070-55-0P	374070-56-1P
	374070-58-3P	374070-60-7P	374070-62-9P	374070-63-0P	374070-65-2P
	374070-66-3P	374070-67-4P	374070-68-5P	374070-69-6P	374070-70-9P
	374070-71-0P	374070-72-1P	374070-74-3P	374070-75-4P	374070-76-5P
	374070-78-7P	374070-81-2P	374070-82-3P	374070-84-5P	374070-85-6P
	374070-86-7P	374070-87-8P	374070-88-9P	374070-89-0P	374070-90-3P
	374070-91-4P	374070-92-5P	374070-93-6P	374070-94-7P	374070-97-0P
	374070-98-1P	374070-99-2P	374071-00-8P	374071-02-0P	374071-03-1P
	374071-04-2P	374071-05-3P	374071-06-4P	374071-07-5P	374071-08-6P
	374071-09-7P	374071-10-0P	374071-11-1P	374071-13-3P	374071-14-4P
	374071-15-5P	374071-17-7P	374071-18-8P	374071-19-9P	374071-20-2P
	374071-21-3P	374071-22-4P	374071-23-5P	374071-24-6P	374071-25-7P
	374071-26-8P	374071-27-9P	374071-29-1P	374071-30-4P	374071-31-5P
	374071-32-6P	374071-33-7P	374071-34-8P	374071-35-9P	374071-36-0P
	374071-37-1P	374071-38-2P	374071-39-3P	374071-40-6P	374071-41-7P
	374071-42-8P	374071-43-9P	374071-44-0P	374071-45-1P	374071-46-2P
	374071-47-3P	374071-48-4P	374071-49-5P	374071-50-8P	374071-51-9P
	374071-52-0P	374071-53-1P	374071-54-2P	374071-55-3P	374071-56-4P
	374071-57-5P	374071-58-6P	374072-29-4P	374553-23-8P	374553-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

- IT 9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase 153190-46-6, MLK3 kinase  
 RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
 (preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)
- IT 50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide 62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2, DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyl chloride 79-37-8, Oxalyl chloride 95-15-8, Benzothiofene 98-09-9, Phenylsulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric acid, reactions 108-00-9, N,N-Dimethylethylenediamine 108-12-3, Isovaleryl chloride 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4, 2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl isocyanate 109-97-7, Pyrrole 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 120-92-3, Cyclopentanone 123-75-1, Pyrrolidine, reactions 124-63-0, Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5, Ethanalamine, reactions 141-75-3, Butyryl chloride 271-89-6, Benzofuran 288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluorindole 541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide 591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0, Bromoacetyl bromide 598-52-7, N-Methylthiourea 614-96-0, 5-Methylindole 623-91-6, Diethyl fumarate 630-08-0, Carbon monoxide, reactions 638-29-9, Valeryl chloride 690-76-6, 2-(tert-Butoxycarbonyl)thioacetamide 762-42-5, Dimethyl acetylenedicarboxylate 933-67-5, 7-Methylindole 999-97-3, Hexamethyldisilazane 1121-92-2 1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl ester 2038-03-1, 4-(2-Aminoethyl)morpholine 2114-02-5 2133-40-6, L-Proline methyl ester hydrochloride 2812-46-6 3303-84-2, N-tert-Butoxycarbonyl- $\beta$ -alanine 3878-55-5, Succinic acid monomethyl ester 4023-34-1, Cyclopropanecarbonyl chloride 4377-33-7, 2-Picolyl chloride 4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5, N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-dione 5070-13-3, Bis(4-nitrophenyl) carbonate 5332-06-9, 4-Bromobutyronitrile 5332-26-3 5437-45-6, Benzyl bromoacetate 5699-40-1, N-Acetylguanidine 6940-76-7, 1-Chloro-3-iodopropane 6971-44-4, 4-(N-Methylaminomethyl)pyridine 7148-07-4, 1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolinamide 13154-24-0, Trisopropylsilyl chloride 15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1, Trimethylsilyldiazomethane 19099-93-5, Benzyl 4-oxo-1-piperidinecarboxylate 21035-59-6, 2-(N-Methylaminomethyl)pyridine 24424-99-5, Di-tert-butyl dicarbonate 40594-97-6 49548-40-5 53300-47-3, 2-(Methanesulfonyl)thioacetamide 53654-35-6, 2-Vinylindole 54663-78-4, 2-(Tributylstannyl)thiophene 57260-71-6 57260-73-8, N-tert-Butoxycarbonylethylenediamine 57294-38-9, 4-(tert-Butoxycarbonylamino)butyric acid 76822-35-0 86864-60-0, (2-Bromoethoxy)-tert-butyl dimethylsilane 89031-84-5, (3-Bromopropoxy)-tert-butyl dimethylsilane 98518-10-6 118486-97-8,

2-(Tributylstannyl)-1-methylpyrrole 124252-41-1, 4-  
 (Tributylstannyl)pyridine 133565-49-8 136088-69-2 138585-09-8,  
 p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,  
 3-(Furan-3-yl)indole 175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide  
 175334-72-2, 5-Isoxazolecarbothioamide 374071-64-4, 5-  
 (Triisopropylsilyloxy)-2-(1-hydroxycyclopentyl)indole 374071-66-6,  
 5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,  
 5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,  
 5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,  
 5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,  
 5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole 374071-71-3,  
 2-(tert-Butoxycarbonyloxy)thioacetamide 374071-77-9,  
 2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-  
 yl)indole 374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole 374071-92-8,  
 2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0 374071-96-2,  
 6-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-97-3,  
 4-Methoxy-2-(1-hydroxycyclopentyl)indole  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of novel multicyclic compds. and their amino acid derivs. as  
 inhibitors of enzymes for treatment of diseases related to  
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3  
 kinase)

IT 90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole  
 118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P,  
 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole  
 374071-61-1P 374071-62-2P 374071-63-3P 374071-65-5P 374071-72-4P  
 374071-73-5P 374071-74-6P 374071-75-7P 374071-76-8P 374071-78-0P  
 374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole 374071-80-4P,  
 3-(Cyclopenten-1-yl)pyrrole 374071-81-5P, 2-(Cyclopenten-1-yl)-1-  
 (triisopropylsilyl)pyrrole 374071-82-6P 374071-83-7P 374071-84-8P  
 374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid  
 374071-86-0P 374071-88-2P 374071-89-3P 374071-95-1P 374071-98-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of novel multicyclic compds. and their amino acid derivs. as  
 inhibitors of enzymes for treatment of diseases related to  
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3  
 kinase)

ALL ANSWERS HAVE BEEN SCANNED

=> s (method? or procedure? or assay?) and (identifying or screening) and  
 ("angiogenesis inhibitor?")  
 L37 1075 (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENING)  
 AND ("ANGIOGENESIS INHIBITOR?")

=> s l37 and phenanthrene  
 L38 0 L37 AND PHENANTHRENE

=> s l37 and phenanthroline  
 L39 3 L37 AND PHENANTHROLINE

=> d l39 1-3 hitstr ibib all

L39 ANSWER 1 OF 3 MEDLINE on STN  
 ACCESSION NUMBER: 2005611849 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 16236503  
 TITLE: C8c-C15 monoseco-analogues of the phenanthroquinolizidine  
 alkaloids julandine and cryptopleurine exhibiting potent  
 anti-angiogenic properties.

AUTHOR: Banwell Martin G; Bezos Anna; Burns Christopher; Kruszelnicki Irma; Parish Christopher R; Su Stephen; Sydnes Magne O

CORPORATE SOURCE: Research School of Chemistry, The Australian National University, Canberra ACT 0200, Australia.. mgb@rsc.anu.edu.au

SOURCE: Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol. 16, No. 1, pp. 181-5. Electronic Publication: 2005-10-19. Journal code: 9107377. ISSN: 0960-894X.

PUB. COUNTRY: England; United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200603

ENTRY DATE: Entered STN: 22 Nov 2005  
Last Updated on STN: 22 Mar 2006  
Entered Medline: 21 Mar 2006

AN 2005611849 MEDLINE

DN PubMed ID: 16236503

TI C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties.

AU Banwell Martin G; Bezos Anna; Burns Christopher; Kruszelnicki Irma; Parish Christopher R; Su Stephen; Sydnes Magne O

CS Research School of Chemistry, The Australian National University, Canberra ACT 0200, Australia.. mgb@rsc.anu.edu.au

SO Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol. 16, No. 1, pp. 181-5. Electronic Publication: 2005-10-19. Journal code: 9107377. ISSN: 0960-894X.

CY England; United Kingdom

DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200603

ED Entered STN: 22 Nov 2005  
Last Updated on STN: 22 Mar 2006  
Entered Medline: 21 Mar 2006

AB Four enantiomerically pure monoseco-analogues, 5, 7, 9, and 11, of the phenanthroquinolizidine alkaloid julandine (1) and four of congener cryptopleurine (2), viz. compounds 6, 8, 10, and 12, have been prepared and subjected to preliminary biological evaluation. These analogues show dramatically reduced cytotoxicity compared with the parent system 2 but they are, nevertheless, potent anti-angiogenic agents.

CT \*Alkaloids: CH, chemistry  
Alkaloids: PD, pharmacology  
Angiogenesis Inhibitors: PD, pharmacology  
Animals  
Aorta: DE, drug effects  
Cell Line, Tumor  
Drug Screening Assays, Antitumor: MT, methods  
Humans  
Inhibitory Concentration 50  
Mice  
Models, Chemical  
\*Phenanthrolines: CH, chemistry  
Phenanthrolines: PD, pharmacology  
\*Quinolizines: CH, chemistry  
Quinolizines: PD, pharmacology  
Rats  
Stereoisomerism

Stilbenes: PD, pharmacology  
 RN 117048-59-6 (combretastatin A-4); 482-22-4 (cryptopleurine)  
 CN 0 (Alkaloids); 0 (Angiogenesis Inhibitors); 0 (Phenanthrolines); 0 (Quinolizines); 0 (Stilbenes); 0 (julandine)

L39 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:332055 CAPLUS  
 DOCUMENT NUMBER: 136:350543  
 TITLE: Metalloprotease inhibitors for treatment of angiogenesis  
 INVENTOR(S): Pan, Duoia; Rubin, Gerald M.; Zhang, Hongbing  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 21 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034289	A1	20020502	WO 2001-US45612	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG US 6436629 B1 20020820 US 2000-697854 20001027 CA 2426043 A1 20020502 CA 2001-2426043 20011025 AU 2002020098 A 20020506 AU 2002-20098 20011025 EP 1333856 A1 20030813 EP 2001-988593 20011025 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2004522702 T 20040729 JP 2002-537340 20011025 AU 2002220098 B2 20050127 AU 2002-220098 20011025 US 20020132778 A1 20020919 US 2002-68591 20020206 US 6872750 B2 20050329 US 20050171024 A1 20050804 US 2005-85949 20050321 US 2000-697854 A 20001027 WO 2001-US45612 W 20011025 US 2002-68591 A3 20020206				
PRIORITY APPLN. INFO.:				

AN 2002:332055 CAPLUS  
 DN 136:350543  
 ED Entered STN: 03 May 2002  
 TI Metalloprotease inhibitors for treatment of angiogenesis  
 IN Pan, Duoia; Rubin, Gerald M.; Zhang, Hongbing  
 PA The Regents of the University of California, USA  
 SO PCT Int. Appl., 21 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K039-00  
 ICS A61K039-395; A61K049-00; C12Q001-00; G01N033-53; G01N033-48  
 CC 1-6 (Pharmacology)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO	2002034289	A1	20020502	WO	2001-US45612	20011025
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US	6436629	B1	20020820	US	2000-697854	20001027
	CA	2426043	A1	20020502	CA	2001-2426043	20011025
	AU	2002020098	A	20020506	AU	2002-20098	20011025
	EP	1333856	A1	20030813	EP	2001-988593	20011025
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP	2004522702	T	20040729	JP	2002-537340	20011025
	AU	2002220098	B2	20050127	AU	2002-220098	20011025
	US	20020132778	A1	20020919	US	2002-68591	20020206
	US	6872750	B2	20050329			
	US	20050171024	A1	20050804	US	2005-85949	20050321
PRAI	US	2000-697854	A	20001027			
	WO	2001-US45612	W	20011025			
	US	2002-68591	A3	20020206			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002034289	ICM	A61K039-00
	ICS	A61K039-395; A61K049-00; C12Q001-00; G01N033-53; G01N033-48
	IPCI	A61K0039-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-48 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N; S01N; S01N
US 6436629	IPCI	C12Q0001-00 [ICM,7]; C12N0005-00 [ICS,7]; A61K0049-00 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]

		[I,A]
	NCL	435/004.000; 424/009.100; 424/009.200; 435/375.000
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573
CA 2426043	IPCI	A61K0039-00 [ICM,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; A61K0039-395 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
AU 2002020098	IPCI	A61K0039-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-48 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
EP 1333856	IPCI	A61K0039-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-48 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N; S01N; S01N
JP 2004522702	IPCI	A61K0045-00 [ICM,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0039-395 [ICS,7]; A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-574 [ICS,7]
	IPCR	A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]



[I,A]; G01N0033-573 [I,C\*]  
 FTERM 2G045/AA29; 2G045/BB20; 2G045/BB50; 2G045/CB01;  
 2G045/CB02; 2G045/FA16; 4C084/AA17; 4C084/ZB26;  
 4C085/AA13; 4C085/CC03; 4C085/CC04; 4C085/CC22;  
 4C085/DD23; 4C085/EE03; 4C206/FA53; 4C206/MA04;  
 4C206/ZB26; 4C206/ZC78  
 AU 2002220098 IPCI A61K0039-00 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53  
 [ICS,7]; C12Q0001-00 [ICS,7]; A61K0049-00 [ICS,7];  
 A61K0039-395 [ICS,7]  
 IPCR G01N0033-48 [I,C\*]; G01N0033-48 [I,A]; A61K0031-185  
 [I,C\*]; A61K0031-198 [I,A]; A61K0031-381 [I,C\*];  
 A61K0031-381 [I,A]; A61K0031-403 [I,C\*]; A61K0031-405  
 [I,A]; A61K0038-43 [I,C\*]; A61K0038-48 [I,A];  
 A61K0039-395 [I,C\*]; A61K0039-395 [I,A]; A61K0045-00  
 [I,C\*]; A61K0045-00 [I,A]; A61P0035-00 [I,C\*];  
 A61P0035-00 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00  
 [I,A]; C07K0016-18 [I,C\*]; C07K0016-18 [I,A];  
 C12Q0001-37 [I,C\*]; C12Q0001-37 [I,A]; G01N0033-53  
 [I,C\*]; G01N0033-53 [I,A]; G01N0033-573 [I,C\*];  
 G01N0033-573 [I,A]; G01N0033-574 [I,C\*]; G01N0033-574  
 [I,A]  
 ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;  
 C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N;  
 S01N; S01N  
 US 20020132778 IPCI A61K0038-05 [ICM,7]; A61K0039-395 [ICS,7]; A61K0031-19  
 [ICS,7]; A61K0031-185 [ICS,7,C\*]  
 IPCR G01N0033-48 [I,C\*]; G01N0033-48 [I,A]; A61K0031-185  
 [I,C\*]; A61K0031-198 [I,A]; A61K0031-381 [I,C\*];  
 A61K0031-381 [I,A]; A61K0031-403 [I,C\*]; A61K0031-405  
 [I,A]; A61K0038-43 [I,C\*]; A61K0038-48 [I,A];  
 A61K0039-395 [I,C\*]; A61K0039-395 [I,A]; A61K0045-00  
 [I,C\*]; A61K0045-00 [I,A]; A61P0035-00 [I,C\*];  
 A61P0035-00 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00  
 [I,A]; C07K0016-18 [I,C\*]; C07K0016-18 [I,A];  
 C12Q0001-37 [I,C\*]; C12Q0001-37 [I,A]; G01N0033-53  
 [I,C\*]; G01N0033-53 [I,A]; G01N0033-573 [I,C\*];  
 G01N0033-573 [I,A]; G01N0033-574 [I,C\*]; G01N0033-574  
 [I,A]  
 NCL 514/019.000; 514/575.000  
 ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;  
 C07K016/18; C12Q001/37; G01N033/573  
 US 20050171024 IPCI A61K0038-04 [ICM,7]; A61K0031-405 [ICS,7]; A61K0031-403  
 [ICS,7,C\*]; A61K0031-19 [ICS,7]; A61K0031-185  
 [ICS,7,C\*]  
 IPCR A61K0031-185 [I,C\*]; A61K0031-198 [I,A]; A61K0031-381  
 [I,C\*]; A61K0031-381 [I,A]; A61K0031-403 [I,C\*];  
 A61K0031-405 [I,A]; A61K0038-43 [I,C\*]; A61K0038-48  
 [I,A]; C07K0016-18 [I,C\*]; C07K0016-18 [I,A];  
 C12Q0001-37 [I,C\*]; C12Q0001-37 [I,A]; G01N0033-573  
 [I,C\*]; G01N0033-573 [I,A]  
 NCL 514/019.000; 514/419.000; 514/575.000  
 ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;  
 C07K016/18; C12Q001/37; G01N033/573  
 AB The invention provides methods and compns. relating to Kuz  
 involvement in angiogenesis. In various embodiments, the invention  
 provides methods for modulating angiogenesis by specifically  
 modulating the activity of Kuz in a vertebrate animal predetd. to have a  
 pathogenic angiogenesis; and subsequently detecting a resultant angiogenic  
 modulation in the animal. Methods are provided for  
 identifying a modulator of angiogenesis by (a) contacting an  
 angiogenic assay system comprising a predetd. amount of Kuz with a

candidate agent, under conditions whereby but for the presence of the agent, the system provides a reference angiogenesis; and (b) detecting an agent-biased angiogenesis of the system.

ST angiogenesis antitumor metalloprotease inhibitor Kuz protein

IT Antibodies and Immunoglobulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Kuz mutant fused to Fc region of; metalloprotease inhibitors for treatment of angiogenesis)

IT Antibodies and Immunoglobulins  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Kuz-specific; metalloprotease inhibitors for treatment of angiogenesis)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Kuzbanian (Kuz); metalloprotease inhibitors for treatment of angiogenesis)

IT Carboxylic acids, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (carboxylates; metalloprotease inhibitors for treatment of angiogenesis)

IT Hydroxamic acids  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydroxamates; metalloprotease inhibitors for treatment of angiogenesis)

IT Angiogenesis inhibitors  
 Antitumor agents  
 Chelating agents  
 (metalloprotease inhibitors for treatment of angiogenesis)

IT Flavanols  
 Thiols, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (metalloprotease inhibitors for treatment of angiogenesis)

IT 81669-70-7, Metalloprotease 151769-16-3, TACE  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitor; metalloprotease inhibitors for treatment of angiogenesis)

IT 60-00-4, EDTA, biological studies 66-71-7, 1,10-Phenanthroline 120-80-9D, o-Hydroxyphenol, derivs. 130370-60-4, Batimastat 142880-36-2, GM6001 421553-77-7, IC 3 421567-09-1, GW 9471  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (metalloprotease inhibitors for treatment of angiogenesis)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE  
 (1) Fambrough; Proc Natl Acad Sci 1996, V93, P13233 CAPLUS  
 (2) Pan; Cell 1997, V90, P271 CAPLUS  
 (3) Wen; Development 1997, V124, P4759 CAPLUS

L39 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:194336 CAPLUS

DOCUMENT NUMBER: 130:232477

TITLE: Methods using NGR receptor binding for identifying molecules that home to angiogenic vasculature in tumors

INVENTOR(S): Ruoslahti, Erkki; Pasqualini, Renata

PATENT ASSIGNEE(S): The Burnham Institute, USA

SOURCE: PCT Int. Appl., 180 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913329	A1	19990318	WO 1998-US18895	19980908
W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6576239	B1	20030610	US 1997-926914	19970910
US 6180084	B1	20010130	US 1998-139802	19980825
AU 9894773	A	19990329	AU 1998-94773	19980908
EP 1015884	A1	20000705	EP 1998-948140	19980908
R: CH, DE, FR, GB, IT, LI				
JP 2001516055	T	20010925	JP 2000-511062	19980908
US 6491894	B1	20021210	US 2000-659786	20000911
US 20030113320	A1	20030619	US 2002-264374	20021003
US 20040096441	A9	20040520		
US 20030152578	A1	20030814	US 2003-375992	20030227
US 20040131623	A9	20040708		
PRIORITY APPLN. INFO.:				
			US 1997-926914	A 19970910
			US 1998-139802	A 19980825
			US 1996-60947P	P 19960910
			US 1996-710067	A 19960910
			WO 1998-US18895	W 19980908
			US 2000-659786	A3 20000911

AN 1999:194336 CAPLUS  
 DN 130:232477  
 ED Entered STN: 25 Mar 1999  
 TI Methods using NGR receptor binding for identifying  
 molecules that home to angiogenic vasculature in tumors  
 IN Ruoslahti, Erkki; Pasqualini, Renata  
 PA The Burnham Institute, USA  
 SO PCT Int. Appl., 180 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM G01N033-50  
 ICS G01N033-574  
 CC 1-6 (Pharmacology)  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913329	A1	19990318	WO 1998-US18895	19980908
W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6576239	B1	20030610	US 1997-926914	19970910
US 6180084	B1	20010130	US 1998-139802	19980825
AU 9894773	A	19990329	AU 1998-94773	19980908
EP 1015884	A1	20000705	EP 1998-948140	19980908
R: CH, DE, FR, GB, IT, LI				
JP 2001516055	T	20010925	JP 2000-511062	19980908
US 6491894	B1	20021210	US 2000-659786	20000911
US 20030113320	A1	20030619	US 2002-264374	20021003
US 20040096441	A9	20040520		
US 20030152578	A1	20030814	US 2003-375992	20030227
US 20040131623	A9	20040708		
PRAI US 1997-926914	A	19970910		

US 1998-139802	A	19980825
US 1996-60947P	P	19960910
US 1996-710067	A	19960910
WO 1998-US18895	W	19980908
US 2000-659786	A3	20000911

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9913329	ICM ICS IPCI IPCR	G01N0033-50 G01N0033-574 G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6] G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
US 6576239	ECLA IPCI IPCR	G01N0033/50D2B; G01N0033/574V4 A61K0039-00 [ICM,7] A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
US 6180084	NCL ECLA IPCI IPCR	424/185.100; 424/001.570; 514/002.000; 514/008.000; 530/300.000; 530/324.000; 530/328.000 A61K047/48R2 A61K0049-00 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-566 [ICS,7] G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
AU 9894773	NCL ECLA IPCI IPCR	424/009.100; 424/009.200; 435/007.800; 436/501.000 G01N0033/50D2B; G01N0033/574V4 G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6] G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
EP 1015884	IPCI IPCR ECLA	G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6] G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A] G01N0033/50D2B; G01N0033/574V4; S01N; S01N

JP 2001516055	IPCI	G01N0033-566 [ICM,7]; A61K0031-122 [ICS,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*]; A61K0045-00 [ICS,7]; A61K0047-48 [ICS,7]; A61K0051-00 [ICS,7]; A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]; C07K0007-00 [ICS,7]; G01N0033-15 [ICS,7]; G01N0033-50 [ICS,7]; G01N0033-574 [ICS,7]
	IPCR	G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
US 6491894	IPCI	A61K0049-00 [ICM,7]
	IPCR	G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/009.100; 424/009.200; 424/093.200; 435/007.230; 435/007.800; 436/501.000; 514/002.000; 530/300.000 G01N033/50D2B; G01N033/574V4
US 20030113320	ECLA	
	IPCI	A61K0039-395 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]; C07K0014-705 [ICS,7]; C07K0014-435 [ICS,7,C*] G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	IPCR	
	NCL	424/143.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500 G01N033/50D2B; G01N033/574V4
US 20030152578	ECLA	G01N0033-574 [ICM,7]; A61K0039-395 [ICS,7]
	IPCI	
	IPCR	A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/178.100; 435/007.230
	ECLA	A61K047/48R2; G01N033/50D2B; G01N033/574V4
AB	A method is disclosed for identifying a tumor homing	
	mol. that homes to angiogenic vasculature by contacting a substantially	
of	purified NGR receptor with one or more mols. and determining specific binding	
	a mol. to the NGR receptor, where the presence of specific binding	
	identifies the mol. as a tumor homing mol. that homes to angiogenic	
	vasculature. The invention also provides a method of directing	
	a moiety to angiogenic vasculature in a subject by administering to the	
	subject a conjugate including a moiety linked to a tumor homing mol. that	
	exhibits specific binding to an NGR receptor, whereby the moiety is	
	directed to angiogenic vasculature. In addition, the invention provides a	
	method of imaging the angiogenic vasculature of a tumor in a	
	subject by administering to the subject a conjugate having a detectable	
	moiety linked to a tumor homing mol. that exhibits specific binding to an	
	NGR receptor and detecting the conjugate.	
ST	NGR receptor tumor homing mol identification; angiogenic vasculature tumor	
	homing NGR receptor; imaging conjugate angiogenic vasculature tumor	
IT	Antitumor agents	
	Antitumor agents	
	(Hodgkin's disease inhibitors; methods using NGR receptor	
	binding for identifying mols. that home to angiogenic	
	vasculature in tumors, and therapeutic and imaging methods)	
IT	Sarcoma	

(Kaposi's; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Peptides, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (NGR-containing; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Leukemia  
 (acute myelogenous; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Mammary gland  
 (carcinoma, inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Ovary, neoplasm  
 (carcinoma; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Mammary gland  
 (carcinoma; tumor homing peptide identification by in vivo panning against a breast tumor)

IT Blood vessel  
 (endothelium; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Hodgkin's disease  
 Hodgkin's disease  
 (inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Antitumor agents  
 (mammary gland carcinoma; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Angiogenesis  
 Angiogenesis inhibitors  
 Blood vessel  
 Drug screening  
 Drug targeting  
 Hodgkin's disease  
 Imaging agents  
 Immobilization, biochemical  
 Melanoma  
 Neoplasm  
 Peptide library  
 Phage display library  
 Scintigraphic agents  
 (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT RGD peptides  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)

(methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Proliferation inhibition  
(proliferation inhibitors, tumor homing mol. conjugates; methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Antitumor agents  
Cytotoxic agents  
Drugs  
(tumor homing mol. conjugates; methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Radionuclides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor homing mol. conjugates; methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 9031-94-1, Aminopeptidase  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(CD13-like, inhibitors; methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 189023-66-3 205117-84-6 221230-70-2  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 221230-69-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 221230-66-6P 221230-67-7P 221230-68-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 149635-29-0D, conjugates 189023-64-1D, conjugates 205117-83-5D, conjugates 221230-65-5D, conjugates  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods using NGR receptor binding for identifying moles. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 66-71-7, o-Phenanthroline 13434-13-4, Actinonin 23214-92-8D, Doxorubicin, tumor homing mol. conjugates 58970-76-6, Bestatin  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

```

(Uses)
  (methods using NGR receptor binding for identifying
  mol.s. that home to angiogenic vasculature in tumors, and therapeutic
  and imaging methods)
IT 162901-68-0 168179-57-5
  RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
  (Properties); BIOL (Biological study); PROC (Process)
  (methods using NGR receptor binding for identifying
  mol.s. that home to angiogenic vasculature in tumors, and therapeutic
  and imaging methods)
IT 9054-63-1P, Aminopeptidase N
  RL: BPR (Biological process); BSU (Biological study, unclassified); PUR
  (Purification or recovery); BIOL (Biological study); PREP (Preparation);
  PROC (Process)
  (methods using NGR receptor binding for identifying
  mol.s. that home to angiogenic vasculature in tumors, and therapeutic
  and imaging methods)
IT 152880-65-4
  RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
  (Biological study)
  (methods using NGR receptor binding for identifying
  mol.s. that home to angiogenic vasculature in tumors, and therapeutic
  and imaging methods)
IT 14133-76-7D, Technetium-99, tumor homing mol. conjugates, biological
  studies 14333-33-6D, Carbon-11, tumor homing mol. conjugates, biological
  studies 14762-74-4D, Carbon-13, tumor homing mol. conjugates, biological
  studies 15750-15-9D, Indium-111, tumor homing mol. conjugates,
  biological studies
  RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  (methods using NGR receptor binding for identifying
  mol.s. that home to angiogenic vasculature in tumors, and therapeutic
  and imaging methods)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Burnham Inst; WO 9810795 A 1998 CAPLUS
(2) Erkki, R; US 5536814 A 1996 CAPLUS
(3) Jolla Cancer Res Found; WO 9514714 A 1995 CAPLUS
(4) Jolla Cancer Res Found; WO 9710507 A 1997 CAPLUS
(5) Koivunen, E; BIO/TECHNOLOGY 1995, V13(3), P265 CAPLUS
(6) Koivunen, E; JOURNAL OF BIOLOGICAL CHEMISTRY 1993, V268(27), P20205 CAPLUS

```

```
=> SET SMA OFF
```

```
SET COMMAND COMPLETED
```

```
=> SEL RAN.CAPLUS(1) L39 3
```

```

L39 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S
Enter SET SMARTSELECT ON before using SELECT to create an L-number of
terms extracted from an L-number that contains answers or terms from
more than one file. SET SMARTSELECT ON must be entered before you
execute the SELECT command.

```

```
=> SET SMA ON
```

```
SET COMMAND COMPLETED
```

```
=> SEL RAN.CAPLUS(1) L39 3
```



SmartSELECT INITIATED  
New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

L40           SEL L39 3 1 :           1 TERM

=>

=>

=> SET SMA LOGIN

=> FIL CAPLUS

SET COMMAND COMPLETED

=> S L40

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	237.04	442.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.00	-23.20

FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24  
FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> D L39 BIB,ABS

L41           1 L40

=> DEL L40 Y

YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:  
YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:n

=>  
=> FIL MEDLINE CAPLUS EMBASE BIOSIS SCISEARCH

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.00	447.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-23.20

FILE 'MEDLINE' ENTERED AT 10:52:54 ON 11 JUN 2008

FILE 'CAPLUS' ENTERED AT 10:52:54 ON 11 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:52:54 ON 11 JUN 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:52:54 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:52:54 ON 11 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

=>  
=>  
=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008  
E US2007-599748/APPS  
E US2006-599748/APPS  
L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008  
L2 162 S E1-E162  
L3 22 S L2 AND DIONE  
L4 0 S L2 AND PHENANTHROLINE DIONE  
L5 2 S L2 AND PHENANTHROLINE  
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008  
L7 224329 S L2  
L8 13877 S L3  
L9 406 S L5  
L10 224329 S L7 OR L8 OR L9  
L11 3300 S 10 AND ANTIANGIOGENIC  
L12 56 S L11 AND ISCHEMIA  
L13 28 S L11 AND ("HEART DISEASE")  
L14 2 S L13 AND L12  
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC  
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"  
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7  
L19 1 S L18 FAM SAM  
SET SMA OFF  
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON  
11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE?")  
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)  
L22 0 S L21 AND ("HEART ATTACK")  
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")  
L24 4 S L21 AND ISCHEMIA  
L25 1 S L16 AND ("MYOCARDIAL INFARCTION")  
L26 0 S L16 AND ("ANGIOGENESIS INHIBITOR?")  
L27 552 S L2 AND ("ANGIOGENESIS INHIBITOR?")  
L28 24 S L3 AND ("ANGIOGENESIS INHIBITOR?")  
L29 2 S L5 AND ("ANGIOGENESIS INHIBITOR?")  
L30 53 S (L27 OR L28 OR L29) AND HEART  
L31 24 S L30 AND ISCHEMIA  
L32 19 S L31 AND (TREAT OR TREATING OR TREATMENT)  
L33 0 S L32 AND ("5,6-DIONE")  
L34 0 S L32 AND ("1,10-PHENANTHRENE")  
L35 5 S L32 AND DIONE  
L36 19 DUP REM L32 L35 (5 DUPLICATES REMOVED)  
L37 1075 S (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENI  
L38 0 S L37 AND PHENANTHRENE  
L39 3 S L37 AND PHENANTHROLINE  
SET SMA OFF  
SET SMA ON  
L40 SEL L39 3 1 : 1 TERM  
SET SMA LOGIN

FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008

L41 1 S L40

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:52:54 ON  
11 JUN 2008

=>  
=>